,ticker,content
0,LLY,astrazeneca azn eli lilly lly become latest tuesday series pharmaceutical company scrap study potential alzheimer disease treatment appear unlikely work drugmaker discontinue phase study drug call lanabecestat independent datum monitoring committee predict lanabecestat miss goal study early alzheimer disease mild alzheimer dementia complexity alzheimer disease pose most difficult medical challenge time lilly research lab president daniel skovronsky say written statement be grateful contribution study participant family lanabecestat belong class drug call bace inhibitor work prevent buildup substance call beta amyloid plaque brain researcher believe toxic substance be center alzheimer disease get newsletter deliver inbox more info product service privacy policy term useastrazeneca lilly be far only pharmaceutical company frustrated pursuit alzheimer disease treatment dow jone component merck mrk end study drug verubecestat mild moderate early alzheimer disease earlier year fellow dow jone stock pfizer pfe abandon research treatment alzheimer parkinson disease johnson johnson jnj stop study bace inhibitor patient late stage alzheimer disease liver worry lilly stock crash drug miss goal phase study lilly study drug solanezumab patient mild alzheimer disease market be increasingly look biogen be work monoclonal antibody drug know aducanumab work remove beta amyloid plaque brain analyst expect biogen have datum key study lilly say tuesday doesn expect significant cost associate decision end study potential alzheimer disease treatment reaffirm guidance midterm guidance remainder decade be commit ensure finding be used inform further research alzheimer community give importance find treatment disease say astrazeneca spokesperson menela pangalos statement stock market today lilly sank fraction close share be consolidate buy point astrazeneca lose collectively share pharmaceutical company be flat related invest stock free new apps aim buy stock ahead earning report be inflation do matter fed
1,LLY,aldr likely seek buyer amgen amgn rivale preventative migraine treatment get approval analyst say thursday share tank hire new chief executive share drop stock market today share break cup base buy point earlier week rally be short live stock sank consecutive day biotech company hire robert azelby former chief commercial officer juno therapeutic new chief executive celgene celg recently acquire juno immuno oncology player azelby work amgen manage oncology business leerink analyst geoffrey porge see azelby tenure likely short get newsletter deliver inbox more info product service privacy policy term use advantage mr azelby view be locality availability be already seattle have presumably become available acquisition juno celgene say report client add hard believe board view mr azelby long term leader company appointment add conviction board ultimately support sale sale be unlikely however get approval preventative migraine treatment know cgrp inhibitor amgen gain approval drug aimovig teva pharmaceutical teva eli lilly lly be also work similar drug earlier year founder former ceo randall schatzman unexpectedly step have plan submit application migraine treatment second half year now expect submit application first quarter fact hire new ceo isn surprising porge say be something surprise individual appoint position have experience neurology have not previously oversee complex multus functional element product introduction say rbc analyst brian abraham other hand call hire sensible fit move commercial stage azelby bring significant experience commercial strategy large small biotechs biopharma say believe be important launch preventative migraine treatment eptinezumab say note understand have also be closely involved regulatory process prior organization experience help eptinezumab application filing related do spot major market top easy look heavy basic sell buy stock ahead earning report
2,LLY,amgen amgn novartis nvs shrewdly price aimovig wall street expectation analyst say friday day drug become first migraine prevention medication grab approval approval come president trump attempt tamp drug price aimovig go month annually institute clinical economic review previously estimate drug same class go year piper jaffray analyst christopher raymond suggest amgen be try avoid battle insurer reimbursement purposefully set price expectation amgen learn lesson cholesterol drug repatha say report client compare pcsk payer experience repatha think prove be shrewd move amgen novartis say think be see reasonable price likely preempt access reimbursement hurdle get newsletter deliver inbox more info product service privacy policy term useon stock market today amgen stock rise close share be consolidate buy point share rival aldr pop close eli lilly lly teva pharmaceutical teva be work similar drug lift fraction aimovig compete drug lilly teva cgrp class short calcitonin gene related peptide receptor drug work block receptor cut number migraine patient suffer month amgen novartis be first gain approval cgrp drug late thursday food drug administration approve aimovig prevent migraine chronic episodic teva lilly likely follow own iteration next year label be broad clean leerink analyst geoffrey porge say note doesn list cautionary warning language further believe amgen have avoid pitfall excessive pricing kind high volume indication say amgen estimate be patient benefit drug prevent migraine be first new class migraine drug nearly decade porge say botox gain approval prevent migraine chronic sufferer now amgen be prepare jump first mover advantage already have number patient ready receive drug next week porge ultimately expect amgen keep market long term other cgrp drug come online lilly drug galcanezumab likely gain approval teva follow next year porge say european official be now review aimovig aimovig approval be risk event rbc analyst brian abraham say report have be pressure year chief executive unexpectedly quit march firm previously guide launch believe price point set amgen enable good patient access adoption class start say be favorable ultimate later entry large market differentiate product meanwhile teva be expect be delay end year issue plant active ingredient be make analyst expect drug fremanezumab launch mid abraham model overall market cgrp drug prevent migraine be long term leerink porge forecast aimovig grab sale consensus view related build long term profit stock take many gain be inflation do matter fed sell take profit hold here be several guideline follow
3,LLY,amgen amgn stock take double hit tuesday dow jone component pfizer pfe grab approval knockoff amgen anemia treatment eli lilly lly report strong result compete headache drug stock market today amgen stock topple close pfizer dip finish lilly slip share stock be consolidate respective buy point share biotech company pharmaceutical company fall fraction food drug administration approve pfizer drug call retacrit midday tuesday retacrit be biosimilar almost identical biologic copy amgen drug epogen procrit epogen procrit be anemia treatment get newsletter deliver inbox more info product service privacy policy term usepfizer approval isn major hit amgen revenue see just first quarter sale epogen epogen be amgen seventh biggest drug first quarter sale decline vs year earlier period other be attempt copy amgen biggest drug neulasta enbrel neulasta increase bone marrow stimulation enbrel treat chronic disease include form arthritis psoriasis be blockbuster novartis nvs have enbrel biosimilar call erelzi drug be approve novartis unit sandoz launch erelzi patent dispute amgen be complete novartis sandoz mylan myl coherus bioscience chrs also be work biosimilar neulasta amgen be also rivale lilly teva pharmaceutical teva aldr migraine drug class call cgrps short calcitonin gene related peptide firm be work treatment prevent chronic migraine tuesday lilly say medicine call galcanezumab meet key goal late stage study patient episodic cluster headach reduce weekly cluster headach compare placebo week month treatment period statistically significantly greater percentage patient treat lilly medicine also see least reduction weekly attack compare placebo week drug prove safe tolerable lilly drug be also be study migraine amgen novartis partner develop aimovig likely be first class get approval prevent chronic migraine food drug administration be expect make decision aimovig later week related chart read basic buy point mark time real tame volatile swing trade half positionlook next nvidia start simple routine
4,LLY,pfizer pfe blockbuster breast cancer drug ibrance lag expectation first quarter tuesday dow jone component see total revenue stall issue light guidance stock market today pfizer tumble close share be currently consolidate buy point first quarter pfizer report adjust income cent share sale adjust income top view cent grow sale increase just vs year period miss consensus accord zack investment research pfizer cite negative customer buy pattern slow sale ibrance xeljanz get newsletter deliver inbox more info product service privacy policy term usetotal sale ibrance grow be expectation reuter say ibrance sale rise pfizer be likely see competition novartis nvs eli lilly lly rival drug xeljanz treatment rheumatoid arthritis also grow globe miss expectation xeljanz sale advanced biggest decline come pfizer unit know essential health include nonviral infective biosimilar injectable medicine sale business decline innovative health unit grow rake year pfizer guide adjust earning share midpoint guidance miss consensus expectation penny firm also see sale midpoint pfizer sale guidance just lag view related much money do need start investing investing basic sell buy stock ahead earning report
5,LLY,eli lilly lly be try leapfrog dow jone stock merck mrk bristol myer squibb bmy acquisition cancer immunotherapy biotech armo bioscience armo industry observer say thursday drugmaker lilly be late game cancer immunotherapy brad loncar tell investor business daily loncar run several biotech stock index include cancer immunotherapy sector index contain armo loncar cancer immunotherapy exchange trade fund pop thursday leader be merck bristol myer squibb roche rhhby say re company have completely miss boat want play area have do something try leapfrog competition early thursday lilly make first big move cancer immunotherapy space area medicine drug immune system fight cancer lilly say pay share armo cash deal get newsletter deliver inbox more info product service privacy policy term usearmo share rocket close lilly stock rise fellow drug stock merck bristol rise less roche have failure early day colon cancer dip lilly expect deal close end second quarter armo late stage biotech go public january quickly pop be hot initial public offer loncar say note price early thursday indicate investor expect bid leerink analyst chang note acquisition price be premium armo close price wednesday initiate coverage stock outperform rating price target earlier year thursday downgrade armo market perform deal confirm investment thesis armo view read positively other emerge immuno oncology stock say be unclear other bidder emerge give short close date acquisition make sense pharmaceutical stock lilly try assert cancer immunotherapy space loncar say armo lead drug call pegilodecakin be know cytokine boost strength drug know pd inhibitor merck keytruda bristol opdivo earlier year bristol validate cytokine drug call nktr pay upfront partner nektar therapeutic nktr deal hit record upfront payment biotech loncar say now little surprise armo be be take loncar have consistently predict be big year biotech deal merger takeout year kick news celgene celg plan buy juno therapeutic sanofi sny bid bioverativ bivv ablynx ablx deal armo be little different say think have happened be middle terrible bear market say other hand be also good example large company eli lilly many have not be forefront innovation re have buy still lilly isn alone trail position cancer immunotherapy roche astrazeneca azn pfizer pfe have immuno oncology drug remain merck bristol be level own say cancer immunotherapy space desperately need good news say earlier year incyte incy drug know ido inhibitor fail late stage combination merck keytruda melanoma incyte pain extend other cancer immunotherapy stock background volatility remain cancer immunotherapy space loncar say key say be be different piece technology armo drug be different incyte drug know epacadostat news item set person mood say everybody be immunotherapy think overrate then deal happen cause opposite reaction have emerge technology go be roller coaster related chart read basic buy point mark time real tame volatile swing trade half positionlook next nvidia start simple routine
6,LLY,japan takeda pharmaceutical clinch acquisition shire shpg early tuesday week tussle company allergan agn also be briefly interested possible merger approve be largest overseas purchase japanese company accord dealogic dealogic say debt deal be worth takeda add roughly market cap shire be north new takeda be close size bristol myer squibb bmy eli lilly lly rbc analyst dougla miehm say deal alleviate concern notably japanese drugmaker lever sufficiently dividend remain intact firm expect general annual pretax cost synergy end third year do anticipate deal spread remain wider normal give complexity transaction require approval various geography ability realize synergy especially research development long date close date say note client get newsletter deliver inbox more info product service privacy policy term total deal be consistent takeda fifth proposal value dublin base shire pound share together takeda pay pound roughly company expect deal close first half term deal shire shareholder receive cash new takeda share takeda american depositary receipt shire share deal wrapped shire shareholder own new takeda takeda new share also trade tokyo stock exchange new york stock exchange rbc miehm note acquisition be expect be significantly accretive earning first full fiscal year follow close also expect provide return interest takeda cost capital same time period takeda confirm still need approval third exist shareholder be confident get vote miehm say pay acquisition takeda enter bridge credit agreement type loan miehm keep outperform rating shire stock stock market today shire rise close first quarter outperformance valeant pharmaceutical vrx didn help drug stock more broadly dip related do spot major market top easy look heavy tame volatile swing trade half positionlook best stock buy watch start here
7,LLY,teva pharmaceutical teva pop early thursday israeli drugmaker top wall street first quarter estimate raise outlook say expect key migraine drug get approval year stock market today teva share lift much wildly reverse course stock end regular trading session share be consolidate buy point meanwhile generic drug group dip fraction mizuho analyst irina koffler reiterate buy rating price target teva note commentary regard teva preventative chronic migraine drug call fremanezumab help stock teva indicated expect pre approval inspection celltrion facility come month launch fremanezumab end say report news remove prior concern weigh stock last quarter get newsletter deliver inbox more info product service privacy policy term usefremanezumab belong class drug design block calcitonin gene related peptide cgrp receptor believe be intricately tie migraine amgen amgn eli lilly lly aldr be also work preventative treatment teva report smaller expect decline first quarter adjust profit cent share fall crushed view cent sale come dip still beat consensus analyst poll zack investment research generic drug teva biggest unit decline north america teva cite price erosion slide europe teva generic drug climb growth counter volume be partially offset price reduction sale multiple sclerosis drug copaxone tumble third globally still beat koffler view revenue decline copaxone now face generic copycat mylan myl novartis nvs partner momenta pharmaceutical mnta austedo bring crush koffler estimate drug be first approve april treat cholera associate huntington disease august get approval treat involuntary body movement tie long term use drug teva also boost guidance now see adjust profit share midpoint beat analyst view also expect sale slightly midpoint top estimate related build long term profit stock take many gain sell take profit hold here be several guideline basic analyze stock cup handle
8,LLY,eli lilly lly top street first quarter estimate tuesday unexpected strength diabetes drug early impact chemotherapy tie dow jone component merck mrk sale psoriasis drug taltz key growth product osteoporosis drug forteo lag expectation wholesale retail buy pattern lilly say press release still firm boost guidance first quarter beat evercore analyst umer raffat characterize good quarter lilly early trading stock market today lilly share tick close get newsletter deliver inbox more info product service privacy policy term first quarter lilly report adjust profit share sale rise respective metric top consensus analyst poll zack investment research adjust income share sale year lilly raise adjust earning forecast share revenue analyst expect adjust earning share sale late monday food drug administration advisory panel dealt lilly partner incyte incy setback panel opposed approve new rheumatoid arthritis drug higher dose drugmaker want panel do favor lower dosage quarter sale diabetes drug trulicity grow worldwide trulicity revenue advanced higher demand drug class know glp receptor agonist same time prescription trulicity grow raffat say imply pricing have not be unfavorable glp class say humalog diabetes drug lilly biggest product grow sale better pricing drive growth raffat say sale erectile dysfunction drug ciali seem be relatively stable light generic competition pfizer pfe viagra ciali sale grow drive higher realize price largely offset decrease demand due entry generic sildenafil lilly say worldwide sale fall meanwhile sale chemotherapy medication alimta increase decrease revenue outside be offset rise sale alimta be used combination merck keytruda treat lung cancer several key drug fall short raffat say sale psoriasis treatment taltz fall quarter quarter drive lower volume due specialty pharma buy pattern partially offset higher demand lilly say sale miss raffat say be important growth product miss say same time sale osteoporosis drug forteo decline due decrease volume wholesale retail buy pattern lesser extent lower realize price lilly say related do spot major market top easy look heavy best stock buy watch start buy stock ahead earning report
9,LLY,merck mrk pop month high monday goldman sachs suggest cancer drug keytruda be asset believe narrative company be quickly change success keytruda drive significant shift product mix large primary care evolve specialty biopharma goldman sachs analyst jami rubin write note client rubin upgrade merck buy rating neutral add stock brokerage americas conviction list also boost price target raise expectation keytruda also late monday european regulator accept merck application combination keytruda chemotherapy untreated lung cancer patient decision be make base result study present last week call keynote merck say get newsletter deliver inbox more info product service privacy policy term useon stock market today share dow jone component climb close earlier stock touch highest point late january meanwhile rival bristol myer squibb bmy dip finish hoopla surround merck follow american association cancer research annual meeting last week then regimen merck keytruda chemotherapy seemingly top combination bristol opdivo yervoy first treatment lung cancer keytruda chemo reduce risk death merck say combination opdivo yervoy cut risk cancer progression death similar group patient compare chemotherapy alone bristol say now analyst expect merck take lion share already large lung cancer market keytruda animal health unit drive merck value rubin say see bottom line get contribution higher keytruda sale rubin assume merck eventually have roughly half immuno oncology market earlier estimate immuno oncology medicine treat cancer teach immune system identify tumor cell keytruda bring stem sale first treatment advanced lung cancer predict rubin expect keytruda generate lone therapy keytruda likely get quarter market serve patient tumor have lot pd protein rubin say amount pd be thought predict well drug keytruda bristol opdivo work doesn expect bristol opdivo get market merck share combination market remain be determine say keytruda likely have access lung cancer market bristol roche rhhby be still run test rival combination be room further upside merck establish more leadership position still need see datum other combination trial give more credit say merck also seek merger further diversify especially diabetes drug januvia look likely see generic competition mid rubin say see potential merck be even better story management take step diversify address longer term growth post januvia complement keytruda say believe have more enough balance sheet firepower do so firm be now compelling mix margin improvement story say mostly be overlooked lung cancer discussion historically investor reward margin expansion story key example include abbvie abbv eli lilly lly related do spot major market top easy look heavy term retirement investing strategy etfssell take profit hold here be several guideline follow
10,LLY,battle brewing liver cancer treatment result exelixis exel end top analyst say wednesday rival eli lilly lly post strong topline result drug lilly be testing drug cyramza combat liver cancer attempt add already approve used stomach lung colon cancer have face exelixis be also testing kidney cancer drug cabometyx liver cancer detail surround level benefit be not disclose press release cyramza historical hepatocellular carcinoma liver cancer datum do not lead view drug significant threat cabometyx rbc analyst kennen mackay say note client model cabometyx take half liver cancer market competition potential combination immuno oncology drug exelixis bristol myer squibb bmy be testing cabometyx immuno oncology drug opdivo liver cancer get newsletter deliver inbox more info product service privacy policy term usecyramza improve rate overall survival used second option liver cancer patient first treatment fail also improve rate disease be progression free study evaluate patient have fail be intolerant drug know sorafenib sorafenib be sell nexavar bayer lilly limit study patient high amount protein call alpha fetoprotein afp half liver cancer patient fall bucket generally patient have poorest prognosis relative other liver cancer patient lilly be mum specific result historical datum don bode well mackay say earlier study cyramza have overall survival rate month patient month patient high afp compare cabometyx recently show month overall survival rate liver cancer patient afp appear be meaningful prognostic biomarker cyramza do not appear have target therapy effect population give overall survival actually decline month patient month afp high patient say mackay keep outperform rating exelixis stock stock market today exelixis jump close lilly rise finish related chart read basic buy point mark time real invest stock free new apps aim beginnerslook best stock buy watch start here
11,LLY,incyte incy plummet friday regimen combine immuno oncology drug merck mrk fail late stage study prompt duo scrap program raymond james analyst reni benjamin mince price target incyte note other combination used incyte drug epacadostat immuno oncology drug merck bristol myer squibb bmy astrazeneca azn be also likely be dud view event taint entire epacadostat franchise therefore be remove revenue associate melanoma other indication model write report client study miss big time share incyte crash close stock market today incyte hit year low fall much merck dow jone component see share fall sympathy bristol lose astrazeneca lift fraction get newsletter deliver inbox more info product service privacy policy term regimen fail improve progression free survival melanoma patient look unlikely have impact overall survival incyte say news release combination test epacadostat inhibit ido enzyme merck keytruda pd protein inhibitor datum study help contribute overall understand ido inhibition combination pd checkpoint inhibitor incyte chief medical officer steven stein say remain dedicate transform treatment cancer continue explore ido inhibition other novel mechanism potentially improve outcome patient need say written statement safety combination be line previous study incyte say patient move regimen manner consistent best interest patient incyte be also testing epacadostat lung cancer patient combination merck bristol astrazeneca investigator be also look epacadostat regimen kidney head neck bladder cancer analyst have be bullish incyte chance epacadostat broadly theorize combine immuno oncology drug offer more potent cancer response bristol have be forefront combine immuno oncology drug opdivo pd inhibitor yervoy be know ctla inhibitor be approve treat melanoma bristol be also testing regimen other cancer merck other hand have work combine keytruda chemotherapy regulator approve combination first treatment advanced lung cancer merck be also study keytruda investigational pd inhibitor call mk friday analyst be less bullish incyte shot epacadostat do see value incyte other drug include baricitinib rheumatoid arthritis drug eli lilly lly cancer drug ruxolitinib brand jakafi jakavi raymond james benjamin keep outperform rating incyte see incyte jakafi generate also have potential book significant royalty baricitinib well ruxolitinib outside be also sell novartis nvs jakavi rbc analyst brian abraham chopped price target incyte completely discounting epacadostat still have outperform rating stock raymond james benjamin still see value jakafi baricitinib expect incyte terminate other epacadostat study only silver line view be result be unequivocal make future decision clear say note base datum see very low likelihood robust signal biomarker defined subgroup emerge support continue anything other study substantially reduce scope exploratory purpose related build long term profit stock take many gain investing basic sell stocklooking best stock buy watch start here
12,LLY,pharmaceutical bhvn crater third early monday unveil result late stage trial migraine drug competitor investigational therapy allergan agn drug call rimegepant be test treatment acute migraine phase trial rimegepant meet key goal pain freedom freedom worst symptom hour mark numerically allergan drug have slight advantage piper jaffray analyst charle duncan warn investor lose forest tree effectiveness datum show rimegepant be approvable clinically meaningful say note client further rimegepant continue improve hour mark be encourage see delta rimegepant placebo widen past hour time point even repeat dose adjunctive therapy rescue med suggest candidate be differentiate prevention recurrence lack rebound effect say get newsletter deliver inbox more info product service privacy policy term usehe see rimegepant drug model peak sale still morning trading stock market today fall much low be stock initial public offer last end regular session monday allergan rise trial patient receive single milligram dose drug rimegepant repeat dose rescue medicine triptan be pain free hour mark vs patient receive placebo receive rimegepant be free worst symptom hour point vs patient receive placebo investor be key compare vs allergan drug ubrogepant drug class medicine call cgrps aim block specific peptide associate migraine allergan drug be be test orally allergan ubrogepant be test milligram milligram dose allow repeat dose rescue medicine hour patient be pain free vs placebo patient worst symptom disappear patient vs placebo group ubrogepant patient have liver issue rimegepant didn allergan trial be patient liver function rise greater time upper limit normal safety board say none case have probable relationship drug leerink analyst geoffrey porge still expect allergan ubrogepant be competitive generic triptan make acute migraine prescription patient carry severe warning patient don respond triptan further note resolution liver worry ubrogepant win be resolve long term safety study allergan drug be available second half rimegepant ubrogepant differ other cgrp drug be investigate aim prevent migraine amgen amgn novartis nvs be lead front teva pharmaceutical teva eli lilly lly aldr be also work drug related much money do need start investing long term retirement investing strategy buy stock ahead earning report
13,LLY,nasdaq composite rise record high fang stock rally slew hot tech ipos soar index be little change dow jone fall trump trade threat weakness many energy financial stock many retailer also fall rh rh canada goose goos etsy etsy soar federal reserve hike rate predict more close takeover time warner federal judge deal adobe system adbe pull back strong earning nasdaq composite advanced techs power ahead index be flat dow jone retreat medium stock health giant rally get court buy time warner many retail stock cool recent run rh rh dave buster play online art craft site etsy etsy soar result guidance fed policymaker see more hike raise rate wednesday federal judge time warner deal condition reject justice department argument merger hurt competition pay tv industry close merger friday landmark ruling boost share price medium firm cbs cbs lionsgate lgf discovery communication disca decision be expect open door more acquisition medium firm telecom giant deal also bode well big vertical health care merger include cvs health cvs buy aetna aet comcast cmsca expect launch takeover bid st century fox entertainment foxa offer cash rupert murdoch entertainment company premium walt disney offer disney november agree buy fox include stake broadcaster sky stock fox board be expect withdraw recommendation disney offer company be unlikely carve fox analyst say get newsletter deliver inbox more info product service privacy policy term video game conference spotlight major title come soon such leader activision blizzard atvi microsoft msft nintendo ntdoy sony sne esport be major topic year show tournament game such fortnite battle royale epic game super smash bro nintendo rise subscription service such electronic art ea origin access premier microsoft msft xbox game pass also be hot topic be future stream video game ea activision clear buy zone take interactive break fed hike key interest rate expect second time year somewhat surprisingly policymaker pencile more hike year chairman jerome powell declare economy be great shape expressed sense hawkish shift policy be risk retail sale rise best gain month back powell assessment spur wall street firm boost second quarter gdp growth projection more meanwhile core consumer price inflation picked year highest early further increase be likely adobe system adbe earn adjust share fiscal year year sale analyst expect digital medium marketing software firm earn adjust share sale current fiscal third quarter adobe guide modestly higher adobe share pull back friday big run last few year share etsy etsy soar thursday art craft online retailer raise revenue guidance announce new subscription package higher seller fee other initiative now see revenue growth prior guidance etsy raise transaction fee seller spend direct marketing last year etsy have active seller platform active buyer earning more double share smash estimate cent share kmg chemical kmg make chemical used chip solar panel consumer electronic also raise full year sale forecast share rocket week blast buy zone canada goose goos swung profit cent share loss cent share year revenue more double analyst expect loss cent sale outerwear company typically make money fall winter lose money warmer month canada goose see fiscal ep growth least revenue more canada goose stock soar friday rh rh furniture purveyor formerly know restoration hardware grow earning share fold vs view revenue dip surprising analyst expect enhance earning guidance strong outlook drive investor confidence share soar tuesday add rh history wild stock swing earning report arcade restaurant chain dave buster play top view ep grow revenue rise same store sale fall narrower decline expect dave buster be roll new virtual reality game tie new movie jurassic world fall kingdom analyst see game changer dave buster ceo steve king retire aug cfo brian jenkin succeed share shot tuesday definitively retake support day line reach month high report opec report rise production saudi arabia raise opec production outlook bpd april report grow shale production international energy agency warn economic turmoil venezuela renew sanction iran lead supply gap late next year opec make lose production president trump blast opec tweet high oil price energy information administration say domestic crude stockpile fall more expect production rise crude fall week barrel private equity giant kkr kkr set buy envision healthcare evhc share cash deal value hospital staffing company include assume debt usg corp usg agree be acquire germany knauf end month talk usg largest investor warren buffett lead berkshire hathaway brkb urge wallboard maker negotiate buffett have rescue usg housing market collapse call investment disappointing last year workday wday pay adaptive insight have be ipo help expand cloud offering business plan stryker syk say not talk fellow medical device company boston scientific bsx potential takeover dispute report have make takeover approach pivotal pvtl report first quarter public company top expectation send share company say lose cent share vs estimate cent loss revenue rise top view share surge astrazeneca azn eli lilly lly tuesday scrap phase study alzheimer disease treatment call lanabecestat drug appear unlikely work early alzheimer disease mild alzheimer dementia also ibd stock invest stock market start simple routinestock buy watch top ipos big small cap growth stock
14,LLY,aldr topple month low wednesday chief executive unexpectedly quit just month firm be expect ask regulator approve key migraine drug firm previously guide submit application migraine drug know eptinezumab second half commercial launch expect late tuesday didn offer update timeline leerink analyst geoffrey porge say note client change ceo so close finish line be not unheard biotech neither be common write jittery market such event lack disclosure commentary information inevitably raise question exert downward pressure stock stock market today plunge close touch lowest point late december share begin consolidate january buy point biotech group other hand lift wednesday get newsletter deliver inbox more info product service privacy policy term userandall schatzman co founder step ceo role effective late tuesday stay consultant time board member paul cleveland serve interim president ceo say news release didn offer much insight schatzman departure release analyst say be look executive more regulatory commercial experience biotech prepare submit application eptinezumab credit suisse analyst vamil divan call move reasonable surprising consider new full time replacement have yet be identify leerink porge suggest transition have already be plan keep wrapped pending pivotal trial datum timing disclosure obviously come directly board director mean company be free openly recruit leader requisite skill experience secure sale company porge say needham analyst danielle brill suggest sudden departure schatzman slightly delay timing eptinezumab note strategy eptinezumab be unchanged be still plan target specialist sale force person delay eptinezumab be headwind credit suisse divan say eptinezumab be part drug class call cgrps target specific peptide prevent migraine amgen amgn novartis nvs eli lilly lly teva pharmaceutical teva be work market divan note first quarter conference call be key timing eptinezumab delay even few month be very meaningful also remain concern compete larger player be well ahead development market likely also face significant pricing pressure say related build long term profit stock take many gain investing basic sell stocklooking next nvidia start simple routine
15,LLY,do novartis nvs amgen amgn merck mrk pfizer pfe celgene celg gilead science gild baxter international bax eli lilly lly have common have licensing other business relationship ligand pharmaceutical lgnd ligand be recently add ibd list top growth stock be lead biotech stock
16,LLY,exelixis exel tank month low thursday combination drug big pharma giant roche rhhby fail late stage study hard treat colon cancer patient regimen test exelixis drug cotellic roche drug tecentriq patient hard treat form colon cancer have advanced spread cancer have progressed be intolerant prior chemotherapy regimen combination prove safe miss mark exelixis roche aim improve overall survival compare drug call regorafenib bayer bayry sell regorafenib stivarga colon cancer drug pre treat patient failure be yet roche cancer immunotherapy industry observer brad loncar tell investor business daily loncar run several biotech index tecentriq be similar rival drug merck mrk bristol myer squibb bmy get newsletter deliver inbox more info product service privacy policy term use be disappointing space maybe roche need do something creative get back lead position say reference eli lilly lly decision earlier day buy armo bioscience armo stock market today exelixis topple close earlier share plunge much roche dip broadly share biotech company lose pharmaceutical stock pop rbc analyst kennen mackay remain bullish exelixis cut price target keep outperform rating exelixis also make cabometyx kidney cancer drug expect be worth failure study call imblaze doesn change bullish cabo centric thesis exelixis mackay say note client be surprise earlier stage datum regimen cotellic single drug be strong say still even combination not much downside say cabometyx be approve kidney cancer food drug administration be also consider treatment liver cancer re buyer dip anticipate cabo growth well ahead street expectation say mackay believe street be mis modele cabometyx see total cabometyx sale kidney cancer vs street view piper jaffray analyst edward tenthoff be similarly bullish keep overweight rating exelixis reduce price target note failure colon cancer doesn impact study cotellic tecentriq roche zelboraf melanoma related do spot major market top easy look heavy basic sell stocksell take profit hold here be several guideline follow
17,LLY,index dow jone industrial average nasdaq tumble week alphabet googl caterpillar cat mmm earning treasury yield spook investor stock market average pare loss strong earning amazon amzn facebook fb boee ba visa other index dow jone nasdaq find support day move average rebound close week fractional loss year treasury hit first time year hit week pull back short term yield continue rise faster long term rate squeeze yield spread alphabet googl expense ongoing chip weakness also hit stock amazon amzn facebook fb boee ba visa rally strong result intel intc microsoft msft initially hit buy point friday pull back amazon first quarter earning sky-rocket more double ep estimate revenue rise fifth straight quarter accelerate sale growth revenue amazon web service rise aw account most amazon overall operate profit amazon share shot record high friday pare gain advance ebay ebay stock drop report result fall short consensus estimate end quarter global active buyer facebook fb stock surge post first quarter result blow past expectation dash fear exodus user advertiser social medium giant twitter twtr report strong earning guidance share fall ceo make cautious comment slow growth get free access ibd digital april
18,LLY,get premium stock list pass fail stock rating more start hereboee ba easily beat forecast raise full year guidance aerospace giant say aircraft completion center china be nearly finished downplay china trade war fear fellow dow jone stock unite technology utx report stronger expect earning sale industrial giant also raise full year adjust ep sale forecast lockheed martin lmt top first quarter estimate defense contractor raise ep revenue target maker didn raise cash flow expectation northrop grumman noc also report earning estimate northrop say didn submit bid air force gps iii contract leave lockheed likely lone bidder raytheon rtn raise full year earning forecast consensus earning revenue top estimate general dynamic gd beat earning meet revenue view share defense contractor sell sharply week software kingpin earn cent share year year sale fiscal third quarter analyst expect cent microsoft msft have be shift business desktop pc software cloud compute infrastructure application such office azure microsoft commercial cloud revenue rise fiscal software giant initially reclaim recent buy point friday pare gain intel intc earning rise sale grow well analyst view chip giant guide higher current quarter sale indicate third straight quarter top line growth share initially jump year high friday reversed close slightly lower texas instrument txn advanced micro device amd stm xilinx xlnx get boost upbeat earning report chip gear maker teradyne ter tumble warning weak demand equipment test mobile device western digital wdc make disk drife memory chip tumble friday beating fiscal view philadelphia semiconductor index fought support day move average google parent alphabet googl report earning revenue top view sharp rise capital spending margin pressure higher traffic acquisition cost spark sell internet search giant capex jump year period include real estate purchase manhattan traffic cost google pay partner website generate advertising revenue jump google have hike spending youtube video content cloud compute smart home consumer appliance artificial intelligence project paypal pypl top earning revenue expectation total payment volume rise year year vs estimate company raise revenue adjust ep guidance management point momentum partnership visa international bank technology platform such baidu bidu exxon mobil xom miss earning view output slip recent surge oil price chevron cvx fall short revenue conocophillip cop crushed estimate hess hes report shallower expect loss royal dutch shell rdsa report highest profit oil price crash energy information administration say crude inventory rise barrel vs drop analyst expect domestic production rise barrel day barrel increase crude oil future briefly top barrel highest level late trade little change week general motor gm ford motor fiat chrysler fcau beat quarterly estimate ford not invest traditional sedan north america go forward almost phase passenger car consumer migrate suvs light truck gm still see small car opportunity home abroad even too shift focus larger more profitable vehicle casino operator la vegas sand lvs top first quarter result estimate help strong demand global gaming hub macau singapore macau also help result wynn resort wynn overall macau sale disappoint analyst wynn resort also approve dividend increase earning report wynn be first steve wynn resign ceo sell stake follow allegation sexual misconduct mgm resort mgm narrowly beat stock tumble decline traffic location mgm be more focuse sand wynn amgen amgn alexion pharmaceutical alxn broadly top view amgen sale adjust profit outlook be bit soft midpoint sale alexion blockbuster soliris miss estimate share pop promising study new drug alxn biogen biib sale lag sluggish spinraza multiple sclerosis drug revenue prothena prta tank monday scrap rare disease drug fail phase study eli lilly lly broadly beat consensus diabetes drug chemotherapy help offset short sale psoriasis drug taltz glaxosmithkline gsk sale adjust profit lag abbvie abbv bristol myer squibb bmy top profit view raise full year guidance bristol sale miss estimate shire shpg say consider raise takeover bid japan takeda vertex pharmaceutical vrtx top view sale decline vs last year vertex say ll move triple pill regimen phase study domino dpz deliver ep gain revenue leap blow view share rise thursday chipotle grill cmg stock vault month high ep unexpectedly jump same store sale also top starbucks sbux be par earning ep rise cent rise sale outdo analyst prediction new oriental education edu earn cent share revenue grow total student enrollment rise year year ibd stock tal education tal ep jump cent share revenue soar student enrollment balloon vs year earlier new oriental tal share pop respective earning day be slightly lower week intraday friday pultegroup phm tuesday crushed view ep jump cent home sale revenue leap homebuilder stock be generally muted due rise interest rate horton dhi biggest builder thursday best view ep surge revenue swell homebuilder stock rally solid gain help cool treasury yield new home sale rise march annualize sale pace unit month high meanwhile exist home price rise february vs year earlier china search engine leader baidu bidu report profit blow past estimate lift share baidu still own majority iqiyi iq hold ipo march video stream iqiyi account roughly parent revenue share iqiyi fall release earning tandem baidu visa report ep gain revenue rise beating fiscal view credit debit card giant raise full year revenue outlook share leap thursday mmm meet ep view revenue rise just consensus dow jone giant slash full year ep target stock plunge caterpillar cat report strong earning sale share heavy construction equipment maker reversed sharply lower tuesday warning operate margin hit high watermark year servicenow now report profit revenue estimate customer now spend annually metric be year year edward lifescience ew top sale adjust profit view share tank sale transcatheter heart valve replacement lag illumina ilmn beat consensus adjust profit rise share sale swell align technology algn report adjust earning share revenue handily beating view cent respectively td ameritrade amtd deliver impressive ep revenue growth fall short lofty expectation share fall week trade financial etfc continue rise last week strong result first solar fslr hit year high earning top expectation due sale several solar project expand production proofpoint pfpt cybersecurity firm top adjust first quarter earning revenue view guide low profit share fall friday advanced protection solution nearly double make new add booking prior quarter
19,LLY,dow future rise ahead tuesday open lag nasdaq market gather face double dose resistance caterpillar cat verizon vz unite technology utx stir dow future early crude oil price gain investor dig session long list earning result dow future rise caterpillar forge strong early lead premarket loss traveler trv mmm limit gain future advanced nasdaq future narrow early gain paccar pcar lead heavy loss incyte incy biogen biib temper advance dow have logged straight decline nasdaq have slip past session past result left index back resistance day move average decline also push dow negative territory year dow industrial end monday year carry decline nasdaq hold gain dow push past day line well positive territory year order put market struggle uptrend back track get newsletter deliver inbox more info product service privacy policy term usecrude oil price edge higher benchmark crude just barrel put price just thursday month high global oil supply continue tighten bloomberg report earlier month organization petroleum export country be target crude oil price europe brent benchmark busy day economic news be bury weighty earning calendar stock market today february case shiller home price index march new home sale national association realtor april consumer confidence estimate conference board richmond federal reserve regional manufacturing index be due et monday hour report session include result alphabet googl barrick gold abx chicago bridge iron cbi name trade narrow range early tuesday hold move less generally strong first quarter report google parent alphabet whirlpool whr be standout early tuesday miss first quarter analyst target company announce plan sell brazilian compressor unit early report tuesday stir more activity germany base software giant sap sap marshaled advance drugmaker eli lilly lly hustle higher oilfield equipment leader weatherford international wft scramble gain dow future caterpillar easily lead crank gain immediately follow earning report verizon be next line also earning counter early gain be traveler drop respectively follow quarterly result caterpillar report strong double digit sale increase north america asia pacific region first quarter drive earning revenue well expectation low end earning guidance be full consensus number caterpillar share consolidate late january end monday early april low back support day move average verizon jump adjust first quarter result top target report much larger anticipate drop subscriber quarter verizon share have be consolidate week line support mid march also dow unite technology muscle more destroy analyst first quarter sale earning target management increase range full year earning guidance shift mid point consensus view unite technology share have be trading tight week bottom month consolidation lockheed martin lmt angled report first quarter result earning revenue easily top expectation quarter company hoist full year earning outlook well consensus target lockheed share end monday bit more buy point week cup base software designer cadence system cdns bang premarket gain san jose calif company report strong first quarter beat broad increase second quarter full year guidance stock be january high monday close bell new oriental education technology edu chalk gain ahead tuesday open chain language test preparation center report earning gain rise revenue fiscal fourth quarter stock have be consolidate mid january end monday january high new oriental peer tal education tal jump tuesday premarket session lead ibd list premarket trading tal report fourth quarter result thursday stock be work sixth week possible cup base pattern earning news ibd stock casa system casa drop nearly premarket action company late monday announce share stock offer stock be sixth week consolidation mid march high trading december ipo price be interested big picture stock index struggle cross key levelwill stock market rally continue watch lockheed wynn buy point earning due action plan
20,LLY,analyst weren surprised wednesday dow merck mrk terminate late stage study potential alzheimer disease drug argue win have implication biogen biib announce expansion key alzheimer trial biogen share fall anyway late wednesday share slide much biogen announce enroll more patient original recruitment plan phase aducanumab trial enrollment be still expect be complete mid leerink analyst geoffrey porge write note client biogen news follow merck decision late tuesday scrap study drug call verubecestat patient early stage alzheimer disease verubecestat be know bace inhibitor aim prevent buildup amyloid plaque brain associate alzheimer context merck recent disappointment merck bace inhibitor verubecestat biogen aducanumab be be now only handful alzheimer medicine still active pivotal trial porge say merck halter late stage trial verubecestat time last year investigator find have virtually chance work patient mild moderate alzheimer credit suisse analyst vamil divan say failure be disappointment not surprising remain hopeful drug potentially show benefit give patient earlier course disease say note client now remove verubecestat revenue model divan cut price target merck keep outperform rating merck likely have seek merger big enough move needle market cap company annual sale north rest business be not strong enough allow growth be see oncology come say today news be not unexpected do believe add incremental pressure merck pursue business development opportunity bring additional growth driver mid late stage pipeline ibd take day move average be used pinpoint time opportunity risk stock head investor corner more tip smart stock buy selling tip evercore analyst umer raffat point failure alzheimer space be never good news other include biogen eisai eli lilly lly astrazeneca azn novartis nvs dow johnson johnson jnj be also work bace inhibitor biogen aducanumab work differently bace inhibitor aim remove plaque buildup brain analyst be particularly hopeful prospect aducanumab look actual amount amyloid plaque reduction bace inhibitor dramatically less biogen see aducanumab raffat say report plaque reduction aducanumab be far most important thing go biogen favor rbc analyst brian abraham be more bullish aducanumab biogen eisai bace inhibitor elenbecestat aducanumab also target beta amyloid not necessarily make direct read through failure bace inhibitor beta amyloid target monoclonal antibody say believe unknown beta amyloid hypothesis be already baked biogen share stock market today biogen tumble close merck be unchanged related biotechs spring back market correction analystbiotech investor flee drove market correction rock biotech stock rocket immuno oncology tie bristol
21,LLY,teva pharmaceutical teva jump monday grab upgrade price target boost restructure plan look more reasonable analyst say credit suisse analyst vamil divan upgrade teva outperform rating neutral raise price target last week teva update investor plan include new organizational structure cut workforce firm be also close plant plan announce closure end also examine portfolio cut specialty program year end teva expect achieve least half spending cut have plan now have more detail plan include outlook believe be achievable be see sign early execution plan be take additional step upgrading teva share divan say note client close bell stock market today teva pop finish guidance sale year include potential impact generic version teva multiple sclerosis drug copaxone milligram teva say earning conference call first quarter be strongest ibd take teva be trading line day move average do line mean be risk head investor corner closer look used day move average pinpoint opportunity risk mylan myl already have approval copaxone copycat dr reddy laboratory rdy be delay generic momenta pharmaceutical mnta novartis nvs sandoz unit have generic market year analyst say copaxone be bright spot fourth quarter divan say revenue decline hold better expect assume second generic enter market first half see rapid sale erosion delay teva migraine drug be new negative be expect divan say class drug call cgrp inhibitor teva be rivale amgen amgn eli lilly lly aldr believe migraine market be large enough multiple blockbuster even teva be third fourth market say generic be likely continue face challenge pricing pressure acceleration food drug administration approval compete generic difficulty acquire share drug originator say divan expect generic sale decline then face single digit decline however here well believe expectation enter be more reasonable have be past provide opportunity company meet beat expectation move forward say related regeneron benefit lackluster datum present rivalscan crispr small biotechs cure diseasesthese biotechs spring back market correction analyst
22,LLY,veeva system veev be coil spring ready jump thank several growth initiative xthat contention canaccord genuity analyst richard davis say veeva stock have have mighty run so far add cloud compute firm focus software application pharmaceutical life science field have room further growth used term coil spring describe veeva outlook davis say future look even more prosperous come view veeva have several growth initiative process range significant new feature upsell adjacent customer breadth move davis say recent note client pleasanton calif base veeva have more customer life science industry range big pharma firm emerge biotechs count company amgen amgn eli lilly lly merck mrk novartis nvs pfizer pfe customer veeva go public october share hit time high march manage avoid most carnage week sell share be friday veeva stock break week consolidation period buy point feb day company post better expect result fiscal fourth quarter give guidance crushed wall street estimate current fiscal year current fiscal year end next jan veeva expect earn adjust share year year sale base midpoint guidance analyst be modele adjust profit share sale veeva growth initiative be likely reach sufficient scale year provide path upside estimate davis say scenario be correct investor figure sometime summer fall point veeva share sustainably move higher say davis rate veeva stock buy veeva begin software application help pharmaceutical sale rep organize drug datum make stronger doctor pitch today product customer relationship management call veeva crm dominate drug market roughly user share now part veeva commercial cloud business big driver company business today be veeva vault launch be create organize content involved clinical drug trial document patient datum work flow vault product now cover clinical quality regulatory commercial aspect drug development manufacturing sale have penetrate less market william blair analyst bhavan suri tell investor business daily veeva also have discover vault offer be useful other heavily regulate industry such chemical consumer product sector company offer company outside life science be call vault qualityone have more company used product launch year get newsletter deliver inbox more info product service privacy policy term useon conference call analyst feb veeva chief executive peter gassner say company have be planting seed future growth especially exciting see franchise re build side life science say veeva be uniquely position help streamline drug development re only technology provider best class application suite major area development include clinical quality regulatory come next year safety single modern cloud platform believe veeva development cloud be industry long term veeva software service offer have be replace legacy vendor use premise hardware software system rival include oracle orcl medidata solution mdso iqv other veeva management have strong track record deliver growth be conservative guidance william blair suri say rate veeva stock outperform veeva have forecast revenue run rate fourth quarter think hit run rate early next year month ahead expectation suri say not only hit dollar run rate early next year sustainability growth be next year meanwhile jpmorgan downgrade veeva stock overweight neutral march cite valuation concern stock have climb year be strong franchise be execute well number growth initiative have little room outperformance current level jpmorgan analyst sterling auty say note client estimate veeva addressable market fraction more spend year life science company information technology fertile market provide greater growth subscription revenue fiscal grow fiscal auty say related veeva rocket top quarterly estimate crush guidance viewsceo gassner make sure veeva have second act more
23,LLY,dozen drug launch heavy hitter roche rhhby gilead science gild johnson johnson jnj be expect reach blockbuster status end analytic firm say clarivate analytic describe year blockbuster drug have launch be expect launch eventually bring north sale year period biggest number clarivate begin make forecast set be exciting year see valuable addition exist treatment well disruption certain market first class treatment option disease firm say report issue late thursday end drug roche gilead nordisk nvo be expect top annual sale remain likely account year revenue analyst say get newsletter deliver inbox more info product service privacy policy term be diabetes drug food drug administration approve medicine derive cannabis plant first series drug expect prevent migraine patient dozen drug be project collectively top sale roche hemlibra treatment patient hemophilia top list be expect generate north sale only hemophilia patient world roughly eligible hemlibra treatment cost first year year drug be approve month early launch december sale be forecast drug set reach blockbuster status forecast hemlibra be expect take share shire shpg feiba nordisk novoseven hemlibra also compete bioverativ bivv eloctate shire advate eloctate be forecast be blockbuster advate continue be market leader estimate sale however advate sale be forecast decline further thereafter clarivate report say gilead biktarvy grab approval february target estimate person globally live hiv be receive antiretroviral therapy suppress viral replication allow immune system strengthen biktarvy add gilead hiv franchise have long rivale glaxosmithkline gsk have trade market share gilead first enter market atripla gilead hiv drug be featured clarivate drug watch report biktarvy become blockbuster generate sale spiking decline report say trajectory be similar gsk drug triumeq be expect bring year year launch round top nordisk get approval diabetes drug ozempic december drug help stimulate body own insulin release limit much sugar get blood liver slow quickly food leave stomach ozempic be expect become blockbuster revenue way immuno oncology treatment novartis nvs gilead grab headline ability revolutionize treatment disease report say more half drug potential blockbuster list be cancer therapy just drug list expect blockbuster be cancer treatment erleada product dow jone component johnson johnson be approve february treat castration resistant prostate cancer hasn spread body fellow dow jone component pfizer pfe have drug treat same cancer once spread zytiga xtandi battle expand market share include market patient metastatic disease second generation oral androgen erleada become first approve set mid february clarivate say drug be project bring rise also be expand treat other form prostate cancer combination zytiga contribute blockbuster potential gsk shingle vaccine call shingrix rare disease drug alnylam pharmaceutical alny know patisiran be expect join blockbuster list sale respectively revenue be expect hit respective gw pharmaceutical gwph be expect grab approval summer first cannabidiol drug derive cannabis plant treat patient seizure disorder drug call epidiolex be expect generate sale approve epidiolex likely encounter bureaucratic barrier distribution political hurdle associate cannabis derive medicine particularly strict guideline use medicinal cannabis exist report say biotech isn alone market cara pharmaceutical cara insys therapeutic insy zynerba pharmaceutical zyne be also work treatment base cannabis plant migraine drug amgen amgn novartis aimovig be project bring sale spiking sale drug other seek prevent migraine block specific peptide group amino acid approve aimovig be first drug know cgrp market ahead teva pharmaceutical teva aldr eli lilly lly allergan agn also be work area first class mover advantage be crucial aimovig competition other subcutaneously administer monoclonal antibody target cgrp be not far clarivate say lilly teva file fda approval drug late last year meanwhile be phase testing drug analyst be worry falter submit application fda co founder randall schatzman unexpectedly step chief executive role tuesday other area shire lanadelumab treatment swell disorder be forecast bring next be abbvie abbv elagolix treatment painful symptom associate menstruation round list pfizer merck mrk diabetes drug steglatro indivior opioid dependence drug sublocade be forecast become blockbuster sale respectively related chart read basic buy point mark time real much money do need start investing build long term profit stock take many gain
24,LLY,nordisk nvo slip tuesday medicine lower metric associate diabetes fail significantly outmatch eli lilly lly rival drug term weight loss specific time point study pit drug semaglutide lilly drug call jardiance patient type diabetes semaglutide outperformed jardiance lower glycate hemoglobin week time difference weight loss drug wasn significant stock market today share topple close same time lilly stock also dip broadly share pharmaceutical company inched get newsletter deliver inbox more info product service privacy policy term usespecifically patient receive milligram semaglutide daily experience improvement glycate hemoglobin week week respectively compare respective improvement milligram jardiance weight loss week week semaglutide be pound pound respectively jardiance patient experience weight loss pound time point weight loss be statistically significant week semaglutide be very excited result demonstrate person treat milligram oral semaglutide year achieve statistically significant reduction blood glucose body weight compare person treat milligram jardiance chief science officer mad thomsen say prepared statement semaglutide be well tolerate safe belong class call glp base therapy most common side effect semaglutide be mild moderate nausea diminish time related chart read basic buy point mark time real best stock buy watch start buy stock ahead earning report
25,LLY,biotech investor turn cheek tuesday president donald trump again vow monday cut prescription drug price analyst suggest policy likely have little impact seem investor be now used trump commentary rbc analyst say report client trump have lambaste drugmaker get away murder hasn do much yet bring price still analyst say rhetoric be term drag group midday trading stock market today biotech stock collectively sank share group have close red past trading day thus far biotech stock be broadly drug pricing rhetoric have return be likely persist investor tolerance have increase believe have negative impact sentiment clarity be provide potential change be enact term say get newsletter deliver inbox more info product service privacy policy term usetrump comment come speech monday opioid epidemic promise be tough drug crime wide range talk also touch prescription drug price president renew pledge lower ll be see drug price fall very substantially not so distant future say go be beautiful health human service secretary alex azar former eli lilly lly executive touch briefly detail plan include change discount middleman pharmacy benefit manager receive azar also note action administration have take thus far curb drug price include encourage quicker food drug administration approval generic drug move reduce pocket cost senior federal action so far close medicare coverage gap often call donut hole have have minimal impact drugmaker analyst say state policymaker target pricing transparency price increase many proposal be face court challenge unlikely be draconian change change be low impact measure rbc analyst say lack further detail be overhang sector policy be release related much volume look stock long term retirement investing strategy etfsstill rule stock investor always cut loss short
26,LLY,migraine prevention treatment eli lilly lly face battle amgen amgn late thursday have strong result long term study approve medicine amgen lilly have migraine prevention drug call cgrps drug work block specific peptide associate migraine amgen drug aimovig grab approval lilly be fast approach approval likely september allergan agn botox be well know treatment wrinkle facial line have other used excessive sweat urinary incontinence prevent migraine wednesday lilly show drug call emgality benefit patient botox didn prevent migraine rbc capital market analyst kennen mackay doesn expect study substantially impact position marketplace get newsletter deliver inbox more info product service privacy policy term use do find post botox analysis provide unique perspective marketing point emgality physician have establish familiarity botox estimate patient step botox cgrp therapy say report stock market today lilly advanced close bell amgen sank share pharmaceutical biotech company rise fraction late wednesday lilly say emgality benefit patient botox didn work prevent migraine lilly test cgrp milligram milligram dose patient fail botox migraine prevention treatment average respectively see migraine day month cut half datum be compelling give botox be commonly used agent prophylactic treatment paradigm migraine potentially be require step therapy prior treatment cgrp class rbc mackay say lilly continue face battle amgen mackay say official approve aimovig drug already have establish safety effectiveness profile also beat rival lilly teva pharmaceutical teva aldr market expect aimovig continue benefit first market status say mackay doesn expect aimovig completely fill revenue hole amgen face grow list challenge legacy product notably amgen drug be face potential competition biosimilar nearly identical drug further amgen partner novartis nvs aimovig meaning have share sale amgen be more bullish biotech release result wednesday survey patient experience least migraine month respondent say miss least week work month due migraine effective migraine prevention help ease estimate annually economic cost amgen say half be due lose productivity additional datum show patient be often reluctant admit suffering migraine suggest already extremely large market see potential upside incident prevalent population estimate medical literature well number underpinning assumption model mackay say mackay estimate be chronic episodic migraine patient however potential migraine market be significantly larger vs establish literature see amgen base business erosion create significant challenge revenue hole fill especially give aimovig revenue be share partner novartis say late thursday amgen say aimovig be test year chronic migraine patient biotech also take interim look datum year ongoing year study episodic migraine patient researcher test patient dose milligram milligram average patient see migraine day month decline respective day day monthly migraine day decline half patient respectively day also drop quarters patient respectively just patient milligram dose patient milligram dose have migraine day datum show sustain effectiveness consistent safety tolerability aimovig extend period time be important migraine patient clinician know stewart tepper professor neurology geisel school medicine dartmouth medical school say prepared statement related chart read basic buy point mark time real trade stock most penny stock fail make investor richsell take profit hold here be several guideline follow
27,LLY,kris bakowski be diagnosed alzheimer disease georgia resident feel relieve finally put name fog be slowly envelop brain even be viable alzheimer treatment month forget own phone number have trouble colleague name mapping route home work become chore day find alone mall recollection be get biopharma company believe be able help soon analyst say biogen biib be first crack code disease modify alzheimer treatment slow disease progression indeed biogen tokyo base eisai announce late thursday phase test alzheimer drug slow progression disease month news send biogen stock soar more point friday novartis nvs roche rhhby amgen amgn other also be develop potential alzheimer drug number development stage biotech company victory be not certain number big pharma company include merck mrk eli lilly lly johnson johnson jnj have be road abandon plan alzheimer treatment least expert see success next decade wouldn come too soon bakowski other alzheimer patient get newsletter deliver inbox more info product service privacy policy term usebakowski now have be blog alzheimer experience year blog post alzheimer association describe month testing lead diagnosis subsequent relief hopeful cure son lifetime family isn so optimistic husband liken titanic ship be sink son be go survive wasn write son reflect be mother be death row innocent crime potential alzheimer market be massive estimate american be live alzheimer other form dementia way intervene alzheimer association expect cost care person disease hit today dollar be estimate bakowski many expert be hopeful privately hold proclara bioscience be cadre biotech company aim develop alzheimer treatment chief medical officer david michelson call field pretty vibrant michelson have hold position merck lilly say steady drumbeat bad news alzheimer treatment reflect not so much failure affect specific target brain issue such side effect specific test recently speak webinar host endpoint news lot really tremendous work ongoing enable new approach be become possible generate promising new target say be actually very hopeful optimistic next year hold research alzheimer several drug have be approve treat dementia alzheimer type include eisai namenda allergan agn treat symptom alzheimer disease neither cure disease elliot goldstein chief executive promis neurosciences count type treatment hand none slow progression disease tell investor business daily promis be also work alzheimer treatment trade toronto stock exchange doesn have sale earning yet goldstein previously work novartis be also develop alzheimer drug biogen strongest hope be drug now dub aducanumab goldstein predict drug come market aducanumab have high potential approval have show small improvement decline patient alzheimer symptom say biogen do not respond request comment article visit ibd stock checkup see biogen rate now key fundamental technical metric total biogen have potential alzheimer treatment pipeline aducanumab be farthest late stage study likely have datum analyst say biogen eisai thursday announcement involved drug know ban test involved patient diagnosed early alzheimer company say drug antibody achieve statistical significance key predefined endpoint evaluate effectiveness month biogen stock jump close have surge intraday high gain point still messy field biogen stock plunge valentine day year add new patient ongoing study aducanumab move catch investor guard also week merck scrap late stage alzheimer treatment study risk look likely outweigh benefit be volatile area canaccord analyst sumant kulkarni tell investor business daily have be very spectacular failure past component investor think next work help stock point view then again say nothing else have work past trouble alzheimer treatment research be scientist aren exactly sure cause disease prevailing theory ty disease buildup toxic plaque brain happen protein call beta amyloid structurally change beta amyloid be sticky clump together become plaque pharmaceutical company be look approach beta amyloid essentially boil remove prevent bace inhibitor work prevent buildup monoclonal antibody biogen aducanumab aim remove promis goldstein note adverse event also be sidestep alzheimer treatment come side effect know amyloid related imaging abnormality aria refer swell brain goldstein say promis alzheimer treatment set begin clinical study doesn cause mizuho analyst salim sy say possible help patient get past aria common idiom industry be don get aria be really treat plaque tell ibd then trouble determine study be design well proclara michelson say first evidence show drug engage intend target beta amyloid second patient be proven actually have alzheimer third study be big appropriate duration turn look back history aren many study many drug have be study way really fulfill element say argue only study have hit design goal be merck now fail bace inhibitor know verubecestat biogen aducanumab february merck scrap study alzheimer treatment patient prodromal very early stage alzheimer disease year earlier say same drug have virtually chance find positive effect patient mild moderate form disease meanwhile field be thin stop midstage test bace inhibitor group patient liver safety concern january pfizer pfe stop research alzheimer parkinson disease lilly alzheimer treatment failure late be acutely painful company monoclonal antibody call solanezumab lose late stage study last study be patient mild form alzheimer promis alzheimer treatment bound several toxic misfold protein cause alzheimer goldstein say function theory be other target alzheimer disease outside beta amyloid drug be also testing theory tangle protein call tau be root cause privately hold unite neurosciences hope come vaccine alzheimer goal be use drug treatment early alzheimer preventive measure physician administer drug too late rescue brain unite neurosciences chief medical officer ajay verma tell investor business daily verma background be biogen direct development drug include aducanumab be merck novartis verma expect aducanumab get approval several sell side analyst model likelihood aducanumab appease food drug administration verma see possibility aducanumab be expensive be first treatment slow progression alzheimer disease think challenge be be solution just rich say verma ultimately expect solution treat alzheimer disease lie combination drug be key treat cancer hiv cardiovascular disease metabolic disease high cholesterol say intervention number alzheimer patient triple james hendrix say endpoint news webinar hendrix be director global science initiative alzheimer association need better therapy need sooner rather later hendrix say alzheimer treatment study be tricky unite neurosciences verma say barrier blood brain make get drug brain difficult animal model aren particularly predictive study run long period time further complicate matter science isn sure stage be best treat reason be center approval rate fda alzheimer treatment accord paper present hendrix industry average be research be improve hendrix say scientist be aware potential impact beta amyloid tau well number approach target different stage end be enough alzheimer treatment just delay begin disease several year say be possible delay onset die something else say also stock market forecast next month build long term profit stock take gain robotic surgery revolution be just get term retirement investing strategy etfsnew option strategy limit risk earning
28,LLY,aldr stock gap friday rival teva pharmaceutical teva scrap late stage study cgrp migraine prevention drug chronic cluster headach close bell stock market today pop share teva dip fraction rival eli lilly lly rise fraction amgen amgn be first get migraine prevention drug market dip teva study fremanezumab chronic episodic cluster headach well long term safety study researcher find fremanezumab be unlikely work chronic cluster headach week treatment period end study fremanezumab belong class call cgrp drug aim block specific peptide associate migraine possible cgrp drug have other used teva spokesperson tushar shah say statement get newsletter deliver inbox more info product service privacy policy term use be disappoint outcome remain optimistic fremanezumab have clinical benefit additional condition migraine calcitonin gene related peptide play contributory role pathophysiology say amgen partner novartis nvs grab approval cgrp drug aimovig migraine prevention week end june aimovig prescription grow week week rbc analyst kennan mackay say note be testing drug eptinezumab preventive treatment episodic chronic migraine also have migraine prevention drug preclinical study lilly galcanezumab be review migraine prevention be also be study cluster headach meanwhile pharmaceutical bhvn have cgrp drug development acute treatment migraine also testing cgrp drug treat prevent migraine allergan agn too have cgrp development acute treatment migraine related chart read basic buy point mark time real much volume look stock investing basic sell stock
29,LLY,plunge share teva pharmaceutical teva weigh generic drug stock thursday sale profit continue drop offer weak guidance top word potential delay key migraine drug fourth quarter teva bring adjust profit cent share sale decline respectively sale multiple sclerosis drug copaxone decline grow generic competition year teva see adjust profit share sale lag consensus respectively teva outlook reflect likelihood increase challenge management note roughly half decline reflect impact loss exclusivity copaxone milligram piper jaffray analyst david amsellem say note client significant chunk decline also not surprisingly reflect continue pressure generic business close bell stock market today teva plunge close earlier fall much generic drug stock collectively dip analyst say rival mylan myl new copaxone generic be price discount teva brand drug dr reddy laboratory rdy be delay momenta pharmaceutical mnta novartis nvs unit sandoz have milligram generic market year pfizer pfe manufacturing facility pass re inspection generic drug sale fall year year teva record goodwill impairment related generic business pricing pressure government regulation accelerate generic approval delay launch continue be challenge sale be teva profit revenue top consensus analyst poll zack investment research adjust profit cent share sale copaxone sale also beat consensus view mizuho analyst irina koffler say note client still expect generic entrant mid ibd take teva relative strength rating have be rise month now have rs rating best possible see go rating visit ibd datum story further teva say manufacturer active pharmaceutical ingredient used migraine drug fremanezumab receive warning letter food drug administration regard fill finish part facility mean fremanezumab be delay fremanezumab be currently set go fda june drug belong class know cgrps aim prevent migraine aldr amgen amgn eli lilly lly be work drug class be source anxiety surround business simply afford have additional misstep particularly context highly competitive cgrp migraine space amsellem say related sanofi regeneron dip eczema drug dupixent lag crispr small biotechs cure disease biotechs spring back market correction analyst
30,LLY,best sector mutual fund last year thrive several area number fund winning ibd mutual fund award jump previous year year best sector mutual fund represent technology defense aerospace medium telecom health care retail top perform sector fund not only surpass past year be also top fund sector rank year performance accord morningstar sector mutual fund invest solely general industry such technology more specific industry internet company be great deal overlap sector example amazon com featured heavily featured sector fund technology retail medium other fang stock hold prominent role well component weighting fund dictate performance compare technology stock be year best performer institution flocked lead name fang stock sector rowe global technology prgtx be top fund technology sector come return more double return also trouncing tech heavy nasdaq return fund target potential winner specific technological theme cloud compute holding drive outperformance include big cap member salesforce com crm fang stock netflix nflx amazon com amzn position have be sell fund also see big gain chinese stock leader tencent tcehy alibaba baba get newsletter deliver inbox more info product service privacy policy term usea dec fund have nearly asset top holding be exhibit strong fundamental technical action new top holding include dynamic electric automaker tesla tsla broadcom avgo share tesla moved have be mostly stagnant september then stock have be trading sideway range meanwhile apple supplier broadcom fall victim slow iphone sale stock fall high early february stock be consolidate day move average line defense industry see strong gain president trump boost military spending blue chip stock defense leader boee ba pace advancer gain nearly fidelity select defense aerospace fsdax jump top holding include dow jone industrial name boee northrop grumman noc general dynamic gd boee northrop be extend recent buy point general dynamic hasn have same torrid advanced be flat base entry social medium have become major segment medium telecom sector company have larger social medium impact facebook fb rowe medium prmtx rise accord morningstar fund be bit different other sector fund communication category fund have several communication tower name american tower amt crown castle cci also look high growth company be disrupt industry amazon tower company have gain respectively such fund performance be drive top holding amazon com alibaba facebook sector not typically know large advance health care fund delaware healthcare dlhix put strong performance rise fund performance be drive position germany base morphosys advanced nearly be involved development research antibody foreign biotech be also fund biggest position end january top base position be ethical drugmaker eli lilly lly didn spark fund performance stock only rise last year retailer continue struggle amazon effect create winner loser sector obvious retail winner be commerce giant amazon fidelity select retail fsrpx deliver return due long term investment industry leader amazon whopping fund portfolio be tie commerce giant amazon home depot hd stock be paramount fund return again position remain big fidelity select retail fund have own amazon august accord morningstar home depot be first purchase august last year amazon run accounting large portion fund annual gain stock be trading high nearly most recent buy point flat base entry meantime home improvement retailer have solid advance retailer be drive higher solid consumer spending strong housing cycle share be consolidate day line also be interested read full ibd best mutual fund award reporthere list best mutual fund award winner categorybest mutual fund news performance report investing invest fidelity stock guru john rothwhich stock be best mutual fund buy selling fang stock news quote facebook amazon netflix google
31,LLY,eli lilly lly issue strong guidance early wednesday follow footstep abbvie abbv dow pfizer pfe improve tax rate earning expectation fourth quarter beat lilly call tax rate result lilly now see adjust income share grow vs sale be expect be lilly cite tax legislation improve tax rate outlook adjust earning sale guidance top view respectively lilly stock drop close stock market today collectively drug stock tumble day amazon amzn berkshire hathaway brka jpmorgan chase jpm pledge cut health care cost evercore analyst umer raffat note lilly animal health business disappoint sale food animal product decline widely miss expectation say report client miss stem lilly be face competitive pressure product used cattle milk supplement call posilac nonsteroidal growth stimulant call optaflexx ibd take lilly have ibd composite rating best possible meaning outperform stock term key growth metric head ibd stock checkup look other strong drug performer milk have be oversupplied market depress price raffat say production have be strong many customer be forgo posilac optaflexx be likely suffering rule china export trade deal meat contain optaflexx say outside animal health be very few miss leerink analyst seamus fernandez say note client sale plaque psoriasis drug taltz diabetes med humulin erectile dysfunction drug ciali lag consensus still total sale grow year year beat consensus adjust earning share increase top analyst view related dow pfizer tumble drug sector beat raiseamazon health care disruption fear clash realitygilead stock break abbvie earning here valeant climb month make sense biotech stock top bigger rival prevent migraine
32,LLY,valeant pharmaceutical vrx have climb hit low share tumble wednesday analyst suggest rise past month make sense believe movement be confluence factor have little do underlie factor have much more do perception surround liquidity bankruptcy risk piper jaffray analyst christopher raymond say note client short underlie dynamic mean valeant be still trouble say close bell stock market today valeant topple finish share have be run breaking cup handle base buy point late november month alone valeant be tuesday close short interest now stand compare high say be related fact valeant also have long term debt maturity have maturity respectively liquidity risk be likely table now say however do not mean dynamic surround business have change prescription volume valeant dermatology brand eye care legacy segment show decline respectively vs raymond say unit be face payer pressure loss exclusivity key drug further appear antibacterial xifaxan be mature say xifaxan be approve treat traveler diarrhea irritable bowel syndrome diarrhea hepatic encephalopathy condition occur patient liver dysfunction ibd take valeant have ibd composite rating best possible meaning outperform more stock term key growth metric still lag leader abbvie cr head ibd stock checkup look other top rate drug stock xifaxan account sale third quarter be likely earning interest taxe depreciation amortization raymond say mean gross margin be likely range pressure be xifaxan be most important revenue driver valeant raymond say require only small specialty salesforce reach community hospital setting such be topline driver continue demonstrate steady track record order anxiety regard liquidity bankruptcy risk not reemerge say xifaxan be also soon face competition cosmo pharmaceutical aemcolo cosmo be aim file approval aemcolo traveler diarrhea term enter market end year new launch valeant be enter glaucoma space vyzulta rival aerie pharmaceutical aeri rhopressa other player include dow stock pfizer pfe allergan agn novartis nvs competition be likely result wide spread gross net sale vyzulta valeant be also launch siliq treat plaque psoriasis physician feedback suggest go treatment drug class be novartis cosentyx eli lilly lly taltz do not believe be opportunity be significant enough drive sustainable ebitda growth say quite contrary continue believe loss exclusivity payer pressure continue be headwind raymond reiterate underperform rating price target valeant related novartis top high crush fourth quarter earningsabbott spike record top quarterly expectationswhy biotech stock outperform peer
33,LLY,aldr successfully compete larger rival amgen amgn eli lilly lly teva pharmaceutical teva prevent chronic migraine pair analyst say tuesday comment come wake result last week phase trial chronic migraine more patient see reduction day re afflict migraine company also say resolve patent dispute drug eptinezumab teva find equity financing be turn thing needham analyst danielle brill say note client have buy rating price target stock bullish note topple close stock market today share rocket day reveal result phase eptinezumab trial jan stock break cup formation buy point jan eptinezumab be be develop intravenous treatment prevent chronic migraine belong class drug call cgrps compete rival drug amgen lilly teva phase trial patient treat eptinezumab have migraine month third patient achieve greater reduction migraine day baseline month see migraine day cut least half time believe datum also showcased intravenous eptinezumab differentiate profile brill say rapidity onset magnitude benefit intravenous eptinezumab be clearly distinguish subcutaneous injection competitor datum ibd take stock rise ibd relative strength rating best possible last week have fall visit ibd datum story go rs rating prompt spike specialist cite credit suisse analyst vamil divan prefer intravenous route eptinezumab lead regular office visit patient monitor progress ensure proper compliance therapy be likely be fourth market cgrp divan say note client analyst have worry put disadvantage larger rival needham brill divan see eptinezumab differentiate still rival face same insurer obstacle competition likely less costly treatment allergan agn botox say botox sale come use chronic migraine base cost novel therapy be possible payer push patient try older label therapy well botox patient be give access cgrp antibody divan say time assume new patient patient be not have satisfactory response botox move cgrp antibody share teva dove close lilly dip finish amgen lose be fraction close related amgen have edge rival prevent cruise upgrade drugmaker miss boatwhy biotech suffer day headache rare disease trial
34,LLY,year be shape be boisterous biotech acquisition celgene celg sanofi sny matter day announce plan spend north take company analyst say celgene sanofi particular be face challenge area insurance company be push back payment rheumatology diabetes also leave like novartis nvo eli lilly lly trouble say brad loncar manage immunotherapy base fund company have buy growth loncar tell investor business daily ve be grow revenue do artificial thing drug price increase tax inversion kind other type financial engineering thing be go away be spend biotech deal mizuho analyst salim sy tell ibd year so far celgene have say spend buy remainder juno therapeutic juno doesn already own sanofi be spending acquire bioverativ bivv ablynx ablx company haven buy anything just matter opportunity sy say buy spree kick august gilead science gild announce plan acquire cancer play kite pharma gilead have be suffering major slowdown hepatitis drug sale high cure rate saturation europe celgene sanofi announce plan acquire juno bioverativ same day january day later sanofi say buy rare disease drugmaker ablynx celgene acquisition follow disappointing third quarter sale psoriatic arthritis plaque psoriasis drug otezla widely miss expectation biotech also cut guidance otezla shortfall terminate several trial crohn disease loncar describe celgene long term growth prospect time bleak picture also face patent cliff mid cancer drug revlimid ibd take challenge hold stock market correction decline help share form new potential base be still possible capture big gain head investor corner tip make gain correction so really couldn afford say sanofi other hand be skunked twice try acquire medivation actelion pharma dow component pfizer pfe beat sanofi medivation dow johnson johnson jnj be able acquire actelion sanofi roy behren fund manager capital management say sanofi commit acquisition make hostile bid medivation go back initially higher bid actelion filing show hostile approach be generally unsuccessful space fact scientist be such important part value equation tell ibd case sanofi medivation couldn arrive price be friendly be very difficult complete acquisition high profile acquisition late early acquirer have suffer pressure sale key moneymaker tax reform allow company pay less corporate taxe repatriate cash lower rate prime pump acquisition strong believer be go be huge year acquisition loncar say larger company growth be slow tax reform deal add fuel fire make easier do deal nordisk lose ablynx sanofi now loncar expect nordisk go other asset contend deep exposure diabetes market lilly too be see challenge diabetes meanwhile amgen amgn older drug be face new competition big company really need do say be outlier mizuho analyst sy say biogen biib instance guide flat sale multiple sclerosis unit include impact royalty get revenue roche rhhby new drug ocrevus perception franchise be dwindle say argument investor make lot guy biogen amgen base business be go away not necessarily case biogen be stable still flat sale win be enough pique investor interest biogen aducanumab potential treatment alzheimer disease be carrot investor clinical trial datum be available end early long carrot be become really difficult hedge fund community short stock say aducanumab produce return work large cap biotechs typically don see behren note biotechs seem be fairly interested immunotherapy oncology include gilead acquisition kite celgene plan acquire juno be work drug know car therapy immune system identify fight cancer have be lot activity oncology space term immunotherapy say larger company be try gobble promising technology still affordable be also see quite few testing company be acquire celgene acquisition juno follow common storyline behren say celgene invest juno create immunotherapy cancer autoimmune disease duo be furthest jcar potential treatment hodgkin lymphoma celgene pull trigger juno jan make sense be premium juno close price prior trading day biotechs even more high tech tend come significant premium trading price say re somewhat risky be huge payoff event re successful nektar therapeutic nktr bristol myer squibb bmy be similar plot september duo pair test nektar drug call nktr bristol opdivo patient melanoma kidney cancer lung cancer november nektar present strong early datum combo loncar peg nektar potential takeover target call nktr revolutionary day later bristol announce pay nektar upfront comprise cash purchase share test nktr opdivo opdivo yervoy deal allow bristol remain leader immuno oncology immuno oncology combination risk bid nektar evercore analyst umer raffat say feb note client have doubt nektar phone have be ring hook november datum be so interesting loncar say someone be bold enough buy put acquirer class own immuno oncology drug call parp inhibitor also look interesting loncar say clovis oncology clvs tesaro tsro have drug approve class be small enough acquire astrazeneca azn also work space sarepta therapeutic srpt neurocrine bioscience nbix biomarin pharmaceutical bmrn have also have successful launch recently company want revenue growth buy rare disease drug say have best sale ramp think type company be really interesting right now wouldn be surprised get buy related biotech investor flee drove market correction rock groupthese biotechs spring back market correction analystwhy biotech stock outperform peer
35,LLY,celgene celg vertex pharmaceutical vrtx incyte incy be worth watch broader market correction see biotech stock lose collective previous day analyst say tuesday biotech stock rebound stock market today diving monday bmo capital market analyst brian belski say note client investor be reap sow intent purpose majority client market pundit especially increasingly boisterous set naysayer have be predict bull market imminent demise day presidential election say doesn mean bull market be dead belski say rbc analyst brian abraham agree see opportune entry point certain biotechs stock datum approval expect thing be look celgene few misstep second half include major miss sale psoriatic arthritis drug otezla third quarter abraham say sale drug rebound fourth quarter believe market cap reduction more reflect believe fourth quarter number guidance point reassure stabilization key revlimid otezla sale say ibd take bull market be good time review stock selling smart once begin stall uptrend too late catch head investor corner brush stock selling rule cancer drug revlimid be celgene biggest drug analyst have worry generic rival take sale start contend celgene recently announce plan acquire remainder juno therapeutic juno didn already own add juno coffer put celgene car space compete novartis nvs gilead science gild latter acquisition kite pharma car therapy immune system identify fight cancer even juno celgene look poise generate enough cash flow buy back virtually entire enterprise value revlimid go completely generic abraham say outside abraham see number catalyst include additional datum revlimid treat lymphoma late stage datum drug partner acceleron pharma xlrn blood disorder celgene rise tuesday abraham say vertex be victim bad timing vertex recently report strong datum triple combination regimen cystic fibrosis datum come just broader market be begin turn stock fall hard past day vertex rebound tuesday rise strong effectiveness drug know vx vx triple regimen head phase study support likelihood vertex expand tough treat population cystic fibrosis patient say also enable multiple additional shot goal set bar be difficult match beat significant lead time likely render mid year competitive datum galapago glpg overhang vertex share much less impactful raise price target vertex macro weakness be mask improve fundamental abraham argue incyte be set read datum phase trial know echo first half study combine incyte immuno oncology drug epacadostat dow stock merck mrk keytruda late stage melanoma drug class know immuno oncology treatment epacadostat work block interaction involve ido enzyme immune system keytruda be call pd inhibitor have similar interaction pd protein instinet analyst christopher marai expect trial read positively be similar regimen bristol myer squibb bmy drug opdivo yervoy bristol be also combine drug treat other cancer include advanced lung cancer so epacadostat become part standard care metastatic melanoma broad adoption augment current pd use say note client lead peak worldwide sale north melanoma alone epacadostat rbc abraham say eventually nearly value epacadostat soon be go incyte share see share jakafi treat bone marrow disorder share olumiant rheumatoid arthritis drug co develop eli lilly lly suggest downside upcoming epacadostat datum be negative be now likely only share fundamental upside now potentially more say make upside downside level much more interesting incyte advanced tuesday related allergan pop consensus top quarter strong migraine biotech stock dive more be sell overdo crispr small biotechs cure disease
36,LLY,index other major average have first week be worst show year apple aapl guide lower many suspect amazon amzn boee ba deliver strong result facebook fb tout strong ad rate alibaba baba miss earning paypal pypl crash former parent ebay ebay moved cut ty move amazon jpmorgan chase jpm berkshire hathaway brkb team tackle health care cost hit insurer pharmacy benefit manager bitcoin meltdown continuedx hot start major average suffer worst weekly loss year dow nasdaq rise bond yield worldwide pressured stock unitedhealth unh cvs health cvs many other insurer fall amazon jpmorgan berkshire health care joint venture amazon boee facebook be earning winner alibaba be notable loser apple aapl do bitcoin plummet loss accelerate facebook joined chorus regulator worldwide crack cryptocurrency apple aapl earning share rise year year sale fiscal first quarter narrowly beat expectation apple sell iphone vs consensus unit average selling price due new iphone iphone model fuel overall result march quarter apple expect sale base midpoint guidance official estimate share fall friday new month low commerce leader report adjust earning share smash consensus big benefit tax cut help revenue rise also beating revenue amazon web service rise sale echo line smart speaker far exceed expectation amazon amzn say share gain hit new high intraday facebook fb report robust earning revenue growth top forecast user growth cool user time spend facebook fall even latest big news feed change executive say conference call ad rate be soar ease analyst revenue fear share hit record high thursday alphabet googl share fall google parent report adjust earning be share year earlier miss view traffic acquisition cost google pay partner website carry ad soar google expect rise tac moderate google rise tac have be link contract renewal apple well internet search shift mobile phone revenue rise top consensus adjust ep exclude impact tax reform result additional expense amazon jeff bezos jpmorgan jamie dimon berkshire warren buffett say new nonprofit company be aim reduce cost employee be successful own firm think be expand service corporate america health insurer pharmacy benefit manager sell unitedhealth largest health insurer also pbm sank drugstore pbm cvs health cvs be buy insurer aetna aet lose pure play pbm express script esrx retreat paypal pypl report strong earning line guidance former parent ebay ebay report line earning stronger expect gross merchandise volume real news be ebay stunned wall street news replace paypal handle payment own site partnership adyen move add revenue stream share ebay soar nearly thursday paypal lose week close buy point day line chinese commerce giant revenue soar best gain least quarters beating view earning share climb slightly miss forecast alibaba buy stake ant financial former unit run payment service alipay replace deal alibaba get ant financial pretax profit alibaba provide intellectual property not cash move clear hurdle possible ant financial ipo alibaba share week tumble recent buy point add job january better expect average hourly wage surge vs year earlier far view best ism manufacturing index continue point raid employment gain fast growth wage gain be good news spur federal reserve raise rate more aggressively year software leader report adjust earning share cent year year sale fiscal second quarter analyst expect cent microsoft get lift cloud compute business include azure office dynamic current quarter microsoft guide earning share cent sale view share hit record high intraday thursday amd amd broadcom avgo qorvo qrvo offer investor positive financial news amd beat wall street target december quarter guide estimate higher current quarter broadcom give preliminary sale earning guidance fiscal first quarter top view qorvo rocket disclose big contract major customer apple aapl next generation iphone qorvo deliver better expect result fiscal guide well wall street target current quarter boee ba report ep share exclude share benefit tax cut way boee beat analyst view revenue climb also top view boee also guide ep revenue forecast higher tax cut spur more investment make case new midmarket jet more compelling boee also get missile defense contract pentagon up up order new jet give venerable jumbo jet new lifeline meanwhile lockheed martin lmt ep jump revenue rise defense giant guide ep view higher boee share rise week lockheed hit new high video game publisher electronic art ea see stock surge record high report big gain online service associate sport game franchise fifa madden nfl boost live service be reveal part ea line december quarter earning report video game hardware software firm nintendo ntdoy post better expect december quarter result thank continue success switch console related software take interactive software announce major delay highly anticipate wild west action game red dead redemption now set release oct instead spring visa mastercard top analyst forecast person break plastic more often spend holiday visa also buyback follow american express axp just suspend buyback visa also hike quarterly cash dividend cent share homebuilder stock continue struggle even big builder report better expect earning prior week surprise miss nvr nvr housing demand price be strong concern be grow rise labor material cost mortgage rate low be rise america largest homebuilder horton dhi beat ep revenue wednesday share meet resistance day line pultegroup phm stock keep fall slide gross margin even earning sale top view smaller meritage home mth also beat smaller home mho holding mdc miss ep slew biotechs drugmaker report earning include pfizer pfe eli lilly lly vertex pharmaceutical vrtx astrazeneca azn merck mrk top wall street fourth quarter earning expectation pfizer come sale adjust profit cent share lilly total sale grow firm bring adjust income share vertex report sale adjust profit cent share astrazeneca report core earning share sale merck result be mixed top line miss view adjust income cent share beat cent amgen amgn report sale adjust earning share lag consensus merger news sanofi sny announce acquire ablynx ablx exxon mobil xom fall well short consensus fellow dow industrial component chevron cvx also miss ep view share plunge day line chevron undercut recent buy point separately crude production continue hit fresh longtime high crude supply rise first time week crude future remain year high ferrari race gap buy zone report strong earning thursday meanwhile auto sale slump january big decline ford fiat chrysler fcau gm gm sale edge higher miss view toyota tm sale sky-rocket strong truck sale
37,LLY,stock fought positive finish wednesday health care construction stock book day widest loss video game stock notch bevy breakout dow jone industrial average lead end boost boee ba monster advance heel glow result nasdaq composite rise struggle fractional gain market drop sharply fed et announcement committee hold target interest rate unchanged offer slightly more wary tone inflation day other economic news be positive early datum adp show january hire slip less expect december pending home sale chicago region manufacturing january gauge easily top expectation dow be hold back medical component merck mrk johnson johnson jnj pfizer pfe drop more drugmaker eli lilly lly tumble follow generally positive fourth quarter report drug sector investor be apparently still react tuesday news innovative health care partnership amazon com amzn berkshire hathaway brka jpmorgan jpm amazon advanced putt past buy point profit take zone other fang stock tech leader lose ground netflix nflx fall furthest nearly still extend early january tesla tsla rise average trade third gain session share be now more november low back support week move average climb right side possible month base pattern video game trade be day winner ninetendo ntdoy take interactive electronic art ea clear buy point add entry ninetendo trim gain afternoon trade remain just buy range cup base buy point electronic art pare advance hold buy range top buy point also cup base take chalk surge end very top buy range cup base buy point concrete aggregate supplier take session worst performance industry concrete uscr tumble more eagle material exp martin marietta mlm vulcan material vmc fall apiece eagle material post mixed fourth quarter report open reaction also have be link public private infrastructure cost sharing question raise president trump state union address ibd name telecom software developer casa system casa gain more soft trade stock be attempt start right side first base end jan high december ipo price argentina base bank grupo servielle supv also ibd name jump almost nearly average trade move technically place stock buy range rebound support week move average volume need kick next day so order confirm buy opportunity bottom ibd list mimedx group mdxg daqo new energy dq shed other important market news wednesday bring game apple amazon alphabet report action planbiggest homebuilder hit resistance earning sell don freeze double digit gain stock shrink fastlooking stock nvidia start list
38,LLY,camille callais be diagnosed spinal muscular atrophy neurologist tell parent nothing do be year biogen biib ionis pharmaceutical ion spinraza become first ever drug approve treat spinal muscular atrophy camille parent try supplement label use medication highly specialize diet
39,LLY,here weekly investing action plan need know investor come week tech sector heavyweight facebook fb apple aapl amazon amzn alphabet googl microsoft msft dominate come week earning news oil major exxon mobil xom chevron cvx also report
40,LLY,here weekly investing action plan need know investor come week earning season be here again give top company chance provide more detail tax cut recently sign law change guidance profit come year delta air line dal
41,LLY,european pharmaceutical firm astrazeneca azn nordisk nvo pull upgrade friday analyst look ahead key clinical trial readout ovarian cancer diabetes respectively astrazeneca rise stock market today nordisk dip fraction jpmorgan analyst james gordon upgrade astrazeneca overweight rating jpm richard vosser boost nordisk neutral rating astrazeneca medium term growth outlook be twice european pharma sector gordon write note client expect return topline growth new launch be key see core earning hit floor rise gordon be bearish year clinical trial testing combination immuno oncology drug advanced lung cancer july astrazeneca say regimen didn shrink tumor have pin hope trial dub mystic immuno oncology general now mystic trial be continue goal improve overall survival os bear key point be expectation mystic pfs progression free survival failure overly high base business divestment expectation say mystic pfs have fail low expectation os readout now see only modest downside astrazeneca be also set have datum trial drug lynparza first treatment form ovarian cancer rival clovis oncology clvs tesaro tsro gordon see high likelihood astrazeneca be successful trial be call solo ibd take large cap biotechs drugmaker suffer mount competition newer therapy generic rivalry theme be likely continue analyst say head ibd industry theme closer look trend mean bigger player gordon forecast astrazeneca achieve compound annual growth rate core earning share more twice sector market likely focus key product launch beat consensus view aggregate say expect sale lung cancer drug tagrisso top expectation forecast sale be achievable just half patient specific mutation receive therapy first treatment base much higher penetration comparable therapy competitor horizon think even own forecast prove conservative say outside assume price cut europe japan patient receive drug first treatment china expect eligible patient receive tagrisso assume similar price cut gordon expect sale immuno oncology drug imfinzi be line see lynparza treat ovarian cancer post small beat see downside long term drug astrazeneca be also launch calquence treatment mantle cell lymphoma only patient see term downside astrazeneca be also look drug chronic lymphocytic leukemia affect larger group patient fasenra be also recently approve monthly treatment form asthma drug rival glaxosmithkline gsk nucala be administer monthly likely regeneron pharmaceutical regn sanofi sny dupixent get approval treat asthma nordisk be story oral semaglutide vosser say oral semaglutide be be investigate phase trial dub pioneer treatment type diabetes oral semaglutide belong class drug know glp receptor agonist currently glp drug be only available injection nordisk look be first market oral glp oramed pharmaceutical ormp be also work oral glp drug far nordisk give see oral semaglutide datum live expectation don see pioneer program be source disappointment investor see market leave more difficult commercial question product clinical profile be nail clinical trial result vosser say note client nordisk be testing oral semaglutide vs own victoza dow stock merck mrk januvia eli lilly lly jardiance series trial related clovis good news ovarian cancer prod rival downtesaro take swipe astrazeneca ovarian cancer drug saleswhy tesaro cancer drug miss prompt rival topple
42,LLY,biotech amgen amgn have edge preventative migraine space compete teva pharmaceutical teva eli lilly lly aldr analyst say thursday late wednesday new england journal medicine publish safety datum drug know cgrps amgen teva drug aim inhibit neuropeptide have long be associate migraine pain share amgen close higher thursday rbc analyst kennen mackay expect amgen take cgrp migraine market value total opportunity amgen drug know erenumab have cleaner safety profile differentiate efficacy datum publication be previously know new safety datum amgen episodic teva chronic migraine trial suggest safety become more differentiate factor additional datum be fully present say liver toxicity remain clean amgen trial partner novartis nvs teva drug dub fremanezumab result slight liver test imbalance be explain other medicine take patient amgen see injection site reaction patient teva report reaction patient receive drug placebo be due teva requirement multiple injection higher injection volume needle size amgen have first mover advantage potential approval date teva be used priority review voucher potential approval date june lilly be expect enter market second half follow ibd take biotech behemoth struggle third quarter leave room small cap swipe headline street crush metric head industry snapshot breakdown third quarter play group payor block reimbursement patient begin continue cgrp therapy mackay say note amgen have extensive experience negotiating payor make highly competitive dynamic drug know triptan be consider reasonable first treatment option acute migraine still past payor policy favore sumatriptan first agent class go generic existence more effective costly brand drug pricier more efficacious agent be relegate patient be contraindicate have recently fail sumatriptan mackay say payor require continue proof benefit continue reimbursement cgrps mackay model patient suffer migraine include chronic migraine episodic migraine headach month estimate patient be see specialist classify cgrp therapy say ultimately view cgrp class penetrating patient market related medicine co be tumble dealteva restructure plan case be here do boston scientific again delay heart valve catch rival
43,LLY,roche rhhby be now real competitor potential first treatment advanced lung cancer analyst say monday drugmaker immuno oncology regimen hit goal phase trial xin early trading stock market today roche jump close run highest point mid october meanwhile share dow component merck mrk have rival combination drop finish top line datum show roche tecentriq combine cancer drug avastin chemotherapy provide statistically significant clinically meaningful reduction risk disease worsening death compare regimen avastin chemo further detail be provide upcoming medical conference december roche say overall survival datum aren mature yet be encourage expect first half firm say result be mixed bag merck merck receive accelerate approval use immuno oncology drug keytruda chemo treat advanced lung cancer keytruda tecentriq be immuno oncology drug respectively pd inhibitor pd inhibitor evidence have suggest drug work better population patient body make more protein call pd october merck pull application regimen europe delay key study combination move lead analyst question ongoing issue regimen merck stock dip month low worry ibd take big biotech player struggle third quarter smaller cap enjoy major sale beat lead exelixis exel neurocrine bioscience nbix top view nearly respectively read industry snapshot deeper dive third quarter roche trial help confirm theory immuno oncology chemo regimen succeed broad population patient advanced lung cancer regardless much protein body make leerink analyst seamus fernandez say not clear avastin have real benefit combination fernandez write note client avastin be approve first treatment form advanced lung cancer isn widely used isn well tolerate say avastin base regimen be used first treatment estimate lung cancer patient vs eli lilly lly drug alimta be used say merck discontinue pursuit avastin base regimen safety concern instead gain approval lilly drug result be more validation benefit immuno oncology chemo combination be most positive roche give tecentriq position model third perhaps even fourth player pd pd market sale say evercore analyst umer raffat agree note news solidify roche regimen real competitor treat advanced lung cancer related biotech just near year high strong cancer rival take chunk medtronic heart unit salesbiotechs sell drove be investor seek merger
44,LLY,franchise be safe large cap biotechs be feel pressure food drug administration speed approval rival brand generic medicine analyst say monday theme be continuation leerink analyst geoffrey porge say note client record number drug approval large cap sector fall favor investor name more punish concentrated product portfolio loom brand generic competitor say head management confidence be low revenue trajectory high profile product face slowdown courtesy payer competitive pressure porge doesn see uncertainty lift possibly not ever competitive pressure slug like celgene celg gilead science gild celgene be feel pain inflammation unit mount competition eli lilly lly novartis nvs gilead see rival hepatitis drug sale abbvie abbv early next year porge expect guidance lion share large cap biotechs be conservative most stock move guidance come alexion pharmaceutical alxn gilead predict alexion be work drug dub alxn treat pair rare blood disease also undergo restructure meanwhile gilead hepatitis franchise again come microscope even attempt pivot further hiv drug bictegravir believe be share value gilead stock hepatitis stock price move hepatitis revenue guidance meaningfully differ consensus estimate porge say ibd take small cap biotechs perform well third quarter large cap suffer mount competitive concern see translate stock price visit industry snapshot note abbvie plan hepatitis product be likely hurt gilead stock abbvie recently launch mavyret treat genotype hepatitis abbvie likely provide guidance fourth quarter call ahead gilead porge expect sale outlook celgene alexion vertex pharmaceutical vrtx gilead amgen amgn abbvie miss analyst estimate biogen biib provide outlook encompass analyst view say later year large cap universe face political pressure porge predict midyear congressional midterm election be underway campaign be likely renew focus pharmaceutical company pricing policy say continue favor stock company be structural demand growth story product protected commercial scientific clinical legal barrier entry top pick be vertex alexion leerink analyst michael schmidt peg clovis oncology clvs puma biotechnology pbyi top pick small midsize biotechs focuse treat cancer group stock have outperformed broader biotech market thus far schmidt write note client dynamic be set continue favorable regulatory environment large cap expand portfolio acquisition incyte incy seattle generic sgen exelixis exel clovis agio pharmaceutical agio puma array biopharma arry be set launch key product count group set unveil pivotal trial result pending regulatory decision total firm emerge technology remain interest car therapy train patient immune cell fight cancer precision oncology have strong success immuno oncology combination cancer vaccine certain antibody have only be modest think next generation antibody drug conjugate be re emerge area interest represent clinically validate category significant room upside schmidt say antibody drug conjugate be antibody link cell kill agent antibody bound specific mark surface cancer cell immunogen imgn mersana therapeutic mrsn seattle be work area latter furthest say related big pharma biotech company be gird pricing knife fight teva restructure plan case be here do generic drug maker face pricing issue other pharmas don
45,LLY,invest disruptor advice wall street giant biotech company incumbent big pharma be brace get crushed more innovative cheaper new drug start continue analyst say generic drug approval be rise interesting new medicine be start take market share legacy maker medication consumer use frequently include big pharma biotech company blockbuster drug represent estimate annual sale be set lose patent protection next decade analyst say disruption come generic drug innovative new biologic alternative come market be brutal jmp security analyst mike king tell investor business daily be knife fight market cholesterol lower drug king expect amgen amgn regeneron pharmaceutical regn sanofi sny feel heat like esperion therapeutic espr medicine co mdco alnylam pharmaceutical alny meanwhile inflammatory treatment celgene celg otezla gain blockbuster status miss sale forecast wide cut third quarter analyst say newly approve drug treat same condition eli lilly lly novartis nvs be take market share gilead science gild be still feel pain mature hepatitis drug unit europe rapid pace gilead hepatitis sale decline be expect slow somewhat newer medicine abbvie abbv mavyret be likely swipe sale big pharma isn get help regulator food drug administration head scott gottlieb continue increase approval copycat drug stoke competition brand generic drug face new rival firm try undercut price big pharma company pfizer pfe be forefront feel sting generic take sale earlier month teva pharmaceutical teva be allow launch generic copy blockbuster erectile dysfunction drug viagra generic drug tend be cheaper brand counterpart viagra be pricey drug tablet accord accessrx pfizer lose exclusivity viagra canada europe worldwide sale fall today generic europe have slash price drug contain same active ingredient viagra generic version viagra cost third price canada viagra price also fall trend repeat generic market teva meanwhile be struggle debt end third quarter thursday teva announce plan cut workforce more quarter close several manufacturing facility suspend dividend ordinary share firm be also plan review generic drug portfolio most specifically change price discontinue product ibd take see giant biotechs fared vs smaller player third quarter visit industry snapshot hint quarter be classify alarm large cap biotech be trouble see more competition traditional moneymaker board spending prescription drug increase just person accord report express script esrx rise represent drop growth rate trend be likely continue fbb capital partner analyst mike bailey tell ibd credit gottlieb decline generic price gottlieb be run fda business allow cycle more approval more competition lower price center medicare medicaid service use tool influence pricing unlikely president trump use executive power enact sweeping drug pricing reform such allow medicare negotiate price enact pricing control bailey say wouldn expect major change trump administration pricing say think mechanically politically difficult get pricing law system politically more acceptable just get more generic drug approval jmp king count drug treat rheumatoid arthritis psoriatic arthritis crowd area drug class cost average prescription benefit increase utilization unit cost accord express script third quarter thing begin look dour like celgene miss expectation inflammation drug otezla lag be even sharper analyst suggest celgene be force take price concession celgene also cut guidance terminate trial drug treat crohn disease condition result chronic inflammation digestive tract now see inflammation immunology drug bring combine outlook issue biotech company big pharma need get realistic pricing competitive arena king say same be say company make treatment hepatitis multiple sclerosis high cholesterol be highly saturate market latter point expect price drug know pcsk inhibitor repatha amgen praluent regeneron sanofi be microscope drug lower bad ldl cholesterol blood evidence show also have benefit cardiovascular outcome repatha be list year praluent cost rival be close medicine co alnylam be work cholesterol drug know inclisiran meanwhile analyst expect bempedoic acid esperion be cheaper big pharma biotech company be probably go get arm twisted lot king say pricing umbrella have create opportunity new company come scale market share be careful own incumbent invest disruptor other area be seemingly immune pricing pressure analyst say price multiple sclerosis drug rise average continue trend fbb bailey say price increase have be so egregious house democrat launch investigation august note many drug carry price tag north year investigation be launch rep elijah cumming peter welch center bayer bayry biogen biib emd sereno novartis roche rhhby sanofi teva pharmaceutical biotech company teva milligram dose copaxone have increase most rise approval annual price today accord national multiple sclerosis society novartis gilenya approve be highest price investigation be year too late say more difficult push price control specialty market multiple sclerosis be massive market now stakeholder view specialty market rare disease innovative cancer therapy also seem immune pricing control analyst say example earlier year novartis gilead acquisition kite pharma gain approval car drug know kymriah yescarta respectively car drug be develop used patient own immune system cell be trained seek destroy cancer cell kymriah go year yescarta be list ark invest analyst manisha samy write recent post gene therapy be begin cure cancer come price cause sticker stock say say compare traditional therapy suppress do not cure cancer cost benefit analysis gene therapy be compelling pricing shock tend tamp excitement really compelling drug bailey say prime example be biogen ionis pharmaceutical ion spinraza first spinal muscular atrophy drug approve cost first year subsequent year sentiment biotech company share be already say so drug pricing concern shouldn be big stock killer past biotech stock go quickly get new drug person be excited lot time someone throw grenade drug pricing bailey say sentiment be already even concern drug pricing see little less downside ibd company biotech industry group be now rank group track have fall first just month share collectively near year high october have shucked almost point same time amgen celgene biggest biotechs have see share price dive respectively regeneron have take hit gilead have tumble meanwhile alnylam esperion look likely rival psck inhibitor drugmaker amgen regeneron have lift respectively abbvie recently launch rival gilead hepatitis franchise be novartis lilly be compete celgene treat inflammatory condition have see share retreat smaller degree respectively share price be match dip ibd company ethical drug industry group generic drug stock rank group have actually broadly rise mid october respective dip teva mylan myl biggest name related teva restructure plan case be here do generic drug maker face pricing issue other pharmas don ttop biotech company innovation earn recognition new award
46,LLY,nektar therapeutic nktr rocket year high tuesday analyst initiate coverage biotech firm outperform rating ahead third quarter earning key presentation immuno oncology drug xat close bell stock market today nektar pop finish hit high last see june hour share jump nearly more approach level nektar used technology call pegylation create drug pegylation improve drug solubility decrease ability provoke immune response body nektar have partner other firm number drug used pegylation cowen analyst chris shibutani see nektar uniquely position capitalize high value opportunity immuno oncology pain used pegylation technology see cancer drug know nktr possibly be transform nktr be be test bristol myer squibb bmy opdivo treatment tumor type potential disease datum combination trial melanoma kidney cancer be present society immunotherapy cancer meeting week immuno oncology refractory set optimism regard melanoma kidney cancer derive proprietary expert survey work consultant view shibutani say note client shibutani see nktr pull risk adjust revenue more upper end consensus expectation also expect sentiment improve drug know nktr potential treatment lower back pain nktr meet first second goal phase trial present drug be design provide pain relief high level euphoria associate abuse addiction standard opioid see potential sentiment improve nktr shibutani say debate novel chronic pain drug nktr center regulatory timeline drug enforcement agency scheduling ibd take nektar have ibd composite rating best possible meaning outperform just half stock term key growth metric still poorly rank biotech head ibd stock checkup look better rate biotech stock update ahead filing food drug administration well potential partnership announcement help reduce uncertainty nktr shibutani say also tuesday nektar present datum drug dub nktr potential treatment address underlie immune system imbalance patient number immune condition nktr be design target specific set receptor body stimulate proliferation immune system cell know regulatory cell help bring immune system back balance drug be used treat autoimmune condition nonhuman primate single dose nktr lead increase regulatory cell day accord datum nektar release tuesday mouse nktr prove efficient treat most common form lupus nektar partner eli lilly lly nktr july late tuesday nektar be expect release third quarter earning analyst call nektar report adjust income cent share sale earning grow cent loss year earlier period sale be related mallinckrodt dife sale lag earning top viewsteva survive price cut billionaire reportedly mull stakeis big pharma addict opioid painkiller
47,LLY,biogen biib eli lilly lly novartis nvs topple early tuesday beating analyst expectation third quarter biogen face pressure multiple sclerosis unit novartis delay strategic decision regard alcon eye unit xlilly close monday buy range novartis be just biogen meanwhile fall buy territory tuesday drop day move average biogen slide close beating top bottom line expectation spinal muscular atrophy drug spinraza fail meet expectation sale biogen partner ionis pharmaceutical ion also tumble hard fall recent action domestic sale spinraza come light lag rbc analyst brian abraham view worldwide however spinraza sale come beating most analyst view accord analyst leerink instinet biogen disclose be increase number spinraza patient compare ex launch be surpass initial trajectory leerink analyst geoffrey porge say note client commercial medicaid life now have access spinraza further complicate biogen result be sale core multiple sclerosis unit trail view lead drug tysabri porge say tysabri decline consensus ms drug sale exclude interferon fall nearly top seller tecfidera have yearly sale gain just consensus view rbc abraham say ibd take president donald trump enact executive order tug drug price day washington base expert say recently head ibd industry theme more mean biotech drug industry overall biogen earn share nearly revenue rise north exclude hemophilia business biogen spun february bioverativ bivv sale grow year year company say analyst have call biogen report revenue adjust earning share lilly fall finish stock market today announce plan potentially spin sell file initial public offer elanco animal health unit decision be expect mid lilly report adjust income share sale respective vs year earlier period metric top consensus analyst poll zack investment research adjust profit share sale sale beat come humalog new product basaglar jardiance animal health unit offset slight miss trulicity vs expectation loss exclusivity effient leerink analyst seamus fernandez say note client revenue diabetes drug humalog rise sale fellow diabetes drug basaglar jardiance increase triple digit percentage respectively taltz plaque psoriasis drug grow sale diabetes drug trulicity post yearly gain miss view firm also raise midpoint full year adjust earning share guidance cent rise year year basis lilly expect make decision regard initial public offer merger sale retention animal health unit elanco animal health middle sale unit rise novartis share slack close drugmaker beat third quarter expectation delay strategic decision regard alcon eye unit say want beef division first quarter novartis report revenue earning share vs year earlier period drugmaker post earning share sale analyst have see respectively swiss drug giant cosentyx approve treat plaque psoriasis rheumatoid arthritis rare form arthritis know ankylose spondylitis bring sale beating consensus leerink fernandez say note client entresto continue linear disappointing growth trajectory sale vs estimate consensus fernandez say entresto be approve treat patient chronic heart failure novartis business unit be expectation fernandez say sandoz segment surprised alcon deliver critically strong performance grow constant currency basis related allergan public relation backlash deepen weekbiogen biomarker mark way alzheimer parkinson treatmentsdoe gilead now have new multus dollar franchise
48,LLY,allergan agn be already face public relation backlash transfer patent right restasis eye medication native american tribe judge monday then invalidate patent xnow allergan face battle regain credibility wall street credit suisse analyst vamil divan write note client cut price target allergan keep outperform rating generally have be fan allergan management team find challenge defend step be take patent agreement write note client believe take time management team regain credibility have lose process process involved transfer right restasis patent st regis mohawk tribe september avoid patent challenge native american tribe st regis mohawk have sovereign immunity play have be call creative well controversial monday judge invalidate patent cover restasis judge william bryson say idea cover patent be too obvious protect also expressed serious concern regard legitimacy transfer st regis mohawk ibd take allergan have ibd composite rating best possible lag top player abbvie cr meaning perform top stock term key growth metric head ibd stock checkup look other high ranking drug stock even monday allergan stock have lose value follow agreement divan write loss district court also do nothing erase public relation backlash company have suffer go agreement first place combine push food drug administration approve generic drug faster clip divan assume generic launch restasis drug mid earlier view mylan myl teva pharmaceutical teva be work generic version drug longer term investor divan see attractive entry point stock short term catalyst include third quarter earning nov potential guidance update generic restasis competition guidance be not provide nov call least high level investor likely have january time frame company guidance divan say datum readout include late stage trial treat acute migraine midstage trial drug prevent migraine first half class drug call cgrps teva amgen amgn eli lilly lly aldr be also work arena close bell stock market today allergan slip close end monday trade related allergan tank judge invalidate restasis patentswhy allergan hepatitis drug likely win get fda approvalgeneric drug maker face pricing issue other pharmas don
49,LLY,eli lilly lly lay employee workforce free annually start massive restructure include close facility drugmaker say early thursday xin early trading stock market today lilly rise close thursday share begin form cup handle buy point late july lion share workforce cut stem voluntary early retirement program remain position come workplace reduction site closure lilly expect incur charge related retirement program severance cost facility closure lilly plan move animal health manufacturing facility larchwood iowa exist plant fort dodge iowa research development office bridgewater center shanghai china be close firm also consolidate work share service center total lilly expect save annually start workforce reduction facility closure be complete dec saving be funneled equally improve company cost structure reinvest business lilly say ibd take lilly have ibd composite rating meaning outperform quarters stock term key growth metric still lag drug leader abbvie have cr best possible head ibd stock checkup closer look top rate drug stock restructure come ahead expiration lilly patent erectile dysfunction drug ciali september ciali be also approve name adcirca treatment high blood pressure lung patent be set expire november meaning generic compete ciali be lilly second most important drug bring second quarter sale accounting total sale just diabetes drug humalog bring total revenue patent cover attention deficit hyperactivity disorder drug strattera expire strattera sale decline second quarter related biogen alzheimer drug show promise break big pharma face tough road upcoming drug trial lilly new formidable rival topple diabetes franchise
50,LLY,cytomx therapeutic ctmx flirted record high wednesday announce deal biotech amgen amgn develop immuno oncology drug have fewer toxic side effect xby close trading stock market today cytomx have rocket earlier rise much almost year high previous record be penny higher december share break cup begin form march entry point meanwhile broader biotech industry rise fraction group be rank second group ibd track amgen cytomx co develop latter call probody base drug probody therapeutic be meant bind selectively specific target tumor not healthy tissue minimize toxicity create safer cancer therapy accord cytomx drug target epidermal growth factor receptor protein egfr help immune system cell identify destroy cancer cell used cytomx probody technology help ensure immune system only target egfr protein tumor cell not healthy tissue ibd take amgen have ibd composite rating best possible meaning trade better stock term key growth metric still just ibd company biotech industry group head ibd stock checkup look other biotech leader egfr target drug be already market instinet analyst christopher marai say note client eli lilly lly erbitux be approve treat cancer head neck well colon be associate severe toxicity marai say boost price target cytomx stock keep buy rating note other datum roche support development drug solid tumor rather just blood cancer cytomx platform reduce immune related side effect toxicity say amgen pay cytomx upfront purchase cytomx common stock cytomx be eligible receive milestone payment amgen lead global commercial activity cytomx be able opt profit sharing receive tiered double digit royalty net product sale outside term deal amgen also receive exclusive worldwide right develop commercialize additional undisclosed target amgen pursue cytomx be eligible receive additional payment high single digit mid double digit royalty cytomx also receive right amgen undisclosed preclinical drug amgen be eligible receive milestone royalty result product develop commercialize program related biotech suffer day headache rare disease trialabbvie patent deal stave amgen competition other lurkwhy amgen drug send abbvie stock stratosphere
51,LLY,nasdaq composite index close week record high heaviest week earning season amazon amzn alphabet googl mmm caterpillar cat be big winner celgene celg boee ba baidu bidu be notable loser nasdaq composite have be week rally friday hit time high rise week amazon amzn alphabet googl microsoft msft surge friday earning apple aapl facebook fb hit buy point ahead earning next week index also rise new high friday week dow climb week hit record level earlier week celgene celg merck mrk several other biotech drug stock sell earning guidance week so do boee ba several defense giant treasury yield rise multimonth high solid economic datum european central bank voting taper bond buy president trump loom decision be next federal reserve chief amazon amzn share soar commerce leader report third quarter adjust earning share cent vs view cent revenue rise include whole food market acquisition amazon complete aug amazon web service revenue soar account well operate profit amazon soar hit record high related amazon blow past earning view beat sale share soargoogle parent alphabet googl vault time high internet giant profit smash estimate google say gaap earning be share year revenue jump top consensus estimate google traffic acquisition cost pay partner website carry ad rise alphabet say grow tac have be overhang google stock share rise friday record high back buy point related google shoot time high beating earning viewsboee ba take charge kc refueling tanker bring total cost overrun taxe taxe charge aerospace giant raise full year cash flow outlook full year core ep prior view ep midpoint be still analyst view boee ep fall top forecast revenue rise estimate boee share fall week related boee shake air force tanker cost outlook imply weak blue chip caterpillar cat mmm throttle earning estimate hike guidance make clear global economy have shift higher gear caterpillar earn share year cent ahead estimate revenue leap construction equipment firm earning guidance share be cent ahead prior estimate see broad growth industrial health care electronic energy segment beating ep cent say expect full year ep earlier outlook week caterpillar rise raise outlook strong earning dow stock gap highcaterpillar soar blowout earning raise martin lmt raise full year outlook earning revenue cut guidance sale aeronautic unit defense giant miss estimate northrop grumman noc also raise ep outlook report result wall street estimate global hawk maker announce wouldn submit bid navy unmanned tanker competition be see major player raytheon rtn report mixed result also raise full year ep outlook however raise guidance be still analyst consensus general dynamic gd quarterly result beat view lockheed raytheon general dynamic share fall northrop rally related lockheed grow leap bound sale slow northrop win bid navy drone contract result beat viewsraytheon report mixed result raise ep outlookbiogen biib slide tuesday beating top bottom line expectation sale spinraza lag view amgen amgn sarepta therapeutic srpt vertex pharmaceutical vrtx deliver board beat third quarter report late wednesday up sale guidance amgen sank sale top drug enbrel fall year year vertex say late stage cystic fibrosis trial fail celgene celg crash thursday revenue miss otezla sale lag consensus lead biotech cut sale guidance alexion pharmaceutical alxn fall weak sale gilead science gild top sale adjust earning view late thursday hepatitis drug sale decline third narrowly miss estimate big pharma giant merck mrk bristol myer squibb bmy novartis nvs eli lilly lly glaxosmithkline gsk fall follow earning report biotech firm top third quarter view only popscelgene result call alarm alexion bristol mixedgilead top sale profit view narrow miss hepatitis drugssoftware giant microsoft msft race past wall street target september quarter point sale view december quarter send stock record high territory friday day microsoft earn cent share year year sale fiscal first quarter analyst expect cent microsoft credit growth cloud compute business related microsoft top september quarter sale earning targetsinvestor cheer intel intc stm teradyne ter september quarter earning report jeered advanced micro device amd ultra clean holding uctt intel top wall street target third quarter sale earning guide analyst higher current quarter rival amd deliver better expect third quarter result disappoint guidance flat gross profit margin current quarter biggest loser be ultra clean plummet thursday mixed third quarter result related intel beat third quarter goal guide highergeneral motor gm ep fall revenue shrank broad slowdown car sale plan reduction fleet sale retreat certain european african asian market result crushed forecast ep revenue gm also guide full year earning consensus gm share have be rally investor see automaker combine strong profit now be lead pack autonomous drive electric car ford earning surge cent revenue rise automotive revenue top estimate ep cent revenue management narrow profit outlook remain consensus fiat chrysler fcau report mixed result china base school operator tal education tal fall short earning estimate penny report flat ep cent revenue climb enrollment more double outlook be line forecast fellow heavyweight new oriental education edu turn mixed result better expect guidance tal education plunge new oriental related china leader be flash long term sell signalsexxon mobil xom report ep rise cent revenue nearly expectation credit higher oil price production refinery margin fellow dow energy stock chevron cvx fall short earning send share friday recent buy point exxon rise friday crude future hit month high mcdonald mcd same store sale beat estimate help drink line signature craft sandwich see thinner margin invest training technology whopper deal burger king likely help comp owner restaurant brand qsr share reversed lower record high friday cost cut promotional switch boneless wing help buffalo wild wing bwld fly nearly thursday even sport bar chain contend elevated price traditional chicken wing question ceo transition chipotle grill cmg share crash concern sale recovery higher menu price next month plan slow new store addition next year visa fiscal fourth quarter result beat top bottom line help solid payment cross border volume strong show visa europe payment volume growth be strong country russia india australia come worry state retail mizuho analyst note mobile tmus sprint call earning call avoid discussion raise speculation merger announcement come november regulatory hurdle mobile add postpaid phone subscriber september quarter sprint add lose report flat profit revenue drop say expect purchase time warner twx close year end analyst say sell be related equity dilution expect twx deal be issue stock finance half deal side analyst say carrier include verizon vz have be restrain promotion soon be release high end apple aapl iphone improve margin december quarter cable tv firm comcast cmcsa charter chtr report higher video subscriber loss lower customer addition comcast have lower guidance early september send stock ahead earning charter stock fall disclose similar trend company aim hike price service video subscriber switch internet tv charter add customer vs estimate charter acquire time warner cable last year comcast add customer vs year earlier baidu bidu crushed third quarter earning estimate chinese search engine giant give weak guidance share plunge friday cisco system csco acquire broadsoft bsft maker communication software telecom company include debt share cisco pass buy ringcentral rng rival software firm fortinet ftnt sank friday maker computer security software forecast december quarter revenue expectation september quarter result beat view grubhub grub report third quarter earning beat estimate provide fourth quarter guidance also top view share surge week breaking buy point td ameritrade amtd top earning view gain revenue growth accelerate fourth straight quarter share online brokerage rise record high servicenow now report earning revenue top expectation billing growth disappoint share enterprise software provider fall earning release close week slightly higher earning call management indicated be strong start aid part few more deal closing normal be push december quarter whirlpool whr crash weak earning news sear longer sell appliance twitter twtr share soar week high better expect adjust earning rise monthly user forecast possible gaap profit
52,LLY,pharmaceutical bhvn continue day free fall tuesday rare disease drug fail trial prompt least analyst downgrade stock xby close bell stock market today plunge close come top drop monday session share fall hard morgan stanley analyst matthew harrison cut price target keep overweight rating note datum migraine trial expect be unveil first quarter send share mid tuesday investor be still reel phase phase datum drug treat degenerative disease brain drug trigriluzole fail improve impairment vs placebo patient disease know spinocerebellar ataxia week week treatment patient treat trigriluzole show improvement point vs improvement point patient placebo higher score indicate greater impairment harrison say placebo result be higher expect harrison write note client remove spinocerebellar ataxia model previously harrison have expect chance success program peak adjust sale ibd take medtech stock have broadly rise year concern drug pricing have send biotech pharma investor hill keep go head industry snapshot closer look setup medtech trigriluzole come call glutamate platform harrison still see other drug platform have chance success treat alzheimer disease rett syndrome al degenerative disease affect nerve cell brain spinal cord also be work migraine drug belong class know cgrps drug dub rimegepant be company primary valuation driver harrison say project peak sale amgen amgn eli lilly lly teva pharmaceutical teva aldr be also work drug class harrison see rimegepant have potential differentiate base safety efficiency phase testing related biotechs slump report suggest discounting biotech crash positive migraine drug testshow small biotech ruffle market migraine drug
53,LLY,here investing action plan tuesday need know investor come day xan earning tsunami hit lead big name such mcdonald mcd general motor gm caterpillar cat unite technology utx lockheed martin lmt just begin here be other company report tuesday
54,LLY,galapago glpg pop wednesday eczema drug compare favorably potential blockbuster dupixent regeneron pharmaceutical regn sanofi sny phase trial xin morning trading stock market today galapago jump close first day black day share break cup earlier month hit buy point galapago be partner morphosys drug know mor phase trial patient roughly treat highest dose see eczema symptom improve least week firm say news release result be maintain month last infusion patient treat placebo only achieve improvement symptom same time period mor now advance phase testing galapago say consider switch drug injection rbc analyst brian abraham note mor compare favorably approve drug call dupixent regeneron sanofi analyst have predict dupixent be blockbuster biopharma giant ibd take galapago be also work cystic fibrosis analyst say lag vertex pharmaceutical lead biotech aim eradicate cystic fibrosis know today head new america deep dive vertex triple pill approach lung disease dupixent combination topical corticosteroid help patient achieve improvement symptom least week accord trial datum drug label monotherapy dupixent achieve similar improvement patient abraham suggest mor also be used treat inflammatory bowel disorder be already treat drug novartis nvs eli lilly lly drug similar class mor be competitive mor need be injection related biotechs mend even glaxo back ionis dealvertex hit record high result cystic fibrosis trialvertex catapult strong trial cystic fibrosis
55,LLY,here weekly investing action plan need know investor come week upcoming week earning give investor much broader look corporate america economy stalwart tech industrial energy medical consumer sector weigh quarterly result such amazon com amzn alphabet ticker
56,LLY,array biopharma arry share be temporarily halter early friday shortly biotech unveil promising result phase trial colon cancer xby close trading stock market today array be highest point mid march array test show patient treat respond triple drug therapy used array binimetinib encorafenib erbitux drug eli lilly lly have be approve treat head neck cancer lion share patient have specific genetic mutation make colon cancer hard treat patient mutation have prior treatment respond triple drug mutation prior treatment respond ibd take september be make break month biotech sector accord industry observer head ibd industry theme see line potential datum make headline month patient be treat median month time analysis be still treatment array say medium severe side effect include nausea vomit urinary tract infection increase level specific enzyme blood array present result ahead presentation saturday european society medical oncology congress madrid spain biotech be also set discuss result phase trial melanoma patient same genetic mutation related biotech catch rally add abbvie chip away regeneron potential biotechs fall cancer partnership bristol myer
57,LLY,theravance biopharma tbph exelixis exel tick most acquisition box big pharma overview biotech merger picture analyst say friday acquisition biotech company pharma be important theme space needham analyst alan carr say note client believe late development stage commercial stage biotech company be particularly attractive acquisition target part due reduce risk company carr cover theravance attract big pharmas amgen amgn eli lilly lly teva pharmaceutical teva total carr count company be interested buy theravance base research area business development interest past acquisition theravance have approve drug antibiotic hard treat infection exelixis agio pharmaceutical agio bavarian nordic pharmaceutical bhvn progenic pharmaceutical pgnx be attract interest pharmaceutical apiece abbvie astrazeneca azn novartis nvs roche rhhby dow stock pfizer pfe johnson johnson jnj be most acquisitive base carr criterium have least potential target biotechs stand better chance be acquire vs other carr say january have be acquisition public biotech company involve payment more upfront more half already have approve drug have least phase datum carr write oncology be key target japanese pharmas rare disease play be likely be acquire later stage ibd take last month potential acquisition target jump ibd relative strength rating best possible today still have rating head ibd datum story closer look stock catalyst rare disease tend be interest mid specialty pharmas biotechs traditional drugmaker be likely avoid drug pricing controversy january only rare disease firm snatch be actelion pharmaceutical european pharma acquire more later stage biotechs vs less risk adverse japanese pharmas allergan agn big area interest include central nervous system rare disease oncology account acquisition respectively january have be new chemical entry approval food drug administration small midsize biotechs gain type approval have be acquire already have drug market time acquisition many oncology company few rare disease company be acquire say gilead science gild acquisition kite pharma kite break approval rule gilead announce plan spend buy kite month ahead expect approval date first drug blood cancer novartis rival treatment be approve day later related small biotech launch month high today here whyexelixi recover bristol inspire pitfall kidney cancerbristol dife still have chance kidney cancer analyst
58,LLY,biogen biib stock jump near buy point monday alzheimer disease treatment show promise year year mark close bell stock market today biogen share climb rise much hit intraday high share be consolidate buy point haven top early march common theory ty alzheimer buildup plaque deposit brain call beta amyloid biogen be work drug reduce amyloid deposit last year eli lilly lly amyloid drug fail prove theory ibd take biogen have ibd composite rating meaning outperform stock term key growth metric still trail top rate biotech celgene celg have best possible cr head ibd stock checkup other highly rate biotechs biogen be close prove hypothesis scan show amyloid reduction be consistent patient treat adjust dose compare fix dose year patient treat year show continue benefit rate amyloid decline phase long term trial most common side effect be headache fall abnormality amyloid related imaging biogen say firm plan share more datum upcoming medical congress related shire near year low cfo announce plan jump shipbiogen teva slip democrat launch ms drug pricing probebiogen alzheimer drug be ms worry overblown
59,LLY,eli lilly lly stock drop week low thursday diabetes drug trulicity prove less effective head head comparison nordisk nvo rival medication semaglutide close bell stock market today lilly be slip close result put potential damper lilly year growth outlook credit suisse analyst vamil divan write note client study dub sustain compare once weekly drug class know glp medicine patient treat semaglutide week see stronger reduction glycate hemoglobin level uncontrolled glucose blood body weight vs treat trulicity say news release semaglutide further prove safe buck worry be associate high level retinopathy common eye disease diabetes earlier trial semaglutide be associate greater risk retinopathy sustain trial trulicity patient develop retinopathy vs semaglutide patient ibd take nordisk lead specialty drugmaker industry group ibd composite rating best possible meaning outperform nearly stock term key growth metric head ibd stock checkup closer look strong drug stock rate retinopathy be low comparable arm likely remove potential commercial advantage trulicity have have semaglutide divan say still keep outperform rating price target lilly stock together result point likelihood semaglutide be fairly formidable competitor trulicity slow growth see lilly most important product write leerink analyst seamus fernandez too see growth trajectory trulicity suffering result semaglutide imminent entrance market lilly be currently work trial determine cardiovascular benefit trulicity set readout second half give uncertainty diabetes reimbursement dynamic unclear market share shift affect semaglutide trulicity sale fernandez write note client keep market perform rating lilly stock related dow merck be credit suisse top pharma pickteva pharma crash year low very tough quarter dow merck be benefit back astrazeneca bristol
60,LLY,astrazeneca azn eli lilly lly face tough task not disappointing upcoming european society medical oncology meeting analyst say thursday note series loom catalyst drug industry market be assume multibillion dollar peak sale astrazeneca imfinzi tagrisso jeffery analyst jeffrey holford write note client astrazeneca be set present trial information september conference imfinzi be immuno oncology drug accelerate approval treat bladder cancer be test trial treat advanced lung cancer tagrisso have accelerate approval treat lung cancer recently wrapped different series test lung cancer shortfall quality even just treatment duration drive downside move study view holford write trial be important astrazeneca immuno oncology combination trial disappoint july eli lilly meanwhile need positively surprise be know monarch trial breast cancer drug abemaciclib setback drug baricitinib trulicity regulator recently delay baricitinib rheumatoid arthritis drug ibd take drugmaker be rank group ibd track keep tab strong sector best performer bookmarking ibd datum story last week nordisk nvo diabetes drug semaglutide prove more effective lilly trulicity measure head head comparison class diabetes drug call glp medicine achieve positive result monarch see midterm earning valuation upside downside miss more conservative expectation holford say dow johnson johnson jnj bayer bayry look likely benefit european society cardiology conference unveil result trial testing ability drug xarelto reduce major cardiovascular event patient heart disease key focus be bleed profile give market appear assume only xarelto aspirin combo arm hit excessive bleed holford say more positive outcome spike bayer stock similarly novartis nvs be expect present full result trial call campos look drug know acz reduce cardiovascular risk patient ve survive heart attack good result prod novartis related drugmaker benefit astrazeneca coattailsall eye be dow component star drug next dow merck be credit suisse top pharma pick
61,LLY,september be make break month number biotechs include alnylam pharmaceutical alny axovant science axon versartis vsar be expect present phase datum upcoming week xbiotech stock be poise run say loncar investment chief executive brad loncar year date ve rise hit month high share have rise follow gilead science gild announcement acquire kite pharma kite come incredibly newsworthy september feature least major medical conference least big investor conference nearly dozen phase trial expect read loncar tell investor business daily be most newsworthy month biotech history say so amazing september be be ton phase trial be schedule read company be go succeed fail trial readout count be make break company loncar say loncar count key trial readout september principal note be alnylam be expect unveil result trial drug dub patisiran rare disease cause buildup abnormal material call amyloid body success be major catalyst technology know rna interference antisense essentially turn malfunctioning gene leerink analyst paul matteis write note client tuesday ibd take novartis ibd relative strength rating be boost friday best possible grade show stock price moved past week other stock database head ibd datum story see novartis stack rival ionis pharmaceutical ion be also work phase drug know inotersen treat disease call ttr amyloidosis matteis call upside depend magnitude success safety downside drug prove effective mixed safety see downside alnylam drug fail completely trial accord loncar most person be convince go succeed cite note see range failure success putt alnylam stock price share close tuesday company window say be bellwether biotech company everyone be count succeed probably trial fail stock crash alnylam loncar note axovant be expect announce result drug dub intepirdine mild moderate alzheimer disease recently biogen biib stock break strong phase datum alzheimer trial axovant be work different theory treat alzheimer intepirdine be know serotonin receptor antagonist have potential cognition memory learn enhance side effect be originally develop glaxosmithkline gsk sell axovant so far nothing have work alzheimer so always excitement trepidation trial readout disease loncar say last december eli lilly lly topple drug solanezumab fail phase trial alzheimer axovant do succeed see stock go day say axovant close tuesday extreme kind euphoria alzheimer create also note trial versartis zogenix zgnx growth hormone deficiency form epilepsy know dravet syndrome respectively win just be september chock full catalyst leerink analyst write note client tuesday solid year return biopharma stock be still number catalyst back half year large cap leerink geoffrey porge note abbvie abbv have datum trial inflammatory cancer drug alexion pharmaceutical alxn be expect grab approval drug soliris treat disease immune system attack healthy cell amgen amgn update label ldl cholesterol lower drug repatha include add benefit cardiovascular outcome meanwhile regeneron pharmaceutical regn sanofi sny be appeal court decision vs amgen rival drug praluent celgene celg have readout ulcerative colitis form hodgkin lymphoma fibrogen fgen be expect have datum fibrosis anemia drug analyst expect vertex pharmaceutical vrtx provide update datum cystic fibrosis trial gilead kite car drug likely be approve treat aggressive form hodgkin lymphoma november follow approval novartis nvs kymriah car drug treat form acute lymphoblastic leukemia patient age expect car remain most closely follow emerge area biotech second half leerink analyst michael schmidt write note launch kymriah read drug bluebird bio blue juno therapeutic juno adaptimmune therapeutic adap related biogen alzheimer drug show promise break partnership bit dust gilead kite break biotech giant close buy novartis cancer approval validate gilead kite dealgilead kite deal boost biotech etf clear buy point
62,LLY,dow jone component merck mrk remain credit suisse top pick head european society medical oncology conference october drugmaker allergan agn eli lilly lly also look strong brokerage say monday time merck be expect unveil result trial dub keynote testing immuno oncology drug keytruda chemotherapy previously untreated patient advanced lung cancer combo receive accelerate approval expect continue discussion potential used keytruda await top line datum confirmatory keynote study september october time frame expect be positive credit suisse analyst vamil divan say second quarter conference call july merck confirm cyberattack delay product year say full recovery cyberattack take time still merck be best position remainder divan say note client merck share end regular trading session investor seem prefer abbvie abbv bristol myer squibb bmy divan be place bet allergan lilly still be several month allergan be expect unveil datum migraine trial say lilly offer diverse pipeline more interest be nordisk nvo trial know sustain be look diabetes drug semaglutide vs lilly trulicity divan see trulicity safer drug lilly be expect unveil datum trial drug abemaciclib breast cancer upcoming oncology conference divan say lilly be also plan file application migraine drug be drive adoption new drug cancer plaque psoriasis ibd take biotechs have struggle lately be now rank seventh group track ibd fifth last week sector hit week low thursday hit month high july head ibd industry theme more happened meanwhile divan isn bullish commercial potential drug abbvie inflammatory disease immuno oncology also call relatively rapid erosion sale key drug humira once generic enter market likely bristol case rumor become takeover target have limit stock term early asset immuno oncology potential approval kidney liver cancer drive upside time divan argue credit suisse also reinstate coverage dow stock johnson johnson jnj july divan note valuation be limit investor interest likely change release datum compass trial european society cardiology meeting meeting be set later month be look ability anticoagulant xarelto prevent major adverse cardiac event include cardiovascular death heart attack stroke patient heart disease expect compass be star meeting have potential dramatically increase uptake xarelto come quarters something move needle even company size divan write divan also note downgrade pfizer pfe teva pharmaceutical teva neutral rating outperform quarter dow stock pfizer be struggle term catalyst lack acquisitive appetite potential tax reform teva other hand be range bound new leadership team be place strategy reduce debt be more certain more clarity potential generic version copaxone multiple sclerosis drug milligram be obtain write related pfizer cancer drug help grow merger generic drug be rebound teva mylan free fallperrigo beat raise lift generic drug buck teva mylan trend
63,LLY,teva pharmaceutical teva crash year low thursday generic drugmaker report second quarter metric lag estimate cut sale earning guidance xit be very tough quarter evercore analyst umer raffat write note client stock market today teva plunge floor last see november second quarter revenue grow year year lag consensus analyst poll zack investment research adjust income share miss cent fall vs year earlier period key multiple sclerosis drug copaxone bring sale year year still beat expectation mizuho analyst irina koffler write note client sale fall teva lose patent drug january decline copaxone sale follow price increase january teva say news release teva blame negative net pricing lower volume copaxone year year decrease raffat note other multiple sclerosis player aren report pricing pressure mizuho koffler say copaxone continue support teva stock price revenue be not durable view pending review model koffler keep price target neutral rating teva ibd take teva be key rival work migraine drug amgen amgn eli lilly lly aldr visit ibd technology page get breakdown rival stack market overall specialty medicine revenue decline quarter sale generic unit grow major growth generic revenue follow acquisition actavis generic august teva also cut sale guidance earlier view earning share be expect come prior expectation furthermore teva cut dividend cent first quarter payout related astrazeneca pop report ceo win jump ship teva pharmaregeneron earning revenue top view stock popsallergan boost outlook beating forecastswhy astrazeneca rumore chief executive exit be bad biotech crash positive migraine drug test
64,LLY,corvus pharmaceutical crvs rocket month high thursday analyst upgrade stock ahead datum expect november immuno oncology partnership roche rhhby genentech xin morning trading stock market today corvus pop much high last see early april recently be recent trade portola pharmaceutical ptla also lift grab upgrade meanwhile downgrade teva pharmaceutical teva sank aldr rise sustain price target haircut credit suisse analyst vamil divan upgrade corvus neutral underperform rating boost price target society immunotherapy cancer meeting november firm be expect unveil phase datum drug know cpi cpi be design block action molecule produce tumor hinder immune response corvus begin phase trial genentech early look cpi alone combination immuno oncology drug know pd antibody underperform rating corus have be drive limit enthusiasm clinical datum date cpi well quiet term catalyst calendar divan write note client ibd take biotech fever have chill past several week follow second quarter earning season ibd company biotech industry group be now rank eighth group track fifth just month head ibd industry theme issue boil surface divan also upgrade portola outperform neutral rating keep price target stock have sell follow second quarter earning report biotech say work manufacturing issue delay launch drug bevyxxa bevyxxa be treatment prevent blood clot hospitalize patient risk due moderate severe mobility restriction portola only approve drug approval also be come drug andexxa anticoagulant teva other hand sustain downgrade underperform neutral rating divan slash price target teva have dramatically reduce fiscal guidance do not expect core challenge be face fade anytime soon write teva continue face pricing pressure generic upcoming competition multiple sclerosis drug copaxone firm have yet appoint full time chief executive be talk potential sale noncore asset pay debt eclipse june quarter divan want see final detail transaction give teva full credit also trim price target keep neutral rating most likely have spend significantly compete crowd market say key migraine drug eptinezumab be phase trial be rivale drug teva eli lilly lly amgen amgn upside risk come positive update self administration formulation more differentiate clinical datum say downside risk come strong competitor launch setback eptinezumab development related teva mylan pressure rivalry loom key drugsbiogen teva slip democrat launch ms drug pricing topple generic drugmaker be poise rebound analyst
65,LLY,delay get rheumatoid arthritis drug market least month send eli lilly lly share lower tuesday drug giant report second quarter earning xon stock market today lilly topple close share have be buy zone monday close breaking cup handle buy point lilly partner arthritis drug incyte incy fall finish food drug administration be require lilly incyte run trial determine benefit risk dose drug now know baricitinib resubmit application approval lilly estimate least month resubmit application putt approval baricitinib baricitinib be approve europe treat moderate severe rheumatoid arthritis also early tuesday lilly report second quarter sale ahead consensus analyst poll zack investment research adjust profit share top cent accord zack revenue grow profit share ibd take biotech stock be hot streak now rank fourth group track ibd merger acquisition send higher say visit ibd industry theme deep dive be sale diabetes drug trulicity plaque psoriasis drug taltz lead growth quarter respectively vs year earlier quarter sale basaglar insulin treat adult child type diabetes grow lilly also raise sale guidance earlier view adjust income be raise share year be related star align biotechs crush earning biotech nearly triple street expectation key small biotech break tie eli lilly
66,LLY,dow merck mrk be benefit back astrazeneca azn bristol myer squibb bmy analyst say monday cite higher expectation immuno oncology drug combine chemotherapy xub analyst marc goodman assessment come merck astrazeneca say team test drug keytruda lynparza several cancer follow merck consensus crush second quarter stock market today merck dip fractionally close astrazeneca inched bristol myer pop finish recent tie clovis oncology clvs breast ovarian prostate cancer past day have be good merck diminish expectation immuno oncology immuno oncology thus higher immuno oncology chemo goodman say note client merck be combine immuno oncology drug keytruda eli lilly lly chemotherapy alimta treat advanced lung cancer combination receive accelerate approval meanwhile rival appear be struggle ibd take earning season be well underway top tech stock be buy point week head ibd research page closer look make strong bet last week astrazeneca announce combination immuno oncology drug imfinzi tremelimumab fail late stage trial advanced lung cancer patient doesn look good bristol myer be work similar combo leerink analyst seamus fernandez say astrazeneca failure imfinzi tremelimumab leave keytruda dominance intact first treatment advanced lung cancer long term growth require more aggressive business development strategy say fernandez boost price target merck cite drugmaker new partnership astrazeneca have outperform rating merck astrazeneca partnership be admission defeat initial immuno oncology race get access keytruda pd inhibitor astrazeneca sell half right lynparza parp inhibitor astrazeneca already have drug similar keytruda drug imfinzi be pd inhibitor operate similar mechanism astrazeneca merck be work theory combine immuno oncology drug parp inhibitor offer stronger cancer response similar astrazeneca bristol theory combination immuno oncology drug be particularly robust cancer merck be now strategic advantage goodman say keytruda sale beat wall street view second quarter grow sale keytruda lung cancer comprise half sale majority come use monotherapy goodman say year expectation be high bristol low merck say expectation have now be reversed so think keytruda sale need ramp materially here datum need support current view keep stock move higher related dow merck crushed keytruda sale view astrazeneca fail not once twice cancer drugswhy clovis regeneron be lead biotech deluge today
67,LLY,dow merck mrk beat analyst expectation star cancer drug keytruda deliver board beat second quarter prod share lift friday xinvestor have be laser focuse keytruda sale launch combination eli lilly lly chemotherapy alimta evercore analyst umer raffat say combo receive accelerate approval first treatment patient advanced lung cancer quarter keytruda sale grow merck credit growth oncology unit higher keytruda sale additional approval keytruda closely rival bristol myer squibb bmy opdivo hepatitis drug zepatier human papillomavirus drug gardasil also help drive topline beat bring respective sale investor likely didn give lot credence zepatier due struggle elsewhere hepatitis drug raffat say note leerink analyst seamus fernandez note sale diabetes drug januvia janumet be lower expect revenue drug decline year year overall sale grow beating analyst expectation adjust earning share grow year year crushed consensus view cent ibd take merck bristol myer squibb be square immuno oncology get latest battle ibd technology page merck also narrow full year guidance sale adjust earning share note cyberattack june disrupt global operation say product see temporary delay certain market stock market today merck advanced continue rebound wednesday month low share have be form flat base early march buy point related astrazeneca fail not once twice cancer drugswhy celgene gamble help small biotech moredeal help celgene rival dow merck bristol cancer drug
68,LLY,bristol myer squibb bmy put hurt dow component merck mrk analyst say merck flagship immuno oncology drug miss goal head neck cancer trial xon stock market today bristol climb merck dip follow news report late monday immuno oncology program merck keytruda gain accelerate approval treat head neck cancer contingent late stage trial confirm prior success trial dub keynote keytruda narrowly miss goal meanwhile bristol say seek new week minute dose schedule rival drug opdivo neither item news be likely meaningfully affect term sale credit suisse analyst vamil divan say note client lead positive upside bristol opdivo pressure merck keytruda look medium longer term divan note be earlier trial merck use confirmation success used keytruda treat head neck cancer keynote assume read positively meantime keytruda keep accelerate approval head neck cancer pending further trial head neck cancer represent merck keytruda sale first quarter ibd take biotechs be now rank fourth group track ibd be cook gas pent demand acquisition larger player come fruition biotech buy head ibd industry theme future keytruda trial head neck cancer also deliver disappointing news then revenue be risk divan say same time merck announce result keynote study bristol say food drug administration have accept application have keytruda rival opdivo dose milligram week minute keytruda opdivo same class immuno oncology drug target protein call pd immune system immuno oncology drug work immune system identify destroy cancer cell opdivo be now approve weight base treatment various cancer include head neck cancer dose course minute infusion patient receive infusion week depend type cancer divan call potentially important commercial milestone make office visit better patient office staff keytruda roche rhhby tecentriq be dose week other company have comment look longer potential regimen bristol now have advantage front say merck say comfortable current week schedule keytruda note line nicely eli lilly lly alimta be dose divan say keytruda alimta be be study combination advanced lung cancer related small biotech break tie eli lilly biotech nearly triple street expectation key drugwhy astrazeneca rumore chief executive exit be bad timing
69,LLY,index future rise early tuesday morning nasdaq future fall google parent alphabet googl report higher expect traffic acquisition cost partner site blame apple aapl meanwhile notable stock be buy point report early tuesday general motor gm eli lilly lly mmm new oriental education technology edu nasdaq composite rise monday hit time high index dip dow jone industrial average retreat nasdaq future fall fraction vs fair value index future rise nearly dow future climb alphabet report better expect second quarter earning revenue factor charge european union regulatory fine traffic acquisition cost tac pay partner carry ad shot be tie revise search deal apple analyst say alphabet have close rise high intraday just buy point flat base google parent fall nearly early trading tuesday overnight action doesn always translate regular session stock performance alphabet show be buy point be not same actually rise still stock approach sound entry bullish pattern be often worth watch here be stock buy point be report quarterly result early tuesday general motor clear cup handle buy point july continue edge higher average volume few day gm share have retreat past session lose drop still valid entry analyst expect gm share profit fall revenue drop accord consensus estimate zack investment research past session eli lilly share have rise intraday buy point cup handle base only close just level lilly end monday eli lilly be expect report ep vs cent year earlier revenue climb vs industrial conglomerate dow jone industrial average component have form short flat base potential entry close monday analyst expect deliver ep jump revenue nearly fellow dow component mcdonald mcd unite technology utx dupont dd caterpillar cat also report tuesday chinese operator profit school be member ibd new oriental education have form cup base buy point share rise monday new oriental be expect report cent share vs year earlier revenue accord thomson reuter figure tal education tal chinese school company be ibd list tal report thursday related google earning beat traffic cost jump apple blame gm ford earning see slowdown watch china big picture bull case still hold waterdow stock report earning tuesday investing action plan
70,LLY,nektar therapeutic nktr stock near monday announce deal eli lilly lly develop drug stoke immune system fight autoimmune inflammatory condition xin morning trading stock market today nektar pop close earlier rise much share be year begin form cup buy point late march same time lilly stock be fractionally lilly nektar codevelop drug know nktr drug work stimulating specific pathway body generate greater immune system response activate certain cell nktr act bring immune system back balance firm say drug be enter phase testing determine correct dose be be develop once twice monthly self administer injection number autoimmune disease company say news release evercore analyst umer raffat see nktr potential treatment lupus crohn disease ulcerative colitis rheumatoid arthritis perhaps even multiple sclerosis graft versus host disease type diabetes ibd take nektar have ibd composite rating meaning outperform just half stock term key growth metric lag leader celgene celg therapeutic cort supernus pharmaceutical supn have best possible crs head ibd stock checkup list top rate biotechs phase trial information be due third quarter raffat write research report term deal lilly pay nektar upfront fee make milestone payment lilly foot bill research development cost phase wrapped nektar be response phase cost nektar receive double digit royalty increase commensurate phase investment product sale company say nektar be able co promote certain treatment raffat note nektar main program be actually drug know nktr be be combine drug bristol myer squibb bmy roche rhhby bristol nektar be look tumor type roche nektar be work lung bladder cancer related biotech dethrone oxycodone treat painis small biotech head market cap pitfall bristol incyte match beat dow merck combination trial
71,LLY,biotechs lead alexion pharmaceutical alxn gilead science gild vertex pharmaceutical vrtx outperformed pharmaceutical brother june quarter analyst say earning season near close xleerink analyst geoffrey porge estimate large cap biotechs sale top wall street expectation average most impressive beat come alexion gilead vertex biogen biib alexion sale top consensus gilead hepatitis unit fall again quarter total revenue top vertex report sale beating biogen top sale comparison pharma company result be more tepid eli lilly lly merck mrk deliver significant revenue surprise otherwise fairly tepid result consist modest beat line result modest miss porge say note client last week dow component merck lilly top consensus respectively bristol myer squibb bmy glaxosmithkline gsk roche rhhby deliver modest beat novartis nvs astrazeneca azn nordisk nvo be line sanofi sny pfizer pfe johnson johnson jnj miss earning side performance be even more robust biotech porge say large cap biotechs beat average relative consensus bigger pharmas deliver earning top consensus average revenue growth vs year earlier quarter be biotechs drug firm average porge say board company report improve patient access drug well positive demand inventory currency effect ibd take biotech fever look chilly late july sector overcome challenge outlined ibd industry theme report
72,LLY,quarter rare disease player biotech side do particularly well brad loncar chief executive loncar investment tell investor business daily biogen vertex sarepta therapeutic srpt positively surprised market spinraza treatment spinal muscular atrophy biogen ionis pharmaceutical ion nearly triple consensus model drug bring obliterate view analyst say sarepta absolutely crushed analyst expectation rise month high july key drug exondys treat duchenne muscular dystrophy bring more analyst have expect sarepta also cut loss expectation half think category drug investor have be expect payer pushback loncar say so far hasn show be ever group company be go boom more rare disease company sentiment have soured biotech sector hit month high late july loncar cite political uncertainty note lion share biotechs drugmaker revenue earn product beat expectation raise guidance fact re not trading indicate investor have already reset expectation year so maybe just hasn be quite impressive context say have big run come earning season play factor well uncertainty tax reform be keep most major player look make big deal porge say trump administration have yet offer further detail plan cut corporate tax rate make corporate inversion less desirable gilead have be gun buy something wake slow hepatitis sale didn comment second quarter call dow pfizer say putt deal pause await more tax situation washington loncar note pfizer call be really crystalize theme broader medtech sector have previously say big deal biotech really send stock higher look unlikely term mega deal be pause happen happen say pretty disappointing shouldn really affect call bolt deal mega deal seem be hold thing related gilead hepatitis franchise topple again share be beatwill pfizer cancer drug help grow merger biotech just blow past buy point sale beatastrazeneca beat stock dife drug failure more reportvertex sing late crush sale profit expectation
73,LLY,eli lilly lly be gouge share johnson johnson jnj nordisk nvo class diabetes drug analyst say monday suggest lilly second quarter metric just meet consensus view prescription trend show lilly sale earning be roughly line wall street view leerink analyst seamus fernandez write note client consensus expect lilly report adjust earning share sale fernandez up price target lilly stock note diabetes drug taltz trulicity be do well meanwhile lilly jardiance trulicity be displacing drug dow nordisk sglt glp class diabetes drug respectively prescription sglt diabetes drug grow year year sequentially second quarter fernandez say same time prescription glp class diabetes drug grow vs year earlier period quarter quarter ibd take biotech space exelixis stock have pop year kidney cancer treatment head new america closer look catalyst be upcoming stock sglt space lilly jardiance be take share invokana study show invokana reduce cardiovascular event diabetes patient also come greater risk amputation study validate class cardiovascular benefit fernandez say also provide clear tailwind lilly jardiance see accelerate growth year year sequential growth compare year year sequential growth expect jardiance overtake invokana sglt class risk amputation wasn see separate jardiance trial lilly meanwhile trulicity be nipping heel nordisk victoza latter market share vs trulicity fernandez say expect trulicity overtake victoza leader glp drug space time frame fernandez expect nordisk overall diabetes business decline competition intensify insulin arena raise estimate nordisk semaglutide competitor glp space have market perform rating nordisk stock outperform rating lilly sanofi sny stock lilly stock end monday flat nordisk stock inched higher stock market today sanofi stock fall related dow host diabetes study lilly benefit mostnovo nordisk diabetes lead unscathed follow astrazeneca triallilly grab diabetes share dow amputation wo
74,LLY,here weekly investing action plan need know investor come week biggest name tech defense energy automotive telecom restaurant industry report include fang stock facebook fb amazon amzn alphabet googl federal reserve hold policy meeting opec
75,LLY,here investing action plan tuesday need know investor come day report season get fast furious result lockheed martin lmt goldman sachs gs bank america bac unitedhealth unh johnson johnson jnj unite airline ual charle schwab schw other lockheed martin
76,LLY,share aldr tuesday lose more quarter value diving low not see late positive datum phase migraine trial make competitive eli lilly lly amgen amgn teva pharmaceutical teva say drug know eptinezumab show statistically significant cut frequent episodic migraine first month patient milligram milligram dose respectively eptinezumab experience sizable reduction roughly fourths monthly migraine day test show psychosomatic placebo effect be nearly effective turn total receive nondrug placebo thought have receive medication part test group also report fourths reduction migraine day appear take massive bite share stock market today stock topple close meanwhile lilly slip amgen drop teva fall eptinezumab drug lilly amgen teva be call cgrps aim reduce peptide cut migraine average patient milligram dose have migraine give month month period say news release compare migraine free rate patient treat amgen erenumab separate study drug also appear be fairly speedy more half patient treat eptinezumab have migraine day vs just patient receive nondrug placebo ibd take stock have ibd composite rating meaning underperform more stock term key growth rate trail stronger biotechs celgene have best possible cr visit ibd stock checkup best idea biotech leerink analyst paul matteis say result put line lilly amgen teva result also indicate milligram dose be stronger now have decide use intramuscular subcutaneous administration management have note needle size intramuscular shot be smaller flu shot say note client investor today be more familiar therefore more comfortable concept subcutaneous shot matteis keep outperform rating stock note didn say much safety other safety profile eptinezumab appear consistent placebo earlier study related small biotech ruffle market migraine drugsteva pharma run migraine trial lilly amgen benefitedcan teva hold own bring migraine drug market
77,LLY,merck mrk keytruda continue gain share immuno oncology drug bristol myer squibb bmy roche rhhby approval keytruda chemotherapy combination overall immuno oncology drug sale grow month month datum symphony health show merck keytruda be gain share expense bristol opdivo yervoy leerink analyst seamus fernandez say keytruda share increase percentage point opdivo yervoy share fall respectively combine end roche drug tecentriq remain steady share year market tecentriq differ keytruda opdivo target pd protein vs pd protein target merck bristol drug pfizer pfe bavencio astrazeneca azn imfinzi be also pd antibody bavencio imfinzi be newest market have achieve only nominal share third first month respectively follow approval fernandez write note client ibd take other immuno oncology news kite pharma kite bluebird bio blue stock have rocket month follow american society clinical oncology meeting chicago head industry snapshot deep dive fernandez expect keytruda keep gain share follow approval advanced lung cancer combination alimta eli lilly lly keytruda also receive recent approval bladder cancer tumor evercore analyst umer raffat say keytruda be tracking analyst projection sale second quarter june sale be month month keytruda be likely beat expectation raffat write note client stock market today merck component dow jone industrial average be close share bristol rise roche stock lift related tesaro overcome clovis lead combo merck co biotech fly nearly strong trial be drug better dow merck pause cancer trial investigate keytruda tie death
78,LLY,johnson johnson jnj diabetes drug invokana cut cardiovascular event long term study eli lilly lly stand benefit most doctor steer clear medication worry increase risk amputation study dub canvas be present late monday dow stock johnson johnson say invokana reduce risk cardiovascular death nonfatal heart attack nonfatal stroke vs drug placebo additional analysis show invokana lower risk hospitalization heart failure invokana also delay progression albuminurium presence specific chemical urine indicate kidney disease rbc analyst glenn novarro say canvas study be unlikely reverse negative trajectory invokana sale first quarter invokana invokamet sale drop year year novarro forecast dip sale eli lilly other hand benefit johnson johnson study merck mrk trail analyst say lilly jardiance be sglt inhibitor work help kidney lower blood glucose level merck januvia be dpp block glucagon release trigger insulin secretion validate cardiovascular benefit boost sglt class credit suisse analyst vamil divan write similar study lilly jardiance also show benefit cardiovascular outcome jardiance also cut risk cardiovascular death mortality even canvas study lilly be poise grab chunk invokana sale food drug administration require johnson johnson physician potential amputation associate invokana invokana double risk amputation recent study expert cite leerink analyst seamus fernandez say amputation worry be biggest differentiate factor physician decision prescribe jardiance invokana show similar cardiovascular benefit diabetes patient close stock market today johnson johnson stock tick finish regular trading session lilly stock add share diabetes drugmaker merck dip end day ibd take johnson johnson stock have ibd composite rating meaning outperform more quarters stock term key growth metric more ibd rating visit ibd stock checkup meanwhile dpp class diabetes drug include merck januvia face incremental pressure credit suisse divan say time however expect enthusiastic response canvas efficacy datum drive use sglt class earlier course treatment concurrently push dpp further back say note client merck pfizer pfe dow stock be jointly work sglt inhibitor call ertugliflozin regulator approve drug december win have datum cardiovascular outcome several year pfizer take chunk sale meaning shift januvia ertugliflozin be net negative merck related lilly grab diabetes share dow amputation woesabbvie expect rival chip away biggest drug franchisedow pfizer face challenge roche lilly loom
79,LLY,wall street be undervalue aldr stand outperform larger rival amgen amgn eli lilly lly teva pharmaceutical teva migraine drug analyst say thursday ahead key conference headache treatment needham analyst danielle brill maintain buy rating price target stock stock market today stock climb be set present datum weekend phase clinical trial treatment frequent episodic migraine phase datum trial dub promise be expect end month brill expect drug eptinezumab achieve statistically significant reduction migraine day vs placebo line earlier result amgen lilly teva be work class drug call cgrps aim reduce peptide order cut migraine view placebo adjust difference day range be line competition brill write note client acknowledge subtle difference trial make direct comparison difficult differentiate reduce migraine day week week least date competitor have hit goal brill say drug hit point patient earlier phase trial expect similar magnitude promise brill say ibd take stock have low ibd composite rating meaning underperform nearly stock term key growth metric head ibd stock checkup list top performer company medical biom biotech industry group trial test patient experience least headache day month include least migraine day patient receive quarter vary dose eptinezumab intravenously main goal reduce migraine day week result first dose type week be expect be present meeting headache treatment specialist weekend early next week boston be schedule poster presentation friday oral presentation saturday say news release plan present result second phase trial filing application food drug administration second half brill see room multiple player migraine market consensus see drug take just patient less estimate prevention therapy candidate just population drive sale say look promise result support commercial differentiation think positive trial comparable finding competitor be still write continue believe market be vast subset patient warrant treatment quarterly iv therapy self administer injection related teva pharma run migraine trial lilly amgen benefitedcan teva hold own bring migraine drug market biotechs cruise day upswing price target cut duo
80,LLY,regeneron pharmaceutical regn go heart debate tuesday question validity amgen amgn patent ldl cholesterol bust drug repatha analyst say follow court hearing wall street be split wednesday appeal court process land analyst investment bank evercore expect regeneron sanofi sny triumph counterpart mizuho say chance amgen succeed stock market today regeneron rise amgen climb share regeneron partner sanofi be tuesday regeneron amgen battle minute appeal court hearing stake be fate regeneron sanofi drug praluent judge previously side amgen say regeneron sanofi praluent infringe amgen patent drug repatha judge stay injunction praluent pending appeal court process be likely end line appeal court side amgen mizuho analyst salim sy say note client supreme court take very few patent case decision have broad implication future patent struggle evercore analyst umer raffat say audio record follow meeting amgen patent cover entire antigen describe bound regeneron say be too broad regeneron do be go heart debate say know patent shouldn be valid begin say regeneron be say be amgen patent focus invention be not do amgen say praluent be too similar drug repatha antibody patent be circumvent tweak amino acid then point investing drug development return win be realize sy say ibd take bioverativ bivv biogen biib spinoff have year average return growth rate see be smart investment visit ibd stock analysis regeneron note dow pfizer pfe time try unsuccessfully develop similar drug also belong pcsk inhibitor class pfizer hold intellectual property pcsk inhibitor neither repatha praluent exist example illustrate even similar antibody be different sy say raffat note report eli lilly lly several other file brief support regeneron important note praluent be boot market amgen repatha be sole pcsk inhibitor market so case boil policy vs emotion sy say amgen win praluent be take market be pushback only have pcsk market lessen competition say praluent be beat injunction signal patent be not relevant think so judge really seem be consider ramification decision evercore analyst akash tewari say record amgen strategy patenting antigen broader antibody have yet be test court related regeneron sanofi undercut amgen abbvie rheumatoid arthritisteva pharma run migraine trial lilly amgen biotechs fall cancer partnership bristol myer
81,LLY,roche rhhby displace dow pfizer pfe segment lung cancer market analyst say wednesday american society clinical oncology meeting highlighted additional challenge pfizer stock market today pfizer fall roche late tuesday roche present datum head head trial drug alecensa vs pfizer xalkori xalkori be approve treat patient advanced lung cancer specific genetic defect alecensa be approve lung cancer patient progressed be intolerant xalkori class drug call alk inhibitor month follow patient treat alecensa survive median month disease progress vs month patient treat xalkori presenter call roche result remarkable outstanding declare alecensa be now optimal alk inhibitor first line set credit suisse analyst vamil divan say note client first line treatment be first defense disease lung cancer doctor have breakfast yesterday also acknowledge xalkori be relatively weak alk inhibitor be likely change practice pattern base trial write divan note pfizer be work next generation alk inhibitor help soften blow lose xalkori sale also lung cancer pfizer be develop second generation drug target specific receptor know egfr inhibitor ibd take biogen biib spinoff bioverativ bivv be near stock announce plan beef pipeline acquisition true north therapeutic head ibd stock analysis closer look bioverativ setup pfizer be still struggle vs newer therapy particularly be consider immuno oncology drug class aim block certain interaction involve protein enzyme immune system prevent immune response pfizer drug bavencio be approve treat rare aggressive skin cancer bavencio have show strong result liver cancer combine inlyta pfizer liver cancer drug help slow decline revenue inlyta divan say class breast cancer drug know cdk inhibitor be get more crowd pfizer ibrance continue dominate divan say acknowledge novartis nvs kisqali eli lilly lly abemaciclib have show strong trial result prostate cancer johnson johnson jnj zytiga put pressure xtandi similar drug pfizer acquire buy medivation related regeneron cholesterol buster get boot amgen battle tesaro crash beating astrazeneca stronger clovis astrazeneca muddy potential deal tesaro
82,LLY,wall street be undervalue foundation dow component merck mrk be make cancer fight drug keytruda analyst say annual american society clinical oncology meeting conclude tuesday veritable star grow immuno oncology market keytruda be now approve treatment cancer accord merck have ongoing study help expand approval credit suisse analyst vamil divan say note client drug continue drive story company acknowledge base business be face pressure oncology pipeline be not robust prefer write hype keytruda isn merck biggest drug januvia janumet be sale diabetes drug fall year year first quarter keytruda revenue grow lead growth company keytruda recently grab food drug administration approval use conjunction eli lilly lly alimta first line defense advanced lung cancer ibd take incyte have be headline year mixed outlook biotech sector get insight company new america competitive datum like rival astrazeneca azn roche rhhby bristol myer squibb bmy be unlikely rock boat merck divan say believe person be underappreciat impact strong foundation merck be build space say merck closest rival bristol be also partner separately incyte incy test drug incyte epacadostat keytruda bristol opdivo work block interaction involve pd protein prevent immune system response cancer incyte epacadostat be know ido inhibitor work block interaction involve different protein ido inhibitor aren establish pd make headline conference bristol too be work similar drug totality epacadostat datum asco look compelling credit suisse analyst alethia young write separate note client datum support epacadostat multiple tumor response be see regardless genetic marker share incyte topple stock market today young blame company decision exclude patient datum effectiveness datum include safety effectiveness datum have october cutoff always see more datum think datum set present meeting give confidence probably shouldn expect significant variance unconfirmed patient write young model peak adjust sale peak unadjusted sale epacadostat meanwhile astrazeneca remain confident immuno oncology combo advanced lung cancer dampen enthusiasm investor specific match astrazeneca be pairing pd ctla inhibitor trial company also see drug lynparza get fda approval second line defense treatment ovarian cancer lynparza be know parp inhibitor block family enzyme cancer cell use proliferate sector astrazeneca rival clovis oncology clvs tesaro tsro related here be winner loser year biggest cancer meetingdow merck clearly win vs bristol roche cancer trial
83,LLY,tesaro tsro stock plunge monday sunday presentation american society clinical oncology meeting show zejula be stronger drug astrazeneca azn breast cancer xon stock market today tesaro stock crash end day share rival astrazeneca pfizer slip less clovis oncology clvs eli lilly lly stock also lose more tesaro dow component merck mrk combine drug zejula keytruda treat ovarian breast cancer patient zejula be know parp inhibitor keytruda be pd inhibitor combine be thought offer more potent response half ovarian cancer patient respond treatment compare favorably historical datum parp pd inhibitor alone patient population leerink analyst seamus fernandez write note client still early datum appear stronger initial result see astrazeneca lynparza imfinzi tumor type write lynparza be parp inhibitor imfinzi be pd inhibitor ibd take tesaro stock have middling ibd composite rating measure performance stock get ibd stock checkup look better rate biotechs breast cancer patient have partial response combo sign cancer disappear patient patient be know triple negative breast cancer form doesn respond normal treatment achieve stability company also have see promising unconfirmed response other patient other presentation astrazeneca say lynparza show month improvement progression free survival chemotherapy patient form breast cancer pfizer show similar datum drug talazoparib saturday fernandez say overall lynparza less severe toxicity profile likely drive use drug chemotherapy say main adverse event associate lynparza be nausea anemia neutropenia be most common adverse event chemotherapy arm lilly also present incrementally positive not groundbreaking datum drug abemaciclib form breast cancer death rate be broadly line pfizer ibrance diarrhea side effect be manageable lilly say abemaciclib belong class drug call cdk inhibitor compete novartis already approve kisqali lilly say continuous dose method treatment do more disrupt cancer cell cycle related do astrazeneca rival just launch potential blockbuster drug bristol incyte match beat dow merck combination trialshow clovis astrazeneca muddy potential deal tesaro
84,LLY,loxo oncology loxo stock defy broad biotech dip monday spiked record high show drug larotrectinib shrink tumor number different cancer share loxo end monday regular session catapult higher follow presentation saturday american society clinical oncology annual meeting chicago company eli lilly lly merck mrk bristol myer squibb bmy roche rhhby be attendance loxo drug belong class immuno oncology agent aim inhibit family protein loxo be now set begin phase trial larotrectinib adult colon cancer child tissue tumor respond treatment big cap name weren big winner wall street instead company bluebird bio blue surge bluebird stock get jump present strong datum drug dub bb treat multiple myeloma monday bluebird say patient trial bb respond treatment relapse therapy be well tolerate leerink analyst michael schmidt say report have outperform rating bluebird stock ibd take supernus pharmaceutical supn stock have ibd composite rating best possible base key growth metric lead ibd company biom biotech industry group keep tab industry leader ibd stock checkup puma biotechnology pbyi stock lift rival roche unveil result yearlong test drug specific group breast cancer patient result be low end investor expectation rbc analyst matthew eckler say bode well puma be work drug call neratinib address same group patient eckler say roche drug herceptin perjeta be test adjuvant treatment treatment be add decrease risk relapse now assume adoption neratinib be largely unencumbered adjuvant use herceptin perjeta eckler write note client keep sector perform rating puma stock boost price target however puma bio share close well intraday high highest november tg therapeutic tgtx stock also cut wide berth monday rise much give gain back close earlier day tg have positive result trial abbvie abbv johnson johnson jnj form leukemia related dow merck clearly win vs bristol roche cancer trialstesaro crash beating astrazeneca stronger datum
85,LLY,eli lilly lly amgen amgn stock get boost wednesday rival teva pharmaceutical teva unveil strong result phase trial treat chronic migraine stock market today lilly stock rise lilly however also benefit strong late stage trial advanced bladder cancer meanwhile amgen stock pop share aldr player migraine treatment fall teva conduct result edge be work calcitonin gene related peptide know cgrps tackle migraine mount evidence have link increase cgrps onset migraine knock cgrps be thought prevent migraine teva be aim reduce migraine monthly quarterly period drug know fremanezumab already have quarterly infusion migraine be important competitive position evercore analyst umer raffat say ibd take ibd company generic drug industry group be rank group track trail sister industry group ethical drug biom biotech be rank no respectively closer look industry layout visit ibd biotech pharma industry stock news page amgen lilly never develop antibody quarterly dose say recall drug teva also have longer half life competitor half life be long take amount drug body be reduce phase study patient chronic migraine teva drug cut monthly headache day least moderate severity day quarter drug reduce headache day day make apple apple comparison be difficult raffat write note client separate study chronic migraine patient lilly drug show day reduction monthly migraine day not just moderate severe headach related teva pharma eagle pharma depome slew get price haircutsdid neurocrine just leave door open teva tourette teva hold own bring migraine drug market
86,LLY,biotech industry always highly technical conundrum investor currently even greater challenge offer even greater opportunity usual early industry innovator amgen amgn biogen biib gilead science gild currently find big trouble accord loncar investment chief executive brad loncar largely victim own success cancer
87,LLY,clovis oncology clvs tesaro tsro deliver blockbuster ovarian cancer drug grab takeover interest analyst say friday ahead key trial clovis expect later month duo rival bigger astrazeneca azn market cap be more time clovis tesaro combine clovis tesaro joined astrazeneca parp inhibitor market last year parp inhibitor work block family enzyme cancer cell use proliferate pfizer pfe abbvie abbv be also work parp inhibitor credit suisse analyst alethia young see class drug also have impact prostate breast lung cancer think parp inhibitor market be big enough clovis have blockbuster product well write strongly believe company be likely attractive target large global biopharma company later month clovis be expect unveil result phase trial dub ariel drug rubraca tesaro previously set high bar trial drug zejula have benefit patient regardless specific genetic top line basis think ariel work group focus be potential commercial difference use biomarker safety write note client young expect tesaro stock be volatile follow clovis trial note lift overhang share have outperform rating tesaro clovis stock rate tesaro stock price target clovis price target stock market today clovis stock rise tesaro stock gain astrazeneca pfizer abbvie stock be respectively ibd take american society clinical oncology layer battlefield fight cancer company merck bristol myer squibb incyte roche be work combine drug immuno oncology spectrum get more ibd industry theme share fellow cancer biotech incyte incy topple sustain price target cut leerink analyst michael schmidt trim price target incyte stock incyte eli lilly lly rheumatoid arthritis treatment be delay april food drug administration delay approval drug call baricitinib instead ask more information trial now schmidt say expect sale see drug launch schmidt be bullish seattle genetic sgen stock small biotech bristol myer squibb bmy unveil strong datum combination drug adcetris opdivo classical hodgkin lymphoma sign cancer disappear patient series trial combination potentially provide chemotherapy free treatment option patient hodgkin lymphoma relapse be treat surgery schmidt have outperform rating seattle genetic bristol myer stock related tesaro crash beating astrazeneca stronger databristol incyte match beat dow merck combination spotlight drug giant donnybrook cancer treatment
88,LLY,veeva system veev stock rushed record high friday ibd software firm report analyst call exceptional quarter issue street top guidance stock market today veeva stock be rise much earlier trading share have run more year uptrend software canaccord genuity analyst richard davis say report software valuation be move leptokurtic distribution be way say valuation have fat tail winner loser say case miss veeva be decisively winner bucket veeva belong ibd company computer software medical industry group be january veeva make software backbone biggest name pharma include eli lilly lly novartis nvs pfizer pfe amgen amgn now veeva be look expand outside life science market have essentially greenfield opportunity other regulate industry outside life science qualityone next generation version vault software used organize clinical trial datum ibd take veeva be look growth outside life science visit new america exclusive chat chief executive peter gassner new initiative look still veeva add nearly new customer vault offer first quarter top pharma begin standardize veeva crm customer relationship management software chief executive peter gassner say late thursday call analyst number customer multiple vault product be increase more year year quarter include top pharma add vault rim vault qualitydocs big deal gassner say be exciting represent top pharma go vault say also bode well newer vault application re build canaccord davis note struggle find anything particularly amiss quarter instead veeva execute far better strategy identify prospect become successful reference drive new customer win revenue year say related ibd stock veeva surge consensus crush
89,LLY,nordisk nvo stock pop tuesday astrazeneca azn say type diabetes drug didn reduce risk cardiovascular event trial leave eli lilly lly break tie stock market today nordisk fall cent astrazeneca be share lilly diabetes rival be astrazeneca drug bydureon meet goal phase study do not increase risk major adverse cardiovascular event include heart attack stroke patient type diabetes meeting food drug administration requirement also didn reduce risk nordisk victoza semaglutide do earlier study victoza cut risk cardiovascular event semaglutide trim risk leerink analyst seamus fernandez write note client drug also have cardiovascular benefit evercore analyst umer raffat say note client so far astrazeneca bydureon sanofi sny adlyxin fail cut risk cardiovascular event nordisk drug have ibd take astrazeneca have ibd composite rating meaning have outperformed stock key growth metric past month still lag leader zoetis zts have cr best possible head ibd stock checkup list top rate drugmaker lilly provide tiebreaker unveil result trial diabetes drug trulicity drug astrazeneca nordisk sanofi trulicity belong class drug increase insulin secretion inhibit glucose release certain level fernandez forecast entire class drug grow worldwide sale meantime drug maintain leadership position class dub glp receptor agonist fernandez say class be underuse diabetes treatment positive heart effect astrazeneca trial have boost prominence lilly trulicity be gain share glp class say count once weekly semaglutide launch stem tide also benefit update label victoza reflect drug ability curb risk cardiovascular event diabetes patient related conference spotlight drug giant donnybrook cancer treatmentlilly grab diabetes share dow amputation woesdow pfizer eli lilly topple month lows downgrade
90,LLY,share eli lilly lly dow component pfizer pfe topple month lows tuesday sustain pair downgrade lilly grab buy rating pfizer sank sell rating close stock market today lilly stock be pfizer stock lose share hit lows last see mid february goldman sachs analyst jami rubin remove lilly conviction list replace ibd member edward lifescience ew product story see potential more upside lilly stock be still rate buy price target lilly stock be year date vs have rise long term fundamental look strong lilly be face term risk patent battle regard chemotherapy alimta decision be expect june be unique situation lilly have already win district court appeal same patent rubin say usually district court process follow patent review likelihood lilly lose patent review process be low result earlier expect generic competition vs alimta second half rubin write note client meanwhile food drug administration decision regard rheumatoid arthritis drug olumiant be weigh lilly stock write earlier year fda ask more dose safety datum drug just month european official sign ibd take lilly have middling ibd composite rating best possible meaning outperform nearly stock term key growth metric still lag leader zoetis cr head ibd stock checkup list top perform drugmaker longer term rubin see upside diabetes drug trulicity breast cancer drug abemaciclib migraine drug galcanezumab take time lilly get credit wall street rubin say pfizer other hand be cut sell rating neutral citi price target cut accord streetinsider citi say medicare part coverage pfizer oncology drug be risk pfizer count prostate cancer drug xtandi breast cancer drug ibrance lung cancer drug xalkori citi analyst andrew baum say pfizer member dow jone industrial average need deal hit consensus view profit consensus expect pfizer report adjust earning share respectively related teva hold own bring migraine drug market drug stock rally relief gop health care bill win roche cancer failure tank bristol pfizer not merck
91,LLY,eli lilly lly jardiance likely benefit most food drug administration require dow component johnson johnson jnj patient leg foot amputation associate diabetes drug invokana analyst say tuesday letter physician tuesday fda cite large clinical trial conclude diabetes med invokana invokamet invokamet xr cause increase risk leg foot amputation fda now require johnson johnson add box warning invokana invokamet label trial dub canvas canvas show leg foot amputation occur twice often patient treat invokana vs placebo amputation toe middle foot be most common however amputation involve leg knee also occur fda write patient have more amputation involve limb leerink analyst seamus fernandez expect lilly benefit influx invokana patient transition diabetes med jardiance invokana jardiance class drug call sglt inhibitor sglt sodium glucose co transporter be protein facilitate glucose reabsorption kidney drug block reabsorption glucose kidney increase glucose excretion lower blood glucose level increasingly differentiate label datum date suggest lilly jardiance likely be term beneficiary further perhaps accelerate market share loss invokana fernandez write note client ibd take stay top biotech drug industry bookmarking ibd biotech pharma industry stock news page physician move patient invokana jardiance astrazeneca azn farxiga likely depend full result canvas canvas trial be present june american diabetes association meeting janssen subsidiary begin canvas trial december examine potential cardiovascular benefit invokana canvas trial begin october researcher examine benefit invokana kidney lilly jardiance be approve fda december cut risk cardiovascular death adult type diabetes jardiance be first type diabetes drug get approval cut risk cardiovascular death believe dramatic impact class be unlikely wake jardiance cardiovascular death claim be further mitigate directionally positive result canvas canvas efficacy cardiovascular risk reduction fernandez write still entire sglt need grow jardiance meet beat forecast fernandez see jardiance sale invokana sale forecast entire class grow year so even jardiance be capture invokana estimate sale immediate future major slowdown category growth likely be bigger issue relative consensus estimate say close stock market today lilly stock be goldman sachs analyst remove stock conviction list share member dow jone industrial average advanced related dow pfizer eli lilly topple month lows downgradescan teva hold own bring migraine drug market drug stock rally relief gop health bill win house
92,LLY,eli lilly lly pfizer pfe novartis nvs be pit battle treat breast cancer wall street struggle thursday compare effectiveness drug lilly unveil new datum drug class call cdk work inhibit specific protein prevent proliferation cancer cell pfizer ibrance be first approve area novartis kisqali grab approval year lilly abemaciclib look promising phase trial lilly abemaciclib combine chemotherapy increase progression free survival median month vs month placebo chemo combo hazard ratio measure likelihood death be pfizer drug ibrance be combine chemo earlier trial combo have lower hazard ratio meaning be lower risk death only extend progression free survival median month vs month placebo combo compare boil wall street see better effectiveness metric evercore analyst umer raffat write report note trial study different population breast cancer patient make apple apple comparison tricky still diarrhea remain concern lilly abemaciclib patient experience diarrhea vs patient placebo chemo combination lilly advise patient begin diarrheal medicine first sign diarrhea ibd take want keep tab market american society clinical oncology meeting next month bookmark ibd biotech pharma industry stock news page result be present late wednesday ahead american society clinical oncology meeting june chicago other abstract upload wednesday include merck mrk bristol myer squibb bmy roche rhhby tesaro tsro regeneron regn sanofi sny incyte incy stock spiked month high thursday epacadostat prove effective combo merck keytruda bristol opdivo outdo roche tecentriq newlink genetic nlnk rival epacadostat wasn merck only note interest merck also offer pair update famous trial dub keynote have find keytruda be better chemo first treatment advanced lung cancer hazard ratio keytruda drop merck say be not statistically significant favorable trend have help recent fda approval evercore raffat say note merck keytruda bristol opdivo be know immuno oncology drug work block interaction pd protein immune system cell pd protein cancer cell help immune system identify cancer keynote trial merck also find lung cancer patient treat keytruda initial round see continue benefit keytruda second round cancer progressed cement role pd inhibitor first line treatment even further raffat say phase trial regeneron sanofi find pd drug know regn have benefit rate patient common form skin cancer drug have control rate be very encourage disease set leerink analyst geoffrey porge say american cancer society estimate patient be diagnosed die basal squamous cell skin cancer year longer term be potential regn treat patient advanced not necessarily fatal skin cancer patient enrolled regeneron sanofi trial show complete response month meaning discernible sign cancer disappear porge keep outperform rating regeneron stock be little note tesaro abstract ahead conference leerink analyst seamus fernandez say most interesting datum present next month be combination trial tesaro zejula merck keytruda breast ovarian cancer zejula compete vs astrazeneca azn clovis oncology clvs class drug call parp inhibitor work block specific enzyme treat ovarian cancer parp inhibitor be currently be investigate breast cancer well combine parp inhibitor immuno oncology drug merck keytruda be thought be more potent treat cancer tesaro be also look zejula pd keytruda advanced lung cancer company be slate present datum dozen patient treat zejula keytruda fernandez note bar be fairly low outperform alone pd inhibitor have response rate group patient parp inhibitor have mid response rate recently publish datum small trial astrazeneca imfinzi pd inhibitor lynparza parp inhibitor show somewhat disappointing response rate ovarian cancer patient tesaro believe combination pd antibody zejula be superior fernandez say related incyte team dow merck trounce roche cancerdid astrazeneca rival just launch potential blockbuster drug
93,LLY,here weekly investing action plan need know investor come week apple aapl hold annual worldwide developer conference management typically unveil have already be leak tech medium blogosphere still be surprise loom gadget chatter well
94,LLY,teva pharmaceutical teva square eli lilly lly amgen amgn novartis nvs aldr next month unveil result phase study migraine look rival lilly beat market friday lilly say drug galcanezumab reduce monthly migraine day phase study patient chronic episodic migraine lilly be plan submit application fda later year approval galcanezumab teva fremanezumab drug amgen novartis lilly galcanezumab be know cgrp calcitonin gene related peptide study indicate subject saliva plasma show spike cgrps migraine attack block cgrps be thought stop attack track more person suffer migraine say leerink analyst seamus fernandez forecast entire cgrp drug market lilly take global peak sale other hand question remain market opportunity particularly give concern potential payer headwind well intensity competition write note client ibd take amgen be hang hope cgrp drug erenumab head ibd technology page exclusive interview chief executive robert bradway december look ahead amgen pipeline teva migraine drug fremanezumab be catalyst bust credit suisse analyst vamil divan write research report divan cut price target teva stock keep outperform rating share follow company lackluster first quarter report thursday believe expectation be already relatively high strong datum help improve sentiment stock potentially drive upside say divan cut expectation adjust earning teva respective note difficulty first quarter sale narrowly lag view analyst earning beat cent specialty drug include multiple sclerosis med copaxone decline follow patent battle mylan wrapped february judge declare key patent protect copaxone teva biggest drug invalid stock market today teva stock fall related teva pharma sale lag key multiple sclerosis drug topplesbiotechs cruise day upswing price target cut duo
95,LLY,dow component merck mrk now have year lead rival treat advanced lung cancer analyst say thursday fda approve drug giant keytruda chemo combo late wednesday fda have grant accelerate approval keytruda eli lilly lly chemotherapy alimta carboplatin chemo drug combination be approve patient regardless tumor have lot be know pd protein exist cancer cell keytruda work block interaction pd protein surface cancer cell pd protein immune system cell do so help immune system identify camouflage cancer ub analyst marc goodman see merck have year lead lung cancer like bristol myer squibb bmy astrazeneca azn roche rhhby other combo therapy like bristol myer astrazeneca be horizon have buy rating price target merck stock merck accelerate approval keytruda chemotherapy be contingent study confirm strength treatment result confirmatory study dub keynote be expect september however believe accelerate approval be tacit admission agency take early peek study interim datum be compelling leerink analyst seamus fernandez say note have market perform rating merck stock stock market today share merck component dow jone industrial average rise earlier rise much share bristol be unchanged astrazeneca roche edge ibd take immuno oncology market be far mature keep tab ibd biotech pharma industry stock news page latest emerge sector credit suisse analyst vamil divan expect approval expand keytruda market patient keytruda be also approve first treatment follow chemo treat lung cancer patient tumor have lot pd protein study have show patient tumor have lot pd protein respond better type therapy offer keytruda well bristol opdivo study present october keytruda chemo improve overall survival rate patient regardless pd status adam schechter executive vice president president merck global human health unit expect physician think keytruda chemo combination differently younger patient vs older patient addition believe ve study drug alimta early adoption probably used physician use alimta say merck first quarter earning conference call not pent demand say look build new patient come market think really be exciting opportunity lung cancer patient also establish keytruda further real prefer treatment therapy keytruda approval chemo regardless pd status doesn bode well bristol be struggle increase competition lung cancer bristol opdivo be approve second line treatment meaning only prescribe patient have undergo round chemo bristol be look opdivo yervoy advanced lung cancer yervoy target ctla interaction immune cell cancer cell astrazeneca mystic study be look imfinzi pd antibody tremelimumab ctla antibody lung cancer datum readout change investor sentiment year ub goodman write note assume first line lung cancer sale keytruda respectively first line mean keytruda be prescribe chemo related roche cancer failure tank bristol pfizer not merckbristol myer too risky acquire merck roche pile pressuredid gilead just provide incyte potential deal
96,LLY,regeneron pharmaceutical regn gilead science gild biogen biib benefit most biotechs president trump propose tax reform measure cut corporate tax rate trump proposal business size fortune mom pop shop freelancer live job job pay more business income taxe make corporate inversion unnecessary corporate tax rate be currently mean regeneron gilead biogen have guide adjust tax rate see serious boost cash trump proposal pass analyst say compromise beltway so rate be still air trump approval rating jump april gain ibd tipp presidential leadership index unveil tax reform proposal be first month month increase trump become president doesn mean big pharma biotech be totally sell trump proposal page document release april share biotechs drugmaker collectively lift less day generic drug stock pop gilead chief executive john milligan note uncertainty washington be norm so think ve kind learn filter focus thing be right company say gilead first quarter earning conference call be tax reform be repatriation count trump plan slash corporate tax rate benefit company consolidated tax rate remain well level consolidate taxe allow firm treat group wholly majority own company single entity tax purpose domicile drugmaker typically pay consolidated taxe canaccord analyst dewey steadman tell investor business daily company acquire foreign firm move tax domicile outside acquire company often lower tax homeland mylan myl acquire generic manufacturer abbott laboratory keep operational headquarters pennsylvania reincorporate netherlands march mylan say expect pay tax rate similarly allergan agn guide february adjust tax rate allergan corporate headquarters be ireland april pfizer pfe scrap attempt acquire allergan day treasury unveil new rule curb inversion former president barack obama call global tax avoidance huge problem urge congress close loophole good trump other hand say tax reform proposal make inversion unnecessary make america tax rate best world regeneron gilead biogen be biggest winner cut evercore analyst umer raffat say april report regeneron have guide effective tax rate gilead see first quarter biogen paid adjust taxe drugmaker pfizer eli lilly lly merck mrk bristol myer squibb bmy guide effective tax rate canaccord steadman mizuho analyst salim sy tell ibd everything politic be subject negotiation smaller biotechs say obviously positive future everyone be take see approach steadman say rate be probably go happen re not change capital expenditure organizational structure meantime ibd take look latest biotech drug news be sure bookmark ibd biotech pharma industry stock news page second facet trump plan allow time repatriation corporate cash park overseas discount tax rate be follow end deferral taxe corporate income earn abroad evercore raffat say amgen amgn benefit most drugmaker provision amgen have cash stash overseas money amgen use help boost war chest generic rivalry battle regeneron sanofi sny cholesterol front same be say gilead overseas cash be face dwindle sale hepatitis drug franchise gilead have be pressure month analyst chatter buy something bolster sale incyte incy be likely candidate analyst say accord raffat merck pfizer have respective cash outside lilly bristol celgene celg biogen abbvie abbv have park overseas cash be repatriate research development used fuel pfizer chief executive ian read offer similar view gilead milligan company first quarter earning conference call expect industry consolidation continue time political atmosphere remain major deterrent believe be simply too much redundancy fragmentation globally sector continually efficiently deliver medicine society say however be lack clarity potential tax reform health care policy uncertainty european market canaccord steadman doesn expect wave even trump tax reform pass muster congress need attempt pfizer allergan merger inversion purpose say appetite biotechs look healthy see decline big inversion type merger be not necessarily strategic see appetite biotech asset just tax picture look better say net result be actually decrease large merger maybe increase valuation biotech don think drife much more much still murky trump tax proposal analyst say general theme be tax reform be good thing biotech mizuho sy tell ibd don exactly know tax reform be go be be still lot piece move repatriation border tax don have component border tax be extreme drawback company manufacturing less expensive country such adjustment exempt export taxation tax import pwc analyst doug strang kathy michael write feb report january speech chamber commerce house way mean committee chairman kevin brady say tax eliminate tax incentive company move manufacturing overseas couple new lower gop tax rate local business end double taxation earning overseas establish america st century magnet new job technology breakthrough headquarters say gop tax plan be already drive company ask soon bring supplier back most company relocate operation back be paperwork nightmare canaccord steadman say current plan doesn include border tax provision nothing incentivize company bring operation back be enough keep newer smaller company re domicile overseas say probably entice future company not leave think core goal re try do say be domicile lower rate wouldn have leave cash foreign subsidiary cash be base encourage investment related do gilead just provide incyte potential deal dow pfizer top earning view sale come lilly new drug spark deeper rivalry pfizer novartis
97,LLY,drug stock pop collective midday thursday gop health care bill repeal replace major portion obamacare narrowly pass house follow vote ibd company medical ethical drug industry group rise month high generic drug biotech stock other hand advanced just apiece zoetis zts stock lift follow consensus crush first quarter earlier day also endo international endp stock rise mallinckrodt mnk stock pop eli lilly lly stock be analyst have say uncertainty regard president trump health care ambition weigh biotech pharma market year april leerink analyst geoffrey porge tell investor business daily doesn seem accumulate worry be go go away hurry re worry donald trump health care reform re worry fda reform now re worry drug pricing regulation say ibd take biotech stock be now rate group track head ibd stock checkup list top rate biotech stock house vote land largely partisan line president trump day office republican laud bill major current form eliminate individual coverage mandate protection patient pre exist condition trumpcare state be allow apply waiver exempt essential health benefit outlined obamacare include coverage maternity newborn care prescription drug mental health accord congressional budget office bill be expect reduce federal deficit average premium single policyholder be expect rise number uninsured grow related biotech surge survive volatile market
98,LLY,dow component pfizer pfe tuesday report mixed first quarter result call essential health unit tug overall sale revenue novartis nvs rivale cancer drug bound vs year earlier quarter pfizer say earn adjust income cent share revenue first quarter respectively analyst have expect drugmaker report earning cent share sale quarter pfizer innovative health unit include newer product grow essential health business include legacy product offset fall september pfizer scrap idea corporate breakup have split business wall street have pin hope pfizer ibrance be approve treat form advanced breast cancer ibrance sale grow period have competition novartis kisqali further eli lilly lly abemaciclib have show promise clinical trial sale pneumonia vaccine prevnar topple vs year earlier quarter dip be primarily due continue decline revenue adult indication due smaller remain catch opportunity pfizer say globally sale fall timing government purchase enbrel also see sale dip outside canada enbrel sale come develop europe enbrel sale fall revenue also topple emerge market other develop part globe respectively ibd take have trouble keep slew pharma biotech earning quarter catch ibd biotech pharma industry stock news page pfizer also reiterate guidance revenue adjust earning share flat respectively analyst be call revenue adjust income share stock market today share member dow jone industrial average dip earlier fall much touch lowest point month stock have potential buy point cup handle begin form august meanwhile fellow dow drug giant merck mrk also issue first quarter earning report merck top earning sale raise full year guidance gilead science gild major biotech player report weaker expect earning sale late tuesday related lilly new drug spark deeper rivalry novartis pfizerpfizer follow baxter get slam subpoena related saline shortage
99,LLY,biotechs cruised sixth day gain monday price target cut like alk aldr follow recent first quarter earning aimmune therapeutic aimt stock remain top pick small midsize cap credit suisse analyst vamil divan say monday slash price target share stock have outperform rating midmorning stock market today investor business daily company biom biotech industry group add continue streak past week stock comply pop close stock lift follow first quarter performance be light top bottom line loss be expect still divan remain bullish stock note adjust loss share vs consensus view cent loss be result ramp research development spending migraine drug compete like amgen amgn eli lilly lly teva pharmaceutical teva class migraine drug call calcitonin gene related peptide cgrp cgrps be peptide thought be related migraine drug work block peptide expense be higher expect quarter be go forward believe key story remain upcoming phase datum say expect have datum frequent episodic migraine midyear chronic migraine first half ibd take investing biotech doesn have be pain head ibd technology page quick tip survive volatile market question ability differentiate eptinezumab competitor cgrp space intellectual property situation be likely remain potentially limit upside see positive phase datum say continue see significant longer term upside case divan be bet opioid dependence pill vivitrol become blockbuster help offset challenge loss patent protect acorda therapeutic acor ampyra manufacturer multiple sclerosis drug acorda divan also lower view sale schizophrenia drug aristada also cut estimate product enthusiasm remain drive upside expect vivitrol midterm then pipeline time write note client aimmune be expect have top line result phase study drug peanut allergy end year divan say base efficacy phase testing seemingly better understand safety tolerability profile be optimistic outcome divan have outperform rating price target aimmune stock be also bullish myokardium foamix pharmaceutical edge therapeutic stock have price target respectively be outperform rate related acorda forward biogen fall multiple sclerosis drug fightlilly regain key migraine drug colucid merck allergan top analyst view pharma
100,LLY,eli lilly lly stock dip early tuesday drugmaker top wall street first quarter sale profit expectation baricitinib lilly incyte incy rheumatoid arthritis drug need more clinical datum fda bless monday lilly say breast cancer drug abemaciclib rivale pfizer pfe novartis nvs meet goal interim analysis breast cancer give lilly stock confidence head early tuesday first quarter earning report call investor likely look commentary regard plan baricitinib also strong number diabetes chemotherapy unit new drug lilly biggest be trulicity diabetes drug cyramza tumor drug trulicity sale launch first quarter cyramza lilly see major outperformance basaglar diabetes drug see sale grow ibd take lilly stock have middling ibd composite rating meaning underperform more half stock term key growth metric better stock bet be jazz pharmaceutical cr best possible head ibd stock checkup list top rate drugmaker consensus consensus expect lilly report cent adjust profit sale year year basis adjust earning share be sale grow result lilly report sale cent adjust ep respectively guidance company reaffirm adjust ep guidance stock action lilly stock fall close stock market today announce first quarter result stock close monday related lilly outperform bigger rival strong diabetes med eli lilly incyte stock break key level fda drug lilly survive rheumatoid arthritis flop breast cancer drug
101,LLY,eli lilly lly stock pop monday drugmaker say breast cancer drug have potential be best class potentially spark deeper rivalry pfizer pfe novartis nvs lilly stock finished higher stock market today stock touch day move average first time trading day ibd company medical ethical drug industry group jump nearly drug abemaciclib improve progression free survival overall survival combine inhibitor type breast cancer treatment interim analysis street expect trial run completion final analysis end year specific result be expect june annual american society clinical oncology meeting most common side effect lilly say be diarrhea fatigue nausea neutropenia lack type white blood cell leerink analyst seamus fernandez call trial result unexpected lilly abemaciclib belong class drug work inhibit cdk enzyme effort treat breast cancer lilly be gear compete pfizer novartis cdk breast cancer market pfizer ibrance lead market launch novartis kisqali recently receive fda approval write note client ibd take eli lilly stock have ibd composite rating meaning underperform majority stock term key growth metric head ibd stock checkup list better stock bet pfizer ibrance be lead market kisqali be approve march abemaciclib now have major win belt put equal foot pfizer ibrance fernandez say abemaciclib also have strong top line result phase study announce march fernandez note have outperform rating lilly stock related lilly outperform bigger rival strong diabetes med eli lilly incyte stock break key level fda drug lilly survive rheumatoid arthritis flop breast cancer drug
102,LLY,novartis nvs tuesday report better expect first quarter earning revenue unexpectedly edge lower adjust earning share fall revenue dip have rise constant currency analyst have expect ep sale cosentyx sale hit plaque psoriasis drug hit blockbuster status make novartis best selling immunological drug chemotherapy drug gleevec novartis top selling drug see continue pressured generic sale tumble eye drug lucentis sale dip novartis say still expect full year sale be roughly equal base constant currency core operate income flat low single digit multiple sclerosis drug gilenya see gain gilenya rival drug biogen biib sanofi sny roche rhhby ibd take novartis stock have low ibd composite rating meaning underperform nearly stock term key growth metric head ibd stock checkup list stronger stock contender drugmaker also recently launch breast cancer drug kisqali be approve march kisqali rival pfizer pfe ibrance not yet approve drug eli lilly lly call abemaciclib novartis share rise tuesday stock market trading share have be form cup handle buy point july related lilly new drug spark deeper rivalry pfizer novartis
103,LLY,stock market hold gain afternoon trading monday nasdaq make favorable move chart nasdaq rise be inch back day move average nasdaq look better jump separated bit own day line index largest nonfinancial nasdaq listing never go day average last week netflix nflx largest nasdaq component be highest volume stock move video stream company announce result close today dow jone industrial average be also remain day average meaning still reason be suspicious rebound market volume be tracking lower be surprise give prior session trading slow ahead day weekend also curious be fact only few stock be heavy volume homebuilder continue provide interesting chart horton dhi be try break past buy point cup handle base price volume activity be insufficient view today move rush institutional buy relative strength line be not new high be damper potential entry homebuilder have shot top ibd industry ranking week william lyon home wlh calatlantic group caa also be form cup handle basis be research further health care stock be mixed pharmaceutical hospital tumble variety reason hca holding hca slide double usual volume breaking day move average hospital operator give preliminary first quarter result today report sale year earning share rise number be expectation ibd hospital industry group be worst perform today market hca be week high other be more baxter international bax fall active trading remain price advance have take stock record high report say justice department be investigate sale practice intravenous saline include sell baxter abiom abmd make impella heart pump gap loss big volume stock have be form base fall day line be news wire pharmaceutical eli lilly lly incyte incy plunge day line heavy volume fda decline approve rheumatoid arthritis drug say more clinical trial be necessary related eli lilly incyte stock break key level fda drug setbacknetflix earning close expect
104,LLY,abbvie abbv get breathe room rheumatoid arthritis eli lilly lly incyte incy drug be hit delay food drug administration weekend leave lilly instead focus pfizer pfe rivale breast cancer med friday fda ask more dose information lilly incyte rheumatoid arthritis drug baricitinib cause be lengthy delay release so lilly breast cancer drug know abemaciclib be now especially important lilly leerink analyst seamus fernandez say abemaciclib compete pfizer ibrance novartis nvs kisqali cdk inhibitor market drug aim inhibit specific set enzyme thought be tie breast cancer lilly model be currently forecasting global sale abemaciclib overall cdk market reach more fernandez write note client fernandez say abemaciclib be next major catalyst lilly stock phase datum abemaciclib be expect june believe abemaciclib ability dose continuously together safe manageable tolerability profile likely make abemaciclib highly competitive novartis kisqali provide opportunity differentiate pfizer ibrance secondary efficacy measure response rate fernandez say analyst keep outperform rating price target lilly stock lilly share topple much stock market today close day ling buy point incyte stock tumble delay baricitinib mean likely win get fda approval launch remove term rival abbvie humira also put lilly incyte year pfizer xeljanz more line generic competition analyst expect drug be delay least year share lilly incyte topple early monday baricitinib already have be approve use europe baricitinib be likely delay fernandez expect peak sale be approve lilly still benefit sale europe drug have attain approval ibd take ibd company ethical drugmaker industry group have rise group track just week head ibd stock checkup list top rate drugmaker other analyst agree year delay baricitinib be more cautious lilly breast cancer drug bmo analyst alex arfaei call abemaciclib biggest remain uncertainty lilly see datum likely disappoint still have not see much datum indicate cdk inhibitor be meaningfully differentiate write report datum american association cancer research suggest abemaciclib be not selective ribociclib kisqali ibrance arfaei cut price target lilly stock maintain forecast sale growth lilly diabetes drug trulicity jardiance basaglar psoriasis drug talz drug offset decline mature franchise write however forecast revenue compound annual growth rate lilly guidance partly more conservative assumption mature franchise related eli lilly incyte stock break key level fda drug biogen takeover prospect soured mere monthsbiotech split axovant ride ceo swap celgene partner dife
105,LLY,eli lilly lly be set outperform bigger drugmaker novartis nvs sanofi sny term first quarter diabetes sale help tug lilly rheumatoid arthritis drug be delay fda analyst say tuesday leerink analyst seamus fernandez keep outperform rating lilly sanofi stock market perform rating novartis ahead first quarter earning note client lilly novartis be set report earning april sanofi come april believe lilly be poise deliver strong top line bottom line performance fernandez say pullback stock follow fda complete response letter baricitinib create attractive trading opportunity view monday lilly stock lose fda say application lilly rheumatoid arthritis drug baricitinib be incomplete further clinical dose information request likely hamper baricitinib produce partnership incyte incy least year other analyst have say baricitinib be likely delay year fernandez see lilly incyte drug delay month late cut annual global sale forecast drug sale diabetes drug trulicity psoriasis drug talz more offset delay baricitinib fernandez say raise peak sale trulicity talz respectively overall consensus analyst poll yahoo yhoo expect lilly report sale vs year earlier period adjust earning cent share fernandez be more bullish cent boost price target lilly share fernandez expect sanofi novartis deliver line revenue firm basal insulin diabetes franchise face pricing pressure drug include lantus toujeo sanofi levemir tresiba novartis ibd take eli lilly have middling ibd composite rating base key growth metric earning sale performance better stock bet include like jazz pharmaceutical jazz have cr best possible head stock checkup see pick stack lantus toujeo prescription be perform better expect face launch basaglar lilly fernandez say note client still see year year pricing decline lantus silver line sanofi be dupixent eczema treat injection conjunction partner regeneron regn drug be approve march so win have sale first quarter consensus see sanofi sale dip first quarter novartis fernandez note victoza be still grow tresiba uptake be track pricing pressure be likely weigh diabetes drug least end third quarter broadly analyst expect novartis report sale growth adjust earning share cent vs year earlier period sanofi fall close stock market today lilly drop novartis dip follow johnson johnson lackluster first quarter result see drug sale eke gain related lilly survive rheumatoid arthritis flop breast cancer drug dow johnson johnson set lackluster result sector
106,LLY,eli lilly lly incyte incy share plunge monday morning food drug administration fail approve rheumatoid arthritis drug baricitinib say more datum be need eli lilly incyte disagree fda friday decision come somewhat surprise european regulator approve baricitinib february lilly incyte have conduct more clinical trial satisfy fda delay set drug several rival lilly reaffirm earning sale guidance year incyte discuss matter conference call eli lilly fall close stock market today eli lilly have fall buy point clear early march incyte tumble plunge day move average setback lilly incyte be good news dow jone industrial average component pfizer pfe have only oral jak inhibitor rheumatoid arthritis market xeljanz gilead science gild have similar oral drug baricitinib phase trial fellow dow component johnson johnson jnj abbvie abbv amgen amgn have injectable drug pfizer gilead amgen johnson johnson abbvie rise less morning action
107,LLY,stock hold solid gain quiet trade early monday earning season pick big bank due report week apple aapl mcdonald mcd initially lead dow jone industrial average analyst rating price target change nasdaq composite rally dow jone industrial average rise volume be lower board stock market today vs same time thursday preholiday session telecom service metal ore miner movie related stock lead upside thank gain netflix nflx report earning close hospital automaker drugmaker lag boee ba caterpillar cat be top gainer dow climb apple mcdonald be respectively pare earlier gain apple share be just week tight follow entry be well extend past cup handle buy point clear january rbc capital maintain outperform rating iphone maker boost price target raise ep forecast cent share mcdonald remain buy range handle entry well fargo upgrade burger giant outperform market perform lift price target range moneygram international mgi pop alibaba group baba ant financial unit sweeten bid global payment service prior offer be top euronet worldwide eeft alibaba advanced nearly euronet be fractionally lower downside incyte incy plunge massive volume gapping undercut day line first time month fda friday fail approve biotech baricitinib rheumatoid arthritis drug say more clinical datum be need goldman lower incyte price target partner eli lilly lly gap fall also breach day line bmo capital downgrade drugmaker underperform market perform cowen raise price target related apple facebook get price target hike mcdonald buyeli lilly incyte stock set break key level fda setbackalibaba ant financial hike moneygram bid
108,LLY,xanalyst action monday include price target hike apple aapl facebook fb upgrade mcdonald mcd downgrade eli lilly lly rbc capital raise price target apple keep outperform rating analyst amit daryanani cite iphone cycle acceleration service revenue potential increase tax profit dividend share buyback trump administration tax cut include change taxation profit hold overseas bump ep estimate cent share share apple rise stock market today move back buy point lose friday credit suisse hike price target social medium leader keep outperform rating meanwhile aegis capital lift facebook target buy rating aegis analyst victor anthony say expect facebook unveil new camera video innovation annual developer conference week help increase engagement monetization anthony also predict solid quarterly earning base strong advertiser check share facebook rise ibd take check fang stock be face big technical test week try rise week move average stock have outperformed well fargo upgrade fast food giant outperform market perform raise target range mcdonald analyst jeff farmer expect market share gain drive company recent adoption mobile order payment give first mover advantage burger chain consumer farmer say be aggressively gravitate concept offer greatest level convenience control order payment distribution share mcdonald add still range buy point bmo capital downgrade eli lilly underperform market perform fda say more clinical datum be need clarify dosage level safety concern approval rheumatoid arthritis drug baricitinib partnership incyte incy still cowen co raise price target eli lilly cite momentum other part business include other late stage drug candidate goldman lower price target incyte keep buy rating analyst richter cut goldman ep estimate loss cent gain cent cite potential incyte drug pipeline share eli lilly slide incyte sank related apple be largest western seller software china reportapple get price target hike expectation huge iphone launchinstagram story pass snapchat facebook assault serve fresh beef quarter pounder stock near buy pointeli lilly incyte stock break key level fda drug setback
109,LLY,exchange trade fund tracking major stock index rise monday stunning setback health sector fda reject eli lilly lly drug treat rheumatoid arthritis spdr spy add shortly open bell stock market today technology lead advance sector health care top decline sector reverse higher health care select sector spdr xlv largest exchange trade fund segment chopped flat line morning trade share eli lilly partner incyte incy tumble more respectively food drug administration reject drug baricitinib safety concern health care etf slice further rise day move average key gauge institutional support early monday now sit march high eli lilly be largest component portfolio stock ishare nasdaq biotechnology ibb give early trading incyte be top hold stock portfolio analyst have expect eli lilly incyte drug generate more sale have be approve accord cnbc pfizer pfe offer popular arthritis drug be fractionally lower early monday ibd take fda setback eli lilly have important ramification other key drugmaker broader health care industry related be go etf market
110,LLY,nasdaq composite show resilience stock market shrug increase tension north korea weekend economic report miss expectation move higher midday trade meanwhile new york federal reserve empire state manufacturing index fall april march estimate read meanwhile nahb housing market index come april vs estimate nasdaq lead way gain attempt recapture day line lose thursday dow jone industrial average moved higher dow jone industrial average give own day support level last wednesday volume be run lower vs same time thursday ahead day easter holiday dow industrial stock be positive component trading red boee ba pace advancer stock market today share take airplane maker look rebound week line megacap industrial defense play have rally more clear buy point long saucer base late october get respectable composite rating ep rating scale rs rating ibd stock checkup drug stock trade lower midday trading drive fda decision share eli lilly lly incyte incy be send lower food drug administration fail approve rheumatoid arthritis drug baricitinib eli lilly drop incyte plunge pierce day line meanwhile abiom abmd drop cardiac pump maker build right side potential base chip stock moved higher industry look recover last week weakness drive apple decision source certain type chip lead fabless semiconductor group name broadcom avgo moved share attempt get back day line meanwhile ibd member nvidia nvda jump chip leader test recent lows level remain well day line other ibd top performer include nutrisystem ntri mortgage insurer essent group esnt gain respectively downside china base momo momo decline close netflix nflx release much anticipate earning report jan video stream company surge nearly exceed earning sale forecast however stock hasn make much progress upside then remain hold day consensus estimate expect company earn cent share revenue totale related more soft economic report just turn less bullisheli lilly incyte stock break key level fda drug setbacknetflix earning tap stream medium stock undercut support
111,LLY,stock open higher monday weak read new york manufacturing activity april dow jone industrial average nasdaq climb be bank financial remain big piece week report news quarterly result due week bank america bac goldman sachs gs morgan stanley ms visa other bank mtb rolled monday early earning report rise more result easily top analyst first quarter expectation company repurchase share quarter raise annual dividend cent cent mcdonald mcd rise apple aapl dow well fargo upgrade mcdonald outperform market perform apple gain rbc capital raise price target maintain outperform rating pacific crest security raise concern difficulty fingerprint sensor apple upcoming iphone pfizer pfe gilead science gild abbvie abbv rise incyte incy drop more early action wilmingon del base biotech report friday food drug administration deny application incyte eli lilly lly rheumatoid arthritis treatment baricitinib estimate have put annual value drug incyte share plunge day move average heavy volume trigger sell signal eli lilly share drop also break day line remain buy point gilead gain abbvie jump pfizer be flat pfizer gilead abbvie compete market rheumatoid arthritic treatment
112,LLY,china alibaba group hold baba climb open financial unit ant financial raise offer global payment service moneygram international mgi ant initial offer be top euronet worldwide eeft place offer march moneygram share rise open euronet share rise ibd leaderboard stock alibaba be buy range alternative handle buy point medical diagnostic product maker alere alr open waltham mass base company announce friday abbott laboratory have mutually dismiss compete lawsuit abbott have reduce takeover offer share deal now value alere be expect close third quarter abbott drop open manufacturing slow sharply new york region april send new york federal reserve empire state manufacturing survey read read be still positive march far economist expectation well level post nearly new order retreat unfilled order slow delivery time lengthen shipment edge gauge employment hour work remain firm national association home builder release builder confidence survey et gauge be april internationally readout global stock market today be spotty due holiday schedule japan tokyo nikkei post gain monday hold back dollar weaken yen concern north korea china shanghai composite end top regulator pledge resolute crackdown risky market action hong kong stock exchange remain close holiday europe exchange london paris frankfurt remain close holiday related big week dow stock earning investing action planinvestor unfazed north korea netflix unite continental earning tap
113,LLY,regeneron regn sanofi sny eczema drug dupixent outstripped psoriasis drug rival company fourth week prescription analyst write monday suggest consensus view drug be beatable friday sanofi say earning call prescription have be written physician dupixent first month market health care tracker im suggest prescription be filled fourth week dupixent launch comparison prescription psoriasis drug novartis nvs cosentyx taltz eli lilly lly have be written point follow launch celgene celg otezla have script most successful drug have be otezla fourth week dupixent launch be double prescription volume otezla leerink analyst geoffrey porge write note client also note recent successful launch cholesterol lower drug amgen amgn repatha regeneron sanofi praluent see prescription otezla estimate monthly net price period be be likely net price dupixent porge write adjust only higher price dupixent sale be base otezla sale record however dupixent indeed continue see double prescription volume otezla revenue be closer beat compare consensus say early post launch information thus far be very encourage ibd take do survive investing market relatively unheard company esperion therapeutic espr launch nearly mere month matter identify right catalyst analyst say head ibd technology page more base sanofi disclosure written dupixent prescription first month porge model fill rate april grow fill rate december more payer open access lead potentially prescription filled fifth week be not unreasonable give prior week week growth prescription porge say analyst broadly model dupixent sale second quarter third fourth porge see dupixent sale grow comparatively otezla cosentyx bring first quarters market comparison dupixent be more expensive otezla significantly cheaper cosentyx be enter much less competitive category more untreated patient appear be faster access major pharmacy benefit manager formulary write porge reiterate outperform rating price target regeneron stock stock market today regeneron stock be sanofi stock fall related amgen trump regeneron sanofi post trial cholesterol drug scriptsamgen payer pushback likely sting battle regeneron sanofiregeneron sanofi get approval eczema drug price
114,LLY,be just year formula seem right biogen biib fourth largest company industry mix biotechnology megamerger biogen multiple sclerosis franchise lineup drug include tecfidera tysabri be grow tecfidera biogen most important drug bring further hemophilia sale small grow just brand name drug eloctate alprolix spinraza spinal muscular atrophy drug grab fda approval just day christmas plot thicken biogen chief executive george scango resign july leave company susceptible takeout like merck mrk allergan agn eli lilly lly pfizer pfe takeout rumor abound biogen stock end make cheaper asset buy thought last year be really time happen leerink analyst geoffrey porge say biogen offer last year be relatively stable ms business be still grow robust cash flow scheme opportunity spinraza hemophilia franchise so acquirer say get fast forward today picture be entirely different biogen be see increase competition ms market payer be balk spinraza price company have already take hemophilia drug equation now only wall street see biogen potential takeout candidate accord mizuho survey porge say biogen probably have see deal roll ever think have become significantly less likely porge say so happened incredibly successful multiple sclerosis include launch zinbryta abbvie abbv biogen ms unit be face loom competition like roche rhhby celgene celg porge tell investor business daily note client april porge call roche ocrevus game changer ocrevus be approve late march treat relapse remit primary progressive form ms separate pack be only approve relapse remit form ms physician patient community have be eagerly await ocrevus launch porge say drug high efficacy reasonable safety profile convenient month dose schedule be major factor drug positive reception spell trouble biogen tecfidera have comprise total product sale well ms unit biogen be actually partner roche ocrevus royalty win be enough offset erosion own ms franchise analyst say porge expect ocrevus get primary progressive ms market year relapse remit ms market porge see erosion tysabri erosion tecfidera novartis nvs gilenya sale meanwhile celgene be work ms drug call ozanimod phase testing function ozanimod be closest novartis gilenya also rival tecfidera sanofi sny aubagio tecfidera gilenya aubagio respectively lead ms market term sale celgene want buy sale force have something overnight help sell ozanimod biogen be company porge tell ibd biogen likely suffer erosion roche competition ms look less probable silver line biogen win patent interference case forward pharma fwp tecfidera be settlement fee forward stock topple decision now lose major royalty biogen spinraza have different set trouble develop ionis pharmaceutical ion spinraza be first only drug approve rare neurological disorder cause muscle weakness wasting infant child wall street largely thought spinraza slam dunk have profound efficacy august study infant child drug be so effective biogen ionis end study early ionis chief executive stanley crooke tell ibd december spinraza be approve dec fairly broad label approve use child adult spinal muscular atrophy remain only drug approve disease crooke call catastrophic drug thing be rapidly adopt widely reimburse porge say have happened be appear be good fortune label have turn liability payer become concern too many patient start drug so restrict access mizuho analyst salim sy call largely spinraza story biogen be set report first quarter earning april be particularly tell follow launch spinraza earlier year analyst say payer be push back hard reimbursement drug insurer anthem antm humana hum be only reimburse patient spinraza most severe form disease type unitedhealth group unh have broader policy cover type patient be spinraza cost treatment first year subsequent year make pricey drug consensus be project first quarter spinraza sale sy say porge lower expectation spinraza sale result first quarter be especially tell tell ibd north patient drug be pretty good long re see continue start then biogen hemophilia drug lineup february biogen spun hemophilia franchise bioverativ bivv then bioverativ share be be great bioverativ company consider biogen takeover think again unit porge say ibd take bioverativ isn standard biotech startup head new america find bioverativ have yet announce quarterly result have only be public early february company be set release first quarter earning result last full quarter biogen hemophilia unit bring year year now porge say be smart biogen also spin multiple sclerosis unit turn focus alzheimer alzheimer biogen be follow eli lilly merck have notable failure december february biogen alzheimer play be strongest sector analyst say march rbc analyst michael yee tell ibd pfizer merck be likeliest player make bid biogen be interested more brand drug particularly alzheimer pipeline biogen be work class alzheimer drug work remove plaque buildup brain associate alzheimer call bace inhibitor eisai bace inhibitor aim prevent plaque buildup porge say biogen likely have see renew takeover interest biogen be expect release result phase trial aducanumab bace inhibitor elenbecestat be also phase trial result expect september eli lilly solanezumab work theory remove plaque buildup call beta amyloid brain merck verubecestat be bace inhibitor fail be only handful potential alzheimer drug development now meanwhile axovant science axon be work different theory treatment doesn involve beta amyloid expect have phase datum drug intepirdine later year too change alzheimer landscape potentially further dent biogen chance merger still biogen board place high premium alzheimer pipeline ever come acquisition table porge say everything else have fail development cost aducanumab elenbecestat have head billion dollar porge say re willing take risk alzheimer still make sense acquisition ve hear person industry be re struggle bridge gap say board want be paid alzheimer go work related roche game changer drug chip away biogen novartisbiogen dife takeover buzz fade drug hit small cap biotech take gilead celgene biogen alzheimer
115,LLY,axovant science axon oncomed pharmaceutical omed diverged ibd company biotech industry group monday axovant stock ride chief executive swap month high oncomed stock topple fail drug trial close bell stock market today axovant stock pop announce former medivation ceo david hung succeed vivek ramaswamy top job axovant ramaswamy move lead axovant parent roivant science hung appointment be effective friday head medivation acquisition pfizer pfe september ramaswamy say news release axovant hadn initially be look new ceo approach david take role mindset study say add david decide want join now mindset study look axovant drug intepirdine mild moderate alzheimer patent result be expect september axovant stock bust cup handle formation begin august pass entry point share be now extend buy point touch high last achieve december meanwhile share oncomed plunge time low drug demcizumab fail extend progression free survival late stage pancreatic cancer patient oncomed stock hit record low fall point session be close oncomed trial look combination demcizumab gemcitabine abraxane oncomed also miss second goal improve overall survival trial compare demcizumab gemcitabine chemotherapy first develop eli lilly lly celgene celg chemo abraxane gemcitabine abraxane placebo ibd take ibd biotech industry group be rank group track just week biotechs celgene stock be clear leader ibd composite rating best possible head ibd stock checkup list top best perform biotechs also monday bayer pharma bayry drop deal license oncomed drug vantictumab strategic reason oncomed say news release drug aim treat solid tumor prove safe effective alone combination chemo early trial have look forward collaborate bayer team late stage development biotherapeutic be very pleased have worldwide right promising phase ready asset ceo paul hasting say statement related axovant confidence not sway rival alzheimer drug fail
116,LLY,eli lilly lly heist johnson johnson jnj type diabetes share leerink analyst seamus fernandez say wednesday day lilly stock outplay mixed quarter president trump related boost lilly stock ramp tuesday continue black wednesday close bell stock market today share end regular session earlier touch nearly month high lilly stock react softer tone trump tuesday pledge deregulate industry cut taxe trump also call drugmaker manufacture meeting executive celgene celg merck mrk lilly novartis nvs trump reportedly backed call revisit allow federal government negotiate behalf medicare medicaid fernandez research note say be reluctant call first event victory be not bad prior commentary keep outperform rating price target lilly stock note drugmaker sale diabetes drug improve lilly sale top estimate tuesday earning miss fernandez credit growth diabetes product sale performance sale diabetes drug trulicity jardiance grow respectively ibd take trump commentary have send drug stock run tuesday immigration ban monday topple airline stock fall survive read ibd industry theme deeper look trulicity belong class drug call glp receptor inhibitor have new brand share year year growth space fernandez write jardiance have new therapy share endocrinologist exceed invokana barclay analyst geoff meacham be less bullish boost price target lilly stock keep outperform rating trump rattle drug industry meacham say investor prefer product drive company lilly give difficulty triangulating drug pricing debate settle continue prefer product drive story lilly relatively low reliance price revenue concentration risk write research report lilly be likely struggle emerge immuno oncology market write company be partner merck combine drug keytruda chemotherapy alimta treat small cell lung cancer fda look likely approve combo write anticipate approval kn phase study keytruda recent favorable patent ruling drive pickup alimta growth meacham say outside oncology meacham expect lilly add drug pipeline baricitinib rheumatoid arthritis galcanezumab cgrp migraine market latter arena lilly compete teva pharmaceutical teva pharmaceutical aldr amgen amgn related eli lilly novartis challenge pfizer potential breast cancer drugpfizer report lag ep rebound trump round trip trump inspire rally fda appointment key
117,LLY,president trump call drugmaker manufacture effort curb rise price meeting big pharma executive white house mere week accuse industry get away murder trump also promise cut regulation appoint fantastic person lead food drug administration tight regulation slow fda often jam approval process drugmaker say last year fda approve new molecular entity year low tenor be reportedly different earlier call have federal government negotiate price behalf medicare medicaid agency cover million american be biggest purchaser health care product service world same meeting trump pledge increase international competition cut taxe business lure company back trump have pledge put america first inaugural speech say decision be make benefit american worker american family ibd take isn first time trump have pledge bring rise drug price actually mean biotech drug stock take look ibd industry theme deeper dive pharma bigwig include ceo eli lilly lly merck mrk celgene celg novartis nvs reportedly attend meeting johnson johnson jnj exec ceo pharmaceutical research manufacturer america also reportedly attend pricing have be astronomical trump say accord bloomberg folk have do very great job year have get price drug biotech stock reversed earlier loss news trump meeting emerge ibd company biom biotech industry group jump more close stock market today ibd company ethical drug industry group gain meanwhile spdr biotech xbi exchange trade fund be more move day line ishare nasdaq biotechnology index ibb etf also be get day day line related biotechs round trip trump inspire rally fda appointment key stock set new high biotechs give back most trump rally
118,LLY,acorda therapeutic acor inhaled migraine drug generate long term sale potentially rival more novel mechanism eli lilly lly janney analyst ken predict monday acorda cvt lack novel molecule novel mechanism such colucid lasmiditan offer potential clinical benefit more rapid consistent administration exist triptan uniquely deliver pulmonary route write lilly last week announce agreement acquire colucid pharmaceutical clinical trial cvt have prove match be faster triptan family medicine used treat migraine cluster headach map pharmaceutical amgen amgn acquire find inhaled dhe be minute faster placebo acorda likely shoot similar result phase trial cvt oral pill be far most common route administer migraine drug oral admission account exist zolmitriptan unit dose say say mean cvt swipe meaningful share triptan market ibd take analyst be generally cautious biotech pharma stock head earning season incyte be grab bullish view potential blockbuster drug dive new america more lilly be buy colucid get hand lasmiditan lilly discover lasmiditan house license drug colucid inhaled dhe lack novelty offer colucid lasmiditan method migraine treatment be enough attract development milestone map pharma amgen spend acquire note see relatively clear path cvt approval follow phase trial phase trial see drug launch device patent protect pending patent pertain cvt formulation protect have neutral rating acorda stock fall monday stay day line related lilly regain key migraine drug colucid plan robust alzheimer migraine oncology ceo exclusivedrug stock tank trump vow attack high drug price
119,LLY,pfizer pfe ibrance grow sale leerink analyst seamus fernandez say drugmaker first have overcome competition eli lilly lly novartis nvs ibrance belong class drug call cdk cdk selective inhibitor food drug administration approve combination ibrance femara inhibitor february treatment estrogen receptor positive advanced breast cancer now eli lilly novartis be creep abemaciclib ribociclib respectively abemaciclib be approve breakthrough designation be several phase test last year fda grant ribociclib priority review first line advanced breast cancer prescription trend show ibrance be slow rapid uptake fernandez lower yearly sale expectation still see ibrance run global annual revenue ibd take pfizer have drug approve else curry favor time period head ibd industry theme more fernandez research report keep market perform rating price target pfizer stock afternoon trading stock market today pfizer rise cent company be set report earning open tuesday fourth quarter sale earning be likely line pfizer fernandez say consensus analyst poll thomson reuter expect pfizer report sale cent ep ex item respective vs year earlier quarter acquisition medivation complete september add sale prostate cancer drug xtandi pfizer top line mostly be offset generic erosion lipitor pristiq fernandez say enbrel tnf inhibitor market amgen amgn pfizer be face biosimilar pressure fernandez expect pfizer overall sale grow vs related lilly near fda nod arthritis drug chemo med stick courtamgen gouge top pick abbvie humira biosimilar jefferiestrump disastrous pharma view doesn rattle jpmorgan drug conference
120,LLY,roche rhhby tecentriq be modestly trail merck mrk keytruda continue chip away bristol myer squibb bmy share second line lung cancer market barclay analyst geoff meacham say tuesday overall immuno oncology drug have swipe total lung cancer market high range see previous quarters meacham say research report drug be most popular second line small cell lung cancer melanoma share respectively bristol myer be struggle second line nsclc set meacham say opdivo see high share market fall tecentriq gain mid single digit sequentially tecentriq be now modestly trail keytruda say investor be seemingly disappoint bristol myer isn seek accelerate approval opdivo yervoy combination first line nsclc combo be widely suspect be more potent combine chemo merck be testing latter keytruda eli lilly lly alimta keytruda already be approve monotherapy first line nscls patient high expression pd gene metastatic melanoma head neck squamous cell carcinoma food drug administration recently grant priority review chemo combination ibd take merck biogen eli lilly tie drug approval apiece lead broader biotech industry trail get more ibd industry theme combo open merck broader patient population only patient fall category have high expression pd gene half patient be be test meacham say have gene regardless expression chemotherapy be dominant first line nsclc have share keytruda still momentum look good keytruda meacham say sentiment be more negative bristol myer follow decision accelerate regulatory route opdivo yervoy bristol recent decision not pursue accelerate first line pathway have little impact term estimate increasingly negative sentiment make premium group harder sustain absent convince pivotal datum write research report meacham trim price target bristol myer stock rating overall biotech industry be positive bristol myer stock fall tuesday come penny more year low merck fall related fda track record bode well merck keytruda chemo merck meaningful keytruda royalty give bristol myer leg bristol myer dife opdivo setback get keytruda royalty
121,LLY,peter gassner launch veeva system veev didn expect outstrip revenue watch stock triple span less year expand arsenal product application instead gassner be survival mode begin have nothing have product customer person nothing say gassner time alum salesforce com crm have exactly so then have start hire person have make product get first customer add grand plan be sort interesting doesn mean anything hire first developer get first customer today veeva provide cloud backbone life science industry rival like medidata solution mdso count company pfizer pfe novartis nvs amgen amgn eli lilly lly customer drugmaker tackle challenge develop testing manufacturing lifesave drug veeva operate cloud system background dual role include organize doctor information pharmaceutical rep clinical trial datum graph company gassner call latter point veeva second act total veeva estimate total addressable market gassner expect nascent third act add become bigger better be exactly company alphabet googl ibm ibm cisco system csco do say important thing company be want keep go second act probably end be big bigger first act tell investor business daily company make second act bigger first act have long term ability reinvent veeva launch year single application help pharmaceutical rep organize drug datum make stronger doctor pitch today globe pharma sale rep use call veeva crm customer relationship management ipad application get drug company manager buy early wasn difficult gassner say ibd take veeva system stock have ibd composite rating best possible meaning outperform stock term key growth metric head ibd stock checkup list strong software leader think life science industry be more business outcome oriented say important thing ceo focus get drug approve get market effectively patent expire tool cloud not cloud help generally want fast forward veeva crm be part company commercial cloud business commercial cloud grow fiscal major crm win expansion top pharmaceutical firm veeva say earning news release business account third veeva sale gassner estimate veeva second act really have wall street key say veeva vault be launch single customer goal organize content involved clinical trial document video image datum record vault represent third veeva total sale target total addressable market gassner say see vault reason recent excitement veeva stock share be january march burst cup handle formation begin november top buy point deeper salesforce partnership stock be now more extend point bottom month veeva ipo time intraday high reach friday share gain nearly share ultimately retreat friday close be again monday gain close vault bring sale gassner say today vault annualize run rate be north whole veeva be aim top annualize run rate veeva be already tracking ahead say cornelio ash analyst william neil co affiliate investor business daily now vault be prep potential third act look opportunity outside life science first veeva gassner say veeva see additional opportunity take vault other manufacturing heavy industry chemical consumer packaging neil ash say success venture be game changer veeva be say be ve get lockdown step tell ibd then just become door do want knock potential be probably veeva stock continue trade premium gassner say veeva gain traction outside life science used same method employ launch major commercial cloud vault division company call veeva way method work life science veeva have estimate crm market sale clinical trial regulatory process match medidata medidata sale vs small grow chunk veeva brand become re good gassner say become good deliver value outside life science then think time ll become know end veeva be part collaboration include astrazeneca azn allergan agn biogen biib lilly novartis glaxosmithkline gsk pfizer other call align biopharma align be aim iron technological standard life science world veeva do same sector outside life science ash say literally get feedback horse mouth develop platform say be successful outside re go need same kind feedback other sector related ibd company break deepen salesforce tie upveeva help medicine go drug giant
122,LLY,xhere weekly investing action plan need know investor come week market get broader view economy lead edge company tech heavy industry defense energy medical sector have turn earning microsoft msft amazon com amzn alphabet googl boee ba caterpillar cat exxon mobil xom
123,LLY,drug stock topple month low tuesday dow component johnson johnson jnj report first quarter pharma sale only advanced offer weak harbinger sector late afternoon trading stock market today ibd company ethical drug industry group be fraction earlier lose much touch low not see november biotech stock be less injured be still collectively lose much report light first quarter sale cent beat bottom line leerink analyst geoffrey porge say result highlight multiple issue large biotechs worldwide pharma sale grow just vs year earlier quarter miss expectation international drug sale beat pharma sale miss porge write research report oncology sale lead growth legacy product remicade stelara xarelto offset volume decline low growth price hike alexion pharmaceutical alxn abbvie abbv celgene celg derive large portion sale international market benefit worldwide pharma growth be reflect sector porge have outperform rating alexion stock market perform rating abbvie celgene stock ibd take ibd ethical drug industry group be now rank group track just week biotech industry group be perform much better rank seventh week head ibd stock checkup list strongest stock higher utilization independent patient assistance program timing medicare part cost higher drug access discount leave celgene amgen amgn vulnerable biotechs porge say cite commentary have market perform rating amgen stock pricing power appear remain strong do report lower price government manage care channel impact annual comparison write do not anticipate issue be isolate alone impact broader biopharma industry drugmaker evercore analyst umer raffat note struggle diabetes unit invokana sale be year year be reflect eli lilly lly diabetes franchise leerink analyst seamus fernandez earlier say unit help lilly overcome struggle rheumatoid arthritis drug raffat note pricing pressure cardiovascular drug xarelto be reflect bristol myer squibb bmy eliquis xarelto sale fall vs year earlier period silver line report year year growth imbruvica cancer drug partnership abbvie company be now look have imbruvica approve treat patient suffering graft versus host disease occur foreign tissue be introduce body organ transplant related dow johnson johnson set lackluster result lilly survive rheumatoid arthritis flop breast cancer drug
124,LLY,many part president trump federal government have yet take shape leaner meaner food drug administration seem almost certain way agency watcher see trump blueprint nation pharmaceutical gatekeeper point funding cut budget outline also suggest user fee charge industry process approval much double yet trump also want speedier fda push more generic drug boost competition have deride astronomical outrageous drug price call competitive fair drug approval process drugmaker analyst say re re just not sure leaner fda accomplish support fda get more funding so approve generic drug faster ll bring drug cost say john maraganore ceo alnylam pharmaceutical alny alnylam make expensive specialty drug treat hemophilia other rare ailment acknowledge more competition generic market help tug rise drug price competitive marketplace base way do preserve market base time limit award really need innovation maraganore tell investor business daily irina koffler analyst mizuho agree fda now face drug backlog generic application tell ibd make dent backlog agency need more funding more staff legislation clear thicket law legal decision slow drug approval koffler say generic submission be sit languish be not enough competition koffler say situation ll have supply monopoly company be only manufacturing certain generic drug therefore charge lot biotech drug stock be touchy come trump march tweet president promising more drug competition send ibd company generic drug industry group generic drug company actually favor more competition say chip davis chief executive association accessible medicine advocate maker generic drug maker generic be know biosimilar drug experience constant price deflation say backlog generic application mean drug provide new revenue stream stay stick hold await fda review action only way time company be financially successful be be able get approval new generic help offset continue deflation see year year current mature portfolio tell ibd fully recognize more competition create downward pressure pricing prescription drug price rise re project jump year active employee early retiree american workforce accord advisory firm segal consult retiree age older price be expect rise slowdown likely take congressional push speed fda approval most recent iteration american health care act gop bill seek replace obamacare didn touch pharmaceutical trump pledge march kentucky rally work legislation bring pricing ibd take swearing trump have continue call drugmaker lower price do biotech drug stock read ibd industry theme trump budget blueprint hint package administrative action design achieve regulatory efficiency speed development safe effective medical product trump be same page alnylam maraganore imagine system fda incentive approve generic quickly congress enact legislation fda be incentivize approve second third manufacturer generic drug faster maraganore say imagine help speed lower drug price fda have prioritize second third drug approval other generic drug action trump not do be reduce drug testing safety effectiveness mizuho koffler say recall thalidomide crisis thalidomide be first market germany counter medication nausea pregnant woman ensue year child worldwide be born phocomelium malformed limb half survive be turn point drug approval process koffler say thalidomide wasn well test be sell vulnerable population pregnant woman result unexpected side effect newborn fda strengthen drug review process drug re take have assume terrible thing happen child take pregnant woman take person have bad kidney bad heart take say so have test drug more realistic representative population patient trump pick fda commissioner dr scott gottlieb have talk overhaul fda process generic complex drug have allow brand drug create monopoly perpetuity generic complex drug have more complex active ingredient formulation route delivery drug device combination typical generic gottlieb be industry insider formerly hold position fda center medicare medicaid service nomination have draw support aisle trump gottlieb support more competition generic market cut brand monopoly march article forbe gottlieb note older generic drug be sell cheaply be sometimes very costly prime example be turing pharmaceutical purchase decade old hiv medicine company spiked price pill overnight be often result failure way fda be regulate generic medicine say agency long costly approach regulate generic drug be reduce competition generic market increase cost manufacturing generic medicine maraganore identify more brand side aisle draw distinction generic groundbreaking treatment fda approve brand drug rare disease biogen biib spinraza spinal muscular atrophy even new treatment come now actually cure cancer drug receive patent protection number year generic make copy period maraganore call market base time limit award need innovation generic market be be greatest amount competition say address challenge system drug price drug approval process need be careful reform look good sound good be fact good preserve innovation engine have country january trump tell exec celgene celg eli lilly lly johnson johnson jnj novartis nvs merck mrk cut regulation fda approval process accord regulatory affair professional society trump pledge streamline process so standpoint actually have drug actually get approve instead wait many many year mizuho koffler note least law be revise drug price competition patent term restoration act stay generic drug application month allow patent holder time litigate generic filer protect patent month clock be place regardless dire need be drug legislate stay away mandatory month help expedite litigation process brand generic company create lot more competition say davis generic drug maker advocacy group argue congress tackle decade old law require maker fda take additional safety measure drug have risky side effect not properly administer brand company be take advantage risk evaluation mitigation strategy law prevent generic purchasing sample drug say davis contend company have used risk evaluation program create limit distribution program doesn allow generic company legally purchase sample drug need do clinical testing so submit application fda compete originator product say need be legislation make sure risk evaluation only be used intend purpose not delay competition generic biosimilar go forward say bill house now just study matter reality be everyone have know year be problem trump budget blueprint offer clearest view yet want run fda doesn clear away smoke trump argue industry benefit fda approval pay share constrain budget environment proposal doesn detail specific budget figure fda fda budget grow year fda have ask increase industry be brace potential cut agency funding indicated propose jump user fee law fda collect fee drugmaker brand generic biosimilar fund drug approval process trump blueprint propose boost fee agree user fee industry fda isn publicly available say davis so difficult know mesh trump blueprint deal be form month month dialogue generic biosimilar come away satisfied say trump blueprint likely include brand generic biosimilar be set pay fee year unclear trump plan include other type user fee fda user fee amount alliance stronger fda coalition consumer patient group health professional trade association call trump user fee jump neither wise realistic march statement not wise fda core responsibility safe effective medical product safe food need be support large measure public be primary beneficiary group say not realistic drug device industry have recently complete user fee agreement negotiation fda
125,LLY,eli lilly lly merck mrk allergan agn stand outperform broad pharma stock credit suisse analyst say monday cite strong pipeline expect clinical datum year merck stock close stock market today share allergan dip lilly finished lower drug stock be broadly stay day move average credit suisse analyst vamil divan expect macro uncertainty pressure drug stock first half continue trend begin raucous election season drug stock end be january merck outperform keytruda immuno oncology drug divan say keytruda similar drug bristol myer squibb bmy roche rhhby patient immune system identify tumor cell immune system then destroy cancer keytruda go head head bristol myer squibb opdivo target specific protein body merck be team test keytruda incyte incy drug epacadostat epacadostat target protein ibd take jazz pharmaceutical top ibd company ethical drug industry group composite rating best possible score mean jazz outperform nearly third stock term key growth metric get rest leader list ibd stock checkup lilly pipeline be now derisked divan write note client see promise diabetes drug jardiance trulicity plaque psoriasis drug talz lartruvo soft tissue sarcoma baricitinib treatment eczema sentiment allergan be finally start thaw write cite further upside pipeline new drug linzess viberzi irritable bowel syndrome well vraylar bipolar disorder small midcap scene divan prefer aldr corvus pharmaceutical crvs aimmune therapeutic aimt be work migraine medicine base inhibit specific peptide body eliminate migraine corvus be peer player divan say related be first immune system cancer drug fdamerck bristol myer incyte race career market
126,LLY,eli lilly lly pipeline have best bang buck analyst say wednesday comparison pit lilly rival pfizer pfe merck mrk bristol myer squibb bmy leerink analyst seamus fernandez say lilly be outperform pack achieve best balance investment limit external investment past year bristol pfizer trail merck struggle metric write still drugmaker lilly have struggle gain fda approval only drug pharma pipeline have gain approval contrast biotechnology company abbvie abbv gilead science gild have be more successful conversion rate top drugmaker bristol myer lilly have have considerably more success phase drug meanwhile pfizer have only converted late stage pipeline drug sell market pfizer have broadest pipeline group disclose new drug fernandez write have struggle fall megamerger disruption limit scale productivity merck be lowest pharma universe ibd take american fund recently up stake bristol myer squibb stock else receive american fund vote confidence find ibd mutual fund page analysis fernandez also look churn turnover new drug burn percentage attrition portfolio bristol have highest burn rate lowest churn rate company appear be focuse more internal asset partnership early stage mid late stage external agent fernandez write note conversely merck churn rate be highest group merck high overall expense be drive part large cubist idenix deal have so far struggle generate sizable return management have hope well company extraordinary investment keytruda write merck isn alone struggle partnership acquisition big drugmaker biotechs only gilead purchase pharmasset appear have succeed fernandez write pharmasset begin development sovaldi hepatitis drug rocket gilead sale gilead hepatitis franchise begin falter high cure rate trio drug sovaldi harvoni epclusa close bell stock market today lilly finished trading bristol myer rise meanwhile merck slip pfizer also lose related gilead hepatitis sale plunge merck swipe share analystabbvie stronger bet gilead amgen least leerinkmerck roche gouge bristol share lung cancer approval
127,LLY,analyst downgrade biogen biib stock thursday prospect be acquire be dim market force take air key drug biogen prospect find suitor be diminish leerink analyst geoffrey porge say downgrading stock market perform rating outperform cut price target investment bank morgan stanley also downgrade stock equal weight overweight rating slash price target be previously mostly opportunity biogen stock have now shift risk porge write note client further competitor roche rhhby be develop own multiple sclerosis drug squeeze biogen tecfidera empire payer pushback be slow launch spinal muscular atrophy drug spinraza biogen remain year develop alzheimer drug stock market today biogen stock crash share ionis pharmaceutical ion biogen partner spinraza fall low leerink analyst paul matteis trim price target ionis slightly ionis rally close porge reduce sale forecast biogen see lower sale later year ibd take biogen spinoff bioverativ isn standard startup head new america find biogen be currently entangled patent litigation interference tecfidera account total sale january biogen agree pay forward pharma fdw settle suit still court process be ongoing most potential outcome seem more likely favor biogen licensor forward pharma biogen porge write note rbc analyst michael yee disagree outcome favor biogen say biogen win have access patent forward biogen stock go few percent notably tail value net present value go current share price write note worst case scenario biogen win interference case lose patent suit stock fall headline worry lower interest pressure do more deal yee say decision case be expect march meanwhile roche generic competitor be likely squeeze tecfidera analyst say roche date start pay fee fund approval process primary progressive multiple sclerosis drug ocrevus be march reality be street be bit nervous drug impact reduce biogen core multiple sclerosis sale yee say ocrevus have impact biogen tysabri relapse remit multiple sclerosis drug analyst seemingly agree opportunity spinraza be strong note pushback payer be slow launch biogen ionis drug be approve december very few physician have prescribe spinraza leerink matteis say half dozen center have contact so far most common response have be haven start anyone yet plan write come surprise give magnitude unmet medical need drug compelling clinical datum biogen strategy have be front load cost spinraza have drive payer scrutiny matteis write payer appear be take time establish reimbursement policy spinraza say investor have year datum biogen alzheimer disease program biogen be work aducanumab drug work remove plaque buildup brain associate alzheimer theory didn pan eli lilly lly solanezumab analyst widely expect solanezumab prove effective late stage trial fail biogen trial alzheimer be pivotal also risky expensive slow leerink porge say rbc yee be more bullish see biogen alzheimer pipeline have big long term optionality yee rate biogen stock outperform rating have price target share related kite ionis outplay med sector perrigo tenet valeant divemerck biogen drug fail be biogen roche astrazeneca next fall biotechs cara report sale ionis downgrade
128,LLY,aerospace industry group send letter congress friday back republican plan overall tax system member dow jone industrial average component boee ba break ground new finishing plant china end month urge enact legislation modernize tax system allow america business better compete global marketplace encourage job creation innovation unite state aerospace industry association america say letter congress say accord reuter letter make public aia group say propose house corporate tax reform blueprint benefit american business american worker board blueprint lower corporate tax rate add border adjustment tax last month boee ceo dennis muilenburg dow industrial peer general electric ge ceo jeffrey immelt other industrial exporter drugmaker celgene celg eli lilly lly other write own letter congress urge support bill boee have lot gain propose tax overhaul morgan stanley ms analyst release note monday say boee stock jump border adjustment tax alone boee share be stock market today ge stock fall not business support house blueprint wal mart wmt dow stock strongly oppose border adjustment tax most retailer good become more expensive wal mart share be retake day move average tax blueprint be suppose support job home boee break ground finishing plant end march accord report china business medium outlet caixin tuesday boee announce plan facility finish start preliminary work look build market share rapidly grow aerospace market worker plant paint plane install flight entertainment other system work be be outsourced china boee have argue plant create more not less american job finishing center be location add value china airplane go be build ceo dennis muilenburg say january great example growth china create growth manufacturing job related trump tariff idea isn bat crazybusiness big small enthusiastic trump economic check boee gop tax reform
129,LLY,biotech industry have mixed outlook few new drug come market year midcap incyte incy be few company potential blockbuster pipeline incyte close start major development first come late last year company discover jakafi drug win be face competition gilead gild previously expect jakafi be used treat malady myelofibrosis bone marrow disorder polycythemia vera type blood cancer gilead rival drug jakafi now know momelotinib fail phase study previously untreated myelofibrosis patient november left incyte primary revenue driver free competition foreseeable future accord ian somaiya biotech analyst bmo capital market rare see drug generate sale face competition say jakafi peak sale potential most recent earning report incyte official say jakafi account net product revenue third quarter year company raise full year net sale outlook drug earlier outlook morgan stanley analyst say note client tuesday see drug revenue grow year then earlier month incyte announce immuno oncology drug epacadostat merck mrk keytruda be used phase study year include treatment small lung cancer well renal bladder head neck cancer opportunity solid tumor be earning multiplier epacadostat somaiya say drug pass trial receive food drug administration approval analyst expect peak sale accord recent goldman sachs note morgan stanley analyst say note expect key datum study prompt company start phase trial be disclose american society clinical oncology conference chicago june epacadostat have potential least be biggest pipeline drug say eric schmidt biotechnology analyst cowen be active so many tumor type finally jan fda extend review period baricitinib investigational rheumatoid arthritis drug jointly develop incyte eli lilly lly morgan stanley take bullish sign fda didn ask new study see imminent approval still analyst lower sale estimate drug delay yet see peak sale management have play key role incyte success recent year incyte chief executive herve hoppenot take helm be previously president oncology novartis nvs many scientist oncology side follow hoppenot incyte always make incyte unique be expertise biology somaiya say management change have expertise develop drug conduct larger trial bring drug market independently market analyst question much longer company remain independent incyte be largest midsize company oncology space potential buyout target endgame most biotechs be be buy larger pharmaceutical firm have less fruitful pipeline accord michael schmidt senior biotech analyst leerink partner be relation cowen eric schmidt ibd take incyte be rank second ibd medical biom biotech group have composite rating share jump buy range flat base buy point jan company announce drug trail epacadostat oncology pipeline be very interesting standpoint scarcity company have good pipeline michael schmidt say wouldn speculate company be interested incyte september poll evercore isi investment bank analyst vote gilead most likely buy incyte next month president donald trump call drug industry disastrous drug price merger activity heat year trump administration be change tax code well possible boost foreign cash increase stock valuation accord reuter report incyte be poise successful biotech world isn risk traditional drug development risk be always regulatory risk michael schmidt say oncology be obviously competitive space particularly immuno oncology cowen eric schmidt say not worry competition oncology sector be too much unmet need too many patient be die say add valuation be prime risk biggest risk be be fair bit good news price incyte say so something go wrong valuation come correct lot share incyte seem ready hit third straight day gain meet resistance cross mark friday share end monday session marginally related fda track record bode well merck keytruda chemo leerinkamgen plan robust alzheimer migraine oncology ceo exclusive
130,LLY,eli lilly lly stock pop week high thursday highest point terminate key alzheimer program november wall street top sale earning guidance early thursday lilly guide sale top consensus analyst poll thomson reuter lilly also see earning share ex item beating analyst model be first time lilly have provide initial guidance consensus metric begin tracking evercore analyst john scottus say research report year only guidance be consensus ep not revenue ibd take drug stock have take hit recently commentary president elect donald trump go spiraling drug price eli lilly management say wall street likely didn account acquisition boehringer ingelheim animal health business be expect pull sale lilly also expect exclusivity chemotherapy alimta next year japan minimal generic competition europe consensus instead model year year decline dip ex sale stock market today lilly stock jump share crash year low nov lilly say scrap work alzheimer drug solanezumab miss primary endpoint late stage trial share be still try recover lilly stock have trade day move average mid november reflect similar trend ibd company medical ethical drug industry group group be more thursday morning related eli lilly continue alzheimer push flop biogen extend risebiogen underplay promising alzheimer datum seizure worry
131,LLY,barclay analyst geoff meacham thursday say expect gilead science gild outlook be hinder limit hepatitis sale also see merck mrk alexion pharmaceutical alxn issue sluggish view be more bullish biogen biib johnson johnson jnj rbc capital wednesday say much same gilead also be more bullish biogen well amgen amgn hepatitis drug prescription dip quarter quarter accord market tracker im gilead make sovaldi harvoni combat hepatitis merck alexion meanwhile guide decline metric heavier spending new management respectively meacham predict argue be widely anticipate meacham say research report see biogen offer upside guidance spinraza launch ionis pharmaceutical ion johnson leverage cost control offer better view ibd take hepatitis sale fall gilead go check ibd industry theme full scoop biotech biggest be expect do ahead pharma earning season start next week report company such stryker syk intuitive surgical isrg meacham boost price target incyte incy stock note company phase tumor effort merck duo be testing immunotherapy keytruda epacadostat tumor meacham expect incyte earning conference call give color jakafi trial graft vs host disease well tumor effort merck bump price target incyte stock incycte hasn yet set date earning report incyte stock last week touch month high just shy rally close stock market today consensus analyst poll thomson reuter expect incyte report sale cent earning share third respectively vs year earlier quarter merck spending be likely ramp keytruda be grant priority review last week combination eli lilly lly chemotherapy alimta treat squamous small cell lung cancer nsclc patient high expression pdl gene keytruda alimta be phase testing datum be strong merck open larger patient population vs patient pdl expression keytruda be already approve monotherapy high express pdl patient nsclc related merck biogen lilly top approval fda slumptrump disastrous pharma view doesn rattle jpmorgan drug trump break republican push major drug reform
132,LLY,drugmaker eli lilly lly likely add rheumatoid arthritis drug fda approve repertoire month say credit suisse analyst vamil divan also predict court decision lilly chemo drug alimta day now prescription drug free user act pdufa date lilly baricitinib be set january drug belong class med call jak janus kinase inhibitor eli lilly submit new drug application nda last january moderate severe rheumatoid arthritis lilly gain worldwide right incyte incy baricitinib now baricitinib compete tofacitinib jak inhibitor develop pfizer pfe national institutes health market xeljanz jakvinus incyte be also codevelop ruxolitinib jak inhibitor target myelofibrosis novartis nvs ibd take president elect donald trump cause flurry drug stock late last year pledge cut spiraling drug price make good promise other catalyst january include separate patent ruling case lilly alimta also teva pharmaceutical teva copaxone patient relapse remit multiple sclerosis also january astrazeneca azn bristol myer squibb bmy be likely have key trial datum divan say astrazeneca be study durvalumab have breakthrough designation treat patient specific type urothelial bladder cancer bristol myer be look nivolumab treat patient small cell lung cancer nsclc close stock market today ibd company medical ethical drug industry group include lilly bristol myer astrazeneca finished day nearly lilly stock tick just relatedlilly spike guidance claw back alzheimer drug flopbiogen underplay promising alzheimer datum seizure worrieseli lilly continue alzheimer push flop biogen extend rise
133,LLY,expect mark high point amgen amgn say company ceo robert bradway share biotech market cap fall nearly stock have still outperformed ibd company medical biom biotech industry group tumble nearly bradway see better day ahead amgen example have datum cardiovascular drug slate release generic chemotherapy approval europe also expect compete robustly cgrp migraine market vs rival such biopharma aldr teva pharmaceutical teva eli lilly lly grab highlight email bradway examine trend catalyst biotech industry fall president elect donald trump proposal amgen plan compete emerge immuno oncology market ibd catalyst do amgen see biotech industry amgen benefit bradway innovation be thrive industry be cusp true revolution biology expect see major improvement immune therapy novel agent base human genomic other advance help many patient serious disease cancer cardiovascular disease alzheimer disease further accelerate long term growth amgen industry world leader biology amgen be ideally position capitalize development ibd sector do particularly well bradway believe innovator bring product strong value proposition disease state unmet medical need remain high be winner long term ibd do amgen have key launch clinical trial datum come bradway yes amgen expect bring forward ambitious portfolio new product indication worldwide well significant new clinical datum focus remain address unmet medical need innovative medicine make difference patient serious disease next wave new medicine key datum be set do just anticipate result large cardiovascular outcome trial first quarter result be significant repatha evolocumab definitively establish importance therapy risk cardiovascular disease neuroscience ve already report successful study erenumab cgrp calcitonin gene related peptide migraine medicine chronic episodic migraine be potentially life change medicine migraine sufferer be pleased be lead position cgrp class anticipate filing approval global regulator parsabiv etelcalcetide be grant marketing authorization european commission treatment secondary adult patient chronic kidney disease hemodialysis parsabiv be first calcimimetic agent be administer intravenously health care provider time week end hemodialysis session be work fda approval biosimilar portfolio include biosimilar various stage development first biosimilar amjevita adalimumab atto be approve also file amg biosimilar bevacizumab approval europe ibd do amgen see stack rival bradway enter follow year launch new product see approval past year new product indication worldwide market strong performance be reflect financial well past year gaap basis have grow earning margin have increase percentage point have grow dividend progress be achieve even effect patent expiry legacy product believe transformation program announce year amgen be well position be industry leader speed innovation responsiveness change financial performance meanwhile continue investigate collaboration opportunity offer expertise domain human genetic tool kit multiple molecular pathway biologic manufacturing help advance program therapeutic area interest ibd set amgen immunotherapy cgrp bace inhibitor therapy apart rival drug bradway approval blincyto blinatumomab validate science regulatory pathway bispecific cell engager bite antibody construct also demonstrate efficacy patient challenge disease acute lymphoblastic leukemia believe novel immuno oncology platform represent attractive way engage immune cell tumor cell establish local tumor immune activity be need most also believe blincyto mechanism be replicate harness immune system fight other tumor type erenumab co development amgen novartis nvs be specifically design prevent migraine block cgrp receptor be believe have critical role reduce incapacitating pain migraine almost patient chronic episodic migraine have participate erenumab clinical trial form basis global regulatory filing be also explore pac bispecific antibody amg phase study potential be synergistic erenumab amgen be first clone characterize bace late subsequently identify corroborate human genetic evidence link alzheimer disease paved way collaboration novartis focuse differentiate genetically validate alzheimer disease program direct individual genetically predispose risk develop disease decode genetic subsidiary give amgen industry lead ability identify validate disease target human population ibd do amgen expect drug pricing debate unfold bradway be sure be more debate drug pricing however not lose sight fact be economic societal burden disease be enemy room innovative drug offer promise address burden advance promising new medicine keep eye price value therapy expect product need deliver clear benefit patient customer end amgen have value base contract place number payer already expect do more medicine deliver value solution patient need be reward don not ibd take donald trump pledge take drug price stop long run rally industry make good promise ibd other key thought be tell biotech bradway amgen be approach development promising new medicine greater understand speed confidence ever part be industry have unprecedented genetic information available large scale diverse array drug pathway more sophisticated analytic tool allow scientist connect dot dna treat disease innovation be now evident virtually stage process get medicine market be exciting time field believe power innovation related keel sixth day eu uphold teva migraine patentregeneron likely jump regeneron ldl buster expectation too high
134,LLY,incyte incy oncology program grow merck mrk partnership tie keytruda epacadostat hot tumor leerink analyst michael schmidt say friday boost price target incyte stock schmidt have outperform rating incyte stock up price target reflect epacadostat opportunity stock market today incyte stock lift fraction earlier share rise much near month high achieve tuesday announcement be make monday annual jpmorgan healthcare conference san francisco merck incyte have test combo type tumor datum msi high colorectal cancer diffuse large cell lymphoma be not yet available keytruda epacadostat win advance ovarian cancer triple negative breast cancer duo continue work melanoma bladder kidney lung head neck cancer accord company announcement monday ibd take donald trump refer pharma industry disastrous accuse get away murder comment overlap annual jpmorgan healthcare conference san francisco tone be see cautiously optimistic
135,LLY,schmidt be bullish incyte epacadostat opportunity phase trial keytruda be likely begin later year thus far datum have be unambiguous researcher company be comfortable move forward epacadostat belong class drug inhibit ido gene ido molecule be thought allow tumor cell escape detection immune system researcher be testing inhibit gene assist battle certain cancer question remain extent partnership schmidt say be unclear merck opt co fund plan trial period exclusivity be grant merck incyte initiate additional phase trial potentially overlapping indication pd inhibitor write note merck be also work eli lilly lly combine keytruda chemotherapy alimta treat small cell lung cancer opportunity epacadostat be nsclc depend development strategy competition schmidt say merck be well position market likely beat rival bristol myer squibb bmy astrazeneca azn market immuno oncology chemo treatment analyst note bristol myer creep merck io io combo merck stock rise fraction friday rise week related eli lilly rebound chemo drug patent vs generic teva
136,LLY,eli lilly lly benefit tune expand jardiance sale evercore analyst john scottus say friday food drug administration approve indication diabetes drug stock market today lilly stock jump follow fda decision share still be nov lilly announce alzheimer drug solanezumab have fail significantly improve cognition friday fda approve lilly new drug application nda jardiance be used reduce cardiovascular mortality adult type diabetes mellitus cardiovascular death be higher adult diabetes adult accord center disease control prevention lilly co develop jardiance germany boehringer ingelheim ibd take eli lilly stock tank last week apple stock retook buy point fang stock surge ahead make sure keep tab ibd week review lead lackluster stock week bottom line indication allow lilly promote jardiance cv reduction quality vs have bury datum scottus write research report somewhat controversial june advisory committee vote allow lilly promote cv side narrow vote clearly reflect committee mixed feeling empa reg cvot cardiovascular outcome trial provide substantial evidence drug reduce cv mortality population study scottus write regardless expand indication jardiance bode well lilly entire sglt class scottus say sglt be protein involved glucose reabsorption kidney inhibitor jardiance lead reduction blood glucose lilly anticipate further indication expect be catalyst jardiance sale scottus say related
137,LLY,eli lilly topple alzheimer darling sola fail biogen merck
138,LLY,celgene kite spark look sidestep lilly alzheimer flop
139,LLY,eli lilly lly friday announce further collaboration astrazeneca azn second alzheimer compound give autopsy own fail late stage drug late thursday meanwhile biogen biib extend gain rise thursday fresh upbeat phase datum treatment small study early stage alzheimer patient eli lilly pay astrazeneca part expand alliance compound still phase trial addition compound stage trial show lilly isn give alzheimer treatment major disappointment eli lilly release detailed phase solanezumab datum ctad event san diego thursday evening late last month lilly stunned investor release datum show experimental alzheimer drug fail show statistically significant cognitive improvement vs placebo eli lilly share fall nov biogen lose merck mrk have own experimental treatment verubecestat fall fractionally day pare early loss result expedtion be question disappointing say eric siemer distinguish medical fellow lilly thursday night release however lilly remain commit find solution devastate disease continue analyze study result work external scientific community hope uncover finding help shape advance future alzheimer disease research detailed report lilly say plasma beta change be similar see previous study statistically significant change amyloid deposition weren significant cognitive decline slow primary endpoint not statistically significant other measurement cognitive decline slow respectively lilly share rise morning trade stock market today astrazeneca also get analyst upgrade climb biogen rise early friday gapping day line climb thursday rebound day move average ibd take biotech stock initially rally election investor relieve hillary clinton not be president populist trump say ll take pharma cost biotechs have take round trip trump pick run fda be key boost dose experimental alzheimer treatment reduce risk brain swell still achieve key benefit biogen disclose thursday step dosage regimen aducanumab see swell patient vs give high fix dose biogen report gradual regime still reduce amyloid plaque brain significantly vs placebo patient phase trial datum also halter mental decline similar fashion fix dosage result biogen release more datum san diego medical conference today be secondary endpoint directionally favore solanezumab raise hope thursday night presentation lilly drug general line research related eli lilly topple alzheimer darling sola fail biogen merck
140,LLY,interview time selection news magazine man year bring president elect trump most definitive statement date drug price go bring drug price don have happened drug price incoming president have be short detail many observer say bigger focus be streamline food drug administration drug approval process effort get boost wednesday same day trump time interview be publish senate approve bill aim speeding approval drug medical device president obama be expect approve so call st century cure bill just action trump take remain unknown resolution issue drug price time jump exponentially critical need patient trump have vow repeal president obama affordable care act promise drain swamp special interest washington help contribute rise big pharma time interview hadn broach drug pricing issue just election boost drug stock ishare nasdaq biotechnologg etf ibb jump day nov election fall ibd company biom biotech industry group jump nov generic ethical drug group rise respectively group have give back gain trump ignore rise drug price say trevor william penn mutual asset management manage director trouble be businessman reality tv star be relative political enigma william tell ibd hard see be champion lower drug price same sense hillary have be so focuse dismantle aca william say trump not have political history really difficult telegraph go go policy proposal be tell trump pledge contract american voter fully repeal aca better know obamacare first day office replace health saving account vein say ll cut fda red tape be drug await approval especially want speed approval life save medication trump write contract trump crack fda be nothing new say credit suisse analyst vamil divan yet recent year fda have work expedite sorely need drug fast track designation prescription drug user fee act help fund drug quickly still be backlog approval generic drug divan tell ibd many proposal work have target make approval process generic drug cheaper drug similar drug long enough ve lose patent protection much easier trump platform remove barrier entry safe reliable cheaper product trump also allow broader label use number drug penn william say replacement plan aca remain somewhat ambiguous trump have backed earlier promise fully repeal act say ll maintain provision require insurer cover patient pre exist condition let parent cover child age obama didn touch pharmaceutical much obamacare legislative centerpiece say divan outside require drugmaker pay expand health care coverage trump completely do away aca be unlikely divan say fee disappear backroom negotiation aca let company come reasonably well divan say repeal aca put cash fee back drugmaker pocket yet wall street be anything reasonably sure trump care affect biotech drug firm trump doesn appear have vendetta pharmacy benefit manager pbms drugmaker pbm tactic undercut amgen amgn eli lilly lly prompt stock topple late october amgen offer dim view eli lilly see diabetes sale take hit pbms be third party administrator commercial government medicare health plan pbms use discount competition keep drug price low help patient raise conflict drugmaker amgen stock topple nearly oct sale enbrel come flat firm say doesn expect net selling price increase business be drive volume amgen executive anthony hooper say company earning conference call ibd take rebate chip away amgen enbrel sale do mean broader industry grab ibd industry theme deeper look eli lilly stock oct sale diabetes drug humalog fall higher volume be more offset lower realize price company say earning conference call ep revenue miss wall street target trump lack commentary pbms be tell divan tell ibd stand government be not involved drug price negotiation trump work change order lower drug price not be focus republican divan say trump be not typical republican question say be new administration willing go something big pharma politically score point general public drug company have own view course merck mrk ceo ken frazier month bloomberg interview say company have be restrain raise price always be individual drug individual year point say look large relation other look whole portfolio see merck have tend be rather restrain come drug price bloomberg report frazier say bloomberg also report month allergan agn ceo brent saunder say trump be more vicious more focuse take do something again term spiking price drug drug bloomberg have interview saunder frazier appear forbe healthcare summit new york dec question patient have have high drug price kaiser foundation find september american last year believe drug price be too high american generally support require firm release information price be set allow government negotiate drug price kaiser survey follow drug pricing controversy erupt september mylan myl boost price pair epipen ceo heather bresch be subject tough question house committee hearing last year similar controversy prompt capitol hill hearing involved turing pharmaceutical former ceo martin shkreli involve big hike decade old hiv drug valeant pharmaceutical vrx have also impose huge hike drug price justice department be investigate be expect file charge generic drug company price collusion year end yes analyst divan say don think issue be go away also say see fewer chance big change drug pricing policy trump related pfizer sale challenged eli lilly novartis breakup busteli lilly topple alzheimer darling sola fail biogen merck downcelgene kite spark look sidestep lilly alzheimer flopalder keel sixth day eu uphold teva migraine patent
141,LLY,stock moved worst level morning dow jone industrial average rise stock market today fresh time high nasdaq fall decline eli lilly lly experimental late stage drug fail slow memory loss patient alzheimer disease company longer seek regulatory approval drug solanezumab share tank biogen biib merck mrk share be also impact lilly trial result fall respectively deere gain indicate better performance lie ahead earning sale still decline vs last year figure company say revenue continue fall less wall street expect share be trading time high ibd stock veeva system veev race past earning sale estimate tuesday bell life science software company report adjust ep cent vs forecast cent revenue increase top consensus additionally veeva operate margin increase significantly consensus veeva vault platform have become main driver total booking first time represent subscription revenue vault be cloud base system streamline pharmaceutical regulatory compliance stock be be breaking cup base entry point relative strength line hit new high today gap be particularly bullish indicator oil price drop dollar index soar new year high better expect durable good order october durable good order increase beating estimate september figure be also revise upwards gold price also fall conjunction rise dollar be weekly initial jobless claim come vs expect new home sale fall october downwardly revise september september housing price index rise vs markit preliminary november manufacturing purchasing manager index be vs expect still come weekly oil inventory report eia et minute federal reserve november meeting et eli lilly alzheimer drug fail key trial lilly biogen diveveeva beat guide high urban outfitter miss hpe hp inc mixeddeere stock soar earning crush estimate
142,LLY,dow jone industrial average component boee ba be downgrade monday analyst be bullish propose border tax boost share morgan stanley ms downgrade boee equal weight overweight light order flow raise price target aerospace giant share hit congress pass border adjustment tax back december morgan stanley analyst say boee pay little corporate income tax bat even get treasury cut check aerospace giant president trump have backed idea border adjustment tax hasn endorse specific version include house gop plan separately boee announce order cbd aviation lease finance max airplane order be previously unidentified boee be list current price boee share reversed higher close stock market today european rival airbus eadsy list share finished lower boee ceo dennis muilenburg dow industrial peer general electric ge ceo jeffrey immelt other industrial exporter drugmaker celgene celg eli lilly lly other write letter last month urge congressional support house corporate tax reform blueprint include border adjustment tax border tax face battle washington sen tom cotton ark call border tax orwellian last month say hit arkansa base wal mart wmt raise consumer price sen david perdue ga have also speak tax wal mart dow stock strongly oppose border adjustment tax most retailer wal mart share fall ibd take trump budget plan be release thursday give more detail increase defense spending putt defense stock buy range fellow dow industrial stock exxon mobil xom have push back tax say continue advocate free market principle globally competitive stable tax framework integrate global oil major exxon dow industrial peer chevron cvx well bp bp royal dutch shell rdsa import oil refinery operation exxon share retreat chevron share fall morgan stanley analyst be also bullish lead economic stimulus possibility grow global military spending rise budget ally match spending peer well new program bid boee related boee shop new midrange aircraft design potential customerswhy trump tariff idea isn bat crazytreasury check boee gop tax reformthese dow component back border tax shallow support show trouble
143,LLY,eli lilly lly stock defy earning miss company post early tuesday instead pop street crush sale president trump pledge ease drug regulation cut taxe business close bell stock market today lilly stock finished trading share be nearly year date compare dip ibd company ethical drug industry group early tuesday trump meet big pharma exec promise cut regulation ease fda process also again say drug price be cut lilly report sale cent earning share ex item respectively vs year earlier quarter sale top analyst view ep lag cent ibd take other industry have catalyze tank trump commentary monday airline stock topple president ban immigrant nation grab more ibd industry theme similar pattern emerge metric sale grow beating consensus ep ex item lag cent be vs year earlier period evercore analyst mark schoenebaum credit sale beat better expect sale diabetes med humalog trulicity erectile dysfunction drug ciali beat respectively say lilly also guide ep ex item meet consensus be midpoint related celgene merck lilly sit trump call manufacture pfizer report lag ep rebound trump commentaryeli lilly novartis challenge pfizer potential breast cancer drug
144,LLY,merck mrk deliver blow late tuesday beta amyloid theory alzheimer disease drug verubecestat fail clinical trial show virtually chance find positive effect investor largely expect phase phase trial fail leerink analyst seamus fernandez say research report close bell stock market today merck stock be share fellow alzheimer drugmaker split wednesday eli lilly lly stock muster gain astrazeneca azn add biogen biib climb roche rhhby lift verubecestat belong class drug call bace inhibitor work block production amyloid brain evercore analyst mark schoenebaum explain drugmaker be explore amyloid buildup brain cause alzheimer lilly astrazeneca biogen conjunction japan eisai be work theory differ drug eli lilly now discontinue solanezumab target plaque buildup month lilly drug fail late stage trial merck drug investor have high hope solanezumab ibd take analyst predict gilead science suffer slow hepatitis drug sale week worry come fruition be warning sign dive ibd industry theme close look datum monitoring committee find verubecestat be safe see little evidence activity perhaps even bace arm be leerink fernandez write merck continue trial patient prodromal alzheimer datum trial be expect february biogen aducanumab roche gantenerumab crenezumab aim cut build plaque brain eli lilly astrazeneca biogen eisai be team bace inhibitor other theory center earlier treatment schoenebaum note remain unclear ad related damage brain be reversed clear plaque prevent creation additional plaque write report failure study futility dampen enthusiasm mechanism schoenebaum say consensus expect peak adjust sale verubecestat merck related merck keytruda sale lag defer revenue analystbiogen trail merck lilly alzheimer hemophilia spinoff begin tradingabbvie merck pressure gilead hep unit gsk battle hiv biz
145,LLY,general electric ge cfo jeffrey bornstein say wednesday industry sit hand wait not invest lawmaker deliver promise change taxe regulation provide more clarity health care policy warning come house republican corporate tax revamp be run opposition congress more gop lawmaker balk propose import tax see key piece overhaul president trump have yet unveil own tax plan trump also want repeal replace obamacare republican have turn squeamish sweeping change health law barclay industrial select conference miami bornstein say be reasonably confident change get pass say investor be very disappoint aren don get corporate tax reform goal line don provide visibility health care be go don deliver regulatory change administration have talk think end very difficult place say tuesday ge ceo jeffrey immelt ceo boee ba unite technology utx other industrial exporter well drugmaker celgene celg eli lilly lly merck mrk pfizer pfe write letter urge congressional support house tax reform blueprint include border adjustment tax total company sign letter more company include wal mart wmt target tgt nike nke dozen trade group have sign american affordable product group create oppose import tax ge share fall stock market today boee share be unite tech rise last month talk repeal obamacare begin ramp ge immelt also indicated customer become more cautious take segment affordable care act be get most attention medium customer say conference call report mixed result think see caution affordable care act go forward haven really see much happen trump say rally florida weekend replacement plan obamacare win be come couple week warn earlier process last next year meanwhile market be still wait white house detail own tax proposal congressional republican take more flak last week trump tell retail ceo massive tax plan come not too distant future follow remark airline ceo prior week vow announce something phenomenal term tax come week related border tax die trump corporate tax cut collapsetrump silent ex im bank hint big boee super hornet order
146,LLY,pfizer pfe stock regain earlier loss tuesday drugmaker report earning lag wall street expectation quarterly full year revenue guidance line outplay continue decline sale adult pneumonia drug stock market today pfizer stock fall much end day rise share be year worry trump go drug pricing trump reportedly reiterate view tuesday meeting pharma exec pfizer report sale vs year earlier period meeting consensus view pfizer report cent earning share ex item miss view cent company guide sale be bit light midpoint midpoint ep item guidance be penny short consensus view pfizer wrapped sale ep item respectively sale be line ep lag consensus penny sale prevnar vaccine plunge year leerink analyst seamus fernandez say higher expect operate cost drag bottom line pfizer eli lilly lly also report largely line early tuesday pfizer see sg cost increase innovative health unit ibd take pfizer be rank second term market cap roche stock underperform stock term key growth metric ibd composite rating just zoetis stock lead group so so cr get other leader ibd stock checkup related see need actelion boost ep pfizer take remicadeeli lilly novartis challenge pfizer potential breast cancer drugamgen gouge top pick abbvie humira biosimilar jeffery
147,LLY,ceo dow stock general electric ge boee ba other big exporter be warning republican embrace controversial tax import once generation chance tax reform fail american worker be loser tax code penalize american worker make product provide service sell abroad favore international competitor ceo write letter leader party congress other company ceo co sign letter be caterpillar cat dow chemical dow raytheon rtn unite technology utx oracle orcl biggest drug biotech company celgene celg eli lilly lly merck mrk pfizer pfe caterpillar merck pfizer unite technology also be member dow jone industrial average addition general electric boee letter put largest company squarely house speaker paul ryan other house gop leader argue levele international play field cut corporate tax rate lower be impossible plan tax import raise decade yet biggest surprise letter be just few company sign more company include wal mart wmt target tgt nike nke american subsidiary toyota tm dozen trade group have sign american affordable product create oppose house border tax proposal wal mart nike be also dow industrial stock retail stock be pressure early december prospect border tax be rise ve make modest recovery lately prospect fade tuesday perhaps help more wal mart positive earning report well receive macy earning weigh rev lobbying campaign tax retail share be rise wal mart rise close stock market today target add ibd take supporter border tax plan say dollar rise vs other currency meaning wouldn harm corporate profit consumer do risk investor hold share company alibaba international etfs house proposal border adjust tax company pay tax rate full value import good export revenue be tax free border tax raise more decade offset cost lower statutory tax rate conservative tax foundation have say border tax ability congress reduce corporate tax rate be limit incremental tweak not level play field american worker dramatically reinvigorate economic growth ceo letter say not clear precisely so few company come favor border tax proposal seem be run buzz see republican senate possible letter wasn widely circulate however caroline freund senior fellow peterson institute international economic have predict many more big lobby be bat border adjust tax favor tax favor labor intensive industry export more import aerospace be rare example nagging question company such ge boee be so dependent export back border tax most trade expert have look tax have big doubt comply world trade organization rule so lead trade war give uncertainty possible consequence hard understand company so dependent trade support border tax yet partly explain list supporter be so small related border tax die trump corporate tax cut collapse gop border tax plan sock tourism include trump hotel
148,LLY,biogen biib trail merck mrk astrazeneca azn eli lilly lly launch bace inhibitor treat alzheimer disease leerink analyst say thursday day biogen hemophilia unit bioverativ bivv begin trading independently biogen stock end trading stock market today be unclear represent drop gain price due bioverativ list list biogen formally distribute share bioverativ share biogen holder early thursday bioverativ stock open appear biogen share drop yee call dive biogen stock opportunity investor have be wait spin buy stock post distribution don want bioverativ issuance be company have very different profile market cap biogen write research report ibd take rbc be bullish amgen biogen remain cautious last month share gilead science grab ibd industry theme full scoop other be count increasingly bullish view spinraza biogen spinal muscular atrophy drug conjunction ionis pharmaceutical ion assume strong launch street become comfortable new growth driver write alzheimer be more mixed bag biogen partner eisai be co develop ban pair alzheimer drug pair be expect deliver top line result phase trial year astrazeneca lilly merck related merck biogen lilly top drug approval fda slumpbiogen sidestep sale miss strong ex hemophilia guidegilead merck alexion view hazy biogen surge analyst
149,LLY,share biogen biib merck mrk be slam early wednesday rival eli lilly lly report alzheimer drug darling solanezumab fail final stage trial secondary sign indicate sola not be totally dead water eli lilly stock plunge much more year low close stock market today share biogen merck be develop similar drug fall much respectively end solanezumab biogen aducanumab merck verubecestat target plaque buildup brain associate alzheimer eli lilly recent expedition trial examine effect sola patient dementia due alzheimer sola fail show statistically significant improvement cognition decline vs patient placebo eli lilly say press release secondary endpoint directionally favore solanezumab magnitude treatment difference be small ibd take biotechs be pressure nasdaq wednesday medical software maker veeva system ibd stock be fly high earning report more veeva growth prospect check recent new america story
150,LLY,eli lilly take charge cent share follow fail trial company say plan continue pursue alzheimer research didn say mean sola full result be present dec lilly have strong growth prospect solanezumab david rick lilly incoming chief executive officer president lilly bio medicine say statement analyst have high hope solanezumab september goldman sachs analyst jami rubi posit sola supercharge lilly earning add peak sale rubin have probability success sola credit suisse analyst vamil divan have chance success solanezumab rbc analyst michael yee have suggest biogen spike eli lilly success wednesday yee keep buy rating biogen stock advise investor buy dip biogen drug include different antibody different amyloid target eli lilly write research report also have show statistically significant reduction beta amyloid imaging benefit cognition evercore analyst john scottus note research report apple apple comparison sola remove less plaque biogen aducanumab sola also target insoluble beta plaque aducanumab aim soluble beta related eli lilly alzheimer drug fail key trial lilly biogen divelilly poise big december alzheimer datum diabetes rulingamgen biogen eli lilly poise rocket most important event
151,LLY,major stock index loss intensified tuesday afternoon day federal reserve policy meeting get underway market be unfazed decent read ism manufacturing index well round healthy economic datum china fall nasdaq composite dow jone industrial average small cap lag russell volume yse nasdaq be tracking slightly higher monday level stock market today chevron cvx be dow best gainer rise stock have be rally mode big earning beat friday megacap oil play be edge closer potential past entry flat base pattern pfizer pfe lag dow fall disappointing earning pfizer also say end development cholesterol lower drug project be blockbuster also reduce earning outlook current quarter ibd take pfizer weakness august be partly due concern grow drug competition eli lilly lly novartis nvs economic news institute supply management manufacturing survey index tick october prior month slightly ahead expectation outside economic datum china look pretty good manufacturing gauge large state own factory come stronger expect separate caixin manufacturing gauge midsize company show best improvement more year third gauge service also rise martin marietta mlm jump nearly earning miss open work right side possible base fresh del monte produce fdp gap earning soar nearly recently retrace modest gain buy point fresh del monte reclaim entry tuesday share alibaba baba ease share slump much new york post article say ongoing sec probe company accounting practice be get help high alibaba staffer amazon com amzn fall fractionally initial pop axiom capital raise price target related ism manufacturing index signal slightly faster growth octoberamazon price target bump chevron twilio get analyst love
152,LLY,eli lilly lly abbvie abbv top credit suisse evaluation pharmaceutical company head leave more challenged pfizer pfe astrazeneca azn nordisk nvo dust pharmavalue list do little ibd company medical ethical drug industry group fall fraction stock market today fifth consecutive day group be more year touch month low monday be trading day move average ibd take biotech pharmaceutical stock have be trample last month earning report come climb wall worry credit suisse rank big pharma stock factor enterprise value net present value pricing replacement power sale growth overall eli lilly top list europe base sanofi sny novartis nvs trail closely abbvie rank highest fundamental investor likely assume long life span humira credit suisse analyst write research report humira be brand name adalimumab abbvie drug treat arthritis plaque psoriasis ankylose spondylitis crohn disease ulcerative colitis abbvie stock slip small fraction monday lilly stock fall nearly meanwhile pfizer be weak board astrazeneca have high ev npv enterprise value net present value nordisk be expose pricing pressure astrazeneca investor be potentially factor oncology pipeline credit suisse say recent result other demonstrate significant risk teva pharmaceutical teva score well ev npv valuation most sale power drive generic division gilead science gild incyte incy vertex pharmaceutical vrtx be trading discount vertex only need minimal further pipeline success justify current valuation report say biotechs vertex top credit suisse list amgen amgn flail bottom pharmaceutical ibd company medical biom biotech industry group have be month group fall fraction monday ethical drug group also fall fifth straight trading day fall seventh day past trading day bottom overall astrazeneca score well term pricing power shift oncology product nordisk be eye diabetes rebate storm credit suisse say pricing power credit suisse analyst note be important help company resist discount pressure formulary manager government regard allergan agn be clear winner only shire shpg rivale dry eye market alexion pharmaceutical alxn focus rare disease be most exceptional biotech analyst say biomarin bmrn incyte vertex also get high mark be unique bristol myer squibb bmy eli lilly beat cohort productivity ability drive current pipeline follow dramatic seesaw bristol myer squibb merck mrk bristol myer lung cancer drug opdivo fail meet key endpoint eli lilly score well launch trulicity diabetes taltz psoriasis
153,LLY,ibd company medical biom biotech industry group drop past week rbc analyst michael yee expect stock rally lackluster earning election season wrapped sector still have nearly week choppiness nov election recent blowout have have investor take profit yee suggest recent video buy dip biotechs climb wall worry earning not be hugely great biotechs combination uncertainty election understand trade choppy spdr biotech etf xbi get clarity election say ibd take biotechs be worst perform group wednesday ibd track group last month biotechs be major roll keep tab industry theme sector grab attention company group share spdr biotech etf have plunge dramatically month past week thursday share be flat entry point flat base biggest biotech player yee be most confident amgen amgn biogen biib respectively no market cap stock market today amgen biogen rise fraction respectively consensus analyst poll thomson reuter expect amgen report sale earning share ex item flat respectively vs year earlier quarter analyst model biogen report sale ep ex item biogen be stock own next month yee say chance biogen get take still lack ceo company announce july rumor george scango step yee also see chance eli lilly lly alzheimer drug trial yield positive result tug rival biogen other catalyst include biogen partnership ionis pharmaceutical ion drug treat type muscular dystrophy spinal muscular atrophy sma ionis be enrolling infant child phase trial sma wall street underappreciate catalyst yee say celgene celg too have number trial stoke stock yee say analyst model jump sale ep ex item celgene share be rise small fraction thursday yee only expect line quarter early next year celgene be expect release result trial drug treat muscular dystrophy crohn disease ulcerative colitis be likely stock catalyst gilead gild biotech market cap be rough quarter shadowy visibility hepatitis drug yee say drug epclusa win fda approval june be used pill form treat type hep lack greater visibility gilead stock be range bound yee say consensus expectation be too high hep sale ep write research report consensus analyst poll thomson reuter model ep ex item yee estimate be broadly analyst be bearish gilead forecasting sale dip ep item share be past week end thursday flat smaller intercept pharmaceutical icpt market cap likely print board beat yee predict share have be pressured recently gilead novartis nvs allergan agn be jump nash alcoholic steatohepatitis train nash drug have make big headline past month allergan buy tobira therapeutic tbra bulk nash battle say yee intercept drug belong class call fxr agonist be more potent intercept drug get liver activate fxr farnesoid receptor liver say other don get much fxr effectivity liver just do gut not potent intercept yee also call prothena prta own likely positive parkinson drug psoriasis drug datum spring respectively prothena stock be sell zone thursday entry point achieve rise nearly thursday related gilead try buy next poll offer incyte prothena build psoriasis science arthritis treatmentincyte stoke fire deep durable melanoma drug result
154,LLY,bristol myer squibb bmy stock crash year low monday competitor merck mrk unveil phase result show lung cancer drug keytruda be twice effective chemotherapy spark stock close bell stock market today bristol myer squibb stock plunge end trading merck stock other hand lift much year high end monday trading share briefly hit entry point flat base add gain january new buy be risky current volatile market environment ibd take merck stock be buy zone far alone check ibd stock buy zone find player be recommend bet share ramp merck presentation european society medical oncology conference copenhagen merck unveil result phase testing keytruda drug treat small cell lung cancer keytruda alone extend progression free survival month vs month chemotherapy lung cancer patient express specific type protein merck say merck also combine keytruda eli lilly lly chemo drug alimta study patient respond combination vs patient receive chemo median progression free survival be month longer combo bristol myer squibb nivolumab rival treatment lung cancer show virtually benefit evercore isi analyst john scottus write research report left investor scratch head say credit suisse analyst vamil divan expect merck take major leadership position lung tumor market vs bristol myer astrazeneca azn roche rhhby say roche pile pressure tecentriq tecentriq have show overall survival benefit second line lung cancer regardless protein expression write estimate peak sale probability success rbc analyst michael yee expect celgene celg fly potential chemo combo merck test keytruda see celgene grow revenue only first line lung cancer patient be treat chemo combo other news conference credit suisse divan expect novartis nvs face pressure post esmo novartis drug combat metastatic breast cancer be effective pfizer pfe ibrance have serious safety concern efficacy appear line ibrance safety observation hy law risk fatal drug induced liver injury qtc prolongation mild cardiac arrhythmia put drug disadvantage pfizer ibrance eli lilly abemaciclib be approve write novartis stock lose end monday trade bristol myer eli lilly astrazeneca roche pfizer novartis merck be ibd ethical drug industry group group have be slumping rank related celgene trio new drug tack rbcamgen biogen gilead spike va pricing skirt california measureroche drug score lung cancer challenge bristol myer
155,LLY,load player here investing action plan need know investor come day apple aapl be expect report third straight quarter year year earning revenue decline tuesday general motor gm fiat chrysler automobile fcau lockheed martin lmt merck mrk edward lifescience ew also be tap
156,LLY,roche rhhby ceo severin schwan shrug president trump crackdown drug price wednesday say swiss drugmaker expect reap benefit literally billion invest market focus truly differentiate medicine medicine make real difference patient say accord cnbc have doubt whatsoever be continue demand such solution particularly convince reward kind innovation market be important roche nearly half roche pharmaceutical sale stem diagnostic tool be sell north america tuesday trump reaffirm pledge go rise drug price have get lower price tell slew pharma bigwig include ceo celgene celg eli lilly lly merck mrk novartis nvs johnson johnson jnj executive also be reportedly attendance president trump promise deregulate drug industry cut taxe trump also abandon proposal revisit idea allow federal government negotiate drug price behalf medicare medicaid cover million american be largest purchaser drug health care service world ibd take trump commentary momentarily boost drug stock tuesday day earlier president ban immigration take bite airline stock read ibd industry theme column more safer entry point travel sector drug stock rise tuesday follow report trump softened stance big pharma ibd company ethical drug industry group edge small fraction stock market today roche stock rise touch nearly month high schwan commentary come roche report growth sale consensus analyst poll thomson reuter expect core earning share rise revenue breast cancer rheumatoid arthritis drug help outplay dip sale drug treat hepatitis pancreatic small cell lung cancer wet age related macular degeneration eye disease hep sector have suffer recently sale dip third fourth quarters accord market researcher ihs share gilead science gild have be pressure recently hep unit hep sale dip virtually nothing fourth quarter swiss roche see similarly painful decline sale hep drug lucentis be only sell fall offset sale breast cancer drug perjeta rheumatoid arthritis drug actemra rise respectively roche also list new launch include oncology drug tecentriq tecentriq be approve previously treat small cell lung cancer previously treat advanced cancer urinary tract compete bristol myer squibb bmy merck small cell lung cancer sector related gilead clobber hep little value too late nash hiv unitsroche gouge bristol myer lung cancer share merck rivalrywill merck let incyte go astrazeneca bristol roche team up too
157,LLY,caterpillar cat csx csx biogen biib costco cost target tgt wal mart wmt be analyst microscope tuesday barclay upgrade stock overweight equal weight raise price target late last month construction equipment maker turn mixed fourth quarter result cut full year revenue outlook strength dollar share rise finish trading day related caterpillar trim outlook strong dollar stock buy pointjp morgan up price target railroad stock last week news surface former canadian pacific railway cp chief hunter harrison be talk potentially lead company activist investor mantle ridge have ask more seat csx board share advanced stock market today related rail vet know improve profit soon head drugmaker get upgrade buy neutral citigroup just late last week leerink analyst say biogen trail merck mrk astrazeneca azn eli lilly lly introduce bace inhibitor treat alzheimer share climb intraday related biogen trail merck lilly alzheimer hemophilia spinoff begin tradingbiogen sidestep sale miss strong ex hemophilia guidebernstein initiate coverage number retailer include membership warehouse costco big box store wal mart target costco wal mart be handed market perform rating price target respectively target be outperform bernstein eye price goal wal mart say tuesday be drop version amazon amzn prime offer free day shipping minimum order match commerce giant meanwhile costco share jump thursday report best monthly same store sale year contrast lackluster result retail peer costco add wal mart tick target inched bernstein also initiate coverage best buy bby home depot hd lowe low best buy lose lowe be home depot tick higher related costco soar biggest comparable sale gain yearswal mart offer free day shipping drop amazon prime rival
158,LLY,fda track record oncology hit accelerate approval program bode well merck mrk keytruda chemo combo leerink analyst seamus fernandez say tuesday suggest administrator have access early datum merck keytruda immunotherapy combination eli lilly lly alimta chemotherapy be be test first line treatment squamous small cell lung cancer nsclc patient have high expression pdl gene last week fda grant combo priority review supplemental biologic license agreement bla base small cohort fernandez say surprise move be better explain fda have access ongoing phase datum thus better visibility efficacy view be controversial interview richard pazdur act director fda oncology center excellence cancer letter suggest agency have access clinical trial datum risk unbind study fernandez write research report ibd take drug stock momentarily tank last week president elect donald trump again pledge curb rise drug price make good promise mean drug biotech pick read ibd industry theme deeper dive accelerate approval last year have already have positive confirmatory phase datum have receive full approval fernandez say only approval take more month review merck case datum keytruda alimta combo be due september approve combo open merck patient population currently approve indication be only patient have high expression pdl gene patient drugmaker be face rival bristol myer squibb bmy be testing combination opdivo yervoy immunotherapy analyst have suggest combine immunotherapy be more potent add chemo immunotherapy merck approach astrazeneca azn too be creep merck tuesday astrazeneca outlined strategy trial test durvalumab monotherapy combination tremelimumab be immunotherapy durvalumab target pdl gene tremelimumab aim ctla gene mystic trial astrazeneca examine progression free survival pfs overall survival os high express pdl patient pfs os be examine comer regardless pdl status combo arm neptune trial be expand patient china be used regulatory filing country fernandez say neptune test combo durvalumab tremelimumab trial recruit asia pearl test durvalumab first line treatment vs chemotherapy datum be expect meaning merck still have month head start fernandez say stock market today merck stock fall lilly stock slip share astrazeneca fall bristol myer squibb edge cent related merck carry incyte keytruda coattail hot tumor leerinkeli lilly rebound chemo drug patent vs generic teva
159,LLY,rise consecutive year fda drug approval rate plunge year low biogen biib merck mrk eli lilly lly add new drug bailiwick accord swiss biotech hbm partner food drug administration approve new molecular entity year marked decade high approval nmes say hbm have not be fewer nmes approve fda give blessing just half nmes be not fully develop house be acquire be license hbm write new drug be first class drug therapeutic area cancer lead nmes new drug project industry lead peak sale be oncology hbm find ibd take ease fda approval process be part donald trump health care initiative president elect really break republican enact major drug reform trend past year oncology drug see major increase fda approval list new cancer drug be approve rise nmes cancer fda have increase appetite drug treat diabetes respiratory disease viral other infection interest cardiovascular genetic immunology drug increase moderately year also see fewer central nervous system drug then merck roche rhhby have have more drug approve other company add johnson johnson jnj pfizer pfe follow closely apiece gilead science gild novartis nvs glaxosmithkline gsk sanofi sny lilly have add new drug ibd company medical biom biotech industry group close stock market today group rank be tumble lawmaker debate issue drug steeply rise price related lilly regain key migraine drug colucid acquisitionfda track record bode well merck keytruda chemo leerinktrump disastrous pharma view doesn rattle jpmorgan drug conference
160,LLY,dow jone industrial average give start week president trump immigration policy other move worry investor moved back level friday job report apple aapl boom return earning growth investor didn care facebook fb amazon amzn result guidance unite parcel service up be struggle commerce boom charle schwab schw launch new stock trading pricing war dow jone industrial average fall back key level regain friday january job report trump move ease dodd frank other financial regulation dow fall week nasdaq rise end week record high trump immigration order create conflict tech firm trading partner earning be mixed bag cboe volatility index vix rally extreme level not much related dow component apple earn share sale quarter end dec be better expect marked return growth straight quarters year year decline apple current quarter guidance be conservative usual apple say iphone demand outstripped supply service revenue apple share rise nearly week hit month high related advanced micro device amd report smaller expect loss forecast sale bullish outlook share shot nearly hit year high nvidia nvda compete amd graphic other market jump ahead earning come week apple chip supplier cirrus logic crus qorvo qrvo top quarterly view give bearish guidance stock sell thursday related facebook ep soar revenue rise easily beating view decelerate second straight quarter mobile ad account ad revenue facebook reiterate ad revenue growth rate come meaningfully deliberate move avoid ad saturation now see heavy expense growth step hire facebook fall week snap parent snapchat file publicly upcoming ipo snap report soar revenue growth also slow user growth facebook instagram imitate key snapchat feature snap use ticker snap win sell voting share related amazon top earning forecast revenue revenue outlook be lower expect amazon web service cloud compute unit generate most commerce giant profit report revenue gain forecast aw be feel pressure rival cloud effort alphabet googl microsoft msft amazon share fall nearly friday undercut recent buy point related amazon result miss revenue beat ep stock fallsunited parcel service up report modest earning revenue growth holiday fourth quarter fall short forecast up also guide profit target lower cite impact strong dollar up see significant shift mix lower revenue product residential delivery accounting total package volume up ceo say result indicate up quicken pace investment network shift handle increase commerce meanwhile amazon announce set air hub cincinnatus northern kentucky international airport seek lessen dependence up fedex fdx up share plunge fedex lose related mastercard edge past earning view revenue be light share have be buy zone pull back nearly even regain day friday larger rival visa late thursday report better expect quarterly result strong payment growth visa rise friday push dow stock past buy point record high related federal reserve left interest rate alone give indication policymaker be hurry raise rate add strong job january well estimate slim wage gain ease fear economy be overheat ism manufacturing index rise fresh year high january related exxon mobil xom report adjust ep view oil major plan boost capital spending activity heat royal dutch shell rdsa say cut spending year report ep view conocophillip cop say plan raise spending energy information administration say crude stockpile rise barrel analyst expect russia opec seem be comply promise output cut accord reuter datum related auto sale decline december longtime high even automaker offer hefty incentive general motor gm ford fiat chrysler fcau report year year decline only gm miss forecast datum offer new evidence auto demand have peaked related charle schwab schw cut stock etf commission trade lower fidelity td ameritrade amtd trade etfc schwab fall thursday td ameritrade trade rely more stock trade schwab tumble interactive broker ibkr charge cent share trade sank related president trump meeting tuesday ceo exec celgene celg eli lilly lly johnson johnson jnj merck mrk novartis nvs say drug price be astronomical reiterate aim bring drug price also urge drugmaker manufacture also promise deregulate industry cut taxe drug stock pop day response related drugmaker eli lilly pfizer pfe disappoint tuesday earning lag consensus sale top meet respectively roche rhhby sale be light revenue earning rise mid single digit merck follow thursday line sale earning include time defer revenue amgen amgn late thursday report better expect earning say ldl cholesterol fighter reduce cardiovascular risk study related miss merger deadline expire walgreen boot alliance wba rite aid rad extend agreement end date july walgreen cut takeover price share share depend many rite aid store have be divest order new term get regulatory walgreen fall rite aid fall concern ftc win approve deal fred have agreement buy rite aid store edge lower related armour uaa miss estimate top bottom ep fall penny cent sale rise revenue guidance be light athletic apparel brand cfo be step personal reason share tumble year low related
161,LLY,eli lilly lly regain late stage migraine drug plan acquire small cap biotech colucid pharmaceutical clcd announcement send colucid stock record high early wednesday deal value colucid share expect close end colucid stock rocket close stock market today eli lilly stock rise finish colucid make ipo mid close acquire colucid let lilly get hand lasmiditan ht agonist phase testing treat acute migraine lilly originally develop lasmiditan license drug colucid pain management then wasn strategic focus lilly then lilly have refocuse pain med emerge market pipeline be focuse cancer osteoarthritis back migraine pain ibd take donald trump send pharma tie stock tailspin last week accuse drugmaker get away murder spiking drug price get deep dive ibd industry theme estimate person suffer migraine lilly say lilly pharmaceutical aldr teva pharmaceutical teva amgen amgn be neck neck cgrp migraine market ll likely be come market month other ceo randall schatzman tell ibd earlier month annual jpmorgan healthcare conference say market be large enough competitor term eli lilly deal acquire colucid lilly incur charge cent share charge likely reduce earning expectation amount lilly doesn foresee change ep ex item guidance result charge related amgen plan robust alzheimer migraine oncology ceo exclusivefda track record bode well merck keytruda chemo leerinkeli lilly rebound chemo drug vs generic teva
162,LLY,eli lilly lly aim take bite animal health market buy unit germany boehringer ingelheim be acquire sanofi sny animal health business zoetis zts spun pfizer pfe be animal health company boehringer likely become evercore isi analyst john scottus say email client wednesday lilly elanco unit get bigger lilly stock rise fraction stock market today zoetis stock fall fraction zoetis stock have be form flat base possible buy point lilly agree pay boehringer vermedica unit include common vaccine dog cat other animal well iowa manufacturing site include common vaccine bordetella parvovirus rabies zoetis sell rabies other vaccine cat dog scottus say speak lilly representative say boehringer vaccine portfolio deal expect close early next year generate annual revenue elanco total sale elanco account lilly revenue lilly buy animal health division novartis nvs early scottus say lilly indicated maintain operate profit margin target high last year say zoetis have target operate margin currently couple robust food animal portfolio addition further strengthen elanco position global animal health business lilly ceo john lechleiter say company press release boehringer say june sell vermedica unit antitrust regulator review acquisition sanofi animal health business ibd take lilly zoetis be ibd company medical ethical drug group rank just group track still group zoetis ty depome highest composite rating cr be broad measure performance look key metric such earning sale growth be good general target company cr rating related zoetis company radar janus fund managerslilly upgrade potential alzheimer drug
163,LLY,biotech prothena prta say late thursday plan launch phase testing psoriatic arthritis drug have similar science psoriasis drug already test drugmaker amgen amgn eli lilly lly novartis nvs psoriatic arthritis be common form arthritis affect patient psoriasis skin disorder white skin cell build cause itchy dry patch credit suisse analyst kennen mackay estimate psoriatic arthritis market market also come high competitive barrier write research report psoriatic arthritis be large market forecast biologic sale crest see multiple entrench biologic brand provide significant competitive barrier entry write remicade entrance market further complicate matter mackay see prothena psoriatic arthritis drug prx have novel mechanism go inhibit cell il cytokine be science psoriasis drug amgen eli lilly novartis compound knock type pro inflammatory cell tie autoimmune disease multiple sclerosis rheumatoid arthritis psoriasis mackay write do so also knock il cytokine be associate psoriasis combat psoriatic arthritis prothena compound have account cell il cytokine other type cytokine rbc analyst michael yee write report phase testing be slate begin trail phase psoriasis drug testing other yee mackay separately keep outperform rating prothena stock close stock market today prothena stock be share be buy zone consecutive day hit entry point flat base aug volatile market investor be cautious new buy ibd take prothena rise wall street today outplay broader downtrend see nasdaq drop check big picture more related bevy biotech stock healthy
164,LLY,drugmaker market cap amgen amgn likely beat eli lilly lly aldr teva pharmaceutical industry teva market protein block migraine med say be game changer industry late wednesday amgen say migraine drug amg cut episodic migraine day month vs day reduction patient treat placebo phase trial center patient experience migraine day month amg drug be erenumab be design block calcitonin gene related peptide cgrp receptor be believe be intricately tie migraine cgrp be protein involved transmission pain drug be administer milligram monthly week have safety profile similar placebo second phase study be ongoing examine mg mg dose week amgen say expect have result study year end person episodic migraine lose substantial portion life migraine many face intolerable pain physical impairment frequently accompany significant disruption daily activity dr sean harper executive vice president amgen say statement migraine research foundation estimate employer lose annually result workday lose migraine episodic migraine be defined less headache day month comprise roughly diagnosed patient say rbc analyst michael yee positive result recent chronic migraine result contribute grow body evidence support erenumab innovative treatment option person be suffering debilitating disease harper say wall street be more bearish cgrp block drug yee write research report amgen partner novartis nvs erenumab eli lilly teva be develop similar drug investor be expect price war yee say however general view be payor pay drug give reasonably low price also migraine be serious issue impact million patient economic burden patient quality life issue write yee see franchise amgen amg have outperform rating amgen stock fall stock market today share be buy zone less extend entry point cup handle formation achieve july volatile market best be cautious new buy amgen stock touch month high friday ibd take amgen be drugmaker market cap ibd composite rating put company ibd medical biom biotech industry group biospecific technology lead group cr meaning perform top stock get stock checkup related amgen multiple myeloma drug bumble key test vs blockbuster velcadeamgen biogen pit scenario acacia draw interest
165,LLY,prothena prta stock nose dive friday political volatility be buy opportunity say rbc analyst michael yee see biotech landing partnership like eli lilly lly pfizer pfe psoriasis drug investor haven be bullish prothena stock rival wednesday ibd company medical biom biotech industry group be worst perform group track share plunge dip day move average ibd take company group be rank group track rise just week share be rake coal wednesday prothena supernus topple markedly check ibd industry theme get idea better stock bet yee chalk weak drug stock late political angst have outperform rating price target prothena stock prothena share close stock market today intraday have fall more entry point touch consolidation investor be advise sell stock fall buy point key take away be recent pullback think be mostly due political uncertainty house senate race be opportunity view company be track very busy full pipeline write research report thursday prothena have key drug line be currently enrolling patient phase phase trial neod drug treat amyloidosis amyloidosis occur normally soluble protein mis fold accumulate become toxic organ yee have confidence neod chance see potential upside price target phase pronto trial show positive datum prothena prx prx be wall street consensus yee say expect duo provide additional upside opportunity prx aim treat parkinson partnership roche rhhby prx be prothena drug psoriasis latter be key consider big pharma interest inflammation drug evidence number allergan agn deal pharma be interested include pfizer eli lilly write think prothena land nice partnership asset phase ii datum summer design also be novel say prothena prx be build science inhibit cell il cytokine be tie inflammatory disease method be used amgen amgn eli lilly novartis nvs psoriasis drug related allergan challenge intercept nash drugeli lilly look coral more animal health business zoetis
166,LLY,biotech gilead gild be most likely scoop incyte incy next month accord survey industry watcher evercore isi investment bank ahead presidential election pit donald trump hillary clinton survey say most see gilead purchase incyte identify incyte biopharma most likely be acquire next year nearly respectively see biogen biib biomarin pharmaceutical bmrn target gilead acadium pharmaceutical acad celgene celg kite pharma kite be least likely be target only industry expert identify likely takeover candidate departure needham analysis last week identify potential suitor acadium incyte takeover likely come heavy price june gilead have cash equivalent market security hand market cap gilead be biotech trail only amgen widely view big biotechs most need be active front incyte have market capitulation smaller coalition say gilead buy vertex vrtx bristol myer squibb bmy outside lion share expert expect biotechs outperform broader market next month respondent say biopharmas merely be line trade election say expert ibd company medical biom biotech industry group be year loss be early year overall market tumble group be more late june now rank group track just week close stock market today group be more buck day downtrend ibd take latest industry snapshot explore biotech promising new drug stock be lead biotech sector drug pricing initiative rout stock year rbc analyst say thursday acknowledge drugmaker amgen amgn gilead celgene biogen regeneron regn vertex easily find loophole skirt new regulation still fewer person poll evercore expect government take meaningful action drug pricing nearly largest chunk say government win ever push reduction drug price other prediction stem specific company only expect eli lilly lly alzheimer drug solanezumab hit cognition function endpoint more broadly say hit cognition miss function more half say celgene phase testing ged oral mongersen treatment crohn fail reach overwhelming efficacy see phase testing phase patient take milligram be clinical remission day small say celgene see better result phase testing only expect study fail entirely result show endoscopic improvement respondent say celgene stock pop third expect share remain stagnant related gilead paralyzed likely hep share lossamgen biogen gilead spike va pricing skirt california pharmaceutical fall combo therapy eylea alone
167,LLY,share big pharmas eli lilly lly abbvie abbv be move opposite direction thursday jpmorgan upgrade downgrade other analyst chris schott write risk reward ratio be look favorable go release late stage trial result lilly alzheimer disease drug solanezumab expect december point lilly have deep pipeline alzheimer drug solanezumab well new drug other disease area see range new product opportunity lilly support company growth target be forecasting top line growth exclude risk adjust solanezumab sale support number product opportunity such trulicity jardiance taltz baricitinib abemaciclib schott write research note upgrading lilly stock overweight neutral aggregate forecast recent upcoming new product launch generate sale lilly stock be late afternoon trading stock market today ibd take jpmorgan action abbvie be rate ibd medical ethical drug group lilly be see read slim investing system meanwhile schott downgrade abbvie neutral overweight say still like long term prospect aren enough term catalyst offset erosion lead drug humira face biosimilar competition be possible humira see limit biosimilar competition expect little clarity potential outcome next month schott write abbvie stock be late afternoon trading thursday related lilly breast cancer drug study roll
168,LLY,small biotech lexicon pharmaceutical lxrx soar much friday diabetes drug succeed late stage trial lexicon drug sotagliflozin significantly reduce type hemoglobin used measure glucose level plasma patient type diabetes sotagliflozin be combination sglt inhibitor similar eli lilly lly jardiance johnson johnson jnj invokana sglt inhibitor help regulate glucose absorption tract study do not see increase severe hypoglycemia be dose related increase diabetic ketoacidosis reach higher dose arm ibd take lexicon hit new week high always good idea check ibd new high list hit new high isn be end good stock new high page explain type diabetes market be fraction size type market lexicon say start phase trial type year collaboration french pharma sanofi sny think dual mechanism action sglt sglt inhibitor differentiate market sglt inhibitor type diabetes assume peak sale exceed indication write morningstar analyst karen andersen research note last november lexicon now see smaller realize sale type diabetes form double digit royalty sanofi deal also open significant potential type diabetes lexicon stock end stock market today nearly year high sanofi stock fall related sanofi rival mylan epipen have troubleseli lilly upgrade pipeline prospect
169,LLY,medical behemoth amgen amgn biogen biib square acquire muscle biologist cytokinetic cytk more dozen potential player prep donnybrook small cap pharmaceutical adms needham analyst suggest friday biotech fodder heated week allergan agn announce back back deal acquire vitae pharmaceutical vtae tobira therapeutic tbra tobira deal give allergan leg battle nonalcoholic steatohepatitis nash gilead gild intercept icpt pharmaceutical also compete ibd company biotech industry group have climb group track just week collectively group have market cap group group fall friday first decline past trading day group be week needham analyst review pipeline business development area interest activity large company gauge interested big pharma be biotechs important theme biotech space write research report allergan amgen bristol myer squibb bmy johnson johnson jnj merck mrk pfizer pfe roche rhhby shire shpg valeant vrx have be most acquisitive buy prep buy more company collectively shire have be most active acquisition believe late development stage commercial stage biotech company be particularly attractive acquisition target write research report title do big pharma want buy peak area interest include oncology cardiovascular needham research show not be big pharma take beaucoup buck needham analyst suggest central nervous system cns player acadium pharmaceutical liver disorder drugmaker intercept be prime acquisition interest firm overlap potential interest acadium abbvie abbv allergan eli lilly lly lundbeck merck novartis pharmaceutical nvs teva pharmaceutical industry teva takeda pharmaceutical needham list potential acquirer allergan make particular sense consider duo already partner next generation formulation memantine fix dose combination product namzaric battle alzheimer year end plan file new drug application food drug administration ad treatment levodopa induced dyskinesia involuntary movement parkinson disease patient multiple sclerosis walking impairment needham write meanwhile acadium potential suitor be interested nuplazid drug ease psychosis associate parkinson launch earlier year needham suggest acadium be look expand label other used similarly intercept draw interest nearly dozen potential buyer include gilead biotech market cap thursday rbc analyst posit intercept continue lead gilead allergan battle nash ibd take biotech stock notch higher week last week check ibd industry theme
170,LLY,big pharma eli lilly lly fall wednesday breast cancer drug didn prove be knockout investor have hope outside committee conduct interim analysis monarch late stage trial lilly drug abemaciclib combine fulvestrant astrazeneca azn faslodex advanced metastatic breast cancer drug be show enough efficacy already then trial have be stop early lilly have go ahead file fda approval committee recommend study continue previously plan completion point have stringent criterium set interim analysis look forward receive final monarch result first half richard gaynor lilly vice president product development medical affair say statement lilly stock fall stock market today fall low intraday leerink analyst seamus fernandez say follow ambiguous result previous study abemaciclib monotherapy fulvestrant single agent response rate seem be better competition pfizer pfe palbociclib ibrance novartis nvs ribociclib do not meet primary endpoint fernandez write research note management indicated file approval monarch interim analysis point believe be unlikely be able file monotherapy fernandez add pfizer novartis stop trial early efficacy so lilly be widely expect do so well drug be same class call cyclin dependent kinase cdk inhibitor pfizer ibrance approve february have already pass sale ibd take timing drug launch be important drug stock future financial estimate be preferably go lilly estimate have recently be rise see stock checkup
171,LLY,share biogen biib shot tuesday report big drugmaker be explore possibility buy company wall street journal say anonymously source report merck mrk allergan agn have talk biogen possibility talk be informal preliminary biogen stock have be slightly day then jump close stock market today hit year high wall street have be toss possibility biogen takeout time rumor start heat ceo george scango announce retirement last week rbc capital market analyst michael yee note video last weekend leave biogen vulnerable takeover especially investor have get restless slowdown company multiple sclerosis franchise risky pipeline most talk pipeline drug be aducanumab alzheimer disease explain merck interest merck be work different class alzheimer treatment call bace inhibitor be think eli lilly lly disease ultimately be treat combination drug allergan inherited drug treat alzheimer symptom acquisition forest laboratory few year so presumably leverage sale force other company be name yee opined roche rhhby also be logical buyer give already have partnership biogen selling lymphoma drug gazyva merck fall tuesday allergan lose roche climb
172,LLY,small biotech aldr surge monday report positive datum ongoing race next big migraine treatment be follow phase trial have first report last march patient depend dose receive single intravenous infusion cgrp antibody ald enjoy least reduction migraine day week week experience same reduction vs control group be compete big name teva pharmaceutical teva amgen amgn eli lilly lly bring cgrp antibody market leerink analyst joseph schwartz write so far clinical trial datum haven much differentiate drug candidate other fact patient take single dose ald low mg improve point possible advantage surprising degree durability mg suggest potential subcutaneous formulation upcoming phase promise trial schwartz write research note benefit tap iv self administration subcutaneous market differentiate ald cgrp competitor teva cgrp antibody produce similar result monthly subcutaneous dose note evercore isi analyst umer raffat email stock end trading day stock market today teva be fraction amgen rise fractionally lilly edge ibd take biopharma have product market so very risky investment amgen be strongest biotech stock rating industry group see amgen stock checkup learn
173,LLY,type diabetes be battle best selling drug world biggest drugmaker company be eyee even bigger sale new generation treatment change field have prove more evolutionary revolutionary several event next few month start soon monday eventually move billion dollar make compliance treatment easier even prevent death heart disease diabetes drug provide single best selling product johnson johnson jnj merck mrk almost nordisk nvo annual revenue come diabetes treatment health care research firm globaldata say diabetes treatment bring nearly re get better better manage diabetes general say funtleyder health care portfolio manager square asset management have more option next phase be go be get person adhere regimen work diabetes patient type diabetes be world most common disease sticking treatment be difficult medication routine get increasingly complicate disease progress diet exercise fail patient go oral drug start cheap generic such metformin prove insufficient doctor add newer brand oral medicine come class dpp inhibitor lead merck januvia more recent sglt inhibitor lead invokana class work different mechanism be sometimes combine yet further intervention be require patient move injectable drug nowadays glucagon peptide glp analog be usually first line attack class include nordisk victoza eli lilly lly trulicity ibd take eli lilly stock have nice year run end year now sport weak composite relative strength rating respectively shouldn get much stock pick attention company aim rebound ceo tell ibd exclusive year come most familiar treatment diabetes insulin modern insulin come different variety include long act version sanofi sny lantus tresiba need be inject only once day faster act one use mealtime such lilly humalog novolog pile med patient have trouble keep so approach simplify routine be create combination drug be do successfully hiv market sanofi nordisk be await fda decision combination insulin glp back back fda advisory panel recommend approval xultophy win unanimous support sanofi lixilan have couple dissenter due safety issue related pen injector used administer drug fda deadline decide xultophy be monday sanofi decision be due next month hasn reveal specific deadline leerink analyst seamus fernandez see blockbuster potential drug expect ll take year hit peak sale have see other recent major primary care launch such pcsk sanofi regeneron regn amgen amgn entresto novartis nvs breo ellipta glaxosmithkline gsk expect slow initial launch class first few year fernandez write research note view xultophy have slight upper hand drug device profile position treatment algorithm lead better physician acceptance market uptake say overall diabetes model forecast peak sale xultophy peak sale lixilan fda decision much anticipate wall street be already approve drug lilly sglt inhibitor jardiance last year lilly stunned industry large year trial show jardiance significantly extend lifespan diabetes patient reduce death rate death cardiovascular cause also sharply reduce hospitalization heart failure analyst say jardiance see instant uptick sale so spectacular be result didn happen lilly closely study issue say enrique conterno president lilly diabetes realize potential thing need happen conterno tell ibd first be need datum label second be need new treatment guideline be establish canada already make change relevant medical society treatment guideline conterno say expect same early next year get label change mean lilly sale rep be able talk cardiovascular benefit customer be important primary care doctor most diabetes prescription aren always specialist research lilly have apply expand label include information least put clinical trial result packaging approval however isn quite slam dunk expect trial result way lilly design trial primary endpoint be normally most important fda be composite different measurement cardiovascular health produce mixed result specific finding heart failure overall death be exploratory endpoint thus fda advisory panel only narrowly recommend change label meet june change label basis secondary endpoint set precedent so remain so unclear fda do analyst compare coin flip view approval actual cv death indication have coin flip odd give unprecedented nature result trial write evercore isi analyst mark schoenebaum email june say also feel better chance fda allow datum be add label also remain be see competition shape last month nordisk report glp call victoza also reduce cardiovascular death not quite much jardiance jardiance be oral victoza be injectable occupy slightly different position treatment regimen jardiance most direct competitor invokana be also subject cardiovascular outcome trial due completion february initial result possibly come earlier different variable company do best diabetes be broadest portfolio funtleyder say cite lilly nordisk have have particularly comprehensive program give advantage salesforce leverage basis same sale guy sample multiple drug say have benefit payer bundle drug together big bill instead pbms pharmacy benefit manager have negotiate separate pill eli lilly share rise stock market today best level late january nordisk climb dip
174,LLY,big pharmas abbvie abbv merck mrk trade higher friday report estimate beating result friday french counterpart sanofi sny close virtually flat abbvie quarterly sale grow year earlier quarter pass analyst consensus largely strength sale immunology drug humira sale blood cancer drug imbruvica also beat expectation abbvie slightly increase tighten full year ep guidance call growth last year share finished higher stock market today merck also beat estimate more narrowly raise low end full year ep guidance range merck also announce friday hepatitis drug zepatier have be approve european union month approval zepatier sell beating consensus evercore isi analyst mark schoenebaum note merck best selling diabetes drug januvia seem be hold competition eli lilly lly jardiance cancer drug keytruda beat consensus largely international sale recall merck recently announce success keynote trial first line nsclc small cell lung cancer attention investor come year focus performance indication schoenebaum write email merck stock edge ibd take abbvie rank ibd medical ethical drug group solid financial decent stock performance group overall be just total check ibd industry theme take temperature stock industry group sanofi meanwhile miss sale estimate quarter affirm full year ep guidance contrast merck sanofi diabetes franchise have be shrink face competition drop worldwide other noteworthy news japan astella marketing partner sanofi takeover target medivation mdvn report quarterly financial suggest medivation lead drug xtandi miss sale consensus globally be line medivation stock rise hit month high edge past buy point sanofi close cent
175,LLY,eli lilly lly stock bound thursday federal appellate court upheld patent chemotherapy alimta vs generic drugmaker teva pharmaceutical teva third court year do so court appeal rule early thursday propose generic teva parenteral medicine subsidiary generic drugmaker same name infringe eli lilly patent alimta leerink analyst seamus fernandez say decision remove overhang lilly stock stock close still outperformed broader industry ibd company medical ethical drug industry group plunge last year lilly stock rise stock market today again rise day move average support line be also important benefit lilly long term sale guidance least particularly wake merck mrk surprise bla biologic license agreement keytruda combination alimta small cell lung cancer ibd take drug stock tank wednesday president elect donald trump comment first post election news conference view drug industry disastrous vow create new bidding procedure grab ibd industry theme deep dive fernandez model alimta sale immuno oncology combo be test now bristol myer squibb bmy competitively pressure lilly merck io chemo combination note analyst broadly expect bristol myer io io combo hit shelve give lilly merck several month advantage io chemo combo also potentially be expand larger range patient meanwhile alimta patent litigation be ongoing europe lilly hasn fared well trial end judge ruling generic chemotherapy wouldn infringe lilly alimta patent france spain italy patent case be still unfold germany fernandez estimate alimta sale be risk europe keep outperform rating lilly stock midday trading stock market today lilly stock lift related lilly near fda nod arthritis drug chemo med stick courtlilly spike guidance claw back alzheimer flop
176,LLY,san francisco less hour president elect donald trump wednesday refer drug industry disastrous aldr ceo randall schatzman classify tone annual jpmorgan healthcare conference cautiously optimistic wide departure event time say sentiment be decidedly pessimistic enter turn be raucous election year drug pricing debate be alive biotech sentiment be grow stronger year schatzman tell ibd interview conference drug industry major event hold week san francisco talk biotech industry whole think finally come maturity say last year almost drug have be approve have come innovation biotechnology not large pharma so dollar be really pay back re see real game changer schatzman include cgrp migraine drug compete directly similar med eli lilly lly teva pharmaceutical teva amgen amgn migraine market be big enough grab sizable share drug hit shelve likely acknowledge trump comment didn help stock price hold phone schatzman pull screen biotech stock red arrow indicate descent point ishare nasdaq biotechnology index ibb exchange trade fund fall wednesday rise fraction thursday friday ibd take trump commentary send drug stock tailspin wednesday get deep dive mean drug biotech pick ibd industry theme so rally wall street expect jpmorgan event didn unfold here be key takeaway investor note trump take office drug firm look sidestep lilly alzheimer flop get early start trump isn alone fixation drug price celgene celg ceo mark alle parry back reporter question biotech follow allergan agn footstep apply so call social contract not raise price more annually celgene have offer free access program year alle say estimate biotech give away drug year free drug price increase help fund new drug add cfo peter kellogg estimate celgene reinvest fund accounting partnership alle say celgene go thoughtful process accounting innovation spending bring drug market price new med schatzman used same word describe plan price cgrp drug once near fda approval head market healthprize technology ceo tom kottler call pricing spike easy way drug company healthprize be software service firm marry behavioral economic consumer marketing analyze improve patient adherence prescription pharma leave worldwide revenue table year not push patient take med kottler tell ibd bridge gap company bring new product market prompt doctor more prescription raise price typically choose latter re miss easy money kottler say raise price be easiest thing say drugmaker merck mrk announce immuno oncology io drug keytruda combination chemo eli lilly alimta have win priority review fda small cell lung cancer have prescription drug free user act pdufa date meanwhile merck incyte incy be move keytruda epacadostat phase trial tumor type small cell lung cancer renal cell carcinoma bladder cancer squamous cell carcinoma head neck incyte stock jump jan news bristol myer squibb bmy be merck tail analyst say bristol myer be testing combination opdivo yervoy io therapy nsclc analyst expect bristol myer readout first half io combo be likely be more effective durable io chemo say monday japan takeda pharmaceutical put share bid ariad pharmaceutical ariad oncology firm base massachusett ariad stock fly news help share oncology firm tesaro tsro lift tesaro stock ipos lead ibd company medical biom biotech industry group stock see triple digit gain tesaro jump group overall fall painful election cycle now analyst wonder tesaro success oncology mind atmosphere reiterate takeda offer ariad garner bid tesaro leerink analyst seamus fernandez see potential takeout price share tesaro stock close friday rise tesaro remain well position grow independently validate parp inhibitor niraparib ovarian cancer drug still development offer durable strategically important product opportunity multiple suitor fernandez write research report jan regeneron regn sanofi sny be ask federal judge stay ban ldl bust drug praluent aftermath patent battle land biotech amgen praluent infringe amgen patent pcsk inhibitor repatha judge say meanwhile ldl buster alnylam pharmaceutical alny medicine co mdco be slowly advance jan medicine co announce day interim analysis study examine pcsk inclisiran datum show inclisiran significantly lower ldl day rbc analyst adnan butt expect month datum be similar efficacy safety detail be expect american college cardiology conference march washington inclisiran do well strong datum patent litigation amgen regeneron sanofi inclisiran be differentiate have patent litigation overhang butt say research report wednesday axovant axon ceo vivek ramaswamy say biotech drug industry have utterly fail alzheimer oncology inflammation cardiology ve see significant advancement last year disease alzheimer dementia include lewy body haven say don find treatment major threat society tell ibd interview wednesday be single area health care have fail deliver major advancement last decade ramaswamy say be root eli lilly december lilly highly laud solanezumab fail meet primary endpoint late stage trial cause lilly stock plunge day announcement lilly drug drug development biogen biib work remove plaque buildup brain associate alzheimer silver bullet theory ramaswamy doesn buy instead see necessary treat various behavioral psychological neurological piece alzheimer dementia axovant be aim build new therapy top older one axovant be next be alzheimer field deliver readout datum be slate say ramaswamy be look just major piece news alzheimer advancement say ramaswamy rise tide lift boat
177,LLY,stock be nearly flat open wednesday investor digest quarterly report look late morning press conference president elect donald trump dow industrial rise nasdaq be fraction merck mrk hammer gain open drugmaker announce expand immuno oncology partnership eli lilly lly clinical trial lilly lartruvo merck keytruda lilly share rise biotechs make early outsized move include achaogen akao signal genetic sgnl agricultural product leader daniel adm fall premarket trade chicago base company announce end tuesday session acquire pet food maker crosswind industry term deal be not disclose stock have generally trend higher past month msc industrial direct msm climb more fiscal first quarter earning top analyst expectation revenue meet estimate management lift industrial maintenance supply distributor second quarter revenue guidance consensus view stock end trade tuesday late october low pull back test support week move average signet jeweler sig shed warning investor fourth quarter earning comparable store sale miss consensus expectation wide margin owner kay jared retail chain have slip past week kill recovery attempt begin september company report result march grocery chain supervalu svu drop more fiscal third quarter result stop well short analyst target ibd stock healthequity hqy fall olin oln rise stage breakout flat basis tuesday healthequity be buy point olin be buy point stock market today have eye president elect trump hold first press conference july et new york oil price also be closely watch crude oil inventory expect energy information administration et otherwise economic calendar take break busy schedule datum report federal reserve speech thursday friday oil price improve diving more tuesday west texas intermediate add barrel gold rise ounce dollar climb bond inched pare basis point year yield overseas market trend narrow gain asia benchmark tokyo hong kong rise shanghai composite slip market europe be also mixed index london frankfurt more paris post narrow loss afternoon trade related trump press conference celgene lead investing action plan
178,LLY,drugmaker roche rhhby merck mrk pfizer pfe likely disappoint guidance abbvie abbv stock remain top pick jeffery analyst jeffrey holford say friday research report rundown ahead earning stock market today abbvie stock fall ibd company medical ethical drug industry group fall fall day move average week abbvie be face pressure amgen amgn biotech market cap prep deploy humira biosimilar abbvie humira world top selling drug be used treat array disease include rheumatoid arthritis psoriatic arthritis crohn disease ulcerative colitis abbvie patent protect dose scheme humira be set be deliberate court feb patent administer milligram antibody day be set expire june patent likely be upheld bar entrant first filer amgen holford say ibd take low holford totem pole merck step eli lilly biogen deliver new drug approval else curry fda support head ibd industry theme more see patent block patent potential humira biosimilar give be assume biosimilar be develop be dose same concentration frequency write worst case scenario amgen launch humira biosimilar mid assume first filer doesn launch risk holford see share downside humira biosimilar launch give consensus expectation launch abbvie holford list novartis nvs bristol myer squibb bmy astrazeneca azn strong pick pfizer merck nordisk sanofi sny be opposite end holford list expect disappointing guidance nearly big cap drugmaker expect disappointing guidance majority eu large cap pharma roche novartis pfizer astrazeneca likely disappointing revenue guidance pfizer astrazeneca merck roche also expect disappoint earning share guidance write upcoming catalyst include datum roche aphinity trial examine perjeta regimen positive breast cancer holford lean positive outcome sense high degree uncertainty write merck keytruda combination eli lilly lly alimta be also pique investor interest combination immunotherapy chemotherapy be grant priority review first line small cell lung cancer month holford note fda accept application small datum set therefore combo be unlikely see wide use also see consensus too bullish combo undervalue immunotherapy combination like bristol myer astrazeneca first line small cell lung cancer related gilead outlook hamstrung hep rbc bullish amgen biogenbristol myer dife opdivo setback get keytruda royaltiesfda track record bode well merck keytruda chemo leerinktrump disastrous pharma view doesn rattle jpmorgan drug conference
179,LLY,biogen biib eli lilly lly amyloid hypothesis fight alzheimer be alive kick presentation clinical trial alzheimer disease conference friday biogen stock underplay promising result investor concern patient seizure stock market today biogen stock fall early biogen stock rise day move average rise much high volume later fall much eli lilly stock rise average trading volume nov lilly stock plunge follow disappointing result alzheimer drug solanezumab rival roche rhhby see share jump late afternoon friday yee like biogen stock fundamentally say alzheimer market be crowd evercore analyst john scottus cite patient seizure receive biogen aducanumab stock fall friday note alzheimer patient be time more susceptible seizure healthy elderly person ibd take lilly alzheimer drug have flopped have potential also diabetes market analyst say pull expand jardiance sale result seizure patient temporarily experience loss pulse patient didn die similar event occur placebo population scottus write research report patient aducanumab treatment year only event seizure seem be rare rate year be similar rate observed historical ad alzheimer disease population year write overall phase result aducanumab be promising safety standpoint patient titration arm experience aria brain swell be fix milligram dose schedule term efficacy titration fix dose patient see point point reduction clinical dementia rating cdr compare placebo patient worsen point scottus write rbc yee see biogen well position say lilly drug be promising lilly datum look not bad expect actually quite promising show modest clear clinical benefit write biogen drug be very well position more potent inhibitor thus show robust decline insoluble plaque lead most robust clinical cognitive benefit biogen eli lilly be operate theory buildup amyloid plaque brain lead alzheimer drug aim cut buildup lilly solanezumab miss primary endpoint improve cognition therefore suggest better drug biogen aducanumab be more likely work lilly drug work just show modest minor statistically significant benefit think biogen aducanumab look better be more potent yee write separate research report related eli lilly continue alzheimer push flop biogen extend risecelgene kite spark look sidestep lilly alzheimer flop
180,LLY,bristol myer squibb bmy astrazeneca azn roche rhhby pressure merck mrk slew lung cancer drug design chip keytruda share jeffery analyst jeffrey holford say monday downgrade merck stock stock market today merck fall bristol myer squibb climb merck bristol myer be lock battle small cell lung cancer market drug leverage patient immune system battle cancer holford downgrade merck stock underperform price target expect strong keytruda performance follow pressure rival drug bristol astrazeneca roche chip away keytruda market ibd take next year be marked new presidency path donald trump take drug price merck screen poorly many valuation metric have downgrade share underperform holford write research report same note upgrade bristol stock buy price target holford expect opdivo trial secure bristol future more broadly prefer abbvie abbv eli lilly lly stock astrazeneca novartis nvs stock europe see pfizer pfe johnson johnson jnj merck sanofi sny nordisk nvo least prefer stock related gilead pay merck hep patent agio stock anemic
181,LLY,celgene celg kite pharma kite spark therapeutic once be look sidestep eli lilly lly recent alzheimer flop ahead annual american society hematology conference saturday tuesday san diego rbc evercore analyst say wednesday ibd biotech group be markedly nov eli lilly announce solanezumab have fail show statistically significant effect cognition alzheimer patient failure surprised analyst investor nov group actually rebound side first fall investor be try look thing more glass half full optimism rbc analyst write research report ahead ash conference be buyer look accumulate biotech give ve come past year ibd take celgene be rank fourth ibd company medical biom biotech industry group composite rating meaning perform top stock term key growth metric also check ibd ranking top perform stock get stock checkup best bet biotech rbc like celgene kite spark prothena prta alexion pharmaceutical alxn seattle genetic sgen evercore analyst john scottus be keep track car cell therapy juno therapeutic juno kite combination datum celgene celgene be expect unveil phase datum revlimid post stem cell transplant multiple myeloma patient expand use drive additional annual revenue help revlimid become standard care rbc say celgene stock drop close bell stock market today touch year high nov ibd company biom biotech group be close wednesday fall lilly alzheimer trial announcement evercore scottus look celgene discuss early clinical datum next generation drug used chemical cereblon cc be aim diffuse large cell lymphoma dlbcl cc treat sarcoidosis growth inflammatory cell different body part other area celgene have partner acceleron pharma xlrn anemia patient rare blood disorder agio pharma agio ag treat mutate protein be tie certain cancer scottus expect update partnership look car cell datum kite acute lymphoblastic leukemia juno last week place jcar trial clinical hold follow death patient kite also have phase dlbcl datum previous datum show overall response rate transplant chemo relapse patient likely support broad label assume presentation cr complete response remain strong rbc analyst write month durability datum be also important win be available note other key report include amyloidosis datum prothena hemophilia datum spark paroxysmal nocturnal hemoglobinurium pnh datum alexion graft vs host datum incyte incy hodgkin lymphoma datum seattle genetic rbc write related kite pharma soar cancer drug trial supportive fda approvaleli lilly alzheimer drug fail key trial lilly biogen diveamgen biogen celgene eye trump pro biotech world
182,LLY,stock continue advance record high territory shopper kick shopping season even black friday fade somewhat importance oil future rise opec optimism output cut talk ahead nov deadline joined other major average record territory dow nasdaq rise more week apple aapl retook buy point fang stock gain ground laggard facebook fb move back day move average retail restaurant earning be generally positive urban outfitter urbn be big exception bad clinical trial news hit drug stock shopper once again rushed store deal day thanksgiving unofficial kickoff holiday shopping season black friday store importance have fade more sale be make online deal be spread november december still online black friday sale be expect top adobe predict wal mart wmt kick cyber monday sale friday amazon amzn predict record black friday not surprise target tgt hailed strong sale discount apple aapl product star war toy hasbro have other well smart speaker alphabet googl unit google amazon amzn likely be popular gift black friday score so far target wal mart macy apple mobileurban outfitter urbn miss earning sale send share tumble wednesday back buy point dollar tree dltr top earning forecast revenue fall short same store sale narrowly top forecast specialty discounter see solid holiday sale price retailer burlington store more double earning crush view sale just edge view signet jeweler sig parent jared zale kay jeweler luxury watchmaker movado mov report lower earning sale top view share company rally related burlington store stock near buy zone earning crush viewsdollar tree see strong holiday quarter sale mixed signet movado share shine earning holidayseli lilly lly say wednesday alzheimer treatment solanezumab fail deliver statistically significant slow cognitive decline stage clinical trial lilly not seek regulatory approval share tumble year low other drugmaker work alzheimer treatment also be hurt include biogen biib merck mrk meanwhile juno therapeutic juno halter trial new patient death latest setback immunotherapy treatment juno share fall sharply immunotherapy peer kite pharma kite initially tumble bounce back related eli lilly alzheimer drug fail key trial lilly biogen divejuno stock plummet patient dieu crude price initially rise oil cartel sound optimistic reach deal curb production nov deadline oil price tumble friday erase nearly week gain plan monday meeting opec member participation be scrap russia have say willing freeze not cut output opec still detailed agreement member tend quota libya nigeria reportedly be exempt iraq say join cut have give mixed signal iran also be question mark meanwhile crude supply fall modestly latest week domestic production rise related oil extend loss doubt grow opec output cut dealjack box jack earning shot cracker barrel cbrl ep rise easily top view restaurant report sale growth be slightly view jack box run jack box burger location qdoba eat also guide low jack share break base new high cracker barrel continue rapid postelection run analyst argue consumer confidence rally area countryside theme chain operate related cracker barrel beat profit raise guidance see trump effect china internet leader see stock jump report better expect earning show trend more chinese consumer go online remain strong weibo wb call twitter twtr china web portal company sina sina own weibo wb beat top bottom line so do social networking firm yy yy palo alto network panw stock tumble cybersecurity firm report fiscal revenue billing miss lower expectation forecast current quarter sale view palo alto network blame miss partly large deal do not close quarter palo alto have forecast pickup security spending latter half ibd company computer software security industry group take hit fall day support line proofpoint other stock fall pc printer firm hp inc hpq earn cent share exclude item year year match view sale rise top analyst estimate current hp see adjust ep cent vs view cent hp share tumble enterprise information technology firm hewlett packard enterprise hpe other half former hewlett packard earn cent share ex item sale analyst project cent current quarter hpe forecast profit cent midpoint vs consensus cent hpe share near buy point related cisco hpe view overseas cash trump cautious outlooksstrong notebook pc sale give hp lift ep guide missesdurable good order jump october best gain year core capital good order business investment proxy rise modestly meanwhile october exist home sale reflect actual closing picked fastest pace february new home sale reflect more recent contract signing fall last month downwardly revise september mortgage rate rise october spiking election borrow cost housing cloud base life science software maker ep rise revenue climb beating view veeva system veev also give bullish guidance veeva share break new high clear buy point meanwhile medtronic mdt fall month low sale guidance lag estimate latest medical device product maker give weak result outlook recent week related veeva system hit buy point outlook beat expand dife month low sluggish diabetes valve farm equipment giant report decline earning sale be better expect ep slide cent analyst have expect just cent deere say equipment sale fall see only drop fiscal share leap record high package food giant hormel hrl be upbeat full year forecast campbell soup cpb beat bottom line tyson food tsn hurt part lower beef price investment business jump feed cost deliver weak result company have face more competition fresher fare have become more popular related hormel upbeat fiscal profit campbell soup beatstyson weak profit outlook sink share other meat producer
183,LLY,drug industry earning season launch week biggest name johnson johnson jnj novartis nvs biogen biib broad portfolio give investor preview business general be do big kahuna johnson johnson tuesday morning be expect report year year sale growth modest decline ep share stock hit record high intraday friday be year credit strong pharma trend flight safety yield write rbc capital market analyst glenn novarro july preview note analyst be expect good quarter pharma business novarro write base prescription datum im health im biggest drug remicade imbruvica invokana xarelto beat consensus credit suisse analyst vamil divan july preview lower estimate invokana raise remicade xarelto say be concern entry cheaper biosimilar version remicade later year pfizer pfe remicade biosimilar be approve fda april ibd take most drug stock have take pound year have prove be exception last month stock market today column highlighted standout defensive dow stock only go higher then biosimilar also probably be topic discussion novartis conference call also tuesday morning wednesday swiss drug giant biosimilar version amgen amgn enbrel win unanimous back fda advisory panel make likely be novartis second biosimilar launch version amgen neupogen enter market last year investor also likely be interested performance novartis newest potential blockbuster drug cosentyx psoriasis entresto heart failure be first class drug be approve last year entresto so far have miss expectation cosentyx have enjoy stronger uptake cosentyx also face new competition however eli lilly lly launch drug same class call taltz monday credit suisse analyst cut ep estimate launch drug appear be cost more expect however write long term outlook drug look good estimate peak annual entresto sale peak cosentyx estimate have be run same analyst expect novartis financial suffer loss patent protection leukemia drug gleevec sale be see fall earning share novartis stock be slowly recover long slide july peak april low share find support day line recent week have moved just day close friday thursday open biogen be expect report quarter stronger growth lower expectation multiple sclerosis franchise have miss expectation last several report nonetheless rbc analyst michael yee see potential upside ms drug tecfidera expect biogen raise ep guidance current ep more consensus depend expense cut represent significant improvement last year analyst estimate earning grow share revenue gain biogen stock crash last july have be trading still slide day line most month biogen do close day line friday aside brief late early june stint biogen have not be day nearly year
184,LLY,first half be exceptionally difficult drug stock not just overall sentiment relative dearth good news compare previous few year second half year however bring very important clinical trial news several lead player potential move stock sharply here look major event ahead probably most anticipate datum drop year be eli lilly lly initial report alzheimer disease drug solanezumab expect december almost sufferer worldwide alzheimer be largest disease doesn have current treatment many company have attempt create have long history failure phase trial suggest solanezumab isn miracle cure only create statistically significant improvement lilly parsed datum focus early stage case lilly create patient pool phase trial expedition compose entirely such case interview year lilly ceo john lechleiter tell ibd alzheimer probably be treat more product not way diabetes be treat today not way cancer be treat lilly first have primary endpoint trial improvement cognitive decline improvement functional decline however march demote functional decline measurement secondary endpoint analyst take sign lilly think miss credit suisse analyst vamil divan note pooled datum previous trial show impact slow cognitive decline only impact slow functional decline regulatory perspective however be able show sign functional benefit remain important point be now incrementally more cautious divan write march research note biogen biib investor be interested spectator lilly report biogen earlier stage drug aducanumab be base same theory solanezumab reduce amyloid plaque form alzheimer patient brain slow disease progression so far hypothesis hasn be definitively proven gilead science gild also have risky potentially high reward program work garner somewhat less attention conquer hepatitis drug sovaldi harvoni epclusa gilead have turn attention hepatitis virus even more common hep only cure rate current treatment june report leerink analyst geoffrey porge say gilead chief science officer norbert bischofberger be place most confidence gs year read first datum human dr bischofberger explain first cohort study be always virally suppress patient datum be available patient presentation november american association study liver disease aasld conference datum second cohort virally naive patient be available next year european association study liver easl conference porge write regeneron pharmaceutical regn big pharma partner sanofi sny report first datum cholesterol lower drug praluent reduce death cardiovascular disease full result trial aren expect next year regeneron do interim analysis see result have achieve overwhelming efficacy justify stopping trial early initially amgen amgn be expect be first report such datum pcsk inhibitor class drug praluent amgen repatha early june however amgen push report early praluent repatha have underperform expectation launch last year regeneron amgen have warn sale likely be slow prove payer drug actually improve patient health earning report april amgen say repatha prescription be reject pharmacy require prior authorization insurer biogen share rise stock market today gilead science climb regeneron amgen ibd take biogen gilead regeneron be trading well high day day move average investor worry slow growth drug pricing pressure regulator politician
185,LLY,british big pharma astrazeneca azn license skin disease drug denmark leo pharma friday include formerly license trouble drugmaker valeant pharmaceutical international vrx astrazeneca have strike deal valeant september commercialize brodalumab psoriasis drug originally develop amgen amgn amgen have abandon report suicidal think emerge clinical trial number be small psoriasis field be fiercely competitive class drug brodalumab belong already produce novartis nvs cosentyx eli lilly lly taltz launch successfully such problem valeant acquire right brodalumab just week scandal erupt accounting specialty pharmacy relationship eventually bring change management drop stock price valeant still have right brodalumab outside europe july schedule make case fda advisory panel hope endorsement fda make ultimate decision approve nov astrazeneca didn specify financial term transfer say leo be pay upfront milestone global right tralokinumab treatment atopic dermatitis type eczema astrazeneca retain right commercialize asthma treatment valeant stock rise high intraday settle gain stock market today huge comedown stock peaked last august astrazeneca stock close higher
186,LLY,big pharma eli lilly lly jump wednesday wall street analyst weigh result narrow food drug administration advisory panel vote late tuesday panel meet decide good idea expand label lilly diabetes drug jardiance include reduce death cardiovascular cause base large clinical trial call empa reg committee vote favor change such close vote leave less clear just decision fda ultimately make most cite reason vote be bar new claim be grant base single study be very high panelist see second trial confirm cv death find leerink analyst seamus fernandez write research note many panelist vote yes also share concern find cv death benefit compelling convince enough tip balance fernandez nonetheless like odd approval note most senior member panel include biostatistician cardiologist vote favor new indication credit suisse analyst vamil divan be also bet favor change add read similar product sglt inhibitor class johnson johnson jnj invokana remain market leader sglt space canvas outcome study schedule be complete february divan write research note assume fda agree include empa reg outcome cv death datum jardiance label see share shift invokana jardiance canvas be complete longer term implication dependent canvas result result outcome study astrazeneca azn forxiga merck mrk pfizer pfe ertugliflozin be expect later decade divan say evercore isi analyst mark schoenebaum be more cautious slight overall majority vote favor new cv indication view approval actual cv death indication have coin flip odd give unprecedented nature result trial schoenebaum write email client say also feel better chance fda allow datum be add label instead indication statement lilly stock rise stock market today once again day move average lilly close just day line be past month johnson johnson stock close fresh record high
187,LLY,drug giant eli lilly lly gilead science gild face key food drug administration action tuesday affect future lead disease treatment franchise advisory committee fda meet discuss expand label jardiance lilly year old drug treat type diabetes lilly want add label be drug also reduce death cardiovascular cause hospitalization heart failure risk death general claim be base large long term trial call empa reg result surprised industry last year patient jardiance show reduction death cardiovascular cause reduction hospitalization heart failure cut death cause fda approve label expansion lilly sale rep be able use marketing drug problem accord leerink analyst seamus fernandez be be not primary endpoint trial be secondary exploratory endpoint primary endpoint be point measurement major adverse cardiac event mace time first cardiovascular related death fatal heart attack fatal stroke result be more mixed only first point do jardiance achieve statistically significant difference fatal stroke incidence be actually slightly higher placebo group fda release briefing document panel friday morning fact conclusion affirm study do show reduction cv death advise include mace heart failure cause death info label be nonetheless interpreted positively analyst lilly stock be stock market today general brexit sell panel also consist substantial portion cardiologist help tilt balance highlight cv benefit panel view fernandez write research note friday preview event june fernandez have predict panel be battle statistical purist vs clinician add clinically large consistent cv death benefit see empa reg trial be view be precedent set precedent also be interest nordisk nvo recently report similar study diabetes drug victoza also bring reduction cardiovascular death not extent jardiance do nordisk have say also file label addition hasn yet decide language danish diabetes specialist fall friday tuesday also be deadline fda decide approve gilead latest hepatitis pill gilead last hepatitis launch sovaldi harvoni break financial record be restrict certain genotype virus new pill be approve genotype not only enlarge market also remove need test patient genotype writing prescription wall street have doubt fda approve drug interesting question be gilead price launch december sovaldi gain notoriety price week regimen harvoni launch october be more however abbvie abbv launch compete viekira pak december company start rebate war hit gilead income then january merck mrk price new hcv drug zepatier well gilead abbvie acknowledge hit financial remain be see gilead value pan genotypic nature new drug gilead stock be friday hit year low abbvie sank merck
188,LLY,share danish diabetes treatment giant nordisk nvo gap month low company drug prove able reduce risk death heart attack stroke not much rival drug eli lilly lly late monday annual american diabetes association meeting present result leader trial tracking long term cardiovascular cv outcome more patient used diabetes drug victoza have already say march drug have lower cv death compare placebo group drive stock analyst be eager see monday presentation victoza match lilly jardiance similar trial cut cv death produce overall relative risk reduction answer be not quite victoza cut cv death relative risk reduction be particular concern be north american subgroup global trial do not show significant effect metric say be due uncooperative patient management indicated reason be still unclear patient group tend have lower compliance adherence compare global rate large cardiovascular study leerink analyst seamus fernandez write research note tuesday management suggest adherent drug treatment drug holiday patient be analyze mace major adverse cardiac event composite be actually slightly better global risk benefit say file label update include mace endpoint relevant regulatory agency lilly have already do jardiance fda advisory panel meet discuss lilly application june nordisk stock fall stock market today
189,LLY,eli lilly lly say wednesday alzheimer treatment solanezumab fail deliver statistically meaningful result stage clinical trial send drugmaker share sharply lower lilly say alzheimer patient mild dementia do not experience statistically significant slow cognitive decline compare patient treat placebo lilly say solanezumab result be directionally favorable be not enough justify seek regulatory approval result solanezumab expedition trial be not have hope be disappoint million person wait potential disease modify treatment alzheimer disease say eli lilly chairman ceo john lechleiter statement evaluate impact result development plan solanezumab other alzheimer pipeline asset investor hope eli lilly alzheimer drug have be high lilly share dive early afternoon trade stock market today trading earlier year low alzheimer be potentially enormous profitable field drugmaker have struggle achieve notable success treat underlie progression disease ibd take donald trump election suggest fewer regulatory hurdle takeover amgen biogen celgene gilead look replenish drug pipeline biogen biib have show promise early stage trial treatment aducanumab fda grant fast track status biogen treatment stock fall trading low merck mrk be move stage trial verubecestat safely lower amyloid beta protein link alzheimer patient unclear reduce cognitive decline merck share slide intraday lilly say provide more datum trial dec clinical trial alzheimer disease lilly take charge related trial update financial result offer guidance dec related health care etfs fall eli lilly juno add trouble sector woesjuno stock plummet patient die rival kite recover
190,LLY,eli lilly lly be downgrade friday alzheimer drug fail key trial whiting petroleum wll deere co have price target raise pharmaceutical giant be downgrade market perform price target bmo capital eli lilly say wednesday alzheimer drug solanezumab fail final stage trial company take charge cent share fourth quarter eli lilly share rise shorten trading session stock market today diving wednesday shale exploration production company price target be raise rbc capital whiting be focuse low cost permian basin have see explosion drill activity year rocky mountain recently inked deal divest midstream asset north dakota share sank lower crude price weigh rbc capital raise farm equipment maker price target wednesday deere report fourth quarter earning crushed wall street estimate signale downturn sector finally be ease deere share rise friday hit fresh time high surge wednesday china lead online travel agency be upgrade buy price target hsbc late wednesday ctrip ctrp report earning fall less expect revenue jump past analyst target thursday ctrip buy scotland travel book site skyscanner share jump retake day average arcelormittal mt be upgrade outperform rbc capital steelmaker have rally election hope higher infrastructure spending share climb related first solar downgrade urban outfitter cut miss veeva tout earningsdelta american unite price target hike fireeye downgradedsina weibo beat palo alto jack guide low boee civil chief leave
191,LLY,drug giant eli lilly lly be poise jolly december datum ruling come positive credit suisse analyst vamil divan say eye be new datum eli lilly solanezumab alzheimer disease drug predict have probability success legal decision regulatory ruling surround lilly jardiance alimta trulicity also be expect next month eli lilly stock use year end bounce share be year fall stock market today ibd company medical ethical drug industry group fall more tuesday phase datum lilly sola be due day now definitely year end divan write research report tuesday sola act neuroprotector patient alzheimer success boost rival biogen biib have similar drug development divan predict lilly stock soar more sola show significant functional benefit show trend function even show functional benefit predict drop sola miss cognition ibd take december be jolly more just eli lilly drug stock have rally election donald trump be see more business friendly hillary clinton happen trump make good promise repeal affordable care act outlook isn certain grab ibd industry theme deeper dive addition food drug administration be due make decision december expand label jardiance type diabetes med risk be skewer downside most observer be expect fda approval divan say also patent litigation be ongoing lilly alimta chemotherapy cancer lung most expect patent expire regardless divan note also come week lilly be due release interim analysis study type diabetes drug trulicity news flow win end initial guidance be expect jan fda approve baricitinib rheumatoid arthritis drug conjunction incyte incy mid january write baricitinib belong class drug call jak inhibitor gilead science gild be work jak inhibitor be abbvie abbv pfizer pfe have approve be currently trial expand use incyte also have jak inhibitor market janus kinase jak be family enzyme drugmaker believe block enzyme treat certain cancer inflammatory disease editor note correct last graph company be work jak inhibitor already have market related gilead scoop incyte cancer drug prove not good enough amgen gilead eli lilly eat abbvie humira sale analyst
192,LLY,stock open higher friday investor look close solid week trade rise nasdaq nearly hit fresh time high dow industrial climb nearly just thursday intraday record best market rolled friday session nasdaq ahead dow industrial sporting gain week index be new high small cap once again outpaced overall market send russell thursday also new high nearly early november low tech stock appear set strong start singapore base broadcom avgo rolled ahead diversify chipmaker top analyst fiscal fourth quarter sale earning target double quarterly dividend stock break base buy point flat base finisar fnsr soar open then reversed trade slightly maker fiber optic networking gear fiscal second quarter result report late thursday clear expectation drive primarily demand company gigabit network transceiver stock be extend flat base buy point sibanye gold sbgl tank stillwater mining swc surge company announce sibanye acquire stillwater third acquisition platinum miner past year make south africa base sibanye world largest platinum producer stillwater be base suburb casino owner be rebound gusto wynn resort wynn jump la vegas sand lvs climb melco crown entertainment mpel spun mgm resort international mgm add group sell thursday report chinese regulator have moved limit atm withdrawal country gamble haven macau casino stock rise atm curb be less fear drug maker biogen biib pop nearly biogen once monthly multiple sclerosis treatment zinbryta have receive approval federal health regulator canada also eli lilly lly give detailed result fail alzheimer drug follow promising datum thursday biogen own treatment biogen have be try july climb long term consolidation have be stymy resistance bound stock restoration hardware rh plunge investor focuse weak fourth quarter guidance rather strong third quarter result company report thursday close stock have be try june start right side be now deep month correction economic news be limit stock market today university michigan report november consumer confidence number commerce department release october wholesale inventory datum et baker hughe bhi deliver weekly rig count et oil future trade modestly higher west texas intermediate hold barrel less week be first price decline week gold trade ounce dollar rise be sharply higher vs yen bond flattened leave year yield china index shanghai hong kong again end mixed friday leave shanghai composite hong kong hang seng index week japan tokyo nikkei pound second straight rally friday rise take gain fifth straight weekly advance stock europe extend gain afternoon trade cac paris be ftse london rise frankfurt dax hold gain related broadcom finisar price target hike la vegas sand wynn mgm dive china half macau atm northrup raytheon get trump investing action plan
193,LLY,biotech stock have nearly round trip donald trump inspire rally rbc analyst michael yee see upcoming food drug administration appointment datum roche rhhby biogen biib act catalyst ishare nasdaq biotechnology ibb spdr biotech xbi exchange trade fund be follow rally trump election wednesday trump dump water analyst theory be less likely go spiraling drug price go bring drug price tell time magazine don have happened drug price trump commentary send biotech stock tumble wednesday ibd company medical biom biotech industry group close ishare biotech etfs end day respectively sink more thursday biotech stock manage climb hole stock market today ibd company biotech group be fractionally be etfs ibd take biotechs recover trump pledge curb drug price get deep dive ibd industry theme yee note trump effect extend far commentary trump have appoint georgia rep tom price health human service secretary price have say favor major overhaul medicare system have advocate affordable care act next appointment light fire biotech stock yee write deck trump be prep announce next commissioner food drug administration medium report target jim neill scott gottlieb lead candidate neill be former venture capitalist manage director peter theil mithril capital have advocate relax fda regulation drug approval gottlieb be vc partner practice physician have serve fda center medicare medicaid service decision follow congress approval late wednesday bill speed fda process trump commentary drug pricing be far set stone yee write research note note republican congress next year be unlikely break conservative dogma work ease drug price worry trump mention drug pricing remind investor have say lot thing past year seem negotiate public eye hasn necessarily be truly perceive actually want do lot yee write outside trump biotechs have suffer industry specific injury include eli lilly lly miss key alzheimer datum lag metric teva pharmaceutical teva medtronic mdt yee write biogen roche have upcoming datum help industry biogen have phase datum alzheimer drug aducanumab due friday roche phase hemophilia datum be due imminently yee say prescription drug free user pdufa be due dec roche multiple sclerosis drug ocrelizumab regeneron regn rival ophthotech opht have phase datum come soon meanwhile look imminent sector johnson johnson jnj be talk buy european biotech actelion sanofi sny be rumore have informal interest actelion insider say pull generalist investor back space yee write perception major term catalyst biotech other cheap need much more get stock rally again write trump tax cut plan republican congress spur biotech trump make drug development great again
194,LLY,nyse stock index trade quietly mixed midday wednesday negative headline biotech sector weigh nasdaq composite nasdaq lose biogen biib be worst decliner nasdaq name nearly share fall sympathy eli lilly lly tumble news alzheimer drug fail key trial biogen also have big presence alzheimer space ease dow jone industrial average add help caterpillar cat rise blue chip have market overlap deere co soar strong earning volume nyse nasdaq be tracking close tuesday level stock market today dollar stay rally mode wednesday economic datum look pretty good home front october durable good order shot more expect weekly jobless claim rise be still depress level consumer confidence come slightly better expect bond sell push year treasury yield higher basis point big mover ibd include veeva system veev gap flat base conventional entry share jump be extend buy point ibd take veeva be several fast grow provider cloud base software more veeva growth prospect check recent new america story burlington store burl be sharply second straight session heel strong earning share be so far week burlington be still buy range buy point leader ibd heavy construction industry group extend gain recent breakout mastec mtz granite construction gva tutor perini tpc show gain reminder stock market be close thursday thanksgiving friday be half session stock market close et related durable good order soar jobless claim rise still loweli lilly alzheimer drug fail key trial lilly biogen divedeere stock soar earning crush estimate
195,LLY,stock open lower wednesday surprise jump october durable good order dow industrial be fraction be nasdaq deere reap premarket gain fiscal fourth quarter earning revenue fall much less expect management say company performance have improve global farm construction market downturn project annual saving efficiency initiative deere share top previous high set june eli lilly lly unraveled announce stage trial result alzheimer treatment solanezumab fail show meaningful result investor apply selling pressure other drugmaker closely watch trial send biogen biib merck mrk hewlett packard company divide year slip report result late tuesday hewlett packard enterprise hpe be cloud service corporate networking business hp inc hpq be focuse pc printing product hp drop open report line fiscal earning better forecast revenue guide earning estimate hewlett packard enterprise slip less report mixed result also offer weak guidance ibd stock veeva system veev surge provider cloud base sale marketing software report earning jump fiscal fourth quarter far analyst target company biggest jump last year june quarter revenue jump also easily clear estimate management raise fiscal first quarter guidance consensus view veeva end tuesday session less buy point week cup base stock market today receive heavy dose datum open commerce department report durable good order surge october sharply reversed september decline clobber economist expectation increase transportation order rise vs prior month increase consensus view gain initial jobless claim jump nearly week end nov accord labor department wasn far consensus estimate increase week average ease second straight decline federal housing finance agency housing price index rise show home price gain steady september increase be just shade august rise well consensus view gain next london base researcher markit preliminary november manufacturing purchasing manager index arrive et october new home sale datum commerce department be due et final estimate november consumer sentiment university michigan be expect et weekly oil inventory report energy information administration roll et last far least minute federal open market committee nov meeting be schedule release et crude future dip west texas intermediate barrel trading higher week gold price be more ounce even week dollar gain ground bond drop lift year yield basis point international front china market post very narrow loss japan tokyo stock exchange be close day holiday trade europe remain turn lower afternoon action ftse london fall dax frankfurt be cac paris show loss major global market remain open week aside tokyo closure today market be close thursday re open short session friday stock market close et bond market shut shop related eli lilly alzheimer drug fail key trial
196,LLY,biotech amgen amgn likely score crowd field protein block migraine drug beat rival market reap adjust sale credit suisse analyst alethia young say late wednesday amgen report strong phase result erenumab patient episodic migraine patient receive milligram mg dose experience respectively reduction monthly migraine day vs day reduction placebo arm safety profile erenumab be similar placebo previous study most common side effect include nasopharyngitis upper respiratory tract infection sinusitis amgen largest biotech market cap partner novartis nvs plan file erenumab potential launch date evercore analyst john scottus expect amgen be first market cgrp calcitonin gene related peptide receptor be closely tie migraine expert say ibd take amgen be do well migraine rebate be chip away expectation be flop check ibd industry theme full scoop pricing be key strong launch credit suisse young write research report erenumab have be test chronic episodic migraine patient company plan file labele indication broadly assume similar share vs competitor market learn more amgen commercial strategy young write also think pricing be especially important successful launch give high disease prevalence rate substantial unmet need patient population field be crowd teva pharmaceutical teva aldr eli lilly lly have cgrp drug pipeline migraine cost business annually worker miss workday migraine research foundation estimate stock market today amgen rise small fraction lilly rise meanwhile teva stock bound stock fall nearly related teva pharma outplay peer light sale lack trump make drug development great again
197,LLY,eli lilly lly have giant albatross hang neck rbc analyst michael yee call clinical trial alzheimer disease conference next month san diego most important event biotech eli lilly deliver strong result phase trial alzheimer drug solanezumab stoke industry say biotechs spiked higher donald trump election trump be see less likely tackle mount drug price have propose incentive company bring more cash stateside spark more small cap biotechs intraday stock market today ibd company medical biom biotech industry group be fraction still day move average key level support group close higher past straight trading day rank ibd industry group ibd take alzheimer isn only area opportunity biotech biogen ionis be partner spinal muscular atrophy drug have interesting result delve ibd industry theme idea success do stock outside trump effect analyst have seize eli lilly solanezumab key driver industry include rival biogen biib have similar alzheimer drug line solanezumab be antibody act neuroprotector patient alzheimer disease believe event ctad be important term driver potentially rally biotech higher really take leg bring more generalist space yee say research note tuesday eli lilly presentation be still just tentative be slate present dec lilly have also say instead present datum expedition phase solanezumab trial medical meeting positive datum give strong credence lilly theory alzheimer be result plaque buildup brain yee write see chance positive statistically significant datum expedition trial result investor get more bullish alzheimer innovation biotech biogen be slate dec report phase result month titration study attempt reduce aria amyloid related imaging abnormality patient specific type allele alternative form gene also present month extension examine safety efficacy biogen stock be consolidate have possible buy point tick close tuesday lilly stock inched just day support line novartis nvs be partner amgen amgn discuss effort pairing alzheimer patient trial base part genetic amgen bace inhibitor act block buildup beta amyloid have be propose drug study lilly merck mrk biogen also have bace inhibitor roche rhhby partner genentech be expect have poster phase trial crenezumab look higher dose response prodromal mild patient axovant also offer analysis phase study intepirdine related biotech lilly upgrade alzheimer drug potentialcan small cap biotech take gilead celgene biogen alzheimer biogen top alzheimer datum vs eli lilly positive
198,LLY,stock turn mixed soft start wednesday wall street digest news trump plunge more point overnight dow jone industrial average be mostly unchanged nasdaq lose ease early leader dow include pfizer pfe caterpillar cat merck mrk jpmorgan jpm goldman sachs gs also outperformed ibd take election result be describe shocking upset ibd tipp presidential tracking poll ultimately have right year treasury yield soar basis point december gold rally ounce drugmaker campaign target democrat hillary clinton due pricing trade generally higher pfizer industry group mallinckrodt mnk shire shpg allergan agn lead gain more hospital operator stand lose president elect trump act promise repeal affordable care act dove deeper early loss tenet healthcare thc topple hca holding hca skid universal health service uhs drop coal mining stock soar consol energy csx arch coal arch add cement construction aggregate supplier surge possibly early commitment infrastructure other large scale project trump vulcan material vmc martin marietta mlm higher martin marietta gap cup shape base buy point vulcan gap cup shape base buy point stock be still buy range early trading early gainer ibd include healthequity hqy eagle material exp gain pra health science prah morgan stanley ms add related clinton vs trump ibd tipp presidential election tracking pollafter initial fall stock rally trump victory agenda
199,LLY,stock open lower wednesday commodity currency market react tuesday come victory donald trump race presidency dow industrial rise nasdaq nasdaq future have fall overnight dow future sank more point lowsdrugmaker campaign target democrat hillary clinton due pricing trade generally higher pfizer pfe leap mylan myl merck mrk rise eli lilly lly add more early trade hospital operator stand lose president elect trump act promise repeal affordable care act dove deeper early loss tenet healthcare thc topple hca holding hca skid lower universal health service uhs drop nearly coal mining stock moved generally higher arch coal arch soar consol energy cnx alliance holding ahgp show gain cement construction aggregate supplier surge possibly early commitment infrastructure other large scale project trump vulcan material vmc vault martin marietta mlm martin marietta top buy point cup base vulcan also break clear buy point earning news tripadvisor trip swoon report third quarter earning narrowly top view revenue gain stop far short analyst expectation fragrance maker coty coty plunge miss analyst fiscal first quarter revenue earning target wide margin gopro gpro tank handful analyst downgrade stock news recall karma drone due battery failure issue ibd list eagle material exp pop gain stock top buy point cup base ibd stock royal gold rgld rumble gold price surge early wednesday gold miner be climb right side possible base pattern find support week move average ibd stock arista network anet fall inphi iphi fall fractionally momo momo rise more international market trade lower election news tokyo stock be hardest hit drop worst single day loss britain june brexit vote exporter market be session biggest loser lead toyota motor tm honda motor hmc nissan motor nsany china hong kong hang seng index shed shanghai composite decline europe cac paris frankfurt dax trim deep early loss turn fractionally higher afternoon trade london ftse rally climb commodity be widely mixed early action oil price hold mostly steady west texas intermediate fraction hold just barrel metal moved broadly higher gold jump almost ounce silver copper be also strongly dollar bounce back initial dive trading moderately lower vs euro pound yen surge bond be sharply lower year yield basis point stock market today show light economic calendar september wholesale inventory datum expect commerce department et energy information administration report weekly oil stockpile number et minneapoli federal reserve bank chairman neel kashkari be due speak et related time warner stock fall trump victorydrug stock rally relief clinton didn white house
200,LLY,injectable drug specialist eagle pharmaceutical egrx stock be sharply monday get downgrade mizuho say thesis have play eagle stock jump june teva pharmaceutical industry teva win patent case several generic drugmaker include pfizer pfe hospira unit sagent pharmaceutical sgnt be try launch generic version blood cancer drug treanda january teva eagle launch low volume faster act version treanda call bendeka say expect replace treanda market eventually mizuho analyst irina koffler write research note expect company retain market exclusivity bendeka say other catalyst be slow come treanda bendeka switch be genuine success story eagle other hospital launch ryanodex docetaxel have be more challenge koffler write downgrade stock neutral buy be remind cost be still critical set insight have influenced longer term outlook bendeka rest eagle portfolio koffler note eagle be prepare file approval version eli lilly lly lung cancer drug alimta be alter way similar bendeka reformulation treanda doubt be lucrative teva deal be concern competition other filer allergan agn have already launch type product eu write reason think replicate bendeka agreement be challenge here eagle turn first annual profit last year cent share analyst expect jump year help bendeka launch stock nonetheless have single digit relative strength rating end trading stock market today
201,LLY,biogen biib say tuesday risky potentially multiple sclerosis drug candidate have fail clinical trial drive big biotech stock sharply tuesday biogen say drug opicinumab better know medical acronym lingo hadn meet primary secondary endpoint mid stage trial measure improvement physical cognitive function well disability disease progression biogen nonetheless say evidence clinical effect complex unexpected dose response be observed so be analyze result hope design study lingo be novel technology promise be first rebuild myelin fatty layer nerve cell erode ms patient thereby actually reverse progression disease result last year earlier trial optic neuritis form vision loss ms patient associate demyelination be technically positive ambiguous enough expectation be low go ms result be most unknown unpredictable major clinical event investor be try do work write rbc capital market analyst michael yee research note also reflect challenge dynamic stock many growth investor be see high risk high reward pipeline company hard get conviction event datum lot potential upside work biogen other high risk high reward program be alzheimer disease be very promising earlier trial be disease area long history failure next batch datum isn expect more year expect eli lilly lly report own alzheimer drug late year provide read analyst say biogen share tumble stock market today stock gap day day move average
202,LLY,share pharma major abbvie abbv be slide wednesday morgan stanley downgrade concern increase competition analyst david risinger downgrade abbvie stock equal weight lower price target note nature abbvie pipeline have become clearer day june presentation cancer drug weekend include negatively receive report rova meantime abbvie still depend immunology drug humira analyst say sale humira be world best selling drug generate abbvie total sale estimate vast majority profit risinger write humira not only face challenge several biosimilar player include amgen amgn novartis nvs sandoz pfizer pfe also novel brand injectable oral abbvie score string patent litigation victory allay investor concern be unable make call risinger write humira market exclusivity already suffer setback last month patent board agree review challenge humira patent bring biosimilar developer coherus bioscience chrs likely take year resolve risinger write newer class drug treat same condition humira do include novartis cosentyx eli lilly lly taltz baricitinib slow humira growth term threat gain support wednesday novartis say presentation european league rheumatism conference run wednesday saturday be new long term analysis suggest cosentyx lead higher response humira improve sign symptom person live ankylose spondylitis psoriatic arthritis psa week novartis say initiate head head trial confirm say abbvie own novel autoimmune disease product help offset moderation include jak il risankizumab risinger write expect launch abbvie stock fall close stock market today share touch month high friday
203,LLY,here investing action plan friday need know investor come day monthly job report be due friday top drugmaker bristol myer squibb bmy merck mrk roche rhhby eli lilly lly abbvie abbv discuss new cancer treatment payroll datum labor department monthly job report be due et
204,LLY,bristol myer squibb vs merck pfizer vs lilly unique treatment abbvie abbv take spotlight next week biggest drug conference focuse treatment biggest disease cancer annual meeting american society clinical oncology chicago june be prime opportunity check potential blockbuster drug abstract most presentation be release public give gist study result leave detail conference most interesting item investor be late breaking abstract past several asco meeting battle immunotherapy be major theme market pd inhibitor bristol myer squibb bmy opdivo merck mrk keytruda be already big seller skin lung cancer opdivo ahead market share ongoing research give idea true market potential well stack other be often case cancer drug opdivo keytruda be approve advanced case disease first largest market opportunity be front line treatment newly diagnosed patient cancer largest market opportunity be small cell lung cancer nsclc bristol myer merck be target first abstract release merck keynote study keytruda combination chemotherapy yielded improvement progression free survival pfs month overall month patient tumor show high expression pd ligand pd inhibitor indirectly target here continue see solid orr overall response rate percentage tumor shrank pfs datum look meeting better understand durability response longer period time write credit suisse analyst vamil divan research note bristol myer be also conduct first line nsclc study most significant be checkmate combine opdivo bristol myer immunotherapy drug yervoy prove be most effective combo then be huge company bristol myer wholly own treatment thus gain revenue be new checkmate info early abstract analyst hope be late breaking datum morningstar analyst damien conover say also want see datum tecentriq roche rhhby entry sister class drug target pd ligand directly coincidence fda approve tecentriq type bladder cancer call urothelial carcinoma same day asco abstract be release be first file bladder cancer conover tell ibd bladder big indication not big lung cancer have niche roche really help drive drug sale leerink analyst seamus fernandez however note tecentriq soon have competition show other asco presentation initial datum bristol myer opdivo astrazeneca azn durvalumab show higher response rate indication fernandez write research note smaller patient number datum set baseline characteristic be present asco be closely watch newer battle seem be shape different drug class call cdk inhibitor used treat breast cancer cdk stand cyclin dependent kinase enzyme tie cell division encode gene cdk cdk inhibitor help stop cancer cell multiply first pfizer pfe ibrance launch early take last year expect swell billion eventually eli lilly lly however have make noise cdk inhibitor abemaciclib show much higher response rate refractory patient do ibrance asco abstract lilly monarch trial month treatment number be only still better ibrance slight disappointment wall street lilly day tuesday company say also be present month datum asco so still be upside surprise nonetheless evercore isi analyst mark schoenebaum write lilly executive didn seem enthusiastic lilly seem not want boost investor expectation regard month datum therefore reiterate orr result report month ask schoenebaum write email client additionally lilly encourage investor also look overall clinical benefit duration response presentation asco hover background not asco be novartis nvs announcement have stop late stage trial own cdk drug early have already hit primary endpoint improvement pfs detail have later medical meeting also positive development space analyst divan tell ibd room more winner meanwhile pfizer score hit treatment late stage datum show ibrance combination estrogen blocker letrozole yielded pfs more month month more letrozole alone prod analyst fernandez raise sale estimate whole cdk class estimate ibrance sale alone late breaking datum other field study many wall street be eyee be midstage trial rova drug abbvie be acquire buyout biotech stemcentryx rova be treatment small cell lung cancer sclc smaller market enormous nsclc population definite opportunity lack specifically approve treatment previous study have show response rate relapse patient high expression delta protein dll appear sclc patient tumor presentation asco be particularly important stemcentryx be report long term survival datum be gold standard cancer trial far fda be concern analyst schoenebaum say rova have improve survival enough differentiate know chemotherapy produce month os overall survival set re testing rova schoenebaum say video record client know be datum asco abstract show pd yervoy produce month lot toxicity punchline be need see os datum well excess month abbvie have estimate peak annual sale rova hit
205,LLY,big pharma abbvie abbv say tuesday recently license drug candidate succeed phase trial crohn disease company seek refresh blockbuster immunology franchise late morning digestive disease week conference san diego abbvie researcher present result ongoing phase study risankizumab drug abbvie license boehringer ingelheim first quarter crohn disease say week treatment patient be remission depend dose compare just placebo group treat group also have fewer adverse event placebo group risankizumab be newer group drug target interleukin small protein cell associate inflammation protein be tnf tumor necrosis factor result be particularly encourage difficult treat population study researcher brian feagan say statement patient have endoscopically confirm moderate more severe disease activity study entry majority have previously fail treatment more tnf antagonist most popular tnf blocker happen be humira abbvie flagship drug treat crohn disease well other immunological condition rheumatoid arthritis psoriasis humira patent be fire however last week abbvie stock tumble patent board agree review challenge method patent bring coherus bioscience chrs other drug target interleukin include novartis nvs cosentyx launch early last year psoriasis well eli lilly lly taltz approve psoriasis march drug target interleukin il risankizumab target il novel mechanism action efficacy drug look be good perhaps even better il evercore isi analyst john scottus say video client record remember cosentyx peak sale consensus right now be abbvie stock end trading stock market today share past week have find support day move average line
206,LLY,here investing action plan need know investor come week federal reserve chair janet yellen take center stage again just week policymaker meet weigh rate hike series key economic indicator flow china report valeant vrx lululemon lulu highlight earning
207,LLY,here investing action plan need know investor come week crude price barrel next meeting organization petroleum export country add upward momentum smack market back meanwhile apple aapl supplier broadcom avgo medtronic mdt report earning drugmaker discuss cancer fight
208,LLY,hedge fund fled equity first quarter apple aapl pepsico pep most sell stock global market intelligence say report wednesday top hedge fund manage equity holding more fund decrease total number stock position hold fewest stock position hold global market intelligence begin tracking such datum be second consecutive quarter equity sell large fund consumer discretionary information technology stock lead sell apple rank see most selling individual stock last quarter major hedge fund sell worth apple stock other top sell include pepsico amazon com amzn priceline pcln boot alliance wba highest volume buy top hedge fund occur facebook fb stock total buy first quarter say other top buy include broadcom avgo alphabet googl eli lilly lly willi tower watson wltw related growth investor flee apple warren buffett see valuestartup bubble burst valuation due reset analyst say
209,LLY,big pharma eli lilly lly issue mixed first quarter earning guidance tuesday send stock early trading lilly earning exclude time item shrank year earlier quarter cent share miss analyst consensus cent accord thomson reuter revenue rise beating consensus lilly add cent ep guidance range now also raise sale guidance slightly same time shave percentage point gross margin guidance now also lift guidance sale general administrative spending lilly stock be nearly morning trading stock market today improve foreign exchange rate be responsible much upside cent share tax benefit same time bottom line be hit rise expense include milestone payment biotech partner incyte incy submission approval jointly develop drug baricitinib level individual product diabetes drug humalog provide biggest surprise sale fall prior year miss consensus accord evercore isi lilly say demand drug have actually increase so have rebate discount lilly negotiate payer lilly say do not expect downtrend continue rest year revenue newer diabetes drug jardiance double compare last year lilly split take partner boehringer ingelheim only receive sale beat expectation lilly say take more share grow sglt class diabetes drug perhaps accounting johnson johnson jnj sglt drug invokana show report last week leerink analyst seamus fernandez write be various upside report expect limit impact investor concern significant miss diminish focus shift abemaciclib datum asco american society clinical oncology meeting june conclusion expedition trial solanezumab alzheimer disease write research note
210,LLY,medical giant johnson johnson jnj beat estimate raise guidance tuesday morning send stock fifth recent record high report earning share year earlier quarter beating analyst consensus cent accord thomson reuter sale rise match consensus say foreign exchange impact knock percentage point sale growth nonetheless forex headwind finally seem be abate cite improve forex outlook reason be raise full year sale guidance also add cent ep guidance now ibd take johnson johnson rate group cr be iffy pharmaceutical business continue deliver impressive level growth have steady improvement consumer business be see momentum medical device business be fuel optimism full year ahead ceo alex gorsky say statement stock be early trading stock market today touch record high intraday stock be more year so far be first medical stock be hit new high be report week other be intuitive surgical isrg evening stryker syk late wednesday morning continue growth momentum company have see recent quarters again deliver organic sale growth acceleration second consecutive quarter double digit ep growth adjust operational basis write leerink analyst danielle antalffy research note note exclude impact foreign exchange activity shrink sale hepatitis drug olysio be make obsolete gilead science gild release harvoni late sale rise operate ep growth be just credit suisse analyst vamil divan write pharma sale beat be drive immunology franchise remicade simponi stelara well stroke prevention treatment xarelto top seller diabetes drug invokana miss consensus investor have be wonder invokana take hit eli lilly lly jardiance last september prove dramatically cut death heart failure didn get sale bump
211,LLY,stock struggle bit moved lower yesterday remain range point yesterday note late morning test level find support rally close bell trading be light investor trader appear unwilling commit market ahead onslaught earning today think apple aapl facebook fb procter gamble pg exxon mobil xom baxter bax mmm freeport mcmoran fcx corning glw lockheed martin lmt eli lilly lly revenue beat ep miss ct whirlpool whr miss top line revenue miss bottom line report vs exp be announce today ahead tomorrow fomc announcement remember today begin day fed meeting be lot anticipation paralysis say tomorrow again mkt do not expect change rate do expect clarification terminology concern june next expect hike recall last hike december send mkts tailspin cause fed become bit more dovish search reason calm mkts time cite unstable global mkts culprit then mkts have come roar back now dow look disastrous year result strength expect janet intimate return path higher rate not necessarily faster just bit higher expect word be parsed sentence be deconstructed everyone look next clue now low volume well be number reason really never mind current regulatory environment abuse suffer so many manager yesterday be news right eco report significant earning speech big international event nothing so do anything mkt hold tight give reason deviate plan so only one really play yesterday be hft guy asset manager be tweak core position tweak do not mean change investment strategy just mean tweak now oil do come bit pressure yesterday fall end day tell be recent run oil be bit premature give current glut lack deal opec nation etc so oil trade current band good break surge higher just yet morning see oil small dollar appear bit weaker think rate hike remember get weekly api american petroleum institute report afternoon now yesterday do get broad measure housing mkt again stat be longer mkt move event be change see yesterday be new home sale typically be good barometer state broader economy guess disappointment new home sale fall vs exp rise be bit concern well be time year new home sale be strong so be disappointment just barometer weaken economic picture be really mind boggle be be now decade housing collapse decade be yr incomplete recovery pocket single family housing continue stall new home sale total unit basis come unit significantly yr average more unit greenspan era subprime loan mortgage propel sale new home stratosphere send high unit yr begin crash crash create adjustable rate mortgage manage destroy so many person trigger wave foreclosure then ignited great financial crisis say crisis be still ongoing ll leave future be pt early trading mkt get ready react slew earning report note whirlpool note miss number be quote buck pre mkt trading quote not trading just yet so let see investor trader think today be also big economic day lot macro datum consider durable good exp ex tran cap good order cap good ship markit pmi richmond fed survey earning be happen prior open macro datum begin go be create lot noise early trading once settle be then expect discussion revolve fed once analyst consider implication today macro datum reveal again expect broader mkt hold tight range tomorrow think fed paralysis individual name today get reward punish depend report say future day work take good care
212,LLY,kpfollow kenny polcari twitter kenny polcari comkenny polcari be vice president director nyse floor operation behalf neil security inc sister company investor business daily market commentary be opinion author be base decade industry market experience however guarantee be make imply respect opinion commentary be not be intend be rely authoritative take substitution exercise judgment comment note herein not be construe offer sell solicitation offer buy sell financial product official statement endorsement neil security incorporate affiliate
213,LLY,small biotech aldr soar more month high early trading monday migraine drug candidate succeed mid stage trial position compete giant rival say single intravenous infusion monoclonal antibody ald have significantly reduce migraine day week period compare placebo depend dose patient experience reduction migraine day experience reduction evaluation ald continue exhibit potential best class profile include immediate significant durable migraine prevention infrequent quarterly dose ceo randall schatzman say statement commitment accelerate development ald reinforce today positive result look forward advance development plan assume fda approval independently marketing ald meet critical medical need patient nationwide be candidate migraine prevention therapy decision market drug big pharma partner unusual small biotech pit very big competitor develop similar drug ald be calcitonin gene related peptide cgrp antibody similar migraine candidate be develop amgen amgn teva pharmaceutical industry teva eli lilly lly drug be distinguish infrequent dose amgen teva drug be inject once month lilly be biweekly also be compete allergan agn botox be also quarterly involve separate shot credit suisse analyst vamil divan write ald result seem roughly equivalent teva term effectiveness do note be significant improvement placebo number patient experience reduction migraine day patient drug achieve be rather lower have be headache free previous trial stock so many other biotech stock have lose more half value touch time peak july early trading stock market today share be be image provide shutterstock
214,LLY,big pharma eli lilly lly change goal much anticipate clinical trial alzheimer disease drug tuesday send stock bad day overall drug stock lilly phase trial drug solanezumab call expedition have previously target primary endpoint slow cognitive decline slow functional decline tuesday lilly say be go keep cognitive decline primary endpoint functional decline become key secondary endpoint lilly be expect report first result trial late year make decision filing approval base outcome emerge scientific evidence support idea cognitive decline precede predict functional decline alzheimer disease particularly earlier stage disease lilly say way explanation press release lilly add regulator globally continue view cognitive functional endpoint necessary clinical trial person mild alzheimer dementia regulatory guidance have be include co primary endpoint so not clear much difference make drug approvability nonetheless trial fail co primary endpoint still be fail trial sound lilly be do everything improve success rate expedition write evercore isi analyst mark schoenebaum email client schoenebaum say lilly tell decision wasn base datum trial company hasn yet see lilly do analyze datum earlier solanezumab study expedition expedition however other dataset field schoenebaum add phase trial possible competitor biogen biib aducanumab be used different test measure cognitive functional decline sole primary endpoint lilly stock hit week low stock market today day stock general drug stock particular be take hit midday be biogen stock be
215,LLY,disgrace drugmaker valeant pharmaceutical vrx continue sell rest medical sector thursday report surface creditor be demand new term company default massive debt reuter cite anonymous source say early talk lender be ask higher interest payment pledge pay larger amount bank loan proceed valeant asset sale valeant have be breach report covenant tuesday miss filing deadline have day resolve however doesn file march also be default bank creditor have only day resolve default valeant be debt year long buy spree culminate fail attempt buy allergan agn last year allergan subsequently merged actavis be now process be buy pfizer pfe late afternoon stock market today valeant stock lose medical group track ibd even unrelated drug account worst perform group ibd industry generic drug group lead slide decline hardest hit individual stock be valeant fellow specialty drugmaker have consciously follow valeant business model mallinckrodt mnk authorize stock buyback be endo international endp be head former valeant executive rajiv silva hit year low trading horizon pharma hznp have be criticize pricing policy much valeant have be selling last day major drugmaker eli lilly lly tumble eli lilly fall intraday lowest level late
216,LLY,be lot news breaking medical sector stock market today let take look medical related stock notable chart valeant pharmaceutical vrx eli lilly lly teva pharmaceutical teva inogen ingn ligand pharmaceutical lgnd valeant report preliminary fourth quarter earning miss expectation slash guidance specialty drugmaker warn potentially default doesn file annual report april deadline valeant financial be ongoing review scandal break last fall share plunge more giant volume hit lowest level year stock be now trading time high reach last august eli lilly crumble much announce change goal phase clinical trial alzheimer treatment signale drug only treat cognitive capability not functional capability well stock close move come big turnover send share year low intraday trade lilly be now high reach september teva pharma acquisition allergan generic unit have be delay june work get regulator approval share drop more intraday trade close volume be heavy share be now trading consolidation buy point july high inogen report better expect quarterly result tuesday company make oxygen tank chronic respiratory condition gap send share much higher day line intraday trade stock struggle hold level pare gain close inogen be able retake day line monday session now september peak meanwhile ibd stock ligand pharma be work double bottom base potential buy point share be currently trading pivot lose tuesday
217,LLY,major index tracking etfs pause wednesday open notch string postelection new high stock rally have come investor cheer president elect donald trump proposal lower taxe less regulation business spdr spy ease stock market today exchange trade fund proxy broad market set new high previous session health care sector help lead decline early trading share juno therapeutic juno plunge cancer immunotherapy drug kill more patient clinical trial report say eli lilly lly too drop alzheimer treatment solanezumab fail late stage trial health care select sector spdr xlv give morning trade pare loss ishare nasdaq biotechnology ibb stumble xlv sit aug high trail suite sector spdr etfs loss week end nov be only sector red period sector make new high etf also trail year date loss health biotech sector be hard hit run election political rhetoric drug price gouge rattle investor quickly surrender postelection gain too ibd take chart be layer case trump bull market stock oil gold be lower early wednesday oil rebound spdr gold share gld fall lowest level roughly month dollar rally strong economic datum durable good jobless number be see support fed plan raise interest rate next month here look performance major exchange trade fund key asset class stock market today relative price strength rs rating measure stock price performance last month vs stock etfs scale best possible spdr spy rs powershare qqq qqq rs spdr dow jone industrial average dium rs ishare core mid cap ijh rs ishare russell iwm rs ishare msci eafe efa rs vanguard ftse emerge market vwo rs spdr gold share gld rs unite state oil uso rs ishare core aggregate bond agg rs powershare db bullish uup rs ipath vix short term future vxx rs related play small cap etfs strong equity market rise rate
218,LLY,small cap biotech axovant science axon pull sale alzheimer drug rbc analyst michael yee say tuesday pit big player gilead science gild celgene celg biogen biib eli lilly lly early tuesday axovant report loss tell investor expect wrap key phase trial alzheimer drug intepirdine year end yee expect datum mid see probability success phase intepirdine alzheimer drug result time potential upside yee write research report have outperform rating price target axovant stock axovant stock topple stock market today share be month low follow earning report loss share ex item widen cent cent year earlier quarter analyst expect cent loss axovant make initial public offer june pricing share company hasn yet report sale ibd take biotech stock be trading positively third consecutive day biogen be leader pack early efficacy phase trial spinal muscular atrophy drug conjunction ionis get full scope industry theme alzheimer market be huge big player gilead celgene biogen eli lilly look take chunk axovant most closely rival danish drugmaker lundbeck have phase trial due drug idalopirdine intepirdine idalopirdine have similar mechanism be ht antagonist aim assist cognition memory lundbeck idalopirdine have safety issue yee give only probability success lundbeck idalopirdine be used dose level need due safety issue drug thus not overly read be negative yee write research report axovant be also testing nelotanserin treat visual hallucination symptom alzheimer lewy body dementia datum be expect february phase trial patient yee note consensus have expectation trial consider size datum be great strong numerical reduction hallucination believe see move axovant vs minor downside negative write note alzheimer datum later year be more important stock related eli lilly revenue ep miss ceo praise drug pipeline
219,LLY,amgen amgn biogen biib celgene celg gilead science gild look follow donald trump election set fewer regulatory hurdle likely biotech resurgence rbc analyst michael yee say monday biotech stock have surge trump election largely notion be less likely pressure drug price hillary clinton likely push business friendly legislation include tax incentive repatriate cash election uncertainty yee expect big biotechs make good plan capital remain inexpensive organic growth slow trump appear poise embrace innovation administration yee write research report monday ibd take biotechs aren alone experience trump effect defensive stock be furious upswing follow election get defensive stock now get ibd industry theme answer end trump meet patrick soon weekend soon be biotech exec former ceo abraxis bioscience celgene acquire tell come trump meeting soon yee note regardless investor be start key pro biz environment election share ibd company medical biom biotech industry group spdr biotech etf xbi be nearly ishare nasdaq biotech etf ibb be more bar big policy surprise trump be increase feel pro business include pro biotech gop yee write so see unlikely major legislation derail innovation increase be merely begin yee write note good thing happen believe stock go much higher alzheimer datum late early eli lilly lly be catalyst biotechs also likely update guidance january potentially push stock higher biotech celgene be most risk postelection world term catalyst fear big disappointment yee write celgene have multiple sclerosis datum due first half likely win raise guidance january celgene stock dip dilutive deal note view pullback buy opportunity long term tail question be sufficient pipeline long term investor want see term earning variance be less important tail question write meanwhile amgen biogen likely be uncertainty remain share biomarin pharmaceutical bmrn vertex pharmaceutical vrtx yee write biogen stock bound strong alzheimer result eli lilly amgen stock be still suffering fallout commentary enbrel pricing stock market today celgene stock lift share amgen biogen gilead be fraction vertex stock be biomarin share related small cap biotech take gilead celgene biogen alzheimer
220,LLY,drugmaker pfizer pfe sale earning be expect diverge early tuesday issue report potentially slow sale breast cancer drug say prescription tracker im symphony consensus analyst poll factset expect pfizer report sale vs year earlier quarter see earning share ex item rise cent evercore analyst john scottus look more color pfizer decision earlier fall forgo long rumore corporate breakup have split innovative establish product business ibd take pfizer mega deal buy allergan go bust april takeover time warner go same direction investor be look better understand exactly be decisive factor shift management think continue operate pfizer single company change future make idea split attractive again write research note pfizer also likely focus ibrance drug battle positive negative breast cancer drug be grant accelerate approval early scottus expect pfizer comment grow competition eli lilly lly abemaciclib novartis nvs ribociclib eli lilly drug have demonstrated positive result monotherapy single drug battle disease novartis have safety concern earlier year wall street be also likely pfizer commentary circle prevnar pneumococcal conjugate vaccine prevnar add worldwide sale pfizer top line sale miss forecast previously pfizer comment expect fiscal sale be comparable slightly level do not expect prevnar be growth driver scottus write investor likely have keen eye pfizer long term growth expectation stock market today pfizer stock fall touch month low pfizer stock have trade day move average key support line nearly month related amgen gilead eli lilly eat abbvie humira sale analystariad follow gilead mylan route drug price battle
221,LLY,multiple sclerosis drug tecfidera help biogen post sale beat early wednesday share nudge early trading biogen biib abandonment lag irritable bowel disorder drug stock market today biogen stock lift share be still well day move average however biogen stock be biogen report sale earning share ex item respective vs year earlier quarter metric top consensus analyst poll thomson reuter tecfidera sale drive lion share beat sale top consensus expectation say evercore analyst john scottus inventory buildup vs prior quarter likely roll ibd take ibd company medical biom biotech industry group be rank group track trade have be volatile evidence movement key biotech etfs follow ibd etfs fund section more also sale fall prior quarter parallel trade dynamic biogen say overall tecfidera sale rise vs biogen say company say increase sale treatment crohn multiple sclerosis hemophilia rheumatoid arthritis be partially offset worldwide decrease interferon sale biogen opted end development mt irritable bowel disorder drug license last year mitsubishi tanabe milestone payment scottus say mt be slate phase testing later year drug have not get much credit yet investor so be interesting be simply commercial issue re other safety differentiation question rbc analyst michael yee write research report biogen be encourage investigation alzheimer disease treatment aducanumab yee write positive datum eli lilly lly solanezumab similar treatment tug sentiment biogen yee have say yee keep outperform rating price target biogen stock editor note correct description biogen drug tecfidera first graph related eli lilly abbvie top ranking pfizer astrazeneca flail
222,LLY,eli lilly lly pfizer pfe gilead science gild be chip away abbvie abbv humira sale credit suisse analyst vamil divan say monday abbvie miss expectation friday primarily decline humira sale divan downgrade abbvie stock neutral cut price target model humira pull sale decline respectively humira account abbvie sale drug be used treat rheumatoid arthritis psoriasis irritable bowel disorder market brand rival be already market biosimilar be pressure abbvie patent humira abbvie be work protect patent divan expect amgen amgn other have biosimilar market be other year point humira start decline divan write research report cope humira decline miss expectation abbvie have late stage drug capable bring combine sale ibd take abbvie earning have grow average past quarters have also decline last period get full scoop ibd income investor pfizer eli lilly incyte incy gilead be work class drug call jak inhibitor compete arthritis celgene celg novartis nvs eli lilly have il il inhibitor psoriasis expect become blockbuster drug year launch johnson johnson jnj already have jak inhibitor be il field abbvie have own il drug development be enter crowd market have more competitive pricing challenge say divan irritable bowel disorder market celgene mongersen ozanimod put pressure humira sale soon divan write ub analyst marc goodman say pressure abbvie stock be overdo share touch month low friday abbvie report earning fall stock market today abbvie stock fall goodman keep buy rating price target abbvie stock company earning guidance growth imply be lower wall street view still goodman write base management commentary humira volume pricing think concern appear overdo earning next year be little light think investment pipeline drive growth longer term related eli lilly abbvie top ranking pfizer astrazeneca flail
223,LLY,insulin pricing animal companion trend wrack eli lilly lly early tuesday post sale earning well wall street expectation prompt share plummet month low eli lilly stock rebound stock market today rise fraction tuesday earlier topple much eli lilly stock be year remain ahead ibd company ethical drug industry group be fellow drugmaker merck mrk rise tuesday post beat novartis nvs fall nearly month low sale miss wall street expectation ibd take drugmaker aren do well biotechs have show sign life late find more ibd industry snapshot good place look industry group be hot heat soon lilly credit sale growth increase volume several pharmaceutical product higher price erectile dysfunction drug ciali forteo used treat osteoarthritis be largely offset lower realize price diabetes med humalog company say normalization discount rebate humalog revenue growth ve be vs pricing effect be evercore analyst john scottus write research report management claim have be see increase rebate board well see more business flow less profitable channel also see worldwide animal health sale decline vs year earlier quarter brunt feel sale fall eli lilly blame wholesaler buy pattern companion animal product decrease sale food animal product decline eli lilly meanwhile report sale cent earning share item respectively vs year earlier quarter metric miss analyst view cent poll thomson reuter solanezumab remain bright spot eli lilly expect have phase trial datum alzheimer treatment year end rbc analyst michael yee see chance positive datum solanezumab chance success eli lilly drag sentiment rival company such biogen biib reminder eli lilly alzheimer drug be biggest swing factor view turn investor sentiment interest biotech biopharma equity yee write research report eli lilly reaffirm guidance ep ex item be pipeline also continue advance wide array promising treatment condition alzheimer disease diabetes cancer eli lilly outgoing ceo john lechleiter say company earning release july company announce lechleiter retirement be replace david rick head company biomedicine unit related eli lilly look coral more animal health business vs zoetisbiogen muscular dystrophy drug add top line
224,LLY,big pharma eli lilly lly partner boehringer ingelheim say thursday diabetes drug jardiance succeed lower risk death cardiovascular disease massive year study send lilly stock sharply detailed result be be hold medical meeting eli lilly boehringer do say empa reg outcome trial
225,LLY,come buyout drugmaker hard keep valeant pharmaceutical vrx rapid pace acquisition canadian drugmaker have already make flurry acquisition year lead stock ethical drug maker group composite rating other highly rate player group include horizon hznp eli lilly lly jazz pharmaceutical jazz nordisk nvo abbvie abbv
226,LLY,group rank tuesday issue spot week
227,LLY,outperform other drug group generic biotechs
228,LLY,latest news valeant progenic tuesday say fda accept new drug application submission oral relistor
229,LLY,last week valeant say buy synergetic usa deal value synergetic make surgical instrument used ophthalmology neurosurgery
230,LLY,also last week valeant announce agreement pay astrazeneca azn licensing deal psoriasis drug candidate brodalumab amgen astrazeneca previous partner drug exit program several trial patient commit suicide valeant plan file fda approval
231,LLY,august also strike deal buy pharmaceutical maker addyi libido pill woman fda reject drug twice approve august day valeant acquisition news first only drug market treat call hypoactive sexual desire disorder
232,LLY,july valeant say acquire amoun pharmaceutical egypt biggest drugmaker
233,LLY,major acquisition get away earlier year be botox maker allergan agn valeant offer target company go higher bid ireland base actavis then change name allergan
234,LLY,many other health care stock valeant be attempt come back trigger multiple sell signal late august market take beating stock find support week move average have be find resistance week line
235,LLY,also still flat base entry clear july point be best new pattern emerge
236,LLY,valeant tuesday ibd have post double digit profit growth double digit better sale gain past quarters analyst expect earning gain higher revenue steady performance help earn earning share rating year earning stability factor scale most stable least stable however poor accumulation distribution rating volume ratio point weak recent demand share
237,LLY,recent price performance weakness valeant be more year horizon nordisk have rally more respectively come buyout drugmaker hard keep valeant pharmaceutical vrx rapid pace acquisition canadian drugmaker have already make flurry acquisition year lead stock ethical drug maker group composite rating other highly rate player group include horizon hznp eli lilly lly jazz pharmaceutical jazz nordisk nvo abbvie abbv group rank tuesday issue spot week outperform other drug group generic biotechs latest news valeant progenic tuesday say fda accept new drug application submission oral relistor last week valeant say buy synergetic usa deal value synergetic make surgical instrument used ophthalmology neurosurgery also last week valeant announce agreement pay astrazeneca azn licensing deal psoriasis drug candidate brodalumab amgen astrazeneca previous partner drug exit program several trial patient commit suicide valeant plan file fda approval august also strike deal buy pharmaceutical maker addyi libido pill woman fda reject drug twice approve august day valeant acquisition news first only drug market treat call hypoactive sexual desire disorder july valeant say acquire amoun pharmaceutical egypt biggest drugmaker major acquisition get away earlier year be botox maker allergan agn valeant offer target company go higher bid ireland base actavis then change name allergan many other health care stock valeant be attempt come back trigger multiple sell signal late august market take beating stock find support week move average have be find resistance week line also still flat base entry clear july point be best new pattern emerge valeant tuesday ibd have post double digit profit growth double digit better sale gain past quarters analyst expect earning gain higher revenue steady performance help earn earning share rating year earning stability factor scale most stable least stable however poor accumulation distribution rating volume ratio point weak recent demand share recent price performance weakness valeant be more year horizon nordisk have rally more respectively
238,LLY,news medicine company mdco monday be reminder innovation be alive well biotech space share surge company announce positive phase trial datum experimental cholesterol drug develop alnylam pharmaceutical alny ibd medical biom biotech group have slip bit ibd industry group ranking still hold own
239,LLY,amazon amzn stock price close higher thursday analyst upgrade second day row apple aapl chip supplier technology avgo close price target be cut raymond james upgrade amazon strong buy give price target early thursday day evercore isi upgrade stock
240,LLY,aftermath world black monday be best quality dividend payer do
241,LLY,not terribly bad actually
242,LLY,ibd want see many name component key stock benchmark be flat year price produce dividend yield more show profit growth latest quarter
243,LLY,total company make list
244,LLY,whittle list yield match yield greater also require minimum ep increase latest quarter positive growth expect current fiscal year list shrink
245,LLY,here quick look elite large cap exceptional earning stability scale most stable most volatile score less
246,LLY,gamestop gme video game chain show annualize yield grapevine texas firm raise payout twice march stock be trading just week high year date
247,LLY,valero energy vlo be week peak still jan full year profit be see share yield be year ep stability factor be decent
248,LLY,column profile leggett platt leg specialize furniture internal mechanism monday ibd reynold american rai have be featured time
249,LLY,altrium group mo year ep stability factor yield eli lilly lly year darden restaurant dri year ep stability yield equinix eqix year dennison avy year essex property trust ess ep factor available carnival ccl year general mill gis year public storage psa factor avalonbay community avb factor also make grade avalonbay be less year aftermath world black monday be best quality dividend payer do not terribly bad actually ibd want see many name component key stock benchmark be flat year price produce dividend yield more show profit growth latest quarter total company make list whittle list yield match yield greater also require minimum ep increase latest quarter positive growth expect current fiscal year list shrink here quick look elite large cap exceptional earning stability scale most stable most volatile score less gamestop gme video game chain show annualize yield grapevine texas firm raise payout twice march stock be trading just week high year date valero energy vlo be week peak still jan full year profit be see share yield be year ep stability factor be decent column profile leggett platt leg specialize furniture internal mechanism monday ibd reynold american rai have be featured time altrium group mo year ep stability factor yield eli lilly lly year darden restaurant dri year ep stability yield equinix eqix year dennison avy year essex property trust ess ep factor available carnival ccl year general mill gis year public storage psa factor avalonbay community avb factor also make grade avalonbay be less year
250,LLY,big pharmas eli lilly lly bristol myer squibb bmy soundly beat earning estimate thursday morning also raise guidance not much quarterly beat seem warrant lilly profit exclude time item rise year earlier quarter cent share beating analyst consensus cent accord thomson reuter revenue rise
251,LLY,biogen share take hit wednesday big cap biotech release ambiguous clinical trial result alzheimer disease drug big pharma eli lilly report stronger datum own alzheimer candidate remain unclear drug make market
252,LLY,biogen biib aducanumab be particular focus attention alzheimer association international conference aaic company report effect aducanumab patient mild prodromal even earlier mild alzheimer week treatment mg dose round reportage biogen phase trial aducanumab initially include mg mg mg arm placebo arm
253,LLY,patient lower dose show little effect mg group show better result worryingly high rate amyloid related imaging abnormality aria brain scan biogen add mg group attempt split difference
254,LLY,thus week result other dose be report back march biogen have now mg datum mature addition drug meeting trial endpoint analyst be hope see correlation efficacy dose be strong indication result be due drug
255,LLY,biogen stock fall wednesday eli lilly lly rally sharp early loss close
256,LLY,biogen lilly drug be base beta amyloid hypothesis theory reduce beta amyloid plaque see brain alzheimer sufferer slow disease progress
257,LLY,consistent previously report result week datum mg kg milligram dose kilogram body weight arm demonstrated statistically significant reduction beta amyloid brain biogen say release exploratory analysis mg kg dose show improvement slow clinical decline measure mini mental state examination mmse clinical dementia rating sum box cdr sb scale be not statistically significant
258,LLY,prespecify analysis placebo dose aducanumab slow clinical decline be show be dose dependent dose dependence achieve statistical significance scale
259,LLY,small study slow disease
260,LLY,fact clinical benefit fail reach statistical significance year isn necessarily deal breaker accord rbc capital market analyst michael yee give be small study slow act disease biogen have announce take aducanumab straight phase giant patient study
261,LLY,evercore isi analyst mark schoenebaum point dose correlation wasn perfect
262,LLY,email client mmse month mg datum have improve compare month datum month look exactly placebo now separation however mg datum be still mg datum cast doubt dose response
263,LLY,also think be generally expect placebo datum change have effect slightly shrink magnitude benefit vs prior datum however benefit still look robust
264,LLY,unpleasantry
265,LLY,unpleasant surprise have do rate aria previous research show higher rate aria patient carry apoe protein so biogen analyze carrier noncarrier again rate aria apoe carrier be right mg mg group noncarrier rate mg group be bit higher mg group
266,LLY,piper jaffray downgrade stock neutral buy lower price target biogen stock
267,LLY,biogen plan move forward potentially mg kg dose biogen be sacrifice potential efficacy limit improvement safety write analyst joshua schimmer datum set be far inspiring confidence view be even more speculative
268,LLY,meanwhile aaic eli lilly report year follow datum phase trial solanezumab own alzheimer candidate
269,LLY,be later stage trial datum be used support fda filing
270,LLY,lilly be conduct large study drug again mainly mild case disease call expedition expedition
271,LLY,wednesday report be expedition ext extension study look happened patient be placebo group start be treat solanezumab
272,LLY,delay start group be compare early start group see catch
273,LLY,result find be still significant difference cognition function group
274,LLY,earlier start benefit
275,LLY,datum today appear consistent previously present extension datum suggest solanezumab prove be effective treat ad potential benefit earlier start treatment build case possible disease modification claim label schoenebaum write email fda describe randomize start design more convince mean demonstrate disease modification believe fda be still wrestling concept
276,LLY,therefore view today datum incrementally positive not thesis stock change biogen share take hit wednesday big cap biotech release ambiguous clinical trial result alzheimer disease drug big pharma eli lilly report stronger datum own alzheimer candidate remain unclear drug make market biogen biib aducanumab be particular focus attention alzheimer association international conference aaic company report effect aducanumab patient mild prodromal even earlier mild alzheimer week treatment mg dose round reportage biogen phase trial aducanumab initially include mg mg mg arm placebo arm patient lower dose show little effect mg group show better result worryingly high rate amyloid related imaging abnormality aria brain scan biogen add mg group attempt split difference thus week result other dose be report back march biogen have now mg datum mature addition drug meeting trial endpoint analyst be hope see correlation efficacy dose be strong indication result be due drug biogen stock fall wednesday eli lilly lly rally sharp early loss close biogen lilly drug be base beta amyloid hypothesis theory reduce beta amyloid plaque see brain alzheimer sufferer slow disease progress consistent previously report result week datum mg kg milligram dose kilogram body weight arm demonstrated statistically significant reduction beta amyloid brain biogen say release exploratory analysis mg kg dose show improvement slow clinical decline measure mini mental state examination mmse clinical dementia rating sum box cdr sb scale be not statistically significant prespecify analysis placebo dose aducanumab slow clinical decline be show be dose dependent dose dependence achieve statistical significance scale small study slow fact clinical benefit fail reach statistical significance year isn necessarily deal breaker accord rbc capital market analyst michael yee give be small study slow act disease biogen have announce take aducanumab straight phase giant patient study evercore isi analyst mark schoenebaum point dose correlation wasn perfect email client mmse month mg datum have improve compare month datum month look exactly placebo now separation however mg datum be still mg datum cast doubt dose response also think be generally expect placebo datum change have effect slightly shrink magnitude benefit vs prior datum however benefit still look robust unpleasant surprise have do rate aria previous research show higher rate aria patient carry apoe protein so biogen analyze carrier noncarrier again rate aria apoe carrier be right mg mg group noncarrier rate mg group be bit higher mg group piper jaffray downgrade stock neutral buy lower price target biogen stock biogen plan move forward potentially mg kg dose biogen be sacrifice potential efficacy limit improvement safety write analyst joshua schimmer datum set be far inspiring confidence view be even more speculative meanwhile aaic eli lilly report year follow datum phase trial solanezumab own alzheimer candidate be later stage trial datum be used support fda filing lilly be conduct large study drug again mainly mild case disease call expedition expedition wednesday report be expedition ext extension study look happened patient be placebo group start be treat solanezumab delay start group be compare early start group see catch result find be still significant difference cognition function group earlier start benefit datum today appear consistent previously present extension datum suggest solanezumab prove be effective treat ad potential benefit earlier start treatment build case possible disease modification claim label schoenebaum write email fda describe randomize start design more convince mean demonstrate disease modification believe fda be still wrestling concept therefore view today datum incrementally positive not thesis stock change
277,LLY,large cap drugmaker valeant pharmaceutical eli lilly bristol myer squibb beat analyst estimate stock go different direction guidance be more mixed valeant vrx rise more say total revenue rise easily top consensus view company organic growth not include acquisition be quarter growth owe valeant dermatology contact lens dental business company also report notable growth china middle east russia valeant adjust earning report cash earning currency impact salix pharmaceutical takeover be vs well consensus view valeant guide cash earning share thomson reuter consensus view put revenue vs consensus addition executive lift full year earning forecast vs prior guidance steer full year revenue expectation range original revenue guidance be same store organic growth be impressive expect roughly write bmo capital market analyst alex arfaei research note be drive organic growth don see business slow time soon salix be add momentum morningstar analyst michael praise pending acquisition egypt largest drugmaker amoun pharmaceutical announce last week strength diversification valeant product portfolio continue support company narrow economic moat write note recent amoun acquisition example not only nearly double valeant middle east africa operation strong manufacturing salesforce foundation region also provide likely opportunity revenue synergy company shift portfolio region help boost economy scale lilly guidance hike mutedlilly lly profit exclude time item rise year earlier quarter cent share beating consensus cent accord thomson reuter revenue rise analyst have expect slight decline cent beat lilly add just cent full year ep guidance now also lift low end revenue guidance range now make revenue essentially same last year represent least profit increase evercore isi analyst mark schoenebaum say email recently patent blockbuster zyprexa cymbalta have hold better face generic competition wall street have expect new drug launch also be go well only weak point be diabetes drug humalog miss expectation shrank overall vs year gross profit margin be slightly higher expect lower taxe sale general administrative spending lilly stock rise fraction bristol myer bmy earning climb last year cent share top consensus cent sale gain more street number bristol myer add cent full year ep range now expect revenue analyst average estimate hepatitis franchise beat consensus huge margin vs analyst firm say benefit time recognition defer revenue france probably most watch single drug bristol myer portfolio be cancer drug opdivo just second full quarter sale beat consensus leerink analyst seamus fernandez write hepatitis sale likely aren sustainable opdivo ramp be especially important overall see quarter expectation accelerate opdivo uptake broad approve label second line squamous nsclc small cell lung cancer continue be robust write research note bristol stock fall alan elliott contribute story
278,LLY,big biotech gilead science gild hit month high monday analyst deliver bullish outlook company sunday rbc capital market analyst michael yee lift ep estimate due stock buyback note several recent piece incremental good news cite late friday successful patent suit merck mrk ionis
279,LLY,drug candidate regeneron pharmaceutical regn sanofi sny jointly develop have beaten abbvie abbv best selling rheumatoid arthritis ra drug late stage study company say friday regeneron sanofi say monoclonal antibody sarilumab meet trial main goal improve symptom week biweekly dose regimen patient sarilumab achieve least improvement sign symptom base american college rheumatology criterium contrast patient humira group group experience same rate negative side effect sarilumab group show higher rate neutropenia lower white blood cell humira be currently top selling ra drug indeed top selling drug kind world today number competitor be rise last fall baricitinib drug eli lilly lly incyte incy co develop also beat humira head head trial injectable humira sarilumab be deliver orally roche rhhby intravenous medicine actemra have also best humira trial regeneron sanofi have already apply fda approval sarilumab base earlier datum decision due oct rbc capital market analyst adnan butt call news modest positive add investor be still concern nearer term issue regeneron stock be pilot program test change medicare part announce week affect great deal reimbursement regeneron flagship drug eylea patent lawsuit amgen amgn file monoclonal antibody regeneron sanofi partnership praluent else be equal beating humira be certainly better not beating least discuss overhang need clear pipeline receive more credit write butt research note late morning stock market today abbvie stock be almost sanofi be regeneron stock be fraction
280,LLY,share diabetes giant nordisk nvo jump friday company say drug victoza reduce heart attack stroke release few detail result study save next american diabetes association meeting june however do say be statistically significant reduction metric heart attack stroke death cardiovascular cause patient take diabetes drug year compare placebo group subject be age have cardiovascular disease multiple risk factor nordisk stock be afternoon trading stock market today highest rate stock low rate medical ethical drug group composite rating effect diabetes drug cardiovascular health have be subject several study lately notably eli lilly lly drug jardiance reduce death heart failure similar large long term study report last september other hand merck mrk januvia show effect good bad outcome trial report few month earlier similarly neutral result be report outcome trial sanofi sny drug lixisenatide be noteworthy lixisenatide be same class victoza be glucagon peptide glp analog similar bydureon astrazeneca azn lilly trulicity jardiance be sglt inhibitor same class invokana johnson johnson jnj farxiga astrazeneca merck januvia belong class call dpp inhibitor conference call analyst friday chief scientific officer mad thomsen say different result have come subtle difference drug think extend victoza plan successor semaglutide not only question be member give class glp agonist say thomsen also part kinetic dynamic distribution half life so get semaglutide have do rather detailed investigation be nothing animal pharmacology negate notion semaglutide do least well cardiovascular performance
281,LLY,drug stock boom newer biotech company tend get most play growth stock last year top perform large cap drugmaker be none other year old eli lilly other big pharmas lilly lly have spend last few year climb earning trough bring loss patent protection biggest drug growth be still slow investor have get ever more interested company pipeline lilly late stage drug candidate solanezumab bring breakthrough currently untreatable disease alzheimer psoriasis treatment ixekizumab be expect launch anytime now eventually achieve blockbuster sale immunology drug baricitinib lilly co develop incyte incy be also recently file fda meanwhile already market diabetes drug jardiance shock wall street last year reduce death heart failure large scale study call empa reg recently lilly ceo john lechleiter sit ibd explain lilly strategy ibd interested immunology strategy give be lot medicine area do see fitting space lechleiter well think only way enter space lay claim disease area be offer something better believe datum have ixekizumab be il antibody psoriasis be excellent look clearance rate person study have clearance plaque so be competitor feel very good profile product think baricitinib study establish superiority methotrexate be current first line standard care study superiority term sign symptom ra rheumatoid arthritis abbvie abbv humira be biggest drug world think re bring something new category case ra know person cycle different course therapy think question even drug have space today still unmet need ibd diabetes area have impressive datum jardiance person be wonder be go be class effect be do have point differentiation lechleiter well think first person be ask class effect meaning entire class drug perform same be person don have jardiance fact be have datum anything else other one be speculation so think advantage have be first mover advantage obviously soon get label change exercise file fda expect get update labele reflect outcome empa reg later year ibd overall diabetes market have be pressure lately sanofi sny nordisk nvo have be warning slower growth be true market general just certain segment lechleiter think several category be still grow diabetes space very competitive drug category have different player happen be only company have complete spectrum treatment paradigm boehringer ingelheim growth insulin be slow bit believe more more person used insulin be used sglt inhibitor jardiance be lower insulin requirement so think interplay drug also know sglt category growth be come expense many case generic sulfonylurea so brand category be expand think market standpoint lot competition great consumer great physician remain differentiate product compete mix ibd build complete portfolio diabetes medicine be advantage be marketing advantage lechleiter well fundamental level work physician address right drug give patient vs do fit patient drug make sense let understand diabetes be progressive disease so understand patient be journey medicine best help patient be agnostic choice physician make have offer step way ultimately also hopefully better understand right combination be have fix dose combination dpp jardiance re only company offer today have not just oral have insulin have not just insulin glp drug trulicity so think advantage term be able optimize treatment ultimately be marketplace advantage have full basket product think negotiating payer insurer example ibd alzheimer have different program go do anticipate be multiple drug category lechleiter first solanezumab be positive ll know end year go generate tremendous amount interest company develop bace inhibitor antibody other drug believe ultimately probably be treat combination not way diabetes be treat today not way cancer be treat be antibody oral bace inhibitor example re also develop agent act tau protein be downstream aspect disease progression remain be see best guess be be combination solanezumab be successful other follow aim be group ibd oncology again think position be lot drug industry activity cancer talk strategy lechleiter pillar oncology business go back year be alimta still be today buy imclone october ve have drug approve imclone pipeine cyramza now have indication gastric cancer colorectal cancer lung cancer then late last year get approval portrazza indicated squamous cell small cell lung cancer type lung cancer first line have not see improvement survival year so re excited have third imclone product ve commence filing fda call olaratumab be soft tissue sarcoma have drug clinic today have immune system component associate begin build immuno oncology portfolio also have drug think everyone be excited call abemaciclib cdk inhibitor ll have phase datum breast cancer year also have phase trial underway also have phase underway cdk inhibitor lung cancer so re focuse immuno oncology be cyramza other word angiogenesis drug cell cycle inhibitor so prong approach think ve get good portfolio product pipeline address
282,LLY,drug candidate regeneron pharmaceutical regn sanofi sny jointly develop have beaten abbvie abbv best selling rheumatoid arthritis ra drug late stage study company say friday regeneron france base sanofi say monoclonal antibody sarilumab meet trial main goal improve symptom week biweekly dose regimen patient sarilumab achieve
283,LLY,big pharma merck mrk deliver mixed quarterly result guidance wednesday send stock lower merck earning exclude time item rise year earlier quarter cent share beating analyst consensus cent accord thomson reuter however sale decline wall street average estimate year revenue
284,LLY,market volatility rev high gear january make investor queasy up down stock end bust first month year back oil slump weak corporate earning nasdaq plunge january sank manager nation best perform fund past month have step brake slow stock buy just select few top rate stock have defy gravity household tech name such facebook fb alphabet googl verizon communication vz equinix eqix have see buy action lead fund latest report period click here see list new buy top mutual fundsa handful property reit such stor capital stor mid america apartment community maa sovran self storage sss be solid performer recent month also favore top perform fund finance property reit group be rank industry wednesday top fund also add defensive utility stock atmos energy ato pnm resource pnm itc hold itc american water work awk black hill bkh ibd spot lead fund buy edward lifescience ew investing estimate latest report period fidelity contrafund fcntx add share portfolio irvine calif base firm make market medical device treat heart disease edward report fourth quarter earning result cent share year earlier beating analyst estimate cent revenue rise fourth quarter earning growth be drive high demand sapien sapien xt heart valf be deliver procedure call transcatheter aortic valve replacement therapy tavr critical care product group include hemodynamic monitoring device also perform well globally fourth quarter edward stock hold steady most stock market sell january stock clear flat month base wednesday upbeat fourth quarter earning nation lead fund have be unload lilly eli co lly latest report period be net selling fund position other drugmaker zoetis zts baxalta bxlt be also slash click here top fund latest sell
285,LLY,merck mrk stock pop tuesday drugmaker post earning top wall street expectation day regulator approve new biologic license application keytruda lung cancer treatment worldwide keytruda sale miss expectation health care tracker symphony health service consult evercore analyst john scottus write research report keytruda sale lag symphony model say stock market today merck stock rise fall intraday share be year ibd company medical ethical drug group be merck report sale vs year earlier quarter earning share ex item year year metric top consensus analyst poll thomson reuter cent merck credit sale beat franchise gardasil proquad vaccine human papillomavirus hpv measles mumps rubella varicella chickenpox respectively scottus note transition dose gardasil regimen hurt merck company decline give specific expectation do say expect revenue decline write gardasil sale come year year proquad sale rise keytruda lead growth merck pull diabetes med januvia janumet bring nearly sale comprise total quarterly revenue merck also update fiscal ep item view be year year basis line analyst broader view ibd take ibd ethical drug group rank lowly group biom biotech group be have show life have learn recent industry snapshot feature help investor identify potentially hot industry group meanwhile drugmaker eli lilly lly novartis nvs post sale miss lilly stock rise fraction novartis stock fall merck result follow decision monday food drug administration allow supplemental biologic license application keytruda merck lung cancer drug drug compete bristol myer squibb bmy opdivo keytruda now be used first line treatment patient metastatic nonsmall cell lung cancer nsclc tumor have high expression pd receptor regulator allow merck include datum show keytruda improve survival vs chemotherapy patient previously treat nsclc high expression pd receptor related merck topple bristol myer lung cancer winnovartis tumble sale miss chemo sale boost incyteeli lilly revenue ep miss ceo praise drug pipeline
286,LLY,novartis nvs stock tumble month low tuesday firm sale miss view double digit growth chemotherapy sale buoy ex partner incyte incy say rbc analyst simo simeonidis stock market today however novartis incyte stock topple share incyte testing day move average novartis stock fall incyte stock dip novartis report sale earning share ex item respectively vs year earlier quarter sale miss consensus analyst poll thomson reuter ep top cent sale chemotherapy drug jakavi jakafi used treat myelofibrosis mf polycythemia vera pv grow year year top consensus view simeonidis write research report ibd take biotech sector have be slogged recently double digit gain last month kite pharma pharmaceutical breathe life back sector get closer look used industry snapshot incyte acquire right develop commercialize jakafi graft vs host disease eli lilly lly april lilly also amend agreement novartis allow novartis right do so outside exchange royalty payment simeonidis estimate incyte pull royalty novartis vs year earlier quarter miss simeonidis earlier view consensus model accord novartis increase revenue come patient gain mf globally launch pv key market write inctye actual royalty likely be report nov inctye earning release novartis firm reiterate full year guidance expect sale be line last year related merck crush expectation follow lung cancer drug wineli lilly revenue ep miss ceo praise drug pipeline
287,LLY,biogen biib add sale myotonic dystrophy drug partnership ionis pharmaceutical ion garner strong phase datum year end say rbc analyst michael yee yee boost price target biogen stock keep outperform rating previous price target be undervalue potential catalyst boost eli lilly lly alzheimer drug grow pipeline write research report stock market today biogen stock edge small fraction remain day line share be year still better ibd company medical biom biotech industry group have fall wall street be undervalue biogen ionis dmkp dystrophia myotonica protein kinsae drug yee say expect positive datum include good safety profile year end also testing include biopsy examine biomarker see key mutate dmpk gene knockdown proof concept drug be already work get rid bad species cause disease write suggest efficacy happen already likely drug ibd take biogen belong bioshare biotechnology product exchange trade fund be year date volatile election season check ibd etfs tracker keep eye potential highflying fund biogen year ceo george scango announce july leave soon new ceo be name long doesn happen yee see chance biogen be acquire also see chance eli lilly have success alzheimer drug solanezumab eli lilly success tug biogen be develop aducanumab remove plaque deposit associate alzheimer dmkp market be likely bigger sma spinal muscular atrophy duchenne muscular dystrophy market yee say be class dmkp more severe class dm be time bigger dmd patient population say biogen ionis drug be be test patient receive shot week patient receive shot week preclinical trial have show knockdown mutate dmkp gene produce significantly improve muscular function yee write think dose dependent knockdown clean safety improve biomarker muscle function lead new derisk give dmpk be specifically toxic accumulate protein prevent production key protein need muscle function write relatedcelgene pit gilead biogen crohn drug battlecan top biotechs climb wall worry rbc call rally
288,LLY,eli lilly lly alzheimer drug solanezumab add peak sale supercharge earning goldman sachs analyst jami rubin say tuesday upgrade stock expectation long term sale acceleration rubin note lilly be highly diversify not dependent solanezumab antibody act neuroprotector patient alzheimer disease sola see new product sale represent nearly half total sale next year eli lilly plan launch drug combat symptom associate rheumatoid arthritis plaque psoriasis diabetes rubin ascribe success probability sola previously even sola lilly eli grow earning double digit next year high single digit have most durable franchise industry write research report rubin upgrade eli lilly stock buy neutral boost price target lilly stock be year be outpace decline ibd company medical ethical drug industry group group be rank group track last week stock market today eli lily lift retake day line undercut support area monday ibd take biotech stock have heated recently speculation big pharma player check ibd industry theme related sanofi backed lexicon diabetes drug score type diabeteslilly breast cancer drug study roll push back launch datelilly upgrade pipeline prospect abbvie downgrade
289,LLY,shire shpg miss analyst target second quarter earning sale lift outlook cite strong drug pipeline irish drugmaker adjust earning share fall penny cent miss cent operate income gaap basis fall wall street view revenue rise short consensus strength dollar cut sale growth percentage point shire now see full year ep growth mid high digit percentage range earlier forecast mid single digit growth share be thursday afternoon trading stock market today stock set consecutive flat basis many month rise buy point thursday retreat bit product sale grow gaap basis exclude intuniv attention deficit hyperactivity disorder drug just enter market june shire develop drug behavioral health disorder rare genetic disease other condition take charge quarter related higher marketing cost newer product new drug used shire wednesday announce positive result week long study vyvanse adult eating disorder base result separate study company plan submit application food drug administration use end year other stock medical ethical drug group valeant pharmaceutical vrx be report strong earning thursday eli lilly lly bristol myer squibb bmy soundly beat earning estimate thursday also raise guidance follow james detar twitter ibd_jdetar
290,LLY,acquisition hungry valeant pharmaceutical vrx rise more stock market today record high weak earning guidance neatly step analyst second quarter revenue earning expectation valeant be several drugmaker biotechs report thursday morning include celgene celg eli lilly lly shire shpg bristol myer squibb bmy laval quebec base
291,LLY,next week bring passel earning report large cap drugmaker biotech pharma stock be trading new high yet again novartis bristol myer squibb eli lilly valeant pharmaceutical abbvie biogen be tap busy earning week here quick rundown be especially big week news biogen biib
292,LLY,exchange trade fund continue flounder friday earning major technology company disappoint investor doubt global growth grow gloom week amazon amzn blowout result buoy nternet consumer discretionary etfs
293,LLY,online retail giant stunned market post profit give upbeat guidance current quarter
294,LLY,be somewhat simplistic describe amazon just retailer now cloud compute juggernaut amazon web service generate more revenue june quarter year say unit be still small part company overall business
295,LLY,amazon stock spiked nearly double average volume stock market today give market cap top rival wal mart wmt
296,LLY,first trust dow jone internet fdn technology etf jump time high hold amazon lead advance
297,LLY,don look amazon largest tech etfs technology select sector spdr xlk vanguard information technology vgt don consider tech stock grow cloud compute clout
298,LLY,consumer discretionary select sector spdr xly pop amazon count hold etf nearly asset
299,LLY,health care select sector spdr xlv ishare nasdaq biotechnology ibb shed nearly week see hefty slate drugmaker biotech earning abbvie abbv valeant pharmaceutical vrx biogen biib celgene celg eli lilly lly shire shpg bristol myer squibb bmy
300,LLY,several stock beat analyst estimate guidance be more mixed key hold biogen plunge stock market today take bite xlv ibb
301,LLY,big cap drugmaker beat ep forecast earning report today miss revenue also lower full year guidance come heel downbeat update week alzheimer drug clinical trial
302,LLY,ibb have lose week set new high recently monday
303,LLY,market vector gold miner gdx stumble more multiyear lows datum china show manufacturing contract sharply july china be world biggest metal consumer
304,LLY,manufacturing datum also show business be struggle europe july hit greece debt crisis
305,LLY,spdr gold share gld tracking physical gold have fall more week more year dollar rise economy show relative strength further pressure metal
306,LLY,here look benchmark exchange trade fund tracking various asset class be perform today follow daily etf market action be key successful investing
307,LLY,bellwether etfs
308,LLY,powershare db bullish uup rs
309,LLY,ishare core aggregate bond agg rs
310,LLY,powershare qqq qqq rs
311,LLY,spdr gold trust gld rs
312,LLY,ishare core mid cap ijh rs
313,LLY,spdr spy rs
314,LLY,spdr dow jone industrial average dium rs
315,LLY,ishare russell iwm rs
316,LLY,ishare msci eafe efa rs
317,LLY,vanguard ftse emerge market vwo rs
318,LLY,follow aparna narayanan twitter ibd_anarayanan exchange trade fund continue flounder friday earning major technology company disappoint investor doubt global growth grow gloom week amazon amzn blowout result buoy nternet consumer discretionary etfs online retail giant stunned market post profit give upbeat guidance current quarter be somewhat simplistic describe amazon just retailer now cloud compute juggernaut amazon web service generate more revenue june quarter year say unit be still small part company overall business amazon stock spiked nearly double average volume stock market today give market cap top rival wal mart wmt first trust dow jone internet fdn technology etf jump time high hold amazon lead advance don look amazon largest tech etfs technology select sector spdr xlk vanguard information technology vgt don consider tech stock grow cloud compute clout consumer discretionary select sector spdr xly pop amazon count hold etf nearly asset health care select sector spdr xlv ishare nasdaq biotechnology ibb shed nearly week see hefty slate drugmaker biotech earning abbvie abbv valeant pharmaceutical vrx biogen biib celgene celg eli lilly lly shire shpg bristol myer squibb bmy several stock beat analyst estimate guidance be more mixed key hold biogen plunge stock market today take bite xlv ibb big cap drugmaker beat ep forecast earning report today miss revenue also lower full year guidance come heel downbeat update week alzheimer drug clinical trial ibb have lose week set new high recently monday market vector gold miner gdx stumble more multiyear lows datum china show manufacturing contract sharply july china be world biggest metal consumer manufacturing datum also show business be struggle europe july hit greece debt crisis spdr gold share gld tracking physical gold have fall more week more year dollar rise economy show relative strength further pressure metal here look benchmark exchange trade fund tracking various asset class be perform today follow daily etf market action be key successful investing bellwether etfs powershare db bullish uup rs ishare core aggregate bond agg rs powershare qqq qqq rs spdr gold trust gld rs ishare core mid cap ijh rs spdr spy rs spdr dow jone industrial average dium rs ishare russell iwm rs ishare msci eafe efa rs vanguard ftse emerge market vwo rs follow aparna narayanan twitter ibd_anarayanan
319,LLY,biogen biib second quarter earning top view flagship drug tecfidera tysabri miss sale expectation cause biotech quarterly revenue growth come well consensus estimate company also cut full year revenue guidance
320,LLY,share be plunge giant volume stock market today gapping lowest level nearly month stock be now trading more mid march high
321,LLY,look weekly chart see biogen be breaking week week move average biggest weekly volume least year be long term sell signal mark end year run
322,LLY,drugmaker abbvie abbv also report quarterly result today too top earning view miss sale estimate
323,LLY,share gap quick turnover stock be look support day line currently buy range cup base buy point
324,LLY,valeant pharmaceutical vrx celgene celg bristol myer bmy eli lilly lly also report earning week
325,LLY,follow alissa william twitter ibd_awilliam biogen biib second quarter earning top view flagship drug tecfidera tysabri miss sale expectation cause biotech quarterly revenue growth come well consensus estimate company also cut full year revenue guidance share be plunge giant volume stock market today gapping lowest level nearly month stock be now trading more mid march high look weekly chart see biogen be breaking week week move average biggest weekly volume least year be long term sell signal mark end year run drugmaker abbvie abbv also report quarterly result today too top earning view miss sale estimate share gap quick turnover stock be look support day line currently buy range cup base buy point valeant pharmaceutical vrx celgene celg bristol myer bmy eli lilly lly also report earning week follow alissa william twitter ibd_awilliam
326,LLY,biotech giant amgen beat analyst estimate late thursday send share fraction hour trading rough day drug stock amgen amgn earning totale year earlier quarter soundly beating analyst consensus estimate accord thomson reuter revenue rise vs analyst full year
327,LLY,biotech pharma stock sell sharply thursday busy earning week even overall market rise ibd medical biom biotech industry group hit month low stock market today be early afternoon separately ethical drug group be number company group report earning thursday
328,LLY,big biotech biogen biib beat analyst earning estimate early wednesday send batter stock early trading biogen earning exclude time item rise year earlier quarter share beating consensus cent accord thomson reuter revenue climb wall street average estimate
329,LLY,stock close mixed tuesday late rush buy save fraction day early gain nasdaq fall climb less dow jone industrial average add nearly small cap struggle however russell slide index open higher descend loss midday rebound final hour restore gain index not quite bounce way back early level volume fall accord preliminary figure energy metal stock lead selling commodity be generally weaker defensive industry group such beverage candy maker utility drugstore be day best perform stock market today banking stock be mainly lower even bank america bac jpmorgan chase jpm beat earning bank still face difficult revenue environment bofa slide week low jpmorgan be barely lower hold friday low mastercard slide almost notch lowest close nearly year stock have be steep descent month technically be form new base eli lilly lly rise share briefly rise back day move average recede back lilly continue work new base company announce file fda approval baricitinib treatment rheumatoid arthritis filing trigger milestone payment incyte incy get more drug win approval incyte share fall surgical care affiliate scai hottest stock last week reversed lower tuesday share fall end buy point cup type base wednesday key company report result include goldman sachs gs brinker international eat consumer price index latest housing start report come et
330,LLY,big pharma eli lilly lly guide wall street expectation tuesday stock rise fall big market plunge monday lilly say expect revenue fraction last year estimate sale analyst consensus accord thomson reuter earning exclude time item
331,LLY,past few year have bring groundbreaking drug launch such record breaking gilead science rollout hepatitis medicine first pd cancer fighter merck bristol myer squibb bmy year look be somewhat slower front drug firm aim most new launch smaller market build
332,LLY,be year distinct part drug stock first month continue bull run last year sudden resurface drug pricing debate lead rocky month overall group come ahead top perform big cap show solid story make political worry eye investor incyte incy be wednesday close year steady gain lone market product jakafi well pipeline potential blockbuster march jakafi win eu approval blood cancer polycythemia vera be already approve blood cancer myelofibrosis disease be rare incyte be shooting much bigger market late stage candidate baricitinib epacadostat baricitinib incyte be develop partnership eli lilly lly test successfully phase trial rheumatoid arthritis placebo methotrexate current market leader abbvie abbv humira nov initiation report incyte goldman sachs analyst richter estimate peak annual sale more expect launch richter add more important future driver share likely be incyte entry bud field immuno oncology incyte have be testing lead candidate field epacadostat combination merck mrk keytruda variety cancer early november incyte stock fall small study combo patient advanced cancer disappoint wall street richter write likely bring more clarity more result come incyte have be operate loss due research spending analyst expect turn first annual profit next year stock current ibd composite rating be danish diabetes giant nordisk nvo be end year flat base follow early gain march stock rise sharply say refile approval long act insulin analogue tresiba shorter act sister drug ryzodeg drug suffer surprise rejection fda seek more datum possible risk heart time agency be convince approve also boost stock early year be february release positive clinical trial datum latest glucagon peptide glp receptor agonist og have be selling earlier glp agonist victoza market have get more competitive last couple year new glp launch sanofi sny glaxosmithkline gsk eli lilly drug be injectable however new candidate be oral announce further positive result drug july september financial result currency suffer foreign exchange headwind hit global drugmaker year still manage solid ibd ep rank relative strength rating regeneron pharmaceutical regn continue multiyear run stock market hit lifetime high aug get catch larger biotech sell still year regeneron flagship eye drug eylea continue perform well aid new approval diabetic retinopathy march draw more attention be launch cholesterol drug praluent july praluent be not only first new class cholesterol drug be follow shortly market amgen amgn repatha also first number novel monoclonal antibody regeneron have be develop partnership sanofi next entry dupilumab be late stage testing asthma eczema be also expect attain multibillion dollar annual sale regeneron be also highest rate stock list highest possible composite rating eli lilly be top perform traditional big pharma year gain sale growth have be flat due age drug well currency headwind company have improve profit margin cost control get lot investor excited pipeline note partnership incyte have bear fruit baricitinib trial lilly doesn have much presence rheumatoid arthritis other immunology disease lilly be plan change not only baricitinib ixekizumab psoriasis treatment plan launch next year be expect sell billion eventually lilly already launch diabetes drug jardiance yielded pharma biggest upside surprise year giant study effect cardiovascular health show reduce death heart failure drive stock year high september turn cup handle base stock hold cr baxalta bxlt be start trading july spin baxter international bax seek unlock shareholder value biopharma arm just day later company receive unsolicited buyout offer british drugmaker shire shpg see baxalta hemophilia franchise ideal addition rare disease portfolio baxalta reject offer situation remain unresolved last week rumor be buzz shire bid hasn yet baxalta financial have be slow steady lead ep rank acquisition hope have lift stock rs rating
333,LLY,flagship etfs struggle gain tuesday investor remain skittish global outlook day new year get worst trading start health care real estate help lead sector higher technology trail trading resume mainland china stock exchange overnight shanghai composite index close modest choppy trade trading exchange be suspend early monday trigger panic global sell powershare dynamic pharmaceutical portfolio pjp give back early gain close stock market today health care be top perform sector pjp top perform health care exchange trade fund climb last year etf hold pharmaceutical stock select weight base various fundamental risk factor top holding eli lilly lly bristol myer squibb bmy rise almost tuesday drugmaker eli lilly gain cut full year guidance give forecast miss wall street expectation stock jump more past year biotech etfs surrender early gain ishare nasdaq biotechnology ibb perked much intraday close almost flat cap weight etf skews larger cap hold biotech pharma company list nasdaq advanced last year gold largest etfs backed physical gold rise fraction tuesday re trading week high attempt retake day move average line gold be see follow strength more safe haven buy short cover future market follow decent gain post monday say jim senior technical analyst commodity monitor kitco news unrest middle east weak chinese economic datum release monday be work favor yellow metal write kitco dollar edge other major world currency include euro british pound lower oil gas price keep lid stock market gain bellwether etfs here look major exchange trade fund tracking various asset class perform today follow daily etf market action be key successful investing spdr spy rs powershare qqq qqq rs spdr dow jone industrial average dium rs ishare core mid cap ijh rs ishare russell iwm rs ishare msci eafe efa rs vanguard ftse emerge market vwo rs spdr gold share gld rs ishare core aggregate bond agg rs powershare db bullish uup rs follow aparna narayanan twitter ibd_anarayanan
334,LLY,so sound so many expect yesterday be day change number high profile tech name report earning result be less stellar not horrible just bit disappointing commodity continue chatter be doom gloom be go be catalyst market correct say china whole world be dependent country herd mentality play
335,LLY,apple aapl report great quarter yet somehow so many seem find something wrong report earn unit sell be expect earn current quarter be trader do react pounce investor do not do analysis strategize lay plan then take advantage opportunity create short term disruption take advantage be do buyer yesterday be pat back today apple begin climb back look struggle bit race yet again just sayin
336,LLY,then get like high profile market strategist dennis gartman see making protracted bear market so many other jump commodity breakdown bandwagon gold copper oil wheat soybean collapse be strong dollar weaken global demand be concept mutually exclusive go hand hand look commodity dollar have inverse relationship go other go commodity be price dollar foreign buyer use dollar buy commodity so value dollar rise have less buy power putt pressure demand conversely dollar weaken then have more buy power naturally produce more demand so go make crazy be global slowdown end world be come again consider natural inverse relationship dollar commodity way weaker oil food price never hurt anybody
337,LLY,add expectation fed be raise rate only cause dollar get stronger put more pressure commodity so issue believe relationship then be buyer line right now wouldn discount be seller get more anxious buyer pull back go vicious circle point investor realize global economy be do just fine action be not global slowdown then market re adjust
338,LLY,today be big day earning parade beauty pageant continue amazon com amzn general motor gm mcdonald mcd caterpillar cat boston scientific bsx dow dow southwest luv eli lilly lly raytheon rtn armour ua pulte group phm american electric aep name just few already pre market have hear couple
339,LLY,lly beat vs
340,LLY,ua beat vs
341,LLY,dhr beat vs
342,LLY,phm beat vs
343,LLY,aep beat vs
344,LLY,look be go be good day so far season report company have beaten analyst estimate original earning decline forecast have now be revise overall aren even halfway thru season revenue report company have beaten case again better forecast so be market go collapse weight better expect earning improve macro datum not likely need much bigger catalyst provoke substantial correction
345,LLY,morning future be pt leave smack middle trading range technically be move average now represent support tone today be more bullish test monday high be not question slew earning beat expectation investor be more convince picture look brighter short run cover
346,LLY,europe market be bit mixed mostly green deal flurry earning well greece continue simmer back burner recent demonstration only keep pressure now do seem be move right direction ftse cac dax eurostoxx spain italy
347,LLY,take good care
348,LLY,kp
349,LLY,kenny polcari be vice president director nyse floor operation behalf neil security inc sister company investor business daily market commentary be opinion author be base decade industry market experience however guarantee be make imply respect opinion commentary be not be intend be rely authoritative take substitution exercise judgment comment note herein not be construe offer sell solicitation offer buy sell financial product official statement endorsement neil security incorporate affiliate so sound so many expect yesterday be day change number high profile tech name report earning result be less stellar not horrible just bit disappointing commodity continue chatter be doom gloom be go be catalyst market correct say china whole world be dependent country herd mentality play apple aapl report great quarter yet somehow so many seem find something wrong report earn unit sell be expect earn current quarter be trader do react pounce investor do not do analysis strategize lay plan then take advantage opportunity create short term disruption take advantage be do buyer yesterday be pat back today apple begin climb back look struggle bit race yet again just sayin then get like high profile market strategist dennis gartman see making protracted bear market so many other jump commodity breakdown bandwagon gold copper oil wheat soybean collapse be strong dollar weaken global demand be concept mutually exclusive go hand hand look commodity dollar have inverse relationship go other go commodity be price dollar foreign buyer use dollar buy commodity so value dollar rise have less buy power putt pressure demand conversely dollar weaken then have more buy power naturally produce more demand so go make crazy be global slowdown end world be come again consider natural inverse relationship dollar commodity way weaker oil food price never hurt anybody add expectation fed be raise rate only cause dollar get stronger put more pressure commodity so issue believe relationship then be buyer line right now wouldn discount be seller get more anxious buyer pull back go vicious circle point investor realize global economy be do just fine action be not global slowdown then market re adjust today be big day earning parade beauty pageant continue amazon com amzn general motor gm mcdonald mcd caterpillar cat boston scientific bsx dow dow southwest luv eli lilly lly raytheon rtn armour ua pulte group phm american electric aep name just few already pre market have hear couplelly beat vs ua beat vs dhr beat vs phm beat vs aep beat vs look be go be good day so far season report company have beaten analyst estimate original earning decline forecast have now be revise overall aren even halfway thru season revenue report company have beaten case again better forecast so be market go collapse weight better expect earning improve macro datum not likely need much bigger catalyst provoke substantial correction morning future be pt leave smack middle trading range technically be move average now represent support tone today be more bullish test monday high be not question slew earning beat expectation investor be more convince picture look brighter short run cover europe market be bit mixed mostly green deal flurry earning well greece continue simmer back burner recent demonstration only keep pressure now do seem be move right direction ftse cac dax eurostoxx spain italy take good care kpkenny polcari be vice president director nyse floor operation behalf neil security inc sister company investor business daily market commentary be opinion author be base decade industry market experience however guarantee be make imply respect opinion commentary be not be intend be rely authoritative take substitution exercise judgment comment note herein not be construe offer sell solicitation offer buy sell financial product official statement endorsement neil security incorporate affiliate
350,LLY,biotech aldr jump new high wednesday credit suisse analyst assume coverage outperform rating
351,LLY,analyst vamil divan write lead drug candidate ald cgrp antibody migraine have potential be best class asset give strong efficacy long duration response position potentially once quarterly treatment
352,LLY,divan write compete candidate amgen amgn teva pharmaceutical industry teva eli lilly lly likely require monthly infusion
353,LLY,nonetheless phase trial still ahead divan assign drug chance success admit unanticipated setback greater expect competitive pressure significantly impact aldr outlook
354,LLY,biopharma stock be more late afternoon trading stock market today have be high surpass divan price target
355,LLY,share teva lilly be fraction late afternoon trading amgen stock slide more
356,LLY,follow amy reeve twitter ibd_areeve biotech aldr jump new high wednesday credit suisse analyst assume coverage outperform rating analyst vamil divan write lead drug candidate ald cgrp antibody migraine have potential be best class asset give strong efficacy long duration response position potentially once quarterly treatment divan write compete candidate amgen amgn teva pharmaceutical industry teva eli lilly lly likely require monthly infusion nonetheless phase trial still ahead divan assign drug chance success admit unanticipated setback greater expect competitive pressure significantly impact aldr outlook biopharma stock be more late afternoon trading stock market today have be high surpass divan price target share teva lilly be fraction late afternoon trading amgen stock slide more follow amy reeve twitter ibd_areeve
357,LLY,stock fought hold slender gain early thursday mixed economic datum further delay eurozone deal greece drag early trade
358,LLY,top index dow jone industrial average nasdaq hover gain russell show small cap same range
359,LLY,volume be soft nyse nasdaq compare action same time wednesday
360,LLY,stock market today receive ve be boost personal income consumer spending number commerce department datum show biggest monthly increase spending almost year news come word europe talk greece eurozone lender be suspend indefinitely greek official creditor harden stance side impasse
361,LLY,weak datum point researcher markit preliminary read june service purchasing manager index fall be sharply april final tally disappointing consensus expectation uptick
362,LLY,stock drugmaker eli lilly lly scramble more early action bank america upgrade stock buy neutral gain lift share just june high past flat base buy point
363,LLY,lead light leader cree cree unwound more announce late wednesday take charge order restructure cost pressure light division management also announce share buyback plan trim june quarter fiscal year revenue projection consensus estimate stock have be erode august
364,LLY,ibd stock open generally positive gain be mild criteo crto vasco datum security vdsi horizon pharma hznp be half dozen stock gain sightly better
365,LLY,best move list ambarella amba jump more start gate fight claw back ground collapse monday stifel maintain buy rating raise price target stock report cite ambarella methodically expand core competency video capture compression energy efficiency increase competitive barrier entry competitor stock be june high week move average still extend rebound week support
366,LLY,nike nke top short list company schedule report quarterly result today close stock fought hold slender gain early thursday mixed economic datum further delay eurozone deal greece drag early trade top index dow jone industrial average nasdaq hover gain russell show small cap same range volume be soft nyse nasdaq compare action same time wednesday stock market today receive ve be boost personal income consumer spending number commerce department datum show biggest monthly increase spending almost year news come word europe talk greece eurozone lender be suspend indefinitely greek official creditor harden stance side impasse weak datum point researcher markit preliminary read june service purchasing manager index fall be sharply april final tally disappointing consensus expectation uptick stock drugmaker eli lilly lly scramble more early action bank america upgrade stock buy neutral gain lift share just june high past flat base buy point lead light leader cree cree unwound more announce late wednesday take charge order restructure cost pressure light division management also announce share buyback plan trim june quarter fiscal year revenue projection consensus estimate stock have be erode august ibd stock open generally positive gain be mild criteo crto vasco datum security vdsi horizon pharma hznp be half dozen stock gain sightly better best move list ambarella amba jump more start gate fight claw back ground collapse monday stifel maintain buy rating raise price target stock report cite ambarella methodically expand core competency video capture compression energy efficiency increase competitive barrier entry competitor stock be june high week move average still extend rebound week support nike nke top short list company schedule report quarterly result today close
367,LLY,drug giant teva pharmaceutical industry teva report success midstage testing new migraine drug thursday offer investor first datum episodic migraine particular result seem be line expectation however stock close slightly higher erase loss more stock continue work base base pattern teva tev
368,LLY,blockbuster hepatitis drug power sale profit gilead science have become drug industry hit stock gilead gild stock have soar nearly last year new run begin gilead market capitalization be now higher drug giant merck mrk even revenue
369,LLY,drug giant teva pharmaceutical industry teva report success midstage testing new migraine drug thursday offer investor first datum episodic migraine particular result seem be line expectation however stock close slightly higher erase loss more stock continue work base base pattern teva tev
370,LLY,celgene celg stock jump new high wednesday morning get several price target increase wake deal buy receptos rcpt celgene agree pay receptos announce preliminary earning beat estimate receptos lead drug candidate ozanimod be clinical testing different immunological disease be
371,LLY,dividend etfs hold equity have struggle beat broad market late performance have be roughly line index longer period time first trust value line dividend fvd have rise past year top performer exchange trade fund hold dividend payer
372,LLY,best etfs december performance update lackluster performance most asset class category large cap growth etfs be top diversify etfs year group large cap smart beta fund be do even better broader counterpart ishare msci usa momentum factor mtum powershare dynamic large cap growth pwb be respectively
373,LLY,big pharmas merck mrk eli lilly lly johnson johnson jnj be trading tuesday get upgrade barclay abbvie abbv seesaw downgrade analyst geoff meacham assume coverage newly combine pharmaceutical sector barclay coverage left most rating same make few tweak lilly be upgrade overweight equal weight price target lift base promising pipeline management commitment lower expense meacham say lilly be build major autoimmune disease franchise late stage drug candidate ixekizumab psoriasis baricitinib rheumatoid arthritis drug develop incyte incy base solid phase datum view baricitinib have significant market share potential rheumatoid arthritis meacham write model conservatively project risk adjust sale vs peak sale pfizer pfe xeljanz meacham call diabetes drug jardiance lilly most important commercial asset intermediate term recent study result show sharply reduce death heart failure admit have be overhang merck derive lot revenue compete drug jardiance argue stock have overreact acknowledge be multiple headwind risk make merck show story think even most potential negative scenario be too much underlie value ignore meacham write raise merck rating overweight equal weight hike price target even pipeline asset aren blockbuster add be nearly free current valuation lilly stock be almost afternoon trading stock market today merck stock be meacham also raise overweight equal weight price target rise merck feel market be undervalue have underperform drg past month due concern impact biosimilar remicade low term earning growth lack significant term pipeline catalyst meacham write have lead call break conglomerate believe be premature meacham view be better acquire growth asset especially pharma stock be afternoon trading meanwhile meacham downgrade abbvie equal weight overweight trim price target many analyst thought abbvie projection recently acquire blood cancer drug imbruvica similar drug pipeline year peak be too high imbruvica other oncology asset likely succeed field be highly competitive meacham write abbvie stock initially drop almost tuesday trading afternoon be follow amy reeve twitter ibd_areeve facebook
374,LLY,amazon amzn price target be raise tuesday online marketplace say have record sale fire device weekend yum brand yum be upgrade china business spinoff
375,LLY,barclay raise amazon price target raise keep overweight rating stock amazon also say tuesday fire device be best selling product black friday sale plan speed production build million more fire tablet
376,LLY,amazon share close stock market today
377,LLY,yum brand operator taco bell pizza hut kfc restaurant be upgrade outperform market perform cowen analyst be bullish company spinoff china business follow food safety issue past few year have hit stock
378,LLY,share yum climb
379,LLY,web host cloud compute service provider rackspace host rax be upgrade outperform sector perform rbc capital market analyst have price target stock rackspace share close
380,LLY,barclay upgrade pharmaceutical medical company merck mrk eli lilly lly johnson johnson jnj overweight merck share jump eli lilly share climb share edge
381,LLY,follow gillian rich twitter ibd_grich amazon amzn price target be raise tuesday online marketplace say have record sale fire device weekend yum brand yum be upgrade china business spinoff barclay raise amazon price target raise keep overweight rating stock amazon also say tuesday fire device be best selling product black friday sale plan speed production build million more fire tablet amazon share close stock market today yum brand operator taco bell pizza hut kfc restaurant be upgrade outperform market perform cowen analyst be bullish company spinoff china business follow food safety issue past few year have hit stock share yum climb web host cloud compute service provider rackspace host rax be upgrade outperform sector perform rbc capital market analyst have price target stock rackspace share close barclay upgrade pharmaceutical medical company merck mrk eli lilly lly johnson johnson jnj overweight merck share jump eli lilly share climb share edge follow gillian rich twitter ibd_grich
382,LLY,manager columbia mid cap growth fund spun wheel bit difficult third quarter have keep mutual fund course outperform broad stock market peer group track morningstar first second quarters mutual fund lag peer come holding energy sector cope fund have cut energy weighting also see energy holding lose value energy weighting be more percentage point lower year earlier case trim proceed be recycle stock manager see better risk reward opportunity investor say lead manager george myer invest growth company aren willing overpay myer say approach have work long term well recently fund gain year go tuesday top peer be fund carry month performance rating ibd have perform top mutual fund period stock add be signature bank sbny be ibd leaderboard bank big bank competitor offer customer single point contact myer say don get pass person bank continue take market share myer say bank pay package attract talented employee bring book business signature stand benefit federal reserve interest rate hike weather fund aim growth stock be able grow earning matter be economic cycle do company need unique least superior product service example higher interest rate win impact person need buy product incyte incy oncology rheumatoid arthritis company myer say manager prospect incyte build revenue new product addition cancer treatment jakafi be work develop cancer immunotherapy myer say test have be promising rheumatoid arthritis drug be develop partnership eli lilly lly think incyte product be superior abbvie abbv humira sell north globally say linkedin lnkd be stock manager long term thesis be talent solution segment be business be better person expect say co manager brian neigut marketing solution segment be pressure also continue do better wall street expect base new product update ancillary product roper technology rop be favorite fund shift money co manager william chamberlain like company knack make accretive acquisition such legal software firm aderant october also like wide variety product chamberlain call roper industrial firm increasingly think tech stock ultimate software group ulti be fund favorite company benefit ongoing shift payroll service cloud expect accelerate revenue growth set apart many other tech company myer say
383,LLY,action camera maker gopro gpro get price target cut monday embattled restaurant chain chipotle grill cmg suffer series downgrade price target cut own
384,LLY,analyst also make call biotech startup bluebird bio blue teva pharmaceutical teva new issue ferrari race
385,LLY,jpmorgan trim gopro target friday robert baird downgrade gopro neutral outperform slash price target share be hit last week chip supplier ambarella amba give weak guidance due part soft sale action camera
386,LLY,gopro share lose stock market today ambarella give
387,LLY,cowen co guggenheim security downgrade chipotle former market perform latter neutral maxim group lower price target stock
388,LLY,report say friday coli outbreak chipotle have expand state outbreak have sicken dozen customer force closure restaurant
389,LLY,chipotle share sank year low early monday recover later session stock close
390,LLY,bluebird bio stock price tumble be downgrade neutral buy roth capital have price target chopped nearly half weekend bluebird present disappointing gene therapy datum american society hematology annual meeting
391,LLY,teva stock price rise be initiate buy rating mizuho security last week reuter report generic drugmaker be divest worth asset address antitrust concern deal buy allergan agn generic drug business
392,LLY,share home depot hd fall even price target be raise telsey advisory group have outperform rating stock
393,LLY,sport luxury car manufacturer ferrari have initial public offer october be initiate overweight give price target morgan stanley ferrari share rise monday be still more close price first day trading
394,LLY,abbott laboratory climb be upgrade buy jeffery give price target
395,LLY,share big pharma firm eli lilly lly lose score upgrade buy deutsche bank follow upgrade overweight barclay last week
396,LLY,follow vance cariaga twitter ibd_vcariaga action camera maker gopro gpro get price target cut monday embattled restaurant chain chipotle grill cmg suffer series downgrade price target cut own analyst also make call biotech startup bluebird bio blue teva pharmaceutical teva new issue ferrari race jpmorgan trim gopro target friday robert baird downgrade gopro neutral outperform slash price target share be hit last week chip supplier ambarella amba give weak guidance due part soft sale action camera gopro share lose stock market today ambarella give cowen co guggenheim security downgrade chipotle former market perform latter neutral maxim group lower price target stock report say friday coli outbreak chipotle have expand state outbreak have sicken dozen customer force closure restaurant chipotle share sank year low early monday recover later session stock close bluebird bio stock price tumble be downgrade neutral buy roth capital have price target chopped nearly half weekend bluebird present disappointing gene therapy datum american society hematology annual meeting teva stock price rise be initiate buy rating mizuho security last week reuter report generic drugmaker be divest worth asset address antitrust concern deal buy allergan agn generic drug business share home depot hd fall even price target be raise telsey advisory group have outperform rating stock sport luxury car manufacturer ferrari have initial public offer october be initiate overweight give price target morgan stanley ferrari share rise monday be still more close price first day trading abbott laboratory climb be upgrade buy jeffery give price target share big pharma firm eli lilly lly lose score upgrade buy deutsche bank follow upgrade overweight barclay last week follow vance cariaga twitter ibd_vcariaga
397,LLY,goldman sachs analyst richter launch coverage group cap biotech stock wednesday rating sector neutral flagging stock worthy investor attention here be top pick bluebird bio blue richter give young biotech buy rating price target whopping premium tuesday close price bluebird stock suffer setback earlier month gene therapy treatment lentiglobin miss investor sky high hope beta thalassemia sickle cell disease setback just make more attractive entry point richter bluebird be also develop lenti gene therapy rare fatal neurological disease childhood cerebral ccald interim pivotal datum expect richter note report beta thalassemia ccald appear somewhat price peak sale respectively sickle cell disease opportunity be upside current level peak sale bluebird stock rise stock market today biomarin pharmaceutical bmrn goldman sachs be transfer coverage rare disease specialist richter fellow analyst terence flynn richter include report price target premium tuesday close analyst note slew catalyst come biomarin include next week fda advisory committee meeting kyndrisa drisapersen treatment duchenne muscular dystrophy company acquire last year approval drug be highly uncertain give lack previously approve drug disease well fact kyndrisa technically fail most recent clinical trial believe event be likely be positive base datum totality include new analysis biomarin ability explain limitation fail phase study controlled phase trial have show benefit unmet need disease precedent prior approval strong lobbying effort patient advocacy group say report biomarin stock rise fraction wednesday kite pharma kite richter assign stock upside give price target peg american society hematology ash conference early december kite be schedule present midstage trial datum kte chimeric antigen receptor car cell therapy blood cancer major term catalyst stock focus be kite reproduce prior efficacy safety datum ongoing pivotal study have bring manufacturing house competitive landscape richter write expect kte interim datum second half support regulatory filing year end richter add next year also bring early stage datum several other program glioblastoma malignant brain tumor cervical cancer head neck cancer kite stock rise wednesday incyte incy richter give stock price target upside call best position biotech immuno oncology io company lead drug jakafi be track sale novartis nvs partnership ex expect revenue stream diversification baricitinib lilly lly partnership market entry rheumatoid arthritis ra likely late early richter write incyte share see more inflection point initial datum phase combination study ido bristol myer squibb bmy pd astrazeneca azn pd roche rhhby pd likely first half asco jun decision advance ido combination pivotal testing small cell lung cancer peak sale base datum become available house incyte collaborator ido be enzyme inhibit growth tumor incyte stock rise wednesday follow amy reeve twitter ibd_areeve facebook
398,LLY,analysis october sale im health im show sanofi sny be continue gain market share biogen biib multiple sclerosis accord rbc capital market biogen sell worth drug tecfidera october week analyst michael yee note be september
399,LLY,biotechs still be generally favor group have be firm recent week hold own ibd industry group ranking even large cap name biogen biib celgene celg unite therapeutic uthr have come selling pressure be still plenty top rate name group show relative strength amgen amgn
400,LLY,european drug giant sanofi sny nordisk nvo see share fall thursday issue weak guidance face increasingly competitive diabetes market sanofi report earning euro cent share year earlier quarter cent analyst consensus accord thomson reuter sale grow
401,LLY,big pharma eli lilly lly beat earning expectation raise ep guidance early thursday company ceo defend industry drug pricing lilly revenue be more mixed bag firm continue struggle foreign exchange headwind stock be flat lilly lly make cent share exclude time item
402,LLY,big pharma eli lilly lly biotech partner incyte incy say wednesday rheumatoid arthritis drug outperformed abbvie abbv market lead humira clinical trial send stock higher
403,LLY,study primary endpoint drug baricitinib be simply do better placebo measure acr test signify least improvement symptom drug also outperformed humira arc disease activity score test week treatment week beat humira measure joint damage lilly incyte do not give exact number say detailed datum come future medical meeting publication
404,LLY,be fourth successful late stage clinical trial drug be janus kinase jak inhibitor class include incyte already market cancer drug jakafi well pfizer pfe rheumatoid arthritis drug xeljanz evercore isi analyst mark schoenebaum note history xeljanz provide reason caution
405,LLY,efficacy result be positive baricitinib think efficacy result be consistent datum pfizer jak inhibitor xeljanz high unapproved dose mg twice daily thus largely expect xeljanz mg twice daily be not approve due question risk benefit profile dose safety trial press release report serious adverse event baricitinib be similar placebo lower humira schoenebaum write email client therefore interested detailed efficacy datum be particularly interested detailed safety datum trial also long term safety believe be major driver uptake chronic therapy ra
406,LLY,abbvie humira be world best selling drug pull last year xeljanz launch have yet crack mark even have advantage be pill humira have be inject
407,LLY,take together believe datum support superiority label claim eu support upside street peak sale estimate incyte earn estimate cost free royalty sale write nomura analyst ian somaiya research note
408,LLY,incyte stock be more late morning trading stock market today lilly stock initially rise late morning be flat abbvie be also flat
409,LLY,follow amy reeve twitter ibd_areeve facebook big pharma eli lilly lly biotech partner incyte incy say wednesday rheumatoid arthritis drug outperformed abbvie abbv market lead humira clinical trial send stock higher study primary endpoint drug baricitinib be simply do better placebo measure acr test signify least improvement symptom drug also outperformed humira arc disease activity score test week treatment week beat humira measure joint damage lilly incyte do not give exact number say detailed datum come future medical meeting publication be fourth successful late stage clinical trial drug be janus kinase jak inhibitor class include incyte already market cancer drug jakafi well pfizer pfe rheumatoid arthritis drug xeljanz evercore isi analyst mark schoenebaum note history xeljanz provide reason caution efficacy result be positive baricitinib think efficacy result be consistent datum pfizer jak inhibitor xeljanz high unapproved dose mg twice daily thus largely expect xeljanz mg twice daily be not approve due question risk benefit profile dose safety trial press release report serious adverse event baricitinib be similar placebo lower humira schoenebaum write email client therefore interested detailed efficacy datum be particularly interested detailed safety datum trial also long term safety believe be major driver uptake chronic therapy ra abbvie humira be world best selling drug pull last year xeljanz launch have yet crack mark even have advantage be pill humira have be inject take together believe datum support superiority label claim eu support upside street peak sale estimate incyte earn estimate cost free royalty sale write nomura analyst ian somaiya research note incyte stock be more late morning trading stock market today lilly stock initially rise late morning be flat abbvie be also flat follow amy reeve twitter ibd_areeve facebook
410,LLY,regeneron pharmaceutical regn pop stock market today share be hit resistance key level biotech now face less competition cholesterol drug eli lilly lly be discontinue development heart disease treatment rbc capital market note be big benefit regeneron larger peer amgen amgn regeneron gap
411,LLY,best mutual fund october performance report
412,LLY,neuberger berman mid cap growth fund be look regain top notch form display earlier year make china sell drag overall market
413,LLY,fund run ken turek nearly year be top midcap growth peer past month end oct gain accord morningstar inc
414,LLY,mutual fund slide past month include august september broad market tumble
415,LLY,longer term neuberger berman mid cap growth be top perform mutual fund have make lot money investor
416,LLY,past year fund average annual gain beat direct rival
417,LLY,many rival get boost october rally ibd office chicago
418,LLY,ibd lot mutual fund portfolio endure challenge third quarter october stock market rally bring relief culprit seem be china correction federal reserve delay long promise interest rate hike political bash drugmaker do square account
419,LLY,turek think hit head macro standpoint first point be spot issue china devaluation cause lot uncertainty global growth impact emerge market
420,LLY,put lot question table especially export
421,LLY,fed punting be not well take marketplace
422,LLY,secular standpoint health care affected quite bit start hillary clinton critical chatter drug pricing be excessive then be pile other pundit politician pricing criticism be not new thing be be so too pass
423,LLY,ibd trim health stock due beating segment be take right
424,LLY,turek weren so concern health care service area hospital trim be couple area therapeutic biotech
425,LLY,have success area so part trimming be profit take part be due uncertainty pricing risk industry create don know play so more less board trim lot position
426,LLY,ibd therapeutic mean type stock
427,LLY,turek specialty pharmaceutical biotech do not include bristol myer squibbs bmy world re too big aren lot regular drugmaker midcap space re too big re interested smaller version eli lilly lly merck mrk bristol myer
428,LLY,smaller company focus be specialize area health care
429,LLY,ibd innovator right
430,LLY,turek yes look re tech health care consumer discretionary
431,LLY,company be do something unique company have competitive advantage moat so much better advantage be something new drug software product consumer discretionary be company be innovative armour ua come new product consistently expand rapidly well couple year only make apparel now re come footwear
432,LLY,ibd sector be increase weight
433,LLY,turek october not much re watch re interested do be tech be quite honest health care price have come so much maybe overdo price have start look pretty cheap past week
434,LLY,so perhaps future ll be point interest area increase quite bit
435,LLY,ll pass ll get back other base fundamental company be do something new innovative deserve be paid
436,LLY,ibd do still palo alto network panw recent pullback
437,LLY,turek still guy be best breed far create next generation firewall security opposed single point product provider
438,LLY,don think anything have change still high degree need security spending kind enterprise government unit well not necessarily go abate
439,LLY,competition be vigorous palo alto have do good job be innovative design offer suite product forestall hacking
440,LLY,ibd describe attractive innovation ultimate software group ulti
441,LLY,turek ultimate be human capital management company niche be marketplace large company company employee be sweet spot long time
442,LLY,offer cloud base solution so get continuous update upgrade suite product make cost ownership affordable especially midsize company don necessarily have expertise house
443,LLY,ve do past year be move market company employee re start high end re have good success
444,LLY,go add top line growth have high retention rate remember correctly
445,LLY,ibd innovation technology avgo interest most right now
446,LLY,turek be fabless semiconductor company outsource manufacturing taiwan semiconductor manufacturing tsm other
447,LLY,big thing be call fbar stand film bulk acoustic resonator fbar be important amount datum signal expansion number wireless phone cause noise fbar noise prevent drop call
448,LLY,technology wireless get more complicate more fbar be need phone
449,LLY,even win last forever so ve buy company diversify business stream
450,LLY,ibd make hardware software provider cdw cdw earning share grow past stanzas
451,LLY,turek cdw be lead distributor thing information related value add be customer many be small midsize don have lot house expertise rely cdw solve problem do partner customer general sale rep sale engineer be expert field wi fi rout
452,LLY,ibd economy be improve car sale be rise do consumer need car part repair older car appeal reilly automotive orly
453,LLY,turek average age car fleet hasn change much recent year even new car sale have rise
454,LLY,transform company be used sell just do yourselfer company do be start sell part professional do channel ve have lot success re not necessarily selling dealer do re selling mom pop car repair shop
455,LLY,ibd be signet jeweler sig innovation
456,LLY,turek get interested buy primary competitor zale signet be better operator so opportunity be signet overlay management ability zale improve top bottom line zale time
457,LLY,ve own year have start have success area unlock value zale be important decision invest
458,LLY,most recently quarter signet plan biggest new product introduction ever diamond ring call ever high quality diamond ring set roll store unusual hope be big product
459,LLY,ibd ve increase stake norwegian cruise line nclh recent disclosure do more other cruiseline
460,LLY,turek attract slightly higher end customer be less sensitive price increase economic shift well
461,LLY,ncl have high yield ship haven add capacity same pace competitor so re easier fill cruise knock wood re accident free help reputation
462,LLY,so recently ve like pricing power better offer royal caribbean rcl low oil price have be tailwind face new opportunity re eager see happen cuba now china be open cruiser aid ncl industry
463,LLY,ibd have boost stake alaska air group alk rather other airline
464,LLY,turek guy be really good operator start west coast airline now re go midcontinental have really good financial good return equity good free cash flow good customer satisfaction level re grow low double digit next couple year joy listen talk business re have fun
465,LLY,ibd do start stake tyler technology tyl year
466,LLY,turek start june july think come something analyst have talk re leader provide financial erp enterprise resource plan software local state government
467,LLY,lot government be technology compare private enterprise so need modernize lot system
468,LLY,tyler be leader criminal justice area have branch other area appraisal taxe public safety vital record government be get move legacy paper base record cloud base record make record easier manage make thing easier consumer public record
469,LLY,wouldn think great market be even headwind lack financing
470,LLY,ibd have be edge stake acuity brand ayi maker light product
471,LLY,turek be play energy efficiency nonresidential area not wholly dependent new construction lot be retrofitting replace lot old fluorescent light led save energy money owner business best mutual fund october performance neuberger berman mid cap growth fund be look regain top notch form display earlier year make china sell drag overall market fund run ken turek nearly year be top midcap growth peer past month end oct gain accord morningstar inc mutual fund slide past month include august september broad market tumble longer term neuberger berman mid cap growth be top perform mutual fund have make lot money investor past year fund average annual gain beat direct rival many rival get boost october rally ibd office chicago ibd lot mutual fund portfolio endure challenge third quarter october stock market rally bring relief culprit seem be china correction federal reserve delay long promise interest rate hike political bash drugmaker do square account turek think hit head macro standpoint first point be spot issue china devaluation cause lot uncertainty global growth impact emerge market put lot question table especially export fed punting be not well take marketplace secular standpoint health care affected quite bit start hillary clinton critical chatter drug pricing be excessive then be pile other pundit politician pricing criticism be not new thing be be so too pass ibd trim health stock due beating segment be take right turek weren so concern health care service area hospital trim be couple area therapeutic biotech have success area so part trimming be profit take part be due uncertainty pricing risk industry create don know play so more less board trim lot position ibd therapeutic mean type stock turek specialty pharmaceutical biotech do not include bristol myer squibbs bmy world re too big aren lot regular drugmaker midcap space re too big re interested smaller version eli lilly lly merck mrk bristol myer smaller company focus be specialize area health care ibd innovator right turek yes look re tech health care consumer discretionary company be do something unique company have competitive advantage moat so much better advantage be something new drug software product consumer discretionary be company be innovative armour ua come new product consistently expand rapidly well couple year only make apparel now re come footwear ibd sector be increase weight turek october not much re watch re interested do be tech be quite honest health care price have come so much maybe overdo price have start look pretty cheap past week so perhaps future ll be point interest area increase quite bit ll pass ll get back other base fundamental company be do something new innovative deserve be paid ibd do still palo alto network panw recent pullback turek still guy be best breed far create next generation firewall security opposed single point product provider don think anything have change still high degree need security spending kind enterprise government unit well not necessarily go abate competition be vigorous palo alto have do good job be innovative design offer suite product forestall hacking ibd describe attractive innovation ultimate software group ulti turek ultimate be human capital management company niche be marketplace large company company employee be sweet spot long time offer cloud base solution so get continuous update upgrade suite product make cost ownership affordable especially midsize company don necessarily have expertise house ve do past year be move market company employee re start high end re have good success go add top line growth have high retention rate remember correctly ibd innovation technology avgo interest most right now turek be fabless semiconductor company outsource manufacturing taiwan semiconductor manufacturing tsm other big thing be call fbar stand film bulk acoustic resonator fbar be important amount datum signal expansion number wireless phone cause noise fbar noise prevent drop call technology wireless get more complicate more fbar be need phone even win last forever so ve buy company diversify business stream ibd make hardware software provider cdw cdw earning share grow past stanzas turek cdw be lead distributor thing information related value add be customer many be small midsize don have lot house expertise rely cdw solve problem do partner customer general sale rep sale engineer be expert field wi fi rout ibd economy be improve car sale be rise do consumer need car part repair older car appeal reilly automotive orly turek average age car fleet hasn change much recent year even new car sale have rise transform company be used sell just do yourselfer company do be start sell part professional do channel ve have lot success re not necessarily selling dealer do re selling mom pop car repair shop ibd be signet jeweler sig innovation turek get interested buy primary competitor zale signet be better operator so opportunity be signet overlay management ability zale improve top bottom line zale time ve own year have start have success area unlock value zale be important decision invest most recently quarter signet plan biggest new product introduction ever diamond ring call ever high quality diamond ring set roll store unusual hope be big product ibd ve increase stake norwegian cruise line nclh recent disclosure do more other cruiseline turek attract slightly higher end customer be less sensitive price increase economic shift well ncl have high yield ship haven add capacity same pace competitor so re easier fill cruise knock wood re accident free help reputation so recently ve like pricing power better offer royal caribbean rcl low oil price have be tailwind face new opportunity re eager see happen cuba now china be open cruiser aid ncl industry ibd have boost stake alaska air group alk rather other airline turek guy be really good operator start west coast airline now re go midcontinental have really good financial good return equity good free cash flow good customer satisfaction level re grow low double digit next couple year joy listen talk business re have fun ibd do start stake tyler technology tyl year turek start june july think come something analyst have talk re leader provide financial erp enterprise resource plan software local state government lot government be technology compare private enterprise so need modernize lot system tyler be leader criminal justice area have branch other area appraisal taxe public safety vital record government be get move legacy paper base record cloud base record make record easier manage make thing easier consumer public record wouldn think great market be even headwind lack financing ibd have be edge stake acuity brand ayi maker light product turek be play energy efficiency nonresidential area not wholly dependent new construction lot be retrofitting replace lot old fluorescent light led save energy money owner business
472,LLY,share big pharma eli lilly lly rise friday credit suisse upgrade rating company largely strength diabetes franchise analyst vamil divan lift rating lilly stock outperform neutral raise price target late thursday divan highlighted recent empa reg outcome trial establish
473,LLY,big pharma eli lilly say monday stopping development cholesterol drug evacetrapib review phase trial datum show wasn have much effect eli lilly lly have be conduct giant study cardiovascular effect evacetrapib isn due completion next year independent datum monitoring committee however review
474,LLY,stock hold mild gain quiet columbus day trade ahead busy week earning dow jone industrial average lead gain nasdaq climb finished volume be quiet board accord preliminary datum winner edge past loser nyse decliner outpaced advancer nearly margin nasdaq
475,LLY,airline travel booker video game maker lead upside stock market today energy stock lag crude oil price fall barrel skywest skyw soar clear flat base buy point fast trade
476,LLY,ibd stock advanced decline hawaiian extend gain fourth straight session rise new high share be extend past cup handle entry analyst expect carrier grow ep revenue dip report oct close
477,LLY,other ibd stock volume include regeneron pharmaceutical regn gap rise nearly regain day move average overall biotech slide regeneron develop cholesterol treatment praluent sanofi sny have get boost news eli lilly lly end late stage trial experimental cholesterol drug lilly share sank
478,LLY,universal insurance uve advanced trigger week hold rule rally more intraday cup handle buy point clear
479,LLY,twitter twtr fall brisk trade report real time messaging platform plan announce companywide layoff week last monday twitter officially name interim ceo jack dorsey chief
480,LLY,other internet player facebook fb alphabet googl add facebook say testing new app let user shop leave social network app
481,LLY,earning watch tuesday include bank ozark ozrk blackhawk network hawk intel intc johnson johnson jnj jpmorgan chase jpm
482,LLY,economic datum tap tuesday include treasury september budget report small business optimism index september national federation independent business fed james bullard be also schedule speak
483,LLY,follow nancy gondo twitter ibd_ngondo stock hold mild gain quiet columbus day trade ahead busy week earning dow jone industrial average lead gain nasdaq climb finished volume be quiet board accord preliminary datum winner edge past loser nyse decliner outpaced advancer nearly margin nasdaq airline travel booker video game maker lead upside stock market today energy stock lag crude oil price fall barrel skywest skyw soar clear flat base buy point fast trade ibd stock advanced decline hawaiian extend gain fourth straight session rise new high share be extend past cup handle entry analyst expect carrier grow ep revenue dip report oct close other ibd stock volume include regeneron pharmaceutical regn gap rise nearly regain day move average overall biotech slide regeneron develop cholesterol treatment praluent sanofi sny have get boost news eli lilly lly end late stage trial experimental cholesterol drug lilly share sank universal insurance uve advanced trigger week hold rule rally more intraday cup handle buy point clear twitter twtr fall brisk trade report real time messaging platform plan announce companywide layoff week last monday twitter officially name interim ceo jack dorsey chief other internet player facebook fb alphabet googl add facebook say testing new app let user shop leave social network app earning watch tuesday include bank ozark ozrk blackhawk network hawk intel intc johnson johnson jnj jpmorgan chase jpm economic datum tap tuesday include treasury september budget report small business optimism index september national federation independent business fed james bullard be also schedule speak follow nancy gondo twitter ibd_ngondo
484,LLY,big pharmas merck mrk bristol myer squibb bmy release new datum hot new immunotherapy cancer drug friday afternoon result send stock opposite direction bristol stock drop release late breaker abstract study drug opdivo pd inhibitor american society clinical oncology asco meeting open
485,LLY,small biotech year old new issue aldr soar more new high friday present positive clinical trial datum migraine drug candidate present challenge such larger player amgen amgn eli lilly lly teva pharmaceutical teva say single intravenous injection drug candidate
486,LLY,drugmaker stock be move monday american society clinical oncology asco meeting continue produce key datum cancer trial top mover be immunogen imgn stock soar much month high base saturday report phase trial mirvetuximab soravtansine imgn ovarian cancer
487,LLY,update tuesday fda advisory panel vote onglyza have acceptable risk profile say label be update heart failure risk astrazeneca stock be more afternoon trading tuesday new fda document release friday say patient popular astrazeneca azn diabetes drug onglyza show increase risk
488,LLY,take do small fry make dent market rule industry big shot software service provider veeva system veev have do make market debut october take share larger rival be used older technology veeva founder specialize provide cloud base software
489,LLY,headach be most universal medical problem merely nuisance most person be much more many sufferer
490,LLY,woman man suffer migraine severe form headache often accompany nausea sometimes visual hallucination many sufferer get only month population suffer chronic migraine pain virtually day
491,LLY,traditionally patient dealt migraine same way everybody deal headach counter sometimes prescription pharmaceutical aim pain general new class biotech medicine set be showcased american headache society meeting washington june bring sea change treatment big opportunity investor
492,LLY,drug giant eli lilly lly teva pharmaceutical industry teva big biotech amgen amgn hot startup aldr be develop calcitonin gene related peptide cgrp monoclonal antibody fight migraine cgrp be produce neuron modulate transmission pain dilation blood vessel decade merck mrk target treat migraine traditional small molecule drug development
493,LLY,marcelo bigal now head teva migraine program work original merck project
494,LLY,never fail efficacy bigal tell ibd small molecule be develop target succeed problem be be cause liver toxicity decide instead develop small chemical antagonize receptor cgrp develop antibody target
495,LLY,antibody be much more specific target bigal say be not degraded liver so wouldn raise liver toxicity problem long half life body meant weren so helpful immediate attack migraine be used patient get frequent migraine
496,LLY,other company watch fail merck program get same idea early result start come industry start take notice
497,LLY,labrys biologic bigal moved develop antibody be acquire teva last june upfront milestone payment same time have be trading flat early ipo start take have more quadruple price trade
498,LLY,interest migraine treatment come partly potential size market not big something lung cancer migraine drug sale reach year advisory firm evercore isi estimate midstage datum have be report company involved have look good
499,LLY,most company be testing product category patient chronic migraine defined occur least day month episodic migraine headach be less frequent still monthly event
500,LLY,ceo randy schatzman tell ibd distinction be basically artificial be create allergan win approval wrinkle drug botox prevent migraine win approval only chronic migraine actavis act have acquire allergan botox
501,LLY,botox regimen be effective not faint hearted involve shot head month generally require full cycle therapy cgrp antibody be also inject make less pincushion patient ald be deliver single iv infusion month teva tev amgen amg subcutaneous monthly injection lilly ly biweekly subcutaneous injection
502,LLY,company have report phase result episodic migraine teva report episodic datum month meeting report chronic migraine result last month
503,LLY,company methodology differ slightly make comparison inexact result have be broadly similar reduce headache day month
504,LLY,attract attention wall street be hyper responder be headache free third month treatment amgen do not use metric lilly drug achieve patient episodic trial do teva chronic migraine trial drug eliminate headach patient third month have suffer headach start treatment
505,LLY,personally think really hyper responder drive commercial opportunity write evercore analyst umer raffat research note
506,LLY,opinion do not seem have coalesce clear front runner be difference drug addition dose regimen already mentioned amgen amg target cgrp receptor other product target ligand substance bound protein other structure serve biological purpose
507,LLY,little early say difference modality be go be schatzman say receptor be used multiple ligand start program worry bring biology didn want modulate so steer ligand stay away receptor
508,LLY,teva bigal also note compare clinical trial investor realize teva subject continue take usual medication top cgrp antibody other trial do not
509,LLY,want test medication condition condition be ordinarily see doctor not idealistic view condition say
510,LLY,lilly meanwhile isn even conduct phase trial chronic migraine do have ongoing episodic trial aaron schacht global brand development leader lilly pain business say lilly schatzman doesn think real biological difference chronic episodic migraine however order approval company run phase trial patient group
511,LLY,lilly be also unique also testing cgrp antibody outside migraine start clinical trial cluster headach much less common excruciatingly painful type headache occur side head usually eye schacht say fda even give lilly orphan drug designation use shield competition approval lilly also run study arthritic knee pain
512,LLY,believe cgrp be involved variety different pain state schacht tell ibd be lilly experience anxiety drug cymbalta be able search concept broad pain indication be something re quite interested regard molecule headach be most universal medical problem merely nuisance most person be much more many sufferer woman man suffer migraine severe form headache often accompany nausea sometimes visual hallucination many sufferer get only month population suffer chronic migraine pain virtually day traditionally patient dealt migraine same way everybody deal headach counter sometimes prescription pharmaceutical aim pain general new class biotech medicine set be showcased american headache society meeting washington june bring sea change treatment big opportunity investor drug giant eli lilly lly teva pharmaceutical industry teva big biotech amgen amgn hot startup aldr be develop calcitonin gene related peptide cgrp monoclonal antibody fight migraine cgrp be produce neuron modulate transmission pain dilation blood vessel decade merck mrk target treat migraine traditional small molecule drug development marcelo bigal now head teva migraine program work original merck project never fail efficacy bigal tell ibd small molecule be develop target succeed problem be be cause liver toxicity decide instead develop small chemical antagonize receptor cgrp develop antibody target antibody be much more specific target bigal say be not degraded liver so wouldn raise liver toxicity problem long half life body meant weren so helpful immediate attack migraine be used patient get frequent migraine other company watch fail merck program get same idea early result start come industry start take notice labrys biologic bigal moved develop antibody be acquire teva last june upfront milestone payment same time have be trading flat early ipo start take have more quadruple price trade interest migraine treatment come partly potential size market not big something lung cancer migraine drug sale reach year advisory firm evercore isi estimate midstage datum have be report company involved have look good most company be testing product category patient chronic migraine defined occur least day month episodic migraine headach be less frequent still monthly event ceo randy schatzman tell ibd distinction be basically artificial be create allergan win approval wrinkle drug botox prevent migraine win approval only chronic migraine actavis act have acquire allergan botox botox regimen be effective not faint hearted involve shot head month generally require full cycle therapy cgrp antibody be also inject make less pincushion patient ald be deliver single iv infusion month teva tev amgen amg subcutaneous monthly injection lilly ly biweekly subcutaneous injection company have report phase result episodic migraine teva report episodic datum month meeting report chronic migraine result last month company methodology differ slightly make comparison inexact result have be broadly similar reduce headache day month attract attention wall street be hyper responder be headache free third month treatment amgen do not use metric lilly drug achieve patient episodic trial do teva chronic migraine trial drug eliminate headach patient third month have suffer headach start treatment personally think really hyper responder drive commercial opportunity write evercore analyst umer raffat research note opinion do not seem have coalesce clear front runner be difference drug addition dose regimen already mentioned amgen amg target cgrp receptor other product target ligand substance bound protein other structure serve biological purpose little early say difference modality be go be schatzman say receptor be used multiple ligand start program worry bring biology didn want modulate so steer ligand stay away receptor teva bigal also note compare clinical trial investor realize teva subject continue take usual medication top cgrp antibody other trial do not want test medication condition condition be ordinarily see doctor not idealistic view condition say lilly meanwhile isn even conduct phase trial chronic migraine do have ongoing episodic trial aaron schacht global brand development leader lilly pain business say lilly schatzman doesn think real biological difference chronic episodic migraine however order approval company run phase trial patient group lilly be also unique also testing cgrp antibody outside migraine start clinical trial cluster headach much less common excruciatingly painful type headache occur side head usually eye schacht say fda even give lilly orphan drug designation use shield competition approval lilly also run study arthritic knee pain believe cgrp be involved variety different pain state schacht tell ibd be lilly experience anxiety drug cymbalta be able search concept broad pain indication be something re quite interested regard molecule
513,LLY,big pharma astrazeneca azn big biotech amgen amgn be nearly heavy trading tuesday amgen say late friday be withdraw partnership develop immunology drug patient kill amgen say suicidal ideation behavior patient clinical trial brodalumab be be test
514,LLY,year biggest cancer meeting bring raft update hot oncology market send stock move wall street sort winner loser biggest upside surprise american society clinical oncology meeting chicago end tuesday probably come immunogen imgn beleaguered biotech come back life thank
515,LLY,aaron levie be always full energy always go
516,LLY,levie left college early create box box enterprise class datum management collaboration platform levie say be
517,LLY,box chairman chief executive levie lead company initial public offer jan raise
518,LLY,levie recently speak ibd company industry
519,LLY,ibd earning conference call analyst say box be create new category so
520,LLY,levie technology move premise system cloud whole bunch change happen
521,LLY,salesforce com crm be able create new sale force automation crm platform cloud workday wday be able disrupt human resource human capital management segment cloud
522,LLY,re go be investment content management software storage technology search appliance thing enterprise need be able store manage datum basically moved cloud platform
523,LLY,be create new category re not just manage content re not just help search secure content re help collaborate well so enterprise content collaboration market be go
524,LLY,ibd be market size opportunity ve hear widely different estimate
525,LLY,levie reason be different calculation be lot depend much technology be replace subsume time platform certainly be disruptive content management industry re disruptive premise storage technology industry combine solution be ten billion dollar opportunity re go
526,LLY,ibd say be dozen company field box remain leader
527,LLY,levie ve be compete landscape year chief information officer set standardize platform critical corporate information be far fewer choice have enterprise really go amazon amzn file sharing tool really go dropbox really go google googl drive
528,LLY,so largely come microsoft msft
529,LLY,think research firm forrester gartner other confirm re really leader market focus enterprise security scalability content management
530,LLY,do go microsoft actually third time even situation customer be still likely buy something microsoft office office productivity suite be used box content management security information
531,LLY,so even do go head head often still see customer buy solution microsoft think differentiation be very clear allow command premium price point premium position market
532,LLY,ibd don also have partnership microsoft
533,LLY,levie recently announce partnership microsoft inaugural member cloud storage partner program be user office box allow seamlessly take datum box interact office product so mentioned even account microsoft customer be still likely buy microsoft solution not sum game have use only product synergy integration product increase time
534,LLY,ibd so be just much partner microsoft competitor
535,LLY,levie think so think be trend be go ll see more partnership integration time microsoft
536,LLY,ibd most user be used free version box be freemium business model still best way go
537,LLY,levie definitely use free user traction way get enterprise once box get bring enterprise then work company sell more secure advanced version product
538,LLY,so look general electric ge eli lilly lly organization first start user free product then be able sell enterprise wide solution more more time mix shift be go go larger enterprise investment sale force key partnership microsoft other be very important
539,LLY,ibd be stickiness product once start tend stay
540,LLY,levie have very high retention rate customer expand investment box time be high degree stickiness once adopt solution have more more critical file platform mean drive more productivity deliver new more use case business lead very high retention rate longer term demand service customer
541,LLY,ibd do find satisfying ve achieve
542,LLY,levie definitely love fact re stage have meaningful conversation world largest enterprise help transform be used datum be deliver organization have work year build differentiate platform now have world largest health care company medium company energy company other be used product really transform re work
543,LLY,have road map think reflect world be go help continue offer premium service aaron levie be always full energy always go levie left college early create box box enterprise class datum management collaboration platform levie say be box chairman chief executive levie lead company initial public offer jan raise levie recently speak ibd company industry ibd earning conference call analyst say box be create new category so levie technology move premise system cloud whole bunch change happen salesforce com crm be able create new sale force automation crm platform cloud workday wday be able disrupt human resource human capital management segment cloud re go be investment content management software storage technology search appliance thing enterprise need be able store manage datum basically moved cloud platform be create new category re not just manage content re not just help search secure content re help collaborate well so enterprise content collaboration market be go ibd be market size opportunity ve hear widely different estimate levie reason be different calculation be lot depend much technology be replace subsume time platform certainly be disruptive content management industry re disruptive premise storage technology industry combine solution be ten billion dollar opportunity re go ibd say be dozen company field box remain leader levie ve be compete landscape year chief information officer set standardize platform critical corporate information be far fewer choice have enterprise really go amazon amzn file sharing tool really go dropbox really go google googl drive so largely come microsoft msft think research firm forrester gartner other confirm re really leader market focus enterprise security scalability content management do go microsoft actually third time even situation customer be still likely buy something microsoft office office productivity suite be used box content management security information so even do go head head often still see customer buy solution microsoft think differentiation be very clear allow command premium price point premium position market ibd don also have partnership microsoft levie recently announce partnership microsoft inaugural member cloud storage partner program be user office box allow seamlessly take datum box interact office product so mentioned even account microsoft customer be still likely buy microsoft solution not sum game have use only product synergy integration product increase time ibd so be just much partner microsoft competitor levie think so think be trend be go ll see more partnership integration time microsoft ibd most user be used free version box be freemium business model still best way go levie definitely use free user traction way get enterprise once box get bring enterprise then work company sell more secure advanced version product so look general electric ge eli lilly lly organization first start user free product then be able sell enterprise wide solution more more time mix shift be go go larger enterprise investment sale force key partnership microsoft other be very important ibd be stickiness product once start tend stay levie have very high retention rate customer expand investment box time be high degree stickiness once adopt solution have more more critical file platform mean drive more productivity deliver new more use case business lead very high retention rate longer term demand service customer ibd do find satisfying ve achieve levie definitely love fact re stage have meaningful conversation world largest enterprise help transform be used datum be deliver organization have work year build differentiate platform now have world largest health care company medium company energy company other be used product really transform re work have road map think reflect world be go help continue offer premium service
544,LLY,box be go have take punch online storage file sharing service stock have fail perform company much anticipate ipo january late wednesday report first quarterly earning go public box stock be hour trading wednesday company release result fiscal end jan box
545,LLY,big swiss pharma roche rhhby halter development alzheimer disease drug report mediocre result clinical trial breast cancer drug kadcyla friday send stock more early trading stock market today late morning be just fraction
546,LLY,roche say be stopping phase trial gantenerumab patient early stage alzheimer disease futility analysis convince wasn do good press release note be first trial kind such late stage drug development bode ill biogen idec biib eli lilly lly have candidate base similar hypothesis disease modification
547,LLY,fact biogen chief medical officer dougla william announce earlier month biib be move phase specifically mentioned gantenerumab comparable drug
548,LLY,most investor view slight negative biib roche also have show positive early datum dose dependent reduction beta amyloid biib do biib also have statistically significant cognition improvement roche didn yet here early stage patient roche drug appear not work write rbc capital market analyst michael yee research note friday point be difference drug do remove potential competitor
549,LLY,biogen stock drop gate friday late morning be fraction eli lilly drug solanezumab be already phase testing carry low expectation street also be fraction
550,LLY,meanwhile roche biotech partner immunogen imgn report combo drug kadcyla alone combine roche perjeta have perform same roche older drug herceptin combine taxane patient previously untreated metastatic breast cancer be disappointment hope superior result expand kadcyla label currently only indicate drug patient ve fail treatment
551,LLY,success study be widely assume broader label be thesis underlie sale acceleration street estimate price target immunogen be likely come estimate be review well write rbc analyst adnan butt research note
552,LLY,immunogen stock crash late morning trading friday
553,LLY,follow amy reeve twitter ibd_areeve big swiss pharma roche rhhby halter development alzheimer disease drug report mediocre result clinical trial breast cancer drug kadcyla friday send stock more early trading stock market today late morning be just fraction roche say be stopping phase trial gantenerumab patient early stage alzheimer disease futility analysis convince wasn do good press release note be first trial kind such late stage drug development bode ill biogen idec biib eli lilly lly have candidate base similar hypothesis disease modification fact biogen chief medical officer dougla william announce earlier month biib be move phase specifically mentioned gantenerumab comparable drug most investor view slight negative biib roche also have show positive early datum dose dependent reduction beta amyloid biib do biib also have statistically significant cognition improvement roche didn yet here early stage patient roche drug appear not work write rbc capital market analyst michael yee research note friday point be difference drug do remove potential competitor biogen stock drop gate friday late morning be fraction eli lilly drug solanezumab be already phase testing carry low expectation street also be fraction meanwhile roche biotech partner immunogen imgn report combo drug kadcyla alone combine roche perjeta have perform same roche older drug herceptin combine taxane patient previously untreated metastatic breast cancer be disappointment hope superior result expand kadcyla label currently only indicate drug patient ve fail treatment success study be widely assume broader label be thesis underlie sale acceleration street estimate price target immunogen be likely come estimate be review well write rbc analyst adnan butt research note immunogen stock crash late morning trading friday follow amy reeve twitter ibd_areeve
554,LLY,eli lilly lly stock jump year high stock market today morgan stanley upgrade stock overweight underweight afternoon trading lilly stock be analyst david risinger raise expectation potential blockbuster pipeline cholesterol drug evacetrapib alzheimer disease treatment solanezumab only put
555,LLY,buzz company have create manner way deal explosion datum have come result cloud compute smartphone tablet be box be set price long await initial public offer late thursday begin trading nyse friday box box provide cloud base online datum storage
556,LLY,big cap biotech biogen idec say move drug candidate alzheimer disease late stage testing early result offer patient hope treatment send biogen stock
557,LLY,tuesday biofest conference boston biogen biib research development head dougla william say interim analysis patient phase trial biib be jointly develop japan eisai drug firm be good enough push straight phase number win be formally report spring william say statistically significant improvement cognition appear week treatment
558,LLY,aggressively prepare
559,LLY,study not do yet be still patient re do additional dose exploration say william re actually plan very aggressively start phase program base ve see so far
560,LLY,interesting feature result support beta amyloid hypothesis alzheimer disease have long be suspect not definitively prove beta amyloid be toxic form normally benign protein amyloid attack neuron alzheimer sufferer eventually visible plaque make beta amyloid dead neuron form brain however remain unclear reduce plaque reduce symptom
561,LLY,william say see dose dependent reduction beta amyloid first time large trial associate improvement cognition support idea biogen drug modify disease progression other drugmaker have base drug hypothesis fail
562,LLY,probably highest profile flameout be bapineuzumab co develop johnson johnson jnj pfizer pfe elan fail clinical trial eli lilly lly solanezumab do well enough move phase testing most analyst give low chance success
563,LLY,early treatment be key
564,LLY,biogen william say know earlier test key be catch disease early patient biogen study have only mild symptom eli lilly used same approach solanezumab william say biib have mechanism somewhat roche rhhby gantenerumab recently start phase testing mildly ill patient
565,LLY,good alzheimer treatment now market opportunity successful drug be enormous note tuesday rbc capital market analyst michael yee write bull case such drug pull much year
566,LLY,bottom line be think today positive phase alzheimer datum biib prodromal mild patient add mount evidence drug work earlier patient rather historical failure moderate sicker patient drug be first test write so believe be new say renew wave investor enthusiasm alzheimer drug go forward
567,LLY,caution past failure
568,LLY,nonetheless yee note bear still point early stage success follow late stage failure have be see leerink analyst joseph schwartz make same point
569,LLY,expect investor take cautiously optimistic view give failure rate disease modify drug alzheimer disease lack kol key opinion leader consensus protein target be most relevant write big cap biotech biogen idec say move drug candidate alzheimer disease late stage testing early result offer patient hope treatment send biogen stock tuesday biofest conference boston biogen biib research development head dougla william say interim analysis patient phase trial biib be jointly develop japan eisai drug firm be good enough push straight phase number win be formally report spring william say statistically significant improvement cognition appear week treatment aggressively prepare study not do yet be still patient re do additional dose exploration say william re actually plan very aggressively start phase program base ve see so far interesting feature result support beta amyloid hypothesis alzheimer disease have long be suspect not definitively prove beta amyloid be toxic form normally benign protein amyloid attack neuron alzheimer sufferer eventually visible plaque make beta amyloid dead neuron form brain however remain unclear reduce plaque reduce symptom william say see dose dependent reduction beta amyloid first time large trial associate improvement cognition support idea biogen drug modify disease progression other drugmaker have base drug hypothesis fail probably highest profile flameout be bapineuzumab co develop johnson johnson jnj pfizer pfe elan fail clinical trial eli lilly lly solanezumab do well enough move phase testing most analyst give low chance success early treatment be keybiogen william say know earlier test key be catch disease early patient biogen study have only mild symptom eli lilly used same approach solanezumab william say biib have mechanism somewhat roche rhhby gantenerumab recently start phase testing mildly ill patient good alzheimer treatment now market opportunity successful drug be enormous note tuesday rbc capital market analyst michael yee write bull case such drug pull much year bottom line be think today positive phase alzheimer datum biib prodromal mild patient add mount evidence drug work earlier patient rather historical failure moderate sicker patient drug be first test write so believe be new say renew wave investor enthusiasm alzheimer drug go forward caution past yee note bear still point early stage success follow late stage failure have be see leerink analyst joseph schwartz make same point expect investor take cautiously optimistic view give failure rate disease modify drug alzheimer disease lack kol key opinion leader consensus protein target be most relevant write
570,LLY,come develop cut edge real estate big pharma tech firm alexandrium real estate equity ceo joel marcus have refine try true formula start marcus back alexandrium be be real estate investment trust focuse develop science technology campuse top urban cluster adjacent lead academic medical institution order create collaborative environment company activity be center science hub such cambridge mass san francisco bay area san diego new york city platform focus irreplaceable urban innovation center marcus tell ibd re great place recruit talent transportation be good have work play environment add try own operate dominate market irreplaceable market facility be high tech advanced say include kind infrastructure company need do research development take campus location state art facility marry intersection science technology marcus say really be secret success build big namesusing approach alexandrium have develop campuse drugmaker such eli lilly lly novartis nvs pfizer pfe ibd leaderboard stock illumina ilmn genetic testing equipment maker year mark alexandrium anniversary company have have plenty cause celebrate earning have start grow again double digit increase past quarters gain end third quarter earning rise share analyst poll thomson reuter expect earning rise share follow decline prior year see rise increase alexandrium stock price have lift year be fuel growth marcus say alexandrium have several factor work favor re very good economic environment fed have keep interest rate low ve see substantially rise rent urban innovation market say also constrain supply demand re see life science tech sector be highest level ve see year history company marcus add company be see strong internal growth drive high occupancy increase rental rate core market cambridge san francisco new york alexandrium have pipeline project construction be lease negotiation say marcus highest pre lease level alexandrium have have company have pipeline project put play say add pipeline help drive strong demand continue earning next few year marcus used work capital market lawyer founder alexandrium address real estate infrastructure need biotech industry say be unfilled time have first mover advantage almost market real estate development say focus urban innovation campuse else really do healthy outlook rbc capital market analyst michael carroll say competitor be biom realty trust bmr reit focuse provide real estate life science industry other reit also dabble space add location alexandrium campuse urban cluster market differentiate factor carroll say macro environment life science industry look good re start see pharma tenant used own own real estate other location be find re get better result term ability do research collaborate more person industry move core cluster market own other landlord alexandrium have be able create cluster market campuse major market carroll add now tech tenant be find atmosphere re get demand tech tenant too say recent tech project announce september be strategic partnership app developer uber technology low fare ride sharing service have catch taxi alternative project include acquisition key parcel mission bay area san francisco deal uber parcel support rentable square foot new ground facility joint venture be own alexandrium uber let uber expand corporate headquarters san francisco conjunction year lease entire project alexandrium be expect break ground project january finish end mission bay be home campus university california san francisco well alexandrium science technology cluster be recently select house future arena golden state warrior nba marcus say uber venture be very significant have very strong yield shareholder reap benefit great cash flow represent milestone bring more tech company mission bay historically be more life science destination marcus add carroll also call venture uber significant lot demand area mission bay south market soma san francisco market cap alexandrium be smaller company ibd finance property reit industry group largest be simon property group spg market cap group rank performance ibd track medical ethical drug industry group several alexandrium customer reside rank medical biom biotech rank
571,LLY,big french pharma sanofi sny fire ceo wednesday push stock sharply second day row spark slew downgrade wall street sanofi sny board issue short statement say have vote unanimously remove christopher year office chairman serge weinberg take
572,LLY,wall street be scramble assess impact drug stock close tax loophole know double irish propose irish government tuesday issue be different overall lower corporate tax rate ireland have drive controversial tax inversion deal have relocate number company ireland
573,LLY,founding software company veeva system peter gassner be certain thing want technology be cloud base address critical issue specific industry decide focus life science have picked something else oil gas picked thing big industry big industry know be massive need good cloud solution tell ibd turn be good idea veeva veev be most successful cloud base software company not only have revenue be grow double digit also profitable cloud company be usually grow not usually profitable say gassner be veeva ceo know be make product not guess game so have lower sale marketing cost help co founder president matt build life science business siebel system acquire oracle orcl have relationship pharmaceutical company say here better version say brendan barnicle analyst pacific crest security lot veeva business be replace old siebel system build steamveeva have more pharmaceutical biotech customer include more largest drug company worldwide range drug giant such merck mrk novartis nvs eli lilly lly emerge biotech veeva customer be gilead science gild maker hepatitis wonder drug gilead have be buy more product veeva grow expand worldwide gassner say plenty customer veeva keep expand coverage user company selling more add module be drive growth be veeva have high margin barnicle say salesforce com crm don have grab new customer re go same customer selling more gassner have key contact past employer be senior vp technology salesforce com charge build software service saas platform crm software drife revenueveeva core customer relationship management crm software be build salesforce com platform veeva be salesforce com prefer partner pharma biotech gassner say be sale channel salesforce com partner crm software account veeva revenue be expect top year accord research firm gartner crm software revenue worldwide grow double digit moreover vertical industry specific software comprise largest segment enterprise software market total most software be still focuse client server rather cloud internet gassner say re bring client server cloud tremendous opportunity re just early stage veeva revenue fiscal grow fiscal end january revenue second quarter end july rise net income quarter jump cent share company go public october figured ep earlier period amount equivalent cent share veeva stock be more ipo price rise first share dip rebound sharply result be announce aug day company raise forecast full year previously share earning guidance year be up cent cent analyst expect veeva earning come cent gain last year see growth next year accord thomson reuter manage clinical say firm make great progress quarter second product category call veeva vault veeva build own infrastructure vault focus content management process such clinical trial quality management manufacturing sale marketing more new vault customer be add include second top drug company sign vault clinical trial product fastest part business barnicle say vault similar veeva crm software replace siebel vault be replace old content management system used life science barnicle say tracking more dataveeva third newest product line be call network cloud base solution integrate firm crm platform help customer track datum health care customer william blair analyst estimate vault network offering expand veeva market opportunity roughly much upper target be base expansion potential network database other region world china veeva largest market be follow western europe asia especially china japan william blair analyst expect veeva revenue reach end veeva be far only company offer health care specific technology william blair analyst say recent initiation report veeva vast majority offer premise product use isolate single client host model believe legacy vendor lose innovation speed market price battle write chief rival be cegedim global tech service firm focuse health care cegedim crm business be be acquire im health im william blair estimate cegedim seat use premise technology gassner see pending acquisition positive veeva be disruption benefit say
574,LLY,biogen idec biib soar nearly new high friday much anticipate alzheimer disease drug result surpass wall street expectation medical conference france biogen report result phase study patient be divide group placebo group other take different dose biogen drug candidate
575,LLY,israeli drug giant teva pharmaceutical industry teva report successful midstage trial result novel migraine treatment appoint new head business development monday send stock year high teva report result phase study tev calcitonin gene related peptide cgrp monoclonal antibody treat episodic migraine trial meet endpoint
576,LLY,biogen idec wow medical community investor much anticipate alzheimer disease drug result friday send stock new high close
577,LLY,medical conference france biogen biib report result phase study patient be divide group placebo group other take different dose biogen drug candidate aducanumab biib week lowest dose group show significant slow decline cognitive function measure mini mental state examination mmse patient mg kg mg kg dose arm demonstrated impressive slow decline only respectively statistically significant write cowen analyst eric schmidt note friday represent impressive point improvement mmse think street expectation be point improvement cowen raise price target biogen stock many other analyst also raise target be upgrade widely buy rate stock expect launch leerink analyst joseph schwartz raise target estimate biogen penetrate even early stage patient drug pull year worldwide peak way future modele launch enormous sale projection be symptom vast unmet need be drug market be able disease way aducanumab appear other lead candidate pipeline be eli lilly lly solanezumab bring just improvement mmse score pooled datum analyst point however group weren directly comparable patient biogen study tilt earlier stage disease biogen also study amyloid plaque patient brain form alzheimer patient be thought cause symptom report reduction highest dose dose rise so do incidence amyloid related imaging abnormality aria raise safety concern highest dose aria affected patient most serious abnormality be edema aria patient aria show symptom other report headach visual disturbance confusion biogen say symptom be classify mild moderate most be resolve week nonetheless half patient aria drop study evercore isi analyst mark schoenebaum write email client be probably biogen add intermediate mg dose arm study want see thread needle efficacy vs safety just phase trialprobably biggest caveat result however be be phase trial small size patient pool meant arm have only subject so much larger confirmatory study be require prove result regulator satisfaction december biogen announce be skip intermediate testing go straight large phase trial first clue market quality phase result other drug have fail scale testing most concern late december roche rhhby stop phase trial alzheimer candidate gantenerumab due futility talk plan phase trial aducanumab few week earlier biogen head dougla william have describe gantenerumab similar drug nonetheless biogen success seem lift boat friday share lilly roche rise former latter have be aducanumab result further support target amyloid plaque most new drug be do have not be clinically proven work
578,LLY,new research note rbc capital market offer bullish take biogen idec biib experimental drug alzheimer disease predict make big splash upcoming international conference alzheimer parkinson disease conference schedule march nice france attract medical scientific professional globe biogen be expect
579,LLY,world biggest drugmaker issue mixture report friday continue be tough earning season abbvie abbv say profit exclude time item rise year earlier quarter cent beating analyst consensus cent accord thomson reuter sale climb ahead consensus full year profit increase share sale gain abbvie affirm guidance issue earlier month call earning didn set revenue range however conference call analyst ceo richard gonzalez say expect newly launch hepatitis combo viekira pak achieve run rate end year midst abbvie hepatitis battle gilead science gild land exclusive deal payer gonzalez say expect insure patient have access viekira pak rbc capital market analyst michael yee calculate mean year be consensus positive abbv announce generation regimen improve possible single pill booster ribavirin have datum soon plan go phase iii later year be way maintain share alternative gild yee write research note friday still abbvie share fall afternoon trading stock market today stock fall month low intraday eli lilly lly still shadow patent cliff report sale shrank miss consensus nearly earning rise cent share beating street average estimate cent full year profit drop share sale slide lilly also affirm earlier profit guidance share shave revenue guidance be now singing familiar tune earning season lilly blame lower guidance solely reflect recent strengthen dollar compare several other currency however capital iq analyst jeffrey loo be hearten ep guidance stay same point better expect gross margin raise price target say be low point sale see improve growth next few year lilly stock rise afternoon trading follow amy reeve twitter ibd_areeve
580,LLY,drugmaker alk pop year high wednesday company report positive midstage result schizophrenia drug candidate alk be combination olanzapine better know eli lilly lly zyprexa novel product call hope reduce olanzapine common side effect weight gain study find
581,LLY,goldman sachs upgrade eli lilly lly neutral thursday say big pharma have turn corner fall hard patent cliff investment bank downgrade johnson johnson cite increase drug competition believe lly have turn corner improve margin new product launch drive company earning trough
582,LLY,french big pharma sanofi layer year plan drug launch say bring cumulative euro first year sale sanofi stock slip early trading stock market today diabetes outlook be soft
583,LLY,sanofi sny issue update press release ahead ir thematic seminar new medicine seek reassure investor fire ceo follow weak quarterly report last month
584,LLY,firm prepared presentation new drug include alirocumab cholesterol fighter co develop regeneron pharmaceutical regn now go brand name praluent recently approve multiple sclerosis pill lemtrada toujeo currently fda eu review update version bestselling sanofi diabetes drug lantus
585,LLY,related note thursday fda also grant breakthrough therapy designation dupilumab drug develop same regeneron partnership alirocumab treatment atopic dermatitis
586,LLY,leerink analyst seamus fernandez write note early thursday pipeline valuation be nearly twice own estimate still concern diabetes franchise be main issue sanofi report
587,LLY,headline grab estimate product launch guidance sny global diabetes business be flat slightly grow constant exchange rate assume substantial conversion patient lantus toujeo europe be assume diabetes sale growth same period write
588,LLY,fernandez add wasn sell widespread toujeo conversion especially light more competitive landscape similar product come online nordisk nvo eli lilly lly
589,LLY,positive side write approval praluent be virtually assured merck mrk recent long term study prove lower ldl cholesterol really do lower death rate heart disease
590,LLY,follow amy reeve twitter ibd_areeve french big pharma sanofi layer year plan drug launch say bring cumulative euro first year sale sanofi stock slip early trading stock market today diabetes outlook be soft sanofi sny issue update press release ahead ir thematic seminar new medicine seek reassure investor fire ceo follow weak quarterly report last month firm prepared presentation new drug include alirocumab cholesterol fighter co develop regeneron pharmaceutical regn now go brand name praluent recently approve multiple sclerosis pill lemtrada toujeo currently fda eu review update version bestselling sanofi diabetes drug lantus related note thursday fda also grant breakthrough therapy designation dupilumab drug develop same regeneron partnership alirocumab treatment atopic dermatitis leerink analyst seamus fernandez write note early thursday pipeline valuation be nearly twice own estimate still concern diabetes franchise be main issue sanofi report headline grab estimate product launch guidance sny global diabetes business be flat slightly grow constant exchange rate assume substantial conversion patient lantus toujeo europe be assume diabetes sale growth same period write fernandez add wasn sell widespread toujeo conversion especially light more competitive landscape similar product come online nordisk nvo eli lilly lly positive side write approval praluent be virtually assured merck mrk recent long term study prove lower ldl cholesterol really do lower death rate heart disease follow amy reeve twitter ibd_areeve
591,LLY,stock sanofi fall tuesday french drugmaker warn sale diabetes product face more challenge environment due mount competition
592,LLY,warning come tension top company monday sanofi sny ceo chris ask do not receive confirmation support chairman serge weinberg board reuter report accord report director say do not communicate well enough action have anger french labor union
593,LLY,sanofi stock be more month low afternoon trading stock market today
594,LLY,diabetes business account sanofi revenue say sanofi cut price diabetes drug last quarter get drug benefit manager reimbursement list face competition denmark nordisk nvo accord report thestreet
595,LLY,threat price war stock be afternoon trading tuesday merck mrk eli lilly lly maker diabetes drug be respectively
596,LLY,merck report third quarter earning open monday revenue fall miss consensus estimate poll thomson reuter earning share item cent beat view cent
597,LLY,sanofi third quarter report revenue euro report net income euro sale diabetes drug rise
598,LLY,have recently see more challenge diabetes price environment impact diabetes sale growth platform globally be expect continue show solid growth say company earning release
599,LLY,follow brian deagon twitter ibd_bdeagon stock sanofi fall tuesday french drugmaker warn sale diabetes product face more challenge environment due mount competition warning come tension top company monday sanofi sny ceo chris ask do not receive confirmation support chairman serge weinberg board reuter report accord report director say do not communicate well enough action have anger french labor union sanofi stock be more month low afternoon trading stock market today diabetes business account sanofi revenue say sanofi cut price diabetes drug last quarter get drug benefit manager reimbursement list face competition denmark nordisk nvo accord report thestreet threat price war stock be afternoon trading tuesday merck mrk eli lilly lly maker diabetes drug be respectively merck report third quarter earning open monday revenue fall miss consensus estimate poll thomson reuter earning share item cent beat view cent sanofi third quarter report revenue euro report net income euro sale diabetes drug rise have recently see more challenge diabetes price environment impact diabetes sale growth platform globally be expect continue show solid growth say company earning release follow brian deagon twitter ibd_bdeagon
600,LLY,market still look bearish top rate medical stock include biogen idec alexion have remain strong demand new treatment breakthrough overcome investor skittishness elsewhere
601,LLY,latest ibd list include thrive medical stock report quarterly result week outlook be healthy revenue earning growth vs same quarter year
602,LLY,biotech drugmaker biogen idec biib announce result early wednesday consensus be earning share shot share jump revenue
603,LLY,biogen blockbuster oral multiple sclerosis drug tecfidera be approve last year europe february management expect european launch be slow last earning call company say uptake be proceed similar pace uptake
604,LLY,stock boast highest possible composite rating ep rating earning growth last quarters
605,LLY,alexion alxn specialty drugmaker be expect record spike ep thursday morning increase revenue
606,LLY,company blockbuster drug soliris treat rare blood disease march alexion say expect soliris sale year
607,LLY,earning call alexion likely talk pipeline drug alfa soliris be target rare orphan disease alfa be design treat genetic disorder affect bone formation child quickly
608,LLY,last wednesday alexion submit application medical official japan approval drug
609,LLY,company stock have hold recent market turmoil almost retook day move average friday give alexion solid relative strength rating
610,LLY,celgene celg develop treatment cancer immune inflammatory disease be also slate announce earning early thursday big cap biotech be branch last week present datum new treatment crohn disease debilitating bowel ailment medical conference vienna
611,LLY,wall street be look hike ep cent rise sale
612,LLY,july celgene say drug otezla fail trial inflammatory spinal disease failure wasn surprise analyst earlier year celgene drug abraxane win approval europe use combination rival eli lilly lly gemzar fight metastatic pancreatic cancer
613,LLY,illumina ilmn be pound gorilla market high speed gene sequence machine be partner pharma giant amgen amgn astrazeneca azn well diagnostic testing company quest diagnostic dgx
614,LLY,analyst project illumina have have beaten earning estimate quarters row report rise ep cent surge revenue
615,LLY,stock have also weather market sell be near day line well
616,LLY,several ibd stock not medical field be also report week include atv maker polaris industry pii railroad giant union pacific unp staffing service provider robert half rhi supply chain management software developer manhattan associate manh
617,LLY,follow james detar twitter ibd_jdetar market still look bearish top rate medical stock include biogen idec alexion have remain strong demand new treatment breakthrough overcome investor skittishness elsewhere latest ibd list include thrive medical stock report quarterly result week outlook be healthy revenue earning growth vs same quarter year biotech drugmaker biogen idec biib announce result early wednesday consensus be earning share shot share jump revenue biogen blockbuster oral multiple sclerosis drug tecfidera be approve last year europe february management expect european launch be slow last earning call company say uptake be proceed similar pace uptake stock boast highest possible composite rating ep rating earning growth last quarters alexion alxn specialty drugmaker be expect record spike ep thursday morning increase revenue company blockbuster drug soliris treat rare blood disease march alexion say expect soliris sale year earning call alexion likely talk pipeline drug alfa soliris be target rare orphan disease alfa be design treat genetic disorder affect bone formation child quickly last wednesday alexion submit application medical official japan approval drug company stock have hold recent market turmoil almost retook day move average friday give alexion solid relative strength rating celgene celg develop treatment cancer immune inflammatory disease be also slate announce earning early thursday big cap biotech be branch last week present datum new treatment crohn disease debilitating bowel ailment medical conference vienna wall street be look hike ep cent rise sale july celgene say drug otezla fail trial inflammatory spinal disease failure wasn surprise analyst earlier year celgene drug abraxane win approval europe use combination rival eli lilly lly gemzar fight metastatic pancreatic cancer illumina ilmn be pound gorilla market high speed gene sequence machine be partner pharma giant amgen amgn astrazeneca azn well diagnostic testing company quest diagnostic dgx analyst project illumina have have beaten earning estimate quarters row report rise ep cent surge revenue stock have also weather market sell be near day line well several ibd stock not medical field be also report week include atv maker polaris industry pii railroad giant union pacific unp staffing service provider robert half rhi supply chain management software developer manhattan associate manh follow james detar twitter ibd_jdetar
618,LLY,pfizer pfe end week speculation wall street announce friday file approval breast cancer drug palbociclib finish clinical trial palbociclib fda filing be base mid stage paloma trial accord pfizer press release pfizer present final result trial last month show strong progression free
619,LLY,big pharma eli lilly lly say monday drug candidate reduce blood sugar diabetic more lead treatment company stock rise fraction stock market today
620,LLY,phase clinical trial show lilly basal insulin peglispro bil outperformed sanofi sny lantus patient type diabetes do not yet release exact number lilly also say patient bil show less weight gain lantus
621,LLY,approve bil offer differentiate profile provide important new treatment option patient diabetes say lilly diabetes president enrique conterno statement be track make regulatory filing next year
622,LLY,nonetheless isi group analyst mark schoenebaum write email client see potential problem not good news be drug cause significant bump liver enzyme potential signal liver toxicity seem increase amount fat present liver write addition hdl good cholesterol decline triglyceride bad increase
623,LLY,schoenebaum add fda demand trial offer assurance drug risk benefit profile agency do last year nordisk nvo diabetes drug tresiba response possible heart risk
624,LLY,nonetheless be worth hassle current worldwide basal insulin market be
625,LLY,follow amy reeve twitter ibd_areevesbig pharma eli lilly lly say monday drug candidate reduce blood sugar diabetic more lead treatment company stock rise fraction stock market today phase clinical trial show lilly basal insulin peglispro bil outperformed sanofi sny lantus patient type diabetes do not yet release exact number lilly also say patient bil show less weight gain lantus approve bil offer differentiate profile provide important new treatment option patient diabetes say lilly diabetes president enrique conterno statement be track make regulatory filing next year nonetheless isi group analyst mark schoenebaum write email client see potential problem not good news be drug cause significant bump liver enzyme potential signal liver toxicity seem increase amount fat present liver write addition hdl good cholesterol decline triglyceride bad increase schoenebaum add fda demand trial offer assurance drug risk benefit profile agency do last year nordisk nvo diabetes drug tresiba response possible heart risk nonetheless be worth hassle current worldwide basal insulin market be follow amy reeve twitter ibd_areeve
626,LLY,big pharmas novartis nvs glaxosmithkline gsk eli lilly lly announce massive exchange business unit tuesday morning set deal total value more novartis glaxo rise stock market today lilly slip fraction
627,LLY,switzerland base novartis agree buy british glaxo oncology business milestone payment depend product pipeline pan turn glaxo pay novartis vaccine business novartis say selling flu vaccine business separately apparently hasn yet find buyer
628,LLY,company also agree form joint venture consumer health care combine counter business novartis own jv hold seat board
629,LLY,meanwhile novartis also sell animal health business lilly
630,LLY,research note leerink analyst seamus fernandez write activity be not wall street be expect have be rumor go january novartis sell merck mrk animal health vaccine exchange merck counter business fernandez say like decision pursue oncology instead
631,LLY,incremental focus oncology transaction bring nvs well opportunity possibly reconsider pursuit certain effort unapproved product be positive financial strategic move fernandez write
632,LLY,go say glaxo be probably biggest surprise participant note glaxo now shift distribution business vaccine consumer exit increasingly fragmented crowd oncology market glaxo core business still depend respiratory product such advair fernandez add
633,LLY,lilly meanwhile be follow commitment keep animal health business pressure street divest email client isi group analyst mark schoenebaum write novartis veterinary unit appear be lose money lilly say expect get ebit earning interest taxe margin combine business mid range
634,LLY,suspect lly shareholder win be inspire lly decision buy animal health company shareholder always want big company buy biotech growth engine easier say do schoenebaum write however elanco lilly animal health unit have be story success lly so shareholder be likely give management benefit doubt deal
635,LLY,novartis stock be morning trading tuesday earlier hit time high glaxo be lilly be
636,LLY,follow amy reeve twitter ibd_areeve
637,LLY,related hcv rivalry heat merck combo shine big pharmas novartis nvs glaxosmithkline gsk eli lilly lly announce massive exchange business unit tuesday morning set deal total value more novartis glaxo rise stock market today lilly slip fraction switzerland base novartis agree buy british glaxo oncology business milestone payment depend product pipeline pan turn glaxo pay novartis vaccine business novartis say selling flu vaccine business separately apparently hasn yet find buyer company also agree form joint venture consumer health care combine counter business novartis own jv hold seat board meanwhile novartis also sell animal health business lilly research note leerink analyst seamus fernandez write activity be not wall street be expect have be rumor go january novartis sell merck mrk animal health vaccine exchange merck counter business fernandez say like decision pursue oncology instead incremental focus oncology transaction bring nvs well opportunity possibly reconsider pursuit certain effort unapproved product be positive financial strategic move fernandez write go say glaxo be probably biggest surprise participant note glaxo now shift distribution business vaccine consumer exit increasingly fragmented crowd oncology market glaxo core business still depend respiratory product such advair fernandez add lilly meanwhile be follow commitment keep animal health business pressure street divest email client isi group analyst mark schoenebaum write novartis veterinary unit appear be lose money lilly say expect get ebit earning interest taxe margin combine business mid range suspect lly shareholder win be inspire lly decision buy animal health company shareholder always want big company buy biotech growth engine easier say do schoenebaum write however elanco lilly animal health unit have be story success lly so shareholder be likely give management benefit doubt deal novartis stock be morning trading tuesday earlier hit time high glaxo be lilly be follow amy reeve twitter hcv rivalry heat merck combo shine
638,LLY,big purse start spill open globe past week glaxosmithkline gsk novartis nvs eli lilly lly announce series business swap value astrazeneca azn straight arm offer pfizer pfe general electric ge offer france alstom britain reckitt benckiser group say monday be duel
639,LLY,specialty drug giant actavis act beat analyst estimate wednesday company warn earning be lower due new competition actavis stock be morning trading stock market today
640,LLY,earning jump year earlier quarter share top analyst consensus cent accord thomson reuter sale gain beating estimate
641,LLY,prior quarter actavis decline give specific guidance close acquisition forest laboratory frx expect midyear actavis however do say earning be lower expect imminent competition generic version painkiller lidoderm actavis have day market exclusivity launch product due settlement lidoderm developer endo health solution endp recently expire
642,LLY,analyst consensus call earning share current quarter vs ep
643,LLY,much company growth come acquisition woman health company warner chilcott complete oct executive also say sale actavis generic version eli lilly lly antidepressant cymbalta be better expect have market exclusivity drug become available december actavis president siggi olafsson say conference call discuss result fewer company have enter market anticipate
644,LLY,ceo paul bisaro say acquisition forest be move expect also comment forest acquisition furiex pharmaceutical furx announce monday fit perfectly kind transaction re look term future acquisition wouldn entirely rule big buyout say actavis be mainly focuse smaller asset sort
645,LLY,actavis stock have be consolidate hit time high feb wednesday midweek update ibd list top perform stock
646,LLY,follow amy reeve twitter drug giant actavis act beat analyst estimate wednesday company warn earning be lower due new competition actavis stock be morning trading stock market today earning jump year earlier quarter share top analyst consensus cent accord thomson reuter sale gain beating estimate prior quarter actavis decline give specific guidance close acquisition forest laboratory frx expect midyear actavis however do say earning be lower expect imminent competition generic version painkiller lidoderm actavis have day market exclusivity launch product due settlement lidoderm developer endo health solution endp recently expire analyst consensus call earning share current quarter vs ep much company growth come acquisition woman health company warner chilcott complete oct executive also say sale actavis generic version eli lilly lly antidepressant cymbalta be better expect have market exclusivity drug become available december actavis president siggi olafsson say conference call discuss result fewer company have enter market anticipate ceo paul bisaro say acquisition forest be move expect also comment forest acquisition furiex pharmaceutical furx announce monday fit perfectly kind transaction re look term future acquisition wouldn entirely rule big buyout say actavis be mainly focuse smaller asset sort actavis stock have be consolidate hit time high feb wednesday midweek update ibd list top perform stock follow amy reeve twitter ibd_areeve
647,LLY,specialty drug giant actavis act beat analyst estimate wednesday management project solid future expand product line aid acquisition earning jump year earlier quarter share top analyst consensus cent accord thomson reuter sale gain beating estimate stock rise
648,LLY,wall street rise second day tuesday leave major index just record high higher oil price boost energy stock dow jone industrial average rise nasdaq climb end latter finishing just time peak volume be higher nyse nasdaq compare monday accord preliminary datum
649,LLY,stock market today oil producer pioneer natural resource pxd driller diamond offshore do rise lead oil price jump more just barrel strike oil worker brazil port shutdown libya
650,LLY,noah holding noah lead ibd jump heavy volume climb right side deep base provider wealth management service china be due report result nov profit period be see rise cent share be biggest gain quarters
651,LLY,medical product stock cambrex cbm rise more better expect earning report also climb right side new base
652,LLY,post session trading luxury electric vehicle maker tesla motor tsla rise sharply narrower expect loss stock fall more regular session end week high
653,LLY,share real estate zillow be hour follow result
654,LLY,also close groupon gpn edge higher report provider discount retailer also announce coo rich william replace eric lefkofsky ceo lefkofsky become chairman
655,LLY,lgi home lgih facebook fb epam system epam cognizant technology solution ctsh be company report quarterly earning wednesday
656,LLY,economic report due wednesday include institute supply management index service sector activity october adp private sector payroll november crude oil inventory week end oct mortgage banker association index mortgage application week end oct wall street rise second day tuesday leave major index just record high higher oil price boost energy stock dow jone industrial average rise nasdaq climb end latter finishing just time peak volume be higher nyse nasdaq compare monday accord preliminary datum stock market today oil producer pioneer natural resource pxd driller diamond offshore do rise lead oil price jump more just barrel strike oil worker brazil port shutdown libya noah holding noah lead ibd jump heavy volume climb right side deep base provider wealth management service china be due report result nov profit period be see rise cent share be biggest gain quarters medical product stock cambrex cbm rise more better expect earning report also climb right side new base post session trading luxury electric vehicle maker tesla motor tsla rise sharply narrower expect loss stock fall more regular session end week high share real estate zillow be hour follow result also close groupon gpn edge higher report provider discount retailer also announce coo rich william replace eric lefkofsky ceo lefkofsky become chairman lgi home lgih facebook fb epam system epam cognizant technology solution ctsh be company report quarterly earning wednesday economic report due wednesday include institute supply management index service sector activity october adp private sector payroll november crude oil inventory week end oct mortgage banker association index mortgage application week end oct
657,LLY,megamerger be back major corporation appetite acquisition near pre recession peak especially tax friendly cross border deal global have reach year earlier accord datum compile thomson reuter mark strongest year deal make peak monday biggest announcement be hillshire brand hsh
658,LLY,online storage company box late monday file long expect ipo pave way most anticipate initial public offering year provider cloud base content management file sharing service plan raise company list nyse ticker box morgan stanley ms credit suisse cs jpmorgan jpm
659,LLY,chinese stock tumble monday fear slow economic growth beij rejection bold new stimulus measure plenty top rate international stock country other china be excellent candidate stock watch list here be top rate company today international leader list be base country other china tata motor ttm be
660,LLY,british drug giant astrazeneca azn agree buy full ownership diabetes program be sharing bristol myer squibb bmy thus end bristol attempt be diabetes powerhouse stock be stock market today astrazeneca agree pay upfront asset include several market drug such bydureon byetta onglyza
661,LLY,eli lilly jr start early road boost eli lilly co work age school vacation firm grandfather founder do dirtiest job graduate pharmacy school begin layer foundation massive expansion occur be president
662,LLY,top rate biotechs biogen idec gilead science celgene get good news europe friday send stock time high
663,LLY,biogen biib multiple sclerosis drug tecfidera moved step closer launch european union be rule new active substance eu committee medicinal product human use chmp eu rule new active substance be protected competition year give product more solid protection patent be subject legal challenge few year
664,LLY,tecfidera launch earlier year get positive panel vote europe march biogen push back launch negotiate regulator new active substance tecfidera actually be similar compound exist ms used
665,LLY,stronger sale share
666,LLY,analyst say uncertainty eu ruling put damper stock have be hit resistance delay be announce be question biogen even launch tecfidera europe exclusivity
667,LLY,remove big overhang write deutsche bank analyst robyn karnauskas raise price target give solid uptake tecfidera be raise peak market share tecfidera vs previously now model worldwide sale vs previously
668,LLY,biogen sale growth have already accelerate past quarters gain ramp tecfidera launch
669,LLY,citi also raise price target
670,LLY,biogen share shot
671,LLY,meanwhile gilead gild hepatitis drug sofosbuvir win chmp vote earlier wall street expect committee recommend approve sofosbuvir now brand sovaldi follow accelerate review procedure drug perform very well clinical trial european commission usually follow chmp advice gilead say drug launch go well
672,LLY,upside
673,LLY,analyst michael yee rbc capital market write client note decision come least month ahead expectation add potential upside sovaldi sale drug be widely expect approval early december
674,LLY,think ll do alone eu add few country country launch eu start primarily germany other country take month full reimbursement pricing distribution launch yee write
675,LLY,analyst already have high expectation sovaldi promise first treatment disease interferon current consensus call sale
676,LLY,gilead stock rise nearly friday
677,LLY,chmp also endorse celgene abraxane treatment pancreatic cancer combination gemcitabine better know eli lilly lly gemzar abraxane have be market breast cancer celgene buy developer abraxis bioscience be testing new indication be approve lung cancer year pancreatic cancer september so far europe still authorize only breast cancer
678,LLY,celgene stock climb seventh straight gain top rate biotechs biogen idec gilead science celgene get good news europe friday send stock time high biogen biib multiple sclerosis drug tecfidera moved step closer launch european union be rule new active substance eu committee medicinal product human use chmp eu rule new active substance be protected competition year give product more solid protection patent be subject legal challenge few year tecfidera launch earlier year get positive panel vote europe march biogen push back launch negotiate regulator new active substance tecfidera actually be similar compound exist ms used stronger sale sharesanalyst say uncertainty eu ruling put damper stock have be hit resistance delay be announce be question biogen even launch tecfidera europe exclusivity remove big overhang write deutsche bank analyst robyn karnauskas raise price target give solid uptake tecfidera be raise peak market share tecfidera vs previously now model worldwide sale vs previously biogen sale growth have already accelerate past quarters gain ramp tecfidera launch citi also raise price target biogen share shot meanwhile gilead gild hepatitis drug sofosbuvir win chmp vote earlier wall street expect committee recommend approve sofosbuvir now brand sovaldi follow accelerate review procedure drug perform very well clinical trial european commission usually follow chmp advice gilead say drug launch go well upsideanalyst michael yee rbc capital market write client note decision come least month ahead expectation add potential upside sovaldi sale drug be widely expect approval early december think ll do alone eu add few country country launch eu start primarily germany other country take month full reimbursement pricing distribution launch yee write analyst already have high expectation sovaldi promise first treatment disease interferon current consensus call sale gilead stock rise nearly friday chmp also endorse celgene abraxane treatment pancreatic cancer combination gemcitabine better know eli lilly lly gemzar abraxane have be market breast cancer celgene buy developer abraxis bioscience be testing new indication be approve lung cancer year pancreatic cancer september so far europe still authorize only breast cancer celgene stock climb seventh straight gain
679,LLY,eli lilly lly stock fall more early trading stock market thursday drug candidate ramucirumab fail breast cancer trial succeed stomach cancer late stage trial look key metric progression free survival overall survival lilly didn say exactly long patient survive say ramucirumab have not show
680,LLY,share woman health company hologic holx gap heavy trading stock market thursday activist investor carl icahn buy large position firm
681,LLY,late wednesday icahn company report own hologic share share outstanding report person acquire position share belief be undervalue state schedule filing security exchange commission report person intend have conversation member hologic management discuss way enhance shareholder value
682,LLY,analyst say investor unhappiness reach critical level string miss quarters now be good time sort aggressive intervention icahn be know last year help engineer sale imclone eli lilly lly medimmune astrazeneca azn also threaten hostile takeover prevent mylan myl expensive buyout king pharmaceutical ultimately didn happen mylan deny be icahn
683,LLY,expect investor react very favorably activist involvement holx share management team have be often criticize destroy shareholder value overpay large acquisition such cytyc lesser extent gen probe write analyst glenn novarro rbc capital market client note open
684,LLY,analyst vijay kumar isi group note hologic have adopt poison pill provision prevent takeover believe management be too unpopular stop major change
685,LLY,look icahn nominate slate director board remove member management then look create shareholder value sale restructure kumar write email client poison pill act mean stop further acquisition holx share icahn associate do not believe have impact ultimate outcome here be likely too little too late share woman health company hologic holx gap heavy trading stock market thursday activist investor carl icahn buy large position firm late wednesday icahn company report own hologic share share outstanding report person acquire position share belief be undervalue state schedule filing security exchange commission report person intend have conversation member hologic management discuss way enhance shareholder value analyst say investor unhappiness reach critical level string miss quarters now be good time sort aggressive intervention icahn be know last year help engineer sale imclone eli lilly lly medimmune astrazeneca azn also threaten hostile takeover prevent mylan myl expensive buyout king pharmaceutical ultimately didn happen mylan deny be icahn expect investor react very favorably activist involvement holx share management team have be often criticize destroy shareholder value overpay large acquisition such cytyc lesser extent gen probe write analyst glenn novarro rbc capital market client note open analyst vijay kumar isi group note hologic have adopt poison pill provision prevent takeover believe management be too unpopular stop major change look icahn nominate slate director board remove member management then look create shareholder value sale restructure kumar write email client poison pill act mean stop further acquisition holx share icahn associate do not believe have impact ultimate outcome here be likely too little too late
686,LLY,fuel obesity epidemic age population diabetes have become global problem
687,LLY,affect estimate person worldwide drug company opportunity
688,LLY,denmark nordisk nvo be lead player market chief rival eli lilly lly sanofi sny target many other disease nordisk focus mostly diabetes therapy
689,LLY,sharp focus be competitive advantage say ronny gal analyst sanford bernstein co
690,LLY,have very good technical skill spend lot money sale marketing say
691,LLY,karen andersen analyst morningstar call nordisk most innovative player diabetes
692,LLY,nordisk get slow start year first quarter sale be hurt pharmacy benefit manager express script esrx remove company top drug prefer provider list favor drug lower price eli lilly astrazeneca azn
693,LLY,analyst expect look healthier nordisk benefit price hike new drug launch raise price insulin drug
694,LLY,growth estimate
695,LLY,have grow market take pricing typically have good business gal say
696,LLY,morningstar estimate global diabetes market grow year next year
697,LLY,even pricing power weaken nordisk see strong growth long run andersen say
698,LLY,say growth be drive increase diagnosis rate patient move newer pricier therapy emerge market such china mexico growth potential be root more richer diet less exercise person move rural urban area obesity be biggest risk factor develop diabetes
699,LLY,andersen expect impact express script decision linger year
700,LLY,drug cut prefer list be novolog firm best selling insulin drug novolog mix insulin drug victoza
701,LLY,sale victoza class know glp have be grow double digit rate first quarter sale slow fourth quarter be still higher year earlier
702,LLY,foreign exchange head wind didn help do industrywide inventory cut wholesaler also company face generic competition prandin blood sugar lower oral drug
703,LLY,not only do nordisk miss sale forecast lower forecast full year first time decade
704,LLY,revenue quarter grow just danish kroner equivalent local currency
705,LLY,new forecast call growth vs previously
706,LLY,quarter sale result break streak straight quarters double digit top line growth say kasper poulsen head investor relation
707,LLY,know be head wind say say company be surprised fast express script implement prefer provider change go effect jan take just month rather typical say
708,LLY,bottom line fared better nordisk earn cent share first quarter penny view earlier year
709,LLY,gross margin operate profit be respectively
710,LLY,still analyst expect share profit growth american depositary receipt slow year last year revenue be see climb
711,LLY,effort cut health cost continue big risk be person begin push back price gal say
712,LLY,poulsen say increase pressure contain cost result higher rebate make more important come differentiate product
713,LLY,company new generation insulin drug tresiba have be launch country outside include germany japan approval depend result new clinical trial
714,LLY,food drug administration ask more datum heart risk long act insulin product
715,LLY,nordisk say trial be progress ahead plan expect have enough datum mid support interim analysis
716,LLY,launch
717,LLY,tresiba show positive datum trial analyst widely expect bode well launch early
718,LLY,tresiba help extend growth renew insulin portfolio say andersen expect drug generate
719,LLY,tresiba be improve version levemir have better pricing power andersen say
720,LLY,tresiba have patent protection vs levemir
721,LLY,levemir compete sanofi lantus modern insulin drug be grow robust clip be different enough other maintain pricing power say
722,LLY,lantus likely see competition biosimilar drug
723,LLY,tresiba launch leave levemir lantus older generation product more likely do better emerge market andersen say
724,LLY,nordisk pipeline include combination drug tresiba victoza call xultophy launch europe new year pending regulatory approval drug treat obesity be review fda official europe
725,LLY,datum other trial be due next year include faster act version novolog oral glp class drug be also development
726,LLY,expect be low event believe be likely bring most important event nordisk analyst peter hugreffe stockholm base seb equity research say recent research report fuel obesity epidemic age population diabetes have become global problem affect estimate person worldwide drug company opportunity denmark nordisk nvo be lead player market chief rival eli lilly lly sanofi sny target many other disease nordisk focus mostly diabetes therapy sharp focus be competitive advantage say ronny gal analyst sanford bernstein co have very good technical skill spend lot money sale marketing say karen andersen analyst morningstar call nordisk most innovative player diabetes nordisk get slow start year first quarter sale be hurt pharmacy benefit manager express script esrx remove company top drug prefer provider list favor drug lower price eli lilly astrazeneca azn analyst expect look healthier nordisk benefit price hike new drug launch raise price insulin drug growth estimate have grow market take pricing typically have good business gal say morningstar estimate global diabetes market grow year next year even pricing power weaken nordisk see strong growth long run andersen say say growth be drive increase diagnosis rate patient move newer pricier therapy emerge market such china mexico growth potential be root more richer diet less exercise person move rural urban area obesity be biggest risk factor develop diabetes andersen expect impact express script decision linger year drug cut prefer list be novolog firm best selling insulin drug novolog mix insulin drug victoza sale victoza class know glp have be grow double digit rate first quarter sale slow fourth quarter be still higher year earlier foreign exchange head wind didn help do industrywide inventory cut wholesaler also company face generic competition prandin blood sugar lower oral drug not only do nordisk miss sale forecast lower forecast full year first time decade revenue quarter grow just danish kroner equivalent local currency new forecast call growth vs previously quarter sale result break streak straight quarters double digit top line growth say kasper poulsen head investor relation know be head wind say say company be surprised fast express script implement prefer provider change go effect jan take just month rather typical say bottom line fared better nordisk earn cent share first quarter penny view earlier year gross margin operate profit be respectively still analyst expect share profit growth american depositary receipt slow year last year revenue be see climb effort cut health cost continue big risk be person begin push back price gal say poulsen say increase pressure contain cost result higher rebate make more important come differentiate product company new generation insulin drug tresiba have be launch country outside include germany japan approval depend result new clinical trial food drug administration ask more datum heart risk long act insulin product nordisk say trial be progress ahead plan expect have enough datum mid support interim analysis launchif tresiba show positive datum trial analyst widely expect bode well launch early tresiba help extend growth renew insulin portfolio say andersen expect drug generate tresiba be improve version levemir have better pricing power andersen say tresiba have patent protection vs levemir levemir compete sanofi lantus modern insulin drug be grow robust clip be different enough other maintain pricing power say lantus likely see competition biosimilar drug tresiba launch leave levemir lantus older generation product more likely do better emerge market andersen say nordisk pipeline include combination drug tresiba victoza call xultophy launch europe new year pending regulatory approval drug treat obesity be review fda official europe datum other trial be due next year include faster act version novolog oral glp class drug be also development expect be low event believe be likely bring most important event nordisk analyst peter hugreffe stockholm base seb equity research say recent research report
727,LLY,danish drug giant nordisk miss sale estimate lower full year revenue forecast thursday loss support payer hurt stock fall nordisk nvo make cent share quarter year earlier quarter danish kroner penny analyst consensus sale increase
728,LLY,big biotechs amgen regeneron launch new cholesterol drug repatha praluent summer wall street uniformly predict blockbuster sale debate just big
729,LLY,adult american have high cholesterol pfizer pfe lipitor be biggest selling drug world go patent get generic rival
730,LLY,yet statin drug class lipitor belong aren enough everyone repatha praluent new class call pcsk inhibitor promise help many person cholesterol be still too high
731,LLY,mid september amgen amgn make acquisition signale future lie company agree pay upfront dezima pharma company develop drug call cholesteryl ester transfer protein cetp inhibitor drug class be also be develop merck mrk eli lilly lly also promise lower cholesterol inadequately treat statin lower ldl bad cholesterol ve also show ability raise hdl good cholesterol
732,LLY,contrast biweekly injection require amgen regeneron regn treatment cetps be take daily pill
733,LLY,dezima drug candidate succeed amgen be hook milestone payment be well worth cetp class turn be real threat
734,LLY,provide natural hedge amgen important cardiovascular franchise give pcsk repatha be drug be injectable phase iii competitor cetp inhibitor lilly merck be oral write rbc capital market analyst michael yee research note day deal be announce
735,LLY,wall street success be big drug class first make phase testing pfizer torcetrapib come screeching halt pfizer realize drug be raise patient death rate increase blood pressure
736,LLY,really shake field be high hope torcetrapib daniel bloomfield vice president clinical research merck cardiovascular program tell ibd announce result put program hold start work issue
737,LLY,bloomfield say merck isolate hormone be responsible raise blood pressure pfizer trial demonstrate own drug anacetrapib do not have risk factor lilly also say confident cetp inhibitor evacetrapib be safer predecessor
738,LLY,enrolled first patient have patient most be many many month treatment evidence safety signal say jeffrey riesmeyer senior medical director lilly cardiovascular program
739,LLY,same time danger make drug too weak happened roche rhhby cetp inhibitor dalcetrapib phase trial show safety problem raise hdl only other candidate have typically raise triple digit didn affect ldl
740,LLY,history be reason pcsk be available now cetp inhibitor win be market least year amgen regeneron be able approval basis cholesterol lower power company demonstrated drug effect overall cardiovascular health merck lilly however be go complete cardiovascular outcome study apply approval
741,LLY,first start work anacetrapib have alignment fda approve drug base ldl lower bloomfield say think now fda want see evidence outcome benefit approve drug class think want see well give shadow overhang mechanism
742,LLY,lilly trial be expect be do mid merck early be also pcsk datum be expect start come company be study similar patient group pcsk trial mainly already have heart disease virtually be already statin many be also take diabetes medicine riesmeyer note
743,LLY,lilly diabetes drug jardiance be recently show improve heart health drug work tandem riesmeyer note
744,LLY,main difference drug be merck anacetrapib have longer half life time drug remain body trace drug have be detected patient year last dose lilly riesmeyer point potential safety issue have yet be prove
745,LLY,so far cetp inhibitor ability lower ldl have lag pcsk phase trial praluent reduce ldl repatha perform similarly anacetripib evacetrapib have lower ve also raise hdl much dezima drug ta have go phase lower ldl raise hdl amgen advertised announce deal
746,LLY,assume ldl hypothesis hold true cetp ta potentially be best class write leerink analyst july deep dive report cholesterol market
747,LLY,uncertainty exact connection cholesterol heart health leave unclear just translate market share merck bloomfield say likely be key factor
748,LLY,not say magnitude benefit safety tolerability profile price vs generic aren go be important say factor be important expect outcome be require entry take significant market share big biotechs amgen regeneron launch new cholesterol drug repatha praluent summer wall street uniformly predict blockbuster sale debate just big adult american have high cholesterol pfizer pfe lipitor be biggest selling drug world go patent get generic rival yet statin drug class lipitor belong aren enough everyone repatha praluent new class call pcsk inhibitor promise help many person cholesterol be still too high mid september amgen amgn make acquisition signale future lie company agree pay upfront dezima pharma company develop drug call cholesteryl ester transfer protein cetp inhibitor drug class be also be develop merck mrk eli lilly lly also promise lower cholesterol inadequately treat statin lower ldl bad cholesterol ve also show ability raise hdl good cholesterol contrast biweekly injection require amgen regeneron regn treatment cetps be take daily pill dezima drug candidate succeed amgen be hook milestone payment be well worth cetp class turn be real threat provide natural hedge amgen important cardiovascular franchise give pcsk repatha be drug be injectable phase iii competitor cetp inhibitor lilly merck be oral write rbc capital market analyst michael yee research note day deal be announce wall street success be big drug class first make phase testing pfizer torcetrapib come screeching halt pfizer realize drug be raise patient death rate increase blood pressure really shake field be high hope torcetrapib daniel bloomfield vice president clinical research merck cardiovascular program tell ibd announce result put program hold start work issue bloomfield say merck isolate hormone be responsible raise blood pressure pfizer trial demonstrate own drug anacetrapib do not have risk factor lilly also say confident cetp inhibitor evacetrapib be safer predecessor enrolled first patient have patient most be many many month treatment evidence safety signal say jeffrey riesmeyer senior medical director lilly cardiovascular program same time danger make drug too weak happened roche rhhby cetp inhibitor dalcetrapib phase trial show safety problem raise hdl only other candidate have typically raise triple digit didn affect ldl history be reason pcsk be available now cetp inhibitor win be market least year amgen regeneron be able approval basis cholesterol lower power company demonstrated drug effect overall cardiovascular health merck lilly however be go complete cardiovascular outcome study apply approval first start work anacetrapib have alignment fda approve drug base ldl lower bloomfield say think now fda want see evidence outcome benefit approve drug class think want see well give shadow overhang mechanism lilly trial be expect be do mid merck early be also pcsk datum be expect start come company be study similar patient group pcsk trial mainly already have heart disease virtually be already statin many be also take diabetes medicine riesmeyer note lilly diabetes drug jardiance be recently show improve heart health drug work tandem riesmeyer note main difference drug be merck anacetrapib have longer half life time drug remain body trace drug have be detected patient year last dose lilly riesmeyer point potential safety issue have yet be prove so far cetp inhibitor ability lower ldl have lag pcsk phase trial praluent reduce ldl repatha perform similarly anacetripib evacetrapib have lower ve also raise hdl much dezima drug ta have go phase lower ldl raise hdl amgen advertised announce deal assume ldl hypothesis hold true cetp ta potentially be best class write leerink analyst july deep dive report cholesterol market uncertainty exact connection cholesterol heart health leave unclear just translate market share merck bloomfield say likely be key factor not say magnitude benefit safety tolerability profile price vs generic aren go be important say factor be important expect outcome be require entry take significant market share
749,LLY,stock be look slightly higher open monday earning season kick high gear week nasdaq future rise point vs fair value future tick fraction point future dow jone industrial average edge point
750,LLY,stock have productive week last week clear day move average nasdaq fail close day line friday today turnover be expect be light due columbus day holiday
751,LLY,earning calendar be light stock market today heavy load report start come tuesday report tomorrow be jpmorgan chase jpm blackhawk network hawk bank ozark ozrk csx csx intel intc
752,LLY,bank america bac well fargo wfc netflix nflx delta air line dal goldman sachs gs citigroup be notable company report later week
753,LLY,premarket action share datum storage giant emc emc jump news be acquire dell partner cash stock deal worth
754,LLY,vmware vmw be majority own emc remain publicly trade company share be nearly premarket trading
755,LLY,infosys infy report fiscal profit rise nearly lower revenue outlook indian firm expect sale rise dollar term vs earlier forecast infosys clear buy point cup base
756,LLY,eli lilly lly tumble scrapping development heart disease drug evacetrapib result tax charge nickel share fourth quarter
757,LLY,overseas stock market be mixed chinese stock surge official person bank china say correction chinese stock market be almost shanghai composite bolt hang seng jump germany dax rise france cac fall
758,LLY,follow vincent mao twitter ibd_vmao stock be look slightly higher open monday earning season kick high gear week nasdaq future rise point vs fair value future tick fraction point future dow jone industrial average edge point stock have productive week last week clear day move average nasdaq fail close day line friday today turnover be expect be light due columbus day holiday earning calendar be light stock market today heavy load report start come tuesday report tomorrow be jpmorgan chase jpm blackhawk network hawk bank ozark ozrk csx csx intel intc bank america bac well fargo wfc netflix nflx delta air line dal goldman sachs gs citigroup be notable company report later week premarket action share datum storage giant emc emc jump news be acquire dell partner cash stock deal worth vmware vmw be majority own emc remain publicly trade company share be nearly premarket trading infosys infy report fiscal profit rise nearly lower revenue outlook indian firm expect sale rise dollar term vs earlier forecast infosys clear buy point cup base eli lilly lly tumble scrapping development heart disease drug evacetrapib result tax charge nickel share fourth quarter overseas stock market be mixed chinese stock surge official person bank china say correction chinese stock market be almost shanghai composite bolt hang seng jump germany dax rise france cac fall follow vincent mao twitter ibd_vmao
759,LLY,biotechs drugmaker stock be lead today loss regeneron pharmaceutical regn be show particular weakness announce european commission marketing approval cholesterol drug praluent biotech share be crumble stock be afternoon trade volume be heavy move be substantial blow share be now trading day line
760,LLY,stock get hammer monday big seller again make presence feel nasdaq slump close session low get close level have stay close basis late october health care stock make nasdaq composite again come heavy fire ibd biotech industry
761,LLY,little lie fleetwood mac tango night turn page time then rearrange just day couldn find way so ll settle day believe tell lie tell sweet little lie disguise
762,LLY,so let confession begin not yesterday citron research firm publish negative research actively make bet company make very high profile allegation valeant pharmaceutical vrx used phrase web deception fraud call enron pharmaceutical industry now actually remember enron scandal be not good do not let outline
763,LLY,height season enron be energy commodity pulp paper service company base houston tx ticker symbol nyse be ene be most actively trade stock time everyone want be enron be always big crowd big trade lot action just name cause blood pump brow sweat be right outside booth so energy excitement be never far away be company claim have bil revenue consecutive year be name america most innovative company fortune magazine then december file bankruptcy go poof
764,LLY,rumor have be build week question raise story written remember be internet facebook twitter so news moved bit slower moved just same then be reveal money suppose financial condition be nothing fraud never forget action floor nyse time stock crash dozen broker vie position roar market work energy excitement tension be broker dream be very definition functionality exchange be very core heart soul capitalism so today something someone be enron be accuse fraudulent corruptive behavior be essentially death knell
765,LLY,be yesterday headline hit twitter citron research be call vrx pharmaceutical enron rest be history stock crash now stock fall mins only rally then fall then bill ackman large shareholder come announce be buy mil more share company defend say report be erroneous full false mislead statement categorically deny allegation boy now gonna get interesting stock close last night day morning pre market stock be trading be story be far so sit pay attention day be book written
766,LLY,so be excitement yesterday pharma healthcare manage cast pall broader market decline add market loss tuesday come top crude oil price weakness investor focuse latest wave company report quarterly financial result lower close reflect ongoing concern corporate earning outlook global economy now yes ba utx do help push industrial name higher broader market suffer negative tone create action vrx buildup oil reserve
767,LLY,doe energy report show mil barrel inventory build crude oil be highest weekly inventory build april rd dramatically higher be expect cause oil price fall close be still hold range be now worry intermediate term be look more more challenge supply continue build morning oil be trading bit so churn remain
768,LLY,have note be keep eye breach barrel bring more selling market chatter fed governor say
769,LLY,weak earning continue pressure stock earning expectation have be lower company beat expectation doesn necessary mean re expand just mean beat lower estimate just buy sell stock pico second do not mean do good job just mean do fast
770,LLY,so now rd quarter earning be come slightly better expect analyst be now call decline profit better original decline have prepared have beaten estimate only be beating top line disconnect now sector moved lower yesterday energy stock fall most back weaker oil industrial only sector rise thank ba utx
771,LLY,more earning come today mcd cat mmm report prior open have already report have be positive swk alaska air lly luv dow aep rtn ua show bottom line beat pre market trading have most name move higher bell look alphabet goog amzn msft eco datum today include inti jobless claim cont claim mil exist home sale mil kansa city fed show lower activity
772,LLY,european market be slightly higher await ecb rate news expect draghi change rate fact leave door open further ease increase current tril euro qe program guess be not yet ftse flat cac dax eurostoxx spain italy flat
773,LLY,future be pt suspect oil bit higher dollar flat long get better earning market hold steady here resistance still hold short term support right here do not hold then look be next real support level
774,LLY,take good care
775,LLY,kp
776,LLY,follow kenny twitter kennypolcari kennypolcari com
777,LLY,kenny polcari be vice president director nyse floor operation behalf neil security inc sister company investor business daily market commentary be opinion author be base decade industry market experience however guarantee be make imply respect opinion commentary be not be intend be rely authoritative take substitution exercise judgment comment note herein not be construe offer sell solicitation offer buy sell financial product official statement endorsement neil security incorporate affiliate little lie fleetwood mac tango night turn page time then rearrange just day couldn find way so ll settle day believe tell lie tell sweet little lie disguise so let confession begin not yesterday citron research firm publish negative research actively make bet company make very high profile allegation valeant pharmaceutical vrx used phrase web deception fraud call enron pharmaceutical industry now actually remember enron scandal be not good do not let outline height season enron be energy commodity pulp paper service company base houston tx ticker symbol nyse be ene be most actively trade stock time everyone want be enron be always big crowd big trade lot action just name cause blood pump brow sweat be right outside booth so energy excitement be never far away be company claim have bil revenue consecutive year be name america most innovative company fortune magazine then december file bankruptcy go poof rumor have be build week question raise story written remember be internet facebook twitter so news moved bit slower moved just same then be reveal money suppose financial condition be nothing fraud never forget action floor nyse time stock crash dozen broker vie position roar market work energy excitement tension be broker dream be very definition functionality exchange be very core heart soul capitalism so today something someone be enron be accuse fraudulent corruptive behavior be essentially death knell be yesterday headline hit twitter citron research be call vrx pharmaceutical enron rest be history stock crash now stock fall mins only rally then fall then bill ackman large shareholder come announce be buy mil more share company defend say report be erroneous full false mislead statement categorically deny allegation boy now gonna get interesting stock close last night day morning pre market stock be trading be story be far so sit pay attention day be book written so be excitement yesterday pharma healthcare manage cast pall broader market decline add market loss tuesday come top crude oil price weakness investor focuse latest wave company report quarterly financial result lower close reflect ongoing concern corporate earning outlook global economy now yes ba utx do help push industrial name higher broader market suffer negative tone create action vrx buildup oil reserve doe energy report show mil barrel inventory build crude oil be highest weekly inventory build april rd dramatically higher be expect cause oil price fall close be still hold range be now worry intermediate term be look more more challenge supply continue build morning oil be trading bit so churn remain have note be keep eye breach barrel bring more selling market chatter fed governor say weak earning continue pressure stock earning expectation have be lower company beat expectation doesn necessary mean re expand just mean beat lower estimate just buy sell stock pico second do not mean do good job just mean do fast so now rd quarter earning be come slightly better expect analyst be now call decline profit better original decline have prepared have beaten estimate only be beating top line disconnect now sector moved lower yesterday energy stock fall most back weaker oil industrial only sector rise thank ba utx more earning come today mcd cat mmm report prior open have already report have be positive swk alaska air lly luv dow aep rtn ua show bottom line beat pre market trading have most name move higher bell look alphabet goog amzn msft eco datum today include inti jobless claim cont claim mil exist home sale mil kansa city fed show lower activity european market be slightly higher await ecb rate news expect draghi change rate fact leave door open further ease increase current tril euro qe program guess be not yet ftse flat cac dax eurostoxx spain italy flat future be pt suspect oil bit higher dollar flat long get better earning market hold steady here resistance still hold short term support right here do not hold then look be next real support level take good care kpfollow kenny twitter kennypolcari kennypolcari comkenny polcari be vice president director nyse floor operation behalf neil security inc sister company investor business daily market commentary be opinion author be base decade industry market experience however guarantee be make imply respect opinion commentary be not be intend be rely authoritative take substitution exercise judgment comment note herein not be construe offer sell solicitation offer buy sell financial product official statement endorsement neil security incorporate affiliate
778,LLY,big pharma abbvie abbv say friday advance rheumatoid arthritis drug successful midstage clinical trial also bail similar drug be develop belgian biotech galapago glpg send latter stock tumble abbvie conduct trial testing various dose placebo study patient respond inadequately methotrexate
779,LLY,mutual fund investor score third straight month gain november stock scale epic high average diversify stock mutual fund return month be year date accord lipper inc back expectation continue monetary stimulus federal reserve stock market climb proverbial wall
780,LLY,merck agree sell consumer business german giant bayer tuesday continue big pharma recent flurry big deal merck stock fall close bayer stock dip company also announce global collaboration develop market bayer bayry line treatment pulmonary hypertension
781,LLY,big money flow pharma tuesday novartis glaxosmithkline gsk eli lilly lly unveil giant swap business valeant pharmaceutical vrx bid roughly allergan novartis nvs agree buy glaxo oncology business milestone payment depend product pipeline fare turn
782,LLY,big pharma pfizer pfe be morning trading stock market today breast cancer drug palbociclib do well trial fall bit short sky high expectation
783,LLY,american association cancer research meeting sunday pfizer present final result phase trial palbo patient metastatic breast cancer ibd report last month investor be greatly interested presentation interim analysis show massive progression free survival benefit question be pfizer translate overall survival benefit
784,LLY,sunday presentation paloma trial pfs benefit be somewhat smaller still substantial month compare month interim analysis overall survival benefit be month be not statistically significant
785,LLY,analyst mark schoenebaum isi group point study enrolled fewer patient have be very difficult produce statistically significant overall survival os benefit company plan launch larger phase trial yet score sunday news seem sink hope pfizer file phase datum alone
786,LLY,be honest message fda filing timeline be bit confuse call schoenebaum write sunday conference call pfizer other analyst prepared remark say envision filing base phase datum get quite excited old man now thus stuff easily excite however seem back away proclaim certainty phase alone be sufficient
787,LLY,leerink swann analyst seamus fernandez say be skeptical fda approve palbo least interim datum phase trial pfe report total vs death median os month vs month hr suggest directionally positive modest effect admittedly immature os datum patient population write research note monday
788,LLY,pfizer license palbo amgen amgn be entitle royalty sale amgen stock drop first hour trading monday midmorning be flat
789,LLY,eli lilly lly also present datum meeting own cdk inhibitor bemaciclib be same class palbo drug be earlier stage development response rate pfs benefit have be similar palbo
790,LLY,reminder lly have argue drug work better be dose continuously vs palbo week week regimen due less severe neutropenia schoenebaum write lly plan announce next step later believe possible phase begin end early
791,LLY,lilly stock be more morning trading monday
792,LLY,follow amy reeve twitter ibd_areeve big pharma pfizer pfe be morning trading stock market today breast cancer drug palbociclib do well trial fall bit short sky high expectation american association cancer research meeting sunday pfizer present final result phase trial palbo patient metastatic breast cancer ibd report last month investor be greatly interested presentation interim analysis show massive progression free survival benefit question be pfizer translate overall survival benefit sunday presentation paloma trial pfs benefit be somewhat smaller still substantial month compare month interim analysis overall survival benefit be month be not statistically significant analyst mark schoenebaum isi group point study enrolled fewer patient have be very difficult produce statistically significant overall survival os benefit company plan launch larger phase trial yet score sunday news seem sink hope pfizer file phase datum alone be honest message fda filing timeline be bit confuse call schoenebaum write sunday conference call pfizer other analyst prepared remark say envision filing base phase datum get quite excited old man now thus stuff easily excite however seem back away proclaim certainty phase alone be sufficient leerink swann analyst seamus fernandez say be skeptical fda approve palbo least interim datum phase trial pfe report total vs death median os month vs month hr suggest directionally positive modest effect admittedly immature os datum patient population write research note monday pfizer license palbo amgen amgn be entitle royalty sale amgen stock drop first hour trading monday midmorning be flat eli lilly lly also present datum meeting own cdk inhibitor bemaciclib be same class palbo drug be earlier stage development response rate pfs benefit have be similar palbo reminder lly have argue drug work better be dose continuously vs palbo week week regimen due less severe neutropenia schoenebaum write lly plan announce next step later believe possible phase begin end early lilly stock be more morning trading monday follow amy reeve twitter ibd_areeve
793,LLY,danish pharmaceutical giant nordisk nvo miss sale estimate lower full year revenue forecast thursday profit be line stock be more early trading stock market today
794,LLY,make cent share quarter year earlier quarter danish kroner penny analyst consensus sale increase kroner equivalent miss consensus
795,LLY,company lower sale growth guidance previous range maintain operate profit growth ceo lar sorensen say know year be challenge pharmacy benefit manager express script esrx take drug victoza novolog prefer treatment list lower reimbursement drug management be also see more competition diabetes market especially new sglt inhibitor class
796,LLY,johnson johnson jnj invokana be first class be approve last year astrazeneca azn farxiga be approve january more be come pike astella roche rhhby eli lilly lly
797,LLY,be also face generic competition year oral glucose lower drug prandin
798,LLY,bright side company say launch tresiba new long act insulin product be go smoothly sale multiply ninefold year earlier quarter have now launch product country be still work fda approval be unexpectedly delay last year agency ask more datum tresiba heart risk
799,LLY,sorensen say study fda request be ahead schedule interim analysis datum be available mid
800,LLY,stock hold excellent ibd composite rating stock have be consolidate hit time high feb midmorning thursday stock be trading
801,LLY,follow amy reeve twitter ibd_areeve
802,LLY,related pfizer confirm pursuit pharmaceutical giant nordisk nvo miss sale estimate lower full year revenue forecast thursday profit be line stock be more early trading stock market today make cent share quarter year earlier quarter danish kroner penny analyst consensus sale increase kroner equivalent miss consensus company lower sale growth guidance previous range maintain operate profit growth ceo lar sorensen say know year be challenge pharmacy benefit manager express script esrx take drug victoza novolog prefer treatment list lower reimbursement drug management be also see more competition diabetes market especially new sglt inhibitor class johnson johnson jnj invokana be first class be approve last year astrazeneca azn farxiga be approve january more be come pike astella roche rhhby eli lilly lly be also face generic competition year oral glucose lower drug prandin bright side company say launch tresiba new long act insulin product be go smoothly sale multiply ninefold year earlier quarter have now launch product country be still work fda approval be unexpectedly delay last year agency ask more datum tresiba heart risk sorensen say study fda request be ahead schedule interim analysis datum be available mid stock hold excellent ibd composite rating stock have be consolidate hit time high feb midmorning thursday stock be trading follow amy reeve twitter pfizer confirm pursuit astrazeneca
803,LLY,columbus day holiday result quiet low volume session stock market monday dow jone industrial average add nasdaq be mostly unchanged
804,LLY,investor have more fedspeak digest atlanta fed president dennis lockhart say improve job market warrant rate hike end year
805,LLY,advance stock have slight edge decliner exchange new york mercantile exchange crude oil future slump
806,LLY,stock market today emc emc add more company agree merger privately hold dell
807,LLY,elsewhere skywest skyw clear base base pattern soar ibd airline group be day top performer rise utility tobacco stock also outperformed
808,LLY,ibd universal insurance uve rise additional now wear crown first gainer follow day oct stock have be tear clear cup handle buy point
809,LLY,biotech space ibd name regeneron regn jump try clear resistance day move average sharp pullback regeneron strength be help news eli lilly lly be end late stage development experimental cholesterol drug last week share regeneron rise help news pharmacy benefit manager express script esrx be cover pcsk inhibitor cholesterol drug alirocumbab praluent
810,LLY,ipo news pure storage pstg soar inauspicious debut last week company make flash chip base storage product enterprise customer columbus day holiday result quiet low volume session stock market monday dow jone industrial average add nasdaq be mostly unchanged investor have more fedspeak digest atlanta fed president dennis lockhart say improve job market warrant rate hike end year advance stock have slight edge decliner exchange new york mercantile exchange crude oil future slump stock market today emc emc add more company agree merger privately hold dell elsewhere skywest skyw clear base base pattern soar ibd airline group be day top performer rise utility tobacco stock also outperformed ibd universal insurance uve rise additional now wear crown first gainer follow day oct stock have be tear clear cup handle buy point biotech space ibd name regeneron regn jump try clear resistance day move average sharp pullback regeneron strength be help news eli lilly lly be end late stage development experimental cholesterol drug last week share regeneron rise help news pharmacy benefit manager express script esrx be cover pcsk inhibitor cholesterol drug alirocumbab praluent ipo news pure storage pstg soar inauspicious debut last week company make flash chip base storage product enterprise customer
811,LLY,stock battle erase early loss thursday couldn avoid finish red nasdaq lose be late morning trade fall ibd slide volume rise major exchange bear slap major index distribution day mark total
812,LLY,share eli lilly lly jump more year high thursday company present more evidence diabetes drug jardiance reduce death heart failure annual european association study diabetes lilly partner boehringer ingelheim present detail massive empa reg outcome trial study long term cardiovascular effect jardiance first headline last month lilly ingelheim report jardiance reduce death cardiovascular cause oddly enough do not reduce risk nonfatal heart attack stroke cause mortality be cut hospitalization heart failure be lilly note jardiance be first diabetes drug show kind effect address burden cardiovascular event include death be core diabetes care now single diabetes medication have be associate reduction mortality lead investigator bernard zinman say statement evercore isi analyst mark schoenebaum report slide study generate applause meeting also note have larger implication field diabetes care jardiance be sglt inhibitor same class drug johnson johnson jnj invokana astrazeneca azn farxiga other hand merck mrk similar outcome study januvia drug different class call dpp inhibitor do not find cardiovascular benefit didn do harm base datum think sglt class be likely be bigger dpp class year schoenebaum write email client remember year additional sale add lilly ep peak sale estimate be currently merck sell januvia today invert schoenebaum add astrazeneca be also conduct outcome study sglt inhibitor result due respectively give clearer idea be class effect new datum be announce just noon et thursday send lilly stock nearly later thursday afternoon merck stock be more afternoon trading stock market today follow amy reeve twitter ibd_areeve facebook
813,LLY,hillary clinton have promote drug pricing plan way take industry say be guilty outrageous price friend medium take hit clinton plan wouldn go far have suggest ban consumer direct drug advertising effect tax advertising dollar be tax profit hope be do so restrain unnecessary prescription drug spending patient wouldn ask doctor be try wonder cure learn tv read newspaper ostensibly decrease pharma ad spending order make brand drug less prevalent mind consumer cheaper generic write cowen co health care analyst charle rhee even more certain result be hit medium company profit expansion loss last year drugmaker spend tv ad magazine ad newspaper ad accord kantar medium pfizer pfe spend more ad roughly same combine total next biggest advertiser abbvie abbv eli lilly lly astrazeneca azn yet rhee write even overall pie be shrink think more ad pie shift favor digital advertiser even accelerate manner advertiser seek greater return investment particular rhee name webmd wbmd everyday health evdy potential winner scenario see unlikely come pass republican dominate congress still maybe hope hillary plan help great friend blogosphere
814,LLY,biotech intra cellular therapy itci soar much wednesday company announce positive late stage trial result schizophrenia drug intra cellular say phase study schizophrenic meet primary endpoint show significant improvement symptom patient take drug iti compare placebo group week treatment mg
815,LLY,many investor view interest rate hike federal reserve inevitable necessary paul schatz president heritage capital woodbridge conn treasurer national association active investment manager disagree say hike be neither necessary desirable right now still fed apparently poise pull trigger schatz cite several
816,LLY,software maker veeva system veev get lot attention last month go public bolt gate stock more double ipo price few day
817,LLY,now share have settle back early high excitement often surround ipo have subside investor focus firm product financial performance growth prospect nearly friday veeva trade open first day market
818,LLY,tech company have lot go analyst say
819,LLY,veeva provide cloud base software solution professional service life science industry software be design help drugmaker other kind customer improve sale marketing effort also operate more efficiently
820,LLY,information manager
821,LLY,veeva lineup include veeva crm customer relationship management solution let pharmaceutical sale rep account manager other manage track optimize interaction health care provider
822,LLY,company also offer veeva vault cloud base content management collaboration solution help customer manage process such clinical trial quality management manufacturing sale marketing
823,LLY,product veeva network be cloud base solution design help life science firm create maintain record health care professional organization interact
824,LLY,cloud base solution customer operate more cheaply efficiently have run software house hardware system
825,LLY,veeva cloud base application increase productivity compliance sale marketing personnel have be successful replace legacy premise solution life science industry deutsche bank analyst nandan amladi note report initiate coverage veeva
826,LLY,kind solution be especially important life science industry have grow increasingly complex regulate
827,LLY,recent interview ibd veeva ceo peter gassner say life science company have tremendous amount business process nature industry
828,LLY,be deal human life government regulation so be perfect industry cloud software gassner say be stick legacy client server system be not able keep regulatory competitive environment change
829,LLY,veeva have life science customer include lead drugmaker such merck mrk eli lilly lly gilead science gild bayer healthcare
830,LLY,veeva revenue come north america come europe remain asia pacific
831,LLY,demand veeva software be reflect company rapid financial growth annual revenue have more triple past year
832,LLY,veeva be founder be also solidly profitable logged net income nearly first month current fiscal year
833,LLY,analyst amladi reckon veeva have penetration core crm market less penetration broader market content management datum management product estimate total addressable market be year
834,LLY,veeva industry cloud model enable deeper specialization achieve greater market share more time amladi note
835,LLY,most veeva competition come privately hold firm such advanced health medium service stayinfront rival cegedim relationship management be publicly trade europe
836,LLY,report earlier month initiate coverage veeva canaccord genuity analyst richard davis say veeva have almost venture capital backed competition
837,LLY,combination cloud technology demand product strong financial growth limit competition high profile client help explain veeva stock price rise so rapidly first day trading oct
838,LLY,ipo pricing share come expect range veeva raise sale share bank involved ipo include morgan stanley ms deutsche bank db well fargo wfc stifel nicolaus pacific crest security canaccord genuity
839,LLY,stock market buzz
840,LLY,veeva share close first day trading rumble higher next few day peak oct
841,LLY,ipo generate level anticipation typically re-serve high profile name such twitter twtr splunk splk tableau datum workday wday say tom roderick analyst stifel nicolaus think enthusiasm be be warrant
842,LLY,early volatility many analyst remain bullish veeva
843,LLY,early cycle disruptive technology stock almost always work davis note add quite conservative estimate almost vc backed segment competition world class reference customer state art cloud technology don see many thing shake investor faith veeva
844,LLY,veeva be schedule report result fiscal third quarter dec analyst expect earning cent share consensus analyst poll thomson reuter see revenue come year earlier full fiscal year revenue be expect rise software maker veeva system veev get lot attention last month go public bolt gate stock more double ipo price few day now share have settle back early high excitement often surround ipo have subside investor focus firm product financial performance growth prospect nearly friday veeva trade open first day market tech company have lot go analyst say veeva provide cloud base software solution professional service life science industry software be design help drugmaker other kind customer improve sale marketing effort also operate more efficiently information managerveeva lineup include veeva crm customer relationship management solution let pharmaceutical sale rep account manager other manage track optimize interaction health care provider company also offer veeva vault cloud base content management collaboration solution help customer manage process such clinical trial quality management manufacturing sale marketing product veeva network be cloud base solution design help life science firm create maintain record health care professional organization interact cloud base solution customer operate more cheaply efficiently have run software house hardware system veeva cloud base application increase productivity compliance sale marketing personnel have be successful replace legacy premise solution life science industry deutsche bank analyst nandan amladi note report initiate coverage veeva kind solution be especially important life science industry have grow increasingly complex regulate recent interview ibd veeva ceo peter gassner say life science company have tremendous amount business process nature industry be deal human life government regulation so be perfect industry cloud software gassner say be stick legacy client server system be not able keep regulatory competitive environment change veeva have life science customer include lead drugmaker such merck mrk eli lilly lly gilead science gild bayer healthcare veeva revenue come north america come europe remain asia pacific demand veeva software be reflect company rapid financial growth annual revenue have more triple past year veeva be founder be also solidly profitable logged net income nearly first month current fiscal year analyst amladi reckon veeva have penetration core crm market less penetration broader market content management datum management product estimate total addressable market be year veeva industry cloud model enable deeper specialization achieve greater market share more time amladi note most veeva competition come privately hold firm such advanced health medium service stayinfront rival cegedim relationship management be publicly trade europe report earlier month initiate coverage veeva canaccord genuity analyst richard davis say veeva have almost venture capital backed competition combination cloud technology demand product strong financial growth limit competition high profile client help explain veeva stock price rise so rapidly first day trading oct ipo pricing share come expect range veeva raise sale share bank involved ipo include morgan stanley ms deutsche bank db well fargo wfc stifel nicolaus pacific crest security canaccord genuity stock market buzzveeva share close first day trading rumble higher next few day peak oct ipo generate level anticipation typically re-serve high profile name such twitter twtr splunk splk tableau datum workday wday say tom roderick analyst stifel nicolaus think enthusiasm be be warrant early volatility many analyst remain bullish veeva early cycle disruptive technology stock almost always work davis note add quite conservative estimate almost vc backed segment competition world class reference customer state art cloud technology don see many thing shake investor faith veeva veeva be schedule report result fiscal third quarter dec analyst expect earning cent share consensus analyst poll thomson reuter see revenue come year earlier full fiscal year revenue be expect rise
845,LLY,stock struggle narrowly mixed formation again wednesday time techs slightly lag overall market
846,LLY,nasdaq droop dow jone industrial average add fought hold gain
847,LLY,volume be soft nasdaq lower nyse vs trade same time tuesday
848,LLY,stock market today open weaker expect january housing datum compound surprise drop builder confidence report tuesday build related stock weather news only narrow loss
849,LLY,earning report drive large share early action fertilizer producer cf industry cf pop gps toolmaker garmin grmn drill contractor nabor nbr jump la boy lzb dive freightcar america rail slide
850,LLY,leader spirit airline save bolt early lead ibd stock florida base airline report ep vs forecast gain revenue rise just shade projection gap gain put share just high fifth week flat consolidation
851,LLY,earning report drugmaker eli lilly lly gap gain heavy trade company report experimental lung cancer treatment ramucirumab improve survival rate late stage trial
852,LLY,steel maker steel slump commerce department decision late tuesday not impose tariff steel pipe import south korea luxembourg base tenaris ts drop possibly due same news steel pipe have see heavy demand pipeline energy production company
853,LLY,busy hour session include report schedule tesla motor tsla avis budget group car homeaway away safeway swy stock struggle narrowly mixed formation again wednesday time techs slightly lag overall market nasdaq droop dow jone industrial average add fought hold gain volume be soft nasdaq lower nyse vs trade same time tuesday stock market today open weaker expect january housing datum compound surprise drop builder confidence report tuesday build related stock weather news only narrow loss earning report drive large share early action fertilizer producer cf industry cf pop gps toolmaker garmin grmn drill contractor nabor nbr jump la boy lzb dive freightcar america rail slide leader spirit airline save bolt early lead ibd stock florida base airline report ep vs forecast gain revenue rise just shade projection gap gain put share just high fifth week flat consolidation earning report drugmaker eli lilly lly gap gain heavy trade company report experimental lung cancer treatment ramucirumab improve survival rate late stage trial steel maker steel slump commerce department decision late tuesday not impose tariff steel pipe import south korea luxembourg base tenaris ts drop possibly due same news steel pipe have see heavy demand pipeline energy production company busy hour session include report schedule tesla motor tsla avis budget group car homeaway away safeway swy
854,LLY,take do small fry take big pharma part game plan adrian adam ceo man health care focuse specialty biotech auxilium pharmaceutical auxl adam take auxilium helm december time company have product testim testosterone gel treat low testosterone level xiaflex
855,LLY,drugmaker actavis act beat analyst estimate top bottom line thursday affirm guidance pending completion buyout forest laboratory frx
856,LLY,stock be morning trading stock market today touch time high third straight day stock be extend early december week tight pattern rank latest ibd
857,LLY,actavis make share quarter exclude time item double year earlier number beating analyst consensus cent sale jump estimate
858,LLY,company affirm guidance issue investor day last month say update complete forest lab buy expect close midyear previous guidance call revenue least last year ep vs last year
859,LLY,actavis buyout warner chilcott last year obvious pump year year comparison ceo paul bisaro say statement birth control pill generess fe urology drug rapaflo see double digit sale growth last year company legacy generic business also see important product launch include knockoff endo endp painkiller lidoderm eli lilly lly antidepressant cymbalta
860,LLY,actavis tuesday cancele earning conference call give lengthy conference call executive have day discuss forest buyout
861,LLY,meanwhile wall street continue digest news massive acquisition leerink analyst jason gerberry write client note thursday be incrementally more positive deal have lunch ceo note integration cost saving probably be quickly realize also say plan pursue bolt acquisition point especially key emerge market russia latin america southeast asia
862,LLY,follow amy reeve twitter ibd_areeve drugmaker actavis act beat analyst estimate top bottom line thursday affirm guidance pending completion buyout forest laboratory frx stock be morning trading stock market today touch time high third straight day stock be extend early december week tight pattern rank latest ibd actavis make share quarter exclude time item double year earlier number beating analyst consensus cent sale jump estimate company affirm guidance issue investor day last month say update complete forest lab buy expect close midyear previous guidance call revenue least last year ep vs last year actavis buyout warner chilcott last year obvious pump year year comparison ceo paul bisaro say statement birth control pill generess fe urology drug rapaflo see double digit sale growth last year company legacy generic business also see important product launch include knockoff endo endp painkiller lidoderm eli lilly lly antidepressant cymbalta actavis tuesday cancele earning conference call give lengthy conference call executive have day discuss forest buyout meanwhile wall street continue digest news massive acquisition leerink analyst jason gerberry write client note thursday be incrementally more positive deal have lunch ceo note integration cost saving probably be quickly realize also say plan pursue bolt acquisition point especially key emerge market russia latin america southeast asia follow amy reeve twitter ibd_areeve
863,LLY,annual meeting american association cancer research convene san diego april be view most drug industry watcher second tier medical conference physician investor be watch closely year pfizer report drug dramatically extend life patient breast cancer pfizer pfe
864,LLY,big biotech amgen amgn agree pay dutch biotech develop new cholesterol drug company say wednesday
865,LLY,amgen pay upfront privately hold dezima have midstage drug candidate call ta lower ldl cholesterol drug succeed amgen be hook milestone payment also pay unspecified royalty mitsubishi tanabe pharma dezima originally license drug
866,LLY,ta be cholesterol ester transfer protein cetp inhibitor class drug eli lilly lly merck mrk be also work analyst have generally be cautious program prior cetp drug roche rhhby pfizer pfe have fail clinical trial july rbc capital market cardiovascular expert source apply only probability success lilly merck program same time however lilly say have conduct futility analysis phase trial result be encourage enough continue result be expect early next year
867,LLY,cetp inhibitor succeed provide competition amgen newly launch cholesterol drug repatha be perhaps amgen decide acquire company press release however amgen chief sean harper suggest drug be complementary
868,LLY,portfolio ta repatha recently launch ldl lower pcsk inhibitor be able offer more treatment option different mechanism action mode administration vary ldl level risk profile harper say
869,LLY,announcement come same morning amgen announce licensing deal xencor xncr develop new cancer inflammation drug used xencor bispecific antibody platform amgen seek fill pipeline face biosimilar competition older drug
870,LLY,xencor stock be morning trading stock market today amgen stock be
871,LLY,follow amy reeve twitter ibd_areeve facebook big biotech amgen amgn agree pay dutch biotech develop new cholesterol drug company say wednesday amgen pay upfront privately hold dezima have midstage drug candidate call ta lower ldl cholesterol drug succeed amgen be hook milestone payment also pay unspecified royalty mitsubishi tanabe pharma dezima originally license drug ta be cholesterol ester transfer protein cetp inhibitor class drug eli lilly lly merck mrk be also work analyst have generally be cautious program prior cetp drug roche rhhby pfizer pfe have fail clinical trial july rbc capital market cardiovascular expert source apply only probability success lilly merck program same time however lilly say have conduct futility analysis phase trial result be encourage enough continue result be expect early next year cetp inhibitor succeed provide competition amgen newly launch cholesterol drug repatha be perhaps amgen decide acquire company press release however amgen chief sean harper suggest drug be complementary portfolio ta repatha recently launch ldl lower pcsk inhibitor be able offer more treatment option different mechanism action mode administration vary ldl level risk profile harper say announcement come same morning amgen announce licensing deal xencor xncr develop new cancer inflammation drug used xencor bispecific antibody platform amgen seek fill pipeline face biosimilar competition older drug xencor stock be morning trading stock market today amgen stock be follow amy reeve twitter ibd_areeve facebook
872,LLY,character do whole lotta damage hillary clinton tweet deplore outrageous price gouge specialty drug market see largest biotech etf tank fear pricing control end third quarter ishare nasdaq biotechnology ibb have give gain year date back roughly loss september august rally tad unsettling decline health care sector belie outlook say capital iq analyst higher enrollment cost management prescription drug sale continue drive best earning growth health care sector index analyst lindsey bell write indeed ibb produce annual average gain past year oct period sector etfs track ibd top target health sector fact now more ever biotech pharma etfs trading much week high capital iq see buy opportunity solid biotech name such gilead gild celgene celg ibd stock nearly person be newly insure obamacare health exchange firm note recent report drive sale health care provider service strong dollar be likely weigh large cap pharmaceutical big pfizer pfe merck mrk bristol myer squibb bmy eli lilly lly once again post top line growth first time year pass patent cliff report say health care index be nicely value vs year average upside be especially attainable biotech pharma equipment subindustry report add big upside potential have see sometimes risky biotech drug stock make way many investor etf strategy now china global slowdown mind investor be more focuse downside risk be right be cautious value stock be risk economic growth estimate continue come momentum company be expose more spike volatility have weigh biotechs lately russ global chief investment strategist blackrock write recently suggest investor consider quality stock generally have strong return equity low debt successful investing market stay choppy analyst bofa lynch global research agree new report say health care rate most attractive sector base measure have historically be best predict result such ep sale revision guidance prior quarter result stick health care stick quality bofa lynch advise
873,LLY,big biotech amgen amgn be early trading wednesday announce neurology partnership novartis nvs well positive datum osteoporosis drug candidate late tuesday
874,LLY,amgen novartis agree combine research program alzheimer disease involve drug bace beta site app cleave enzyme inhibitor class bace inhibitor more advanced alzheimer disease candidate biogen biib eli lilly lly target beta amyloid deposit appear brain alzheimer patient use different mechanism action amgen work field be preclinical novartis drug cnp be just enter clinical trial
875,LLY,exchange cost profit sharing arrangement cnp novartis gain overseas commercial right amgen migraine drug more advanced amg be cgrp antibody phase testing
876,LLY,deal raise eyebrow amgen isn traditionally know have significant neurology expertise publish early clon bace write rbc capital market analyst michael yee research note tuesday result suspect many investor initially shrug deal bace inhibitor be early street be focuse biogen lilly phase
877,LLY,however believe bace inhibition be very interesting target be combine beta amyloid antibody together many company be go bace phase include biogen eisai datum spring lilly phase merck mrk johnson johnson jnj
878,LLY,however nomura analyst ian somaiya write research note tuesday bace inhibitor have also have safety issue past cause lilly roche rhhby cancel testing earlier candidate
879,LLY,amgen also say late tuesday osteoporosis drug romosozumab have succeed phase trial compare head head lilly forteo do not provide detail await future medical conference
880,LLY,romosozumab view positive phase datum incremental positive somaiya write estimate romosozumab be peak sale opportunity be focuse safety full datum be present give postmenopausal osteoporosis patient population
881,LLY,early trading stock market today amgen stock be fraction novartis stock be flat
882,LLY,follow amy reeve twitter ibd_areeve facebook big biotech amgen amgn be early trading wednesday announce neurology partnership novartis nvs well positive datum osteoporosis drug candidate late tuesday amgen novartis agree combine research program alzheimer disease involve drug bace beta site app cleave enzyme inhibitor class bace inhibitor more advanced alzheimer disease candidate biogen biib eli lilly lly target beta amyloid deposit appear brain alzheimer patient use different mechanism action amgen work field be preclinical novartis drug cnp be just enter clinical trial exchange cost profit sharing arrangement cnp novartis gain overseas commercial right amgen migraine drug more advanced amg be cgrp antibody phase testing deal raise eyebrow amgen isn traditionally know have significant neurology expertise publish early clon bace write rbc capital market analyst michael yee research note tuesday result suspect many investor initially shrug deal bace inhibitor be early street be focuse biogen lilly phase however believe bace inhibition be very interesting target be combine beta amyloid antibody together many company be go bace phase include biogen eisai datum spring lilly phase merck mrk johnson johnson jnj however nomura analyst ian somaiya write research note tuesday bace inhibitor have also have safety issue past cause lilly roche rhhby cancel testing earlier candidate amgen also say late tuesday osteoporosis drug romosozumab have succeed phase trial compare head head lilly forteo do not provide detail await future medical conference romosozumab view positive phase datum incremental positive somaiya write estimate romosozumab be peak sale opportunity be focuse safety full datum be present give postmenopausal osteoporosis patient population early trading stock market today amgen stock be fraction novartis stock be flat follow amy reeve twitter ibd_areeve facebook
883,LLY,stock sell broadly tuesday index start swerve monthlong uptrend nasdaq gap loss fall be second decline more past session index trim loss afternoon price chart be left distinct
884,LLY,apple aapl stock price moved higher monday iphone maker price target be hike cyberark cybr lululemon athletica lulu be upgrade canaccord genuity maintain buy rating apple raise price target apple share close stock market today cyberark share gap be upgrade buy deutsche bank cybersecurity software developer focus advanced cyberthreat such use insider privilege attack enterprise share athletic wear maker lululemon athletica rise be upgrade overweight morgan stanley give price target lululemon stock sank session period earlier month offer disappointing guidance google googl share climb price target be raise jmp security reiterate market outperform rating stock tech giant intel intc have price target lower mizuho still see share rise monday paypal pypl rise be upgrade hold buy price target stifel nicolaus anheuser busch inbev bud be downgrade sector perform outperform rbc capital market have price target lower stock price fall last week brewing giant say plan make offer rival sabmiller homebuilder horton dhi be downgrade hold buy deutsche bank share lose big pharma firm eli lilly lly be maintain neutral jpmorgan give price target july jpmorgan give stock price target eli lilly stock price lose monday la vegas sand lvs be maintain neutral nomura security give price target be most recent analyst pt share dip monday follow vance cariaga twitter ibd_vcariaga
885,LLY,specialty drug giant ibd stock valeant pharmaceutical vrx agree pay big pharma astrazeneca azn licensing deal psoriasis drug candidate have prove effective also show suicide risk clinical trial
886,LLY,valeant agree pay astrazeneca upfront brodalumab commit prelaunch milestone sale milestone phase study psoriasis psoriatic arthritis axial have already be complete drug valeant say plan file fda approval
887,LLY,be delighted be able reach licensing agreement astrazeneca commercialize brodalumab be potentially most efficacious therapy yet moderate severe plaque psoriasis valeant ceo michael pearson say statement remain fully commit dermatology continue advance pipeline internally develop acquire product
888,LLY,valeant press release didn mention be astrazeneca previous partner brodalumab amgen amgn have abandon program back several patient clinical trial kill number be small compare subject go trial amgen conclude label be too restrictive be worth continue investment
889,LLY,novartis lilly have il
890,LLY,amgen reasoning be doubt influenced fact brodalumab face crowd field brodalumab be new class call il antibody include novartis nvs recently approve cosentyx eli lilly lly still development ixekizumab neither have show suicide risk trial
891,LLY,january valeant acquire dendreon maker innovative underperform cancer drug provenge company go bankrupt last month picked pharmaceutical maker much publicize risky female libido pill addyi
892,LLY,very valeant esque many way evercore isi analyst umer raffat write brodalumab deal email client pick abandon biopharma asset also signal valeant increase interest launch ready asset hence continue organic growth recall recent deal salix ib launch addyi launch now il ahead fda filing
893,LLY,raffat note valeant commit little money upfront entree large market year psoriasis alone cosentyx be already annualizing sale just sixth month industry drug typically take year hit peak sale
894,LLY,nonetheless valeant stock be early trading stock market today stock market general get poor start astrazeneca stock be
895,LLY,connect amy reeve ibd_areeve facebook specialty drug giant ibd stock valeant pharmaceutical vrx agree pay big pharma astrazeneca azn licensing deal psoriasis drug candidate have prove effective also show suicide risk clinical trial valeant agree pay astrazeneca upfront brodalumab commit prelaunch milestone sale milestone phase study psoriasis psoriatic arthritis axial have already be complete drug valeant say plan file fda approval be delighted be able reach licensing agreement astrazeneca commercialize brodalumab be potentially most efficacious therapy yet moderate severe plaque psoriasis valeant ceo michael pearson say statement remain fully commit dermatology continue advance pipeline internally develop acquire product valeant press release didn mention be astrazeneca previous partner brodalumab amgen amgn have abandon program back several patient clinical trial kill number be small compare subject go trial amgen conclude label be too restrictive be worth continue investment novartis lilly have il samgen reasoning be doubt influenced fact brodalumab face crowd field brodalumab be new class call il antibody include novartis nvs recently approve cosentyx eli lilly lly still development ixekizumab neither have show suicide risk trial january valeant acquire dendreon maker innovative underperform cancer drug provenge company go bankrupt last month picked pharmaceutical maker much publicize risky female libido pill addyi very valeant esque many way evercore isi analyst umer raffat write brodalumab deal email client pick abandon biopharma asset also signal valeant increase interest launch ready asset hence continue organic growth recall recent deal salix ib launch addyi launch now il ahead fda filing raffat note valeant commit little money upfront entree large market year psoriasis alone cosentyx be already annualizing sale just sixth month industry drug typically take year hit peak sale nonetheless valeant stock be early trading stock market today stock market general get poor start astrazeneca stock be connect amy reeve ibd_areeve facebook
896,LLY,big pharma eli lilly lly say wednesday drug candidate ramucirumab improve survival lung cancer patient late stage study lilly stock gap early trading stock market today
897,LLY,study look patient metastatic small cell lung cancer nsclc have fail previous round platinum base chemotherapy group patient take standard cancer drug docetaxel best know sanofi sny taxotere placebo take docetaxel ramucirumab company say ramucirumab group show significant improvement progression free survival exactly much improvement win be reveal unspecified scientific meeting future
898,LLY,piece datum firm didn yet reveal be survival rate patient squamous form nsclc vs squamous be potentially significant most popular lung cancer drug today roche rhhby avastin be used squamous patient potentially leave market opportunity open
899,LLY,assume ram work nonsquamous set only get peak sale worldwide isi group analyst mark schoenebaum write email client assume penetration avastin pricing month duration therapy price discount eu squamous population represent nsclc patient market be wide open so drug work squamous well sale top
900,LLY,current consensus be call peak annual sale less include expect approval gastric colorectal liver cancer represent quite potential upside schoenebaum point
901,LLY,needham analyst serge belanger say be also good news biotech dyax dyax licensing deal get royalty drug dyax stock be year high just early trading wednesday
902,LLY,follow amy reeve twitter ibd_areeve
903,LLY,related lilly other big pharmas face new breed specialty pharmas big pharma eli lilly lly say wednesday drug candidate ramucirumab improve survival lung cancer patient late stage study lilly stock gap early trading stock market today study look patient metastatic small cell lung cancer nsclc have fail previous round platinum base chemotherapy group patient take standard cancer drug docetaxel best know sanofi sny taxotere placebo take docetaxel ramucirumab company say ramucirumab group show significant improvement progression free survival exactly much improvement win be reveal unspecified scientific meeting future piece datum firm didn yet reveal be survival rate patient squamous form nsclc vs squamous be potentially significant most popular lung cancer drug today roche rhhby avastin be used squamous patient potentially leave market opportunity open assume ram work nonsquamous set only get peak sale worldwide isi group analyst mark schoenebaum write email client assume penetration avastin pricing month duration therapy price discount eu squamous population represent nsclc patient market be wide open so drug work squamous well sale top current consensus be call peak annual sale less include expect approval gastric colorectal liver cancer represent quite potential upside schoenebaum point needham analyst serge belanger say be also good news biotech dyax dyax licensing deal get royalty drug dyax stock be year high just early trading wednesday follow amy reeve twitter lilly other big pharmas face new breed specialty pharmas
904,LLY,biotech celgene celg receive double dose good news tuesday drug abraxane win key approval europe partner epizyme epzm produce positive result leukemia drug early trading celgene stock be epizyme vault stock market today european commission approve abraxane combine gemcitabine better
905,LLY,european exchange be high scorer world map tuesday investor return vigor day holiday
906,LLY,germany frankfurt exchange lead pack dax index vaulting higher italy milano ftse mib punch cac paris surge london ftse post gain
907,LLY,european market rally sign thursday agreement russia europe ease rise tension ukraine be falter tuesday ukraine order resumption terror operation
908,LLY,massive complex deal swiss drug giant novartis nvs glaxosmithkline gsk be centerpiece session company effectively restructure single swap novartis buy glaxosmithkline oncology unit glaxosmithkline grab novartis vaccine business separate deal glaxo say receive indianapoli base eli lilly lly animal health business
909,LLY,glaxo rise london exchange drugmaker bayer bayry merck mrk be day biggest mover frankfurt
910,LLY,base astrazeneca azn climb london report new york base pfizer pfe have approach company last year takeover offer talk have reportedly end
911,LLY,financial time quote mirabaud security steve clayton say crucial point underlie pfizer interest deal be avoid tax penalty company repatriate overseas cash acquisition have allow pfizer avoid hit secure new portion market
912,LLY,addition ireland base drugmaker shire group shpg jazz pharmaceutical jazz rise heavy trade respectively jeffery report name possible takeover target allergan agn event california base company attempt fend hostile takeover attempt make public monday persh square capital management valeant pharmaceutical vrx
913,LLY,market also receive assist euro hold week low vs dollar pledge european central bank intercede single currency show sign strength european exchange be high scorer world map tuesday investor return vigor day holiday germany frankfurt exchange lead pack dax index vaulting higher italy milano ftse mib punch cac paris surge london ftse post gain european market rally sign thursday agreement russia europe ease rise tension ukraine be falter tuesday ukraine order resumption terror operation massive complex deal swiss drug giant novartis nvs glaxosmithkline gsk be centerpiece session company effectively restructure single swap novartis buy glaxosmithkline oncology unit glaxosmithkline grab novartis vaccine business separate deal glaxo say receive indianapoli base eli lilly lly animal health business glaxo rise london exchange drugmaker bayer bayry merck mrk be day biggest mover frankfurt base astrazeneca azn climb london report new york base pfizer pfe have approach company last year takeover offer talk have reportedly end financial time quote mirabaud security steve clayton say crucial point underlie pfizer interest deal be avoid tax penalty company repatriate overseas cash acquisition have allow pfizer avoid hit secure new portion market addition ireland base drugmaker shire group shpg jazz pharmaceutical jazz rise heavy trade respectively jeffery report name possible takeover target allergan agn event california base company attempt fend hostile takeover attempt make public monday persh square capital management valeant pharmaceutical vrx market also receive assist euro hold week low vs dollar pledge european central bank intercede single currency show sign strength
914,LLY,slowly more big capitalization leader be get closer complete new basis few week many big cap stock be depth price decline late march share price have be trend higher degree chart be well track potential buy point facebook fb chipotle grill cmg nike nke
915,LLY,canadian specialty drug giant valeant pharmaceutical international agree pay pharmaceutical thursday day much debate female aphrodisiac addyi receive fda approval
916,LLY,market seem unimpressed move valeant vrx stock fall thursday week low top perform stock recent year valeant share touch record high aug
917,LLY,valeant agree pay upfront first quarter next year share future profit base achievement certain milestone accord company press release
918,LLY,valeant expect deal have impact earning be modestly accretive
919,LLY,addyi also know generic name flibanserin have often be compare pfizer pfe blockbuster viagra press viagra affect only physics impotence addyi treat hypoactive sexual desire disorder hsdd low libido
920,LLY,third time charm
921,LLY,fda reject drug twice finally approve tuesday fairly heavy safety restriction drug cause dizziness nausea fainting especially combine alcohol physician prescribe addyi pharmacy selling be certify risk evaluation mitigation strategy rem program counsel patient risk
922,LLY,nonetheless addyi be first only drug treat hsdd market massive social medium campaign backed approval indicate substantial demand kind libido drug
923,LLY,deliver first ever treatment commonly report form female sexual dysfunction give perfect opportunity establish new portfolio important medication uniquely impact woman valeant ceo michael pearson say statement
924,LLY,applaud effort team address important area unmet need look forward work bring benefit addyi additional market world say
925,LLY,woman health hasn be traditional focus valeant largest product line be dermatology opthalmology include giant bausch lomb contact lens brand
926,LLY,bmo capital market analyst alex arfaei see fitting valeant strategic focus aesthetic market limit big pharma competition
927,LLY,write research note valeant management expect hire sale rep addyi be expect launch mid october valeant shouldn have spend much compare possible income
928,LLY,management believe female hsdd be very large market potentially similar size male erectile dysfunction ed market arfaei say note thursday
929,LLY,moreover management believe be significant pent demand so salesforce be run end year sale ramp quickly
930,LLY,however believe uptake be significantly lower ed give safety issue product
931,LLY,price month
932,LLY,difference addyi ed drug be addyi have be take constantly instead specific sex act maintenance dose have be price month say be par ed drug spending
933,LLY,insurer be still work cover product not insurer cover sexual performance treatment
934,LLY,anthem antm have put addyi third tier have put viagra eli lilly lly ciali offer reimbursement not much prefer drug
935,LLY,other insurer pharmacy benefit manager have say re still think
936,LLY,high level uncertainty product seem area valeant management generally try avoid write morningstar analyst michael research note
937,LLY,additionally likelihood insurance coverage also suppress customer willingness pay pocket say drug avoidance reimbursement do fit nicely valeant preference cash pay product canadian specialty drug giant valeant pharmaceutical international agree pay pharmaceutical thursday day much debate female aphrodisiac addyi receive fda approval market seem unimpressed move valeant vrx stock fall thursday week low top perform stock recent year valeant share touch record high aug valeant agree pay upfront first quarter next year share future profit base achievement certain milestone accord company press release valeant expect deal have impact earning be modestly accretive addyi also know generic name flibanserin have often be compare pfizer pfe blockbuster viagra press viagra affect only physics impotence addyi treat hypoactive sexual desire disorder hsdd low libido third time fda reject drug twice finally approve tuesday fairly heavy safety restriction drug cause dizziness nausea fainting especially combine alcohol physician prescribe addyi pharmacy selling be certify risk evaluation mitigation strategy rem program counsel patient risk nonetheless addyi be first only drug treat hsdd market massive social medium campaign backed approval indicate substantial demand kind libido drug deliver first ever treatment commonly report form female sexual dysfunction give perfect opportunity establish new portfolio important medication uniquely impact woman valeant ceo michael pearson say statement applaud effort team address important area unmet need look forward work bring benefit addyi additional market world say woman health hasn be traditional focus valeant largest product line be dermatology opthalmology include giant bausch lomb contact lens brand bmo capital market analyst alex arfaei see fitting valeant strategic focus aesthetic market limit big pharma competition write research note valeant management expect hire sale rep addyi be expect launch mid october valeant shouldn have spend much compare possible income management believe female hsdd be very large market potentially similar size male erectile dysfunction ed market arfaei say note thursday moreover management believe be significant pent demand so salesforce be run end year sale ramp quickly however believe uptake be significantly lower ed give safety issue product price monthanother difference addyi ed drug be addyi have be take constantly instead specific sex act maintenance dose have be price month say be par ed drug spending insurer be still work cover product not insurer cover sexual performance treatment anthem antm have put addyi third tier have put viagra eli lilly lly ciali offer reimbursement not much prefer drug other insurer pharmacy benefit manager have say re still think high level uncertainty product seem area valeant management generally try avoid write morningstar analyst michael research note additionally likelihood insurance coverage also suppress customer willingness pay pocket say drug avoidance reimbursement do fit nicely valeant preference cash pay product
938,LLY,canadian specialty drug giant valeant pharmaceutical international agree pay pharmaceutical thursday day much debate female aphrodisiac addyi receive fda approval
939,LLY,market seem unimpressed move valeant vrx stock fall thursday week low top perform stock recent year valeant share touch record high aug
940,LLY,valeant agree pay upfront first quarter next year share future profit base achievement certain milestone accord company press release
941,LLY,valeant expect deal have impact earning be modestly accretive
942,LLY,addyi also know generic name flibanserin have often be compare pfizer pfe blockbuster viagra press viagra affect only physics impotence addyi treat hypoactive sexual desire disorder hsdd low libido
943,LLY,third time charm
944,LLY,fda reject drug twice finally approve tuesday fairly heavy safety restriction drug cause dizziness nausea fainting especially combine alcohol physician prescribe addyi pharmacy selling be certify risk evaluation mitigation strategy rem program counsel patient risk
945,LLY,nonetheless addyi be first only drug treat hsdd market massive social medium campaign backed approval indicate substantial demand kind libido drug
946,LLY,deliver first ever treatment commonly report form female sexual dysfunction give perfect opportunity establish new portfolio important medication uniquely impact woman valeant ceo michael pearson say statement
947,LLY,applaud effort team address important area unmet need look forward work bring benefit addyi additional market world say
948,LLY,woman health hasn be traditional focus valeant largest product line be dermatology opthalmology include giant bausch lomb contact lens brand
949,LLY,bmo capital market analyst alex arfaei see fitting valeant strategic focus aesthetic market limit big pharma competition
950,LLY,write research note valeant management expect hire sale rep addyi be expect launch mid october valeant shouldn have spend much compare possible income
951,LLY,management believe female hsdd be very large market potentially similar size male erectile dysfunction ed market arfaei say note thursday
952,LLY,moreover management believe be significant pent demand so salesforce be run end year sale ramp quickly
953,LLY,however believe uptake be significantly lower ed give safety issue product
954,LLY,price month
955,LLY,difference addyi ed drug be addyi have be take constantly instead specific sex act maintenance dose have be price month say be par ed drug spending
956,LLY,insurer be still work cover product not insurer cover sexual performance treatment
957,LLY,anthem antm have put addyi third tier have put viagra eli lilly lly ciali offer reimbursement not much prefer drug
958,LLY,other insurer pharmacy benefit manager have say re still think
959,LLY,high level uncertainty product seem area valeant management generally try avoid write morningstar analyst michael research note
960,LLY,additionally likelihood insurance coverage also suppress customer willingness pay pocket say drug avoidance reimbursement do fit nicely valeant preference cash pay product canadian specialty drug giant valeant pharmaceutical international agree pay pharmaceutical thursday day much debate female aphrodisiac addyi receive fda approval market seem unimpressed move valeant vrx stock fall thursday week low top perform stock recent year valeant share touch record high aug valeant agree pay upfront first quarter next year share future profit base achievement certain milestone accord company press release valeant expect deal have impact earning be modestly accretive addyi also know generic name flibanserin have often be compare pfizer pfe blockbuster viagra press viagra affect only physics impotence addyi treat hypoactive sexual desire disorder hsdd low libido third time fda reject drug twice finally approve tuesday fairly heavy safety restriction drug cause dizziness nausea fainting especially combine alcohol physician prescribe addyi pharmacy selling be certify risk evaluation mitigation strategy rem program counsel patient risk nonetheless addyi be first only drug treat hsdd market massive social medium campaign backed approval indicate substantial demand kind libido drug deliver first ever treatment commonly report form female sexual dysfunction give perfect opportunity establish new portfolio important medication uniquely impact woman valeant ceo michael pearson say statement applaud effort team address important area unmet need look forward work bring benefit addyi additional market world say woman health hasn be traditional focus valeant largest product line be dermatology opthalmology include giant bausch lomb contact lens brand bmo capital market analyst alex arfaei see fitting valeant strategic focus aesthetic market limit big pharma competition write research note valeant management expect hire sale rep addyi be expect launch mid october valeant shouldn have spend much compare possible income management believe female hsdd be very large market potentially similar size male erectile dysfunction ed market arfaei say note thursday moreover management believe be significant pent demand so salesforce be run end year sale ramp quickly however believe uptake be significantly lower ed give safety issue product price monthanother difference addyi ed drug be addyi have be take constantly instead specific sex act maintenance dose have be price month say be par ed drug spending insurer be still work cover product not insurer cover sexual performance treatment anthem antm have put addyi third tier have put viagra eli lilly lly ciali offer reimbursement not much prefer drug other insurer pharmacy benefit manager have say re still think high level uncertainty product seem area valeant management generally try avoid write morningstar analyst michael research note additionally likelihood insurance coverage also suppress customer willingness pay pocket say drug avoidance reimbursement do fit nicely valeant preference cash pay product
961,LLY,stock stretched loss thursday afternoon be session lows uncertainty regard fed rate hike september fresh slate economic datum nasdaq lead way plunge fall slice day move average dow jone industrial average fall dow be now negative year volume be sharply board stock market today dow walt disney fall slice day move average first time october thursday stock receive analyst downgrade sanford bernstein day be downgrade well fargo wfc disney have crater aug valeant pharmaceutical vrx lose announce buy pharmaceutical maker recently approve woman libido drug addyi stock have breach support day line be buy point shallow cup base upside few defensive flex strength pharma giant eli lilly lly shot big trade news diabetes drug jardiance develop partner boehringer ingelheim lower risk death cardiovascular disease massive year study stock be year high set july buy point flat base pattern hormel food hrl jump nearly huge volume new record high deutsche bank upgrade stock buy hold raise price target wednesday hormel gain response mixed earning report stock be now past flat base buy point
962,LLY,world look bit flat market standpoint early tuesday global market commodity largely unmoved stock future steering market mixed open dow future be point ibm ibm pull hard downside future be fraction nasdaq future be point focal point stock market today microsoft msft yahoo yhoo chipotle grill cmg also report close do number lead stock include blackhawk network hawk illumina ilmn gopro gpro economic calendar be blank tuesday big name motion early earning report include verizon vz traveler trv lockheed martin lmt unchanged unite technology utx ibm drag lower report earning beat revenue fall slightly more analyst have expect be tech giant straight quarter decline revenue profit margin software division source half company profit narrow quarter ibm share have be gradual uptrend january fight climb month consolidation tesla motor tsla slump nearly ahead open stock have be nick ub downgrade sell note reportedly question company battery storage auto delivery target share rise almost strong trade monday stock be extend rebound week support cup handle buy point india base software engineer infosys infy surge country second largest software developer report better expect earning raise full year revenue guidance consensus expectation management say company sign contract quarter total value infosys have be consolidate february battle retake week line support past week dollar be mixed commodity be generally flat mining stock have drag hard monday be rebound agnico eagle aem barrick gold abx yamana gold auy newmont mining nem post solid premarket gain
963,LLY,drugmaker aptalis holding file go public thursday ipo expect raise half dollar company formerly trade axcan pharma return new incarnation private equity firm tpg capital acquire axcan have merged several other company notably pharmaceutical acquire company have
964,LLY,eli lilly lly announce wednesday schizophrenia drug candidate didn do better placebo phase study study question look drug call pomaglumetad methionil sole treatment mental disease ongoing trial be still study compound supplemental treatment other medicine lilly say trial be
965,LLY,drugmaker bristol myer squibb sell diabetes business partner astrazeneca thursday shedding trouble acquisition advance strategy become more specialize biopharma company stock hit year high close astrazeneca azn agree pay upfront asset include market drug such bydureon byetta onglyza
966,LLY,eli lilly lly gain more month market exclusivity antidepressant cymbalta now expire december next year
967,LLY,lilly win extension conduct study child be practice government sometimes award patent extension lilly say statement however doesn mean child take cymbalta be officially labele only patient older
968,LLY,cymbalta generate year lilly several revenue stream lilly be lose generic competition lilly lose patent schizophrenia drug zyprexa last fall help drive sale profit last quarter lilly share tuesday hit more year high be fraction afternoon trading friday
969,LLY,related lilly work alzheimer treatment eli lilly lly gain more month market exclusivity antidepressant cymbalta now expire december next year lilly win extension conduct study child be practice government sometimes award patent extension lilly say statement however doesn mean child take cymbalta be officially labele only patient older cymbalta generate year lilly several revenue stream lilly be lose generic competition lilly lose patent schizophrenia drug zyprexa last fall help drive sale profit last quarter lilly share tuesday hit more year high be fraction afternoon trading friday related lilly work alzheimer treatment
970,LLY,share big pharma eli lilly lly be stock market tuesday morning lung cancer drug turn unexpectedly good result clinical trial lilly announce drug necitumumab improve survival lung cancer patient recently complete phase trial do not say exactly much longer patient survive
971,LLY,share big pharma eli lilly lly be stock market tuesday morning lung cancer drug turn unexpectedly good result clinical trial lilly announce drug necitumumab improve survival lung cancer patient recently complete phase trial do not say exactly much longer patient survive
972,LLY,merck co inc mrk free report present new datum study evaluate type ii diabetes drug januvia sitagliptin treatment option type ii diabetes patient initiate insulin therapy mild renal impairment composit study show higher reduction blood glucose level patient initiate insulin dosage continue treatment januvia compare discontinue januvia composit trial evaluate subject mild renal impairment be not adequately controlled metformin datum study show treatment januvia result inferiority superiority reduce blood glucose level compare patient treat astrazeneca azn free report farxiga dapagliflozin datum be present american diabetes association meeting orlando fl share merck have gain year date versus industry decline combine sale januvia janumet decline due ongoing pricing pressure merck januvia franchise be face pricing pressure due higher discount rebate maintain good manage care coverage first quarter sale januvia janumet rise last april fda deny approval include cardiovascular outcome label januvia janumet death toll cardiovascular disease be significantly higher adult suffering diabetes comparison addition positive cardiovascular finding have help drive sale drug moreover eli lilly lly free report boehringer ingelheim include cardiovascular indication label sglt inhibitor jardiance dpp iv inhibitor januvia see patient switch sglt inhibitor latest addition merck diabetes franchise be steglatro ertugliflozin approve monotherapy well fix dose combination metformin januvia unite state last december eu march be important note merck market steglatro partnership pfizer inc pfe merck currently carry zack rank hold better rank stock same sector be lundbeck hluyy free report sporting zack rank strong buy see complete list today zack rank stock hereh lundbeck earning estimate have be revise upward past day stock have soar year date hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
973,LLY,eli lilly company lly free report have receive favorable ruling district court patent dispute india generic drugmaker dr reddy laboratory limit rdy free report case be related vitamin regimen patent lilly key cancer drug alimta pemetrexed disodium district court southern district indiana validate alimta vitamin regimen patent state be infringe dr reddy propose generic product be alternative salt form pemetrexed concurrently lilly also inform earlier month district court also rule favor lawsuit hospira subsidiary pfizer inc pfe free report court deny hospira motion summary judgement instead grant lilly cross motion summary judgement compound patent cover alimta unite state expire january vitamin regimen patent remain valid alimta patent be ultimately upheld remain challenge compound patent already expire major european country japan dec other hospira dr reddy several other generic manufacturer include teva teva free report sandoz be seek approval unite state marketing generic form alimta prior expiration vitamin regimen patent remind investor last october patent trademark office have validate alimta vitamin regimen latest win hospira dr reddy mean company launch generic version alimta only patent expire however company be expect appeal district court decision notably alimta be top revenue grosser lilly longer commercial life alimta provide top line support several product lilly portfolio be already face patent expiration entry generic competition alimta follow loss effective patent protection cause rapid decline revenue product first quarter alimta sale rise higher sale unite state offset sale decline international market outside unite state sale cancer drug be be hurt due loss exclusivity several country well competitive pressure sale be also be affected increase competition due entry immuno oncology agent market favourable patent decision lower chance generic competition alimta patent expiration have hampered sale more year date share lilly have rise industry decline lilly currently carry zack rank buy see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
974,LLY,merck co inc mrk free report share have perform well year so far contrast industry performance merck belong zack large cap pharmaceutical industry be stock group comprise largest drugmaker world zack large cap pharmaceutical industry have underperform well zack medical sector stock industry have collectively decline zack composite zack medical sector have rise year date respectively however merck share have rise year so far industry decline also earning estimate rise rise past day rally significant part merck outperformance year be drive strong performance positive regulatory update related pd inhibitor keytruda very short span time keytruda have become merck largest product be already approve use different setting involve different tumor type year have already gain approval new indication include third line treatment adult well pediatric patient primary mediastinal cell lymphoma pmbcl type hodgkin lymphoma second line treatment recurrent metastatic cervical cancer label expansion approval drive sale keytruda future quarters treatment generate sale first quarter sequentially year year upside be drive global launch indication further boost demand keytruda sale be gain particularly strong momentum first line lung cancer indication fact keytruda be only pd approve first line set certain lung cancer patient monotherapy well combination therapy eli lilly lly free report cancer drug alimta pemetrexed carboplatin pem carbo recently conclude annual meeting american society clinical oncology pd inhibitor steal limelight encourage datum multiple clinical study datum presentation merck garner most attention physician investor be second interim analysis pivotal lung cancer study keytruda phase iii keynote study keytruda be also be study more type cancer more study include excess combination study merck be collaborate several company include amgen amgn free report incyte glaxo pfizer separately evaluation keytruda combination other regimen other year merck partner astrazeneca azn free report gain approval europe japan parp inhibitor lynparza advanced ovarian cancer unite state metastatic breast cancer merck also announce positive datum several late stage study mainly evaluate keytruda further line extension merck also sign deal japan eisai co ltd jointly develop commercialize latter tyrosine kinase inhibitor lenvima monotherapy well combination keytruda several type cancer also agree buy viralytic limit australian pharmaceutical company develop oncolytic immunotherapy range cancer strengthen oncology portfolio conclusionmerck carry zack rank hold have share challenge form generic competition several drug pricing pressure rise competitive pressure diabetes franchise product isentress hiv zepatier hcv zostavax vaccine nonetheless go forward new product keytruda lynparza bridion continue contribute meaningfully top line merck animal health unit be also strong remain core growth driver company meanwhile merck also continue focus cost cut initiative drive bottom line see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
975,LLY,large cap pharmaceutical sector comprise largest drugmaker world develop drug human veterinary use be strong start however struggle thereafter probably market instability few negative update pipeline regulatory front importantly relatively weaker top line performance bigwig due slower sale older drug have also hurt industry performance year so far meanwhile concern government move check higher price drug medicine remain overhang nonetheless ace investor know drug sector have be best perform industry stock market be widely expect sector rebound second half year believe new product sale ramp rise demand successful innovation product line expansion strong clinical study result frequent fda approval bring sector back track year also many company have accelerate cost save initiative enable investment new product defend exist product optimize long short term growth cost saving drive earning upside importantly merger acquisition activity be ramp tax reform place new tax law cut corporate tax rate encourage company bring back huge cash hold overseas time tax rate be spur merger activity year however headwind put pressure sector be drug pricing scrutiny pricing competitive pressure concern regard amazon interest enter healthcare arena major pipeline setback most importantly slowdown sale most high profile older drug courtesy payer competitive pressure brand generic drug be concern sector industry lag shareholder zack large cap pharmaceutical industry be stock group broader zack medical sector have underperform sector belong year date basis stock industry have collectively decline zack composite zack medical sector have rise year date respectively year date price performance large cap pharma stock trading cheapthank industry year valuation look really cheap now get good sense industry relative valuation look forward month price earning ratio be most appropriate multiple value large drug company industry currently have be lowest level past year well past year compare highest level median level past year be apparently upside left space also look inexpensive compare medical market large current well median ratio medical sector be respectively price earning forward month compare zack composite too space look cheap current ratio median level same period be zack large cap pharmaceutical industry respective ratio price earning forward month earning outlook appear negativewhile ratio analysis show be solid value oriented path ahead not really consider current price level good entry point be convince reason predict rebound term reliable measure help investor understand industry prospect be earning outlook member company empirical research show company earning outlook significantly influence performance stock get good sense company earning outlook compare consensus earning expectation current financial year last year report number effective measure be magnitude direction recent change earning estimate consensus earning estimate zack large cap pharmaceutical industry share imply decent year year improvement trend earning estimate revision have not be favorable lately price consensus zack large cap pharmaceutical industry look aggregate earning estimate revision appear analyst have begin lose confidence group earning potential consensus ep estimate current fiscal year have be revise downward current fiscal year ep estimate revision zack industry rank indicate prospect group zack industry rank be basically average zack rank member stock zack large cap pharmaceutical industry currently carry zack industry rank place bottom more zack industry research show top zack rank industry outperform bottom factor more however proprietary heat map show industry rank be top past week deteriorate only past week large drugmaker promise long term long term year ep growth estimate zack large cap pharmaceutical industry appear promising group mean estimate long term ep growth rate have be increase january reach current level compare unfavorably zack composite be highest level past year mean estimate long term ep growth rate fact basis long term ep growth be recovery top line large drugmaker have be show begin revenue large cap pharmaceutical market fact grow demand drug particularly target personalize therapy increase incidence chronic disease technological advancement evolve treatment regimen age population increase health care spending be factor keep sector track long term faster drug approval process propose removal outdated regulation drive cost slowdown innovation also provide benefit important indication solid long term prospect be improvement group return equity roe be key metric evaluate large cap drug stock return equity large cap pharmaceutical marketbottom linesuccee shift global market evolv ing healthcare landscape require pharma ceutical company adopt innovative business model invest new technology increase investment personalize medicine seek external partner collabora tor complementary strength sector face volatility due drug pricing issue pricing re imbursement pressure increase competition slowdown legacy product sale loss patent exclusivity key drug pipeline related setback however pipeline success innovative important therapeutic area cost cut share buyback new product launch increase activity appropriate utilization cash bring sector back track year large cap pharmaceutical universe only stock currently sport zack rank strong buy have zack rank buy company have witness positive earning estimate revision see complete list today zack rank stock here lundbeck hluyy free report share danish drugmaker have gain year so far zack consensus estimate current year ep be revise upward last day lundbeck have zack rank price hluyyeli lilly company lly free report stock indianapoli base drugmaker have rise year consensus ep estimate current year be revise upward last day lilly have zack rank price consensus lly stock stay away fromdue short term concern related large cap pharmaceutical stock suggest avoid stock have zack rank sell stock have witness negative earning estimate revision glaxosmithkline plc gsk free report consensus ep estimate brentford uk base drug consumer giant moved lower current fiscal year last day price consensus gsk novartis ag nvs free report consensus ep estimate swiss drug giant decline current fiscal year last day stock have decline year so far price consensus nvs today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
976,LLY,allergan plc agn free report announce positive top line result phase iii study evaluate pipeline candidate bimatoprost sr bimatoprost sr be allergan investigational implant develop first sustain release drop free treatment option lower intraocular pressure iop patient open angle glaucoma ocular hypertension phase iii study compare bimatoprost sr apply patient open angle glaucoma ocular hypertension timolol eye drop trial used dosage bimatoprost sr administer cycle day week week compare timolol eye drop used twice daily month datum study show bimatoprost sr reduce iop approximately week primary efficacy period demonstrate inferiority case timolol well receive patient bimatoprost sr show potential patient stay treatment free more year last implant be insert glaucoma patient uncontrolled elevated iop lead vision loss order reduce elevated iop patient be prescribe eye drop however glaucoma patient fail use eye drop prescribe bimatoprost sr approve provide such patient option drop free therapy free daily eye drop regimen bimatoprost sr be design lower iop least month allergan be expect report additional datum result second phase iii study identical design first half new drug application nda filing fda be also anticipate second half remind investor earlier week allergan announce second cgrp candidate atogepant meet primary endpoint mid stage study cgp md study evaluate dose atogepant prevention episodic migraine week atogepant achieve reduction statistical significance monthly migraine probable migraine mpm headache day baseline dose allergan oral cgrp acute migraine treatment ubrogepant have already show positive result phase iii study however migraine market be grow extremely competitive amgen amgn free report partner novartis nvs free report receive approval commercialize cgrp drug aimovig treat episodic migraine so far year share allergan have increase compare industry rise allergan currently carry zack rank hold better rank stock large cap pharma sector be eli lilly company lly free report zack rank buy see complete list today zack rank strong buy stock hereeli lilly earning share estimate have be revise upward last day stock have inched year date medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
977,LLY,allergan agn free report calcitonin gene related peptide cgrp candidate atogepant meet primary endpoint phase ii part phase iib iii study cgp md study be evaluate oral dosage candidate acute treatment episodic migraine meanwhile company have cgrp candidate ubrogepant pipeline demonstrated positive result phase iii study evaluate treatment single migraine attack positive datum readout cgp md study boost company cgrp pipeline company be currently discussion regulatory authority follow advance atogepant phase iii stage development allergan share have increase year so far industry rise cgp md study evaluate dose atogepant once daily mg mg mg twice daily mg mg prevention episodic migraine week atogepant achieve reduction statistical significance monthly migraine probable migraine mpm headache day baseline dose allergan present additional detail upcoming scientific meeting moreover potential approval candidate boost company migraine product line include botox treatment chronic migraine oral administration also help ubrogepant atogepant gain advantage other injectable drug approve meanwhile migraine space be attract lot interest due high unmet need several company be develop treatment disease amgen amgn free report partner novartis nvs free report receive approval commercialize cgrp drug aimovig treat episodic migraine other cgrp candidate development include eli lilly lly free report galcanezumab teva pharmaceutical fremanezumab eptinezumab galcanezumab fremanezumab be review unite state migarine be multus dollar market approximately person unite state suffering patient have episodic chronic migraine allergan plc price allergan plc price allergan plc quotezack rankallergan currently carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
978,LLY,incyte corporation incy free report announce phase ii trial reach evaluate lead drug jakafi combination corticosteroid treatment patient steroid refractory acute graft versus host disease gvhd meet primary endpoint datum study show jakafi demonstrated overall response rate orr day moreover number patient achieve response point time study be propel positive datum reach study incyte now plan file supplemental new drug application snda fda label expansion jakafi treatment steroid refractory acute gvhd third quarter incyte also plan present full detail study upcoming scientific meeting note jakafi first class jak jak inhibitor be already approve fda treatment person polycythemia vera pv have have inadequate response be intolerant hydroxyurea drug be also indicated treatment person intermediate high risk myelofibrosis mf include primary mf post polycythemia vera mf post essential thrombocythemia mf incyte have collaboration agreement novartis nvs free report jakafi jakafi be market incyte unite state be market novartis outside country jakafi performance have be impressive so far order expand patient population increase commercial potential drug company be work expand drug label further october fda approve label update drug include addition new patient report outcome pro datum comfort study well update warning related progressive multifocal potential label expansion gvhd further boost sale incyte stock have lose year so far compare industry decline meanwhile apart steroid refractory acute gvhd study reach trial program also include ongoing phase iii study steroid refractory acute gvhd reach steroid refractory chronic gvhd reach collaboration novartis datum study be expect incyte be also make effort develop other candidate reduce dependence jakafi fda have recently approve mg dose olumiant baricitinib once daily oral medication treatment adult moderately severely active rheumatoid arthritis ra have have inadequate response more tumor necrosis factor tnf inhibitor therapy incyte eli lilly lly free report have partnership olumiant however incyte suffer setback epacadostat external datum monitoring committee edmc review pivotal phase iii study echo evaluate epacadostat combination merck mrk free report keytruda patient unresectable metastatic melanoma determine study do not meet primary endpoint improve progression free survival overall population compare pembrolizumab monotherapy zack rankincyte currently carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
979,LLY,astrazeneca plc azn free report announce european commission have approve label expansion lung cancer drug tagrisso osimertinib latest development tagrisso be used first line treatment adult patient locally advanced metastatic small cell lung cancer nsclc tumor have egfr mutation tagrisso be hitherto approve unite state european union japan china second line treatment option patient egfr mutation positive nsclc earlier april fda give nod tagrisso osimertinib first line set eu approval be expect april committee medicinal product human use lend positive opinion recommend approval tagrisso first line set approval be base encourage datum phase iii flaura study compare tagrisso standard care egfr tyrosine kinase inhibitor therapy first line lung cancer set datum study show chance progression death risk be reduce more half tagrisso arm compare commonly used egfr inhibitor median progression free survival be month patient tagrisso compare month comparator arm tagrisso be well receive trial safety profile consistent previous study first quarter tagrisso record sale year year drive increase testing rate unite state japan approval first line set be likely boost sale tagrisso come quarters apart tagrisso astrazeneca market several cancer drug imfinzi lynparza other company market lynparza partnership merck co inc mrk free report oncology sale now comprise almost astrazeneca total product sale metric also rise share astrazeneca have gain year date versus industry decline astrazeneca currently carry zack rank hold see complete list today zack rank strong buy stock here better rank stock same sector include lundbeck hluyy free report eli lilly company lly free report lundbeck sport zack rank eli lilly carry zack rank buy lundbeck earning share estimate have be revise upward last day stock have substantially soar year date eli lilly company earning share estimate have rise last day stock have increase year date hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
980,LLY,abbvie inc abbv free report announce fda have grant approval combination use cancer drug venclexta roche rhhby free report rituxan treatment patient relapse refractory chronic lymphocytic leukemia cll small lymphocytic lymphoma sll deletion have receive least prior therapy venclexta be jointly market abbvie roche pharma arm genentech unite state abbvie outside unite state fda approval combination use be base positive datum phase iii murano study venclexta rituxan relapse refractory clldata study present september last year show combination lead profound improvement progression free survival compare teva pharmaceutical teva free report treanda rituxan br result study show fix duration treatment venclexta rituxan significantly reduce risk disease progression death compare br overall response rate orr be venclexta rituxan arm compare br concurrently fda also approve venclexta monotherapy cll sll patient deletion now monotherapy venclexta be approve treat patient cll deletion detected fda approve test fda approval label expansion venclexta indication expand patient population venclexta significantly boost commercial potential latest approval venclexta rituxan become first oral chemotherapy free fix duration treatment option cll patient also summer abbvie file regulatory application unite state venclexta acute myeloid leukemia aml phase iii program multiple myeloma be also progress well abbvie share have gain year so far industry decline abbvie currently carry zack rank hold better rank large cap pharma stock be eli lilly company lly free report zack rank buy see complete list today zack rank strong buy stock here lilly earning estimate increase past day company deliver positive earning surprise trail quarters average beat share lilly have gain year so far hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
981,LLY,nordisk nvo free report announce positive headline result phase iii study pioneer compare mg oral formulation ozempic semaglutide treatment adult type ii diabetes victoza mg placebo pioneer compare oral formulation ozempicas treatment adult type ii diabetes sitagliptin mg remind investor december fda approve ozempic once daily pre filled pen improve glycaemic control type ii diabetes patient be also approve europe japan canda same indication week pioneer study achieve primary objective accord primary statistical approach demonstrate inferior reduction blood glucose level hba statistically significant superior weight loss week oral ozempic compare victoza ozempic also provide statistically significant superior reduction hba weight compare placebo week week respectively person treat ozempic experience reduction hba compare victoza placebo decline increase ozempic also demonstrated weight loss kg week kg week versus kg kg victoza kg kg placebo week respectively increase weight loss oral ozempic be also significant compare victoza placebo week pioneer study also achieve primary objective accordingto primary statistical principle demonstrate person treat oral semaglutide experience statistically significant reduction hba compare sitagliptin week reduction body weight kg oral semaglutide be statistically significantly greater week compare kg sitagliptin nordisk plan report pioneer study compare mg oral semaglutide mg sitagliptin end second quarter share company have moved year date compare industry decline remind investor nordisk announce headline result pioneer second phase iiia study oral formulation ozempic treatment adult type ii diabetes study evaluate efficacy safety mg oral ozempic compare mg eli lilly lly free report boehringer ingelheim jardiance empagliflozin type ii diabetes inadequately controlled metformin week study achieve primary objective demonstrated statistically significant superior improvement hba oral ozempic compare jardiance week mid company plan initiate cardiovascular outcome study call soul ozempic also company plan initiate phase iiia program call step explore potential once weekly ozempic treatment person obesity also include cardiovascular outcome trial select investigate impact ozempic incidence major adverse cardiovascular event compare placebo patient establish cardiovascular disease overweight obesity glp market lilly trulicity astrazeneca azn free report once weekly bydureon be competitor nordisk ozempic nordisk price nordisk price nordisk quote zack rank stock considernovo nordisk have zack rank strong sell better rank stock same space be aeglea biotherapeutic inc agle free report carry zack rank buy see complete list today zack rank stock here aeglea loss share estimate have narrow past day company deliver positive earning surprise trail quarters average beat stock have rally so far year make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
982,LLY,smart beta exchange trade fund spdr pharmaceutical etf xph free report debut offer broad exposure health care etfs category equity market be smart beta etfs etf industry have traditionally be dominate product base market capitalization weight index be design represent market particular segment market investor believe market efficiency consider market cap index replicate market return low cost convenient transparent way be investor think possible beat market great stock selection group likely invest class fund know smart beta track cap weight strategy attempt pick stock have better chance risk return performance cap weight index be base certain fundamental characteristic combination such space offer number choice investor include simplest equal weighting fundamental weighting volatility momentum base weighting methodology not strategy have be able deliver superior result fund sponsor indexmanage state street global advisor xph have amassed asset make average size etfs health care etfs particular fund seek match performance pharmaceutical select industry index fee expense pharmaceutical select industry index represent pharmaceutical sub industry portion total market index tmi track common stock list nyse amex nasdaq national market nasdaq small cap exchange pharmaceutical index be modify equal weight index cost other expensescost be important factor select right etf cheaper fund significantly outperform more expensive cousin other fundamental be same operate expense annual basis be xph make least expensive product space month trail dividend yield come sector exposure top holdingseven etfs offer diversify exposure minimize single stock risk investor also look actual holding fund luckily most etfs be very transparent product disclose holding daily basis represent portfolio fund have heaviest allocation healthcare sector take account individual holding allergan plc agn free report account fund total asset follow eli lilly company lly free report jazz pharmaceutical plc jazz free report top holding account approximately xph total asset management performance etf have lose so far year be last year past week period have trade etf have beta standard deviation trail year period make high choice space holding have more concentrated exposure peer pharmaceutical etf be reasonable option investor seek outperform health care etfs segment market however be other etfs space investor consider ishare pharmaceutical etf ihe free report track dow jone select pharmaceutical index powershare dynamic pharmaceutical portfolio pjp free report track dynamic pharmaceutical intellidex index ishare pharmaceutical etf have asset powershare dynamic pharmaceutical portfolio have ihe have expense ratio pjp charge investor look cheaper lower risk option consider traditional market cap weight etfs aim match return health care etfs bottom lineto learn more product other etfs screen product match investment objective read article latest development etf investing universe please visit zack etf center
983,LLY,response president donald trump tweet monday pfizer inc pfe free report say defer recent price increase several prescription drug maximum end year chief executive officer ceo ian read announce decision follow extensive discussion president last week new york base company have announce increase list price several drug effective jul be second time year pfizer increase price medicine pfizer raise price medicine average be agree limit price rise year however price few drug xalatan viagra chanix have already increase double digit include january hike pfizer defend price rise state list price do not reflect actual price include discount also mentioned have hike price only tenth drug portfolio reduce price drug first tweet monday president criticize pfizer price increase trump warn administration act response pfizer other drugmaker be ashamed have raise drug price reason tweet also say raise drug price unite state drug company be offer bargain basement price overseas latest statement read say price medicine return pre jul level soon technically possible also say price be defer president drug pricing blueprint go effect end year be sooner meanwhile price cut company remain effect tweet tuesday president appreciate pfizer decision hope other follow suit incidentally pfizer announcement price hike come only few week trump claim pharma company soon take massive price cut voluntarily however have be sign such price cut pfizer face criticism price hike be concern price hike company soon trigger market wide increase price drugmaker jnj free report merck mrk free report lilly lly free report other year so far pfizer share have increase decrease industry pfizer currently carry zack rank buy see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
984,LLY,merck co inc mrk free report pd inhibitor keytruda rule annual meeting american society clinical oncology asco chicago drug giant present additional datum pivotal lung cancer study drug merck present additional datum pivotal keynote study patient locally advanced metastatic nonsquamous squamous small cell lung cancer nsclc tumor express pd protein level percent greater tps percent april merck have say such patient keytruda lead significant survival benefit compare platinum base chemotherapy latest release company say patient tps percent median overall survival os be month keytruda arm versus month chemotherapy arm pd tps percent patient population median os be month patient tps percent be month versus month month respectively chemotherapy alone also merck say risk progression death progression free survival pfs secondary endpoint be pd tps percent population time interim analysis be not statistically significant notably keytruda monotherapy be already market first line treatment patient metastatic nsclc tumor express pd protein level percent greater tps percent base datum keynote study os datum keynote study be approve be include keytruda label drug be prescribe treat expand lung cancer patient population further reinforce position lung cancer market later year merck file regulatory application get os datum study include label keytruda merck also announce datum second interim analysis pivotallung cancer study keytruda phase iii keynote study evaluate keytruda combination carboplatin paclitaxel nab paclitaxel chemotherapy first line treatment metastatic squamous nsclc datum study show combination keytruda chemotherapy lead significant improvement os pfs regardless pd expression risk death os be reduce compare chemotherapy alone median os be month keytruda combination group versus month chemotherapy arm pfs improvement be nearly half patient keytruda combination group compare chemotherapy alone median pfs be month keytruda combination group versus month chemotherapy arm regulatory application include datum study be submit fda same time company have present datum first interim analysis keynote study say study meet pre specify secondary endpoint overall response rate orr early cohort participant asco company say orr be keytruda arm compare chemotherapy alonemetastatic squamous nsclc be difficult treat population account lung cancer case keytruda combination be approve treat difficult treat population lung cancer sale drug improve further year so far merck share have outperformed industry share have rise period industry decline keytruda be second largest product merck portfolio be market many type cancer treatment setting include lung cancer melanoma head neck cancer classical hodgkin lymphoma gastric cancer bladder cancer microsatellite instability high msi mismatch repair deficient cancer treatment fetch sale almost year year upside be drive global launch new indication further bolster demand keytruda sale be gain particularly strong momentum first line lung cancer indication fact keytruda be only pd approve first line set certain lung cancer patient monotherapy well combination therapy eli lilly lly free report cancer drug alimta pemetrexed carboplatin pem carbo meanwhile keytruda be be evaluate several lung cancer study multiple setting stage disease monotherapy well combination therapy asco merck also present datum several combination study tyrosinekinase inhibitor lenvimaplus keytruda asco study evaluate lenvima keytruda combination different tumor type unresectable hepatocellular carcinoma hcc squamous cell carcinoma head neck scchn advanced renal cell carcinoma rcc advanced endometrial carcinoma ec demonstrated encourage orr well safety profile cancer combination remind investor march merck form deal japan eisai co develop commercialize lenvima monotherapy well combination keytruda several type cancer asco merck also present interim datum mid stage study keynote evaluate keytruda monotherapy first line treatment advanced clear cell rcc datum show keytruda arm orr primary endpoint be meanwhile sub group patient tumor expressed pd orr be keytruda be be study more type cancer more study include excess combination study merck be collaborate several company include amgen amgn free report incyte glaxo gsk free report pfizer separately evaluation keytruda combination other regimen merck currently carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
985,LLY,allergan plc agn free report announce nationwide recall sample pack taytulla softgel oral contraceptive capsule mg mcg allergan say hormonal placebo pill be erroneously place contraceptive capsule have be instigate recall follow physician report same allergan warn inactive pill raise risk unintended pregnancy patient have concern consult doctor share allergan be almost tuesday follow recall fact so far year allergan share price have decline compare industry decline strong first quarter performance positive regulatory update share pharma company continue decline year believe be allergan be face loss exclusivity several key product continue be concern analyst first generic version alzheimer treatment namenda xr estrace cream be launch first quarter blockbuster dry eye drug restasis allergan second best selling drug be expect be launch second quarter generic version delzicol be also expect be launch early second quarter allergan estimate product face loss exclusivity wereworth sale product be expect decline significantly introduction generic first quarter conference call management address disconnect business performance stock value allergan ceo brent saunder say company be conduct strategic review business unlock shareholder value allergan currently carry zack rank hold better rank drug biotech stock include eli lilly company lly free report biomarin pharmaceutical inc bmrn free report ligand pharmaceutical lgnd free report zack rank buy see complete list today zack rank strong buy stock here lilly earning estimate increase past day company deliver positive earning surprise trail quarters average beat biomarin earning estimate rise past day share biomarin have rally year so far ligand earning share estimate increase last day company deliver positive earning surprise trail quarters average beat company share have rally year date today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
986,LLY,pfizer inc pfe free report be reportedly raise price almost drug effective july be second time drug giant have raise price drug year scrutiny drug price have increase trump assume office however softer drug pricing policy form last month expect other company follow suit increase price be nearly majority drug agree limit price rise year however price few drug xalatan viagra chanix have already increase double digit include price hike january trump announce plan control drug price unite state however group investor believe plan be not likely have major impact profit large pharma company instead include provision direct negotiation medicare pharma company trump target intermediary certain small pharma company foreign country thus medicare be major customer drug pay nearly dollar value prescription filled medicare have negotiate lower price directly manufacturer president also expect increase competition streamline approval related regulatory process promote faster approval generic biosimilar plan allow more substitution addition medicare drug list single source generic contain price rise give sponsor more negotiation power manufacturer also instruct company display list price advertising plan also focus more transparency related pricing availability generic moreover announcement price hike pfizer come week trump claim pharma company take massive price cut voluntarily soon pfizer have defend price rise state list price do not reflect actual price include discount also mentioned have hike price only tenth drug portfolio also reduce price drug meanwhile price hike company soon trigger market wide increase drug price thus pfizer move again stir opposition related drug price rise especially large pharma company pfizer stock price several other large cap pharma company moved north jul include johnson johnson jnj free report eli lilly company lly free report abbvie inc abbv free report rise drug price certainly help company boost profit so far year large cap pharma industry have decline rise expect investor remain focuse other pharma company announcement related drug price subsequent move government restrict further hike look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
987,LLY,teva pharmaceutical industry ltd teva free report confirm fda have extend action date biologic license application bla fremanezumab action date fremanezumab be now set september be previously set mid june be additional datum request fda fremanezumab be investigational therapy currently review fda quarterly monthly injection preventive treatment migraine adult be also review european union share teva increase year date industry decline remind investor fda accept review company bla fremanezumab december grant fast track designation candidate however january teva partner celltrion receive warning letter fda facility south korea follow inspection fill finish side facility thus delay approval drug facility manufacture active pharmaceutical ingredient apis fremanezumab teva thus state first quarter earning call do not expect receive fda approval bla fremanezumab mid june date company be constructive dialogue fda close collaboration partner celltrion recently note amgen amgn free report partner novartis nvs free report have receive fda approval pipeline candidate aimovig erenumab prevention migraine drug be first fda approve treatment specifically develop treat migraine block calcitonin gene related peptide cgrp receptor pharma giant eli lilly lly free report have cgrp candidate galcanezumab be review unite state decision galcanezumab be expect third quarter year teva carry zack rank hold see complete list today zack rank strong buy stock hereteva pharmaceutical industry ltd price teva pharmaceutical industry ltd price teva pharmaceutical industry ltd quotewall street next amazon zack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
988,LLY,merck mrk free report announce pivotal study keynote evaluate keytruda chemotherapy combination first line metastatic squamous small cell lung cancer nsclc meet dual primary endpoint overall survival os progression free survival pfs drug combination chemotherapy demonstrated significantly longer os pfs versus chemotherapy alone merck supplemental biologic license application sbla seek continue approval keytruda combine eli lilly lly free report alimta platinum chemotherapy treat metastatic squamous nsclc be review unite state sbla be file base encourage datum phase iii study keynote company plan share datum keynote study fda expand sbla include patient squamous histology company present detailed datum keynote study upcoming annual meeting american society clinical oncology next month share merck be market trading news be announce year so far merck share have outperformed industry share have rise period industry decline notably keytruda be already approve monotherapy first line treatment patient metastatic nsclc tumor express pd protein level greater keytruda also have accelerate approval treat first line patient metastatic nsclc combination alimta chemotherapy merck remain focuse develop keytruda monotherapy combination therapy treatment lung cancer various mutation histology first line set bid further reinforce position segment lung cancer be attractive market be largest cause death cancer patient moreover keytruda be only immune oncology drug be approve treatment lung cancer first line set remind investor bristol myer bmy free report be also develop immune oncology drug opdivo first line lung cancer however keytruda early entry positive datum readout several phase iii study expand first line lung cancer patient bode well company top line note keytruda be market many type cancer treatment setting include lung cancer melanoma head neck cancer classical hodgkin lymphoma gastric cancer bladder cancer microsatellite instability high msi mismatch repair deficient cancer meanwhile keytruda be be study more type cancer more study include excess combination study merck be collaborate several company include amgen amgn free report incyte glaxo pfizer separately evaluation keytruda combination other regimen merck co inc price merck co inc price merck co inc quotemerck currently carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
989,LLY,investor interested large cap pharmaceutical stock be likely familiar eli lilly lly free report nordisk nvo free report company be best option look undervalue stock let take closer look everyone have own method find great value opportunity model include pairing impressive grade value category style score system strong zack rank zack rank be proven strategy target company positive earning estimate revision trend style score work grade company base specific trait eli lilly have zack rank buy nordisk have zack rank strong sell right now system place emphasis company have see positive earning estimate revision so investor feel comfortable know lly be likely see earning outlook improve greater extent however value investor care much more just value investor analyze variety traditional try true metric help find company believe be undervalue current share price level value category grade stock base number key metric include try true ratio ratio earning yield cash flow share well variety other fundamental value investor frequently use lly currently have forward ratio nvo have forward also note lly have peg ratio popular figure be similar widely used ratio peg ratio also consider company expect ep growth rate nvo currently have peg ratio notable valuation metric lly be ratio be method compare stock market value book value be defined total asset total liability comparison nvo have metric several other help lly earn value grade nvo have be give value grade lly have see stronger estimate revision activity sport more attractive valuation metric nvo so seem value investor conclude lly be superior option right now
990,LLY,medical group have plenty great stock investor always be look company be outperform peer eli lilly lly free report be stock certainly grab attention many investor do recent return compare favorably sector whole simple way answer question be take look year date performance lly rest medical group stock eli lilly be individual stock medical sector collectively company sit zack sector rank zack sector rank consider different sector group average zack rank individual stock group be measure sector be list best worst zack rank be proven model highlight variety stock right characteristic outperform market next month system emphasize earning estimate revision favor company improve earning outlook lly be currently sporting zack rank buy zack consensus estimate lly full year earning have moved higher past quarter show analyst sentiment have improve company earning outlook be stronger accord latest datum lly have moved year date basis comparison medical company have return average see eli lilly be perform better sector calendar year look more specifically lly belong large cap pharmaceutical industry group include individual stock currently sit zack industry rank average stock group have lose year meaning lly be perform better term year date return investor medical sector want keep close eye lly attempt continue solid performance
991,LLY,celldex therapeutic inc cldx free report announce failure lead pipeline candidate glembatumumab vedotin phase iib breast cancer study metric candidate fail meet primary endpoint progression free survival pfs benefit roche rhhby free report chemotherapy xeloda treatment metastatic triple negative breast cancer overexpress gpnmb assessment datum mid stage study show glembatumumab vedotin achieve pfs month versus month xeloda candidate be also not able demonstrate significant advantage key secondary endpoint include overall response rate duration response overall survival follow failure celldex have decide discontinue study evaluate glembatumumab vedotin indication company be currently restructure pipeline focus candidate ongoing clinical study include varlilumab also reduce workforce approve product celldex portfolio discontinuation clinical study follow failure lead candidate come major setback pull stock more apr stock have decline so far year compare industry decline celldex be evaluate varlilumab cd agonist combination bristol myer bmy free report opdivo mid stage study several indication phase ii study be currently enrolling patient evaluate cdx combination eli lilly lly free report erbitux treatment head neck cancer company provide revise estimate first quarter earning release include impact restructure initiative celldex therapeutic inc price celldex therapeutic inc price celldex therapeutic inc quotecelldex carry zack rank hold see complete list today zack rank strong buy stock here breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
992,LLY,merck mrk free report announce encourage datum phase iii study eortc keynote evaluate pd therapy keytruda high risk stage iii melanoma patient adjuvant set datum study demonstrated adjuvant treatment keytruda significantly increase recurrence free survival rfs surgery compare placebo such patient drug reduce risk disease recurrence death placebo study rfs be achieve patient treat keytruda year compare placebo keytruda also significantly prolong rfs patient pd positive tumor reduce risk recurrence death placebo datum study be present american association cancer research aacr annual meeting be publish new england journal medicine share merck have outperformed industry so far year share have return industry decline say period study be be conduct collaboration european organisation research treatment cancer merck claim keytruda be first pd therapy achieve rfs benefit stage iiia iiib iiic melanoma patient drug have achieve rfs benefit patient irrespective braf mutation merck be evaluate keytruda broad clinical development program melanoma comprise clinical study setting stage disease separate press release merck astrazeneca azn free report announce final overall survival os datum phase iii olympiad study evaluate parp inhibitor lynparza metastatic breast cancer aacr annual meeting median os be month lynparza arm compare chemotherapy please note bristol myer bmy free report pd immune checkpoint inhibitor opdivo have receive approval intravenous administration melanoma patient adjuvant treatment december however keytruda have achieve rfs benefit higher proportion patient compare opdivo clinical study merck co inc price merck co inc price merck co inc quotezack rank stock considermerck carry zack rank hold eli lilly company lly free report be better rank stock pharma sector carry zack rank buy see complete list today zack rank strong buy stock here lilly earning estimate slightly increase last day company deliver positive earning surprise trail quarters average beat company be schedule report first quarter earning apr investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
993,LLY,abbvie inc abbv free report have announce pipeline candidate upadacitinib meet primary endpoint phase iii study select program evaluate candidate treatment patient rheumatoid arthritis ra upadacitinib be investigational oral jak selective inhibitor be be study once day oral therapy phase iii select compare study be design evaluate efficacy safety upadacitinib mg compare placebo abbvie market drug humira adalimumab week patient moderate severe ra be stable background methotrexate have inadequate response study upadacitinib meet primary well secondary endpoint compare placebo show superiority compare humira primary endpoint study register acr response clinical remission datum trial demonstrated patient receive oral once daily dose upadacitinib mg achieve acr response compare patient receive placebo week moreover subject treat upadacitinib achieve complete remission comparison placebo additionally datum study also show patient experience low disease activity secondary endpoint treat upadacitinib compare receive humira receive placebo week notably select compare be fourth ongoing phase iii study select ra clinical trial program conduct upadacitinib remind investor last december abbvie announce upadacitinib meet primary endpoint rd phase iii study select trial other research be also underway upadacitinib treat crohn disease ulcerative colitis atopic dermatitis share abbvie have rally past year outperform industry rise notably abbvie already have strong presence ra market blockbuster drug humira however several company be work develop biosimilar version humira induce competition market company also ra market be extremely crowd include drug johnson johnson simponi ucb cimzia other significantly eli lilly lly free report jak inhibitor olumiant be approve eu ra last february pfizer pfe free report xeljanz be market unite state same indication strong competition upadacitinib approval also late biogen biib free report have announce resolution ongoing patent dispute abbvie regard biogen biosimilar version humira eu settlement agreement biogen plan launch humira biosimilar europe october however upadacitinib be approve reduce potential negative impact humira generic abbvie top line abbvie inc price abbvie inc price abbvie inc quotezack rankabbvie carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
994,LLY,alzheimer candidate fail clinical study week independent datum monitoring committee idmc recommend lilly lly free report astrazeneca azn free report discontinue study lanabecestat share israel base small biotech galm pharmaceutical ltd glmd free report rise announce positive datum mid stage study nash candidate aramchol merck mrk free report gain fda approval new indication blockbuster pd therapy keytruda glaxo gsk free report late stage hiv study meet primary endpoint abbvie abbv free report roche rhhby free report astrazeneca gain regulatory nod label expansion key cancer drug recap week most important storieslilly astrazeneca alzheimer candidate fail lilly astrazeneca be discontinue late stage study alzheimer disease candidate lanabecestat recommendation idmc idmc say study early alzheimer disease other mild alzheimer disease dementia be unlikely meet primary endpoint completion lead decision discontinue study oral beta secretase cleave enzyme bace inhibitor latest setback add long list fail treatment option deadly brain disease read more lilly astrazeneca scrap study alzheimer candidate merck keytruda get fda nod new indication merck gain fda accelerate approval new indication blockbuster pd therapy keytruda week include third line treatment adult well pediatric patient primary mediastinal cell lymphoma pmbcl type hodgkin lymphoma second line treatment recurrent metastatic cervical cancer label expansion approval drive sale keytruda future quarters also merck regulatory application seek approval expand age indication hpv vaccine gardasil be grant priority review fda merck be look get gardasil approve woman man age hpv vaccine be presently approve man woman age read more merck keytruda get fda nod lymphoma indication glaxo gemini study drug hiv regimen succeed glaxo late stage study testing drug hiv regimen dolutegravir tivicay lamivudine show inferiority hiv control standard drug regimen regimen dolutegravir tenofovir alafenamide fumarate emtricitabine study be conduct treatment naïve hiv infected adult have not receive prior antiviral therapy regulatory application get drug regimen dolutegravir lamivudine approve be expect be file later year positive news glaxo mylan generic version glaxo blockbuster respiratory drug advair be delay again second complete response letter fda galm share hit roof nash candidate succeed study galm announce positive top line result mid stage study lead candidate aramchol treatment alcoholic steatohepatitis nash study demonstrated aramchol be effective reach primary endpoint importantly reduction liver fat measure magnetic resonance spectroscopy be demonstrated patient have complete week treatment aramchol mg compare placebo result strongly support advancement aramchol pivotal phase iii study share company sky-rocket news be announce read more galm soar positive nash datum aramchol allergan cgrp drug meet goal study allergan announce second cgrp candidate atogepant meet primary endpoint mid stage study cgp md study evaluate dose atogepant prevention episodic migraine week atogepant achieve reduction statistical significance monthly migraine probable migraine mpm headache day baseline dose allergan oral cgrp acute migraine treatment ubrogepant have already show positive result phase iii study separately allergan announce positive top line datum phase iii study pipeline candidate bimatoprost sr investigational implant develop first sustain release drop free treatment option lower intraocular pressure iop patient open angle glaucoma ocular hypertension datum study show bimatoprost sr reduce iop approximately week primary efficacy period thereby demonstrate inferiority study comparator timolol eye drop abbvie roche cancer drug get fda nod combo use abbvie roche announce fda approval combination use cancer drug venclexta rituxan previously treat chronic lymphocytic leukemia cll fda approval be base positive datum phase iii murano study venclexta rituxan relapse refractory cll venclexta be jointly market abbvie roche subsidiary genentech unite state abbvie outside unite state separately roche announce fda approval cancer drug avastin combination chemotherapy carboplatin paclitaxel treatment woman advanced ovarian cancer follow initial surgery latest approval avastin be now approve different type cancer unite state tagrisso get eu approval first line set astrazeneca azn free report lung cancer drug tagrisso gain eu approval first line treatment adult patient metastatic nsclc tumor have egfr mutation similar label expansion application be approve unite state april now tagrisso be approve unite state european union japan china second line treatment option patient egfr mutation positive nsclc label expansion first line set drive sale tagrisso higher future quarters read more astrazeneca tagrisso win eu nod first line lung cancer accept offer sell diabetes unit formally accept bound offer receive march approximately private equity firm platinum equity lifescan diabetes device unit lifescan unit make blood glucose monitoring product generate revenue last year transaction be expect be close end year read more accept platinum equity offer lifescan unit nyse arca pharmaceutical index rise last trading session large cap pharmaceutical industry yr return large cap pharmaceutical industry yr return here be major stock perform last trading session last week pfizer decline most glaxo generate highest return past month too glaxo have be biggest gainer bristol myer decline most see last pharma stock roundup here pharma stock roundup mrk impress asco lly get fda nod olumiant next pharma world watch fda decision several pipeline drug line extension market product month wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
995,LLY,ever president trump imposition tariff steel aluminum import china market large have suffer dearly have be number meeting trade representative country vain further escalate trade war tension report have surface treasury department have be draft policy prohibit firm have more chinese ownership benefit emerge technology unite state such policy have negative ramification industry healthcare biotech pharmaceutical be tech heavy need acquire industrially efficient technology growth sustenance so trade war china turn be nightmare healthcare sector let have look trump protectionism dampen healthcare fortunesearly stage pharmaceutical startup biotech company have historically benefit increase access chinese investment resource intellectual property right protection be go hamper grow entrepreneurial spirit biotech space long run brunt be bear more relatively small scale startup american vcs focus more larger startup top notch university further china have not include medical product retaliatory tariff impose unite state be not likely do so future well however case such scenario occur not be too good healthcare industry norm china refrain used copy drug american biotech company expert fear china get violate patent right due escalation trade war start copy drug company have significant exposure asian country such circumstance company pharmaceutical drug industry have pay dearly such turn event also result dwindle global share healthcare industry market leader zack large cap pharmaceutical industry such abbvie abbv free report glaxosmithkline gsk free report eli lilly lly free report merck mrk free report pifzer pfe free report end be biggest loser such company not only have significant chinese exposure be highly vulnerable instance right infringement see complete list today zack rank stock here chinese investment be oxygen biotech pharma chinese venture capital fund have invest whopping biotech drug company period january march surpass investment chinese vcs whole part such increase be attribute china effort become leader healthcare investment globe china increasingly want make use manufacturing intensive nature economy reason typically increase investment biotech firm be china want access novel therapy make use high return such investment however restriction trump administration chinese involvement biotech spell doomsday industry big reason be be relatively cheaper drug pharmaceutical company perform clinical trial china china drug administration cda chinese fda take less third time take fda approve result consequently cost involved be also lower pharmaceutical industry have suffer recent past due rise cost associate raw material trump act tariff imposition china have prove be rather several industry large turn be nightmarish healthcare industry be know fact chinese investment breathe life small mid scale healthcare company america finally event china infringe drug patent right american company have significant operation chinese shore bloodbath healthcare industry be inevitable wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
996,LLY,merck co inc mrk free report announce fda have accept supplemental biologic license application sbla keytruda pd therapy review company be seek approval blockbuster drug adjuvant therapy treatment patient resect high risk stage iii melanoma decision be expect feb year so far merck share have outperformed industry share have rise period industry decline sbla include datum pivotal eortc keynote study demonstrated keytruda achieve significant increase recurrence free survival rfs surgery compare placebo patient population recurrence free survival be achieve patient treat keytruda year compare placebo drug also reduce risk disease recurrence death placebo merck have claim keytruda be first pd therapy achieve rfs benefit stage iiia iiib iiic melanoma patient drug have achieve rfs benefit patient irrespective braf mutation remind investor drug be already approve type cancer indication several setting include first line melanoma recently approve cervical cancer large cell lymphoma keytruda garner sale first quarter sequentially year year sale drug be particularly boost strong momentum first line lung cancer indication be only approve pd therapy monotherapy combination eli lilly lly free report cancer drug alimta pemetrexed carboplatin merck be focuse further develop successful drug other indication keytruda be be evaluate more study include excess combination study more type cancer company have collaborate several company include amgen amgn free report incyte glaxo pfizer pfe free report separately evaluation keytruda combination other regimen merck co inc price merck co inc price merck co inc quotemerck currently carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
997,LLY,merck co inc mrk free report announce fda accelerate approval pd inhibitor keytruda third line treatment adult well pediatric patient primary mediastinal cell lymphoma pmbcl type hodgkin lymphoma company need evaluate drug confirmatory study indication gain continue approval be second indication keytruda have gain fda approval week tuesday keytruda gain fda accelerate approval advanced cervical cancer second line set label expansion approval drive sale keytruda future quarters latest approval keytruda become first pd therapy approve pmbcl be also second indication keytruda hematologic malignancy first be refractory classical hodgkin lymphoma chl fda approval be receive march approval be base datum keynote study year so far merck share have outperformed industry share have rise period industry decline keytruda be largest product merck portfolio prior latest approval keytruda be approve use different setting involve different tumor type treatment generate sale first quarter sequentially year year upside be drive global launch indication further boost demand keytruda sale be gain particularly strong momentum first line lung cancer indication fact keytruda be only pd approve first line set certain lung cancer patient monotherapy well combination therapy eli lilly lly free report cancer drug alimta pemetrexed carboplatin pem carbo recently conclude annual meeting american society clinical oncology pd inhibitor steal limelight encourage datum multiple clinical study datum presentation merck garner most attention physician investor be second interim analysis pivotal lung cancer study keytruda phase iii keynote study keytruda be be study more type cancer more study include excess combination study merck be collaborate several company include amgen amgn free report incyte glaxo gsk free report pfizer separately evaluation keytruda combination other regimen separate press release merck announce supplemental biologic license application sbla seek approval expand age indication hpv vaccine gardasil be grant priority review fda sbla be aim get gardasil approve woman man age prevention certain hpv related cancer disease vaccine be presently indicated man woman year age fda have set action date oct first quarter gardasil gardasil record sale year yearmerck currently carry zack rank buy see complete list today zack rank strong buy stock here medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
998,LLY,month have go last earning report eli lilly company lly free report share have add time frame recent positive trend continue lead next earning release be lly due pullback dive investor analyst have react late let take quick look most recent earning report order get better handle important driver lilly top earning sale raise viewlilly report first quarter adjust earning share beat zack consensus estimate share earning rise ex fx year quarter backed robust growth new product sale lower operate cost meanwhile lower tax rate reduction share outstanding share repurchase also lead higher earning quarter include asset impairment restructure other special charge first quarter earning share be loss cent first quarter revenue detailquarterly revenue also beat zack consensus estimate sale grow year year ex fx backed strong demand new drug favorable currency movement make lower sale establish product strattera ciali forteo volume rise increase demand new product trulicity cyramza taltz basaglar jardiance lartruvo offset decline sale establish product strattera effient axiron due loss exclusivity ciali due lower demand however volume growth be softer previous quarter new product product launch drive volume growth generate revenue represent nearly total revenue previous quarter other hand loss exclusivity effient strattera zyprexa cymbalta evista axiron hurt volume basis point lower demand ciali food animal product hurt volume basis point respectively higher realize price several drug contribute sale growth quarter foreign exchange rate also have favorable impact revenue grow ex revenue rise pharmaceutical revenue rise quarter however decrease demand food animal product continue hurt sale lilly animal health segment sale decline quarter establish product record growth quarter include humalog year year humulin trajenta forteo sale decline due decrease volume unfavorable wholesale retail buy pattern unite state however ex market sale forteo increase cymbalta sale decline erbitux sale decline zyprexa sale decline alimta sale rise higher sale unite state offset sale decline international market ex market sale decline due competitive pressure loss exclusivity certain country however sale alimta increase unite state due increase volume higher realize price ciali sale decline hurt lower demand unite state due entry generic sildenafil loss exclusivity europe strattera sale decline due loss exclusivity new product trulicity generate revenue year year revenue benefit growth glp market market share gain cyramza revenue be year year backed strong demand cyramza ex revenue increase benefit strong volume currency benefit partially offset lower realize price cyramza revenue increase drive increase volume higher realize price jardiance sale surge drive increase market share grow sglt class unite state increase volume outside unite state basaglar record revenue compare previous quarter generate revenue unite state improve sequentially drive increase demand drug gain medicare part formulary access sale growth be flat ex market taltz bring sale compare previous quarter higher ex revenue be offset lower sale ex sale benefit continue uptake new launch sale unite state be hurt unfavorable specialty pharmacy buy pattern lartruvo olaratumab generate revenue quarter compare previous quarter olumiant baricitinib have be launch select european country japan moderate severe rheumatoid arthritis drug generate sale quarter backed strong launch uptake germany compare previous quarter verzenio be launch unite state fourth quarter generate sale quarter compare previous quarter quarter verzenio gain fda approval be launch first line set metastatic breast cancer base monarch datum elanco animal health segment sale decline ex fx due decrease demand food animal product food animal product revenue decline hurt market access pressure companion animal revenue rise due higher realize price currency benefit gross margin operate income adjust gross margin quarter decrease basis point manufacturing efficiency higher realize price be offset negative product mix effect foreign exchange rate international inventory sell exclude effect foreign exchange international inventory sell gross margin increase nearly bps operate income increase year year due lower operate cost total operate expense include research development marketing selling administrative expense percent revenue decline basis point quarter due company cost save effort marketing selling administrative expense decline decline quarter adjust effective tax rate be lower year quarter drive primarily impact tax reform guidance uppedlilly raise previously issue outlook adjust earning well sale adjust earning share be now expect range higher expect previously reflect expect benefit higher operate profit lower tax rate revenue range be also slightly up expect previously sale guidance increase be due lower anticipate rebate discount result lower expect medicaid utilization payer mix positive impact currency gross margin be expect be approximately same previously expect adjust tax rate be expect be approximately previously approximately marketing selling administrative expense guidance be tighten range compare previously research development expense guidance be slightly increase range compare previously due increase funding requirement pipeline development go forward new product trulicity taltz basaglar cyramza jardiance lartruvo verzenio olumiant be expect drive revenue be slightly negative first half animal health revenue be expect improve second half support new product launch have estimate be move then past month investor have witness upward trend fresh estimate have be revision higher current quarter eli lilly company price consensus eli lilly company price consensus eli lilly company quotevgm scoresat time lly have average growth score however momentum be do bit better charting somewhat similar path stock be allocate grade value side putt middle investment strategy overall stock have aggregate vgm score aren focuse strategy score be be interested base score stock be more suitable momentum investor look value growth outlookestimate have be trend upward stock magnitude revision look promising notably lly have zack rank hold expect line return stock next few month
999,LLY,eli lilly company lly free report announce fda have approve inclusion additional datum label psoriasis injection taltz latest approval taltz label now include datum psoriasis involve genital area impact roughly psoriasis patient course disease taltz be already market treatment adult patient moderate severe plaque psoriasis be candidate systemic therapy phototherapy well active psoriatic arthritis taltz work specifically target il protein play role drive underlie inflammation psoriasis drug record sale first quarter label expansion expand eligible patient population drug drive sale go forward approval genital psoriasis be base datum study evaluate patient moderate severe psoriasis involve genital area study taltz demonstrated significant improvement compare placebo week severity psoriasis affect genital area overall psoriasis genital itch impact genital psoriasis sexual activity such patient many other drug novartis nvs free report cosentyx jnj free report tremfya abbvie abbv free report humira be approve treat plaque psoriasis lilly claim taltz be now first only fda approve treatment genital psoriasistaltz be also be study late stage study axial year date lilly share have decline compare industry decline lilly currently carry zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1000,LLY,amgen inc amgn free report announce fda have approve supplemental biologic license application sbla seek label expansion prolium treatment glucocorticoid induced osteoporosis giop man woman high risk fracture have fail be intolerant other available osteoporosis therapy be fifth approve indication prolium approval be backed increase bone mineral density bmd achieve drug phase iii study drug be presently market unite state treatment postmenopausal woman osteoporosis high risk fracture well increase bone mass man osteoporosis high risk fracture share amgen be market trading follow news company share have rally year so far industry decline phase iii study evaluate prolium treatment giop patient man woman high risk fracture have fail be intolerant other available osteoporosis therapy compare allergan agn free report actonel risedronate study comprise patient group patient have receive glucocorticoid treatment less month prior study enrollment glucocorticoid initiate arm second patient have receive glucocorticoid treatment least month glucocorticoid continue arm arm glucocorticoid treatment be continue least month datum study show prolium increase lumbar spine bmd compare actonel glucocorticoid initiate arm lumbar spine bmd patient treat prolium glucocorticoid continue arm increase compare actonel glucocorticoid induced osteoporosis be most common form secondary osteoporosis serious condition be presently treat glucocorticoid treatment increase fracture risk first month treatment prolium now cater expand patient population drive sale higher prolium be key revenue generator amgen be witness market share gain unite state internationally competition generic other drug approve osteoporosis drug generate sale year year prolium face competition several drug especially generic version eli lilly lly free report evista alendronate merck mrk free report fosamax raloxifene novartis zometa zoledronate amgen inc price amgen inc price amgen inc quotezack rank amgen currently carry zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1001,LLY,share vtv therapeutic inc vtvt free report plummet significantly company announce dismal result part phase iii trial steadfast pipeline candidate azeliragon vtv therapeutic stock have plunge last month industry decline candidate be be evaluate patient suffering alzheimer disease result show candidate do not meet co primary efficacy endpoint patient take azeliragon versus placebo do not improve cognitive functional outcome measure thealzheimer disease assessment scale cognitive subscale ada cog clinical dementia rating scale sum box cdr sb study comprise independent identical randomize double blind placebo controlled phase iii trial part part azeliragon treat group part show point decline baseline ada cog point dip baseline cdr sb compare placebo fall respectively however difference be not statistically significant azeliragon be generally well tolerate withdrawal rate month be similar placebo treatment arm consequently vtv therapeutic discontinue ongoing study involve azeliragon include open label extension study part steadfast study nevertheless substantial portion patient part steadfast have complete month treatment study protocol failure late stage study be disappointing investor successful development subsequent candidate have significantly boost growth prospect give complexity drug late have be many failure drug be develop alzheimer february merck mrk free report announce stop phase iii study apecs be evaluate verubecestat mk investigational small molecule inhibitor beta site amyloid precursor protein cleave enzyme bace patient prodromal alzheimer disease decision be take external datum monitoring committee assessed overall benefit risk recent interim safety analysis conclude be unlikely positive benefit risk be possible january pfizer pfe free report announce plan end research effort new drug alzheimer parkinson disease eli lilly lly free report be major company have suffer many failure attempt develop drug alzheimer zack rankvtv therapeutic currently carry zack rank sell see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1002,LLY,merck co inc mrk free report announce datum phase iii study show treatment pd inhibitor keytruda monotherapy lead significantly improve overall survival os first line therapy certain lung cancer patient pivotal keynote study evaluate patient locally advanced metastatic nonsquamous squamous small cell lung cancer nsclc tumor express pd protein level percent greater tps percent such patient keytruda show significant survival benefit compare platinum base keytruda monotherapy be already market first line treatment patient metastatic nsclc tumor express pd protein level percent greater tps percent base datum keynote study os datum keynote study be approve be include keytruda label drug be prescribe treat expand lung cancer patient population further reinforce position lung cancer market study continue evaluate progression free survival pfs secondary endpoint base recommendation independent datum monitoring committee dmc later year merck present datum keynote study medical meeting also file regulatory application get os datum study include label keytruda share merck be more apr news be announce market open year so far merck share have outperformed industry share have rise period industry decline meanwhile keytruda be be evaluate several lung cancer study multiple setting stage disease monotherapy well combination therapy keytruda be second largest product merck portfolio be market many type cancer treatment setting include lung cancer melanoma head neck cancer classical hodgkin lymphoma gastric cancer bladder cancer microsatellite instability high msi mismatch repair deficient cancer treatment fetch sale almost year year upside be drive global launch new indication further bolster demand keytruda sale be gain particularly strong momentum first line lung cancer indication fact keytruda be only pd approve first line set certain lung cancer patient monotherapy well combination therapy eli lilly lly free report cancer drug alimta pemetrexed carboplatin pem carbo keytruda development program also significantly advanced several regulatory approval unite state europe japan new approval expand patient population drive sale last year positive momentum be expect sustain well meanwhile keytruda be be study more type cancer more study include excess combination study merck be collaborate several company include amgen amgn free report incyte glaxo gsk free report pfizer separately evaluation keytruda combination other regimen merck carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1003,LLY,johnson johnson jnj free report have accept offer private equity firm platinum equity sale lifescan diabetes device unit company have announce receipt bound offer platinum equity march lifescan unit make blood glucose monitoring product generate revenue last year stock have decline year so far compare unfavorably decrease record industry move be line strategic plan diabetes business company have be plan streamline core asset last year part streamline effort have announce close operation corporation diabetes care unit october last year company have arrange deal medical device maker medtronic inc mdt free report transition patient insulin pump medtronic pump meanwhile also receive offer fortive corporation ftv free report earlier month advanced sterilization product business moreover sale diabetes care franchise decline due price decline competitive pressure thus streamline asset be likely boost margin well cash position company johnson johnson price johnson johnson price johnson johnson quotezack rankj currently carry zack rank hold eli lilly company lly free report be better rank large cap pharma stock carry zack rank buy see complete list today zack rank strong buy stock here lilly earning share estimate moved last day share company be year so far hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1004,LLY,eli lilly company lly free report swiss partner astrazeneca azn free report announce discontinuation late stage study alzheimer disease ad candidate lanabecestat recommendation independent datum monitoring committee idmc idmc say amaranth study evaluate lanabecestat early alzheimer disease daybreak alz study mild alzheimer disease dementia be unlikely meet primary endpoint completion lead decision discontinue study oral beta secretase cleave enzyme bace inhibitor company claim recommendation stop study be not base safety concern lilly do not expect incur significant cost related discontinuation maintain previously issue earning guidance meanwhile partnership lilly astrazeneca develop bace inhibitor remain intact lilly astrazeneca be also develop treatment alzheimer disease antibody target beta amyloid early stage study year date lilly share have rise industry decline be not first failure lilly alzheimer disease market november lilly amyloid candidate solanezumab fail meet primary endpoint late stage ad study lilly decide drop development solanezumab lilly also suffer major setback august have halt development phase iii alzheimer candidate semagacestat alzheimer disease market have attract lot attention several company however successful development therapy treatment alzheimer disease fatal illness cause progressive decline memory be challenge note several company have fail regard year jnj free report halter development atabecestat investigational bace inhibitor be be develop preclinical stage alzheimer disease due safety concern february year merck mrk free report discontinue second late stage study evaluate bace inhibitor verubecestat treatment prodromal alzheimer disease success be unlikely february last year merck discontinue late stage study evaluate verubecestat mild moderate alzheimer disease due lack efficacy late biogen alzheimer disease study ban fail show early positive result raise investor concern candidate chance success alzheimer disease market represent huge commercial potential successfully develop product generate billion dollar sale once launch lilly currently carry zack rank buy see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1005,LLY,alzheimer fatal illness cause progressive decline memory have always be highly challenge area not much progress be make spite significant investment fund resource tuesday lilly lly free report swiss partner astrazeneca azn free report say be discontinue late stage study alzheimer disease candidate lanabecestat recommendation independent datum monitoring committee idmc idmc say study be unlikely meet primary goal completion prompt decision stall study oral beta secretase cleave enzyme bace inhibitor several company have fail develop safe effective treatment option deadly brain disease year jnj free report halter development atabecestat investigational bace inhibitor be be develop preclinical stage ad due safety concern february year merck mrk free report discontinue second late stage study evaluate bace inhibitor verubecestat treatment prodromal ad success be unlikely february last year merck discontinue late stage study evaluate verubecestat mild moderate ad due lack efficacy january pfizer pfe free report say end effort alzheimer parkinson disease area long back pfizer have shelved late stage ad candidate bapineuzumab iv fail phase iii study late biogen biib free report ad study ban fail show early positive result raise investor concern candidate chance success clinical stage company axovant science suffer major setback september investigational ad candidate fail meet co primary efficacy endpoint late stage study company decide discontinue development mg dose treatment ad lilly decide november not seek approval investigational ad treatment solanezumab follow disappointing result late stage study candidate be be evaluate see slow progression memory problem associate amyloid protein form plaque brain person alzheimer accord alzheimer association year drug be test alzheimer study register clinicaltrial gov only succeed go gain fda approval be somewhat underlie cause severe neurological ailment alzheimer not be clear disease cancer also alzheimer progress go unnoticed year time symptom ailment become evident significant function be already lose make develop drug treat disease difficult interest still alive setback several company continue invest heavily develop alzheimer disease treatment give high commercial potential market success area mean huge return consider more american be live alzheimer disease number expect triple datum alzheimer association be consider be biggest burden society be sixth lead cause death age unite state market have immense commercial potential company come new treatment rake billion dollar sale biogen novartis nvs free report eisai astrazeneca amgen be presently work alzheimer disease treatment biogen ad pipeline comprise mid well late stage candidate different mechanism action include tau candidate biib amyloid aducanumab candidate well bace inhibitor elenbecestat program candidate be be develop collaboration eisai meanwhile novartis amgen be collaborate bace inhibitor cnp have fast track status unite status roche be collaborate ac immune development alzheimer disease treatment lilly astrazeneca be also develop treatment alzheimer disease antibody target beta amyloid early stage study earlier year fda propose new guideline be aim lower clinical study goal alzheimer disease drug aim treat earlier stage patient have not yet display functional disability clinical abnormality strategy be part fda ongoing effort expand access safe effective treatment option many serious condition effort fda also reinvigorate research effort alzheimer drug repeat failure lilly merck carry zack rank buy see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1006,LLY,last year turn be pretty good pharma biotech stock far fda decision be concern regulatory body approve novel drug easily surpass total tally landmark decision last year include approval couple gene base therapy cancer novartis nvs free report kymriah gilead science gild free report yescarta therapy have potential change way look cancer treatment just quarter go year fda have already grant approval new treatment key approval include jnj free report next generation oral androgen receptor ar inhibitor erleada apalutamide pre metastatic prostate cancer crpc vertex pharmaceutical incorporate vrtx free report third medicine treat underlie cause cf symdeko be combination tezacaftor ivacaftor gilead once daily single tablet hiv regimen biktarvy novartis lutathera certain neuroendocrine tumor drug development process be lengthy time consume require utilization lot fund resource key pipeline event include datum readout regulatory update be paramount importance act major catalyst let take look few important regulatory event schedule month april note month fda have already approve pacira pharmaceutical exparel new indication nerve block regional analgesia clovis oncology parp inhibitor rubraca maintenance therapy recurrent ovarian cancer second indication novartis kymriah apr fda be expect give decision novartis supplemental biologic license application bla look approval kymriah second indication latest filing novartis be look get kymriah approve treatment adult patient relapse refractory diffuse large cell lymphoma dlblc most common form hodgkin lymphoma have fail more prior therapy kymriah be approve treatment deadly cancer call acute lymphoblastic leukemia last august accord company annual report dlblc patient do not respond initial therapy relapse month treatment indicate significant market potential kymriah dlblc indication fda decision mallinckrodt label expansion amitiza child mallinckrodt plc mnk free report supplemental new drug application snda look get constipation drug amitiza approve paediatric functional constipation year be review fda be expect give decision apr amtiza be add mallinckrodt portfolio february acquisition sucampo pharmaceutical amitiza be already approve chronic idiopathic constipation cic adult irritable bowel syndrome constipation ib adult woman opioid induced constipation oic patient chronic cancer pain accord company press release amitiza approve paediatric functional constipation be first only prescription medication specifically approve such patient have limit treatment option address disease fda panel back gw pharmaceutical epidiolex incyte lilly olumiant fda panel be expect give opinion gw pharmaceutical lead cannabinoid pipeline candidate epidiolex next week gw pharmaceutical be look get epidiolex approve adjunctive treatment seizure associate lennox gastaut syndrome lgs dravet syndrome be highly treatment resistant form childhood onset epilepsy fda grant priority review epidiolex nda response fda be expect jun epidiolex represent blockbuster potential especially be approve possible indication fda panel be also expect give opinion month incyte lilly lly free report olumiant baricitinib treatment adult patient moderately severely active rheumatoid arthritis april company have receive complete response letter crl fda baricitinib fda require additional clinical datum thenda olumiant be re submit january olumiant have already be launch select european country japan fetch sale fda take recommendation panel advisory committe account review application be not bound follow same fda decision rigel tavalisse ultragenyx burosumab april fda be expect give decision rigel pharmaceutical nda tavalisse fostamatinib treatment chronic immune itp apr rigel be prepare launch oral spleen tyrosine kinase syk inhibitor second quarter approve exist therapy treat chronic itp include steroid blood platelet production booster tpos splenectomy however still disease remain inadequately treat many patient mean approve tavalisse enjoy significant market potential fda decision expect apr be ultragenyx pharmaceutical bla burosumab treat pediatric adult patient link xlh burosumab be approve treat xlh trade name crysvita eu february fda decide prometic ryplazim fda decision expect apr be canadian biotech prometic life science biologic license application bla ryplazim treatment congenital plasminogen deficiency ryplazim enjoy orphan drug fast track designation fda say indication bristol myer opdivo yervoy combo get fda approval bristol myer bmy free report have file sbla look get blockbuster drug opdivo approve combination cancer drug yervoy patient previously untreated advanced metastatic renal cell carcinoma rcc fda decision be expect apr clinical study combination have demonstrated superior overall survival os compare current standard care sunitinib intermediate poor risk patient bode well drug give potential target market pd inhibitor be presently approve several country include unite state eu japan several cancer indication label expansion boost opdivo sale further opdivo generate sale almost bristol myer be zack rank hold stock see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1007,LLY,migraine be serious neurological disease have significant effect patient daily life patient suffer debilitating pain physical impairment fear next attack be estimate patient frequent migraine attack lose more half life disease last week amgen amgn free report partner novartis nvs free report announce fda approval drug aimovig erenumab prevention migraine aimovig be first fda approve drug specifically develop treatment migraine block calcitonin gene related peptide cgrp receptor approval be base positive datum several mid late stage study drug achieve significant reduction monthly migraine day use acute migraine medication compare placebo datum study moreover aimovig show time higher probability reduce migraine day half compare placebo patient episodic migraine patient fail prior treatment approval aimovig investor focus have shift cgrp drug candidate treatment migraine eli lilly lly free report teva pharmaceutical industry limit teva free report respective cgrp candidate galcanezumab fremanezumab be review unite state inc aldr free report be also develop cgrp candidate eptinezumab treat migraine first quarter regulatory filing state be approximately person live serious neurological disease unite state alone include episodic chronic migraine migraine be rank top cause year live disability worldwide however traditional preventive therapy have tolerability limitation several side effect represent huge unmet need new cgrp therapy aimovig other review candidate cnbc article regulatory filing migraine market be worth next few year amgen have price aimovig once monthly mg single use prefil sureclick autoinjector annually price certainly pinch patient thus acceptance drug remain be see however insurance coverage aimovig copay program significantly bring cost moreover potential approval galcanezumab fremanezumab come month increase competition put downward pressure pricing look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1008,LLY,week astrazeneca azn free report novartis nvs free report eli lilly lly free report announce regulatory pipeline update line extension market drug astrazeneca asthma drug fasenra fail meet primary endpoint late stage study evaluate expand indication chronic obstructive pulmonary disease copd lilly migraine candidate galcanezumab meet same late stage study evaluate indication prevention episodic cluster headache novartis multiple sclerosis ms drug gilenya gain fda approval use adolescent cgrp antibody aimovig also gain fda approval prevention migraine zoetis zts free report lilly announce acquisition deal recap week most important storieslilly buy small cancer biotech lilly have agree buy early phase oncology asset ak aurka pharma expand oncology pipeline lilly make upfront payment acquire share aurka pharma be lilly second cancer acquisition less week last week lilly have announce cash deal tobuy immuno oncology biotech armo bioscience read more eli lilly buy aurka pharma expand cancer pipeline development migraine candidate galcanezumab meet primary endpoint late stage study evaluate indication prevention episodic cluster headache galcanezumab be already review unite state migraine prevention decision expect third quarter year however separate phase iii study evaluate galcanezumab patient chronic cluster headache do not meet primary endpoint read more eli lilly cluster headache candidate succeed phase iii zoetis buy abaxis zoetis announce definitive agreement buy california base abaxis be lead global provider veterinary point care diagnostic instrument approximately share cash deal be aim enhance zoetis presence animal health diagnostic market diagnostic category be fast grow portion animal health industry have grow compound annual growth rate approximately last year read more zoetis inks deal acquire abaxis novartis aimovig get fda nod novartis partner amgen amgn free report gain fda approval cgrp antibody aimovig prevention migraine fda approval aimovig be now first only fda approve treatment migraine work block calcitonin gene related peptide receptor cgrp play critical role migraine attack meanwhile lilly teva pharmaceutical industry ltd teva free report be also await fda approval cgrp migraine candidate galcanezumab fremanezumab year novartis ms drug gilenya gain fda approval treatment child adolescent age relapse form multiple sclerosis approval expand patient population boost sale gilenya drug record sale first quarter represent year year growth rate constant currency basis read more novartis multiple sclerosis drug get fda nod adolescent astrazeneca fasenra fail meet endpoint phase iii copd study astrazeneca respiratory biologic medicine fasenra benralizumab fail meet primary endpoint late stage study evaluate new indication severe copd fasenra be already approve unite state eu japan add maintenance treatment patient severe eosinophilic asthma top line result pivotal phase iii galathea study show treatment fasenra do not result statistically significant reduction exacerbation compare placebo patient moderate very severe copd read more astrazeneca asthma drug fasenra fail copd study astrazeneca announce weak first quarter result miss zack consensus estimate earning sale due lower sale cholesterol drug crestor maintain previously issue outlook pfizer biosimilar retacrit get fda nod pfizer pfe free report retacrit be biosimilar version anemia drug amgen epogen jnj free report procrit gain fda approval indication reference product include treatment anemia due chronic kidney disease ckd pfizer already market biosimilar europe last year fda advisory committee have recommend approval retacrit read more pfizer get fda nod amgen anemia drug biosimilar fda name drugmaker block approval generic fda issue list company week say be used certain gaming tactic delay generic competition market drug fda say company be prevent generic player obtain necessary sample brand product be require secure approval generic drug inability secure such sample slow approval process list include big name shire novartis mylan astrazeneca teva biomarin gilead bayer other fda decision publish such list be part broader effort congress encourage approval low cost generic drug nyse arca pharmaceutical index rise last trading session large cap pharmaceutical industry yr return large cap pharmaceutical industry yr return here be major stock perform last trading session stock be green last week decline bristol myer rise most past month glaxo gsk free report have be biggest gainer bristol myer decline most see last pharma stock roundup here pharma stock roundup lly buy cancer biotech azn roche announce update next pharma world watch fda decision many pipeline drug line extension market product month more stock news be bigger iphoneit become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1009,LLY,astrazeneca plc azn free report miss zack consensus estimate earning sale first quarter hit decline sale cholesterol drug crestor swiss pharma giant maintain previously issue outlook stock decline more pre market trading friday year so far astrazeneca share have rise industry decline first quarter core earning be cent american depositary share ad miss zack consensus estimate cent core earning share cent decline year year constant exchange rate cer hurt lower revenue operate profit meanwhile lower other income due unfavorable timing divestment also hurt earning quarter total revenue decline cer report quarter due lower product sale well externalization revenue revenue also miss zack consensus estimate growth rate mentioned be year year basis cer product sale declineproduct sale decline cer quarter higher sale newer medicine strong performance china be offset rapid erosion sale crestor lower sale many other legacy medicine externalization revenue be quarter externalization revenue be revenue arise astrazeneca externalization agreement older productscrestor sale decline unite state accounting europe contribute cer europe sale be weak multiple generic version drug enter market seroquel xr sale decline due competition generic launch symbicort sale decline quarter due sale decline market symbicort sale unite state decline quarter due pricing pressure unfavorable timing government buy sale rise europe emerge market nexium record sale due decline sale unite state europe other key legacy product record sale decline quarter include zoladex arimidex casodex pulmicort daliresp daxas synagis very few older drug grow quarter include faslodex seloken toprol xl newer productsamong newer medicine lynparza sale rise quarter sale unite state surge gain recent label expansion approval europe sale rise push higher number successful launch high brca testing rate encourage level reimbursement first quarter lynparza gain approval japan ovarian cancer unite state breast cancer drive sale further please note astrazeneca have partnership agreement merck mrk free report lynparza brilinta brilique sale be report quarter year year brilinta maintain leadership position brand oral platelet market well number european market farxiga record sale quarter medicine continue lead market volume new respiratory product fasenra get strong start record sale quarter support strong launch uptake unite state germany fasenra be approve unite state november last year eu japan january year quarter onglyza sale decline reflect pressure dpp class increase competitive pressure class diabetes medicine label include cv benefit tagrisso record sale year year drive increase testing rate unite state japan last month astrazeneca secure fda approval tagrisso first line set advanced lung cancer drive sale higher future quarters other new medicine movantik moventig record sale quarter less previous quarter iressa sale decline bevespi lama laba pressurize meter dose inhaler launch commercially unite state january record sale quarter less previous quarter slower anticipate growth lama laba class pd inhibitor imfinzi generate sale first quarter compare fourth quarter february imfinzi be approve immediately launch second indication unite state early stage lung cancer nsclc drive sale first quarter imfinzi be launch unite state first indication second line advanced bladder cancer calquence be launch unite state october last year generate sale first quarter compare previous quarter regional performancein unite state product sale be flat higher sale newer product be offset lower symbicort sale unfavorable manage care pricing generic launch european market witness decline sale due weak crestor sale revenue emerge market be primarily back strong growth china sale decline ex china market due challenge condition healthcare market russia establish row market comprise japan canada other market sale decline profit core gross margin decline basis point bps core selling general administrative sg expense rise due investment new product launch quarter core research development expense decline drive efficiency saving operate margin decline bps quarter maintain previously issue earning sale outlook astrazeneca expect core ep range adr company expect product sale grow low single digit percentage however product sale growth be expect be weight second half year astrazeneca be hopeful effect crestor patent expiration europe japan recede materially second halfmanagement guide total externalization revenue other income be less currency movement be expect favorably impact product sale core earning share low single digit percentage adjust cost be expect be line decline low single digit percentage range level company anticipate sg cost increase low mid single digit percentage support product launch fasenra imfinzi adjust tax rate be expect be range compare astrazeneca currently carry zack rank hold see complete list today zack rank strong buy stock here better rank pharma biotech stock include ligand pharmaceutical incorporate lgnd free report eli lilly lly free report ligand have zack rank lilly be rank stock ligand earning estimate rise past day stock have gain year so far lilly earning estimate increase respectively past day more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1010,LLY,be happen week pharma stock key development week include new car deal pfizer pfe free report successful study result pfizer lilly lly free report allergan agn free report positive regulatory update astrazeneca azn free report recap week most important storiespfizer car deal tafamidis succeed late stage study pfizer announce alliance private biotech allogene therapeutic expedite development allogeneic car therapy pfizer own stake allogene also get representation latter board meanwhile cnbc report say pfizer be talk consumer giant procter gamble regard sale consumer healthcare segment last month glaxo gsk free report reckitt benckiser group pull discussion pfizer buy same unit read more pfizer inks new car deal talk unit sale pfizer pipeline candidate tafamidis develop treatment transthyretin cardiomyopathy ttr cm meet main goal late stage study attr act top line datum attr act study show treatment tafamidis lead statistically significant reduction combination cause mortality frequency cardiovascular related hospitalization primary endpoint compare placebo month read more pfizer rare disease candidate meet endpoint phase iii pfizer regulatory application pipeline candidate dacomitinib be accept priority review unite state response expect september company be look get drug approve first line treatment patient locally advanced metastatic small cell lung cancer nsclc egfr activate mutation read more pfizer lung cancer candidate get fda priority review lilly cyramza meet os endpoint liver cancer study lilly announce already approve cancer drug cyramza show overall survival benefit thereby meeting primary endpoint late stage study evaluate second line treatment liver cancer study also meet secondary endpoint progression free survival read more lilly cyramza show survival benefit liver cancer study astrazeneca provide regulatory update astrazeneca diabetes treatment bydureon gain fda approval add therapy insulin glargine also biologic license application bla seek approval astrazeneca cd recombinant immunotoxin candidate moxetumomab pasudotox second later line treatment hairy cell leukaemia hcl be grant priority review fda fda grant priority review decision be expect third quarter regulatory development astrazeneca partner merck mrk free report regulatory submission look expand label parp inhibitor lynparza include breast cancer indication be accept eu lynparza be already approve treat ovarian cancer eu latest filing astrazeneca look get lynparza approve brca mutate negative metastatic breast cancer eu unite state lynparza be approve same indication january read more astrazeneca bydureon get fda nod expand use allergan vraylar succeed label expansion study allergan partner gedeon richter say vraylar cariprazine meet primary endpoint late stage study adult major depressive episode associate bipolar disorder bipolar depression be third pivotal study conduct indication datum study be include company label expansion application company plan file second half read more allergan vraylar meet endpoint bipolar phase iii bio path mid stage study leukemia candidate show positive early datum bio path holding announce positive interim datum phase ii study bp lead pipeline candidate prexigebersen be be evaluate combination low dose cytarabine ldac treatment patient acute myeloid leukemia aml elect not be treat more intensive chemotherapy combination therapy demonstrated early leukemic activity nearly evaluable aml patient study total patient achieve form response combo treatment share bio path shot response read more bio path leukemia combo study show positive early datum fda approve sonoma skin gel sonoma pharmaceutical small solution maker skin condition advanced tissue care gain fda approval antimicrobial post treatment gel gel aim treat itch pain associate procedure include laser skin resurface post therapy chemical peel share sonoma shot more response nyse arca pharmaceutical index rise last trading session large cap pharmaceutical industry yr return large cap pharmaceutical industry yr return here be major stock perform last trading session stock record gain bristol myer bmy free report glaxo be biggest gainer rise bristol myer decline last month astrazeneca have be biggest gainer merck decline most see last pharma stock roundup here pharma stock roundup abbv rova disappoint unit get buyout offer next pharma world watch regulatory pipeline news pharma stock make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1011,LLY,amgen amgn free report announce european commission ec have approve label expansion blockbuster drug prolium drug be now approve treatment bone loss associate long term systemic glucocorticoid therapy adult patient increase risk fracture be also call glucocorticoid induced osteoporosis be third approve indication prolium europe approval be backed increase bone mineral density bmd achieve drug phase iii study similar line extension application receive approval unite state last month prolium be presently market europe treatment man postmenopausal woman osteoporosis high risk fracture well increase bone mass man prostate cancer receive hormone ablation amgen share have increase year so far industry decline phase iii study evaluate prolium improvement bmd patient receive glucocorticoid treatment compare allergan agn free report actonel risedronate study comprise patient group patient sustain glucocorticoid treatment glucocorticoid continue arm second patient initiate glucocorticoid therapy glucocorticoid initiate arm arm prolium demonstrated greater improvement lumbar spine bmd patient year year compare actonel study primary endpoint glucocorticoid induced osteoporosis be most common form secondary osteoporosis press release patient receive glucocorticoid treatment long term have show vertebral fracture proportion eligible patient be small line extension be likely boost sale drug further prolium be major revenue source amgen be witness growth market share unite state internationally competition generic other drug approve osteoporosis first quarter drug generate sale almost half dollar year year drug face competition generic other brand drug include eli lilly lly free report evista alendronate merck mrk free report fosamax raloxifene novartis zometa zoledronate amgen inc price amgen inc price amgen inc quotezack rankamgen currently carry zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1012,LLY,be approve therapy completely cure autoimmune inflammatory disease development new treatment technology be ongoing meanwhile be difficult control autoimmune disease majority patient newest class medication treat disease be janus kinase jak inhibitor be provide patient better treatment option class therapy have generate significant interest due better efficacy compare tumor necrosis factor tnf inhibitor therapy autoimmune diseasesin patient autoimmune disease body immune system mistakenly attack healthy cell scientist be yet find reason abnormality however incidence autoimmune disease be rise be multiple type autoimmune disease include rheumatoid arthritis ra psoriasis multiple sclerosis ms inflammatory bowel disease ibd etc several company be dedicate bring better drug treatment disease symptom include fatigue muscle ach swell redness affected body part most common first line treatment autoimmune disease be disease modify rheumatic drug dmard especially methotrexate apart methotrexate be several class dmard include tnf inhibitor therapy approve disease be perform well abbvie abbv free report humira amgen amgn free report enbrel be blockbuster tnf inhibitor drug other however treatment have serious safety issue include increase risk tuberculosis lymphoma other jak pharma company be develop jak inhibitor work block particular signal body immune response cytokine instead suppress immune system do dmard patient treat jak inhibitor clinical study have show faster better response disease however safety concern still loom large segment be attractive company be only jak inhibitor presently approve treatment autoimmune disease especially ra however several company be develop candidate be likely increase competition go forward segment be news recently eli lilly lly free report olumiant jak inhibitor receive approval unite state abbvie abbv free report announce top line datum late stage study evaluate jak inhibitor candidate upadacitinib pharma biotech company grow interest jak inhibitor let take look pharma biotech company be look change way autoimmune disease be treat pfizer pfe free report xeljanz tofacitinib be first approve jak inhibitor unite state treatment ra have be available market drug be also approve psoriatic arthritis generate sale first quarter year year regulatory application seek line extension drug ulcerative colitis be approve late last month unite state regulatory application seek approval indication be review europe company currently carry zack rank hold see complete list today zack rank strong buy stock here eli lilly jak inhibitor olumiant baricitinib be second drug receive approval treat ra unite state drug be approve early month however be launch certain european country note fda reject company new drug application seek approval olumiant april cite safety concern lilly develop commercialize drug partnership incyte corporation drug generate sale first quarter sequentially lilly be currently evaluate drug autoimmune indication atopic dermatitis eczema late stage study company currently carry zack rank buy abbvie be company be focuse develop jak inhibitor base treatment company jak inhibitor upadacitinib show promising result late stage study evaluate candidate ra patient be also be develop atopic dermatitis late stage study enjoy breakthrough therapy status unite state late stage study be evaluate candidate crohn disease company currently carry zack rank galapago nv glpg free report be develop jak inhibitor candidate filgotinib collaboration gilead science inc gild free report separate late stage study be evaluate candidate ra crohn disease ulcerative colitis moreover several mid stage study be evaluate candidate multiple autoimmune indication include ankylose spondylitis psoriatic arthritis cutaneous lupus erythematosus other datum mid stagei study evaluate filgotinib psoriatic arthritis show significant improvement patient company currently carry zack rank prospect jak inhibitor several blockbuster dmard near patent expiration new class drug hold potential replace exist treatment boost prospect company have drug candidate pipeline commercial portfolio however jak inhibitor also have several side effect delay approval note lower dose lilly olumiant be approve box warning state risk serious infection malignancy thrombosis hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1013,LLY,eli lilly company lly free report report first quarter adjust earning share beat zack consensus estimate share earning rise year quarter backed robust volume drive growth new product sale lower operate cost tax rate include asset impairment restructure other special charge first quarter earning share be loss cent first quarter revenue detailquarterly revenue also beat zack consensus estimate sale grow year year backed strong performance new drug favorable currency movement make lower sale establish product strattera ciali forteo volume rise increase demand new product trulicity cyramza taltz basaglar jardiance lartruvo offset decline sale establish product however volume growth be softer previous quarter higher realize price several drug contribute sale growth quarter foreign exchange rate also have favorable impact revenue grow ex revenue rise pharmaceutical revenue rise quarter however decrease demand food animal product continue hurt sale lilly animal health segment establish product record growth quarter include humalog year year humulin trajenta sale other establish product decline quarter forteo sale decline due decrease volume unfavorable wholesale retail buy pattern unite state cymbalta sale decline erbitux sale decline alimta sale rise higher sale unite state offset sale decline international market ex market sale decline due competitive pressure loss exclusivity certain country however sale alimta increase unite state due increase volume higher realize price zyprexa sale decline due loss exclusivity japan ciali sale decline hurt lower demand unite state loss exclusivity europe strattera sale decline due loss exclusivity new product trulicity generate revenue year year revenue benefit growth glp market market share gain cyramza revenue be year year backed strong demand cyramza ex revenue increase benefit strong volume currency benefit partially offset lower realize price revenue increase drive increase volume higher realize price jardiance sale surge drive increase market share grow sglt class unite state increase volume outside unite state basaglar record revenue compare previous quarter generate revenue unite state improve sequentially drive increase demand drug gain medicare part formulary access taltz bring sale compare previous quarter higher ex revenue be offset lower sale be hurt unfavorable specialty pharmacy buy pattern lartruvo olaratumab generate revenue quarter compare previous quarter olumiant baricitinib have be launch select european country japan moderate severe rheumatoid arthritis drug generate sale quarter backed strong launch uptake germany compare previous quarter drug be review unite state lilly partner incyte corporation incy free report re submit nda baricitinib january setback company monday lilly inform fda advisory committee have recommend approval mg dose jak inhibitor not recommend higher dose mg ground safety profile be not adequate support approval relative benefit final decision fda be expect june year please note april last year fda have issue complete response letter crl new drug application nda baricitinib safety concern verzenio be launch unite state fourth quarter generate sale quarter compare previous quarter elanco animal health segment sale decline due decrease demand food animal product lilly be explore strategic alternative business include sale merger create separate company initial public offer decision regard same be expect be announce july lilly ultimately opt retain business gross margin operate income adjust gross margin quarter decrease basis point manufacturing efficiency higher realize price be offset negative product mix effect foreign exchange rate international inventory sell operate income increase year year due lower operate cost total operate expense include research development marketing selling administrative expense percent revenue decline basis point quarter due company cost save effort ep guidance uppedlilly raise previously issue outlook adjust earning well sale adjust earning share be now expect range higher expect previously reflect expect benefit higher operate profit lower tax rate revenue range be also slightly up expect previously gross margin be expect be approximately same previously expect adjust tax rate be expect be approximately previously approximately marketing selling administrative expense guidance be tighten range compare previously research development expense guidance be slightly increase range compare previously due increase funding requirement pipeline development takelilly first quarter result be impressive beat estimate earning sale also raise guidance metric share drug giant rise more pre market trading however year date lilly share have decline compare industry decline go forward lilly new product trulicity taltz basaglar cyramza jardiance lartruvo verzenio olumiant be expect continue drive revenue however competitive pressure lilly drug be expect rise year challenge remain company form loss patent exclusivity product ciali year impact generic competition strattera effient axiron latest baricitinib setback be disappointment lilly carry zack rank buy see complete list today zack rank strong buy stock here eli lilly company price consensus ep surprise eli lilly company price consensus ep surprise eli lilly company quotestock considerother top rank large cap pharma stock include merck mrk free report pfizer pfe free report carry zack rank merck share have rise year so far earning estimate increase respectively past day pfizer earning estimate rise respectively past day stock have go year so far make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1014,LLY,eli lilly company lly free report announce late stage study evaluate already approve cancer drug cyramza second line treatment liver cancer meet primary well secondary endpoint primary endpoint be overall survival os percentage patient be alive certain length time secondary endpoint be progression free survival pfs amount time patient live tumor grow larger phase iii reach study evaluate benefit cyramza single agent patient hepatocellular carcinoma hcc also know liver cancer be intolerant experience disease progression treatment bayer bayry free report amgen amgn free report nexavar also have elevated level alpha fetoprotein afp accord lilly press release approximately half advanced hcc patient have high afp marker poor prognosis result reach study show such patient derive survival benefit cyramza treatment follow first line treatment nexavar please note cyramza be already market single agent combination agent second line treatment advanced metastatic gastric cancer be also approve use combination agent second line treatment metastatic small cell lung cancer metastatic colorectal cancer lilly plan file regulatory application seek label expansion cyramza specify subgroup liver cancer patient population mid many cancer drug be be approve base progression free survival evidence benefit survival quality life however os datum once available sometimes show drug do not help person live longer fact cyramza offer overall survival benefit reach study probably impressed investor lead stock rise wednesday however year so far lilly share have decline compare unfavorably industry decrease cyramza generate revenue record year year increase meanwhile cyramza be be evaluate several study additional iii study cyramza advanced urothelial carcinoma first line egfr mutation positive nsclc be ongoing os datum urothelial carcinoma study be expect first half year pfs datum egfr mutation positive nsclc study be expect be release late december lilly announce top line datum phase iii study rainfall evaluate cyramza first line treatment patient advanced gastric cancer study meet primary endpoint pfs fail improve os lilly decide not seek regulatory approval first line set base datum study lilly carry zack rank buy see complete list today zack rank strong buy stock here large cap stock carry same zack rank lilly be glaxosmithkline gsk free report glaxo stock have return year so far earning estimate go respectively past day today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1015,LLY,fda refusal review plc alk free report depression candidate alk week be major setback company decision send stock tumble more alk once daily oral medication have be develop major depressive disorder mdd patient have not respond standard antidepressant therapy fda refuse review candidate state new drug application nda do not have enough evidence oral medication work fdawa opinion additional study be conduct ascertain drug effectiveness propose indication go say unexpected pipeline setback shift investor focus company market be develop drug treatment depression latest pipeline setback have shift investor focus market depression type depression be medical condition affect brain individual depression feel melancholic have intricacy enjoy routine activity factor such stress brain chemistry be most common cause depression also be genetic be different form depression such persistent depressive disorder perinatal depression disorder psychotic depression seasonal affective disorder bipolar depression psychotic depression persistent depressive disorder bipolar disorder be most severe form depression accord estimate person worldwide be affected depression have be see carry suicidal tendency thus rise press need develop drug condition know antidepressant drug be instrumental identify sign symptom ailment several pharma biotech company be involved develop selling depressantdrug stock focuslet look company be actively pursue development treatment various type depression allergan plc agn free report zack rank hold stock look well position depression market company have quite few product portfolio include vraylar schizophrenia bipolar disorder viibryd major depressive disorder saphris bipolar disorder drug be also several label expansion study earlier week allergan announce pivotal study evaluate vraylar treatment adult major depressive episode associate bipolar disorder bipolar depression meet primary endpoint moreover allergan moved rapastinel nmda receptor modulator phase iii development major depressive disorder rapastinel potentially game change treatment be expect be launch drug be expect generate revenue rapastinel be grant breakthrough therapy status adjunction major depressive disorder fda allergan be also evaluate flagship product botox treatment major depressive disorder allergan have outperformed industry year date company share have moved industry decline johnson johnson jnj free report healthcare giant have strong presence neuroscience segment be core therapeutic area company have product risperdal consta schizophrenia bipolar disorder portfolio most promising candidate pipeline be esketamine investigational antidepressant medication blockbuster potential esketamine nmda receptor antagonist have novel mechanism action get breakthrough therapy designation fda major depressive disorder imminent risk suicide esketamine have be grant breakthrough therapy designation treatment resistant depression regulatory application indication unite state be expect be file year zack rank buy stock have underperform industry year date company stock have lose compare industry decline see complete list today zack strong buy rank stock here eli lilly company lly free report pharmaceutical giant lilly major drug cymbalta be used treatment major depressive disorder generalized anxiety disorder fibromyalgia neuropathic pain neuroscience portfolio lilly include drug prozac treatment major depressive disorder obsessive compulsive disorder bulimia nervosa panic disorder zyprexa treatment schizophrenia acute mixed manic episode associate bipolar disorder bipolar maintenance lilly zack rank stock have underperform industry company share have decline compare industry sdecline sage therapeutic inc sage free report sage be company work development cns treatment company portfolio include novel pipeline candidate target critical cns receptor system gaba nmda company lead program brexanolone sage be late stage development super refractory status epilepticus rare severe seizure disorder well postpartum depression ppd brexanolone have be grant breakthrough therapy designation unite state priority medicine designation eu treatment postpartum depression sage be schedule move phase ii placebo controlled study therapeutic indication mdd ppd essential tremorand parkinson disease sage zack rank stock underperform industry year date company share have lose compare industry decline today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1016,LLY,indianapoli base eli lilly company lly free report be global healthcare company core product number primary care pharmaceutical market lilly generate revenue pharmaceutical product animal health segment company portfolio include zyprexa schizophrenia bipolar disorder humalog diabetes evista osteoporosis cymbalta depression ciali erectile dysfunction strattera attention deficit hyperactivity disorder adhd erbitux cancer alimta chemotherapy lilly also have strong presence diabetes market however many key product cymbalta alimta be face generic competition company also have new product trulicity cyramza jardiance basaglar lartruvo taltz portfolio be drive revenue lilly earning performance have be pretty impressive earning beating expectation last quarters bring average positive surprise currently lilly have zack rank buy definitely change follow company earning report be just release have highlighted key stat just reveal announcement earning beat lilly beat first quarter earning company report ep share consensus call ep revenue beat revenue also beat expectation lilly post revenue compare consensus estimate ep outlook up lilly raise previously issue outlook adjust earning well sale adjust earning share be now expect range higher expect previously reflect expect benefit higher operate profit lower tax rate revenue range be also slightly up expect previously zack consensus estimate earning revenue be share respectively stock price impact earning sale beat increase guidance share be pre market trading eli lilly company price consensus eli lilly company price consensus eli lilly company quotecheck back later full lilly earning report later make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1017,LLY,amgen amgn free report partner novartis nvs free report announce fda have approve pipeline candidate aimovig erenumab prevention migraine drug be first fda approve treatment specifically develop treat migraine block calcitonin gene related peptide cgrp receptor aimovig be available pre filled self administer autoinjector sureclick once monthly mg dosage aimovig be review eu amgen share be hour trading follow announcement year date amgen share have increase compare industry decline aimovig approval be backed positive datum several mid late stage study drug significantly reduce monthly migraine day use acute migraine medication versus placebo study datum phase iiib liberty study episodic migraine patient fail prior treatment show aimovig have time higher probability reduce migraine day half compare placebo new treatment option specifically develop treat migraine be make way suggest potential demand aimovig amgen have price drug once monthly mg single use prefil sureclick autoinjector annually expect drug boost amgen top line go forward remind investor eli lilly lly free report teva pharmaceutical industry limit teva free report also have cgrp candidate galcanezumab fremanezumab respectively be review unite state decision galcanezumab be expect third quarter yeara fda decision fremanezumab be expect june however earlier month teva inform do not expect get fda approval fremanezumab pdufa date june be teva manufacturing partner fremanezumab celltrion make api receive warning letter fda year delay approval drug however teva expect fremanezumab be approve launch end year amgen inc price amgen inc price amgen inc quoteamgen currently carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1018,LLY,roche hold ag rhhby free report announce encourage interim datum phase iii study impower evaluate tecentriq combination regimen first line treatment metastatic squamous small cell lung cancer nsclc datum show immuno oncology drug tecentriq combination blockbuster cancer drug avastin carboplatin paclitaxel significantly improve median overall survival os rate month compare avastin chemotherapy tecentriq combination regimen show survival benefit key lung cancer population such person egfr alk positive mutation liver metastase vary level pd expression november last year roche impower study meet co primary endpoint progression free survival pfs benefit march year roche announce study also meet primary endpoint median os however roche do not provide os number detailed datum study be present annual meeting american society clinical oncology asco early next month remind investor combination regimen be already priority review unite state indication first line set supplemental biologic license application be file base pfs os datum impower study decision be expect sep positive datum impower study be likely boost prospect favorable decision fda drug be approve nsclc second line set note merck mrk free report keytruda be only immuno oncology drug approve alone combination eli lilly lly free report alimta pemetrexed carboplatin treat nsclc patient first line set share roche have lose year date compare industry decline impower study consist cohort evaluate tecentriq combination avastin carboplatin paclitaxel tecentriq combination only carboplatin paclitaxel avastin carboplatin paclitaxel nsclc patient datum show tecentriq avastin arm achieve median os co primary endpoint month compare month avastin arm however tecentriq chemotherapy do not achieve statistically significant improvement os compare avastin chemotherapy roche be evaluate tecentriq monotherapy combination regimen late stage study include impower separate press release roche announce follow datum phase iii alex study compare alecensa pfizer pfe free report xalkori crizotinib treatment naive alk positive nsclc patient datum study demonstrated long term pfs benefit treat alecensa median pfs almost triple month compare month xalkori roche hold ag price roche hold ag price roche hold ag quotezack rankroche currently carry zack rank hold see complete list today zack rank stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1019,LLY,eli lilly company lly free report pipeline candidate galcanezumab meet primary well secondary endpoint late stage study evaluate prevention episodic cluster headache study show treatment galcanezumab mg once monthly lead statistically significant difference reduction weekly cluster headache attack compare placebo week month treatment period primary endpoint meanwhile week statistically significantly greater percentage patient galcanezumab arm achieve least reduction weekly cluster headache attack secondary endpoint compare placebo safety tolerability be consistent previous study evaluate galcanezumab migraine prevention lilly say work regulatory authority determine best path forward candidate however separate phase iii study evaluate galcanezumab patient chronic cluster headache do not meet primary endpoint accord lilly press release chronic cluster headache represent cluster headache case episodic cluster headache account cluster headache market galcanezumab be already review unite state migraine prevention decision expect third quarter year galcanezumab used calcitonin gene related peptide cgrp antibody prevention migraine amgen amgn free report partner novartis nvs free report aimvog erenumab teva pharmaceutical industry limit teva free report fremanezumab have be develop chronic episodic migraine prevention used cgrp mechanism be also review unite state fda decision fremanezumab be expect june however earlier month teva inform do not expect get fda approval fremanezumab pdufa date june be teva manufacturing partner fremanezumab celltrion make api receive warning letter fda year delay approval drug however teva expect fremanezumab be approve launch end year meanwhile fda action date amgen cgrp antibody aimovig prevention migraine be amgen look confident gain fda approval make first medicine cgrp class get approval year date lilly share have decline compare industry decline lilly currently carry zack rank buy see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1020,LLY,eli lilly company lly free report announce deal buy early phase oncology asset ak aurka pharma inc venture capital firm establish tvm capital life science ak be aurora kinase inhibitor be study phase study multiple type solid tumor lilly make upfront payment acquire share aurka pharma addition aurka pharma shareholder be entitle potential regulatory sale milestone worth ak be originally discover lilly later sell tvm capital part former strategic review do tvm capital later form aurka part tvm life science venture vii fund investment model seek develop early stage pharmaceutical asset year date lilly share have decline compare industry decline lilly have well layer oncology strategy involve build key cancer treatment cyramza lartruvo verzenio foundational agent focuse develop new standard care change therapy combination regimen include immuno therapy meanwhile lilly be constantly lookout external innovation bolster growth oncology franchise aurka pharma acquisition add promising cancer compound target distinct cell cycle pathway further expand lilly oncology pipeline lilly latest acquisition deal come less week announce cash deal tobuy california base immuno oncology biotech armo bioscience inc share approximately acquisition add armo lead product candidate pegilodecakin lilly cancer pipeline pegilodecakin pegylate il be be study late stage study pancreatic cancer well early stage study lung renal cell cancer melanoma other solid tumor type armo bioscience go public january year transaction be expect close end second quarter armo bioscience acquisition add promising next generation immunotherapy pipeline asset lilly portfolio be also line lilly oncology strategy lilly currently carry zack rank buy see complete list today zack rank strong buy stock here other stock considerother top rank pharma biotech stock include ligand pharmaceutical incorporate lgnd free report merck mrk free report ligand have zack rank merck be rank stock ligand earning estimate rise past day stock have go year so far merck share have rise year so far earning estimate increase respectively past day more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1021,LLY,week be rule cancer datum presentation annual meeting american society clinical oncology asco chicago pharma bigwig bristol myer bmy free report merck mrk free report roche rhhby free report other jak inhibitor be news week lilly lly free report finally gain fda approval rheumatoid arthritis ra candidate olumiant baricitinib unite state abbvie abbv free report present positive top line datum fifth late stage study upadacitinib ra recap week most important storiesupdate asco merck steal show asco present datum several cancer study pd inhibitor keytruda key presentation be pivotal lung cancer trial keynote study evaluate keytruda monotherapy newly diagnosed lung cancer patient keynote study evaluate keytruda combination chemotherapy difficult treat squamous small cell lung cancer nsclc study show treatment keytruda lead improve survival particularly datum keynote study evaluate keytruda combination chemotherapy first line treatment metastatic squamous nsclc be consider practice change investor year follow datum present advanced melanoma study show treatment keytruda lead long term survival benefit interim datum cohort phase ii study keynote evaluate keytruda monotherapy patient previously treat advanced small cell lung cancer sclc demonstrated encourage response rate overall population sclc patient well patient tumor express pd keytruda also demonstrated encourage orr study evaluate lenvima keytruda combination different tumor type keytruda monotherapy first line treatment advanced clear cell rcc bristol myer nektar therapeutic nktr present preliminary datum mid stage study evaluate nktr combination bristol myer pd inhibitor opdivo several tumor type response rate melanoma kidney cancer patient do not impress investor result drop nektar stock monday read more nektar bristol myer present datum cancer study bristol myer also present datum opdivo asco late stage study evaluate opdivo versus yervoy broad range patient resect stage iii iv melanoma opdivo demonstrated sustain superior recurrence free survival versus yervoy study opdivo chemotherapy show improve pfs versus chemotherapy first line lung cancer patient pd expression novartis nvs announce positive datum combination study breast cancer drug kisqali long term leukemia study tasigna read more novartis announce positive datum kisqali tasigna roche present datum late stage study show tecentriq atezolizumab chemotherapy reduce risk disease worsening death pfs advanced squamous nsclc patient versus chemotherapy alone abbvie present early datum phase ii study evaluate combination cancer drug imbruvica venclexta venetoclax first line treatment patient chronic lymphocytic leukemia cll datum demonstrated high rate response such patient also interim datum late stage study evaluate imbruvica roche rituxan waldenström rare form hodgkin lymphoma show combination significantly reduce risk disease progression death compare placebo rituxan pfizer pfe free report astrazeneca also make cancer datum presentation meeting lilly get fda nod lower dose olumiant eli lilly partner incyte gain fda approval lower dose mg company jak inhibitor olumiant fda do not approve higher dose mg drug label be approve box warning state risk serious infection malignancy thrombosis olumiant be already market europe japan generate sale first quarter unite state lilly face significant trouble get fda nod olumiant april last year fda have issue complete response letter new drug application seek approval olumiant request additional information determine most appropriate dose year april fda advisory committee have recommend approval lower dose drug not recommend higher dose mg inadequate safety profile support approval relative benefit read more eli lilly olumiant get fda nod rheumatoid arthritis abbvie late stage upadacitinib study succeed abbvie oral jak selective inhibitor upadacitinib meet primary well secondary endpoint fifth phase iii study select program top line datum study show thata significantly higher proportion patient treat upadacitinib mg dose achieve superior response compare chemotherapy agent methotrexate abbvie plan submit regulatory application upadacitinib rheumatoid arthritis second half year read more abbvie upadacitinib fifth ra study datum positive allergan activist pressure split ceo chairman role allergan agn free report be pressure week hedge fund firm senator investment group appaloosa disclose letter urge company engage management board overhaul firm ask pharmaceutical company split chairman chief executive role presently hold brent saunder other management change appaloosa run david tepper senator investment group run dougla silverman suggest outsider be hire role letter come heel allergan strategic plan announce last week divest woman health infectious disease unit allergan respond say board have be refreshed addition member last month read more allergan request shareholder veto management change glaxo complete buyout novartis stake consumer healthcare jv glaxo announce have complete previously announce deal buy novartis stake consumer healthcare joint venture acquisition novartis stake glaxo now have ownership consumer healthcare unit include product such sensodyne flonase glaxo novartis create jv part part transaction company combine consumer division pfizer invest more venture capital arm pfizer plan invest venture capital arm pfizer venture be invest small biotechs other emerge growth company be earmark company involved promising early stage neuroscience research read more pfizer boost venture capital effort neuroscience focus meanwhile pfizer regulatory application orally available parp inhibitor talazoparib metastatic breast cancer patient inherited brca mutation be accept review fda european medicine agency unite state new drug application nda be grant priority review fda decision accept december year top line result talazoparib registrational study embraca germline brca mutate breast cancer present december demonstrated superiority talazoparib chemotherapy improve progression free survival roche haemophilium candidate get priority review roche sbla look label expansion drug hemlibra person haemophilium factor viii inhibitor be grant priority review fda hemlibra be presently market routine prophylaxis prevent reduce frequency bleed episode haemophilium patient factor viii inhibitor fda grant priority review decision be expect oct separately roche cancer drug rituxan gain fda approval new indication moderate severe pemphigus vulgaris pv potentially life threaten nyse arca pharmaceutical index rise last trading session large cap pharmaceutical industry yr return large cap pharmaceutical industry yr return here be major stock perform last trading session stock be green last week astrazeneca decline merck rise most asco strength past month glaxo gsk have be biggest gainer bristol myer decline most see last pharma stock roundup here pharma stock roundup zoetis buy abaxis nvs get fda nod migraine drug next pharma world watch fda decision many pipeline drug line extension market product month look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1022,LLY,merck co inc mrk free report be steal limelight annual meeting american society clinical oncology asco chicago present practice change lung cancer datum pd inhibitor keytruda drug giant present encourage datum study evaluate drug advanced melanoma small cell lung cancer sclc patient share merck be monday response positive news year so far merck share have outperformed industry share have rise period industry decline year follow datum present pivotal advanced melanoma study show treatment keytruda lead long term survival benefit new analysis year datum phase iii keynote study show advanced melanoma patient remain progression free month complete year treatment keytruda year datum melanoma cohort phase ib keynote study demonstrated significant survival benefit advanced melanoma patient year os rate secondary endpoint study be patient previously untreated metastatic melanoma patient interim datum cohort phase ii study keynote evaluate keytruda monotherapy patient previously treat advanced small cell lung cancer sclc demonstrated encourage response rate overall population sclc patient well patient tumor express pd overall population sclc patient overall response rate orr primary endpoint be patient tumor expressed pd orr be keytruda be be evaluate combination chemotherapy first line treatment patient extensive stage small cell lung cancer phase iii study keynote earlier asco merck present datum pivotal lung cancer trial keynote study evaluate keytruda monotherapy newly diagnosed lung cancer patient keynote study evaluate keytruda combination chemotherapy difficult treat squamous small cell lung cancer nsclc study show treatment keytruda lead improve survival further cement merck position lung cancer market be most lucrative oncology sector meanwhile keytruda also demonstrated encourage orr study evaluate lenvima keytruda combination different tumor type keytruda monotherapy first line treatment advanced clear cell rcc keytruda hold dominant position lung cancer be only pd approve first line set certain lung cancer patient monotherapy well combination therapy eli lilly lly free report cancer drug alimta pemetrexed carboplatin pem carbo fact keytruda sale be gain particularly strong momentum first line lung cancer indication meanwhile keytruda be be evaluate several lung cancer study multiple setting stage disease monotherapy well combination therapy keytruda be be study more type cancer more study include excess combination study merck be collaborate several company include amgen amgn free report incyte glaxo gsk free report pfizer separately evaluation keytruda combination other regimen merck currently carry zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1023,LLY,share immunogen inc imgn free report have shot year time massively outperform industry increase let analyze factor lead skyrocket rally immunogen rapid pipeline progress positive readout strategic collaboration consistently drive share price performance company make significant advancement regard lead pipeline candidate mirvetuximab soravtansine last month be be evaluate phase iii study forward single agent therapy treat patient platinum resistant ovarian cancer more site study enrolment third quarter aim complete middle readout primary endpoint be anticipate first half also candidate be be evaluate phase expansion cohort ovarian cancer patient fda nod mirvetuximab soravtansine be huge boost immunogen give immense commercial potential target market ovarian cancer cause maximum annual death gynecologic cancer majority patient diagnosed advanced stage meanwhile combination regimen mirvetuximab soravtansine ovarian cancer be also be examine phase ib ii forward ii study trial consist cohort assess mirvetuximab soravtansine combination roche rhhby free report avastin merck mrk free report keytruda immunogen have report initial result forward ii study show mirvetuximab soravtansine potential complement currently available therapy indication approval combo therapy significantly expand eligible patient population mirvetuximab soravtansine apart mirvetuximab soravtansine immunogen be work develop couple early stage candidate include imgn imgn december immunogen present positive finding ongoing phase study evaluate imgn patient relapse refractory adult acute myeloid leukemia aml annual meeting american society hematology moreover january company moved imgn phase study treat hematological malignancy include aml be also important note immunogen sign agreement several big healthcare player include amgen bayer eli lilly lly free report novartis roche sanofi takeda dint contract other company be allow use immunogen antibody drug conjugate adc technology provide fund form license milestone fee royalty clinical material revenue research development support fee platinum resistant ovarian cancer market offer immense commercial potential immunogen be notably set face intense competition approval however mirvetuximab soravtansine look promising juncture approval lend big boost company immunogen inc price immunogen inc price immunogen inc quote zack rankimmunogen carry zack rank hold seethe complete list today zack rank strong buy stock here hacker put money portfolio earlier year credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
1024,LLY,bristol myer squibb company bmy free report have announce supplemental biologic license application sbla pd immune checkpoint inhibitor opdivo nivolumab combination yervoy ipilimumab have be accept fda priority review company seek approval label expansion combination therapy address patient previously treat microsatellite instability high msi mismatch repair deficient dmmr metastatic colorectal cancer mcrc response regulatory body be await jul opdivo yervoy combo regimen have also be grant breakthrough therapy designation fda aforementioned indication notably opdivo acquire nod several country include unite state eu japan several cancer indication share company have rally past year outperform industry gain acceptance application be base positive datum phase ii checkmate study announce january evaluate combination therapy give indication result study show primary endpoint objective response rate investigator assessment be median follow month overall survival rate year be median os be not yet reach outcome show opdivo yervoy provide durable clinical relief patient dmmr msi metastatic colorectal cancer datum demonstrated statistically significant clinically meaningful improvement key patient report include symptom function quality life significantly combination procedure be also assessment phase iii checkmate trial first line treatment small cell lung cancer nsclc last month bristol myer announce positive datum program reflect superior progression free survival first line nsclc patient compare chemotherapy be first study examine combination regime immune oncology drug first line nsclc patient high tumor mutation burden company press release colorectal be most common cancer type third lead cause terminal disease related death unite state approximately new case crc be expect be diagnosed annually country moreover patient msi dmmr metastatic crc have mild possibility benefit conventional chemotherapy treatment hence approval combo treatment provide company access huge patient population base need alternative treatment option apprehend disease however bristol myer face fierce competitive pressure immuno oncology space fact opdivo battle stiff rivalry merck mrk free report pd immunotherapy keytruda roche tecentriq merck keytruda be also be analyze phase iii study crc hence label expansion opdivo yervoy combination lend company wider population base patient opdivo few approve drug treat patient crc be lilly lly free report cyramza roche rhhby free report avastin amgen vectibix bristol myer squibb company price bristol myer squibb company price bristol myer squibb company quote zack rankbristol myer carry zack rank hold see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1025,LLY,eli lilly company lly free report partner incyte corporation incy free report announce fda have approve mg dose olumiant baricitinib treat moderately severely active rheumatoid arthritis ra once daily oral jak inhibitor be approve monotherapy combination methotrexate treat adult patient inadequate response tumor necrosis factor tnf inhibitor therapy approval unite state be not much surprise consider fda advisory committee have recommend approval lower dose drug april however mg dose drug be not approve moreover drug label include box warning state risk serious infection malignancy thrombosis company expect launch drug end second quarter be available price lower lead tnf inhibitor approve ra include abbvie abbv free report humira amgen amgn free report enbrel other remind investor fda have issue complete response letter april new drug application seek approval olumiant request additional information determine most appropriate dose olumiant be already approve europe japan generate sale first quarter approval further boost sale drug lilly share price have increase year date compare industry decline approval be base datum ra beacon study evaluate olumiant combination disease modify rheumatic drug versus placebo datum show patient treat olumiant achieve improvement sign symptom ra compare placebo company conduct long term safety study olumiant ra patient part approval follow approval unite state incyte be now eligible receive milestone payment lilly expect record full second quarter olumiant be also be evaluate late stage study treatment atopic dermatitis eli lilly company price eli lilly company price eli lilly company quotelilly currently carry zack rank buy see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1026,LLY,nektar therapeutic nktr free report report loss cent share first quarter be wider zack consensus estimate loss cent year figure cent due higher cost nektar stock be follow earning release share nektar have outperformed industry so far year stock have rise industry be quarterly revenue soar year period upside mainly be attribute milestone payment collaboration agreement shire plc shpg free report related approval hemophilia drug adynovi europe top line come line zack consensus estimate quarter top line comprise product sale royalty revenue cash royalty revenue license collaboration other revenue first quarter product sale rise year moreover cash royalty revenue increase company report royalty revenue quarter review register improvement year license collaboration other revenue come compare prior year upside research development expense escalate primarily due investment pipeline include key candidate nktr nktr nktr general administrative expense be report quarter primarily due higher stock base compensation pipeline company receive major boost february announce global strategic collaboration agreement bristol myer squibb bmy free report agreement company jointly develop commercialize nektar lead immuno oncology candidate nktr combination bristol myer opdivo nivolumab opdivo yervoy ipilimumab moreover pursuant contract company receive upfront payment proceed share purchase april same month nektar begin dose phase ii study reveal evaluate combination candidate nktr toll receptor agonist nktr immuno stimulatory cd bias agonist advanced metastatic solid tumor cancer moreover company have also collaborate takeda develop nktr combination latter tak dual syk flt inhibitor liquid solid tumor first study collaboration be expect start second half evaluate combination hodgkin lymphoma nektar initiate dose range phase ib study evaluate nktr regulatory cell stimulator patient systemic lupus erythematosus autoimmune disease company have worldwide license agreement eli lilly lly free report related development nktr apart company pipeline include late stage candidate onzeald nktr onzeald be currently evaluation phase iii attain study treatment adult advanced breast cancer have brain metastase company be develop nktr treatment chronic pain new drug application be expect be file fda month nektar therapeutic price ep surprise nektar therapeutic price ep surprise nektar therapeutic quotezack ranknektar carry zack rank sell see complete list today zack rank strong buy stock here medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
1027,LLY,astrazeneca plc azn free report new asthma drug fasenra benralizumab do not meet primary endpoint late stage study evaluate respiratory biologic medicine expand indication chronic obstructive pulmonary disease copd fasenra be approve eu january unite state november last year add maintenance treatment patient severe eosinophilic asthma fasenra be give fix dose subcutaneous injection prefil syringe once week make first respiratory biologic medicine be approve unite state eu convenient week maintenance dose schedule glaxosmithkline gsk free report nucala subcutaneous administration teva pharmaceutical industry teva free report cinqair intravenous infusion be presently market same indication administer once week come back latest news phase iii study galathea evaluate safety efficacy fasenra patient moderate very severe chronic obstructive pulmonary disease copd top line result study show treatment fasenra add dual triple inhaled therapy copd patient history exacerbation range baseline blood eosinophil do not result statistically significant reduction exacerbation compare placebo full datum pivotal galathea study be expect be present future medical meeting pivotal study terranova be also evaluate fasenra similar indication astrazeneca determine next step fasenra copd get result terranova study full datum galathea study astrazeneca share have rise so far year industry decline astrazeneca currently carry zack rank hold see complete list today zack rank strong buy stock here better rank large cap pharma stock be eli lilly company lly free report zack rank buy company earning estimate increase past day medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
1028,LLY,celldex therapeutic inc cldx free report incur first quarter loss exclude goodwill impairment charge cent share wider zack consensus estimate loss cent narrower year loss cent lower cost higher revenue lead year year improvement total revenue quarter soar year year beating zack consensus estimate manufacturing service agreement international aids vaccine initiative frontier biotechnology drive top line share company fall wider expect loss discontinuation development candidate include earlier announce glembatumumab vedotin however stock have not do too well so far year have decline compare industry decrease quarterly detailsresearch development expense be year year quarter general administrative expense be year year mar celldex have cash cash equivalent marketable security compare mar biotech company weaken cash position be due higher operate expense partially offset net proceed raise sale common stock month contract cantor outlookcelldex expect cash position end december net proceed generate sale common stock last month anticipate proceed future sale common stock agreement cantor be adequate fund work capital requirement well plan operation discontinue clinical studiesin april company announce failure antibody drug conjugate adc candidate glembatumumab vedotin phase iib metric study evaluate breast cancer follow failure company have decide discontinue development candidate indication include metastatic melanoma apart glembatumumab vedotin celldex announce earning release discontinuation development early phase adc candidate cdx antibody fusion protein candidate cdx company have take decision better allocation resource pipeline focuscelldex be now focuse development cdx cdx varlilumab cdx be evaluate externally investigator sponsored study however company evaluate varlilumab cdx internally combination study be several preclinical candidate pipeline include cdx january company close enrollment phase ii trial evaluate varlilumab bristol myer bmy free report opdivo include cohort indication namely colorectal cancer ovarian cancer head neck squamous cell carcinoma renal cell carcinoma glioblastoma phase ii study be currently evaluate cdx human monoclonal antibody combination eli lilly lly free report erbitux treatment advanced head neck squamous cell cancer phase study be evaluate cdx several solid tumor celldex be plan add cohort evaluate cdx combination cdx varlilumab investigator initiate study be evaluate cdx advanced small cell lung cancer celldex therapeutic inc price consensus ep surprise celldex therapeutic inc price consensus ep surprise celldex therapeutic inc quotezack rank stock considercelldex currently carry zack rank hold enanta pharmaceutical inc enta free report be better rank stock drug sector carry zack rank buy see complete list today zack rank stock here enanta earning share estimate significantly increase cent last day company come average beat stock have surge so far year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1029,LLY,roche hold ag rhhby free report subsidiary genentech announce phase iii study evaluate combination pd inhibitor tecentriq atezolizumab avastin bevacizumab carboplatin paclitaxel first line treatment advanced lung cancer meet co primary endpoint overall survival os impower study show patient advanced squamous small cell lung cancer nsclc be treat combination treatment live longer compare avastin carboplatin paclitaxel company plan submit additional datum global health authority well fda european medicine agency ema soon year share roche have decline industry growth december company have announce interim result impower study impower study show tecentriq avastin chemotherapy reduce risk disease worsening death compare be treat avastin chemotherapy november roche mentioned iii impower study meet co primary endpoint progression free survival tecentriq be approve treatment second line metastatic nsclc label expansion first line set boost drug sale further tecentriq be also approve treatment patient suffering locally advanced metastatic urothelial carcinoma muc be not eligible cisplatin chemotherapy drug record sale chf remind investor merck mrk free report pd inhibitor keytruda be approve fda monotherapy combination lilly lly free report alimta carboplatin first line treatment patient metastatic nonsquamous nsclc roche hold ag price roche hold ag price roche hold ag quote zack rank other stock considerroche carry zack rank buy top rank stock same space be regeneron pharmaceutical regn free report sporting zack rank strong buy see complete list today zack rank stock here regeneron earning share estimate have moved last day company pull positive earning surprise last quarters average beat medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
1030,LLY,first quarter earning season start solid note show sign yet report cycle emerge strong latest earning preview member accounting index have already release financial figure apr total earning index participant jump year quarter drive improve revenue beat ratio be bottom line top line further good news be ongoing earning phase seem have also begin encouragingly drug biotech sector major large cap player johnson johnson jnj free report kick season strongly beating zack consensus estimate earning well sale first quarter large cap player have report earning performance last week be novartis nvs free report also surpass earning revenue expectation quarter remind investor drug biotech sector face severe volatility last couple month due broader market pressure mainly drive china trade war sector be still likely improve year progress expect surge new product sale sync rise demand apart successful innovation product line expansion strong clinical study result more frequent fda approval consistently sturdy performance key product grow demand drug especially address rare treat disease agee populace increase healthcare expenditure be factor keep sector well place also accord earning preview broader medical sector inclusive drug biotech well medical device company be likely record year year growth revenue rise earning period discussion pharma biotech giant be schedule report earning number apr let see thing be shape company upcoming release eli lilly company lly free report eli lilly company price ep surprise eli lilly company price ep surprise eli lilly company quote lilly be slate release first quarter earning market open company deliver positive surprise last quarter moreover company performance have be impressive recent past earning surpass expectation trail quarters average positive surprise however proven model do not conclusively show lilly be likely beat earning quarter company favorable zack rank buy increase predictive power esp earning espof leave surprise prediction inconclusive company require positive esp be confident probable surprise zack consensus estimate quarterly earning be peg share lilly strong uptake new product trulicity taltz basaglar cyramza jardiance lartruvo compensate sale decline establish product namely zyprexa alimta ciali strattera effient expect uptrend find reflection result soon be report quarter read more lilly lly free report report earning card biogen inc biib free report biogen inc price ep surprise biogen inc price ep surprise biogen inc quote biogen be also slate release first quarterearning market open company track record have also be impressive so far deliver positive surprise trail quarters average beat however biogen come negative surprise fourth quarter moreover proven model do not conclusively show biogen be likely beat earning quarter company favorable zack rank hold increase predictive power esp earning esp leave surprise prediction inconclusive zack consensus estimate be peg share see complete list today zack rank strong buy stock here sale biogen multiple sclerosis drug improve patient growth major european market well growth strong emerge market drive international tecfidera sale inventory build quarter benefit sale expect momentum continue impending result soon be report quarter read more store biogen biib free report earning season amgen inc amgn free report amgen inc price ep surprise amgen inc price ep surprise amgen inc quote amgen be schedule release first quarter earning market close company deliver negative surprise previous quarter amgen earning performance have be quite robust metric beating expectation last quarters miss same remain average beat proven model show amgen be likely beat earning quarter combination amgen zack rank increase predictive power esp positive earning esp make confident earning beat upcoming report consensus mark quarter be report be peg share uncover best stock buy sell re report earning esp filter amgen latest product prolium kyproli xgeva blincyto be likely perform well backed higher demand upside make weak sale stiff competition mature brand such enbrel aranesp epogen neulasta neupogen be report quarter read more amgen amgn free report report earning be beat card today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1031,LLY,eli lilly company lly free report report first quarter result apr market open last quarter company deliver positive earning surprise lilly share have decline year so far underperform industry decrease lilly performance have be pretty impressive earning beating expectation last quarters bring average positive surprise eli lilly company price ep surprise eli lilly company price ep surprise eli lilly company quotelet see thing be shape quarter factor considerlike previous couple quarters strong uptake trend new product trulicity taltz basaglar cyramza jardiance lartruvo make decline sale establish product zyprexa alimta ciali strattera effient trulicity sale be be drive growth glp market market share gain jardiance sale be likely be drive increase market share grow sglt class positive trend be expect continue first quarter zack consensus estimate trulicity first quarter revenue be continue strong uptake outside unite state be likely drive sale cyramza strong launch uptake be expect drive sale taltz lartruvo loss exclusivity country cymbalta strattera effient axiron zyprexa evista continue hurt volume also lower demand unite state due competitive pressure mainly immuno oncology agent be hurt alimta sale country trend believe persist first quarter zack consensus estimate alimta sale first quarter be peg olumiant baricitinib be launch select european country japan generate sale year support strong launch uptake germany drug be review unite state lilly partner incyte corporation incy free report re submit nda baricitinib january verzenio be launch unite state fourth quarter generate sale expect new cancer drug generate higher sale first quarter also advanced breast cancer treatment gain fda approval first line set february have lead additional sale first quarter older product humulin forteo be expect do well other ciali be likely see weak sale due lower demand elanco animal health segment sale be hurt global competitive pressure trend have continue first quarter fourth quarter conference call management have say be slightly negative first half animal health revenue be expect improve second half support new product launch zack consensus estimate sale animal health segment be lilly be explore strategic alternative business include sale merger create separate company initial public offer decision regard same be expect be announce july lilly ultimately opt retain business investor look update first quarter conference call earning whispersour proven model do not conclusively show lilly beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp be zack consensus estimate earning be share uncover best stock buy sell re report earning esp filter zack rank lilly zack rank increase predictive power esp however need have positive esp be confident earning beat caution sell rate stock zack rank go earning announcement especially company be see negative estimate revision stock considerhere be large cap health care stock worth consider model have right combination element beat earning time merck co inc mrk free report have earning esp zack rank company be schedule report first quarter earning see complete list today zack rank stock here pfizer inc pfe free report be also slate announce financial figure company have earning esp be also zack rank stock wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1032,LLY,amgen inc amgn free report have announce full result phase iiib study cgrp receptor antibody aimovig erenumab once again demonstrate significant reduction migraine frequency company be look get aimovig mg approve treatment episodic migraine patient previous experience preventive treatment failure due lack efficacy intolerable side effect phase iii liberty study randomize patient aforementioned indication receive aimovig mg placebo week datum study demonstrated reduction episodic migraine least half aimovig treat patient multiple treatment failure compare patient treat placebo moreover aimovig patient complete double blind phase liberty trial adverse event be find lead discontinuation treatment aimovig group outcome study be present annual meeting american academy neurology los angele share amgen increase more apr follow news release stock have gain so far year industry decline remind investor january year company announce aimovig meet primary endpoint libarty study significantly more patient aimovig dosage experience least reduction baseline monthly migraine day compare placebo study meet secondary endpoint well notably amgen be develop aimovig collaboration novartis ag nvs free report company be focuse develop commercialize treatment migraine alzheimer disease approve amgen novartis co commercialize aimovig unite state however amgen retain right japan novartis have right europe canada rest world importantly candidate be review unite state same indication response expect notably candidate be first investigational therapy target cgrp pathway have receive regulatory filing acceptance fda give indication company person unite state be affected migraine approximately be preventive therapy likely discontinue treatment year thus approval drug address hugely unmet need patient suffering disease country however several company namely teva pharmaceutical teva free report eli lilly lly free report other be develop migraine treatment target cgrp amgen inc price amgen inc price amgen inc quote zack rankamgen carry zack rank hold see complete list today zack rank strong buy stock here hacker put money portfolio earlier year credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
1033,LLY,first quarter earning season have just kick latest earning preview bottom line company be expect increase highly impressive rate year year basis prospective upside mark maximum quarterly earning growth pace year report further predict zack sector be project exhibit double digit earning growth be report quarter total revenue same set company be project grow however focuse attention large cap pharma medical drug sector note sector have decrease respectively february year due broader market pressure further index have register decline second month remind investor stock market be face severe volatility last couple month strong start year downside mainly be attributable potentially damage trade war world largest economy unite state china february president donald trump announce plan impose tariff annual chinese import china retaliate notify intention levy tariff product such aggressive exchange have trigger tension possible trade dispute country moreover sluggish large cap tech stock be cite reason plummet market recent market unrest optimistic sentiment revolve remain year notably biotech sector be likely improve year advance expect new product sale thrive tandem rise demand apart successful innovation host product launch strong clinical study outcome more frequent fda nod solid performance key product grow demand drug especially deal rare treat disease agee population escalate healthcare expenditure be factor keep sector stable see complete list today zack rank stock here be important note outlook upcoming first quarter result look bright earning preview broader medical sector inclusive drug biotech well medical device company be expect record year year growth revenue rise earning pick potential winnersgiven enormity healthcare space task select stock possibility beat estimate appear quite daunting zack proprietary methodology make job fairly simple way carve top choice report cycle be look stock combination favorable zack rank zack rank strong buy buy hold positive earning esp be observed positive earning surprise deliver company mostly lead stock price appreciation well research quantitative model earning esp be used identify stock higher chance pull positive surprise impending earning announcement show percentage difference most accurate estimate zack consensus estimate uncover best stock buy sell re report earning esp filter proven methodology cull stock large cap pharma medical drug sector poise surpass estimate be report quarter large cap stock be follow first pick be abbvie inc abbv free report north chicago il base company have earning esp zack rank stock have see zack consensus estimate first quarter earning be peg share company boast encourage earning track record exceed expectation last quarters average beat abbvie be schedule report earning number apr next choice be eli lilly company lly free report stock have earning esp zack rank consensus mark first quarter earning stand share headquarter indianapoli lilly have excellent positive earning surprise history company average beat trail quarters be lilly be slate announce result apr pfizer inc pfe free report too have please earning profile company have consistently outpaced expectation last quarters average beat look perfectly poise repeat winning streak time well new york base player be zack rank have earning esp consensus mark first quarter bottom line be peg cent share pfizer be schedule release financial figure give be medical drug stock first pick medical drug sector be catalent inc ctlt free report new jersey base company have earning esp zack rank zack consensus estimate first quarter earning be peg cent share company flaunt positive earning surprise record outshine expectation last quarters average beat catalent be expect report earning next choice be aratana therapeutic inc petx free report stock have earning esp be rank player consensus mark first quarter loss stand cent share base kansa aratana have outstanding earning history consecutive estimate beat trail quarters average be company be slate announce result investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
1034,LLY,roche hold ag rhhby free report subsidiary genentech announce phase iii study evaluate combination pd inhibitor tecentriqplus chemotherapy carboplatin abraxane first line treatment advanced lung cancer meet co primary endpoint progression free survival pfs impower study show combination reduce risk disease worsening death pfs compare chemotherapy alone initial treatment patient advanced squamous small cell lung cancer nsclc however result do not show statistically significant overall survival os benefit hence study be continue interim datum be present upcoming oncology congress year share roche have decline industry growth tecentriq be market treatment second line metastatic nsclc label expansion first line set boost drug sale further tecentriq be also approve treatment patient suffering locally advanced metastatic urothelial carcinoma muc be not eligible cisplatin chemotherapy drug recore sale chf february roche announce positive result phase iii immotion study tecentriq combination oncology drug avastin bevacizumab first line treatment advanced metastatic renal cell carcinoma study meet co primary endpoint investigator assessed pfs patient disease expressed pd protein result show patient receive tecentriq avastin have reduce risk disease worsening death pfs compare person treat sutent remind investor merck mrk free report pd inhibitor keytruda be approve fda monotherapy combination lilly lly free report alimta carboplatin first line treatment patient metastatic nonsquamous nsclc roche hold ag price roche hold ag price roche hold ag quote zack rank stock considerroche carry zack rank buy top rank stock same space be regeneron pharmaceutical regn free report sporting zack rank strong buy see complete list today zack rank stock here regeneron earning share estimate have moved last day company pull positive earning surprise last quarters average beat today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1035,LLY,merck mrk free report share increase apr present full datum pivotal phase iii keynote study datum same show keytruda combine eli lilly lly free report alimta pemetrexed platinum chemotherapy cisplatin carboplatin significantly improve overall survival thereby reduce death risk half compare chemotherapy alone study evaluate combination therapy first line treatment patient metastatic squamous small cell lung cancer nsclc regardless pd expression combo treatment show progress overall survival irrespective pd expression include patient tumor testing negative pd meanwhile significant improvement progression free survival pfs be observed decrease death risk keytruda combination arm compare chemotherapy arm median pfs be month keytruda arm compare month chemotherapy pfs improvement be also observed patient tumor test negative pd result be present annual meeting american association cancer research notably january year merck have announce study meet primary endpoint pfs os well importantly keytruda be first pd inhibitor combination show os patient nsclc last combination therapy be grant accelerate approval fda aforementioned indication nod be base tumor response rate pfs datum keynote trial hence positive readout keynote confirmatory study help company gain continue approval combo therapy turn support uptake sale remind investor third quarter merck have mentioned be include overall survival os co primary endpoint keynote program defer readout study be then estimate evaluation be complete february however company release datum keynote study year earlier expect january merck share have gain so far year versus decline industry concurrently bristol myer bmy free report also report datum phase iii study blockbuster drug opdivo nsclc however merck keytruda combination demonstrated better overall survival compare opdivo zack rank key pickmerck carry zack rank hold better rank stock health care sector be ligand pharmaceutical incorporate lgnd free report sporting zack rank strong buy see complete list today zack rank stock here ligand earning share estimate have moved last day company deliver positive surprise trail quarters average beat share price company have soar year breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
1036,LLY,biogen inc biib free report share be market trading thursday positive top line datum mid stage study evaluate pipeline candidate ban treatment early alzheimer disease ad biogen be develop ban humanize beta amyloid antibody collaboration japan eisai co ltd amyloid be protein form plaque brain person alzheimer candidate be be investigate see slow progression memory problem associate amyloid top line result final analysis phase ii study demonstrated statistically significant slow disease progression key clinical endpoint adcom month treatment patient receive highest treatment dose mg kg biweekly ban compare placebo meanwhile treatment high dose month also lead reduction amyloid beta accumulate brain study include dose regimen datum marked important breakthrough biogen eisai challenge ad market lead share price increase however so far year biogen share have decline almost inline industry decline same time frame late datum announce same study fail show early positive result raise investor concern candidate chance success independent datum monitoring committee say ban do not meet criterium success base bayesian analysis month primary endpoint study fail show early positive result company say blind study be be conduct patient mild cognitive impairment mci due ad mild alzheimer dementia collectively know early alzheimer disease continue comprehensive final analysis be conduct month detailed datum study be expect be present future conference alzheimer fatal illness cause progressive decline memory have always be highly challenge area not much progress be make spite significant investment fund resource several company have fail develop safe effective treatment option deadly brain disease last month lilly lly free report swiss partner astrazeneca azn free report discontinue late stage study alzheimer disease candidate lanabecestat recommendation idmc idmc say study be unlikely meet primary goal completion back november lilly say not seek approval investigational ad treatment solanezumab follow disappointing result late stage study year jnj free report halter development atabecestat investigational bace inhibitor be be develop preclinical stage ad due safety concern february year merck discontinue second late stage study evaluate bace inhibitor verubecestat treatment prodromal ad success be unlikely february last year merck discontinue late stage study evaluate verubecestat mild moderate ad due lack efficacy january pfizer say end effort alzheimer parkinson disease area long back pfizer have shelved late stage ad candidate bapineuzumab iv fail phase iii study setback several company continue invest heavily develop alzheimer disease treatment give high commercial potential market success area mean huge return consider more american be live alzheimer disease number expect triple datum alzheimer association be consider be biggest burden society be sixth lead cause death age unite state market have immense commercial potential company come new treatment rake billion dollar sale biogen currently carry zack rank hold see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1037,LLY,merck co inc mrk free report gain priority review yet supplemental biologic license application sbla pd inhibitor keytruda latest application merck be look get keytruda approve combination chemotherapy first line treatment metastatic squamous small cell lung cancer nsclc be difficult treat lung cancer patient population fda grant priority review sbla decision schedule oct sbla filing be base datum keynote study recently conclude annual meeting american society clinical oncology datum presentation pivotal lung cancer study result merck emerge winner annual key cancer event datum study show combination keytruda chemotherapy lead significant improvement overall survival os progression free survival regardless pd expression pd be protein present surface cell risk death os be reduce compare chemotherapy alone pfs improvement say reduction risk progression death be nearly half patient keytruda combination group compare chemotherapy alone datum be term practice change cnbc change way doctor look prescribe drug cancer patient further cement merck position lung cancer market be most lucrative oncology sector year so far merck share have rise industry decline short span time keytruda have become merck largest product be already approve use different setting involve different tumor type year have already gain approval new indication include third line treatment adult well pediatric patient primary mediastinal cell lymphoma pmbcl type hodgkin lymphoma second line treatment recurrent metastatic cervical cancer label expansion approval drive sale keytruda future quarters treatment generate sale first quarter sequentially year year upside be drive global launch new indication further boost demand keytruda sale be gain particularly strong momentum first line lung cancer indication fact keytruda be only pd approve first line set certain lung cancer patient monotherapy well combination therapy eli lilly lly free report cancer drug alimta pemetrexed carboplatin pem carbo keytruda be also be study more type cancer more study include excess combination study merck be collaborate several company include amgen amgn free report incyte incy free report glaxo pfizer separately evaluation keytruda combination other regimen merck have zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1038,LLY,pharma giant eli lilly company lly free report announce positive top line result second phase iii study arthritis drug taltz ixekizumab treatment ankylose spondylitis also know radiographic axial axspa phase iii study coast evaluate safety efficacy taltz treatment be first trial patient population inadequate response tumor necrosis factor tnf inhibitor intolerance tnf inhibitor result show taltz demonstrated statistically significant improvement sign symptom measure proportion patient have achieve assessment international society asas response week compare placebo study meet primary major secondary endpoint be type affect pelvic joint spine notably company have earlier report positive result phase iii coast study taltz therapy lilly plan submit detailed datum coast study scientific meeting peer review journal later base positive result coast coast study company plan submit same approval unite state later year remind investor apart psoriatic arthritis taltz be approve treat moderate severe plaque psoriasis adult eligible systemic therapy phototherapy well active psoriatic arthritis many other drug novartis nvs free report cosentyx abbvie abbv free report humira be approve treat plaque psoriasis lilly claim taltz be now first only fda approve treatment genital psoriasis taltz logged sale first quarter label expansion turn expand eligible patient population drug drive sale go forward drug record sale share lilly have inched year date industry decline lilly currently carry zack rank hold top rank stock same sector be lundbeck hluyy free report carry zack rank strong buy see complete list today zack rank stock here lundbeck earning estimate have be revise upward past day stock have surge year date wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1039,LLY,nordisk nvo free report announce headline result pioneer second phase iiia study oral formulation ozempic semaglutide treatment adult type ii diabetes study evaluate efficacy safety mg oral ozempic compare mg eli lilly lly free report boehringer ingelheim jardiance empagliflozin type ii diabetes inadequately controlled metformin week study achieve primary objective demonstrated statistically significant superior improvement blood glucose level hba oral ozempic compare jardiance week study show statistically significant improvement hba week week compare improvement hba mg empagliflozin week also demonstrated weight loss kg week kg week versus kg mg jardiance week week increase weight loss oral ozempic be also significant compare jardiance week time point remind investor december fda approve ozempic once daily pre filled pen improve glycaemic control type ii diabetes patient be also approve europe japan canda same indication share nordisk have decrease compare industry decline february nordisk successfully complete first phase iiia trial pioneer oral ozempic treatment adult type ii diabetes trial achieve primary objective demonstrate statistically significant superior improvement blood glucose level hba dose oral ozempic compare placebo mid company plan initiate cardiovascular outcome study call soul ozempic also company plan initiate phase iiia program call step explore potential once weekly ozempic treatment person obesity also include cardiovascular outcome trial select investigate impact ozempic incidence major adverse cardiovascular event compare placebo patient establish cardiovascular disease overweight obesity glp market lilly trulicity astrazeneca azn free report once weekly bydureon be competitor nordisk ozempic zack rank stock considernovo nordisk have zack rank hold better rank stock same space be illumina inc ilmn free report sporting zack rank strong buy see complete list today zack rank stock here illumina earning share estimate have moved past day company deliver positive earning surprise trail quarters average beat stock have rally so far year nordisk price nordisk price nordisk quotetoday stock zack hottest strategy hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1040,LLY,value investing be easily most popular way find great stock market environment wouldn want find stock be fly radar be compelling buy offer tantalize discount compare fair value way find company be look several key metric financial ratio many be crucial value stock selection process let put eli lilly company lly free report stock equation find be good choice value oriented investor right now investor subscribe methodology look elsewhere top pick pe ratioa key metric value investor always look be price earning ratio pe short show much investor be willing pay dollar earning give stock be easily most popular financial ratio world best use pe ratio be compare stock current pe ratio ratio have be past compare average industry sector compare market whole front lilly have trail month pe ratio see chart level actually compare pretty favorably market large pe stand focus long term pe trend lilly current pe level put midpoint past year moreover current level be fairly high stock suggest be good entry point further stock pe also compare favorably sector trail month pe ratio stand very least indicate stock be relatively undervalue right now compare peer also point lilly have forward pe ratio price relative year earning just so be fair say slightly more value oriented path be ahead lilly stock term too ratioanother key metric note be price sale ratio approach compare give stock price total sale lower read be generally consider better person metric more other value focuse one look sale something be far harder manipulate accounting trick earning right now lilly have ratio be marginally higher average come right now nonetheless see chart be well high stock particular past few year also lly be lower end range time period metric suggest level undervalue trading least compare historical norm broad value outlookin aggregate lilly currently have zack value style score putt top stock cover look make lilly solid choice value investor other key metric make pretty clear too example peg ratio lilly be just level be lower industry average peg ratio be modify pe ratio take account stock earning growth rate stock overall lilly be good choice value investor be plenty other factor consider investing name particular be worth note company have growth grade momentum score give lly zack vgm score overarch fundamental grade read more zack style score here meanwhile company recent earning estimate have be mostly trend higher current quarter have see estimate go higher past day compare lower full year estimate have see upward downward revision same time period result current quarter consensus estimate have rise past month full year estimate have increase see consensus estimate trend recent price action stock chart eli lilly company price consensus eli lilly company price consensus eli lilly company quoteeven lilly have better estimate trend stock have just zack rank hold be be look line performance company term bottom linelilly be inspire choice value investor be hard beat incredible lineup statistic front furthermore robust industry rank top boost investor confidence however past year industry have underperform broader market see poor past performance industry good industry rank signal stock be likely benefit favorable broader factor immediate future add positive estimate revision robust value metric believe have strong value contender lilly hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1041,LLY,dow endure volatile week marked key geopolitical development begin week treasury secretary make encourage remark progress trade negotiation china however later week president trump expressed dissatisfaction progress trade talk also cancel much await summit north korea leader kim jong result stock gain lose alternate session last week dow gain point last friday close session nearly unchanged trade negotiation unite state china continue weigh investor sentiment president donald trump say doubt negotiation have positive outcome also bond yield reach highest level last week index decline last week trade talk unite state china remain focus week continue weigh investor sentiment moreover high interest rate too push stock lower week year note yield crossed mark first time dent investor confidence see investor panic yield hit psychological level trigger fear equity become less appeal dow index gain nearly point monday dow also close mark first time march trade tension unite state china decline treasury secretary steve mnuchin sunday say be putt trade war hold industrial be biggest gainer stand benefit most trade war be avert share boee ba free report caterpillar cat free report unite technology utx free report jump respectively index decline tuesday erase early gain president trump say wasn satisfied progress unite state china trade talk moreover trump also say highly await summit unite state north korea not happen meanwhile white house say order get fresh nuclear deal unite state iran need stop enrich uranium withdraw support militant group middle east statement cause stock plummet further index gain wednesday lead lead rally share boee gain share mcdonald mcd surge stock gain minute fed meeting conclude earlier month hint policy maker aren worry inflation briefly run target level further such occurrence not result faster interest rate hike rate sensitive stock rally news broader market be able pare earlier loss result geopolitical tension close black index decline thursday president trump scrap summit north korea leader kim jong schedule next month have be maiden face face encounter north korean leader sit president energy stock emerge biggest loser day oil price decline follow unexpected increase domestic crude inventory share exxon mobil xom chevron cvx free report decline respectively lead blue chip index finish red component move index general electric company ge free report recently enter definitive agreement wabtec corporation wab free report lead manufacturer rail equipment agreement company merge operate segment ge transportation wabtec completion synergistic deal zack rank hold general electric obtain cash company shareholder own ownership interest combine company remain stake combine company be retain wabtec shareholder notably deal be likely close early latest move combine ge transportation digital solution railroad marine drill wind mining industry wabtec extensive range electronic solution result market capability be stronger add momentum development implementation innovative solution key market help improve safety efficiency productivity offering notably combine company have large global install base more locomotive create significant opportunity aftermarket service growth read general electric transportation unit merge wabtec johnson johnson inc jnj free report partner glaxosmithkline plc gsk free report announce european commission ec have grant marketing approval juluca make europe first drug hiv treatment johnson johnson have zack rank juluca combine approve hiv drug tivicay mg edurant mg single once daily pill treatment virologically suppress hiv infection juluca gain approval unite state november last year generate sale first quarter read glaxo drug hiv regimen juluca get eu approval merck co inc mrk free report announce pivotal study keynote evaluate keytruda chemotherapy combination first line metastatic squamous small cell lung cancer nsclc meet dual primary endpoint overall survival os progression free survival pfs drug combination chemotherapy demonstrated significantly longer os pfs versus chemotherapy alone merck supplemental biologic license application sbla seek continue approval keytruda combine eli lilly lly free report alimta platinum chemotherapy treat metastatic squamous nsclc be review unite state sbla be file base encourage datum phase iii study keynote company plan share datum keynote study fda expand sbla include patient squamous histology company present detailed datum keynote study upcoming annual meeting american society clinical oncology next month stock have zack rank see complete list today zack rank strong buy stock here pfizer inc pfe free report announce fda have grant breakthrough therapy designation rare disease candidate tafamidis candidate be be develop treatment transthyretin cardiomyopathy ttr cm designation fda be intend expedite development review drug early evidence substantial potential clinical benefit patient benefit patient current treatment option designation tafamadis be primarily base encourage top line datum phase iii attr act study demonstrated significant reduction combination cause mortality frequency cardiovascular related hospitalization ttr cm patient read pfizer tafamadis get breakthrough therapy designation separate development zack rank pfizer announce phase iii study evaluate epilepsy drug lyrica pregabalin pediatric patient meet primary endpoint read pfizer epilepsy drug lyrica succeed pediatric study microsoft corporation msft free report recently unveil new gamepad xbox adaptive controller be aim ensure gaming everyone controller price be personalize requirement gamer controller comprise big programmable button mm port round back connect blow tube pedal other accessory zack rank microsoft blog development story date back almost feature copilot release xbox witness creative use company imagination inspire developer bring inclusivity boost engagement consequently bolster user base go forward read microsoft unveil xbox controller specially able gamer performance top dow company table give show price movement largest component dow be price weight index last day last month last trading day dow have decline next week outlookcomment president trump have guide market lower more occasion week only nature fed minute have prove be encourage investor otherwise absence major earning report geopolitical event have weigh heavily investor sentiment give backdrop only be natural investor turn economic report encouragement several key piece datum be line release next week include important gdp report most be encourage nature stock soon return winning way look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1042,LLY,pfizer inc pfe free report announce smoking cessation drug chantix varenicline fail phase iv study evaluate adolescent smoker study be be conduct regulatory post marketing commitment smoker age year unite state year europe complete study result be expect be present upcoming scientific congress be publish later peer review medical journal chantix be already market prescription drug help adult age counsele stop smoking share company be mar meanwhile pfizer share have decline so far year compare industry decline period dose range multus centre phase iv study evaluate chantix smoking cessation nicotine dependent adolescent combination age appropriate counsel study evaluate dosage drug mg once twice daily chantix fail meet primary endpoint week continuous abstinence rate compare placebo week adverse event observed study be similar see earlier study conduct adult smoker pfizer be plan submit datum study fda pediatric exclusivity determination pediatric exclusivity be grant month return conduct study pediatric patient failure study young smoker be unlikely receive exclusivity setback pfizer glaxosmithkline gsk free report terminate talk buy former consumer healthcare business last week england base reckitt benckiser also announce drop buyout plan segment pfizer inc price pfizer inc price pfizer inc quotezack rank other key pickspfizer currently carry zack rank buy other top rank stock health care sector include horizon pharma public limit company hznp free report eli lilly company lly free report stock carry zack rank see complete list today zack rank strong buy stock here horizon pharma earning estimate increase last day company deliver positive earning surprise trail quarters average beat lilly earning share estimate increase last day company deliver positive earning surprise trail quarters average beat company share have increase so far year medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
1043,LLY,share radius health rdus free report fall company suffer setback once again europe overall radius health share have lose last month industry gain scientific committee european commission committee medicinal product human use chmp render negative trend vote benefit risk balance marketing authorization application maa abaloparatide sc oral explanation chmp therefore adopt negative opinion same company be plan get abaloparatide sc approve treatment osteoporosis postmenopausal woman increase risk fracture radius health plan seek re examination chmp opinion december chmp issue third day list outstanding issue inform company intend refer maa scientific advisory group additional advice company have earlier issue second day list outstanding issue delay get approval europe be disappointing give market potential note abaloparatide injection be approve fda april brand name tymlos treatment postmenopausal woman osteoporosis high risk fracture multiple risk factor fracture patient have fail be intolerant other available osteoporosis therapy tymlos continue gain traction approximately cover life coverage commercial plan tymlos market share reach approximately new patient start anabolic therapy nbrx total prescription anabolic market osteoporosis market unite sate have great potential approximately postmenopausal woman experience osteoporotic fractur year tymlos be expect face significant competition eli lilly co lly free report forteo amgen amgn free report prolium radius health pipeline include abaloparatide patch potential use osteoporosis elacestrant rad treatment hormone receptor positive breast cancer rad steroidal selective androgen receptor modulator be be evaluate use hormone receptor positive breast cancer zack rank key pickradius health currently carry zack rank hold better rank stock health care sector be regeneron pharmaceutical regn free report sport zack rank strong buy see complete list today zack rank stock here regeneron earning share estimate have moved last day company pull positive earning surprise last quarters average beat look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1044,LLY,merck co inc mrk free report announce committee medicinal product veterinary use cvmp have recommend marketing authorization europe bravecto spot combination topical solution fluralaner moxidectin cat bravecto be part company animal health unit company share be so far year industry gain period veterinary medicinal product approval be used treatment internal external parasite infestation tick flea heartworm roundworm hookworm cat drug start kill activity tick flea immediately continue week prevent heartworm disease week bravecto be first approve chewable tablet formulation dog spot version be launch topical solution dog cat unite state bravecto be major growth driver animal health unit due rise demand formulation bravecto be ultimately approve eu sale product increase further however product company animal health unit face competition product other company zoetis inc zts free report eli lilly company lly free report elanco generic product merck co inc price merck co inc price merck co inc quotezack rank stock considermerck currently carry zack rank hold pfizer inc pfe free report be better rank stock pharma sector carry zack rank buy see complete list today zack rank strong buy stock here pfizer earning estimate increase last day company deliver positive earning surprise trail quarters average beat hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
1045,LLY,radius health inc rdus free report report loss share first quarter narrower zack consensus estimate loss wider year period loss increase general administrative expense lead wider anticipate net loss year year company report sale tymlos abaloparatide surpass zack consensus estimate quarter detailtymlos sale increase fourth quarter radius health receive fda approval tymlos april treatment postmenopausal woman osteoporosis high risk fracture company begin shipment drug wholesaler end tymlos continue gain traction approximately cover life coverage commercial plan tymlos market share reach approximately new anabolic patient start anabolic therapy nbrx total anabolic osteoporosis market base patient month therapy trx pmot first quarter research development expense report quarter be year year general administrative expense report quarter increase due increase incompensation travel related expense increase selling general administrative expense pipeline company be develop formulation abaloparatide sc abaloparatide transdermal radius health suffer setback committee medicinal product human use european medicine agency ema adopt negative opinion radius health marketing authorization application abaloparatide sc march consequently april radius health submit request re examination chmp opinion radius health initiate phase iii study atom abaloparatide treatment osteoporosis male abaloparatide sc treatment osteoporosis man successful form basis supplemental nda seek expand drug label randomize double blind placebo controlled trial enroll approximately man osteoporosis high risk fracture study include primary endpoint change lumbar spine bone mineral density month versus placebo specialize high resolution imaging bone structure subset study participant estimate male osteoporosis be estimate account approximately total treat osteoporotic patient population quarter radius health finalize development pathway abaloparatide patch regulatory alignment fda enter scale commercial supply agreement company meanwhile radius health conduct single randomize comparator controlled phase iii trial elacestrant third line monotherapy approximately patient positive negative advanced metastatic breast cancer feedback fda ema result be expect support application global marketing approval positive patient study be randomize receive elacestrant investigator choice approve hormonal agent primary endpoint study be progression free survival study be plan be initiate second half phase study evaluate safety maximum tolerate dose rad patient hormone receptor positive locally advanced metastatic breast cancer be currently enrolling radius health expect provide update rad development program end company narrower expect loss first quarter be encourage sale tymlos be pick radius health see increase total number physician prescribe tymlos first quarter compare fourth quarter tymlos share new prescription physician increase fourth quarter first quarter price drug be increase implement feb go forward radius health expect tymlos capture average anabolic osteoporosis market anabolic market unite state be expect increase volume radius health share have rally last month compare industry gain osteoporosis market unite sate have great potential approximately postmenopausal woman experience osteoporotic fracture year tymlos be expect face significant competition eli lilly co lly free report forteo amgen amgn free report prolium zack rank stock considerradius health currently carry zack rank sell better rank stock healthcare sector be exelixis exel free report currently sport zack rank strong buy see complete list today zack rank stock here exelixis earning share estimate increase cent cent past day look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1046,LLY,aveo pharmaceutical inc aveo free report report fourth quarter adjust loss cent share exclude gain due change fair value warrant liability wider zack consensus estimate loss cent well year loss cent however include gain related change fair value warrant liability company report earning cent aveo first drug fotivda tivozanib receive eu approval august first line treatment advanced renal cell carcinoma rcc subsequently november aveo partner eusa pharma launch drug europe start germany company be entitle receive double digit royalty payment eusa pharma net sale drug europe however fotivda be not yet approve unite state rcc aveo top line mainly comprise collaboration revenue milestone other payment total collaboration revenue fourth quarter be approximately compare year figure revenue miss zack consensus estimate share company have decline more mar follow earning release due wider loss lower sale however year date basis aveo share price movement show stock have outperformed industry specifically company share have gain compare industry increase quarterly development expense be however general administrative expense increase year year pipeline updatesin october aveo announce result pre plan futility analysis phase iii tivo study compare fotivda bayer bayry free report nexavar treatment patient refractory advanced rcc base result company continue study unmodified datum study previously complete tivo study support regulatory application approval unite state december company announce completion enrollment phase ii portion phase ib ii tinivo study evaluate fotivda combination bristol myer bmy free report opdivo rcc company expect provide update study second half apart fotivda aveo be also develop ficlatuzumab combination lilly lly free report erbitux phase ii study treat metastatic head neck squamous cell carcinoma phase ib study be evaluate ficlatuzumab combination nab paclitaxel gemcitabine treatment naive pancreatic cancer study be initiate december last year resultsfull year sale stand miss zack consensus estimate however top line drastically increase compare year figure full year earning cent share be narrower zack consensus estimate cent however bottom line be wider year loss cent cash guidanceaveo expect present cash resource allow company fund plan operation first quarter aveo pharmaceutical inc price consensus ep surprise aveo pharmaceutical inc price consensus ep surprise aveo pharmaceutical inc quotezack rankaveo carry zack rank hold see complete list today zack rank strong buy stock here breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
1047,LLY,radius health inc rdus free report be schedule report first quarter result radius health inc price consensus ep surprise radius health inc price consensus ep surprise radius health inc quote radius health have disappointing track record company have report wider expect loss trail trail quarters average negative earning surprise last report quarter increase general administrative expense lead wider anticipate net loss year year radius health share have lose year industry gain let see thing be shape quarter review factor playradius health develop therapeutic treatment osteoporosis oncology endocrine disease company lead drug tymlos be approve unite state april drug be approve treat postmenopausal woman osteoporosis high risk fracture defined history osteoporotic fracture multiple risk factor fracture drug also be used patient have fail be intolerant other available osteoporosis therapy company report sale tymlos abaloparatide fourth quarter hence expect investor focus uptake drug upcoming earning call osteoporosis market unite state have great potential approximately postmenopausal woman suffer osteoporotic fracture year tymlos be expect face significant competition eli lilly co lly forteo amgen amgn prolium meanwhile company marketing authorisation application eladyno abaloparatide sc europe treatment postmenopausal woman osteoporosis be review however scientific committee european commission committee medicinal product human use chmp give negative trend vote benefit risk balance marketing authorization application maa abaloparatide sc oral explanation chmp therefore adopt negative opinion same company be plan get abaloparatide sc approve treatment osteoporosis postmenopausal woman increase risk fracture radius health plan seek re examination chmp opinion december chmp issue third day list outstanding issue inform company intend refer maa scientific advisory group additional advice company have earlier issue second day list outstanding issue delay get approval europe be disappointing give market potential meanwhile company present positive datum elacestrant breast cancer december fda also grant fast track designation elacestrant october february radius health obtain scientific advice ema regard potential single arm monotherapy phase ii trial elacestrant patient positive negative advanced metastatic breast cancer base feedback ema fda company conduct single randomize controlled phase ii trial elacestrant third line monotherapy approximately patient positive negative advanced metastatic breast cancer hence expect management throw more light pipeline progress earning whispersour proven model do not show radius health be likely beat estimate quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp radius health be currently peg be most accurate estimate be peg loss zack consensus estimate stand loss uncover best stock buy sell re report earning esp filter zack rank radius health have zack rank sell note caution stock zack rank strong sell go earning announcement stock considerhere be pharma company consider model show have right combination element deliver earning beat quarter gw pharmaceutical plc gwph free report be expect report quarterly result company have earning esp zack rank see complete list today zack rank stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1048,LLY,biotech sector witness series event past week quite few company report quarterly result week announce pipeline update past week amgen revise annual guidance biogen report quarterly number sale miss estimate recap important story prothena plunge discontinuation study share prothena corp prta free report plunge company decide discontinue development lead pipeline candidate neod candidate antibody be be evaluate treatment al amyloidosis phase iib study pronto do not meet primary secondary endpoint hence company ask independent datum monitoring committee dmc phase iii vital study review futility analysis ongoing vital study thereafter dmc recommend discontinuation vital study futility hence company decide discontinue study development neod include vital study well open label extension study decision come major blow investor company have very limit number candidate pipeline neod be lead candidate prothena carry zack rank buy see complete list today zack rank strong buy stock here incyte lilly drug get fda advisory committee nod incyte corp incy free report eli lilly company lly free report announce fda arthritis advisory committee have recommend approval mg dose baricitinib once daily oral medication treatment moderately severely active rheumatoid arthritis adult patient have have inadequate response intolerance methotrexate however advisory committee do not recommend approval mg dose baricitinib propose indication base adequacy safety benefit risk profile fda be generally not require follow advisory committee recommendation consider same review nda baricitinib fda have earlier issue complete response letter same drug be approve olumiant europe amgen revise annual guidance amgen inc amgn free report revise guidance concurrent first quarter result company beat sale earning first quarter drive strong performance newly recently launch drug company now expect revenue be compare earlier estimate earning share be now project come compare earlier estimate biogen miss sale biogen biib free report miss revenue estimate first quarter spinraza sale be drab company lead multiple sclerosis franchise also see sale decline biotech have be struggle nevertheless earning beat estimate share re-cover end positive note end session earlier company also extend collaboration ionis pharmaceutical ion free report new year agreement develop novel antisense drug candidate broad range neurological disease agreement biogen pay ionis cash include purchase share ionis common stock price share read more biogen earning beat sale miss share calithera kidney cancer candidate get fast track status share calithera bioscience inc cala free report gain company announce fda have grant fast track designation lead candidate cb candidate be be develop combination exelixis exel cabozantinib treatment metastatic kidney cancer calithera cb selective potent inhibitor glutaminase be be evaluate phase ii study cantata combination cabometyx clear cell renal cell carcinoma patient previously treat least vascular endothelial growth factor tyrosine kinase inhibitor combination opdivo yervoy read more calithera kidney cancer candidate get fast track status biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index lose last trading session major biotech stock alexion lose last month regeneron lose vertex gain see last biotech stock roundup here biotech stock roundup alk cldx alxn acquire wilson therapeutic next biotech world stay tune quite be schedule report result later week early next week investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
1049,LLY,monday president trump step rhetoric pharma company say administration soon take action bring drug price be keep promise make campaign trail well comment make last year state union address meanwhile industry watcher have grow skeptical trump intermittent pronouncement issue also key government databasis reveal quantum fund spend healthcare have not be update recently raise question administration seriousness take action give backdrop make good sense invest select biotech stock especially small company focuse develop cut edge treatment drug price cut corner monday trump deliver speech federal government initiative fight country opioid addiction crisis manchester new hampshire speech trump launch pharma company raise issue exorbitant drug pricing once again trump say consumer unite state be pay more drug many other country world administration work change situation president say citizen unite state witness drug price fall very substantially avoid mention specific health human service secretary alex azar also pitch event reveal entire raft proposal be introduce reduce price prescription drug azar too refrain mention concrete plan choose only praise unitedhealth group incorporate unh free report decision pass discount obtain pharma company customer skepticism concrete action aboundsapart comment make election trail trump have call strong action drug price intermittently november last year trump appoint azar current position claim former chief arm eli lilly company lly free report be star better healthcare lower drug price trump even choose take issue state union address say drug price come tenure little action have follow tough talk much discuss executive order drug pricing have fail materialize fact pharma company have raise price several drug trump tenure trump meet lead pharma official complete first month president even have seat table world economic forum davos further trump have hire several former pharma industry employee administration include azar tenure price several drug increase more meanwhile department health human service have fail update databasis reveal quantum government fund spend healthcare include cost drug be prove be advantageous pharma company now avoid reveal detail drug pricing turn affect effort researcher profit group work lower price key drug choicesindustry watcher feel pharma investor have get used trump rhetoric drug price largely choose ignore such comment meanwhile trump have induct several former pharma industry employee administration appoint key position be outlook pharma company especially biotech industry focuse unique treatment remain undim investing select biotech stock look good option point have narrow search follow stock base good zack rank other relevant metric pharmaceutical hold company ltd bhvn free report be company focus identification development orphan neurologic indication other neurological pathway pharmaceutical have zack rank strong buy company have expect earning growth current year zack consensus estimate current year have improve last day protagonist therapeutic inc ptgx free report be clinical stage company proprietary technology platform focuse discover develop peptide base new chemical entity address significant unmet medical need protagonist therapeutic have zack rank company have expect earning growth current year zack consensus estimate current year have improve last day regeneron pharmaceutical inc regn free report be company focuse discovery development treatment target serious medical condition regeneron pharmaceutical have expect earning growth current year zack consensus estimate current year have improve last day stock have zack rank see complete list today zack rank strong buy stock here horizon pharma plc hznp free report be focuse identify develop acquire commercialize product address unmet therapeutic need arthritis pain inflammatory orphan disease horizon pharma have zack rank buy company have expect earning growth current year zack consensus estimate current year have improve last day ligand pharmaceutical incorporate lgnd free report be biotechnology company business model be base develop acquire royalty revenue generate asset couple lean corporate cost structure ligand pharmaceutical have zack rank company have expect earning growth current year zack consensus estimate current year have improve last day make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1050,LLY,radius health inc rdus free report announce positive result phase iii study activextend endo endocrine society annual meeting expo chicago phase iii study active abaloparatide comparator trial vertebral endpoint trial be randomize double blind placebo controlled comparative multicenter month international study postmenopausal woman osteoporosis study evaluate efficacy safety abaloparatide sc mcg reduce risk vertebral nonvertebral fracture activextend be extension active trial trial enrolled patient complete month abaloparatide sc placebo active receive additional month open label alendronate patient complete month tymlos injection placebo active trial be transition receive additional month open label alendronate bisphosphonate bone mineral density bmd be measure lumbar spine total hip femoral neck begin active end activextend result show bmd response rate increase abaloparatide follow alendronate group placebo follow alendronate group active baseline month activextend additionally greater bmd response rate more be note abaloparatide follow alendronate group versus placebo follow alendronate group site combine month anatomic site bmd increase more be note respectively visit month abaloparatide follow alendronate patient experience bmd increase more site compare patient receive placebo follow alendronate result activextend responder analysis be consistent significant bmd response tymlos versus placebo observed active trial remind investor april fda approve tymlos abaloparatide sc treatment postmenopausal woman high risk osteoporosis fracture defined history osteoporotic fracture multiple risk factor fracture patient have fail be intolerant other available osteoporosis therapy radius health share have moved last month compare industry gain tymlos continue gain traction approximately cover life coverage commercial plan tymlos market share reach approximately new patient start anabolic therapy nbrx total prescription anabolic market osteoporosis market unite sate have great potential approximately postmenopausal woman experience osteoporotic fractur year tymlos be expect face significant competition eli lilly co lly free report forteo amgen amgn free report prolium company also suffer setback chmp issue third day list outstanding issue zack rank key pickradius health currently carry zack rank hold better rank stock health care sector be regeneron pharmaceutical regn free report sport zack rank strong buy see complete list today zack rank stock here regeneron earning share estimate have moved last day company pull positive earning surprise last quarters average beat more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1051,LLY,celldex therapeutic inc cldx free report have incur fourth quarter loss exclude income tax benefit cent share narrower zack consensus estimate loss cent well year loss cent lower cost higher revenue lead upside total revenue quarter soar year year beating zack consensus estimate manufacturing service agreement international aids vaccine initiative drive top line share company rise hour trading mar however stock have not do too well past year share company have underperform industry have decline compare industry decrease quarterly detailsresearch development expense decline year period general administrative spend improve dec celldex have cash cash equivalent marketable security compare sep biotech company weaken cash position be due higher operate expense partially offset net proceed raise sale common stock month contract cantor resultstotal revenue year surge higher zack consensus estimate net loss exclude income tax benefit come cent share slightly wider zack consensus estimate cent however company have report loss year outlookcelldex expect cash position december end net proceed generate sale common stock last month anticipate proceed future sale common stock agreement cantor be adequate fund work capital requirement well plan operation pipeline updatecelldex most advanced pipeline candidate be antibody drug conjugate glembatumumab vedotin currently evaluation treatment triple negative breast cancer phase iib metric study metastatic melanoma phase ii enrolment key metric study be complete august top line datum expect second quarter company also plan file biologic license application second half melanoma study celldex add fourth cohort glembatumumab cdx arm combination be study patient fail prior checkpoint therapy apart glembatumumab vedotin promising candidate company pipeline include varlilumab cdx cdx january company close enrollment phase ii trial evaluate varlilumab bristol myer bmy free report opdivo include cohort indication namely colorectal cancer ovarian cancer head neck squamous cell carcinoma renal cell carcinoma glioblastoma celldex expand phase study january assess cdx advanced renal cell carcinoma include patient ovarian clear cell carcinoma november company initiate phase ii program cdx combination eli lilly lly free report erbitux patient head neck squamous cell carcinoma have develop resistance erbitux company also commence phase study same month evaluate cdx treat locally advanced metastatic solid tumorscelldex therapeutic inc price consensus ep surprise celldex therapeutic inc price consensus ep surprise celldex therapeutic inc quote zack rank stock considercelldex carry zack rank hold better rank stock health care sector be ligand pharmaceutical incorporate lgnd free report sporting zack rank strong buy see complete list today zack rank stock here ligand earning share estimate have moved last day company pull positive surprise trail quarters average beat share price company have climb year hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1052,LLY,eli lilly company lly free report boehringer ingelheim announce plan expand clinical program sglt inhibitor jardiance empagliflozin chronic heart failure emperial clinical trial lilly share have lose year industry upside emperial clinical trial comprise phase iii study be aim assess possible benefit lilly type ii diabetes drug jardiance improve exercise capacity heart failure symptom person chronic heart failure irrespective have type ii diabeteswe remind investor late fda approve new indication drug lower risk cardiovascular death adult type ii diabetes approval be base datum empa reg outcome study inclusion cardiovascular indication jardiance label have be surge sale drug emperial clinical study be base datum obtain empa reg outcome study effect jardiance heart failure outcome meanwhile jardiance be already be evaluate phase iii emperor study outcome study jardiance treatment chronic heart failure patient diabetes emperor study focus long term morbidity mortality outcome person heart failure emperial study investigate treatment jardiance help improve everyday life person chronic heart failureaccord company press release heart failure be serious condition affect person worldwide include more american be associate high morbidity mortality lilly boehringer be look way see jardiance improve patient health outcome jardiance sale rise drive increase market share grow sglt class unite state increase volume outside unite state eli lilly company price eli lilly company price eli lilly company quote zack rank stock considerlilly carry zack rank hold few better rank stock same space be regeneron regn free report ligand pharmaceutical lgnd free report enanta pharma enta free report regeneronand ligandsport zack rank strong buy enanta pharma carry zack rank buy see complete list today zack rank stock here regeneron earning share estimate have moved respectively last day company pull positive earning surprise last quarters average beat ligand earning share estimate have moved respectively last day company deliver positive earning surprise trail quarters average beat company share have rally year enanta pharma deliver positive earning surprise last quarters average beat company share surge year hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1053,LLY,merck co inc mrk free report announce datum phase ii keynote study evaluate use pd therapy keytruda patient advanced hepatocellular carcinoma hcc form liver cancer be previously treat systemic therapy sorafenib datum show treatment keytruda monotherapy lead overall response rate orr datum also show complete response rate partial response rate treatment datum also include month overall survival os progression free survival pfs rate median pfs keytruda arm be month month pfs rate percent however datum show median os be not reach time analysis month os rate be datum be present present american society clinical oncology asco gi cancer symposium san francisco notably keytruda be already market several cancer indication include lung cancer melanoma head neck cancer classical hodgkin lymphoma bladder cancer last week merck announce keytruda combination lilly lly free report alimta pemetrexed acisplatin carboplatin meet dual primary endpoint phase iii keynote study combination be evaluate first line treatment patient metastatic squamous nsclc study meet primary endpoint progression free survival pfs os co primary endpoint remind investor third quarter call merck have mentioned be include overall survival os co primary endpoint keynote study defer readout study be then estimate study complete february therefore year earlier expect positive read keynote study be big boost company share merck have lose past year compare unfavorably industry increase remind investor keytruda be key top line driver merck bring sale third quarter sequentially year year sale continue be drive launch new indication globally significantly keytruda sale unite state have gain particularly strong momentum new indication first line lung cancer meanwhile keytruda development program also significantly advanced regulatory approval new indication unite state additional disease europe keytruda be continuously grow expand new indication market globally be trial more type cancer study include excess combination study merck be collaborate separately several company namely amgen inc amgn free report incyte glaxo pfizer inc pfe free report evaluation keytruda combination other regimen merck company inc price merck company inc price merck company inc quotezack rankmerck carry zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1054,LLY,jan issue update report nektar therapeutic nktr free report company focuse develop treatment utilize pegylation advanced polymer conjugate technology platform company portfolio comprise drug movantik opioid induced constipation oic adynovate treat hemophilia drug be show impressive performance nektar share global license agreement astrazeneca azn free report grant latter worldwide exclusive right develop market sell movantik well fix dose combination product company also have licensing collaboration manufacturing contract shire plc shpg free report adynovate receive royalty sale milestone related drug licensing agreement be expect provide regular fund company nektar share have substantially outperformed industry year skyrocking industry have register rise be pleased nektar effort build pipeline company have robust pipeline early late stage candidate nektar have make significant progress lead candidate onzeald formerly know nktr currently accelerate assessment eu treat adult advanced breast cancer well brain metastase response be anticipate first half nektar have also initiate randomize phase iii confirmatory study attain onzeald compare single agent chemotherapy respective physician choice trial be be conduct patient advanced breast cancer shortly complain brain metastase positive result evaluation support regulatory filing unite state company be further develop several other candidate important therapeutic area include oncology pain infective immunology interesting one include nktr phase iii chronic pain nktr phase ii solid tumor nktr phase autoimmune disease remind investor july nektar have announce positive top line result oral human abuse potential study nktr order assess abuse potential compare oxycodone notably fda grant fast track designation nktr development program successful development candidate turn drive company revenue consider lucrative market target importantly nektar enter co development deal eli lilly company lly free report nktr last july pursuant agreement nektar be responsible complete ongoing phase study candidate however go forward phase ii trial same lilly be capture total cost further lower nektar development expense nktr however nektar proprietary market product well underdeveloped candidate be subject stiff competition various other pharmaceutical biotechnology company company be expect face intense rivalry pain market several manufacturer develop pain therapy competitor include collegium pharmaceutical xtampza teva pharmaceutical naproxen name few also player pegylation polymer conjugate chemistry technology space be biogen savient pharmaceutical dr reddy nordisk other nektar heavy reliance partner revenue still remain huge concern partnership related setback seriously weigh company nektar therapeutic price nektar therapeutic price nektar therapeutic quote zack ranknektar carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1055,LLY,week eli lilly lly free report announce cash deal tobuy immuno oncology biotech armo bioscience inc jnj free report multiple myeloma drug darzalex gain fda approval combination use first line set roche rhhby free report announce couple regulatory pipeline update pd inhibitor tecentriq astrazeneca azn free report sell right schizophrenia product parp inhibitor lynparza gain marketing approval eu recap week most important storieslilly expand immunotherapy pipeline armo eli lilly announce definitive agreement buy california base immuno oncology biotech armo bioscience share approximately cash deal acquisition add armo lead product candidate pegilodecakin lilly cancer pipeline pegilodecakin pegylate il be be study late stage study pancreatic cancer well early stage study lung renal cell cancer melanoma other solid tumor type armo bioscience go public january year lilly have well layer oncology strategy involve build key cancer treatment cyramza lartruvo verzenio foundational agent focuse develop new standard care change therapy combination regimen include immuno therapy armo bioscience acquisition add promising next generation immunotherapy pipeline asset lilly portfolio be line strategy transaction be expect close end second quarter darzalex get fda nod first line set multiple myeloma drug darzalexgain fda approval first line set latest approval darzalex now be prescribe combination bortezomib melphalan prednisone vmp treatment ofpatient newly diagnosed multiple myeloma be ineligible autologous stem cell transplantation theapproval first line set expect year be expect darzalex saleswill improve further go forward also announce datum phase iii study evaluate investigational compound esketamine nasal spray combination newly initiate oral antidepressant niod patient treatment resistant depression compare placebo nasal spray niod combination demonstrated statistically significant clinically meaningful rapid reduction depressive symptom treatment flexibly dose esketamine nasal spray niod compare placebo niod study adult however study conduct elderly patient age older esketamine arm witness clinically meaningful effect compare placebo arm study narrowly miss statistical significance primary efficacy endpoint result be present annual meeting american psychiatric association astrazeneca sell seroquel right luye pharma astrazeneca announce agreement sell seroquel seroquel xr treatment schizophrenia bipolar disease right uk china other international market luye pharma group total consideration be include upfront payment well certain future payment astrazeneca transaction expect close second quarter be part company effort focus main therapy area oncology cardiovascular renal metabolism respiratory sale seroquel seroquel xr have be decline drug be face generic competition november seroquel xr record sale represent year year decline astrazeneca merck parp inhibitor lynparza tablet gain euapproval use maintenance therapy platinum sensitive relapse ovarian cancer regardless patient brca mutation status approval thus expand eligible patient population lynparza approval same indication unite state be receive august last year roche tecentriq focus roche supplemental biologic license application sbla label expansion pd inhibitor tecentriq be grant priority review fda latest application roche be look get tecentriq approve combination avastin bevacizumab carboplatin paclitaxel first line treatment advanced squamous small cell lung cancer nsclc fda decision be expect sep tecentriq be presently market treatment second line metastatic nsclc label expansion first line set boost drug sale further tecentriq be also approve treatment patient suffering locally advanced metastatic urothelial carcinoma muc be not eligible cisplatin chemotherapy drug record sale chf news tecentriq roche announce late stage study evaluate drug combination cotellic heavily pre treat patient advanced metastatic colorectal cancer crc do not meet primary endpoint overall survival os compare regorafenib nyse arca pharmaceutical index rise last trading session large cap pharmaceutical industry yr return large cap pharmaceutical industry yr return here be major stock perform last trading session stock be green last week bristol myer bmy free report decline lilly rise most past month glaxo gsk free report have be biggest gainer bristol myer decline most see last pharma stock roundup here pharma stock roundup mixed mrk pfe fda nod kymriah indication next pharma world watch fda decision many pipeline drug line extension market product month medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
1056,LLY,merck co inc mrk free report announce supplemental biologic license application sbla pd therapy keytruda have be accept priority review fda latest application merck be look expand label keytruda treatment advanced cervical cancer disease progression chemotherapy fda grant priority review decision be expect jun be first time fda have accept filing pd therapy cervical cancer meanwhile be fourteenth regulatory submission keytruda accept fda sbla be base part datum phase ii keynote study year so far merck share have underperform industry merck share have decline period increase industry keytruda be second largest product merck portfolio be market many type cancer treatment setting include lung cancer melanoma head neck cancer classical hodgkin lymphoma gastric cancer bladder cancer microsatellite instability high msi mismatch repair deficient cancer treatment fetch sale almost year year upside be drive global launch new indication further boost demand keytruda sale be gain particularly strong momentum first line lung cancer indication be only pd approve first line set monotherapy well combination therapy eli lilly lly free report cancer drug alimta pemetrexed carboplatin pem carbo keytruda development program also significantly advanced several regulatory approval unite state europe japan new approval expand patient population drive sale last year positive momentum be expect continue well meanwhile keytruda be be study more type cancer more study include excess combination study merck be collaborate several company include amgen amgn free report incyte glaxo gsk free report pfizer separately evaluation keytruda combination other regimen merck carry zack rank hold see complete list today zack rank strong buy stock here breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
1057,LLY,aveo pharmaceutical inc aveo free report report first quarter loss cent share wider zack consensus estimate loss cent narrower year loss cent however exclude gain related change fair value warrant liability company report loss cent share aveo first drug fotivda tivozanib receive eu approval august first line treatment advanced renal cell carcinoma rcc company be focuse launch drug european country currently drug be available germany austria unite kingdom company be entitle receive double digit royalty payment eusa pharma net sale drug europe however fotivda be not yet approve unite state rcc company do not record fotivda sale quarter aveo top line comprise collaboration licensing revenue partnership royalty total revenue first quarter be approximately year figure revenue be almost line zack consensus estimate share company crash presumably company say be postpone datum readout key phase iii tivo study aveo share price movement show stock have underperform industry so far year specifically company share have lose compare industry decrease operate development expense be however general administrative expense increase year year cash guidanceaveo expect present cash resource allow company fund plan operation first quarter pipeline earning release company announce be defer anticipate topline datum readout tivo study evaluate fotivda first line rcc third quarter be previously expect second quarter aveo be conduct study address overall survival concern tivo study identify fda datum tivo study tivo study be include regulatory application approval fotivda unite state april aveo announce launch fotivda partner eusa pharma austria february drug be launch unite kingdom trigger milestone payment eusa pharma february aveo announce datum phase ii portion tinivo study evaluate tivozanib combination bristol myer bmy free report pd inhibitor opdivo metastatic rcc datum study show patient achieve orr disease control rate achieve combination therapy be january datum present phase ii study evaluate fotivda advanced hepatocellular carcinoma show fotivda achieve median pfs month week median os achieve be month apart fotivda aveo be also develop ficlatuzumab combination lilly lly free report erbitux phase ii study treat metastatic head neck squamous cell carcinoma phase ib study be evaluate ficlatuzumab combination nab paclitaxel gemcitabine treatment naive pancreatic cancer study be initiate december last year other updatesin february company appoint industry veteran john johnson year experience board director january aveo announce have refinance exist debt facility hercule capital company say term new facility help have additional cash flow compare prior loan aveo pharmaceutical inc price consensus ep surprise aveo pharmaceutical inc price consensus ep surprise aveo pharmaceutical inc quotezack rank stock consideraveo currently carry zack rank hold better rank stock health care sector be ligand pharmaceutical incorporate lgnd free report sporting zack rank strong buy see complete list today zack rank stock here ligand earning share estimate moved remain stable respectively last day company pull positive earning surprise last quarters average beat company stock be so far year hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1058,LLY,total earning total healthcare market capitalization be revenue growth growth rate seem unimpressive compare other sector earning revenue beat ratio respectively be also not great most notable player johnson johnson jnj free report be first major drug company report earning apr follow eli lilly company lly free report bristol myer squibb company bmy free report apr apr respectively other major drug company merck mrk free report pfizer pfe free report report industry bigwig come earning revenue beat earning focusjohnson world biggest maker healthcare product continue long streak earning beat earning share come cent ahead zack consensus estimate higher year quarter revenue grow year year edge past estimate johnson johnson raise revenue guidance maintain earning share outlook reflect growth read healthcare etfs focus johnson johnson earning drug giant surpass earning estimate lag revenue earning share cent come cent zack consensus estimate revenue fall shy estimate annual basis earning share revenue rise respectively pfizer expect revenue range earning share merckmerck also beat earning estimate miss revenue earning share come surpass zack consensus estimate cent improve year quarter revenue inched year year be estimate merck increase revenue guidance earning share guidance bristol myersbristol myer top estimate front report earning share cent cent zack consensus estimate ahead year earning cent revenue grow edge past zack consensus estimate company raise earning share guidance see healthcare etfs here eli lillyeli lilly also surpass earning revenue estimate earning outpaced zack consensus estimate cent come higher year quarter revenue grow beat estimate other drug maker eli lilly also raise revenue guidance earning guidance etf anglepharma etfs see terrible trading past month mediocre result fail boost confidence space push many fund week lows have highlighted detail fund have zack etf rank hold ishare pharmaceutical etf ihe free report etf provide exposure pharma stock tracking dow jone select pharmaceutical index focus firm be top holding basket accounting combine total asset suggest heavy concentration product have aum charge bps fee expense volume be light exchange share day fund have shed month spdr pharmaceutical etf xph free report fund provide exposure pharma company tracking pharmaceutical select industry index aum trade good volume share day charge bps fee year total product hold security focus firm take share product be same period read be spdr pharmaceutical etf xph free report hot etf right now vaneck vector pharmaceutical etf pph free report etf follow mvis list pharmaceutical index hold stock basket focus firm account more share product have amassed asset base trade moderate volume share day expense ratio come fund have lose month powershare dynamic pharmaceutical fund pjp free report be far most popular choice pharma space follow dynamic pharmaceutical intellidex index product have aum see lower volume share day fund charge bps fee expense hold stock fund invest least share bmy pfe lly etf have lose month first trust nasdaq pharmaceutical etf ftxh free report fund track nasdaq smart pharmaceutical index hold security basket pfizer johnson johnson account more share merck bristol myer eli lilly make more ftxh have lower level aum share average daily volume charge bps annual fee have shed same time frame want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
1059,LLY,unite therapeutic corporation uthr free report report adjust earning share first quarter rise year quarter due lower sg cost tax rate zack consensus estimate be peg share adjust earning exclude impact share base compensation gain revenue report quarter be beating zack consensus estimate revenue rise year year sale however decline sequentially due unfavorable timing pricing distributor order unite therapeutic first quarter revenue be usually flat prior year fourth quarter level due unfavorable timing magnitude distributor order be typically place once month base current utilization trend contractual minimum inventory requirement share unite therapeutic be almost wednesday fact stock have underperform industry year so far have decline compare industry decline period quarter detailunite therapeutic market product treatment pah remodulin tyvaso adcirca orenitram please note unite therapeutic buy exclusive right commercialize adcirca tadalafil treatment pah unite state eli lilly lly free report november lilly market tadalafil ciali erectile dysfunction lilly carry zack rank buy see complete list today zack rank strong buy stock here adcirca sale be year year drive price increase orenitram sale amount quarter year year due patient growth time positive impact amendment contractual minimum inventory level distributor remodulin sale be year year due reduction order international distributor tyvaso sale totale year year due price increase however amendment contractual minimum inventory level discuss hurt sale remodulin tyvaso please note remodulin adcirca be expect face generic competition year reduce sale product unituxin treatment pediatric patient high risk neuroblastoma sale be flat year year research development expense escalate due higher cost support company pipeline cardiopulmonary cancer drug develop organ manufacturing project selling general administrative sg expense decline pipeline update unite therapeutic be work expand indication market product orenitram tyvaso company present have phase iii program field cardiopulmonary disease oncology phase iii freedom ev study be evaluate oral combination therapy orenitram oreniplus full datum study be expect year meanwhile phase iii beat study be evaluate tysuberprost esuberaprost combination tyvaso datum study be also expect year unite therapeutic be also work new delivery mechanism remodulin company be work medtronic plc mdt free report get remosynch implantable pump deliver remodulin intravenously approve fda order launch remosynch unite state unite therapeutic medtronic be pursue parallel regulatory filing related device drug medtronic premarket approval application pma catheter remosynch be approve fda december unite therapeutic resubmit new drug application get remosynch approve fda january month review period fda action be expect jul unite therapeutic expect launch remosynch system early unite therapeutic have also develop pre filled semi disposable pump system subcutaneous delivery remodulin remunity partnership deka february deka file remunity fda filing be accept review fda clinical study remopro pain free new chemical entity version treprostinil be expect begin year several datum read out regulatory update be expect acquire week unite therapeutic announce definitive merger agreement steadyme ltd stdy free report unite therapeutic acquire steadyme include contingent payment deal unite therapeutic add steadyme drug device pipeline product trevyent pah patient portfolio have pose competition unite therapeutic remosynch trevyent be single use pre filled pump have be develop steadyme deliver day supply treprostinil subcutaneously used steadyme patchpump technology treat pah steadyme receive refuse file letter fda want further information steadyme intend resubmit nda end unite therapeutic corporation price consensus ep surprise unite therapeutic corporation price consensus ep surprise unite therapeutic corporation quote medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
1060,LLY,last week senator tina expressed concern big pharma company plan use large corporate tax saving reward shareholder instead bring cost expensive drug benefit consumer senator question letter ceo big pharma company pfizer pfe free report merck mrk free report johnson johnson jnj free report abbvie abbv free report abbott lab free report plan use extra cash please note conference call hold earlier year most big pharma company discuss plan do extra cash save new tax bill company plan invest extra cash capital expenditure product pipeline licensing acquisition deal reward shareholder higher dividend share buyback not many talk take step lower prescription drug cost apart key announcement week include failure dermira inc derm free report acne candidate pivotal late stage study merck oncology collaboration japan eisai expansion jardiance clinical study eli lilly lly free report fda committee back pfizer xeljanz third indication recap week most important storiesdermira share sink acne candidate fail share dermira plunge announce acne candidate olumacostat glasaretil surprisingly fail meet primary endpoint pivotal phase iii study clareo clareo company say likely stop olumacostat glasaretil development follow failure read more dermira acne candidate fail pivotal trial share sink merck jointly develop eisai cancer drug lenvima similar last year profit sharing deal astrazeneca azn free report merck announce oncology collaboration japan eisai co ltd deal company jointly develop commercialize eisai tyrosine kinase inhibitor lenvima monotherapy combination merck pd therapy keytruda several type cancer deal merck give eisai upfront payment company share global development marketing cost well gross profit lenvima equally read more merck pay upfront co develop eisai cancer drug pfizer xeljanz snda get fda committee back pfizer supplemental new drug application include ulcerative colitis uc indication label receive back fda advisory committee fda drug advisory committee gidac vote unanimously favor jak inhibitor fda decision be expect june xeljanz be already approve treat rheumatoid arthritis active psoriatic arthritis record sale represent growth year year astrazeneca look forxiga eu approval type diabetes astrazeneca application look get sglt inhibitor forxiga approve new indication oral adjunct treatment insulin type diabetes patient be accept european medicine agency forxiga be presently approve monotherapy well combination therapy treat type diabetes approve forxiga become first sglt inhibitor approve europe treatment oral treatment adjunct insulin read more astrazeneca forxiga label expansion filing accept eu glaxo present asthma hiv datum glaxo gsk free report present datum osmo study new respiratory medicine nucala american academy allergy asthma immunology aaaai world allergy organization wao joint congress orlando datum study show patient asthma be uncontrolled xolair witness improve asthma control switch glaxo new respiratory medicine nucala glaxo also present interim datum phase iiib study inspiring investigational hiv candidate dolutegravir medical conference boston read more glaxo encourage asthma hiv datum medical meeting meanwhile glaxo gain approval expand european label once daily laba ics combination treatment relvar ellipta now relvar ellipta be used eu patient asthma be already adequately controlled ics laba label update doctor prescribe asthma patient switch once daily relvar ellipta current twice daily ics laba experience comparable benefit lung function safety profile lilly boehringer expand jardiance clinical study lilly partner boehringer ingelheim announce plan initiate phase iii emperial study evaluate effect lilly sglt inhibitor jardiance exercise ability heart failure symptom person chronic heart failure irrespective have type ii diabetes presently ongoing phase iii emperor outcome study be evaluate effect jardiance long term morbidity mortality outcome person heart failure emperial study investigate treatment jardiance help improve everyday life person live chronic heart failure read more lilly boehringer expand jardiance heart failure program nyse arca pharmaceutical index be last trading session large cap pharmaceutical industry yr return large cap pharmaceutical industry yr return here be major stock perform last trading session major stock rise largest gainer be glaxo lilly last month bristol myer bmy free report gain merck decline see last pharma stock roundup here azn imfinzi get fda nod mrk buy australian firm next pharma world watch regulatory pipeline news pharma stock don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
1061,LLY,merck co inc mrk free report announce oncology collaboration japan eisai co ltd jointly develop commercialize latter tyrosine kinase inhibitor lenvima monotherapy well combination merck pd therapy keytruda several type cancer deal merck pay eisai upfront amount lenvima develop eisai be presently approve treatment thyroid cancer monotherapy second line treatment renal cell carcinoma rcc type kidney cancer combination novartis nvs free report afinitor everolimus meanwhile lenvima monotherapy be review unite state eu japan hepatocellular carcinoma type liver cancer also late stage study be already ongoing evaluate lenvima separate combination study keytruda afinitor rcc meanwhile keytruda lenvima combination enjoy breakthrough therapy designation fda rcc merck eisai plan jointly develop lenvima cancer type potential indication company share global development marketing cost well gross profit lenvima equally however eisai book lenvima worldwide product sale monotherapy combination other upfront payment merck also pay certain option right well reimbursement cost other eisai be entitle regulatory sale milestone payment so far year merck share have underperform industry merck share have decline period compare decrease industry keytruda be second largest product merck portfolio be market many type cancer treatment setting include lung cancer melanoma head neck cancer classical hodgkin lymphoma gastric cancer bladder cancer microsatellite instability high msi mismatch repair deficient cancer treatment fetch sale almost year year upside be drive global launch new indication further boost demand keytruda sale be gain particularly strong momentum indication first line lung cancer be only pd approve first line set monotherapy well combination therapy eli lilly lly free report cancer drug alimta pemetrexed carboplatin pem carbo keytruda development program also significantly advanced several regulatory approval unite state europe japan new approval expand patient population drive sale last year positive momentum be expect continue well meanwhile keytruda be be study more type cancer exceed study include excess combination study merck be collaborate several company include amgen inc amgn free report incyte glaxo pfizer separately evaluation keytruda combination other regimen expect merck present datum several key keytruda study year include combination study incyte epacadostat first line metastatic melanoma also keytruda get approval relapse refractory primary mediastinal large cell lymphoma indication year fda action expect april merck carry zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1062,LLY,spite increase incidence alzheimer be recognize drug cure slow progress disease alzheimer association claim second american develop alzheimer person live alzheimer find extremely difficult carry daily function hence need be supervision round clock come other life threaten condition cnbc report death related alzheimer have sky-rocket follow heart disease have drop turn century detection year onset alzheimer sa blood test have be introduce detect alzheimer almost decade patient show noticeable symptom last year dr randall bateman washington university announce test be able detect accumulation amyloid beta brain buildup toxic protein be first sign deadly disease also january team researcher japan australia introduce blood test accuracy high detection disease dr bateman employ mass spectrometry testing identify protein accord email bateman cnbc scientist japan have develop identical mass spectrometry investigative procedure protein detection come similar result blood test speed drug trial drug delay start disease fail number time thank unavailability decent number qualify patient reveal dr jeff cumming cleveland clinic hence wider patient base higher be possibility meaningful clinical trial new blood test doctor be able detect patient early include clinical trial development effective preventive treatment also be proper utilization million dollar federal government funding preventive treatment importantly blood test be most efficient way detect alzheimer other alternative be quite expensive lumbar puncture early diagnosis be alternative collect cerebrospinal fluid process needle be insert lower back patient give rise need local anesthetic positron emission tomography be process cost least also accuracy pet scan be significantly lower blood test dr robert vassar northwestern university have also backed efficiency blood test other method diagnosis alzheimer meanwhile dr bateman add blood test be more demand once proper preventive measure have be establish stock gainpeople world likely gain access test come few year dr bateman however question loom large be be next course action find be risk develop alzheimer meanwhile launch blood test pave way advanced clinical trial more person be estimate be live disease unite state alzheimer association notably health organization expect number rise more time alzheimer be press concern be massive business potential space hence launch blood test help company focuse develop preventive treatment make billion base cambridge biogen inc biib free report have be pay particular attention step research work alzheimer company surpass zack consensus estimate last quarters average positive earning surprise be also expect company witness earning growth respectively have be almost year eli lilly company lly free report headquarter indianapoli be fight alzheimer company beat zack consensus estimate last quarters also expect company post earning growth respectively fact treat patient early alzheimer symptom astrazeneca plc azn free report eli lilly be jointly develop lanabecestat small molecule therapy candidate merck co inc mrk free report headquarter kenilworth nj have be focuse research treat alzheimer company be expect post earning growth respectively merck also manage beat zack consensus estimate last quarters biogen eli lilly merck carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1063,LLY,abbvie abbv free report share jump follow release better expect fourth quarter result upbeat outlook result be drive performance humira imbruvica mavyret imbruvica continue witness strong uptake chronic lymphocytic leukemia cll indication humira performance be drive robust demand introduction new mechanism action competition indirect biosimilar meanwhile mavyret hepatitis virus hcv have be witness strong uptake unite state international market mavyret exit market share unite state be expect become major growth driver company rosy outlook company provide upbeat outlook reflect mavyret strong uptake continue robust underlie performance other product lower tax rate thank passage tax reform abbvie expect earning share range revenue almost mid point earning guidance range reflect year year growth improvement company previously provide guidance growth mid point provide third quarter result humira sale be expect grow approximately unite state ex sale be expect be company expect record imbruvica revenue more mavyret sale be expect cross other product venclexta androgel duodopa be expect record sale respectively creon sale be expect grow synagis lupron synthroid sale be expect remain flat zinbryta sale be expect come reflect impact competition label change cash repatriation capital deployment tax reform allow abbvie more efficient access foreign cash ability use unite state company intend invest capital unite state next year be currently evaluate additional expansion facility abbvie also intend accelerate pension funding enhance executive employee compensation company be also plan time shareable contribution select not profit organization support initiative such puerto rico rebuild effort child healthcare access program certain charity abbvie also say be increase shareholder return be combination acceleration dividend growth more share buyback detail be provide later company deal far deal be concern company key focus be opportunity drive growth timeframe abbvie say be look early stage asset catalyst rich abbvie spend be expect be sale reflect higher spending support late stage pipeline mid stage program addition work expand label approve product imbruvica venclexta abbvie late stage pipeline include candidate upadacitinib rheumatoid arthritis ra crohn disease risankizumab psoriasis crohn disease abbvie be look file regulatory approval risankizumab psoriasis indication first half year regulatory filing upadacitinib ra indication be expect second half meanwhile elagolix be priority review endometriosis response fda expect second quarter abbvie share be last year compare rally industry belong abbvie be zack rank buy stock see complete list today zack rank strong buy stock here week pharma company pfizer pfe free report eli lilly company lly free report nordisk nvo free report be report fourth quarter result pfizer have earning esp fourth quarter lilly nordisk have earning esp respectively earning esp be very valuable tool investor look stock be most likely beat earning estimate moreover add zack rank have produce positive surprise time pfizer lilly be zack rank hold stock nordisk be zack rank stock uncover best stock buy sell re report earning esp filter zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
1064,LLY,merck mrk free report share gain more jan company announce pd therapy keytruda combination eli lilly lly free report alimta pemetrexed carboplatin pem carbo meet dual primary endpoint confirmatory phase iii keynote study combination be evaluate first line treatment patient metastatic squamous small cell lung cancer nsclc notably combination therapy be grant accelerate approval fda aforementioned indication hence positive readout phase iii confirmatory study help company gain continue approval combo therapy remind investor third quarter company mentioned be include overall survival os co primary endpoint keynote study keytruda first line nsclc defer readout study therefore datum now release come much earlier investor expectation be big boost company merck share have inched year time compare unfavorably rally industry study be design evaluate combination therapy compare chemotherapy alone study meet primary endpoint progression free survival pfs os co primary endpoint datum study demonstrated significant improvement os pfs nsclc patient receive keytruda combo therapy compare receive chemotherapy alone be base interim analysis conduct independent datum monitoring committee be important note keytruda be first pd inhibitor combination show os patient nsclc company say datum trial be present upcoming medical meeting submit regulatory authority significantly october last year merck also announce have withdraw european regulatory application seek approval combination keytruda alimta carboplatin nsclc application be base positive datum cohort keynote trial however new positive readout possibility drug get nod eu increase note roche rhhby free report recently present datum tecentriq novel combination broad range tumor include lung cancer remind investor keytruda be first pd therapy gain fda approval be be study more type cancer study include combination trial keytruda fetch global sale first month year year merck company inc price merck company inc price merck company inc quote zack rank key pickmerck carry zack rank hold better rank stock health care sector be exelixis inc exel free report sporting zack rank strong buy see complete list today zack rank stock here exelixis earning share estimate have be revise upward cent cent last day company pull positive earning surprise trail quarters average beat share price company have surge year time more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1065,LLY,dow endure volatile week index hit fresh record high fall bank share lead loss index monday index slip tuesday follow positive news major component surge treasury yield lead loss index wednesday ultimately index surge record high thursday follow investor optimism economic growth last week dow gain last friday due optimism build implementation gop tax bill such broad base gain ensure improvement major benchmark negating effect dismal economic datum nonfarm payroll month december come lower consensus estimate job addition further trade deficit increase november settle be highest deficit january ism service index december decline point index add impressive point friday finish session milestone second straight day marked third straight record close last trading session best open week gain blue chip index be rather broad base last week index gain marked dow best weekly run dec period dow touch psychological level first time be index fastest point rise inception optimism strong market performance contribute gain favorable economic datum include upbeat manufacturing report record construction spending boost market dow index lose almost nearly point monday due fall bank share snap winning run marked end day streak gain blue chip index hit intraday record earlier session suffer broad base loss finish negative territory share major bank such goldman sachs group inc gs free report jpmorgan chase co jpm free report decline respectively weigh dow bank share decline analyst estimate be time charge fourth quarter earning bank suffer due implementation tax reform index increase tuesday follow report boee company ba free report have deliver record number airplane push dow record territory such event lead share boee gain contribute much point dow blue chip index amassed point finish record also contribute dow gain be increase share johnson johnson jnj free report gain add point dow index lose wednesday yield year benchmark note surge follow report china be consider halter purchase treasury market also suffer loss report canada surface government expect trump pull nafta soon meanwhile cost import good unite state surge year high index gain point thursday hit time high follow investor optimism economic growth share boee gain emerge largest contributor dow aircraft manufacturer likely be major beneficiary higher economic growth meanwhile ppi index decline move lower first time more year component move indexboee delivery show rise commercial shipment decline defense shipment year year basis company report commercial delivery jet higher delivery figure be company delivery guidance zack rank hold boee deliver model airplane follow delivery model boee deliver unit model compare unit year other delivery include compare unit respectively defense space business boee delivery be year total delivery consist apache helicopter new remanufacture chinook helicopter new renew read boee commercial defense jet delivery meanwhile boee defense space security unit recently secure modification contract worth production increment lot small diameter bomb sdb term deal company purchase additional quantity sdbs read boee win fms deal build small diameter bomb apple inc aapl free report announce be work feature provide increase parental control smartphone usage child announcement be make follow apprehension apple shareholder jana partner llc california state teacher retirement system regard role company shape child future bloomberg zack rank apple response criticism also mentioned iphone other apple product run io have be offer parent tool enable control child access company also offer ask buy feature require consent parent buy good service add bloomberg company be focuse make vigilance stricter new tool read apple develop tool increase parental control merck co inc mrk free report japanese partner easai co ltd announce fda have grant breakthrough therapy designation btd combination regimen zack rank merck pd therapy keytruda easai multiple receptor tyrosine kinase inhibitor lenvima company be develop combination potential treatment advanced metastatic renal cell carcinoma rcc kidney cancer be btd keytruda second lenvima designation aim expedite development review drug intend treat serious life threaten condition provide patient access soon possible read merck keytruda combo get breakthrough therapy status meanwhile merck announce phase iii study evaluate pd therapy keytruda monotherapy treatment high risk melanoma meet primary endpoint recurrence free survival rfs read merck keytruda succeed high risk melanoma study chevron corporation cvx free report effort divest stake south africa business china petroleum chemical corporation snp free report better know sinopec have be approve country competition commission notably sinopec acquire stake asset subsidiary soihl hong kong hold limit completion deal soihl manufacturer supplier petroleum petrochemical product enter south african petroleum market stock have zack rank strong buy see complete list today zack rank strong buy stock here pfizer inc pfe free report reportedly say statement end effort alzheimer parkinson disease area result layoff decision end neuroscience discovery program mainly affect employee facility andover cambridge groton ct zack rank pfizer however intend continue development pain candidate tanezumab be develop late stage study partnership eli lilly lly free report label expansion effort pain drug lyrica rare disease program read pfizer stall alzheimer parkinson cut job coca cola co ko free report affiliate chile local bottler brand enter agreement buy novaverde sa move be line strategy invest newer revenue generate platform company specialize juice canned fruit vegetable mainly brand guallarauco coca cola have zack rank embotelladora andina coca cola del valle new venture coca cola chile enter stock purchase agreement ownership novaverde share be transfer completion deal coca cola del valle new venture own share coca cola chile embotelladora andina own share respectively gain ownership share embotelladora andina direct indirect ownership novaverde be approximately be already shareholder coca cola del valle new venture deal be value accord reuter report read coca cola chilean arm buy novaverde diversify portfolio performance top dow table give show price movement largest component dow be price weight index last day last month last trading day dow have gain next week outlookdespite recent hiccup market continue be fuel expectation strong economic growth bullish fourth quarter earning recently release datum manufacturing construction have also bear such sentiment several economic report be line release next few day release reveal critical insight retail sale industrial production housing most report be encourage nature market be likely maintain upward trajectory week ahead zack editor chief go stockfull disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
1066,LLY,eli lilly company lly free report animal health subsidiary elanco partner aratana therapeutic inc petx free report have together announce veterinary medicine galliprant grapiprant tablet have be grant marketing authorization eu treatment pain associate mild moderate osteoarthritis oa dog notably oa be incurable be most common cause chronic pain dog however diagnosed early pain inflammation be controlled enable arthritic dog lead improve quality life drug be approve unite state march aforementioned indication subsequently launch last january be first piprant approve use unite state once daily use dog oa also be administer patient young month share lilly have underperform industry year stock have rally compare unfavorably industry increase period remind investor approval eu be make positive opinion grant european medicine agency committee medicinal product veterinary use recommend approval november lilly elanco have exclusive marketing right galliprant globally co promote product aratana unite state elanco make parasiticide pain dermatology medicine food well companion animal last january division acquire german drugmaker boehringer ingelheim vetmedica pet vaccine unit fully integrate manufacturing research development site notably lilly buy animal health division novartis nvs free report early strengthen elanco division company elanco segment record sale third quarter year year eli lilly company price eli lilly company price eli lilly company quote zack rank key pickslilly carry zack rank hold better rank stock health care sector be exelixis inc exel free report sporting zack rank strong buy see complete list today zack rank stock here exelixis earning share estimate have be revise upward cent cent last day company pull positive earning surprise trail quarters average beat share price company have soar year time zack editor chief go stock full disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
1067,LLY,merck co inc mrk free report announce pd therapy keytruda pembrolizumab have be approve japan previously treat patient urothelial carcinoma type bladder cancer approval make keytruda eligible be indicated type cancer japan notably keytruda have already be approve unite state eu first second line treatment patient aforementioned indication apart bladder cancer keytruda be approve many malignant disease type treatment setting include lung cancer melanoma head neck cancer classical hodgkin lymphoma be also approve combination therapy eli lilly lly free report lung cancer drug alimta pemetrexed carboplatin pem carbo merck share have lose last year compare unfavorably increase industry approval be base positive datum phase iii keynote study trial outcome show clinically meaningful improve overall survival os benefit keytruda compare chemotherapy patient give indication program keytruda demonstrated reduction death risk compare chemotherapy moreover median os be month keytruda arm comparison chemotherapy significantly merck commercialize keytruda japan collaboration taiho pharmaceutical company company press release incidence bladder cancer japan be anticipate increase time approximately patient be detected bladder cancer country new case diagnosed hence market opportunity keytruda be fairly wide country keytruda fetch global sale first month year year sale continue be drive launch new indication globally keytruda sale unite state gain particularly strong momentum new indication first line therapy lung cancer outside unite state keytruda sale be primarily drive melanoma indication remind investor keytruda be first pd therapy gain fda approval be be study more type cancer study include combination trial merck company inc price merck company inc price merck company inc quote zack rank key picksmerck carry zack rank hold better rank stock health care sector be sucampo pharmaceutical inc acelrx pharmaceutical inc acrx free report carry zack rank buy see complete list today zack rank strong buy stock here sucampo earning share estimate have moved north current year last day company deliver positive earning surprise trail quarters average beat share price company have surge year date acelrx stock have see zack consensus estimate current year loss share be narrow cent last day investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
1068,LLY,merck co inc mrk free report announce be discontinue study evaluate verubecestat treatment prodromal alzheimer disease success be unlikely apecs be phase iii study evaluate efficacy safety verubecestat oral amyloid precursor protein site cleave enzyme bace inhibitor versus placebo study be stop recommendation external datum monitoring committee assessed study overall benefit risk recent interim safety analysis committee say chance observe positive risk benefit profile study continue be slim share merck decline almost tuesday past year merck share have underperform industry merck share have decline period increase industry february last year merck have discontinue study epoch phase ii iii verubecestat be evaluate mild moderate alzheimer disease due lack efficacy time committee have recommend apecs study continue unchanged alzheimer disease market have attract lot attention several company however successful development therapy treatment alzheimer disease be challenge note several company have fail regard last month pfizer pfe free report reportedly say statement end effort alzheimer parkinson disease area result layoff long back pfizer shelved late stage alzheimer candidate bapineuzumab iv fail phase iii study december biogen biib free report announce alzheimer disease study ban fail show early positive result raise investor concern candidate chance success november lilly lly free report amyloid candidate solanezumab fail meet primary endpoint late stage ad study lilly decide drop development solanezumab lilly also suffer major setback august have halt development phase iii alzheimer candidate semagacestat alzheimer disease market represent huge commercial potential successfully develop product generate billion dollar sale once launch merck carry zack rank hold see complete list today zack rank strong buy stock here don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
1069,LLY,new drug application nda pfizer pfe free report anaplastic lymphoma kinase alk tyrosine kinase inhibitor tki candidate lorlatinib have be accept fda nda seek approval lorlatinib treatment patient alk positive metastatic small cell lung cancer nsclc have receive prior treatment more alk tkis nda have also be grant priority review decision be expect august similar application seek marketing authorization europe japan have also be accept regulatory agency respective country share pfizer be almost follow news stock have return past year underperform industry gain period pfizer submit regulatory application base positive datum phase ii portion phase ii study evaluate lorlatinib several cohort base prior therapy small cell lung cancer occur patient have lung cancer lead cause cancer death worldwide lung cancer be attractive avenue pharmaceutical company due widespread occurrence disease however be also most competitive space due presence large number player several large small company be develop have approve therapy treatment various form lung cancer remind investor last month merck mrk free report announce encourage result phase iii study evaluate pd therapy keytruda combination eli lilly lly free report alimta carboplatin nsclc also note roche rhhby free report recently present datum tecentriq novel combination broad range tumor include lung cancer blockbuster drug bristol myer opdivo be approve treat nsclc other pfizer inc price pfizer inc price pfizer inc quotezack rankpfizer carry zack rank buy see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1070,LLY,incyte corporation incy free report be schedule report fourth quarter result feb market open last quarter company beat estimate incyte earning track record have be mixed so far last quarters company surpass expectation miss estimate overall incyte deliver average positive surprise incyte stock lose last month industry decline let see thing be shape quarter likely positive surprise proven model show incyte be likely beat earning quarter have right combination key ingredient stock need have positive earning esp favorable zack rank strong buy buy hold happen zack esp incyte have earning esp represent difference most accurate estimate loss cent share zack consensus estimate loss cent positive esp hint earning surprise uncover best stock buy sell re report earning esp filter zack rank incyte have zack rank increase predictive power esp further combine positive esp chance earning beat be usually peg higher caution sell rate stock go earning announcement especially company be see negative estimate revision incyte corporation price ep surprise incyte corporation price ep surprise incyte corporation quote factor drive growthincyte lead drug jakafi ruxolitinib be first class jak jak inhibitor approve treatment patient polycythemia vera pv patient intermediate high risk myelofibrosis mf include primary mf post pv mf post essential thrombocythemia mf incyte market drug unite state be market novartis nvs free report jakavi outside country incyte continue gain traction jakafi performance jakafi sale be be drive patient demand jakafi be include recommend treatment patient myelofibrosis patient latest national comprehensive cancer network nccn clinical practice guideline oncology neoplasms mpns july be likely boost demand further base strong performance first month company up guidance jakafi now expect revenue range earlier project range company be also work expand drug label result phase iii trial reach evaluate jakafi treatment patient steroid refractory chronic graft versus host disease gvhd be expect first half assume positive result incyte plan submit snda seek accelerate approval jakafi indication further update be expect fourth quarter earning call remind investor jakafi sale royalty be key component incyte revenue growth iclusig sale olumiant royalty be also contribute top line february european commission approve olumiant patient rheumatoid arthritis approval trigger payment incyte eli lilly lly free report additional potential milestone payment well royalty sale olumiant approval provide incyte further valuable source revenue give potential milestone royalty company license agreement eli lilly olumiant be be study additional indication well atopic dermatitis phase iia systemic lupus erythematosus phase ii incyte pipeline also hold promise phase iii trial echo evaluate epacadostat keytruda patient unresectable metastatic melanoma be now fully recruit datum be expect first half expense be now expect range earlier forecast due acceleration phase iii plan epacadostat sg expense be expect range stock considerhere be other health care stock worth consider right combination element beat earning exelixis exel free report be expect release fourth quarter result feb have earning esp zack rank see complete list today zack rank stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1071,LLY,radius health inc rdus free report report loss share fourth quarter wider zack consensus estimate loss year quarter loss increase general administrative expense lead wider anticipate net loss year year radius health inc price consensus radius health inc price consensus radius health inc company report sale tymlos abaloparatide surpass zack consensus estimate quarter detailresearch development expense report quarter be year year due reduction expense associate elacestrant project development tymlos radius health receive fda approval tymlos april treatment postmenopausal woman osteoporosis high risk fracture begin shipment wholesaler end tymlos continue gain traction approximately cover life coverage commercial plan tymlos market share reach approximately new patient start anabolic therapy nbrx total prescription anabolic market general administrative expense report quarter jump primarily due personnel promotional consult expense related launch tymlos pipeline company be develop formulation abaloparatide sc abaloparatide transdermal labele supplement tymlos be submit fda fourth quarter positive month datum activextend study show continue significant risk reduction fracture patient be transition receive additional month bisphosphonate therapy january radius health meet fda discuss regulatory development path abaloparatide patch fda agree depend study result single randomize open label active controlled inferiority abaloparatide sc study patient postmenopausal osteoporosis high risk fracture be sufficient gain approval abaloparatide patch primary endpoint study be change lumbar spine bone mineral density month radius health expect initiate pivotal trial mid meanwhile radius health marketing authorisation application maa eladyno abaloparatide sc treatment postmenopausal woman osteoporosis europe be review committee medicinal product human use chmp european medicine agency ema company however suffer setback chmp issue second day list outstanding issue december chmp issue third day list outstanding issue inform company intend refer maa scientific advisory group additional advice company expect opinion chmp regard maa first half radius health fda have also agree design clinical trial man osteoporosis successful form basis snda seek expand use tymlos treat man osteoporosis high risk fracture study be expect be initiate first quarter company also plan initiate clinical trial man osteoporosis successful form basis snda seek expand label treat man osteoporosis high risk fracture study be expect be initiate first quarter meanwhile company present positive datum elacestrant breast cancer december fda also grant fast track designation elacestrant october february radius health obtain scientific advice ema regard potential single arm monotherapy phase ii trial elacestrant patient positive negative advanced metastatic breast cancer base feedback ema fda company conduct single randomize controlled phase ii trial elacestrant third line monotherapy approximately patient positive negative advanced metastatic breast cancer company wider expect loss fourth quarter be due escalate expense tymlos drug continue gain traction grab further market share radius health share have gain last month compare industry gain osteoporosis market unite sate have great potential approximately postmenopausal woman experience osteoporotic fractur year tymlos be expect face significant competition eli lilly co lly free report forteo amgen amgn free report prolium moreover approve label carry box warning osteosarcoma malignant bone tumor company also setback chmp issue third day list outstanding issue zack rank key pickradius health currently carry zack rank hold better rank stock health care sector be regeneron pharmaceutical regn free report sport zack rank strong buy see complete list today zack rank stock here regeneron earning share estimate have moved respectively last day company pull positive earning surprise last quarters average beat don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
1072,LLY,month have go last earning report eli lilly company lly free report share have lose past month underperform market recent negative trend continue lead next earning release be lly due dive investor analyst have react late let take quick look most recent earning report order get better handle important driver lilly top earning sale up earning outlooklilly report fourth quarter adjust earning share beat zack consensus estimate share earning rise year quarter backed robust volume drive growth new product sale lower sg cost higher other income include charge related tax reform restructure amortization other charge fourth quarter loss share be share earning cent fourth quarter revenue detailquarterly revenue also beat zack consensus estimate sale grow year year backed strong performance new drug favorable currency movement make lower sale establish product strattera humalog ciali effient volume rise strong performance new product trulicity taltz basaglar jardiance lartruvo offset decline sale establish product higher realize price several drug also contribute sale growth quarter foreign exchange rate also have favorable impact new product drive volume growth generate revenue represent nearly total revenue previous quarter other hand loss exclusivity cymbalta strattera effient axiron zyprexa evista hurt volume basis point revenue grow ex revenue rise pharmaceutical revenue rise quarter however worldwide competitive pressure hurt sale lilly animal health segment establish product record growth quarter include forteo humulin cymbalta erbitux sale other establish product decline quarter humalog sale decline due lower realize price unite state alimta sale decline reflect lower demand ex market due competitive pressure loss exclusivity certain country however sale alimta increase unite state due increase volume partially offset lower realize price zyprexa sale decline due loss exclusivity japan ciali sale decline hurt worldwide lower demand strattera sale decline effient sale decline quarter drug see lower demand due loss exclusivity new product trulicity generate revenue year year revenue benefit growth glp market market share gain cyramza revenue be year year backed strong demand cyramza ex revenue increase benefit strong volume japan partially offset lower realize price revenue increase drive increase volume jardiance sale rise drive increase market share grow sglt class unite state increase volume outside unite state basaglar record revenue compare previous quarter generate revenue unite state almost flat sequentially change estimate rebate discount increase revenue third quarter be miss fourth taltz bring sale compare previous quarter lartruvo olaratumab generate revenue fourth quarter compare previous quarter olumiant baricitinib have be launch select european country japan drug generate sale fourth quarter compare previous quarter backed strong launch uptake germany verzenio be launch unite state fourth quarter generate sale elanco animal health segment sale decline worldwide competitive pressure continue hurt sale segment food animal product revenue decline hurt market access pressure competitive pressure cattle companion animal revenue rise due inclusion revenue acquisition boehringer ingelheim vetmedica feline canine rabies acquire january exclude boehringer ingelheim companion animal revenue decline due competitive pressure lower distributor inventory level lilly be explore strategic alternative business include sale merger create separate company initial public offer decision regard same be expect be announce july lilly ultimately opt retain business gross margin operate incomeadjusted gross margin quarter decrease basis point manufacturing efficiency higher realize price be offset negative product mix effect foreign exchange rate international inventory sell exclude effect foreign exchange international inventory sell gross margin increase bps operate income increase year year due lower operate cost total operate expense include research development marketing selling administrative expense percent revenue decline basis point quarter marketing selling administrative expense decline expense rise quarter resultsfull year sale top zack consensus estimate revenue be guide range sale rise year year adjust earning be share top zack consensus estimate share well guide range earning rise year year ep guidance uppedlilly raise previously issue adjust earning outlook reflect expect benefit new tax law adjust earning share be now expect range compare expect previously however revenue be still expect range gross margin be expect be approximately same previously expect adjust tax rate be expect be approximately previously approximately marketing selling administrative expense be still expect range research development expense be project be go forward new product trulicity taltz basaglar cyramza jardiance lartruvo verzenio olumiant be expect drive revenue animal health revenue be expect be flat slightly versus be slightly negative first half animal health revenue be expect improve second half support new product launch expect impact tax reformas result new tax law lilly anticipate pay taxe overseas cash earning approximately increase access foreign cash follow tax reform lilly believe now have more extra fund global operation do not intend hold long time lilly plan use cash first support product pipeline then business development licensing acquisition finally return shareholder dividend share buyback also plan use roughly repatriate cash reduce gross debt level have estimate be move then past month investor have witness downward trend fresh estimate have be revision lower current quarter eli lilly company price consensus eli lilly company price consensus eli lilly company quotevgm scoresat time lly have great growth score be lag lot momentum front charting somewhat similar path stock be allocate grade value side putt top investment strategy overall stock have aggregate vgm score aren focuse strategy score be be interested base score stock be primarily suitable growth investor also be suitable look value lesser degree momentum outlookestimate have be broadly trend downward stock magnitude revision look promising interestingly lly have zack rank hold expect line return stock next few month
1073,LLY,eli lilly company lly free report announce new advanced breast cancer treatment verzenio abemaciclib have gain fda approval first line set latest approval verzenio be approve combination inhibitor ai anastrozole letrozole initial endocrine base therapy postmenopausal woman hr advanced metastatic breast cancer have have prior systemic treatment advanced disease lilly share have decline year so far industry record increase approval be base positive interim result monarch study study compare verzenio cdk inhibitor ai versus ai placebo mentioned patient datum study show verzenio ai substantially reduce tumor size delay disease progression such be already market breast cancer indication monotherapy treatment hr advanced breast cancer have prior endocrine therapy chemotherapy metastatic disease combination therapy astrazeneca azn free report faslodex fulvestrant hr advanced breast cancer patient have disease progression follow endocrine therapy verzenio be launch unite state fourth quarter generate sale first quarter launch believe verzenio label expansion previously untreated breast cancer population drive sale higher future quarters verzenio be review eu other available cdk inhibitor market include pfizer inc pfe free report ibrance novartis nvs free report kisqali lilly carry zack rank hold see complete list today zack rank strong buy stock here zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
1074,LLY,rise demand immuno oncology drug combination merck co inc mrk free report pd therapy keytruda be fast become key top line driver pharma giant keytruda be market many type cancer treatment setting include lung cancer melanoma head neck cancer classical hodgkin lymphoma bladder cancer have crossed mark sale third quarter keytruda become second largest product merck portfolio treatment fetch sale first month year year upside be drive global launch new indication further boost demand keytruda sale be gain particularly strong momentum indication first line lung cancer therapy be only pd approve first line set keytruda development program also significantly advanced regulatory approval secure new indication unite state europe japan key approval indication include advanced bladder cancer advanced microsatellite instability high cancer first approval combination therapy eli lilly lly free report cancer drug alimta pemetrexed carboplatin pem carbo first line lung cancer new approval expand patient population drive sale third quarter momentum be maintain fourth quarter well meanwhile keytruda be be study more type cancer study include excess combination trial merck be collaborate several company include amgen inc amgn free report incyte glaxo pfizer inc pfe free report separately evaluation keytruda combination other regimen datum several program keytruda be present medical conference expect merck present datum several key keytruda study year include combination study incyte epacadostat first line metastatic melanoma also keytruda get approval relapse refractory primary mediastinal large cell lymphoma indication year fda action expect april conclusionmerck do witness setback regard keytruda pipeline program october company announce delay readout important lung cancer study postpone be due inclusion overall survival co primary endpoint keynote phase iii study keytruda first line lung cancer turn raise investor concern delay readout give competitor chance gain traction lung cancer market also combination study keytruda multiple myeloma be put clinical hold follow report death keytruda group last july also merck top line have be lately hurt generic competition several drug pricing pressure believe keytruda have immense commercial potential couple other newer drug ease impact genericization rivalry immuno oncology market have rise follow fda approval newer oncology treatment pfizer bavencio avelumab merkel cell carcinoma mcc bladder cancer indication astrazeneca imfinzi durvalumab bladder cancer believe keytruda give drug tough run money be ample scope growth immuno oncology space merck carry zack rank hold see complete list today zack rank strong buy stock here share merck have decline year industry rally zack editor chief go stock full disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
1075,LLY,quite few pharmaceutical industry merger include large deal be card now tax reform be place tax bill be sign law president donald trump december last tax rate corporate now go boost profit large drug biotech company meanwhile change tax code also allow company bring back huge cash hold overseas time tax rate also tax cut be expect prevent inversion be rampant drug industry change definitely leave more cash hand drug biotech company cash be invest merger acquisition have be few compare gilead gild free report nearly acquisition kite pharma johnson johnson jnj free report acquisition swiss biotech actelion be only noteworthy deal week senior executive largest pharmaceutical biotech company discuss impact tax reform merger acquisition plan use excess cash jp morgan healthcare conference ceo say brent saunder chief executive officer ceo allergan agn free report say first half year be likely see smaller deal such celgene celg free report bigger high profile merger large pharmaceutical biotech company probably happen latter half year next year last week celgene announce have offer buy small cancer drug developer impact biomedicine read more celgene acquire impact biomedicine boost pipeline lilly lly free report ceo dave rick chief financial officer dominic caruso say tax cut american company compete better foreign counterpart operate better tax environment caruso say new tax law provide more flexibility ease analysis term get transaction do same line merck mrk free report ceo meg tirrell say have access overseas cash give more financial flexibility think different way go transaction tirrell however confidently say even new tax law be implement company have enough power balance sheet make bolt acquisition want do michel vounatsos biogen biib free report ceo smartly argue tax overhaul spur activity rationale activity not be cash available go say be look set potential target gilead ceo john milligan say tax reform be good company allow plan long term fda approval process be quite lengthy meanwhile maintain goal investing replenish pipeline also say excess cash allow clean balance sheet repay debt conclusion overall be quite clear drug industry be optimistic tax reform fuel greater activity be major drug biotech player struggle organic growth need infusion new growth driver pipeline product portfolio internal development buyout strategic licensing deal be therefore inevitable innovation starve drug biotech company look growth highly competitive global marketplace give take several year million dollar develop new therapeutic scratch large pharmaceutical company sit huge pile cash prefer buy innovative small mid cap biotech company build pipeline matter company look buy drug biotech stock be current sale performance latter drug product prospect sale growth quality pipeline wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1076,LLY,abbvie inc abbv free report announce investigational oral jak selective inhibitor upadacitinib meet primary endpoint phase iii study select program evaluate candidate treatment patient rheumatoid arthritis ra abbvie share have outperformed industry so far year stock have surge compare industry rally phase iii study select monotherapy evaluate upadacitinib monotherapy moderate severe ra patient be not responsive methotrexate period week once daily dose mg mg evaluate study demonstrated superiority acr response low disease activity lda compare methotrexate acr response be achieve patient receive mg dose response rate be mg dose versus methotrexate lda be achieve patient receive mg mg methotrexate respectively upadacitinib be be evaluate large program include study ra patient abbvie be also develop candidate psoriatic arthritis crohn disease ulcerative colitis ankylose spondylitis atopic dermatitis candidate have also meet endpoint phase iii study select program select monotherapy study support potential candidate treat ra patient background methotrexate therapy successful development upadacitinib boost abbvie ra portfolio already include blockbuster drug humira sale humira account net revenue first month approval incyte corporation incy free report eli lilly company lly free report olumiant europe february have not have significant impact humira sale be approve patient be unresponsive tnf inhibitor humira moreover olumiant new drug application receive complete response letter fda april year meanwhile upadacitinib be direct line competition olumiant be jak inhibitor abbvie inc price abbvie inc price abbvie inc quotezack rank stock considerabbvie carry zack rank hold celldex therapeutic inc cldx free report be better rank stock pharma sector carry zack rank buy see complete list today zack rank strong buy stock here celldex loss estimate narrow cent cent cent cent last day company deliver positive earning surprise trail quarters average beat zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
1077,LLY,array biopharma inc arry free report share increase more feb announce encourage overall survival os datum pivotal phase iii study evaluate combo combination medicine binimetinib encorafenib array partner pierre fabre have develop combo therapy treat patient braf mutant advanced unresectable metastatic melanoma notably combine regime be review unite state eu aforementioned indication response fda be expect jun be accept review base encourage progression free survival datum phase iii study report september array share have outperformed industry year time stock have soar compare industry increase same time frame phase iii columbus study be design examine efficacy safety combination therapy compare roche hold ag rhhby free report zelboraf vemurafenib alone braf mutant melanoma patient datum trial demonstrated median os month patient treat combo comparison month patient treat vemurafenib monotherapy os find complement median progression free survival overall response rate result report previously combination cure be generally well tolerate study be line outcome report earlier array present also evaluate encorafenib collaboration eli lilly company lly free report erbitux cetuximab binimetinib phase iii beacon crc program patient braf mutant colorectal cancer study be be perform special protocol assessment fda patient enrollment same be await be complete remind investor array have regain development right binimetinib novartis pharma ag nvs free report back march be important note french pharmaceutical company pierre fabre medicament sas hold right commercialize binimetinib encorafenib europe asia latin america array retain exclusive right commercialize drug key market namely unite state canada israel again ono pharmaceutical possess exclusive right product japan south korea press release new case melanoma be diagnosed year globally approximately have braf mutation key target treat metastatic melanoma hence approval combo therapy be likely provide company access potentially strong huge market separate press release company also announce earning second quarter fiscal report loss cent share narrower zack consensus estimate loss cent company report revenue year year however top line surpass zack consensus estimate release drive company share together array biopharma inc price array biopharma inc price array biopharma inc quote zack rankarray carry zack rank sell see complete list today zack rank strong buy stock here zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
1078,LLY,turn be notable year pharma biotech industry fda give nod novel drug well several biological license application bla include path breaking cancer treatment kymriah yescarta number compare favorably not only just novel drug be approve earlier year well look chart show highest number approval record be novel drug be approve accord fda center drug evaluation research cder higher number new application be submit compare year average nov regulatory application be approve meet pdufa goal date quite few approval come ahead fda action date drug be approve first review cycle be approve priority review status nov approval action rate be many drug approve have also gain breakthrough therapy designation breakthrough therapy be approve last year nov inception breakthrough therapy designation have be grant cder total request nov major part breakthrough therapy request be cancer drug follow hematology antiviral landmark decision last year include approval couple gene base therapy cancer novartis nvs free report kymriah gilead science gild free report yescarta therapy have potential change way look cancer treatment other key approval include lilly lly free report verzenio advanced metastatic breast cancer gilead vosevi hepatitis virus puma nerlynx reduce risk breast cancer return tremfya moderate severe plaque psoriasis regeneron regn free report sanofi kevzara rheumatoid arthritis roche rhhby free report multiple sclerosis treatment ocrevus regeneron sanofi eczema treatment dupixent tesaro parp inhibitor zejula biomarin brineura treatment specific form batten disease other many drug have blockbuster potential store fda intend continue work recruitment hire new drug program staff agency also work continue implementation new pdufa vi bsufa ii agreement other aspect fda reauthorization act fdara st century cure act st century cure act be expect encourage more innovation sector maybe surge new drug approval drug development process be lengthy time consume require utilization lot fund resource key pipeline event include datum readout regulatory update be paramount importance act major catalyst key drug currently fda review decision expect come month include amgen amgn free report investigational migraine drug aimovig target action date dova pharmaceutical avatrombopag gw pharmaceutical gwph free report epidiolex cannabidiol cbd investigational treatment seizure associate lennox gastaut syndrome lgs dravet syndrome epidiolex be currently priority review rare difficult treat condition childhood onset epilepsy response fda expect jun dova avatrombopag be also priority review treatment patient chronic liver disease cld be schedule undergo procedure response regulatory body be expect amgen be zack rank hold stock see complete list today zack rank strong buy stock here zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
1079,LLY,radius health inc rdus free report be schedule report fourth quarter result mar radius health share have lose year compare industry slip radius health have disappointing track record company have report wider expect loss trail trail quarters average negative earning surprise let see thing be shape quarter radius health inc price consensus radius health inc price consensus radius health inc quote factor play radius health develop therapeutic treatment osteoporosis oncology endocrine disease company lead drug tymlos be approve unite state april drug be approve treat postmenopausal woman osteoporosis high risk fracture defined history osteoporotic fracture multiple risk factor fracture drug also be used patient have fail be intolerant other available osteoporosis therapy company report sale tymlos abaloparatide third quarter hence expect investor focus uptake drug upcoming earning call osteoporosis market unite state have great potential approximately postmenopausal woman experience osteoporotic fracture year tymlos be expect face significant competition eli lilly co lly free report forteo amgen amgn free report prolium meanwhile company marketing authorisation application eladyno abaloparatide sc europe treatment postmenopausal woman osteoporosis be review however december radius health announce committee medicinal product human use chmp issue third day list outstanding issue regulatory review abaloparatide sc chmp inform company refer marketing authorisation application scientific advisory group additional advice part ongoing risk benefit assessment hence chmp expect give opinion same first half july chmp provide second day list outstanding issue request additional datum analysis related safety efficacy abaloparatide sc ongoing regulatory review delay approval europe be disappointing give potential market hold meanwhile fda grant fast track designation pipeline candidate elacestrant experimental selective estrogen receptor regulator treatment woman advanced metastatic breast cancer elacestrant clinical development program be currently ongoing phase study patient advanced metastatic breast cancer have be heavily pre treat median prior line therapy have evaluable disease december radius health provide encourage datum phase clinical study elacestrant rad patient estrogen receptor positive breast cancer san antonio breast cancer symposium approximately patient be treat mg dose elacestrant phase dose escalation expansion cohort enrolled patient patient meet recist measurable disease criterium baseline be confirm partial response group elacestrant be well tolerate most common adverse event be low grade nausea dyspepsia vomit consequently radius health plan initiate phase ii study elacestrant monotherapy potentially pivotal study woman suffering advanced metastatic breast cancer early hence expect management throw light pipeline progress earning whispersour proven model do not conclusively show radius health be likely beat estimate quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp radius health be currently peg be most accurate estimate be peg loss zack consensus estimate stand loss uncover best stock buy sell re report earning esp filter zack rank radius health have zack rank rank be favorable company negative esp make surprise prediction difficult note caution sell rate stock zack rank go earning announcement especially company be see negative estimate revision stock considerhere be pharma company consider model show have right combination element deliver earning beat quarter gemphire therapeutic gemp free report be expect release fourth quarter result mar company have earning esp zack rank see complete list today zack rank stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1080,LLY,unite therapeutic corporation uthr free report report adjust earning share fourth quarter decline year quarter due higher operate cost zack consensus estimate be peg share adjust earning exclude impact share base compensation expense impact tax reform revenue report quarter be beating zack consensus estimate revenue also grow year year stronger sale pah franchise pull top line quarter quarter detailunite therapeutic market product treatment pah remodulin tyvaso adcirca orenitram please note unite therapeutic buy exclusive right commercialize adcirca treatment pah unite state eli lilly lly free report november adcirca sale be year year orenitram sale amount quarter year year due patient growth remodulin sale be year year tyvaso sale totale year year sale tyvaso however improve sequentially quarter unituxin treatment pediatric patient high risk neuroblastoma sale surge year year research development expense escalate due higher cost support company pipeline cardiopulmonary cancer drug develop organ manufacturing project conference call company say cost continue rise advance company expand pipeline share unite therapeutic be almost wednesday probably management hint potentially higher cost fact stock have underperform industry past year have decline industry have increase period selling general administrative sg expense rise pipeline update unite therapeutic be work expand indication market product orenitram tyvaso company present have phase iii program field cardiopulmonary disease oncology phase iv freedom ev study be evaluate oral combination therapy orenitram oreniplus full datum study be expect year meanwhile phase iii beat study be evaluate tysuberprost esuberaprost combination tyvaso unite therapeutic have also begin clinical development dinutuximab active ingredient unituxin small cell lung cancer phase ii iii distinct study other high risk form cancer gd express cell tumor such ovarian cancer several sarcomas unite therapeutic be also work new delivery mechanism remodulin company be work medtronic plc mdt free report get remosynch implantable pump deliver remodulin intravenously approve fda unite therapeutic expect launch remosynch system year unite therapeutic be also work deka development pre filled semi disposable pump system subcutaneous delivery remodulin remunity clinical study remopro pain free new chemical entity version treprostinil be expect begin year several datum read out regulatory update be expect patent settlementslast week unite therapeutic announce settlement ongoing patent litigation actavis laboratory subsidiary teva pharmaceutical industry teva free report related orenitram actavis be look bring generic version orenitram settlement deal actavis launch generic version orenitram jun however investor remember remodulin adcirca start face generic competition middle year unite therapeutic carry zack rank hold see complete list today zack rank strong buy stock here unite therapeutic corporation price consensus ep surprise unite therapeutic corporation price consensus ep surprise unite therapeutic corporation quotemore stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1081,LLY,day market sell suddenly everything come rose again president trump state union address last night be follow strong earning result today open bell also see better expect result adp adp free report monthly private sector payroll report fact new job create january be well ahead anticipate december result be revise downward job still tally be outstanding job growth past month especially consider have be peak employment quite time now service lead way new job manufacturing add construction farm payroll figure bureau labor statistic bls friday morning be very interesting light today result thing analyst certainly be look aside unemployment rate be expect dip be average hourly wage growth job market tight stand reason employee start see rise take home pay proof say be pudding earning rolleven strong adp report come morning dow be already trading pre market more point not quite erase loss earlier week definitely help fill hole big part come huge earning report home run boee ba free report airplane make giant bring share earning report far ahead share expect zack consensus estimate revenue trounce analyst be look backlog be compare year zack rank buy company guidance be also sharply raise full year compare expectation result share shot initially be approach hour pre market more ba earning click here big pharma eli lilly lly free report also top estimate earning revenue ahead open bell share beating cent revenue zack consensus guidance be also up full year share revenue guidance stay pat now more lly earning click here even zack rank sell base simon property group spg free report meet estimate top bottom line ffo fund operation important metric reit respectively guidance be also raise full year ffo more spg earning click here mark vickerysenior editorlook stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1082,LLY,be still few day left year end have turn be pretty good pharma biotech sector fda approval be concern date regulatory agency have give nod novel drug well drug approve last year immuno oncology be key focus area be do scientific conference clinical trial collaboration acquisition fda approval approval novartis nvs free report kymriah gene cell therapy gilead gild free report yescarta car chimeric antigen receptor cell cell treatment ensure highly lucrative immuno oncology market remain limelight acquisition immuno oncology focuse kite gilead also increase interest category investor expect more acquisition announcement area see year focuse immuno oncology here be look therapeutic area think garner lot interest immuno oncologyimmuno oncology remain key focus area well basic concept cancer immunotherapy immuno oncology be utilize certain part immune system fight disease be do stimulating immune system attack cancer cell introduce immune system component body immuno oncology treatment have potential be effective monotherapy other be more effective combine other treatment different type immunotherapy include monoclonal antibody mab man make version immune system protein be design attack very specific part cancer cell immune checkpoint inhibitor recognize attack cancer cell vaccine help prevent treat cancer other boost overall immune system encourage result generate company demonstrate partial complete response late stage cancer patient recent fda approval kymriah yescarta have raise hope cancer patient increase interest segment cancer market immuno oncology set change treatment paradigm cancer area represent huge commercial potential company have progressed quite bit area include juno therapeutic incyte bluebird bio blue free report company often consider be acquisition target alzheimer disease be area many company have try luck not much success last several year big player merck lilly lly free report pfizer have face setback quest find treatment alzheimer company be currently work alzheimer disease treatment include player biogen biib free report novartis astrazeneca eisai amgen biogen aducanumab be most important candidate company pipeline candidate currently couple late stage study biogen be also work elenbecestat bace inhibitor phase iii program ban humanize beta amyloid antibody phase ii development top line result expect end january candidate be be develop collaboration eisai lilly also have quite few alzheimer disease candidate pipeline include lanabecestat be be develop collaboration astrazeneca datum readout expect meanwhile novartis amgen be collaborate bace inhibitor cnp have fast track status unite status roche be also collaborate ac immune development alzheimer disease treatment alzheimer have historically be very challenge therapeutic area quite few stock stumbling effort find treatment market be highly lucrative result several company continue invest heavily develop alzheimer disease treatment accord alzheimer association year drug be test alzheimer study register clinicaltrial gov only succeed go gain fda approval number be far encourage success area mean huge return consider more american be live alzheimer disease number expect increase much datum alzheimer association be consider be biggest burden society be sixth lead cause death age unite state market have immense commercial potential company come new treatment rake billion dollar sale medical segment pharma biotech industry remain limelight next year be medical marijuana industry industry get first exchange trade fund etf earlier year have be attract interest investor last few quarters industry be expect grow rapidly legislator allow look allow more legal used marijuana marijuana related product especially medical life science industry key player area include gw pharmaceutical plc gwph free report insys therapeutic corbus pharmaceutical holding zynerba pharmaceutical gw pharma commercialize world first plant derive cannabinoid prescription drug sativex be approve treatment spasticity due multiple sclerosis however company have be news lead cannabinoid pipeline candidate epidiolex cannabidiol cbd be development number rare childhood onset epilepsy disorder company be currently seek fda approval epidiolex dravet syndrome lennox gastaut syndrome approval come early mid priority review be grant epidiolex represent blockbuster potential especially be approve possible indication gw pharma have several new formulation cbd development include improve liquid formulation solid dose form intravenous formulation specialty pharma company insys used proprietary spray technology capability development pharmaceutical cannabinoid wide range indication include treat addiction opioid opioid overdose epilepsy other disease area significant unmet need gw pharma insys be zack rank hold stock see complete list today zack rank strong buy stock here medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
1083,LLY,indianapoli base eli lilly company lly free report be global healthcare company core product number primary care pharmaceutical market lilly generate revenue pharmaceutical product animal health segment company portfolio include zyprexa schizophrenia bipolar disorder humalog diabetes evista osteoporosis cymbalta depression ciali erectile dysfunction strattera attention deficit hyperactivity disorder adhd erbitux cancer alimta chemotherapy lilly also have strong presence diabetes market however many key product cymbalta alimta be face generic competition company also have new product trulicity cyramza jardiance basaglar lartruvo taltz portfolio be drive revenue lilly earning performance have be mixed earning beating expectation last quarters miss same bring average negative surprise currently lilly have zack rank hold definitely change follow company earning report be just release have highlighted key stat just reveal announcement earning beat lilly beat fourth quarter earning company report ep share consensus call ep revenue beat revenue also beat expectation lilly post revenue compare consensus estimate ep outlook up lilly raise previously issue adjust earning outlook reflect anticipate impact tax reduction unite state adjust earning share be now expect range compare expect previously company continue expect revenue range zack consensus estimate earning revenue be share respectively additional datum quarter line extension taltz active psoriatic arthritis unite state europe company have also launch drug indication unite state moreover cyramza improve progression free survival phase iii study patient gastric pancreatic cancer stock price impact share be pre market trading check back later full lilly earning report later hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1084,LLY,fda have propose new guideline be aim lower clinical study goal alzheimer disease drug treat earlier stage patient have not yet display functional disability clinical abnormality strategy part fda ongoing effort expand access safe effective treatment option many serious condition suggest agency be open accelerate approval process such drug fda propose guideline come week major disappointment field be announce company develop drug treat deadly brain disease earlier week merck mrk free report announce be discontinue study evaluate verubecestat treatment prodromal alzheimer disease success be unlikely biogen biib free report also announce have decide increase number patient enrolment study be conduct crucial alzheimer disease candidate aducanumab raise concern regard chance success treatment december biogen alzheimer disease study candidate ban fail show early positive result raise investor concern candidate chance success alzheimer disease market have attract lot attention several company however successful development therapy treatment alzheimer disease be challenge be somewhat underlie cause severe neurological ailment alzheimer not be clear disease cancer also alzheimer progress go unnoticed year time symptom ailment become evident significant function already be lose make develop drug treat disease difficult note several company have fail regard last month pfizer pfe free report reportedly announce termination effort alzheimer parkinson disease area result layoff long back pfizer shelved late stage alzheimer candidate bapineuzumab iv fail phase iii study november lilly lly free report amyloid candidate solanezumab fail meet primary endpoint late stage ad study lilly decide drop development solanezumab lilly also suffer major setback august have halt development phase iii alzheimer candidate semagacestat alzheimer disease market represent huge commercial potential successfully develop product generate billion dollar sale once launch fda latest effort reinvigorate research effort alzheimer drug repeat failure wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1085,LLY,eli lilly company lly free report announce positive top line datum phase iii label expansion study evaluate psoriasis drug taltz ixekizumab patient ankylose spondylitis drug meet primary endpoint improvement sign symptom secondary endpoint well taltz il antagonist be currently approve treatment adult moderate severe plaque psoriasis active psoriatic arthritis psa share company be past year underperform industry gain period phase iii study coast evaluate drug patient have not receive prior treatment biologic disease modify rheumatic drug study consist placebo arm active control arm abbvie abbv free report arthritis drug humira datum study show treatment taltz lead statistically significant improvement measure proportion patient achieve assessment international society week additional datum study be expect be present later year ankylose spondylitis be type affect pelvic joint spine be characterize chronic inflammatory back pain stiffness impair function mobility taltz sale increase quarter quarter last quarter back strong uptake january drug receive approval europe psa be expect boost sale drug first quarter however several drug be approve treatment include humira novartis nvs free report cosentyx other company be develop therapy treat include galapago glpg free report filgotinib eli lilly company price eli lilly company price eli lilly company quote zack ranklilly carry zack rank hold see complete list today zack rank strong buy stock here don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
1086,LLY,pfizer inc pfe free report reportedly say statement end effort alzheimer parkinson disease area result layoff decision end neuroscience discovery program mainly affect employee facility andover cambridge groton ct pfizer however intend continue development pain candidate tanezumab be develop late stage study partnership eli lilly lly free report label expansion effort pain drug lyrica rare disease program share pfizer have rise past year compare unfavorably increase industry successful development therapy treatment alzheimer disease be challenge note several company have fail regard fact pfizer shelved late stage alzheimer candidate bapineuzumab iv fail phase iii study pfizer be develop candidate collaboration johnson johnson jnj free report elan corporation november lilly amyloid candidate solanezumab fail meet primary endpoint late stage ad study lilly decide drop development solanezumab lillyalso suffer major setback august have halt development phase iii alzheimer candidate semagacestat last month biogen inc biib free report announce alzheimer disease study ban fail show early positive raise investor concern candidate chance success pfizer plan use saving terminate program re allocate spend potentially more fruitful pipeline project pfizer expect approximately drug approval next year product have blockbuster potential include line extension cancer drug xtandi ibrance well rheumatoid arthritis drug xeljanz half potential blockbuster be expect receive approval pfizer carry zack rank hold see complete list today zack rank strong buy stock here medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
1087,LLY,alzheimer disease ad area be focus once again pfizer inc pfe free report say be drop plan develop treatment alzheimer parkinson disease accord news source pfizer expect decision result elimination position neuroscience discovery early development program expect additional detail be available company presentation annual jpmorgan healthcare conference today pfizer have have long association alzheimer disease research area company become part dementia discovery fund be form speed development new treatment neurological disease bring together major pharma company uk government alzheimer research uk fund be involved financing new early stage drug development project however alzheimer have always be highly challenge area not much progress be make investment lot fund resource fact pfizer have face major setback way back development effort alzheimer disease treatment company partner johnson johnson jnj free report decide discontinue development bapineuzumab iv follow late stage failure other company eli lilly company lly free report merck mrk free report have also stumble effort develop treatment alzheimer lilly decide november not seek approval investigational ad treatment solanezumab follow disappointing result late stage study candidate be be evaluate see slow progression memory problem associate amyloid protein form plaque brain person alzheimer meanwhile evaluation merck investigational alzheimer disease treatment verubecestat be halter phase ii iii study epoch february base interim analysis external datum monitoring committee edmc study fail study be ongoing result expect february biogen also suffer setback recently independent datum monitoring committee say ban do not meet criterium success base bayesian analysis month primary endpoint phase ii study failure show early positive result come major disappointment biogen be develop candidate association eisai clinical stage company axovant science axon free report suffer major setback september investigational alzheimer disease candidate fail meet co primary efficacy endpoint late stage study company decide discontinue development mg dose treatment alzheimer disease last year company share be compare decline industry belong accord alzheimer association year drug be test alzheimer study register clinicaltrial gov only succeed go gain fda approval road setback several company continue invest heavily develop alzheimer disease treatment give high commercial potential market success area mean huge return consider more american be live alzheimer disease number expect triple datum alzheimer association be consider be biggest burden society be sixth lead cause death age unite state market have immense commercial potential company come new treatment rake billion dollar sale company be currently work alzheimer disease treatment include biogen novartis nvs free report astrazeneca eisai amgen amgn free report biogen aducanumab be most important candidate company pipeline candidate currently couple late stage study biogen be also work elenbecestat bace inhibitor phase iii program candidate be be develop collaboration eisai lilly also have quite few alzheimer disease candidate pipeline include lanabecestat be be develop collaboration astrazeneca datum readout expect meanwhile novartis amgen be collaborate bace inhibitor cnp have fast track status unite status roche be also collaborate ac immune development alzheimer disease treatment company pfizer lilly merck be zack rank hold stock see complete list today zack rank strong buy stock here medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
1088,LLY,spectrum pharmaceutical inc sppi free report announce termination chief executive officer ceo rajesh shrotriya cause other leadership change company appoint present chief operate officer coo joseph turgeon new ceo immediate effect management turgeon also continue serve president company currently have be elect board director well meanwhile spectrum promote thomas riga present executive vice president chief commercial officer head business development post coo furthermore company have elect director stuart krassner chairman board director notably change be effective immediately share spectrum pharma have sky-rocket last month significantly outperform industry gain markedly turgeon riga have combine experience nearly year pharmaceutical industry turgeon have year pharma experience include year vice president sale amgen inc amgn free report riga have carry number executive role amgen eli lilly company lly free report privately hold dendreon year lackluster product sale have keep investor focuse pipeline development company stock have be surge begin year backed progress lead pipeline candidate company be currently develop poziotinib phase ii study small cell lung cancer patient qapzola phase iii study muscle invasive bladder cancer rolontis phase iii study treat chemotherapy induced neutropenia patient breast cancer company expect file biologic license application rolontis end candidate hold promise target multus dollar market however remain be see change leadership position impact company spectrum pharmaceutical inc price spectrum pharmaceutical inc price spectrum pharmaceutical inc quotezack rank stock pharma carry zack rank hold therapeutic incorporate cort free report be better rank health care stock carry zack rank buy see complete list today zack rank strong buy stock here earning share estimate have increase cent cent last day company deliver positive earning surprise trail quarters average beat company stock be so far year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1089,LLY,merck mrk free report announce disappointing result pivotal phase iii keynote study evaluate pd therapy keytruda pembrolizumab second line treatment patient advanced gastric junction gej adenocarcinoma notably keytruda be already approve unite state monotherapy third line treatment advanced gastric gej additionally be approve many type cancer treatment setting include lung cancer melanoma head neck cancer classical hodgkin lymphoma bladder cancer share merck have lose year so far compare unfavorably industry increase phase iii study fail meet primary endpoint overall survival os notably progression free survival pfs show statistical significance pd positive patient population however company say continue evaluate keytruda other phase iii study monotherapy well combination chemotherapy first line treatment patient gej remind investor keytruda be key top line driver merck bring sale third quarter sequentially year year sale continue be drive launch new indication globally significantly keytruda sale unite state have gain particularly strong momentum new indication first line lung cancer drug sale be primarily drive melanoma outside unite state meanwhile keytruda development program also significantly advanced year regulatory approval new indication unite state additional disease europe important approval include nod advanced bladder cancer unite state eu advanced microsatellite instability high cancer first sanction combination therapy eli lilly company lly free report cancer drug alimta pemetrexed carboplatin pem carbo commonly used chemo regimen lung cancer keytruda be continuously grow expand new indication market globally be trial more type cancer study include excess combination study merck be collaborate separately several company namely amgen inc amgn free report incyte glaxo pfizer inc pfe free report evaluation keytruda combination other regimen merck company inc price merck company inc price merck company inc quotezack rankmerck carry zack rank hold see complete list today zack rank strong buy stock here investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
1090,LLY,key announcement week be teva pharmaceutical industry ltd teva free report restructure plan eli lilly company lly free report outlook focus also remain datum presentation annual conference american society hematology ash company roche rhhby free report bristol myer squibb bmy free report merck mrk free report be present recap week most important storiesash highlight several company be ash datum approve pipeline drug roche present phase ii datum show polatuzumab vedotin bendamustine mabthera rituxan br increase complete response rate compare br alone previously treat aggressive lymphoma complete response rate increase addition polatuzumab vedotin br patient treat combination live longer compare patient br alone month versus month roche also present datum tecentriq avastin combination certain person advanced kidney cancer read more roche report positive datum tecentriq combination study venclexta venclyxto mabthera rituxan combination previously treat chronic lymphocytic leukemia read more roche abbvie report positive phase iii result venclexta bristol myer be also present ash datum sprycel dasatinib add standard chemotherapy show year survival benefit pediatric patient newly diagnosed ph acute lymphoblastic leukemia read more bristol myer report positive datum leukemia drug company partner seattle genetic also present interim result phase ii study combination adcetris opdivo relapse refractory hodgkin lymphoma combination datum show objective response rate complete response rate lilly provide outlook lilly provide outlook say expect recently launch product trulicity taltz basaglar jardiance verzenio cyramza olumiant lartruvo drive low single digit revenue growth company expect earning share revenue however challenge remain company form loss patent exclusivity product ciali impact generic competition strattera effient axiron pricing access pressure also remain headwind meanwhile company continue expect earning share revenue lilly raise quarterly dividend well company also reaffirm guidance average annual revenue growth least say expect operate margin least pipeline front lilly expect regulatory action unite state baricitinib treatment rheumatoid arthritis galcanezumab migraine treatment new indication verzenio breast cancer launch new indication taltz psoriatic arthritis read more lilly issue guidance new drug drive top line stock have gain year date compare rally industry belong teva share restructure plan week speculation teva be cut workforce company announce restructure plan see job cut more company global workforce next year majority expect new ceo goal be reduce cost base simplify organization improve business performance profitability cash flow generation productivity company expect cut cost base estimate end plan also call optimization global generic portfolio especially unite state price adjustment product discontinuation several manufacturing plant unite state europe israel growth market well facility headquarters other office location geography be shut divest far pipeline be concern program be review so core project be identify other project be terminate immediately company also suspend dividend payment annual bonus say continue look opportunity divest core asset step come time teva be face several challenge company have significant financial obligation come year environment remain challenge company largest generic market unite state teva also expect fewer generic product launch unite state teva share be restructure announcement investor cheer step take company execution remain key priority review bristol myer opdivo yervoy combination fda have grant priority review bristol myer supplemental biologic license application sbla label expansion opdivo use combination yervoy treatment intermediate poor risk patient advanced renal cell carcinoma rcc regulatory agency grant priority review response be apr update sanofi sanofi sny free report provide update pipeline project include new molecular entity novel vaccine analyst meeting week company say expect start least late stage study least pivotal phase iii study be expect start next month period sanofi expect file regulatory approval investigational cancer drug cemiplimab isatuximab type diabetes treatment sotagliflozin potential treatment uncontrolled persistent asthma dupilumab fact sanofi partner regeneron announce positive topline result pivotal mid stage study cemiplimab patient advanced cutaneous squamous cell carcinoma cscc second deadliest skin cancer melanoma overall response rate orr be observed study company have start submit roll biologic license application bla pd antibody submission expect complete first quarter read more regeneron sanofi report positive top line skin cancer datum meanwhile sanofi gain fda approval admelog insulin lispro injection rapid act insulin similar lilly humalog management blood sugar level mealtime admelog be approve eu earlier year july read more sanofi win fda approval biosimilar lilly humalog update merck keytruda merck provide couple update related pd therapy keytruda week company say sbla seek label expansion use keytruda treatment relapse refractory primary mediastinal large cell lymphoma pmbcl have be grant priority review fda company also present datum ash show use keytruda result overall response rate difficult treat patient population fda grant priority review response agency be apr approval make second blood cancer indication keytruda earlier indication be use certain patient classical hodgkin lymphoma read more merck keytruda get fda priority review rare lymphoma however keytruda fail meet primary endpoint overall survival pivotal study second line treatment patient advanced gastric junction gej adenocarcinoma progression free survival pd positive population also fail show statistical significance merck be zack rank hold stock see complete list today zack rank strong buy stock here cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index decline last trading session major stock astrazeneca be merck gain last month bristol myer be glaxosmithkline gsk free report decline see last pharma stock roundup here fda nod nvo ozempic second indication lilly taltz next pharma world watch regulatory pipeline news pharma stock investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
1091,LLY,eli lilly company lly free report issue financial guidance be line market expectation company also re affirm previously issue projection well long term expectation share be more wednesday so far year lilly share price have rise compare increase industry forecastin adjust earning share be expect be represent growth range low double digit revenue be expect be represent growth mid point range foreign exchange impact be expect benefit revenue basis point zack consensus estimate sale earning be peg share respectively lilly new product trulicity taltz basaglar cyramza jardiance verzenio lartruvo have be drive revenue trend be expect continue strong uptake trend lilly new drug have be instrumental lead company increase sale outlook twice year however competitive pressure lilly drug be expect rise next year nordisk nvo free report ozempic semaglutide receive fda approval month strong competition lilly key new growth driver trulicity launch meanwhile sanofi sny free report admelog biosimilar version lilly blockbuster rapid act insulin humalog also receive fda approval month hurt sale lilly brand drug launch be company be face loss exclusivity number product various market pricing headwind be hurt sale older diabetes product far pipeline be concern company expect regulatory action rheumatoid olumiant migraine galcanezumab new drug application nda galcanezumab already review unite state nda olumiant be expect be re submit january remind investor april year lilly receive complete response letter crl fda olumiant fda require additional clinical datum delay approval drug olumiant be approve eu february company also expect label expansion newly launch breast cancer drug verzenio marketing selling administrative expense be expect range research development expense be project be adjust gross margin be expect be approximately adjust tax rate be expect be approximately importantly company mentioned guidance assume major healthcare reform unite state continuation current corporate tax system guidance reaffirmedlilly maintain previously issue adjust earning sale outlook adjust earning share be expect range revenue be expect range gross margin be expect be approximately adjust tax rate be expect be approximately marketing selling administrative expense be still expect range research development expense be project be long term target placelilly further reiterate annual revenue growth target least constant currency basis backed robust volume additionally company expect operate margin exclude currency impact international inventory sell be least percentage revenue lilly carry zack rank hold see complete list today zack rank strong buy stock here better rank stock biotech genetic sector be emergent biosolution inc ebs free report zack rank strong buy emergent biosolution earning estimate have moved last day share price company have rise year date zack editor chief go stock full disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
1092,LLY,share immunogen inc imgn free report have be massively year so far outperform industry increase let analyze factor lead skyrocket rally immunogen rapid pipeline progress positive readout strategic collaboration have drive share price consistently company have make significant progress regard lead pipeline candidate mirvetuximab soravtansine year be be evaluate phase iii study forward single agent therapy treat patient platinum resistant ovarian cancer immunogenha activate more site study enrolment third quarter year aim complete middle readout primary endpoint be anticipate first half also candidate be be evaluate phase expansion cohort ovarian cancer patient company report positive datum trial demonstrated promising safety efficacy profile candidate meanwhile combination regimen mirvetuximab soravtansine ovarian cancer be also be examine phase ib ii forward ii study trial consist cohort assess mirvetuximab soravtansine combination roche rhhby free report avastin merck mrk free report keytruda immunogen have report initial result study show mirvetuximab soravtansine potential complement currently available therapy indication approval combo therapy significantly expand eligible patient population mirvetuximab soravtansine fda nod mirvetuximab soravtansine be huge boost immunogen give immense commercial potential target market ovarian cancer cause maximum annual death gynecologic cancer majority patient diagnosed advanced stage datum provide american cancer society approximately new case ovarian cancer be estimate be diagnosed unite state alone thereby take death toll more apart mirvetuximab soravtansine immunogen be work develop couple other clinical pre clinical candidate include imgn imgn notably imgn be be analyse phase study treat acute myeloid leukemia aml encourage datum report earlier month other hand company plan move imgn clinical development soon address hematological malignancy include aml company have sign agreement several big healthcare player include amgen bayer eli lilly lly free report novartis roche sanofi takeda dint contract other company be allow use immunogen adc technology provide fund form license milestone fee royalty clinical material revenue support fee notably august immunogen have announce strategic collaboration option agreement jazz pharmaceutical development candidate adc program namely imgn imgn pursuant deal immunogen be eligible receive milestone payment base certain pre decide condition platinum resistant ovarian cancer market offer immense commercial potential immunogen be notably set face intense competition approval however mirvetuximab soravtansine look promising juncture approval be big boost company immunogen inc price immunogen inc price immunogen inc quotezack rankimmunogen carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1093,LLY,intersect ent inc xent free report receive approval fda sinuva sinus implant company have be focuse develop innovative therapy chronic sinusitis patient sinuva be exclusive approach treat recurrent nasal polyp disease patient have undergo ethmoid sinus surgery management approximately american have go surgery be look treatment cure side effect intersect ent expect sinuva be costlier other product portfolio however higher price not dent company gross margin upcoming fourth quarter have long term expect earning growth rate notably nasal polyp be inflammation line nasal passage sinus result congestion infection low sense smell sinuva be intersect ent fourth commercial product be likely be introduce physician country follow month share shine brightyear date intersect ent have have solid run bourse trading market large company return compare favorably industry rally only also current return be higher index increase same time frame stock have zack rank hold see complete list today zack rank strong buy stock here market trend buoy new technology rapid innovation healthcare market be create opportunity company be strive make profit sinusitis treatment market report persistence market research center disease control prevention cdc have reveal person unite state get diagnosed chronic sinusitis regular basis consider solid prospect market believe intersect ent gain strong market traction upcoming day few other major market player engage manufacturing treatment product sinusitis include sanofi sny free report abbott laboratory free report eli lilly company lly free report takeintersect ent fourth quarter operate expense be likely rise thank time expense related sinuva launch production demo unit cost related market access infrastructure latest development propel contour be expect be important driver intersect ent product propel propel mini be drug eluting implant patient suffering chronic sinusitis offer product therapy ear nose throat surgeon improve treatment patient chronic disease make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1094,LLY,fourth quarter earning season be full swing financial figure member index already jan latest earning preview total earning index member jump year quarter drive improvement revenue beat ratio be bottom line top line positive note ongoing earning phase seem have begin well drug biotech sector major large cap player johnson johnson jnj free report kick season earning beating estimate sale slightly miss same few other large pharma company release earning result last week picture look quite encourage pharma bigwig have report last week be novartis nvs free report abbvie abbv free report surpass earning sale estimate quarter review novartis raise sale guidance abbvie increase previously issue earning expectation year major player biotech sector biogen biib free report announce mixed performance report period earning lag estimate sale exceed same however celgene corp celg free report outpaced metric expectation fourth quarter drug biotech stock remain growth trajectory courtesy slew fda approval rise demand new product sale successful innovation product line expansion strong clinical report well continue robust performance legacy product moreover impressive factor regular acquisition be expect drive sector growth well also earning preview broader medical sector inclusive drug biotech well medical device company be likely record year year growth revenue rise earning period discussion pharma biotech giant be schedule report earning number jan let see thing be shape company upcoming release eli lilly company lly free report lilly be schedule release fourth quarter earning market open company deliver positive surprise last quarter lilly earning performance have be modest earning miss expectation last quarters beating same remain thus bring average beat proven model show lilly be likely beat earning quarter combination lilly zack rank increase predictive power esp solid zack rank positive earning esp make confident earning beat impending report zack consensus estimate quarter be report be peg share uncover best stock buy sell re report earning esp filter expect sturdy uptake new product trulicity taltz basaglar cyramza jardiance lartruvo upside be likely make decline sale establish product zyprexa alimta ciali strattera effient fourth quarter read more lilly report earning card vertex pharmaceutical inc vrtx free report vertex be slate release fourth quarter earning market close company track record have also be impressive so far deliver positive surprise trail quarters average beat third quarter vertex come positive surprise however proven model do not conclusively show vertex be likely beat earning quarter company favorable zack rank hold increase predictive power esp earning esp leave surprise prediction inconclusive zack consensus estimate be peg cent share see complete list today zack rank strong buy stock here vertex cystic fibrosis cf drug kalydeco orkambi perform consistently first quarters expect uptrend be reflect result soon be report quarter read more vertex report earning card don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
1095,LLY,expect eli lilly company lly free report beat expectation report fourth quarter full year result jan market open last quarter company deliver positive earning surprise lilly share have rise past year industry record increase lilly earning performance have be modest earning miss expectation last quarters beating same remain bring average positive surprise eli lilly company price ep surprise eli lilly company price ep surprise eli lilly company quotelet see thing be shape quarter factor considerlike previous couple quarters strong uptake new product trulicity taltz basaglar cyramza jardiance lartruvo be likely make decline sale establish product zyprexa alimta ciali strattera effient trulicity sale be likely benefit growth glp market share gain jardiance sale be expect be drive increase market share grow sglt class continue strong uptake outside unite state continue drive sale cyramza strong launch uptake be likely drive sale basaglar taltz lartruvo please note taltz be approve new indication active psoriatic arthritis psa december bring additional sale fourth quarter meanwhile loss exclusivity alimta cymbalta strattera effient axiron zyprexa evista continue hurt volume also lower demand unite state due competitive pressure mainly immuno oncology agent be hurt alimta sale country trend be likely be reflect fourth quarter result new drug olumiant baricitinib be launch select european country japan last year be review unite state third quarter strong launch uptake germany lead better sale drug trend be likely be reflect soon be report quarter result lilly partner incyte corporation incy free report plan re submit new drug application nda olumiant unite state month older product humalog trajenta forteo be also expect do well animal segment sale be hurt global competitive pressure first quarters trend be likely see time well third quarter conference call management have say be explore strategic alternative business include sale merger create separate company initial public offer decision regard same be expect be make later middle year company then say lilly ultimately opt retain business investor look update related same conference call earning whispersour proven model show lilly be likely beat earning have right combination key ingredient stock need have positive earning esp zack rank strong buy buy hold happen zack esp earning esp represent difference most accurate estimate zack consensus estimate be be meaningful indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank lilly have zack rank combination lilly zack rank positive esp make confident earning beat upcoming release sell rate stock zack rank other hand never be consider go earning announcement especially company be see negative estimate revision other stock considerhere be other large cap health care stock worth consider model have right combination element beat earning time merck co inc mrk free report have earning esp zack rank company be schedule report fourth quarter earning feb see complete list today zack rank stock here astrazeneca plc azn free report be slate announce financial figure feb company have earning esp be zack rank stock zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
1096,LLY,total earning total healthcare market capitalization be revenue growth not only be growth rate impressive earning revenue beat ratio respectively be great too robust number have push healthcare stock higher average gain response earning announcement most notable player johnson johnson jnj free report be first major drug company report earning jan follow pfizer pfe free report eli lilly company lly free report jan jan respectively other major drug company merck mrk free report bristol myer squibb company bmy free report report feb feb respectively industry prime post solid result earning revenue beat johnson johnson earning world biggest maker healthcare product continue long streak earning beat earning share come couple cent ahead zack consensus estimate higher year quarter revenue grow year year fall shy zack consensus estimate johnson johnson issue outlook earning share revenue read healthcare etfs focus post jnj result pfizer earning drug giant come earning revenue beat earning share cent come cent zack consensus estimate revenue be also ahead estimate annual basis earning share revenue rise respectively pfizer guide revenue range earning share merck earning focusmerck beat earning estimate miss revenue earning share come cent surpass zack consensus estimate cent improve year quarter revenue inched year year be zack consensus estimate merck issue revenue guidance earning share guidance bristol myer earning focusbristol myer top estimate front report earning share cent penny zack consensus estimate year earning cent revenue grow edge past zack consensus estimate company provide earning share guidance see healthcare etfs here eli lilly earning focuseli lilly also surpass earning revenue estimate earning outpaced zack consensus estimate cent come higher year quarter revenue grow beat estimate other drug maker eli lilly raise earning guidance maintain revenue outlook range etf pharma etfs see terrible trading past month latest global market rout string earning beat bolster confidence space compelling investor cash beaten price have highlighted detail fund have zack etf rank hold suggest room upside day ahead read inverse equity etfs bet historic selloff powershare dynamic pharmaceutical fund pjp free report be far most popular choice pharma space follow dynamic pharmaceutical intellidex index product have aum see lower volume share day fund charge bps fee expense hold stock fund invest more share bmy pfe jnj lly etf have lose month ishare pharmaceutical etf ihe free report etf provide exposure pharma stock tracking dow jone select pharmaceutical index focus firm be top holding basket accounting combine total asset suggest heavy concentration product have aum charge bps fee expense volume be light exchange share day fund have shed month spdr pharmaceutical etf xph free report fund provide exposure pharma company tracking pharmaceutical select industry index aum trade good volume share day charge bps fee year total product hold security focus firm take share product be same period vaneck vector pharmaceutical etf pph free report etf follow mvis list pharmaceutical index hold stock basket focus firm account least share product have amassed asset base trade moderate volume share day expense ratio come fund have lose month read new pharma etf pill investor need know first trust nasdaq pharmaceutical etf ftxh free report fund track nasdaq smart pharmaceutical index hold security basket pfizer johnson johnson account more share merck bristol myer eli lilly makeup more ftxh have lower level aum share averaged daily volume charge bps annual fee have shed same time frame want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
1097,LLY,share biogen inc biib free report decline almost company alzheimer candidate ban fail meet criterium success base month interim analysis primary endpoint mid stage trial company be develop candidate collaboration eisai co ltd so far year share biogen have gain compare industry growth phase ii study study involve patient prodromal mild alzheimer disease positive biomarker brain amyloid pathology study used bayesian adaptive randomization design allow automatic change design study early success study explore efficacy dose response ban interim analysis month evaluation base eisai house develop alzheimer disease composite score adcom month comprehensive assessment treatment placebo active arm bayesian analysis month indicated success be judge higher probability achieve least reduction rate decline adcom versus placebo interim analysis assessed potential futility stopping safety neither condition be meet study continue full analysis month biogen state month blind study continue further analysis follow predefined study protocol comprehensive final analysis be conduct month look demonstrate clinically significant result datum study be expect second half biogen be look strengthen ad other disorder pipeline notably company alzheimer disease ad pipeline comprise candidate different mechanism action include tau candidate biib bms potential ad well progressive supranuclear palsy psp amyloid aducanumab candidate well bace inhibitor elenbecestat program however successful development therapy treatment alzheimer disease be challenge note several company have fail develop treatment same november eli lilly company lly free report amyloid candidate solanezumab fail meet primary endpoint late stage ad study consequently lilly decide drop development candidate meanwhile pfizer pfe free report shelved late stage alzheimer candidate bapineuzumab iv fail phase iii study pfizer be develop candidate collaboration johnson johnson jnj free report elan corporation alzheimer disease market represent huge commercial potential successfully develop product generate billion dollar sale once launch biogen inc price biogen inc price biogen inc quotezack rankbiogen carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1098,LLY,merck mrk free report announce fda have grant priority review supplemental biologic license application sbla look label expansion market drug keytruda pembrolizumab rare lymphoma indication snda be look expand keytruda label treatment adult pediatric patient refractory primary mediastinal cell lymphoma pmbcl type hodgkin lymphoma nhl fda grant priority review response be expect apr finally approve be second nod keytruda regulatory body treat hematologic malignancy indication march april keytruda be approve unite state well eu refractory classical hodgkin lymphoma first keytruda approval hematologic malignancy indication merck share have decline year so far underperform industry rally sbla be accept fda base encourage datum ongoing phase ii keynote phase ib keynote study trial be evaluate safety tolerability efficacy keytruda monotherapy patient various blood cancer same press release company release outcome keynote study datum study demonstrated patient relapse refractory pmbcl achieve overall response rate additionally patient achieve complete response rate partial response rate median follow month drug be however unable achieve median duration response find study be present annual meeting american society hematology notably keytruda be grant breakthrough therapy designation fda january aforementioned indication company press release pmbcl account almost nhl unite state hence approval drug expand indication provide company access wider patient population pmbcl remind investor keytruda be first pd therapy gain fda approval be be study more type cancer study include combination trial key recent approval drug have be give indication include advanced bladder cancer advanced microsatellite instability high cancer first approval combination therapy be grant eli lilly lly free report cancer drug alimta pemetrexed carboplatin pem carbo lung cancer merck company inc price merck company inc price merck company inc quotezack rank key picksmerck carry zack rank hold better rank stock health care sector be therapeutic inc cort free report achillion pharmaceutical inc achn free report carry zack rank buy see complete list today zack rank strong buy stock here earning share estimate have moved cent cent last day company deliver positive earning surprise trail quarters average beat share price company have sky-rocket year date achillion loss share estimate have narrow cent cent cent cent last day company come positive earning surprise last quarters average beat more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1099,LLY,sanofi sny free report receive fda approval admelog biosimilar version eli lilly company lly free report blockbuster rapid act insulin humalog insulin lispro admelog be technically follow biologic version humalog record sale so far admelog be first follow humalog product be approve fda help adult patient type ii diabetes child year older type diabetes manage blood sugar level mealtime admelog unit ml be available unite state vial solostar pen please note admelog receive marketing approval eu july year sanofi share have rise so far year compare unfavorably gain record industry sanofi diabetes franchise be significant pressure key product lantus face increase competitive pressure payor level biosimilar competition several european market japan moreover follow product lantus hit market form lilly boehringer ingelheim basaglar mid december so far lantus sale have decline unite state due lower average net price exclusion cvs health corporation cvs free report unite health formulary plan diabetes sale have decline so far fact diabetes franchise sale be expect decline accelerate rate fourth quarter due cvs unite health formulary exclusion plan continue lower average pricing difficult comparison last year sanofi carry zack rank sell see complete list today zack rank strong buy stock here better rank large cap pharma stock be lundbeck hluyy free report carry zack rank buy share lundbeck have rise so far year earning estimate have go past day more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1100,LLY,bristol myer squibb company bmy free report announce pd immune checkpoint inhibitor opdivo combination yervoy demonstrated superiority improve progression free survival pfs phase iii lung cancer study positive datum again show blockbuster potential opdivo be already approve multiple indication be also be evaluate several other share company have return past year outperform industry gain period phase iii study checkmate be evaluate opdivo monotherapy combination regimen squamous squamous advanced small cell lung cancer nsclc first line set study be be conduct part datum be announce part study evaluate combination regimen overall survival os patient tumor express pd pfs patient high tumor mutation burden tmb regardless pd expression datum show regimen significantly improve pfs patient compare chemotherapy however datum monitoring committee have recommend continue study overall survival endpoint base interim analysis be first study evaluate combination regimen immune oncology drug first line nsclc patient high tmb part study be evaluate opdivo combination chemotherapy broad patient population remind investor combination regimen have achieve durable clinical benefit phase ii study patient dna mismatch repair deficient microsatellite instability high metastatic colorectal cancer please note merck mrk free report pd immunotherapy keytruda be approve first line nsclc datum announce late stage study january show keytruda combination eli lilly company lly free report alimta result significantly improve os pfs metastatic squamous nsclc patient bristol myer squibb company price bristol myer squibb company price bristol myer squibb company quotezack rank stock considerbristol myer carry zack rank hold exelixis inc exel free report be better rank stock pharma sector carry zack rank buy see complete list today zack rank strong buy stock here exelixis earning estimate increase cent cent last day company deliver positive earning surprise trail quarters average beat stock be past year more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1101,LLY,day market sell suddenly everything come rose again president trump state union address last night be follow strong earning result today open bell also see better expect result adp adp free report monthly private sector payroll report fact new job create january be well ahead anticipate december result be revise downward job still tally be outstanding job growth past month especially consider have be peak employment quite time now service lead way new job manufacturing add construction farm payroll figure bureau labor statistic bls friday morning be very interesting light today result thing analyst certainly be look aside unemployment rate be expect dip be average hourly wage growth job market tight stand reason employee start see rise take home pay proof say be pudding earning rolleven strong adp report come morning dow be already trading pre market more point not quite erase loss earlier week definitely help fill hole big part come huge earning report home run boee ba free report airplane make giant bring share earning report far ahead share expect zack consensus estimate revenue trounce analyst be look backlog be compare year zack rank buy company guidance be also sharply raise full year compare expectation result share shot initially be approach hour pre market more ba earning click here big pharma eli lilly lly free report also top estimate earning revenue ahead open bell share beating cent revenue zack consensus guidance be also up full year share revenue guidance stay pat now more lly earning click here even zack rank sell base simon property group spg free report meet estimate top bottom line ffo fund operation important metric reit respectively guidance be also raise full year ffo more spg earning click here
1102,LLY,dexcom inc dxcm free report recently announce signing development agreement eli lilly company lly free report agreement dexcom flagship continuous glucose monitoring system cgm be add lilly connect diabetes ecosystem integration cgm lily smart insulin delivery device dexcom aim provide holistic approach diabetes management customer notably clinical trial be expect begin end dexcom fda clear cgm system dexcom platinum be contribute significantly top line dexcom platinum be most innovative cgm system market june dexcom have announce fda approval dexcom mobile app android device moreover dexcom have collaborative agreement several company not only bring cash form milestone payment royalty also help expand product use september dexcom announce tie lead wearable brand fitbit develop market product help person better manage diabetes get clearer picture overall health first plan initiative be bring dexcom cgm datum fitbit new smartwatch fitbit ionic company aim make smartwatch available continue explore way develop tool improve diabetes management believe glucose monitoring market represent significant commercial opportunity dexcom report mordor intelligence global market diabetes care device be project reach value cagr also international diabetes federation idf estimate worldwide incidence person suffering diabetes reach recently management dexcom confirm company be well poise congregate unmet demand global diabetic space especially come cgm dexcom increase patient convenience enhance connectivity datum analytic lower cost platform fortify company foothold global diabetic space however diabetes market be dominate many well establish player abbott free report be most prominent space abbott recently announce receipt fda approval freestyle libre flash glucose monitoring system unite state share price have be gain investor confidence consistently positive result last month company share price outperformed broader industry stock have gain compare broader industry company have also outperformed gain market zack rank key pickdexcom carry zack rank hold better rank medical stock be petm express inc pet free report zack rank strong buy see complete list today zack rank stock here petm have long term expect earning growth rate stock have rally roughly year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1103,LLY,novartis ag nvs free report ceo oncology business bruno strigini have announce plan retire cite personal reason strigini step executive committee dec novartis name successor shortly earlier novartis announce ceo joseph jimenez step position vasant global head drug development chief medical officer replace effective feb be member executive committee joined novartis novartis be currently go transitional stage march novartis acquire certain oncology product pipeline compound glaxosmithkline plc gsk free report exchange sell influenza vaccine business glaxo january novartis divest animal health division eli lilly lly free report approximately novartis stock have rally year so far compare industry gain company blockbuster drug diovan be face stiff generic competition unite state eu japan gleevec lose exclusivity unite state february company also lose patent protection drug eu december lead generic competition loss patent protection top selling drug continue hurt sale performance alcon business be weak due competition face intraocular lens slowdown demand equipment purchase consequently novartis moved ophthalmic pharmaceutical business company pharmaceutical division alcon now focus medical device surgical vision care business major business iol consumable equipment contact lense turnaround have be encourage management believe create standalone company capital market exit create additional shareholder value decision be expect first half depend alcon performance future zack rank key picknovartis currently carry zack rank hold better rank stock healthcare sector be therapeutic inc cort free report currently carry zack rank buy see complete list today zack rank stock strong buy here earning share estimate have moved cent cent last day company deliver positive earning surprise trail quarters average beat company stock have moved so far year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1104,LLY,radius health inc rdus free report announce committee medicinal product human use chmp provide third day list outstanding issue regulatory review abaloparatide sc chmp inform company refer marketing authorisation application maa scientific advisory group additional advice part ongoing risk benefit assessment hence chmp expect issue opinion same first half july chmp issue second day list outstanding issue request additional datum analysis related safety efficacy abaloparatide sc ongoing regulatory review delay approval europe be disappointing give potential market radius health share price have decrease year so far compare industry gain note tymlos abaloparatide be approve fda april treatment postmenopausal woman osteoporosis high risk fracture defined history osteoporotic fracture multiple risk factor fracture patient have fail be intolerant other available osteoporosis therapy osteoporosis market unite sate have great potential approximately postmenopausal woman experience osteoporotic fractur year tymlos be expect face significant competition eli lilly co lly free report forteo amgen inc amgn free report prolium moreover approve label carry box warning osteosarcoma malignant bone tumor meanwhile radius health be also develop abaloparatide td short wear time transdermal patch december company initiate human replicative clinical evaluation compare optimized abaloparatide td patch subcutaneous formulation company post positive result trial september company be currently focuse complete manufacturing scale other require activity need initiate pivotal study evaluate abaloparatide sc transdermal patch program have potential allow physician treat osteoporosis rarely use injectable drug expand practice include use anabolic therapy zack rank key pickradius health currently carry zack rank hold better rank stock healthcare sector be therapeutic inc cort free report currently carry zack rank buy see complete list today zack rank stock strong buy here earning share estimate have increase cent cent last day company deliver positive earning surprise trail quarters average beat company stock be so far year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1105,LLY,eli lilly company lly free report report fourth quarter adjust earning share beat zack consensus estimate share earning rise year quarter backed higher operate profit revenue beatquarterly revenue also beat zack consensus estimate sale grow year year backed strong performance new drug favorable currency movement lesser extent partially offset lower sale establish product strattera humalog ciali effient lilly establish product portfolio record decline worldwide revenue volume rise strong performance new product trulicity taltz basaglar jardiance lartruvo offset decline sale establish product higher realize price several drug also contribute sale growth quarter foreign exchange rate also hada favorable impact segment revenue rise quarter backed volume growth new product revenue grow ex revenue rise establish product record growth quarter include forteo humulin cymbalta erbitux sale other establish product decline quarter humalog sale decline due lower realize price unite state moreover december fda approve sanofi sny free report admelog biosimilar version humalog approval certainly increase competition alimta sale decline reflect lower demand ex market due competitive pressure loss exclusivity certain country however sale alimta increase unite state due increase volume partially offset lower realize price zyprexa sale decline due loss exclusivity japan ciali sale decline hurt worldwide lower demand strattera sale decline effient sale decline quarter drug see lower demand due loss exclusivity new product trulicity generate revenue year year revenue benefit growth glp market market share gain cyramza revenue be year year backed strong demand cyramza ex revenue increase benefit strong volume japan partially offset lower realize price revenue increase drive increase volume jardiance sale be drive increase market share grow sglt class unite state increase volume outside unite state basaglar record revenue compare previous quarter basaglar lilly partner boehringer ingelheim follow insulin sanofi blockbuster drug lantus be launch unite state mid december taltz bring sale compare previous quarter reflect strong uptake december drug be approve psoriatic arthritis launch unite state european commission also approve drug last week lartruvo olaratumab generate revenue fourth quarter compare previous quarter lartruvo be launch unite state eu soft tissue sarcoma fourth quarter lilly partner incyte corporation incy free report rheumatoid arthritis drug olumiant baricitinib have be launch select european country japan drug generate sale fourth quarter compare previous quarter backed strong launch uptake germany however unite state lilly receive complete response letter fda baricitinib april want additional datum company have re submit application late verzenio be launch unite state fourth quarter generate sale lilly elanco animal health segment sale decline due decrease food animal revenue however companion animal revenue increase include revenue acquisition boehringer ingelheim vetmedica feline canine rabies vaccine portfolio acquire january be offset competitive pressure lower demand unite state gross margin operate income risesadjust gross margin quarter decrease basis point manufacturing efficiency be offset negative product mix effect foreign exchange rate international inventory sell operate income increase year year total operate expense percent revenue decline basis point quarter ep guidance uppedlilly raise previously issue adjust earning outlook adjust earning share be now expect range compare expect previously reflect positive impact tax reform however revenue be still expect range gross margin be expect be approximately same previously expect adjust tax rate be expect be approximately previously approximately marketing selling administrative expense be still expect range research development expense be project be takelilly fourth quarter result be strong company beating estimate count meanwhile expectation lower tax rate due new tax law propel company raise earning outlook share be pre market trading lilly share price have rise past year compare increase industry go forward new product trulicity taltz basaglar cyramza jardiance lartruvo be expect see higher revenue lilly be also progress well pipeline fda approval taltz line extension also boost lilly product revenue october lilly have announce be look sell spin elanco animal health business potential sale underperform animal health segment help improve margin however alimta continue be impact competition other headwind include competition immuno oncology agent well loss exclusivity many drug emerge market eli lilly company price consensus ep surprise eli lilly company price consensus ep surprise eli lilly company quote zack rank stock considerlilly carry zack rank hold better rank stock pharma sector be abbvie inc abbv free report carry zack rank buy see complete list today zack rank strong buy stock here abbvie earning estimate increase last day company come positive surprise trail quarters average beat stock be past year hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1106,LLY,indianapoli base eli lilly company lly free report be global healthcare company core product number primary care pharmaceutical market lilly generate revenue pharmaceutical product animal health segment company portfolio include zyprexa schizophrenia bipolar disorder gemzar pancreatic cancer evista osteoporosis cymbalta depression ciali erectile dysfunction strattera attention deficit hyperactivity disorder adhd erbitux cancer alimta chemotherapy lilly also have strong presence diabetes market however many key product cymbalta alimta be face generic competition company also have new product trulicity cyramza jardiance taltz portfolio be drive revenue lilly earning performance have be mixed earning miss expectation last quarters beating same other bring average negative surprise currently lilly have zack rank hold definitely change follow company earning report be just release have highlighted key stat just reveal announcement earning beat lilly beat third quarter earning company report ep share consensus call ep revenue beat revenue also beat expectation lilly post revenue compare consensus estimate outlook up lilly raise previously issue adjust earning sale outlook second time year adjust earning share be now expect range compare expect previously revenue be expect range expect previously zack consensus estimate earning revenue be share respectively strategic initiative concurrent earning release lilly say be explore strategic alternative elanco animal health business include spin sale merger create separate company initial public offer decision regard same be expect be make middle next year lilly ultimately opt retain business stock price impact share be pre market trading check back later full lilly earning report later eli lilly company price consensus eli lilly company price consensus eli lilly company quotetoday stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1107,LLY,expect merck co inc mrk free report beat expectation report third quarter result oct market open last quarter company deliver positive earning surprise merck performance have be pretty impressive company exceed earning expectation trail quarters average positive earning surprise last quarters be merck share have rise year so far compare unfavorably increase industry factor considermerck new product keytruda cancer zepatier hcv bridion sugammadex injection be likely drive top line quarter keytruda sale unite state be gain particularly back strong momentum new indication first line lung cancer keytruda development program significantly advanced first half regulatory approval new indication unite state additional indication europe key recent approval include advanced bladder cancer advanced microsatellite instability high cancer first approval combination therapy eli lilly lly free report cancer drug alimta pemetrexed carboplatin pem carbo lung cancer new approval have expand patient population be expect drive sale third quarter however call management warn zepatier uptake be impact ongoing decline overall patient volume many market increase competition previously strong underlie demand trend unite state europe japan have support zepatier sale company also face headwind form genericization well increase competition negative impact currency exchange sale remicade lose exclusivity europe face stiff biosimilar competition region cubicin lose patent protection unite state june zetia lose market exclusivity unite state december vytorin lose exclusivity april be likely decline quarter sluggish growth integrase class continue competitor dynamic unite state europe continue affect isentress sale zack consensus estimate isentress sale be third quarter investor also be focuse performance merck dpp inhibitor januvia pricing pressure hurt sale januvia janumet franchise first half vaccine animal health franchise be expect boost sale quarter zack consensus estimate vaccine total animal health segment be respectively call merck mentioned network cyber attack june disrupt global operation include manufacturing research sale time merck have say full recovery cyber attack take time result temporary delay fulfill order product not keytruda zepatier januvia certain market expect update upcoming conference call remediation expense related cyber attack increase investment ongoing launch additional cost associate new oncology collaboration astrazeneca be expect result higher operate cost quarter earning whispersour proven model show merck be likely beat estimate quarter have right combination key ingredient stock need have positive earning esp zack rank strong buy buy hold likely positive surprise zack esp earning esp represent difference most accurate estimate share zack consensus estimate share be uncover best stock buy sell re report earning esp filter zack rank merck have zack rank combination merck zack rank positive esp make confident earning beat upcoming release sell rate stock zack rank other hand never be consider go earning announcement especially company be see negative estimate revision merck company inc price ep surprise merck company inc price ep surprise merck company inc quoteother stock considerother large cap pharma stock have positive esp favorable zack rank include bristol myer squibb company bmy free report schedule release result oct have earning esp zack rank see complete list today zack rank stock here pfizer inc pfe free report have earning esp zack rank company be schedule release result oct today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1108,LLY,third quarter report cycle be positive start evident accelerate revenue growth trend meanwhile proportion positive surprise be average quarter also estimate revision trend next quarter have be mostly favorable estimate have actually go past couple week oct member accounting index total market capitalization report result accord latest earning preview total earning index member be year quarter improvement revenue beat ratio be earning revenue report total earning company be expect grow year year higher revenue please note broader medical sector include drug biotech well medical device company be expect record year year growth revenue earning biotech pharma bigwig only johnson johnson jnj free report have report third quarter result so far report better expect third quarter result raise sale profit outlook sale growth accelerate third quarter lead company post first positive sale surprise almost year here have biotech pharma giant be set report third quarter result oct let see thing be shape quarter eli lilly company lly free report lilly be schedule release earning market open have deliver positive earning surprise last quarter lilly earning performance have be mixed earning miss expectation last quarters beating same other bring average negative surprise quarter lilly have earning esp zack rank hold zack consensus estimate be peg share uncover best stock buy sell re report earning esp filter new product trulicity cyramza taltz jardiance have support top line past few quarters expect trend continue third quarter well however decline sale alimta cymbalta zyprexa be expect continue due loss exclusivity read more eli lilly report earning store biogen inc biib free report biogen well know name multiple sclerosis ms market be also schedule announce result open bell biogen earning performance have be pretty impressive so far have deliver positive surprise last quarters average earning beat last quarters be last quarter company deliver positive earning surprise company have earning esp zack rank indicate likely positive surprise zack consensus estimate be peg share see complete list today zack rank strong buy stock here global patient growth be likely drive prescription trend sale biogen ms drug tecfidera however rise competition roche rhhby free report newly launch ms drug ocrevus hurt sale tysabri modestly investor focus also be spinraza performance read more biogen earning deliver beat again novartis ag nvs free report swiss pharma giant be expect report market open last quarter novartis deliver positive earning surprise company post average positive earning surprise trail quarters company have earning esp zack rank zack consensus estimate be peg share new product cosentyx entresto be expect boost top line however loss exclusivity key drug novartis portfolio be expect continue hurt company top line investor focus novartis earning call be update related newly approve car therapy kymriah acute lymphoblastic leukemia read more card novartis earning season make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1109,LLY,johnson johnson jnj free report kick third quarter earning season pharmaceutical sector strong note company beating earning revenue focus remain strong earning result company allergan agn free report be also news regard patent litigation recap week most important storiesj result impress raise outlook earning result be strong company beating earning revenue segment consumer medical device pharmaceutical do well oncology record robust growth result include contribution pulmonary hypertension product become part company portfolio follow acquisition actelion base solid third quarter result raise outlook year well read more beat earning actelion buyout drife sale company have gain year date compare rally industry belong sanofi dupixent top allergic inflammatory disease study sanofi partner regeneron pharmaceutical announce positive phase ii result dupixent dupilumab adult active moderate severe eosinophilic esophagitis chronic allergic inflammatory disease patient receive dupixent weekly report significant improvement ability swallow versus placebo read more sanofi regeneron dupixent succeed phase ii study market be huge dupixent gain timely approval give lack fda approve treatment dupixent have orphan drug status unite state indication dupixent have blockbuster potential be currently approve eczema be be evaluate additional indication apart eosinophilic esophagitis fact last month company have announce positive top line datum late stage study dupixent uncontrolled persistent asthma regeneron sanofi be also collaborate aimmune therapeutic clinical stage company focuse development treatment potentially life threaten food allergy clinical collaboration aimmune ar be evaluate adjunctive dupixent peanut allergic patient mid stage study be schedule commence next year study be sponsored regeneron aimmune provide clinical supply ar food challenge material datum merck keytruda priority review lynparza snda merck mrk free report present update overall survival os datum pd therapy keytruda first line treatment patient suffering metastatic small cell lung cancer high level pd company say additional month available datum continue show reduction risk death keytruda compare chemotherapy keytruda more double median os compare chemotherapy year follow keytruda be key product merck portfolio drug bring sale first half merck partner astrazeneca also announce have be grant priority review fda supplemental new drug application snda use parp inhibitor lynparza tablet patient gbrca negative metastatic breast cancer mbc have be previously treat chemotherapy neoadjuvant adjuvant metastatic setting response agency be expect first quarter nordisk diabetes drug get fda panel support nordisk nvo free report get boost fda advisory panel endocrinologic metabolic drug advisory committee voting unanimously favor approve once weekly semaglutide use type ii diabetes patient give favorable vote chance gain fda approval look pretty high second quarter call nordisk have say expect decision fda year end semaglutide approval be major positive company drug expect be key growth driver nordisk be zack rank buy stock see complete list today zack rank strong buy stock here priority review bmy drug label expansion bristol myer squibb company bmy free report immuno oncology therapy opdivo have be grant priority review fda label expansion treatment melanoma patient be high risk disease recurrence follow complete surgical resection opdivo prioritize brand bristol myer portfolio bring sale first half read more bristol myer get priority review opdivo label expansion adverse ruling allergan restasis patent litigation allergan continue make headline related blockbuster eye drug restasis time round company announce have receive adverse ruling district court eastern district texas regard patent cover drug court find patent be invalid allergan intend appeal ruling say fda be yet approve generic version drug however ophthalmology focuse company imprimis pharmaceutical announce be work make lower cost alternative restasis available company say initial prescription be cent month supply refill start month include shipping accord allergan restasis patent be schedule expire aug allergan enter settlement agreement generic challenger recently innopharma have be adopt different way protect restasis generic competition company come fire enter agreement saint regis mohawk tribe lawmaker question unconventional move adopt company protect drug generic competition restasis be allergan second best selling drug bring sale almost lawmaker point sovereign status native american tribe make patent challenge lengthy complex tribe be immune legal claim make generic drug maker challenge patent deal have basically raise concern curb generic competition pharmaceutical industry discourage generic drugmaker make cheaper copy cat version expensive drug impax combine amneal specialty pharma company impax laboratory be merge privately hold generic company amneal pharmaceutical stock transaction merger combine company have high value generic product pipeline grow specialty business deal be expect boost impax stand alone earning share first month generate double digit revenue earning share growth year follow close transaction annual cost synergy be expect be achieve year merger be expect go first half read more impax laboratory amneal pharmaceutical agree merge cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index be week sector react positively result major stock be bristol myer decline last month bristol myer be see last pharma stock roundup here pfizer mull option consumer healthcare lly pipeline setback next pharma world watch earning result company novartis eli lilly lly free report bristol myer other come week wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1110,LLY,eli lilly company lly free report announce top line datum phase iii study rainfall evaluate cyramza ramucirumab first line treatment patient advanced gastric cancer study meet primary endpoint progression free survival pfs fail improve overall survival os result be present future medical meeting company have also announce not seek regulatory approval first line set base datum study cyramza be presently approve single agent combination chemotherapy drug paclitaxel treat advanced metastatic gastric stomach junction gej adenocarcinoma patient disease have progressed prior therapy drug be also approve treat metastatic small cell lung cancer metastatic colorectal cancer tradename folfiri share lilly have gain past month outperform industry rise period rainfall study evaluate cyramza combination cisplatin capecitabine fluorouracil first line treatment negative metastatic gastric gej adenocarcinoma versus company be hopeful positive pfs lead os benefit treat advanced gastric cancer be challenge be further underscored fact major advance chemotherapy have be achieve treat metastatic gastric cancer moreover initial datum phase iii study cyramza present esmo congress show drug meet pfs endpoint patient advanced urothelial carcinoma press release gastric cancer be fifth most common form cancer world disease be expect affect new patient cause death unite sate alone eli lilly company price eli lilly company price eli lilly company quotezack rank stock considerlilly carry zack rank hold better rank stock pharma sector include johnson johnson jnj free report acadium pharmaceutical inc acad free report therapeutic inc cort free report stock carry zack rank buy see complete list today zack rank strong buy stock here earning estimate increase last day company deliver positive earning surprise trail quarters average beat company share have return so far year acadium loss estimate narrow last day company come positive earning surprise trail quarters average beat company share have return so far year earning share estimate have increase cent cent last day company deliver positive earning surprise trail quarters average beat company stock be so far year today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1111,LLY,novartis ag nvs free report announce european commission ec have approve tasigna treatment pediatric patient newly diagnosed philadelphia chromosome positive chronic myeloid leukemia chronic phase ph cml cp pediatric patient ph cml cp resistance intolerance prior therapy include imatinib approval be card european medicine agency committee medicinal product human use have give positive opinion same note tasigna be already approve treatment chronic phase accelerate phase philadelphia chromosome positive chronic myelogenous leukemia ph cml adult patient resistant intolerant least prior therapy include glivec be also approve treatment adult patient newly diagnosed ph cml chronic phase drug be also approve european union treatment ph cml chronic phase pediatric patient resistance intolerance prior therapy include glivec hence label expansion treatment child cml boost sale drug give limit treatment option same june tasigna become first only tki include information stopping therapy adult patient ph cml cp first line set switch glivec eu label novartis stock have rally year date compare industry gain remind investor novartis broaden oncology portfolio acquire glaxosmithkline plc gsk free report certain oncology product pipeline compound march have divest animal health division eli lilly co lly free report first half novartis announce be mull strategic option alcon include retain business separation capital market transaction such spin initial public offer company believe alcon division have revive hence decision possible spin be take recent approval kymriah kisqali further boost oncology portfolio drive growth zack rank key picknovartis currently carry zack rank hold better rank health care stock be sucampo pharmaceutical inc sport zack rank strong buy see complete list today zack rank stock here sucampo earning share estimate have moved last day company deliver positive earning surprise trail quarters average beat wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1112,LLY,unite therapeutic corporation uthr free report report fda have grant month pediatric exclusivity pulmonary arterial hypertension pah drug adcirca tadalafil delay generic competition drug additional month pediatric exclusivity have push back patent expiry oral pde inhibitor patent be otherwise set expire month mean generic version drug be approve then share unite therapeutic be monday response positive development however look unite therapeutic share price movement show stock have underperform industry year so far unite therapeutic stock have decline period industry rise remind investor unite therapeutic buy exclusive right commercialize adcirca treatment pah unite state eli lilly lly free report november tadalafil be also sell lilly ciali erectile dysfunction additional exclusivity adcirca be base study datum submit lilly fda separately unite therapeutic be require pay higher royalty sale adcirca effective next month previously announce amendment licensing agreement royalty rate adcirca sale be unite therapeutic also have make milestone payment net product sale adcirca generate sale month year year meanwhile company have more pah product portfolio remodulin tyvaso orenitram product unite therapeutic have varied range therapy target pah market lately growth orenitram tyvaso remodulin have slow due competition mainly actelion new drug uptravi selexipag actelion be now part johnson jonson jnj free report also patient be stay longer front line oral ambition combination therapy adcirca gilead gild free report letairis delay transition inhaled injectable therapy tyvaso remodulin thereby hurt demand meanwhile remodulin account more unite therapeutic total sale start face generic competition june unite therapeutic carry zack rank hold see complete list today zack rank strong buy stock here zack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
1113,LLY,celldex therapeutic inc cldx free report announce initiation phase ii study human monoclonal antibody cdx patient advanced head neck squamous cell carcinoma hnscc approve product portfolio investor focus remain progress celldex pipeline candidate share company be more friday follow news however celldex share be so far year underperform industry gain period phase ii study evaluate cdx combination eli lilly lly free report erbitux patient advanced hnscc be erbitux resistant previously treat pd checkpoint company believe patient population be evaluate study have limit availability treatment option particularly poor prognosis study continue treatment progression disease start patient become intolerant combination therapy primary objective study be achieve objective response rate stage study enroll patient first stage initiate second stage achieve partial complete response least patient remind investor complete phase ib study combination therapy have show promising tumor activity hsncc patient include durable complete response single patient disease have progressed erbitux monotherapy celldex be also progress well lead pipeline candidate glembatumumab vedotin be be evaluate phase iib study patient triple negative breast cancer phase ii study melanoma patient company be also evaluate candidate combination bristol myer bmy free report opdivo merck mrk free report keytruda separate cohort melanoma study celldex therapeutic inc price celldex therapeutic inc price celldex therapeutic inc quotecelldex currently hold zack rank buy see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1114,LLY,week company nordisk nvo free report eli lilly company lly free report be news provide regulatory update nordisk gain approval new type ii diabetes drug fda expand label lilly taltz recap week most important storiesnovo nordisk diabetes drug get fda nod nordisk get major boost fda approve company new type ii diabetes drug ozempic ozempic once weekly glp agonist be approve use adjunct diet exercise improve glycemic control adult type ii diabetes mellitus approval come shortly fda advisory panel have vote favor approve drug ozempic enter highly crowd market have be show lead clinically meaningful statistically significant reduction hba compare placebo januvia sitagliptin bydureon exenatide extend release lantus insulin glargine ozempic be also associate weight loss ozempic be expect enter market early represent blockbuster potential read more nordisk semaglutide get fda approval diabetes positive datum abbvie imbruvica rituxan combo wm johnson johnson jnj free report partner abbvie present datum combination btk inhibitor imbruvica rituxan treatment newly previously treat patient waldenström wm primary endpoint progression free survival pfs be achieve late stage study imbruvica be approve different indication include chronic lymphocytic leukemia previously treat mantle cell lymphoma wm well chronic graft versus host disease read more abbvie imbruvica succeed combo study rituxan be zack rank buy stock see complete list today zack rank strong buy stock here stock have gain year date compare rally industry belong sanofi present toujeo head head datum end vaccine development sanofi sny free report present positive datum toujeo head head study versus insulin degludec effect toujeo blood sugar level be find be similar insulin degludec read more sanofi toujeo meet key objective head head study sanofi also announce have decide end development clostridium vaccine base plan interim analysis show chance vaccine meeting primary endpoint late stage study be low be latest blow company vaccine segment be face issue dengue vaccine dengvaxia due safety concern earlier week philippine fda ask company suspend sale distribution marketing dengvaxia withdraw market pending compliance directive agency second indication approve lilly taltz lilly taltz ixekizumab gain fda approval second indication agency give nod use drug treatment adult active psoriatic arthritis psa taltz be initially approve treatment adult patient moderate severe plaque psoriasis be candidate systemic therapy phototherapy taltz work specifically target il protein play role drive underlie inflammation psoriasis read more lilly taltz get approval label expansion fda nod first herceptin biosimilar fda grant approval mylan myl free report biocon biosimilar version roche rhhby free report blockbuster cancer drug herceptin trastuzumab remind investor earlier year july fda oncologic drug advisory committee odac have vote favor approve biosimilar ogivri have be approve indication reference product herceptin include treatment positive breast gastric cancer cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index decline last trading session major stock lilly be bristol myer decline last month bristol myer be glaxosmithkline gsk free report decline see last pharma stock roundup here pfizer merck kgaa drug fail study teva ceo announce change next pharma world watch regulatory pipeline news pharma stock several company be present annual meeting american society hematology ash december datum approve pipeline drug wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1115,LLY,pfizer inc pfe free report announce encourage new datum post analysis phase iii study evaluate combination breast cancer drug ibrance palbociclib novartis nvs free report femara letrozole first line treatment metastatic breast cancer notably datum study be present san antonio breast cancer symposium sabcs dec ibrance be approve unite state treat hr advanced metastatic breast cancer combination inhibitor initial endocrine base therapy postmenopausal woman be also approve be used astrazeneca azn free report faslodex woman disease progression follow endocrine therapy presently ibrance be approve more country pfizer share be so far year compare unfavorably industry return paloma study be see combination ibrance femara lead improvement progression free survival pfs time recurrence tumor growth more year compare femara placebo other word study show median pfs woman treat ibrance femara be month compare month femara placebo combination arm thereby indicate reduction risk disease progression paloma have enrolled woman global site country update result safety profile post analysis be consistent primary datum paloma study report last november remind investor ibrance combination femara be clear unite state accelerate approval february treatment hr advanced metastatic breast cancer april pfizer receive regular approval drug base datum paloma trial also same time ibrance label be expand cover few more indication be used combination inhibitor not just femara pfizer be explore possibility expand ibrance recurrent subsequent early breast cancer well several breast cancer indication pancreatic head neck cancer ibrance have be generate strong sale key driver company top line drug logged sale first month year year successful label expansion drug reap more revenue however breast cancer market competition ibrance have increase recent launch eli lilly lly free report verzenio novartis kisqali pfizer inc price pfizer inc price pfizer inc quotezack rankpfizer carry zack rank hold see complete list today zack rank strong buy stock here zack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
1116,LLY,eli lilly company lly free report announce fda have approve label expansion psoriasis drug taltz include treatment active psoriatic arthritis psa adult note taltz be presently approve treat moderate severe plaque psoriasis adult have systemic therapy phototherapy drug have grow more first month contribute significantly revenue volume approval expand label unite state be expect further boost growth lilly stock price have increase past year outperform industry gain come back news fda approval taltz label expansion be base datum phase iii study spirit spirit evaluate drug active psa patient have not receive antirheumatic drug therapy have fail tumor necrosis factor tnf inhibitor respectively drug achieve reduction more composite measure disease activity acr more half patient population study week drug mg ml be inject single agent combination disease modify antirheumatic drug methotrexate however taltz face competition several drug especially novartis nvs free report cosentyx drug work target il cosentyx be also approve psa plaque psoriasis psa be chronic form inflammatory arthritis be painful progressive well press release approximately person unite state be affected disease apart cosentyx johnson johnson jnj free report stelara abbvie inc abbv free report humira other be fight market share eli lilly company price eli lilly company price eli lilly company quotelilly carry zack rank hold see complete list today zack rank strong buy stock here zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
1117,LLY,share immunogen inc imgn free report have be massively year so far outperform industry register increase let analyze factor lead rally immunogen rapid pipeline progress positive readout strategic collaboration have push share price consistently immunogen have make significant progress regard lead pipeline candidate mirvetuximab soravtansine year candidate be be evaluate phase iii study forward single agent therapy treat patient platinum resistant ovarian cancer company have presently activate site enrolment trial aim complete middle also candidate be be evaluate phase expansion cohort ovarian cancer patient company report positive datum study demonstrated promising safety efficacy profile candidate meanwhile combination regimen mirvetuximab soravtansine ovarian cancer be also be evaluate phase ib ii forward ii study forward ii trial consist cohort assess mirvetuximab soravtansine combination roche rhhby free report avastin merck mrk free report keytruda immunogen have report initial datum study show mirvetuximab soravtansine potential complement currently available therapy indication approval combination regime significantly expand eligible patient population mirvetuximab soravtansine approval mirvetuximab soravtansine be huge boost immunogen give immense commercial potential target market ovarian cancer result maximum annual death gynecologic cancer majority patient diagnosed advanced stage datum provide american cancer society approximately new case ovarian cancer be diagnosed unite state result more death apart mirvetuximab soravtansine immunogen be work develop couple other clinical pre clinical candidate include imgn imgn notably imgn be be evaluate phase study treat acute myeloid leukemia aml datum expect later year other hand company plan move imgn clinical development year end treat hematological malignancy include aml immunogen have agreement several big healthcare company include amgen bayer eli lilly lly free report novartis roche sanofi takeda contract allow other company use immunogen adc technology provide fund form license milestone fee royalty clinical material revenue support fee notably august immunogen have announce strategic collaboration option agreement jazz pharmaceutical development candidate adc program imgn imgn pursuant deal immunogen be eligible receive milestone payment base certain pre decide condition platinum resistant ovarian cancer market offer immense commercial potential immunogen be notably set face intense competition approval however mirvetuximab soravtansine look promising juncture approval be big lift company immunogen carry zack rank hold see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1118,LLY,be not much activity cancer space week however see drug get regulatory nod european commission ec zejula receive approval monotherapy maintenance treatment recurrent ovarian cancer patient be set give astrazeneca azn free report merck mrk free report lynparza run money parp inhibitor space europe other hand novartis nvs free report tasigna receive approval label expansion first line set paediatric patient chronic myeloid leukemia meanwhile johnson johnson jnj free report submit regulatory application label expansion darzalex first line therapy multiple myeloma unite state europe moreover roche hold rhhby free report announce encourage result phase iii study evaluate tecentriq combination chemotherapy stage iv squamous small cell lung cancer nsclc recap week most important storiestesaro zejula approve europe european commission have grant marketing authorization zejula maintenance treatment woman recurrent ovarian cancer be first parp inhibitor receive approval europe do not require brca mutation other biomarker testing drug be already market unite state same indication zejula now compete lynparza be already approve europe however zejula have edge lynparza require brca mutation status europe zejula have perform well unite state launch similar adoption drug europe aid company read more tesaro ovarian cancer drug zejula get approval eu tesaro inc price tesaro inc price tesaro inc quotenovartis tasigna get label expansion europe ec approve label expansion tasigna include paediatric patient newly diagnosed philadelphia chromosome positive chronic myeloid leukemia chronic phase ph cml cp label also include ph cml cp resistance intolerance prior therapy include imatinib gleevec tasigna be already approve adult similar indication accelerate phase cml second later line set read more novartis receive ec nod tasigna label expansion novartis ag price novartis ag price novartis ag quotej seek darzalex label expansion submit regulatory application unite state europe seek label expansion darzalex first line set treat multiple myeloma mm drug approve be used combination proteasome inhibitor mm drug velcade bortezomib melphalan prednisone treatment naïve patient have autologous stem cell transplantation bone marrow darzalex contribute almost sixth total oncology sale potential label expansion approval geography further boost prospect read more seek darzalex label expansion first line set johnson johnson price johnson johnson price johnson johnson quoteroche tecentriq impress phase iii combination study roche announce encourage result phase iii impower study evaluate tecentriq nsclc patient study be evaluate efficacy safety tecentriq combination chemotherapy carboplatin paclitaxel avastin combination tecentriq avastin chemotherapy achieve statistically significant clinically meaningful reduction risk disease worsening death compare avastin chemotherapy person stage iv nsclc study be conduct patient do not receive prior therapy read more roche report positive datum tecentriq combination study roche hold ag price roche hold ag price roche hold ag quoteapart celldex therapeutic inc cldx free report announce initiation phase ii study pipeline candidate cdx combination eli lilly lly free report erbitux study evaluate candidate patient advanced head neck squamous cell carcinoma more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1119,LLY,weak performance due drug pricing issue pharma industry have bounce back year minor correction recently merck co inc mrk free report be very few company share be last year notwithstanding industry decline other way round year share merck have decline year increase large cap pharma industry let discuss merck have suffer notable pipeline setback year october merck decide not seek approval cetp inhibitor anacetrapib cholesterol management clinical profile be not strong enough support regulatory filing last month company also announce delay readout important lung cancer study say be include overall survival co primary endpoint keynote phase iii study keytruda first line lung cancer delay readout study raise investor concern delay readout give competitor chance gain strength lung cancer market october merck also withdraw regulatory application europe be look get keytruda approve first line combination therapy lung cancer please note october share merck be result back back pipeline setback september merck discontinue development hcv combination program mk mk say hcv market be become extremely crowd also combination study keytruda multiple myeloma be place clinical hold follow report death keytruda group july keytruda be see key long term growth driver merck such setback do not bode well company remain be see strong performance new drug particularly keytruda strong vaccine animal health business cost save effort help merck pick here merck carry zack rank hold see complete list today zack rank strong buy stock heremost other large cap pharma stock include astrazeneca azn free report jnj free report eli lilly lly free report bristol myer be year more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1120,LLY,eli lilly company lly free report boehringer ingelheim announce positive top line datum clinical study ease ease phase iii ease program evaluate sglt inhibitor jardiance empagliflozin type diabetes datum show jardiance addition insulin therapy meet primary endpoint reduction average blood sugar level baseline week treatment detailed result be present european association study diabetes annual meeting october study evaluate dose jardiance mg mg mg adult patient type diabetes be chronic disease impact production insulin body control blood sugar level disease affect approximately adult unite state more third meet target blood sugar level require life long daily insulin administration jardiance be approve treat type ii diabetes potential approval type diabetes boost prospect drug year date share lilly have rise industry decline separate press release lilly announce datum phase iii vivid study evaluate humulin deliver insulet corporation podd free report investigational insulin pump omnipod compare multiple daily injection mdi study evaluate humulin highly concentrated insulin formulation insulin resistant type ii diabetes patient require daily dose more unit insulin datum show drug administer investigational pump reduce level baseline week compare mdi administration moreover administration pump also lower total daily insulin dose unit kg compare mdi eli lilly company price eli lilly company price eli lilly company quotezack rank stock considerlilly currently carry zack rank hold see complete list today zack rank strong buy stock here couple better rank stock same space be aeglea biotherapeutic inc agle free report ani pharmaceutical inc anip free report stock carry zack rank buy aeglea loss share estimate narrow past day company deliver positive earning surprise trail quarters average beat stock have rally so far year ani pharmaceutical earning share estimate moved past day company deliver positive earning surprise trail quarters average beat stock have rally so far year more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1121,LLY,merck co inc mrk free report report third quarter adjust earning share beat zack consensus estimate earning rise year year other item adjust earning exclude charge related new oncology collaboration britain astrazeneca azn free report revenue quarter decline year year sale also miss zack consensus estimate currency movement positively impact revenue exclude currency impact sale decline year year lose sale market due network cyber attack june hurt top line quarter meanwhile unfavorable comparison third quarter last year hurt sale quarter pharmaceutical segment generate revenue exclude fx impact year year continue strong sale pd inhibitor keytruda be offset lower sale key product diabetes drug januvia hpv vaccine gardasil gardasil previous quarters loss market exclusivity several drug also hurt top line keytruda bring sale third quarter sequentially year year sale continue be drive launch new indication globally keytruda sale be gain particularly strong momentum indication first line lung cancer keytruda be already approve many type cancer treatment setting include lung cancer melanoma head neck cancer classical hodgkin lymphoma bladder cancer meanwhile keytruda development program significantly advanced first half regulatory approval new indication unite state additional indication europe key recent approval include advanced bladder cancer advanced microsatellite instability high cancer first approval combination therapy eli lilly lly free report cancer drug alimta pemetrexed carboplatin pem carbo lung cancer new approval have expand patient population believe drive sale third quarter zepatier bring sale previous quarter bridion sugammadex injection generate sale quarter year year drive strong uptake follow launch unite state meanwhile combine sale remicade lose exclusivity europe face stiff biosimilar competition region cubicin lose patent protection unite state june zetia lose market exclusivity unite state december vytorin lose exclusivity april decline quarter remicade sale decline quarter merck market brand version remicade outside unite state johnson johnson jnj free report market rheumatoid arthritis drug country cubicin sale plunge quarter zetia vytorin franchise record sale due loss exclusivity zetia vytorin sale isentress januvia janumet diabetes franchise also decline quarter januvia janumet franchise record sale quarter year quarter due continue pricing pressure isentress sale decline quarter lower volume demand due competitive pressure hurt sale isentress gardasil gardasil sale decline production shutdown follow cyber attack result supply constraint adversely impact sale unite state however sale rise europe boost addition sale terminate vaccine joint venture sanofi sny free report asia pacific backed strong demand merck animal health segment generate revenue exclude fx impact year quarter primarily drive higher sale companion animal product primarily bravecto companion animal vaccine contribution vallée acquisition gross margin cost rise adjust gross margin come basis point bps year quarter attributable favorable effect product mix offset cost related cyber attack marketing administrative expense increase report quarter research development spend increase quarter guidancemerck raise previously issue adjust earning guidance raise sale guidance marginally second time year company expect adjust earning range compare expect earlier adjust earning guidance include less negative impact currency fluctuation compare favorably approximately previously revenue be expect range compare earlier forecast include negative currency impact less versus approximately previously operate expense be still expect increase year year mid single digit rate increase cost be attributable increase investment ongoing launch remediation expense related cyber attack well additional cost associate new oncology collaboration astrazeneca takemerck third quarter result be mixed company beat estimate earning miss same sale relatively weaker sale performance merck raise previously issue adjust earning guidance also up sale guidance marginally share be pre market trading response lower sale merck multiple medicine year so far merck share have underperform industry merck share have rise year compare unfavorably increase industry eye be performance keytruda be be tout key long term growth driver merck drug continue strong performance sale cross mark quarter however company have suffer notable pipeline setback year earlier month merck decide not seek approval cetp inhibitor anacetrapib cholesterol management clinical profile be not strong enough support regulatory filing last month merck discontinue development hcv program say hcv market be become extremely crowd also combination study keytruda multiple myeloma be place clinical hold follow report death keytruda group julymerck carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1122,LLY,oct issue update report immunogen inc imgn free report immunogen be development stage biotechnology company focuse develop target cancer therapeutic used proprietary antibody drug conjugate adc technology immunogen have make significant progress regard lead pipeline candidate mirvetuximab soravtansine candidate be currently phase iii study forward single agent therapy treat patient platinum resistant ovarian cancer tumor express high medium level fr alpha additionally have receive prior treatment regimen successful development subsequent approval be huge boost company ovarian cancer market represent huge potential notably combination regimen mirvetuximab soravtansine ovarian cancer be phase ib ii forward ii study trial consist cohort assess mirvetuximab soravtansine combination roche avastin merck keytruda immunogen report initial datum forward ii study demonstrate candidate have potential complement currently available therapy indication notably mirvetuximab soravtansine enjoy orphan drug status unite state eu treatment ovarian cancer platinum resistant ovarian cancer market provide immense commercial potential immunogen be set face intense competition approval establish product roche avastin johnson johnson jnj free report doxil also several company be work introduce treatment market target disease apart mirvetuximab soravtansine immunogen be work develop couple other candidate include imgn imgn notably imgn be be evaluate phase study treat acute myeloid leukemia datum expect later year other hand company plan move imgn clinical development year end treat hematological malignancy include acute myeloma leukemia aml immunogen have agreement several big healthcare company include amgen inc bayer eli lilly company lly free report novartis nvs free report roche sanofi takeda contract turn allow other company use immunogen adc technology provide fund form license milestone fee royalty clinical material revenue research development support fee today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1123,LLY,radius health inc rdus free report be schedule report third quarter result nov radius share price have decrease year date compare industry decline radius health have disappointing track record so far company report wider expect loss trail quarters negative average surprise let see thing be shape quarter factor playradius focus development therapeutic treatment osteoporosis oncology endocrine disease company lead drug tymlos be approve unite state april drug be approve treat postmenopausal woman osteoporosis high risk fracture defined history osteoporotic fracture multiple risk factor fracture drug also be used patient have fail be intolerant other available osteoporosis therapy company report sale tymlos first week launch company be move ahead plan contract manage care organization access cover life commercial medicare part plan hence expect investor focus uptake drug upcoming earning call osteoporosis market unite state have great potential approximately postmenopausal woman experience osteoporotic fracture year tymlos be expect face significant competition eli lilly co lly free report forteo amgen inc amgn free report prolium meanwhile company marketing authorisation application eladyno abaloparatide sc europe treatment postmenopausal woman osteoporosis be review however company suffer setback committee medicinal product human use chmp european medicine agency issue second day list outstanding issue request additional datum analysis related safety efficacy abaloparatide sc consequently radius be work chmp address issue company expect response eladyno prior end radius health announce positive top line result complete month activextend clinical trial tymlos meet primary secondary endpoint company expect submit snda fda connection activextend result year end fda grant fast track designation pipeline candidate elacestrant experimental selective estrogen receptor regulator treatment woman advanced metastatic breast cancer elacestrant clinical development program be currently ongoing phase study patient advanced metastatic breast cancer have be heavily pre treat median prior line therapy have evaluable disease hence expect management throw light pipeline progress earning whispersour proven model do not conclusively show radius be likely beat estimate quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp radius health be currently peg be most accurate estimate zack consensus estimate be peg loss uncover best stock buy sell re report earning esp filter zack rank radius health have zack rank rank be favorable company esp make surprise prediction difficult note caution sell rate stock zack rank go earning announcement especially company be see negative estimate revision stock considerhere be pharma company consider model show have right combination element post earning beat quarter incyte corporation incy free report have earning esp zack rank company be expect release result oct see complete list today zack rank stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1124,LLY,astrazeneca plc azn free report announce fda have grant approval new indication breast cancer drug faslodex label faslodex now be expand include combination use eli lilly lly free report new cdk inhibitor verzenio abemaciclib treat woman hr advanced metastatic breast cancer disease have progressed endocrine therapy fda approval be base monarch study datum show faslodex improve progression free survival month compare faslodex placebo share london unite kingdom base pharma giant have gain so far year compare favorably industry growth august faslodex have receive fda approval label extension first line monotherapy set treatment postmenopausal woman hr advanced breast cancer approval faslodex be only approve advanced breast cancer later line treatment believe fda approval new indication faslodex month improve sale drug future quarters drug have generate sale so far year year also please note be second time faslodex have be approve use combination cdk inhibitor be already market combination pfizer pfe free report ibrance astrazeneca carry zack rank hold better rank stock large cap pharma sector be johnson johnson jnj free report zack rank buy see complete list today zack rank strong buy stock here share be so far year earning estimate have go past day zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
1125,LLY,third quarter earning season draw close focus be back deal regulatory approval pipeline update week company astrazeneca azn free report bayer bayry free report be news former announce fda approval severe asthma drug bayer sign cancer focuse deal loxo oncology recap week most important storiesfda approval astrazeneca severe asthma drug astrazeneca continue deliver pipeline company score couple fda nod week regulatory body grant approval company respiratory biologic fasenra benralizumab add maintenance treatment severe asthma patient age year disease be drive eosinophilic inflammation read more astrazeneca asthma drug benralizumab approve fda moreover astrazeneca get positive opinion committee medicinal product human use chmp european medicine agency ema fasenra read more astrazeneca get positive chmp opinion asthma candidate astrazeneca also gain fda approval use cancer drug faslodex expand patient population faslodex now be used combination eli lilly lly free report cdk inhibitor verzenio abemaciclib woman hr advanced metastatic breast cancer mbc disease have progressed endocrine therapy study result have show month progression free survival pfs combination treatment mark second fda approval faslodex cdk inhibitor treatment be already approve use combination pfizer cdk inhibitor ibrance palbociclib fda advisory panel meeting pacira exparel snda specialty pharma company pacira pharmaceutical inc pcrx free report announce supplemental new drug application snda exparel use nerve block regional analgesia be discuss fda anesthetic analgesic drug product advisory committee aadpac meeting be schedule be hold feb final response fda regard approval snda be expect apr read more pacira exparel snda be review fda advisory committee bayer oncology deal loxo bayer enter collaboration agreement loxo company focuse development highly selective medicine patient genetically defined cancer deal see bayer shell see company collaborate global development loxo highly selective trk inhibitor larotrectinib loxo patient trk fusion cancer agreement term include upfront payment loxo receive achievement certain regulatory commercial milestone additional milestone related loxo development cost be split equally company company co promote unite state loxo receive tiered double digit royalty net sale sale milestone totale ex territory larotrectinib be schedule be file fda approval late early janssen biotech licensing deal zymework janssen biotech johnson johnson jnj free report company have enter licensing agreement zymework development next generation bispecific antibody therapeutic deal janssen get worldwide royalty bearing license research develop commercialize bispecific antibody used zymework azymetric efect platform zymework be entitle upfront payment development milestone commercial milestone payment well tiered royalty potential sale janssen also have option add more bispecific program deal mean additional money zymework johnson johnson be zack rank buy stock see complete list today zack rank strong buy stock here chmp positive merck drug merck mrk free report get positive opinion chmp prevymis recently gain approval unite state merck be seek eu approval prevymis prevention cytomegalovirus cmv reactivation disease adult cmv seropositive recipient allogeneic hematopoietic stem cell transplant hsct chmp give positive opinion chance gain approval look high decision regard eu approval be expect month read more merck get chmp nod infection candidate prevymis update datum bristol myer immuno oncology combination bristol myer squibb bmy free report announce update result combination opdivo bms selective once daily oral ido inhibitor ongoing phase iia dose escalation expansion study study show maximum tolerate dose combination be mg mg dose be determine be recommend dose base safety pharmacodynamic datum moreover company say encourage response be observed heavily pre treat patient advanced cancer objective response rate orr disease control rate dcr be respectively bladder cancer cohort orr dcr be respectively cervical cancer cohort bristol myer also announce expansion label blockbuster drug sprycel now be used treatment child ph chronic phase cp chronic myeloid leukemia cml bristol myer have gain year date compare rally industry belong cap pharmaceutical industry yr returnlarge cap pharmaceutical industry yr nyse arca pharmaceutical index decline last trading session major stock astrazeneca be merck decline last month bristol myer be glaxo decline see last pharma stock roundup here astrazeneca earning roche merck drug get fda nod next pharma world watch regulatory pipeline news pharma stock zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
1126,LLY,johnson johnson jnj free report present new datum large canvas outcome program type ii diabetes drug invokana sglt inhibitor demonstrate improve renal outcome datum be present annual meeting american heart association scientific session california publish circulation so far year johnson johnson share price have increase compare favorably rally industry belong new analysis canvas show reduction risk composite renal endpoint patient group history cv disease secondary prevention only risk factor cv disease primary prevention also invokana demonstrated reduction risk hospitalization due heart failure hhf patient group new adverse event be report additional analysis remind investor june company report datum canvas program demonstrated invokana be successful reduce risk cardiovascular cv outcome type ii diabetes patient have establish cardiovascular cv disease be risk cv disease invokana reduce major adverse cv event mace compare placebo mace be composite endpoint cv death fatal myocardial infarction fatal stroke however study also show drug increase risk amputation last month submit supplemental new drug application snda fda label expansion invokana include cardiovascular indication base datum canvas program many pharma company be work hard get label diabetes medicine update include cardiovascular benefit death cardiovascular disease be significantly higher adult diabetes compare addition positive cv outcome label diabetes drug give sale shot arm eli lilly company lly free report receive fda eu approval last year include cv risk reduction datum empa reg outcome study label jardiance additionally august nordisk nvo free report victoza liraglutide be approve fda new indication reduce risk major adverse cardiovascular cv event adult type ii diabetes establish cv disease however merck co inc mrk free report be deny approval fda include cardiovascular outcome datum tecos trial label dpp iv inhibitor januvia sitagliptin other medicine contain januvia astrazeneca bydureon also fail reduce cardiovascular risk phase iiib iv cardiovascular outcome study exscel johnson johnson price johnson johnson price johnson johnson quotezack rankjohnson johnson carry zack rank buy see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1127,LLY,teva pharmaceutical industry ltd teva free report announce submission biologic license application bla fda seek approval monoclonal antibody candidate fremanezumab preventive treatment migraine bla submission be support positive datum phase iii study halo program evaluate candidate patient episodic migraine chronic migraine cm fremanezumab be subcutaneously administer once month month quarterly dose regimen high mg low dose mg monthly dose regimen study cm patient datum demonstrated statistically significant reduction number monthly headache day treat placebo study also meet secondary endpoint show significant improvement placebo datum study patient show patient be treat monthly well quarterly dose regimen fremanezumab experience clinically statistically significant improvement monthly average number migraine day pre specify analysis give limit treatment option fremanezumab represent significant commercial potential accord teva press release more person suffer migraine world include unite state remind investor bla amgen inc amgn free report partner novartis ag nvs free report approval cgrp receptor erenumab prevention migraine be accept fda july eli lilly company lly free report be also plan file fda approval investigational migraine drug galcanezumab second half year today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1128,LLY,novartis ag nvs free report announce encourage result revolade extend study open label extension study trial tra tra tra raise tra repeat show long term disease control chronic persistent immune itp patient research evaluate patient year continuous treatment study find majority patient maintain substantial clinical response not need concomitant itp medication further patient suffering itp have low number platelet turn do not let blood clot result bruise bleed study result show nearly patient maintain platelet count rescue therapy prolong period reduce overall risk bleed addition more third patient permanently stop more concomitant itp medication include corticosteroid danazol azathioprine result establish long term safety profile demonstrate treatment benefit revolade note drug be approve unite state europe treatment pediatric patient year older chronic itp have have insufficient response corticosteroid immunoglobulin be market promacta unite state remind investor drug be acquire glaxosmithkline plc gsk free report novartis have collaboration agreement ligand pharmaceutical inc lgnd free report marketing drug novartis be currently go transitional stage march novartis acquire certain oncology product pipeline compound glaxo exchange sell influenza vaccine business glaxo january novartis divest animal health division eli lilly company lly free report company blockbuster drug diovan be face stiff generic competition unite state eu japan gleevec lose exclusivity unite state february company also lose patent protection drug eu december lead generic competition loss patent protection top selling drug continue hurt sale nevertheless novartis have strong oncology portfolio drug afinitor exjade jakavi zykadia tasigna jadenu kisqali recent approval kymriah acute lymphoblastic leukemia be major boost novartis give potential car therapy space growth driver cosentyx entresto more offset impact generic erosion mainly due glivec today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1129,LLY,johnson johnson jnj free report be first large cap pharma stock report earning result season oct beat zack consensus estimate earning revenue third quarter also raise sale profit outlook share be more tuesday sale growth accelerate third quarter lead company post first positive sale surprise almost year higher sale pharmaceutical segment well positive contribution actelion deal pull top line quarter acquire swiss biotech actelion june year overall pharma sector have witness great turnaround year drug pricing issue cripple performance last year decline last year large cap pharma industry have rise year so far outpace gain same time frame new product sale ramp rise demand successful innovation product line expansion strong clinical study result more frequent fda approval new drug approve alone continue strong performance legacy product have play pivotal role bring sector track year factor be likely drive sector rest year probably next challenge rise competition pipeline setback slowdown growth mature product generic competition certain key drug better expect result especially strong performance pharmaceutical segment have raise optimism strong quarterly performance pharma sector mainly large cap company let have closer look expect big pharma stock report month early next month company be expect deliver earning beat quarter pfizer inc pfe free report pfizer be schedule announce third quarter result oct market open zack rank hold earning esp chance stock beating zack consensus estimate third quarter be high uncover best stock buy sell re report earning esp filter new product xeljanz rheumatoid arthritis ibrance breast cancer well older product lyrica neuropathic pain eliquis blood thinner be expect contribute pfizer top line meaningfully however loss exclusivity associate generic competition product pristiq vfend zyvox celebrex expiration few co promotion agreement continue hamper top line growth blockbuster drug enbrel sale continue be soft quarter due biosimilar competition pfizer surpass zack consensus estimate trail quarters show chart pfizer inc price ep surprise pfizer inc price ep surprise pfizer inc quotebristol myer squibb company bmy free report bristol myer be schedule release result oct market open similar pfizer quantitative model indicate earning beat bristol myer zack rank stock have earning esp see complete list today zack rank strong buy stock here bristol myer high profile immuno oncology drug opdivo be likely drive company top line be report quarter opdivo sale be drive melanoma second line small cell lung cancer renal cell carcinoma indication recent label expansion classical hodgkin lymphoma head neck cancer indication also boost drug sale bristol myer outpaced zack consensus estimate trail quarters reflect chart bristol myer squibb company price ep surprise bristol myer squibb company price ep surprise bristol myer squibb company quotemerck company inc mrk free report merck be schedule release result oct market open zack rank earning esp chance stock beating zack consensus estimate third quarter be high merck new product keytruda cancer zepatier hcv bridion sugammadex injection likely drive revenue quarter well keytruda sale unite state be gain particularly strong momentum new indication first line lung cancer keytruda development program significantly advanced first half regulatory approval new indication unite state additional indication europe new approval expand patient population be expect drive sale further however genericization increase competition likely remain overhang merck outpaced zack consensus estimate trail quarters reflect chart merck company inc price ep surprise merck company inc price ep surprise merck company inc plc gsk free report brentford uk base glaxosmithkline be expect report result oct glaxosmithkline be also expect outperform third quarter due zack rank buy earning esp glaxo pharmaceutical vaccine business segment be expect perform well glaxo pharmaceutical segment be expect continue be drive strong sale new hiv product tivicay triumeq however many glaxo key drug lovaza avodart be face decline sale due generic competition moreover sluggish sale growth consumer healthcare segment due slowdown market condition impact divesture negatively impact top line third quarter notably company surpass zack consensus estimate trail quarters show chart glaxosmithkline plc price ep surprise glaxosmithkline plc price ep surprise glaxosmithkline plc quoteeli lilly company lly free report eli lillyis slate announce third quarter result oct market open zack rank earning esp chance earning beat be report quarter be high continue trend past few quarters new product trulicity cyramza taltz jardiance be likely support top line report quarter however sluggish performance alimta cymbalta zyprexa be expect continue third quarter due loss exclusivity notably eli lilly surpass zack consensus estimate trail quarters show chart eli lilly company price ep surprise eli lilly company price ep surprise eli lilly company quotenovartis ag nvs free report swiss company novartis be schedule report result oct market open novartis be not expect beat estimate third quarter due zack rank earning esp recent approval kymriah acute lymphoblastic leukemia be major boost novartis give potential car therapy space moreover new product cosentyx entresto be expect boost top line cosentyx have be strong company have grab market share rival abbvie humira amgen enbrel cosentyx achieve blockbuster status however weak alcon business generic competition several key drug be expect hurt revenue quarter notably novartis outpaced zack consensus estimate trail quarters reflect chart novartis ag price ep surprise novartis ag price ep surprise novartis ag hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1130,LLY,eli lilly company lly free report report third quarter result oct market open last quarter company deliver positive earning surprise lilly share have rise year so far industry record increase lilly performance have be mixed earning miss expectation last quarters beating same other bring average negative surprise let see thing be shape quarter factor considernew product trulicity taltz jardiance have support top line past few quarters expect trend continue third quarter well trulicity sale be expect be drive growth glp market market share gain jardiance sale be likely be drive increase market share grow sglt class newer product basaglar lartruvo taltz continue witness better sequential sale backed strong launch uptake however sale alimta cymbalta zyprexa be expect decline due loss exclusivity cymbalta have lose exclusivity europe canada zyprexa japan alimta several country outside unite state meanwhile lower demand unite state due competitive pressure mainly immuno oncology agent be hurt alimta sale country consensus estimate alimta third quarter be new drug olumiant baricitinib have be launch select european country july drug be approve japan be likely add top line third quarter however unite state drug be review august lilly partner incyte corporation incy free report announce re submit nda baricitinib much faster previously expect nda be expect be re submit january next year meanwhile older product humulin trajenta forteo continue do well animal health segment sale past quarters have be hurt global competitive pressure conference call management have say global competitive pressure continue hurt revenue segment rest year lesser extent consensus estimate animal health segment third quarter be earning whispersour proven model do not conclusively show lilly be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp be uncover best stock buy sell re report earning esp filter zack rank lilly zack rank increase predictive power esp however need have positive esp be confident earning beat caution sell rate stock zack rank go earning announcement especially company be see negative estimate revision eli lilly company price ep surprise eli lilly company price ep surprise eli lilly company quotestock considerstock pharmaceutical sector have positive esp favorable zack rank includebristol myer squibb company bmy free report schedule release result oct earning esp zack rank see complete list today zack rank stock here pfizer inc pfe free report earning esp zack rank company be schedule release result oct hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1131,LLY,major pharma company eli lilly lly free report bristol myer squibb bmy free report glaxosmithkline plc gsk free report novartis read more novartis earning sale top new drug strength report third quarter result week be beat raise quarter lilly bristol myer result be mixed recap week most important storieslilly top expectation mull option animal health segment lilly third quarter result be better expect company beating top bottom line raise outlook year reflect uptake trend new pharmaceutical product company also announce be explore strategic alternative animal health business elanco animal health update expect mid company be weigh option initial public offer merger sale retention business segment bring revenue so far read more lilly beat earning explore sale elanco lilly be zack rank buy stock see complete list today zack rank strong buy stock here mixed quarter bmy be mixed quarter bristol myer company miss earning surpass revenue expectation opdivo performance remain strong presence increase competition sale grow eliquis also perform well company say business development remain top priority expect buy back share worth additional year end read more bristol myer miss earning opdivo focus company have gain year date compare rally industry belong sanofi file patent infringement lawsuit mylan lantus french drugmaker sanofi sny free report have file patent infringement suit mylan myl free report lantus lantus solostar lawsuit file unite state district court district new jersey allege infringement patent sanofi diabetes product sale be immense pressure lantus franchise remain major contributor top line earlier year august sanofi have file patent infringement suit merck allege infringement patent related lantus product interest increase pfizer consumer healthcare business ever pfizer pfe free report announce be explore strategic option consumer healthcare business include full partial separation spin sale quite few company have be rumore be interested striking deal week british pharma major glaxo be ask third quarter call interest acquire pfizer consumer healthcare business glaxo own consumer segment have be witness material slowdown global growth key category factor pricing pressure increase competition tougher emerge market weigh performance read more glaxo earning beat revenue line share meanwhile accord reuter article pfizer expect start auction process consumer healthcare business november accord source possible bidder apart glaxo reckitt benckiser include name procter gamble sanofi johnson johnson nestle nyse arca pharmaceutical index decline week major stock glaxo decline mainly reflect concern company dividend payout especially strike deal pfizer consumer healthcare business last month be see last pharma stock roundup here beat raise quarter allergan hit restasis ruling next pharma world watch earning result company merck mrk free report pfizer wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1132,LLY,biotech industry have witness great turnaround year drug pricing issue cripple performance last year decline last year large cap pharma industry have rise so far year outpace gain same time frame nasdaq biotechnology index be almost year date slide nyse arca pharmaceutical index have rise year date ytd decline almost last year pharma biotech sector have number thing go favor strong quarterly result new product sale ramp rise demand successful innovation product line expansion strong clinical study result more frequent fda approval new drug approve alone continue strong performance legacy product have play pivotal role bring sector track year factor have contribute sector surge be president trump expect action drug price not be onerous previously fear factor be likely drive sector rest year probably next challenge rise competition pipeline setback slowdown growth mature product generic competition certain key drug broader macro front propose tax reform approve leave more cash hand company cash be invest merger acquisition have be relatively fewer year compare last meanwhile outlook upcoming third quarter result look bright earning trend article broader medical sector include drug biotech well medical device company be expect record year year growth revenue earning pick likely winnersgiven enormity healthcare space select stock have potential beat estimate appear be quite daunting proprietary methodology make fairly simple way narrow list choice earning season be look stock have combination favorable zack rank zack rank strong buy buy hold positive earning esp more often not positive earning surprise deliver company lead stock price appreciation earning esp be proprietary methodology identify stock have high chance deliver positive surprise upcoming earning announcement show percentage difference most accurate estimate zack consensus estimate research show stock combination chance positive earning surprise be high uncover best stock buy sell re report earning esp filter here be large cap pharma stock be poise beat estimate third quarter accord methodology investing stock large market cap be much more reliable investment fact control large portion give industry also company larger market cap have perform well first pick be eli lilly company lly free report indianapoli base company have earning esp zack rank hold see complete list today zack rank strong buy stock here zack consensus estimate third quarter be share company have mixed earning surprise record fact lilly earning surpass expectation last quarters average negative surprise lilly be schedule report result oct next choice be pfizer inc pfe free report carry zack rank stock have earning esp zack consensus estimate third quarter be peg cent share new york base pfizer have mixed earning surprise track record average negative earning surprise trail quarters be pfizer be schedule announce result oct astrazeneca plc azn free report too have impressive track record company consistently beating earning expectation company earning surpass estimate last quarters average positive surprise look poise beat expectation third quarter well london uk base company carry zack rank have earning esp zack consensus estimate be peg cent share astrazeneca be schedule report result nov bristol myer squibb company bmy free report be solid bet zack rank stock have earning esp new york base company deliver average positive earning surprise trail quarters bristol myer be schedule release result oct zack consensus estimate third quarter peg cent share brentford uk base glaxosmithkline plc gsk free report make list likely outperformer third quarter virtue zack rank earning esp zack consensus estimate be peg cent share glaxo be expect report result oct bottom line challenge form competitive pricing pressure remain however number company healthcare space have fared well pick outperformer space backed solid zack rank positive earning esp lead investor gain earning season stock watch massive equifax stock spiked recent news datum breach affect american stock be best buy candidate right now do future hold cybersecurity industry equifax be just most recent victim computer hacking identity theft be more common ever zack have just release cybersecurity investor guide inform zack com reader year space more importantly highlight cybersecurity pick strong profit potential get new investing guide now
1133,LLY,major news cancer segment week be failure eli lilly company lly free report newly approve breast cancer drug verzenio pivotal lung cancer study latest failure lilly join list large pharma company have fail respective lung cancer pivotal study recent past however verzenio be grant priority review status first line treatment breast cancer meanwhile fda grant breakthrough therapy designation astrazeneca plc azn free report tagrisso egfr mutation positive small cell lung cancer nsclc well astella leukemia candidate gilteritinib also abbvie seattle genetic announce collaboration agreement strengthen oncology pipeline let see news detail key newseli lilly company face yet pipeline setback phase iii juniper study fail meet primary endpoint overall survival study be compare verzenio roche astella pharma tarceva patient stage iv nsclc have kra mutation lilly announce fda have grant priority review new drug application nda seek approval first line treatment advanced breast cancer verzenio be approve treat metastatic breast cancer last month patient disease progressed platinum base chemotherapy read more verzenio fail phase iii lung cancer study eli lilly company price consensus eli lilly company price consensus eli lilly company tagrisso be grant breakthrough therapy designation first line treatment metastatic nsclc egfr mutation week company be develop drug phase iii study flaura compare standard care soc egfr tyrosine kinase inhibitor tki therapy datum study be present earlier astrazeneca also announce european medicine agency have accept marketing authorization application maa imfinzi treatment locally advanced unresectable small cell lung cancer astrazeneca plc price consensus astrazeneca plc price consensus astrazeneca plc quoteseattle genetic inc sgen free report partner astella pharma initiate phase ii study enfortumab vedotinin locally advanced metastatic urothelial cancer meanwhile seattle genetic announce clinical collaboration evaluate sgn liv triple negative breast cancer tnbc study evaluate sgn liv combination merck co mrk free report keytruda other study evaluate candidate combination standard chemotherapy neoadjuvant treatment read more seattle genetic inks clinical collaboration cancer drug seattle genetic inc price consensus seattle genetic inc price consensus seattle genetic inc quoteother week also see application submit clovis oncology clvs free report label expansion rubracaas maintenance treatment patient platinum sensitive recurrent ovarian cancer fda also grant fast track designation expedite development astella pharma gilteritinib adult patient relapse refractory acute myeloid leukemia be flt mutation positive meanwhile abbvie abbv free report enter research option license agreement turnstone biologic gain right latter next generation oncolytic viral immunotherapy deal be expect boost abbvie immuno oncology potential stock watch massive equifax stock spiked recent news datum breach affect american stock be best buy candidate right now do future hold cybersecurity industry equifax be just most recent victim computer hacking identity theft be more common ever zack have just release cybersecurity investor guide inform zack com reader year space more importantly highlight cybersecurity pick strong profit potential get new investing guide now
1134,LLY,eli lilly company lly free report announce fda have grant priority review new drug application nda verzenio abemaciclib drug be look forward get approve first line treatment advanced breast cancer markedly nda be base positive interim result monarch study study compare abemaciclib combination inhibitor versus inhibitor alone initial endocrine base therapy patient hr advanced breast cancer decision fda be expect june so far year lilly share have underperform industry stock have be industry gain generally priority review designation fda be grant drug have potential provide significant improvement safety effectiveness treatment prevention diagnosis serious disease verzenio cdk inhibitor be such drug be approve fda last week breast cancer indication drug get approve monotherapy treatment hormone receptor positive hr human epidermal growth factor receptor negative advanced breast cancer have prior endocrine therapy chemotherapy metastatic disease combination therapy fulvestrant hr advanced breast cancer patient have disease progression follow endocrine therapy monotherapy submission be base datum monarch study combination application be base datum monarch study remind investor novartis ag nvs free report kisqali be already approve fda drug be used combination inhibitor first line treatment postmenopausal woman hr advanced metastatic breast cancer also astrazeneca plc azn free report breast cancer drug faslodex receive fda approval august label extension first line monotherapy set advanced breast cancer eli lilly company price eli lilly company price eli lilly company quotezack rank stock considerlilly carry zack rank hold better rank stock health care sector include acadium pharmaceutical inc acad free report carry zack rank buy see complete list today zack rank strong buy stock here last day acadium loss share estimate narrow company deliver positive earning surprise trail quarters average beat share price company increase year date stock watch massive equifax stock spiked recent news datum breach affect american stock be best buy candidate right now do future hold cybersecurity industry equifax be just most recent victim computer hacking identity theft be more common ever zack have just release cybersecurity investor guide inform zack com reader year space more importantly highlight cybersecurity pick strong profit potential get new investing guide now
1135,LLY,company pfizer pfe free report merck mrk free report eli lilly lly free report be news week pfizer be mull strategic option consumer healthcare business merck say not file cetp inhibitor recap week most important storiespfizer divest consumer healthcare segment pfizer be currently review different strategic option consumer healthcare business include full partial separation spin sale company also ultimately decide retain business be not first time pfizer have decide spin sell core business segment strategic step take pfizer include sale hospira infusion system business icu medical february spin animal health business lead creation zoetis well divestment nutrition business nestle pfizer have sell capsugel business affiliate kohlberg kravis robert co divestment consumer healthcare business help pfizer focus innovative health segment also bring fund company use return value shareholder form share buyback dividend read more pfizer consider sale spin consumer healthcare unit pfizer be zack rank hold stock see complete list today zack rank strong buy stock here company have gain year date compare rally industry belong merck collaborate kalvista clinical stage pharma company kalvista pharmaceutical see share shoot collaboration agreement merck kvd future oral diabetic macular edema dme compound base plasma kallikrein inhibition kvd investigational intravitreal ivt injection be schedule move phase ii proof concept study later year merck have option acquire right candidate follow completion study merck have similar option certain other dme candidate kalvista receive refundable upfront payment well payment associate exercise option merck achievement milestone program add company also stand receive tiered royalty net sale candidate commercialize deal merck also acquire ownership stake kalvista worth pipeline setback lilly lilly suffer setback recently approve breast cancer drug verzenio fail meet primary endpoint late stage study kra mutate advanced small cell lung cancer cdk inhibitor fail meet primary endpoint overall survival os analysis secondary endpoint progression free survival pfs overall response rate orr show evidence monotherapy activity read more lilly verzenio fail phase iii lung cancer study meanwhile verzenio have be grant priority review fda use initial treatment advanced breast cancer mean response agency be month receive regulatory application instead usual timeframe month seek fda nod new prostate cancer treatment johnson johnson janssen biotech be seek fda approval apalutamide investigational next generation oral androgen receptor ar inhibitor man metastatic castration resistant prostate cancer crpc be significant unmet need patient population give absence fda approve treatment patient prostate cancer most common cancer american man be expect be diagnosed more man american cancer society apalutamide become part pipeline follow acquisition privately hold aragon pharmaceutical apalutamide approval strengthen expand presence prostate cancer market company currently sell zytiga be approve use combination prednisone treatment patient metastatic castration resistant prostate cancer mcrpc be look expand zytiga label earlier stage metastatic prostate cancer allergan settle restasis litigation innopharma allergan agn free report enter settlement agreement innopharma related litigation regard restasis patent challenged patent be list orange book be schedule expire aug settlement agreement innopharma start selling generic version eye drug unite state feb earlier certain circumstance moreover certain circumstance innopharma be allow launch authorize generic version restasis aug allergan be adopt different way protect restasis generic competition company recently come fire enter agreement saint regis mohawk tribe lawmaker question unconventional move adopt company protect blockbuster eye drug generic competition restasis be allergan second best selling drug bring sale almost lawmaker point sovereign status native american tribe make patent challenge lengthy complex tribe be immune legal claim make generic drug maker challenge patent fact tribe be filing dismiss ongoing parte review ipr restasis patent base sovereign immunity ipr challenge deal tribe have basically raise concern curb generic competition pharmaceutical industry discourage generic drugmaker make cheaper copy cat version expensive drug allergan have be ask committee oversight government reform provide certain document information deal oct merck not file anacetrapib merck have decide not seek regulatory approval investigational cetp inhibitor anacetrapib company decision be base thorough review clinical profile drug note merck be not first company drop cetp inhibitor plan company lilly roche pfizer have have high profile setback cetp inhibitor class be more less written read more merck not seek approval cetp inhibitor anacetrapib crl acelrx acelrx pharmaceutical acrx free report share plunge company get complete response letter crl fda sufentanil sublingual tablet fda say approve regulatory application current form have ask additional safety datum agency have also ask company make certain change direction use ensure proper administration tablet acelrx have be ask validate same human factor study acelrx be look get approve reduction moderate severe acute pain dose error associate iv administration invasive single dose applicator sda medically supervised setting cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index gain week major stock be lilly decline last month bristol myer squibb bmy free report be see last pharma stock roundup here mylan teva copaxone news lawmaker question allergan deal next pharma world aerie pharmaceutical aeri free report rhopressa be evaluate fda advisory panel treatment patient open angle glaucoma ocular hypertension october company share be favorable briefing document be report earning october read more kickstart pharma earning store stock watch massive equifax stock spiked recent news datum breach affect american stock be best buy candidate right now do future hold cybersecurity industry equifax be just most recent victim computer hacking identity theft be more common ever zack have just release cybersecurity investor guide inform zack com reader year space more importantly highlight cybersecurity pick strong profit potential get new investing guide now
1136,LLY,world diabetes day be celebrate year november theme year be woman diabetes right healthy future focus be emphasize importance provide woman diabetic well risk be diagnosed diabetes affordable equitable access essential diabetes drug technology self management education information need achieve optimal diabetes outcome strengthen capacity prevent type ii diabetes ninth lead cause death woman world diabetes account death year accord information provide international diabetes foundation idf more woman have diabetes figure expect rise more woman be reproductive age birth be affected gestational diabetes gestational diabetes be associate higher risk type ii diabetes mother well child moreover many person type ii diabetes remain unaware condition long period time lead diabetes related complication time disease be diagnosed woman type ii diabetes be consider be time more likely suffer heart disease compare woman condition other diabetes related complication include blindness lower limb amputation kidney failure give statistic complication be not surprising several healthcare company devote significant amount dollar develop treatment device diabetes diabetes management diabetes market be highly crowd company come innovative treatment promising higher efficacy lower side effect currently available diabetes drug include different class treatment dpp inhibitor januvia onglyza trajenta glp receptor agonist victoza sglt invokana farxiga apart metformin insulin addition drug diabetes care market include glucose monitoring system insulin delivery system well insulin pump stock watch world diabetes world diabetes day here be look key pharma company diabetes market denmark base nordisk nvo free report be key player global diabetes market company diabetes portfolio comprise product tresiba once daily new generation insulin xultophy once daily single injection combination tresiba victoza ryzodeg soluble formulation tresiba novolog fiasp fast act mealtime insulin new formulation novolog victoza glp recent development include victoza tresiba label update victoza label now reflect prevention cardiovascular event tresiba eu label reflect significant reduction risk severe hypoglycemia well positive fda advisory panel vote semaglutide approval come later quarter however pricing pressure unite state remain major challenge diabetes care market intense competition globe also remain headwind share nordisk have gain year date significantly outperform industry rally nordisk be zack rank hold stock see complete list today zack strong buy rank stock here french drugmaker sanofi sny free report be key player diabetes market however company diabetes franchise be pressure key product lantus face increase competitive pressure payor level biosimilar competition several european market toujeo apidra amaryl lyxumia soliqua be other diabetes product company portfolio sanofi expect global diabetes sale decline annually constant exchange rate timeframe pricing pressure increase competition formulary exclusion continue impact segment challenge diabetes market sanofi continue work expand strengthen diabetes portfolio currently have diabetes candidate pipeline include sar glp gipr dual agonist phase type ii diabetes sar glp gcgr dual agonist phase ii type ii diabetes sotagliflozin oral sglt inhibitor phase iii type type ii diabetes sar rapid act insulin phase iii type ii diabetes efpeglenatide long act glp receptor agonist phase iii type ii diabetes schedule commence quarter late stage combination study sotagliflozin type ii diabetes be schedule commence quarter share sanofi be year date compare industry rally diabetes new cardiovascular metabolic disease be growth platform astrazeneca plc azn free report key product astrazeneca diabetes portfolio include farxiga onglyza bydureon other recent approval include improve device bydureon bydureon bcise combination farxiga bydureon type ii diabetes astrazeneca diabetes franchise sale unite state be also feel impact intense pricing pressure competition share astrazeneca zack rank stock be year date compare industry rally eli lilly company lly free report be well know player diabetes market lilly have strong portfolio diabetes treatment include trulicity glp jardiance sglt trajenta humulin basaglar humalog glyxambi company have diabetes alliance boehringer ingelheim several product lilly also have strong diabetes pipeline company expect pricing pressure continue diabetes market exclusion jardiance cvs health formulary also impact company diabetes franchise sale share lilly be year date compare industry rally lilly be also zack rank stock merck co inc mrk free report diabetes franchise account third quarter pharma segment sale consist product januvia janumet however peer merck diabetes segment sale continue be affected pricing pressure merck partner pfizer pfe free report be currently seek fda approval ertugliflozin fix dose combination product ertugliflozin januvia ertugliflozin metformin response fda expect december merck be also zack rank stock company share have decline year date compare industry rally diabetes market be currently face intense pricing pressure competition market remain lucrative consider grow prevalence disease demand new better treatment today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1137,LLY,earning remain focus week company astrazeneca azn free report report third quarter result meanwhile company roche rhhby free report merck co inc mrk free report be news due regulatory update recap week most important storiesmixed result astrazeneca astrazeneca third quarter result be mixed company miss earning beating revenue company have several pipeline event line come quarters include datum cancer drug lynparza imfinzi well regulatory submission moxetumomab pasudotox leukemia selumetinib thyroid cancer other read more astrazeneca miss earning tweak ep view fda nod merck cmv drug merck gain fda approval prevymis letermovir prevention cytomegalovirus cmv infection disease adult allogeneic hematopoietic stem cell transplant hsct patient common potentially serious viral infection allogeneic hsct recipient level cmv infection be associate increase mortality hsct patient merck say prevymis be first new cmv medicine be approve unite state year merck intend launch drug december list price day tablet injection merck be zack rank hold stock see complete list today zack rank strong buy stock here sanofi sign ms deal worth sanofi sny free report have enter agreement principia biopharma inc latter clinical stage blood brain barrier cross oral btk inhibitor prn have potential be develop treatment multiple sclerosis ms other central nervous system cns disease sanofi be willing shell include upfront payment balance be payable achievement milestone principia also earn royalty product sale moreover company have option co fund late stage development cost exchange higher royalty global sale profit loss sharing arrangement unite state sanofi already have presence ms market form lemtrada aubagio glaxo file nucala label expansion unite state glaxosmithkline plc gsk free report be look expand label il antagonist nucala mepolizumab be currently approve fda add maintenance treatment patient severe asthma age year older eosinophilic phenotype glaxo be now seek fda approval drug be used add maintenance treatment patient have chronic obstructive pulmonary disease copd eosinophilic phenotype accord information provide company copd be estimate affect person world be currently fourth lead cause death world however give prevalence become third lead cause death glaxo have also file fda approval nucala treatment adult patient eosinophilic granulomatosis polyangiitis egpa roche lung cancer drug get fda nod first line set roche gain fda approval lung cancer drug alecensa alectinib first line treatment person specific type lung cancer label expansion be base phase iii datum show alecensa significantly extend time person live disease worsening compare xalkori crizotinib risk cancer spread grow brain central nervous system be also significantly lower alecensa arm approval expand patient population alecensa significantly treatment previously be approve second line set roche also gain fda approval melanoma drug zelboraf treatment erdheim chester disease ecd rare blood disease roche have gain year date compare rally industry belong cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index decline marginally week major stock eli lilly lly free report be astrazeneca be last month johnson johnson jnj free report be glaxo decline see last pharma stock roundup here pfizer teva earning novartis seek new indication kymriah next pharma world third quarter earning season almost watch regulatory pipeline news pharma stock more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1138,LLY,total earning total healthcare market capitalization be revenue growth earning growth appear solid compare many other sector earning revenue beat ratio respectively look disappointing most notable player johnson johnson jnj free report be first major drug company report earning oct follow eli lilly company lly free report bristol myer squibb company bmy free report oct oct respectively other major drug company merck mrk free report pfizer pfe free report report oct oct respectively industry prime post solid result earning revenue beat johnson johnson earning world biggest maker healthcare product continue long streak earning beat earning share come cent ahead zack consensus estimate higher year quarter revenue grow year year edge past zack consensus estimate johnson johnson raise full year earning share guidance revenue guidance read healthcare etfs focus johnson johnson earning pfizer earning drug giant come earning beat line revenue earning share cent come couple cent zack consensus estimate revenue be line estimate year year basis earning share revenue rise respectively pfizer narrow revenue guidance range raise earning share guidance range merck earning focusmerck beat earning estimate miss revenue earning share come surpass zack consensus estimate improve year quarter revenue decline year year be zack consensus estimate merck raise revenue guidance earning share guidance year bristol myer earning focusbristol myer miss earning beat revenue report earning share cent couple cent estimate revenue grow edge past zack consensus estimate company raise earning share guidance see healthcare etfs here eli lilly earning focuseli lilly top zack consensus estimate front earning outpaced zack consensus estimate couple cent come higher year quarter revenue grow beat estimate other drug maker eli lilly also raise revenue earning guidance now expect revenue range compare previous expectation earning share range versus expect previously etf string earning beat fail boost pharma etfs see rough trading past month have highlighted detail fund have zack etf rank hold high risk outlook powershare dynamic pharmaceutical fund pjp free report be far most popular choice pharma space follow dynamic pharmaceutical intellidex index product have aum see lower volume share day fund charge bps fee expense hold stock fund invest share focus firm etf have lose month ishare pharmaceutical etf ihe free report etf provide exposure pharma stock tracking dow jone select pharmaceutical index focus firm be top holding basket accounting combine total asset suggest heavy concentration product have aum charge bps fee expense volume be light exchange share day fund have shed month read lie store pharma etfs spdr pharmaceutical etf xph free report fund provide exposure pharma company tracking pharmaceutical select industry index aum trade good volume share day charge bps fee year total product hold security focus firm take nearly share product be same period vaneck vector pharmaceutical etf pph free report etf follow mvis list pharmaceutical index hold stock basket johnson johnson pfizer bristol myer eli lilly account least share merck make asset product have amassed asset base trade moderate volume share day expense ratio come fund have lose month want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
1139,LLY,celldex therapeutic inc cldx free report incur third quarter loss adjust time item cent share be narrower zack consensus estimate loss cent well year loss cent share lower cost higher revenue lead narrower loss quarter total revenue quarter rise year year beating zack consensus estimate manufacturing service agreement international aids vaccine initiative lead higher revenue quarter share biotech company rise hour trading tuesday however stock have not do too well year so far have decline year date increase register industry research development expense decline year period due lower varlilumab contract manufacturing clinical study expense general administrative spend decline due lower commercial plan cost stock base compensation expense sep celldex have cash cash equivalent marketable security compare jun celldex expect cash net proceed raise sale common stock month agreement cantor be enough fund work capital requirement plan operation pipeline updatecelldex most advanced pipeline candidate be antibody drug conjugate glembatumumab vedotin currently be evaluate treatment triple negative breast cancer phase iib metric study metastatic melanoma phase ii enrolment key metric study close august datum expect second quarter melanoma study celldex add new cohort glembatumumab varlilumab arm glembatumumab checkpoint inhibitor arm include bristol myer bmy free report opdivo merck mrk free report keytruda apart glembatumumab vedotin other promising candidate pipeline include varlilumab cdx phase advanced renal cell carcinoma other varlilumab be be evaluate combination opdivo phase ii study include cohort indication colorectal cancer ovarian cancer head neck squamous cell carcinoma renal cell carcinoma glioblastoma celldex plan complete enrolment cohort phase ii portion study first quarter earning release celldex announce datum phase ii study evaluate combination glembatumumab vedotin varlilumab melanoma patient have progressed checkpoint inhibitor eligible patient only have confirm partial response patient have partial response single timepoint median progression free survival be month patient have stable disease week more full datum set be present society immunotherapy cancer sitc annual meeting week kolltan acquisition nov celldex gain right kolltan cancer pipeline candidate cdx cdx cdx be be evaluate phase study refractory stromal tumor gist other kit positive tumor phase ii study cdx patient recurrent metastatic head neck squamous cell cancer be refractory eli lilly lly free report bristol myer erbitux be expect be initiate year end celldex carry zack rank hold see complete list today zack rank strong buy stock here celldex therapeutic inc price consensus ep surprise celldex therapeutic inc price consensus ep surprise celldex therapeutic inc quotewall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1140,LLY,merck co inc mrk free report announce pd therapy keytruda have receive approval european commission ec first second line treatment certain patient locally advanced metastatic urothelial carcinoma type bladder cancer keytruda have be approve first line therapy patient receive standard care chemotherapy contain cisplatin keytruda be also approve second line treatment patient have be previously treat platinum contain approval be expect july committee medicinal product human use chmp european medicine agency ema have grant positive opinion recommend approval keytruda unite state keytruda receive accelerate approval advanced bladder cancer indication year approval be base datum phase ii keynote trial phase iii keynote trial datum study have show clinically meaningful improve overall survival benefit keytruda versus chemotherapy difficult treat population keytruda be presently approve many type cancer treatment setting include lung cancer melanoma head neck cancer classical hodgkin lymphoma bladder cancer keytruda bring sale second quarter sequentially year year sale continue be drive launch new indication globally keytruda sale gain particularly strong momentum new indication first line lung cancer outside keytruda sale be primarily drive melanoma indication meanwhile keytruda development program also significantly advanced first half regulatory approval new indication additional indication europe important approval include advanced bladder cancer advanced microsatellite instability high cancer first approval combination therapy eli lilly company lly free report cancer drug alimta pemetrexed carboplatin pem carbo commonly used chemo regimen lung cancer further keytruda datum readout be pending second half keytruda be continuously grow expand new indication market globally keytruda be be study more type cancer more study include more combination study merck be collaborate several company include amgen inc amgn free report incyte glaxo pfizer inc pfe free report separately evaluation keytruda combination other regimen merck share have rise year so far increase industry merck carry zack rank hold see complete list today zack rank strong buy stock here surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
1141,LLY,radius health inc rdus free report post loss share third quarter wider loss share year quarter zack consensus estimate loss year year increase net loss be attributable increase general administrative expense radius health inc price ep surprise radius health inc price ep surprise radius health inc quoteradius health share price have decrease last month compare industry fall company report sale tymlos abaloparatide license revenue come however total revenue miss zack consensus estimate quarter detailresearch development expense report quarter be year year due decrease vasomotor project related spending decline abaloparatide sc project cost fall elacestrant rad oncology project cost general administrative expense report quarter jump increase be primarily result increase approximately professional fee support cost include cost associate increase headcount prepare tymlos unite state higher compensation expense include stock base compensation due increase headcount be also responsible increase cost pipeline fda approve tymlos abaloparatide injection treatment postmenopausal woman high risk osteoporosis fracture company be develop formulation abaloparatide sc abaloparatide transdermal radius health announce positive top line result complete month activextend clinical trial tymlos meet primary secondary endpoint company expect submit snda fda connection activextend result year end company also plan initiate clinical trial man osteoporosis successful form basis snda seek expand label treat man osteoporosis high risk fracture study be expect be initiate first quarter meanwhile radius health marketing authorisation application eladyno abaloparatide sc treatment postmenopausal woman osteoporosis europe be review committee medicinal product human use chmp european medicine agency company however suffer setback chmp issue second day list outstanding issue consequently radius health be work chmp address issue company expect response prior end company schedule meeting fda january align regulatory pathway pivotal study abaloparatide td meanwhile company discuss regulatory pathway elacestrant breast cancer meeting fda indicated depend study result demonstrate improvement available therapy plan single arm phase trial be consider pivotal study accelerate approval however confirmatory study be ongoing time nda submission radius health provide further study detail phase study be initiate expect early fda also grant fast track designation elacestrant october candidate be also be evaluate low dose estrogen receptor ligand potential relief frequency severity moderate severe hot flash postmenopausal woman vasomotor symptom update be provide end company wider expect loss third quarter be disappointing expense continue increase tymlos potential label expansion drug further boost performance osteoporosis market unite sate have great potential approximately postmenopausal woman experience osteoporotic fractur year tymlos be expect face significant competition eli lilly co lly free report forteo amgen inc amgn free report prolium moreover approve label carry box warning osteosarcoma malignant bone tumor company also setback chmp issue second day list outstanding issue zack rank key pickradius health currently carry zack rank hold better rank stock healthcare sector be exelixis inc exel free report currently carry zack rank buy see complete list today zack rank stock strong buy here exelixis report strong result third quarter earning share estimate inched cent cent last day company have deliver positive earning surprise trail quarters average beat look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1142,LLY,incyte corporation incy free report report strong result third quarter earning sale top estimate incyte report earning cent share beating zack consensus estimate cent lower year quarter report figure cent quarterly revenue be year year beat zack consensus estimate top line be drive higher sale jakafi unite state iclusig europe well royalty sale jakavi olumiant outside unite state incyte share have moved year so far compare industry gain quarter detailjakafi sale grow year year drive strong patient demand indication net product revenue iclusig amount year quarter product royalty revenue novartis ag nvs free report jakafi ex market grow research development expense be year quarter increase be primarily due expansion portfolio well upfront milestone expense related collaboration license agreement selling general administration sg expense amount year year outlook updatedbased strong performance so far company up guidance jakafi now expect revenue range earlier project range iclusig revenue be still expect range expense be now expect range earlier forecast due acceleration phase iii plan epacadostat sg expense be still expect range incyte corporation price ep surprise incyte corporation price ep surprise incyte corporation quotepipeline updateresult phase iii trial reach evaluate jakafi treatment patient steroid refractory chronic graft versus host disease gvhd be expect first half assume positive result incyte plan submit snda seek accelerate approval jakafi indication phase iii trial gravita itacitinib patient treatment naïve acute gvhd be initiate july phase iii trial echo evaluate epacadostat keytruda patient unresectable metastatic melanoma be now fully recruit datum be expect first half european commission approve olumiant february treatment moderate severe active rheumatoid arthritis adult patient have respond inadequately be intolerant more disease modify rheumatic drug drug be approve japan too however company suffer setback fda issue complete response letter olumiant seek additional clinical datum determine appropriate dosage fda further state additional datum be necessary further characterize safety concern treatment arm august partner eli lilly lly free report announce nda be submit january earlier anticipate concurrent third quarter result incyte announce expansion collaboration agreement astrazeneca plc azn free report global biologic research development arm medimmune company evaluate efficacy safety epacadostat combination astrazeneca imfinzi durvalumab human monoclonal antibody direct pd compare imfinzi alone company conduct phase iii trial patient locally advanced stage iii unresectable small cell lung cancer nsclc disease have not progressed follow platinum base chemotherapy concurrent radiation therapy crt trial be expect begin first half cost be share takeincyte beat earning sale third quarter strong jakafi performance jakafi sale be drive patient demand increase sale guidance be also encourage inclusig also perform well exceed expectation go forward label expansion jakafi gvhd further boost sale meanwhile partner lilly plan resubmit nda olumiant earlier expect potential approval further boost top line zack rankincyte currently carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1143,LLY,abbvie inc abbv free report report mixed result third quarter company surpass earning estimate post line revenue period importantly company raise long term sale expectation blockbuster rheumatoid arthritis drug humira rise competition market response share nudge almost pre market trading year so far abbvie share have surge significantly outperform industry rally company report third quarter earning share beating zack consensus estimate bottom line grow year year company post revenue report quarter have meet zack consensus estimate revenue also increase year year exclude favorable impact foreign exchange rate fluctuation operational revenue climb quarter detailkey drug humira record sale growth operational basis revenue come sale unite state rally humira sale ex market be operational basis report basis growth major market category drive upside increase competition new class drug well indirect biosimilar competition international market third quarter net revenue imbruvica stand year year sale imbruvica be compare year figure abbvie record international profit sharing johnson johnson jnj free report other product deliver impressive performance include duodopa show revenue growth operational report basis product call creon witness increase revenue operational report basis hcv chronic hepatitis virus product record sale operational report basis respectively downside be attributable intense pricing competitive pressure hcv market adjust sg expense be expense escalate quarter adjust operate margin be sale report quarter abbvie announce hike quarterly dividend cent share cent share increase payment begin dividend payable february next year outlookabbvie raise adjust earning range compare expect previously earning guidance reflect year year growth mid point zack consensus estimate be currently peg share long term guidanceabbvie project adjust ep range show approximate rally mid point revise range outlook abbvie estimate humira generate global sale higher predict previously several company be work biosimilar version humira amgen amgn free report humira biosimilar receive fda approval september launch be delay due settlement patent dispute abbvie make humira free competition few more year also abbvie have robust intellectual property be expect generate positive sentiment investor zack rank key picksabbvie currently carry zack rank hold better rank stock health care sector be eli lilly company lly free report carry zack rank buy see complete list today zack rank strong buy stock here eli lilly earning share estimate increase last day company deliver positive earning surprise trail quarters average beat wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1144,LLY,merck co inc mrk free report report second quarter earning share easily beat zack consensus estimate cent earning also rise year period revenue quarter increase year year beating zack consensus estimate currency movement negatively impact revenue exclude currency impact sale rise year year quarter pharmaceutical segment post revenue exclude fx impact year year mainly backed strong sale pd inhibitor keytruda keytruda bring sale second quarter sequentially year year sale continue be drive launch new indication globally keytruda sale gain particularly strong momentum new indication first line lung cancer approve oct last month be series regulatory approval label expansion keytruda drive sale go forward important approval include advanced bladder cancer advanced microsatellite instability high cancer first approval combination therapy eli lilly company lly free report cancer drug alimta pemetrexed carboplatin pem carbo lung cancer however earlier month pivotal phase iii study keytruda head neck squamous cell carcinoma fail meet primary endpoint overall survival also combination study keytruda multiple myeloma be place clinical hold month follow report death keytruda group meanwhile competition immuno oncology market be rise follow recent fda approval pfizer inc pfe free report bavencio avelumab merkel cell carcinoma mcc bladder cancer astrazeneca plc azn free report imfinzi durvalumab bladder cancer zepatier bring sale previous quarter attributable ongoing launch globally bridion sugammadex injection generate sale quarter year year drive strong uptake launch meanwhile combine sale remicade lose exclusivity europe face stiff biosimilar competition region cubicin lose patent protection jun zetia lose market exclusivity dec vytorin lose exclusivity apr decline quarter sale isentress januvia janumet diabetes franchise also decline quarter remicade sale decline quarter merck market brand version remicade outside johnson johnson jnj market rheumatoid arthritis drug week merck launch renflexis biosimilar version remicade cubicin sale plunge quarter zetia vytorin franchise record sale due loss exclusivity zetia vytorin januvia janumet franchise record sale quarter year quarter due lower sale due pricing pressure lower customer inventory level isentress sale decline quarter lower volume demand due competitive pressure be hurt sale isentress vaccine sale be primarily drive increase gardasil pneumovax vaccine vaccine sale be also boost addition approximately gardasil sale terminate vaccine joint venture sanofi gardasil gardasil sale climb drive strong demand asia pacific favorable timing sale brazil merck animal health segment post revenue exclude fx impact year quarter primarily drive higher sale companion animal product margin gross margin come basis point bps quarter attributable favorable effect product mix lower inventory offsmarketing administrative expense increase report quarter research development spend increase quarter guidancedespite lower expectation negative impact currency exchange rate company maintain previously adjust earning guidance raise sale guidance marginally company expect adjust earning range include approximately negative foreign exchange impact versus previously revenue be expect range compare earlier forecast include negative currency impact approximately versus previously operate expense be expect increase year year mid single digit rate compare low single digit rate expect previously takemerck second quarter earning be encourage company beat sale earning strong performance new product keytruda bridion zepatier higher sale vaccine animal health franchise offset lower sale diabetes franchise loss market exclusivity many drug merck share have rise year so far compare unfavorably increase industry merck also announce cancer collaboration astrazeneca jointly commercialize develop latter parp inhibitor lynparza monotherapy combination study multiple cancer type lynparzais presently market advanced ovarian cancer meanwhile merck independently develop combination medicine lynpraza keytruda deal merck pay total consideration include upfront payment merck also say network cyber attack june disrupt global operation result temporary delay fulfill order product merck company inc price consensus ep surprise merck company inc price consensus ep surprise merck company inc quotemerck carry zack rank buy see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1145,LLY,industrial good manufacturer idex corporation iex free report be schedule report third quarter result close bell oct last report quarter adjust earning beat zack consensus estimate cent idex earning track record have be quite healthy have beaten estimate trail quarters average beat let see thing be shape upcoming quarterly result key factor operation continent idex performance be expose adverse impact macroeconomic cycle unite state international market rise dollar strength unfavorable foreign currency movement be further likely add wo impact bottom line addition company operate highly competitive industry maintain improve competitive position entail continue investment manufacturing engineering quality standard support distribution network involve huge recur expense increase operate cost also reduce idex price control product often lead loss market share decline top line growth lower operate margin impending quarterly result be likely witness trend well affect bottom line be report quarter idex revenue be likely be affected volatility market procure substantial amount raw material component supplier globe make susceptible various operate risk include availability price raw material curtailment change part component interruption production supplier prevailing price level however idex be strive counter muted growth environment improve productivity conduct heavy restructure initiative portfolio same time aim exploit suitable acquisition opportunity fuel inorganic growth momentum acquisition expand geographic reach fill technology gap strengthen foothold exist market expand product line company also aim increase market exposure improve sale mix continually develop new product flexible yet discipline focus expense productivity intend optimize cost structure increase competitiveness reallocate resource improve profitability earning whispersour proven model do not conclusively show idex be likely beat earning quarter do not possess key component stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp represent difference most accurate estimate zack consensus estimate be peg uncover best stock buy sell re report earning esp filter idex corporation price ep surprise idex corporation price ep surprise idex corporation quotezack rank idex have zack rank increase predictive power esp need have positive esp be confident earning surprise note caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision momentum stock considerhere be company want consider model show have right combination element post earning beat quarter apply material inc amat free report have earning esp zack rank see complete list today zack rank stock here eli lilly company lly free report have earning esp zack rank kemet corporation kem free report have earning esp zack rank stock watch massive equifax stock spiked recent news datum breach affect american stock be best buy candidate right now do future hold cybersecurity industry equifax be just most recent victim computer hacking identity theft be more common ever zack have just release cybersecurity investor guide inform zack com reader year space more importantly highlight cybersecurity pick strong profit potential get new investing guide now
1146,LLY,be historic week not just novartis nvs free report also medical community patient fda give nod first gene therapy unite state novartis kymriah mark begin new era treatment cancer other serious life threaten disease recap week most important storiesnovartis get head start car market kymriah approval novartis get huge boost fda approve company car cell therapy kymriah child young adult cell acute lymphoblastic leukemia be refractory have relapse least twice make kymriah first car cell treatment be approve unite state path breaking immunocellular therapy be time treatment used patient own cell fight cancer cancer bone marrow blood progress quickly be most common childhood cancer unite state accord national cancer institute patient year younger be diagnosed year kymriah not only provide patient new treatment option have also show promising remission survival rate study novartis intend seek label expansion kymriah later year additional indication include treatment adult patient diffuse large cell lymphoma also read novartis car therapy kymriah receive fda approval share novartis have gain year date outperform industry rally novartis be zack rank hold stock see complete list today zack rank strong buy stock here allergan settlement agreement famy care restasis allergan agn free report enter settlement agreement famy care be look bring generic version allergan eye drug restasis market patent infringement lawsuit be settle famy care get license market generic version unite state feb earlier certain circumstance patent be schedule expire aug teva austedo nabs fda approval second indication teva pharmaceutical industry teva free report get good news finally company gain fda approval second indication austedo austedo have gain fda approval apr treatment chorea associate huntington disease be now approve treatment dyskinesia adult well dyskinesia debilitating often irreversible movement disorder be estimate affect person unite state also read teva austedo get fda nod label expansion dyskinesia teva be currently go tough time company performance be impact generic pricing erosion teva have many challenge ahead pay debt divest core business increase focus core area generate cash hire permanent ceo deliver pipeline get generic business back track lilly provide baricitinib regulatory update eli lilly company lly free report partner incyte provide update regard resubmission regulatory application unite state experimental rheumatoid arthritis ra treatment baricitinib company have previously say expect delay least month resubmission regulatory application baricitinib announce be resubmit regulatory application jan new safety efficacy datum be include resubmission also read lilly incyte re file baricitinib nda faster expect bayer hemophilia drug submit fda approval bayer ag bayry free report have submit biologic license application bla unite state long act site specifically pegylate recombinant human factor viii bay treatment hemophilia bayer portfolio already include hemophilia product form kogenate approve bay provide patient less frequent dose option astrazeneca inks deal takeda astrazeneca azn free report have sign takeda pharmaceutical joint development medi alpha synuclein antibody be develop parkinson disease pd investigational treatment be schedule enter early stage development later year phase development be conduct astrazeneca future clinical development activity be handled takeda future development cost well future revenue be share company deal term include astrazeneca include initial revenue development sale milestone thereafter parkinson disease second most common disease be estimate affect person world also read astrazeneca takeda ink deal develop parkinson drug cap pharmaceutical industry yr returnlarge cap pharmaceutical industry yr nyse arca pharmaceutical index be last trading session major stock record gain bristol myer squibb rise lilly be baricitinib update last month be merck mrk free report decline see last pharma stock roundup here roche drug get priority review eu nod novartis drug next pharma world watch usual pipeline regulatory update company astrazeneca be present european society medical oncology esmo congress datum presentation approve pipeline candidate more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1147,LLY,eli lilly company lly free report partner incyte corporation incy free report announce re submit new drug application nda rheumatoid arthritis ra drug baricitinib much faster previously expect nda be expect be re submit january next year july lilly have say nda resubmission baricitinib not occur year be delay minimum month time lilly have say evaluate option resubmission include further discussion fda conduct additional clinical study latest press release lilly incyte say matter be discuss fda month lilly expect revise submission include new safety efficacy datum be classify fda class ii resubmission decision fda be therefore expect month importantly new clinical study not be require share incyte be more wednesday lilly be so far year lilly share price have rise compare increase industry fda have issue complete response letter crl baricitinib earlier year april time agency have tell company be unable approve baricitinib nda current form fda have ask additional clinical datum determine most appropriate dose well further characterize safety concern treatment arm baricitinib once daily oral medication be already market eu trade name olumiant drug generate sale second quarter first quarter baricitinib be also be study phase ii study treatment atopic dermatitis systemic lupus erythematosus phase iii program psoriatic arthritis be expect begin next year ra market be highly crowd give presence treatment humira xeljanz other latest entrant crowd market be sanofi inc sny free report regeneron pharmaceutical inc regn free report kevzara be launch junelilly carry zack rank hold see complete list today zack rank strong buy stock here simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
1148,LLY,merck co inc mrk free report announce detailed datum large phase iii cardiovascular outcome study reveal evaluate anacetrapib cholesteryl ester transfer protein cetp inhibitor patient cardiovascular disease datum phase iii study show anacetrapib statin reduce risk major coronary event composite coronary death myocardial infarction coronary relative placebo patient atherosclerotic vascular disease be already receive effective cholesterol treatment anacetrapib reduce risk same be patient placebo statin however significant benefit be observed reduce risk ischemic stroke detailed datum be publish new england journal medicine present european society cardiology congress merck share have rise year so far compare unfavorably increase industry top line datum study be announce june company say study have meet primary endpoint also say cetp inhibitorled significant reduction major coronary eventsversus placebo patient high risk cardiovascular event be already receive effective cholesterol treatment however detail have only be mentioned now company funded reveal study be conduct more patient be take atorvastatin common medicine lower bad cholesterol ldl median duration least year be also say anacetrapib safety profile be line observed previous study most significant side effect be accumulation anacetrapib fat tissue year take drug announce june merck be not sure datum be strong enough seek approval plan review result external expert company then consider file regulatory application fda other agency remind investor previous experimental cetp inhibitor have fail respective study cetp inhibitor be design raise hdl cholesterol level be know good cholesterol eli lilly company lly free report terminate development late stage cetp inhibitor evacetrapib base recommendation independent datum monitoring committee suggest chance meeting primary endpoint be low back pfizer inc pfe free report have suspend late stage development cetp inhibitor torceptrapib due safety issue roche rhhby free report discontinue development cetp inhibitor dalcetrapib due lack efficacy however uncertainty regard not company actually file datum regulator remain be apprehend accumulation anacetrapib fat tissue get way regulatory approval merck carry zack rank hold see complete list today zack rank strong buy stock here surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
1149,LLY,merck co inc mrk free report announce be not go ahead filing regulatory application seek approval anacetrapib cholesteryl ester transfer protein cetp inhibitor have develop cholesterol management stock be more wednesday merck share have rise year so far compare increase industry detailed datum large phase iii cardiovascular outcome study reveal announce august show anacetrapib statin reduce risk major coronary event composite coronary death myocardial infarction coronary relative placebo patient atherosclerotic vascular disease be already receive effective cholesterol treatment anacetrapib reduce risk same be patient placebo statin however significant benefit be observed reduce risk ischemic stroke top line datum study be announce june company say study have meet primary endpoint be also say anacetrapib safety profile be line observed previous study most significant side effect be accumulation anacetrapib fat tissue year take drug merck have clearly say then be not sure datum be strong enough seek approval merck say consider file regulatory application fda other agency review result external expert be apprehend investor accumulation anacetrapib fat tissue get way regulatory approval follow thorough evaluation datum discussion external expert merck decide not seek approval anacetrapib clinical profile do not support regulatory filing remind investor previous experimental cetp inhibitor have fail respective study cetp inhibitor be design raise hdl cholesterol level be know good cholesterol eli lilly lly free report terminate development late stage cetp inhibitor evacetrapib base recommendation independent datum monitoring committee suggest chance meeting primary endpoint be low back pfizer pfe free report suspend late stage development cetp inhibitor torceptrapib due safety issue roche rhhby free report discontinue development cetp inhibitor dalcetrapib due lack efficacy merck carry zack rank sell see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1150,LLY,series setback continue eli lilly company lly free report company announce phase iii juniper study fail meet primary endpoint study be evaluate verzenio advanced small lung cancer nsclc kra mutation share fall tuesday announcement verzenio receive approval treat metastatic breast cancer last month patient disease progressed platinum base chemotherapy lilly share be so far year slightly underperform industry gain period juniper study compare verzenio roche astella pharma tarceva stage iv lung cancer patient have progressed platinum base chemotherapy have receive additional systemic therapy study do not meet primary endpoint overall survival however show improvement secondary endpoint progression free survival patient overall response rate successful completion study have give verzenio edge pfizer inc pfe free report ibrance novartis ag nvs free report kisqali be only approve breast cancer lilly be currently evaluate verzenio multiple study nsclc include combination therapy merck mrk free report keytruda pd therapy remind investor lilly face major setback past year include complete response letter fda rheumatoid arthritis candidate baricitinib april fail study alzheimer candidate solanezumab november last year meanwhile lilly be also face generic competition due loss exclusivity several key drug include zyprexa cymbalta moreover alimta be face competition immuno oncology agent unite state give recent setback generic competition absence drug near approval lilly struggle maintain growth pace have show so far year eli lilly company price consensus eli lilly company price consensus eli lilly company quotelilly carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1151,LLY,seattle genetic inc sgen free report astella pharma inc announce initiation phase ii study ev enfortumab vedotin study evaluate patient locally advanced metastatic urothelial cancer have be previously treat checkpoint inhibitor cpi therapy enfortumab vedotin be investigational antibody drug conjugate adc target nectin cell adhesion molecule be expressed many solid tumor seattle genetic share have underperform industry year date stock have surge compare industry gain study evaluate antitumor activity safety enfortumab vedotin order get approval fda study enroll patient enfortumab vedotin be administer week duration treatment primary endpoint study be confirm objective response rate orr independent review secondary endpoint include assessment overall survival progression free survival safety tolerability company move ahead ev study base result ongoing phase study ongoing phase study be assess safety tumor activity enfortumab vedotin escalate dose milligram kilogram mg kg weekly week cycle company june announce update datum patient be diagnosed muc median age year patient be previously treat checkpoint inhibitor cpis have undergo treatment platinum base chemotherapy result show positive antitumor activity well tolerate safety profile patient heavily pretreat metastatic urothelial cancer treatment option metastatic urothelial cancer be limit patient do not respond chemotherapy checkpoint inhibitor be therapy approve fda patient progress follow cpi treatment thus see be number company evaluate candidate treatment locally advanced metastatic urothelial cancer last month merck co inc mrk free report announce pd therapy keytruda receive approval european commission ec first second line treatment certain patient locally advanced metastatic urothelial carcinoma type bladder cancer keytruda have be approve first line therapy patient receive standard care chemotherapy contain cisplatin keytruda be also approve second line treatment patient have be previously treat platinum contain chemotherapy eli lilly company lly free report also announce positive result phase iii study range evaluate oncology drug cyramza ramucirumab expand use combination docetaxel patient locally advanced unresectable metastatic urothelial carcinoma study meet primary end point demonstrated improve progression free survival pfs patient give indication seattle genetic inc price seattle genetic inc price seattle genetic inc quotezack rank stock seattle genetic carry zack rank buy top rank stock health care sector include bayer bayry free report see complete list today zack rank strong buy stock here bayer earning share estimate have moved last day company pull positive earning surprise trail quarters average beat be share price company have increase year date wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1152,LLY,second quarter report cycle be full swing quarter undoubtedly be strong start jul member accounting index total market capitalization report result accord earning preview total earning index member be year quarter improvement revenue beat ratio be earning revenue earning momentum be expect continue season report total earning company second quarter be expect grow year year higher revenue follow earning growth first quarter increase revenue highest almost year pharma bigwig eli lilly company lly free report biogen inc biib free report release second quarter result week company beat earning revenue estimate raise sale earning expectation full year moreover vertex pharmaceutical incorporate vrtx free report amgen inc amgn free report report encourage second quarter result jul beating estimate count however glaxosmithkline plc gsk free report report mixed second quarter result same day beating earning miss sale let take look large cap pharma company be set report second quarter result jul abbvie inc abbv free report abbvie be schedule release earning market open have deliver positive earning surprise last quarter abbvie earning performance have be mixed earning beating expectation last quarters meeting same remain result average positive surprise quarter abbvie have earning esp zack rank hold do not conclusively show abbvieis likely beat estimate quarter zack consensus estimate be peg share uncover best stock buy sell re report earning esp filter abbvie inc price ep surprise abbvie inc price ep surprise abbvie inc quoteabbvie key drug humira be perform well be expect continue do well second quarter imbruvica have be record strong sale past few quarters expect trend continue however hcv franchise continue be pricing pressure read more abbvie earning disappointment store merck co inc mrk free report merck be also schedule announce result open bell merck have beaten estimate last quarters result average positive surprise last report quarter merck deliver positive surprise merck company inc price ep surprise merck company inc price ep surprise merck company inc company have earning esp zack rank buy thus do not look poise deliver beat time see complete list today zack rank strong buy stock here merck new product keytruda cancer zepatier hcv bridion sugammadex injection drive top line quarter however company be expect face headwind form genericization increase competition negative impact currency exchange read more merck pull surprise earning season more stock news tech opportunity worth driverless car artifical intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
1153,LLY,yesterday big pharma player eli lilly company lly free report report better expect second quarter result raise outlook year however share be investor focuse company update regard investigational rheumatoid arthritis ra treatment baricitinib here be look few key takeaway lilly conference call do key drug perform lilly second quarter revenue increase year quarter top zack consensus estimate new product trulicity taltz basaglar jardiance lartruvo cyramza perform well drive volume growth late life cycle product ciali forteo drive price growth alimta continue face significant competitive headwind zyprexa cymbalta evista strattera axiron be impact loss exclusivity ciali be also affected lower volume reflect decline overall erectile disorder ed market well presence generic animal health revenue decline quarter reflect market access pressure competitive pressure cattle swine read more lilly earning top baricitinib re filing delay baricitinib face significant delaylilly announce be delay least month resubmission regulatory application baricitinib be be develop collaboration incyte incy free report mean resubmission not take place year fda have issue complete response letter crl baricitinib earlier year april time agency have tell company be unable approve baricitinib once daily oral medication treatment moderate severe ra current form fda have ask additional clinical datum determine most appropriate dose well further characterize safety concern treatment arm lilly disagree fda conclusion believe comprehensive clinical datum support positive benefit risk profile company enter discussion fda determine kind study need better define benefit risk profile baricitinib meanwhile lilly incyte have plan explore baricitinib other indication late stage study psoriatic arthritis slate commence next year study atopic dermatitis lupus continue phase ii atopic dermatitis datum be present scientific forum year end note baricitinib be approve eu trade name olumiant feb european medicine agency ema committee medicinal product human use chmp recently agree label be update include precaution patient have risk factor deep venous thrombosis dvt pulmonary embolism pe oncology strategylilly provide depth look oncology strategy company strategy involve build key treatment cyramza lartruvo abemaciclib foundational agent focus develop new standard care change therapy clear very high bar span variety mechanism include immune oncology now lilly focus candidate priority internal development additional candidate mab csf mab merestinib study datum pending rest molecule pipeline be partner molecule have make lilly priority development list include abemaciclib be already fda review tim mab pd mab erk inhibitor tgfb ri ki pi mtor inhibitor prexasertib molecule be earmark external partner development asset be own third party lilly be look partner remain fgfr adc ralimetinib fgfr inhibitor notch inhibitor galunisertib cxcr peptide antagonist emibetuzumab bottom lilly deliver beat raise quarter company result get overshadowed baricitinib update investor be disappoint delay resubmission baricitinib regulatory filing company say be minimum delay month several product face generic competition competitive pressure increase lilly need focus bring new product market company decision prioritize oncology pipeline make sense lilly be zack rank buy stock see complete list today zack rank strong buy stock here year date lilly share have gain just top industry rally watch earning report other large cap pharma company merck co inc mrk free report pfizer inc pfe free report merck zack rank stock have pretty good earning track record have surpass expectation last quarters average surprise merck be report result jul pfizer track record be mixed company top expectation last quarters pfizer be report aug have positive earning esp second quarter hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1154,LLY,heart earning reason be numerous company provide update firm performance past quarter course beating revenue earning estimate positively affect company financial outlook share price so important investor stay tune right now few key company release impressive quarterly earning report tuesday morning look have potential stir investor interest future earning report not only demonstrate past quarter solid performance also preview financial outlook next operational quarter check company just perform extremely well earning season caterpillar inc cat free report caterpillar post impressive earning surprise adjust earning share compare favorably zack consensus estimate caterpillar report earning be good astounding year year increase drive company discipline cost control effort also caterpillar report revenue beat zack consensus estimate represent year year growth impressive revenue growth be cause rise asia pacific construction sale well gain north america caterpillar earning report also include full year revenue guidance range be increase previously expect range additionally caterpillar now project earning share substantially previous prediction caterpillar currently sport zack rank buy eli lilly company lly free report eli lilly company report adjust earning share surpass zack consensus estimate solid eli lilly earning demonstrate strong year year growth furthermore company post revenue billon surpass zack consensus estimate respectable company report revenue present year year growth revenue increase primarily due high realize price several product such ciali forteo alimta next operational quarter eli lilly project ep fall range also company raise full year revenue expectation range range eli lilly company currently hold zack rank buy rowe price group inc trow free report rowe price group post earning share be modest beat zack consensus estimate however company notch impressive year year ep growth additionally firm report net revenue beat zack consensus estimate rowe price revenue demonstrated strong year year growth asset management massive investment advisor increase quarter represent growth prior year quarter advisory revenue investment portfolio quarter be increase comparable quarter average asset management portfolio increase company do not provide update guidance report investor expect more good thing come zack rank buy stock more stock news tech opportunity worth driverless car artifical intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
1155,LLY,be enter peak period second quarter report cycle week quarter undoubtedly be strong start jul member accounting index total market capitalization report result accord earning preview beat revenue earning estimate compare first quarter total earning index member be year quarter improvement revenue beat ratio be earning revenue earning momentum be expect continue season report total earning company second quarter be expect grow year year higher revenue follow earning growth first quarter increase revenue highest almost year pharma bigwig johnson johnson jnj free report report mixed second quarter result beating earning miss sale other hand novartis nvs free report second quarter result be encourage company top earning sale estimate jul lilly lly free report biogen inc biib free report release second quarter result company beat earning revenue estimate lilly raise previously issue adjust earning sale outlook biogen also raise earning sale outlook let take look pharma giant be set report second quarter result jul let see thing be shape quarter gilead science inc gild free report gilead be schedule release earning close bell have deliver positive earning surprise last quarter gilead earning performance have be mixed earning miss expectation last quarters beating remain result average positive surprise quarter gilead have earning esp zack rank hold indicate likely beat quarter zack consensus estimate be peg share uncover best stock buy sell re report earning esp filter hiv other antiviral product be expect boost sale however hcv franchise continue be pricing pressure read more be gilead poise beat earning season gilead science inc price ep surprise gilead science inc price ep surprise gilead science inc quotevertex pharmaceutical inc vrtx free report vertex be also schedule announce result close bell vertex average positive earning surprise last quarters be last report quarter vertex post positive surprise company have earning esp zack rank strong buy be thus expect beat earning estimate quarter see complete list today zack rank stock here investor focus vertex second conference call be triple combination cystic fibrosis cf regimen be crucial long term growth vertex datum vx vx phase ii vx phase triple combination study present last week have show combination lead pronounce improvement lung function read more be beat card vertex earning vertex pharmaceutical incorporate price ep surprise vertex pharmaceutical incorporate price ep surprise vertex pharmaceutical incorporate plc gsk free report company be expect report market hour glaxosmithkline report line earning last quarter glaxo performance have be pretty impressive company report positive surprise consistently average earning beat last quarters be company have earning esp zack rank glaxo pharmaceutical vaccine segment be expect drive sale second quarter well meanwhile consumer healthcare segment have slow due impact general sale tax continue slowdown nutrition category india challenge economic condition other international market nigerian beverage business divestment factor impact second quarter result well read more lie store glaxo earning season glaxosmithkline plc price ep surprise glaxosmithkline plc price ep surprise glaxosmithkline plc quotemore stock news tech opportunity worth driverless car artifical intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
1156,LLY,biogen inc biib free report announce datum long term study alzheimer disease ad candidate aducanumab datum study show continue benefit rate amyloid decline year period patient prodromal mild alzheimer disease treat aducanumab share be monday response promise show amyloid candidate company say result recently conduct analysis long term extension lte ongoing phase ib study prime aducanumab be consistent previously report datum prime prime be randomize double blind placebo controlled multiple dose phase ib study be conduct evaluate safety tolerability pharmacokinetic pharmacodynamic aducanumab patient suffering prodromal mild ad so far year biogen share have rise industry record increase biogen be conduct other phase iii study engage emerge aducanumab treatment early ad result lte study support design engage emerge study biogen be look strengthen ad other disorder pipeline biogen ad pipeline comprise candidate different mechanism action include tau candidate biib bms potential ad well progressive supranuclear palsy psp amyloid aducanumab candidate well bace inhibitor elenbecestat program however successful development therapy treatment alzheimer disease be challenge note several company have fail develop treatment same november last year eli lilly company lly free report amyloid candidate solanezumab fail meet primary endpoint late stage ad study lilly decide drop development solanezumab lilly suffer major setback aug have halt development phase iii alzheimer candidate semagacestat meanwhile pfizer pfe free report shelved late stage alzheimer candidate bapineuzumab iv fail phase iii study pfizer be develop candidate collaboration johnson johnson jnj free report elan corporation alzheimer disease market represent huge commercial potential successfully develop product generate billion dollar sale once launch biogen have zack rank hold see complete list today zack rank strong buy stock here zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
1157,LLY,pharma biotech stock start strong note part market remain favor year progress so far year nasdaq biotechnology index nyse arca pharmaceutical index be respectively investor be more comfortable drug pricing scenario focus have shift fundamental sector drug pricing issue remain headwind expectation be step take trump administration drive drug price not be draconian previously expect deregulation increase competition seem be way be used control drug price fda be work lower healthcare cost speeding development next generation treatment especially rare disease target cancer therapy be also work clear backlog orphan drug application fda have approve far more drug year do whole key approval year include novartis nvs free report kymriah first gene therapy unite state lilly verzenio advanced metastatic breast cancer gilead gild free report vosevi hepatitis virus puma nerlynx reduce risk breast cancer return tremfya moderate severe plaque psoriasis regeneron sanofi kevzara rheumatoid arthritis roche multiple sclerosis treatment ocrevus regeneron sanofi eczema treatment dupixent tesaro parp inhibitor zejula biomarin brineura treatment specific form batten disease other quite few drug have blockbuster potential meanwhile other factor continue have positive impact pharma biotech stock be new product sale ramp success innovation strong result higher number fda approval continue strong performance legacy product accord zack earning trend report medical sector have be better perform sector last several quarters be expect record earning growth revenue growth third quarter give scenario medical sector earning round corner make sense look pharma biotech stock be expect report positive earning surprise quarter investing such stock prove beneficial investor earning beat usually lead significant share price appreciation drug stock keep eye earning help zack stock screener have zero pharma biotech stock sport zack rank strong buy buy hold have positive earning esp earning esp be very valuable tool investor look stock be most likely beat earning estimate moreover add zack rank have produce positive surprise time see complete list today zack rank stock here uncover best stock buy sell re report earning esp filter pfizer inc pfe free report pfizer be focuse development wide range medicine vaccine well consumer health care product company have surpass earning expectation first quarters key revenue driver include ibrance eliquis xeljanz pfizer expect revenue be affected due loss exclusivity loe be work bring new product market make lose sale company have potential blockbuster line next year half potentially focus also remain grow new product ibrance eliquis xeljanz meanwhile impact loe continue decline come year well less pfizer zack rank stock carry vgm score vgm score be useful tool allow investor gain insight stock strength weakness research show stock vgm score combine zack rank offer best upside potential company be report third quarter result october have earning esp eli lilly company lly free report lilly have strong presence pharmaceutical well animal health segment be slate report third quarter result october zack rank stock have earning esp third quarter lilly surpass earning expectation first quarters company be face challenge include generic competition new product drive result lilly have several important pipeline catalyst line come quarters well estimate earning growth current year be lilly have gain year date compare rally industry belong vertex pharmaceutical vrtx free report vertex key player cystic fibrosis cf market surpass earning expectation last quarters average surprise company hold strong position cf market product orkambi kalydeco portfolio early august vertex have say expect cf franchise deliver revenue include orkambi revenue company be work expand cf portfolio be currently seek fda ema approval tezacaftor ivacaftor combination fda grant priority review response be feb vertex zack rank stock have gain year date substantially outperform rally industry belong company be expect report third quarter result october have earning esp quarter biogen inc biib free report biogen be key name multiple sclerosis ms market several approve product tecfidera tysabri avonex portfolio company also have spinal muscular atrophy product spinraza portfolio be work develop treatment disease alzheimer parkinson amyotrophic lateral sclerosis biogen earning track record be good company surpass earning expectation last quarters average surprise company be schedule report third quarter result october have earning esp last day stock have see zack consensus estimate third quarter current year earning be revise respectively biogen zack rank stock have gain year date outperform rally industry belong merck mrk free report merck zack rank stock have consistently surpass earning expectation last quarters average surprise company be report earning october earning esp be company do have challenge form generic competition well safety issue related study be conduct keytruda new product keytruda strong performance base business provide support merck also have deep pipeline bode well long term growth today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1158,LLY,eli lilly company lly free report announce have inked development deal dexcom inc dxcm free report integrate latter continuous glucose monitoring cgm product tool lilly connect diabetes ecosystem connect diabetes ecosystem connect device technology provide solution cater individual unique need manage diabetes fact device such cgm smart pen insulin pump drug apps other analytical tool link patient care team deal disease better way connect diabetes ecosystem depend lilly core diabetes expertise device tool provide dexcom lilly agreement dexcom enable company reduce daily burden person diabetes study be expect begin end so far year share lilly have increase compare industry gain lilly have strong portfolio diabetes treatment include trulicity glp jardiance sglt trajenta humulin basaglar humalog glyxambi also have diabetes alliance boehringer ingelheim many product company be seek label expansion drug zack rank stock considerlilly carry zack rank hold better rank health care stock same space be sucampo pharmaceutical ligand pharmaceutical lgnd free report carry zack rank buy see complete list today zack rank strong buy stock here sucampo earning share estimate have moved last day company deliver positive earning surprise trail quarters average beat ligand earning share estimate have climb last day company pull positive earning surprise trail quarters average beat share price company have increase year date wall street next amazon zack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
1159,LLY,eli lilly company lly free report report second quarter adjust earning share beat zack consensus estimate earning rise year quarter backed volume drive pharma sale growth higher profit revenue beatquarterly revenue beat zack consensus estimate sale grow year year backed higher volume realize price however foreign exchange pull sale volume rise higher volume new product trulicity taltz basaglar jardiance lartruvo offset lower volume establish product zyprexa alimta ciali strattera pharmaceutical volume rise quarter however worldwide competitive pressure hurt sale lilly animal health segment revenue detailu revenue grow reflect higher volume product trulicity taltz basaglar jardiance lartruvo offset lower volume establish drug ex revenue decline mainly due lower volume increase competition lower realize price higher volume newer product cyramza trulicity be offset lower volume zyprexa cymbalta alimta due loss exclusivity cymbalta have lose exclusivity europe canada zyprexa japan alimta several country lower sale food companion animal product hurt outside sale well establish product record growth quarter include forteo humulin effient alimta sale however decline reflect lower demand due competitive pressure mainly immuno oncology agent outside sale alimta be hurt loss exclusivity several country increase competition lower realize price zyprexa sale decline due loss exclusivity humalog sale decrease quarter due lower realize price volume ciali sale be flat hurt lower demand well increase competition generic sale decline quarter strattera sale decline cymbalta sale decline new product trulicity generate revenue year year revenue benefit growth glp market market share gain cyramza revenue be year year backed mainly higher outside revenue cyramza ex revenue benefit strong volume japan however revenue increase only higher realize price make lower demand due competitive pressure jardiance sale be drive increase market share grow sglt class basaglar record revenue compare previous quarter basaglar lilly partner boehringer ingelheim follow insulin sanofi sny free report blockbuster drug lantus be launch mid dec generate revenue quarter taltz bring sale compare previous quarter reflect strong launch uptake lartruvo olaratumab generate revenue second quarter compare previous quarter lartruvo be launch eu soft tissue sarcoma fourth quarter revenue be compare previous quarter meanwhile lilly partner incyte corporation incy free report rheumatoid arthritis ra drug olumiant baricitinib be approve eu feb drug generate sale second quarter compare previous quarter drug receive marketing approval japan earlier month however company receive complete response letter crl fda april regard new drug application nda baricitinib concurrent earning release lilly announce nda resubmission baricitinib not occur year be delay minimum month company say fda have indicated additional clinical study be need resubmission lilly animal health segment sale decline inclusion revenue acquisition boehringer ingelheim vetmedica feline canine rabies acquire jan animal health revenue be hurt due global competitive pressure affected sale food animal companion animal revenue quarter gross margin operate income riseadjust gross margin quarter increase basis point primarily drive higher realize price manufacturing efficiency operate income increase higher gross margin operate expense remain flat quarter however total operate expense percent revenue decline basis point quarter outlook uppedlilly raise previously issue adjust earning sale outlook adjust earning share be now expect range compare previously revenue be expect range compare expect previously zack consensus estimate earning revenue be share respectively gross margin be expect be approximately lower previously adjust tax rate be still expect be approximately marketing selling administrative expense be still expect range research development expense be project be slightly higher expect previously takelilly second quarter result be strong company beating estimate count pharma giant also raise sale earning outlook year however news delay re filing baricitinib send share almost pre market trading so far year lilly share price have rise compare increase industry company also say build oncology portfolio work develop next generation immunotherapy prioritize development pipeline candidate go forward new product trulicity taltz basaglar cyramza jardiance lartruvo be expect see higher revenue lilly also expect establish product trajenta forteo humalog continue do well however alimta continue be impact competition other headwind include competition immuno oncology agent well loss exclusivity many drug emerge market meanwhile recent high profile pipeline setback be investor concern so be weak performance animal health segment first half lilly carry zack rank buy see complete list today zack rank strong buy stock here eli lilly company price consensus ep surprise eli lilly company price consensus ep surprise eli lilly company quotebiogen inc biib free report also report second quarter result today beat estimate earning sale share be almost pre market trading more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
1160,LLY,third quarter report cycle be witness revenue acceleration positive revision trend result third company member be already revenue beat ratio company be slightly precede quarter be unusually high compare historically total earning member have report already be same period last year higher revenue beating ep estimate accord latest earning preview report company account index total market capitalization report total earning company be expect grow year year higher revenue biotech pharma bigwig eli lilly company lly free report biogen inc biib free report amgen inc amgn free report have report third quarter result week company beat expectation earning sale lilly also raise earning sale outlook amgen slightly raise lower end previously issue sale outlook raise earning guidance back effective cost management however share biogen amgen decline follow result announcement concern regard biogen multiple sclerosis franchise sale well sale recently launch spinal muscular atrophy sma treatment spinraza hurt investor sentiment amgen year year decline sale lead share price fall here have large pharma company be set report third quarter result oct let see thing be shape quarter abbvie inc abbv free report abbvie be schedule release earning market open have deliver positive earning surprise last quarter lilly earning performance have be mixed earning breaking even last quarters beating same other bring average surprise quarter abbvie have earning esp almost zack rank hold zack consensus estimate be peg share uncover best stock buy sell re report earning esp filter company key drug humira be likely remain main growth driver backed higher demand quarter abbvie expect humira sale rise high teen range internationally same be estimate increase mid single digit range operational basis other drug duopa creon be also expect continue perform well soon be report quarter read more abbvie spring surprise earning season abbvie inc price consensus abbvie inc price consensus abbvie inc quotemerck co inc mrk free report merck be schedule release earning market open merckhad deliver positive earning surprise last quarter company earning performance have be pretty impressive so far have deliver positive surprise last quarters average earning beat last quarters be company also have earning esp almost zack rank zack consensus estimate be peg share see complete list today zack rank strong buy stock here merck new product keytruda cancer zepatier hcv bridion sugammadex injection be likely drive top line quarter keytruda sale unite state be gain particularly back strong momentum new indication first line lung cancer read more merck keep earning streak alive previous article show merck be likely beat earning quarter however estimate change thereafter be not certain beat earning season merck company inc price consensus merck company inc price consensus merck company inc quotelook stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1161,LLY,third quarter earning season be strong start result company have report number show earning revenue growth pace be accelerate first quarters particular revenue growth have show significant momentum evident proportion positive revenue surprise total earning index third quarter be expect be higher revenue oct company account index total market capitalization have report result result reveal earning company be year quarter increase revenue beat earning estimate beat revenue estimate medical sector medical sector have perform relatively well date quarter be not go be different estimate company have report so far beat revenue company surpass earning expectation go forward sector be expect record year year growth revenue earning bellwether sector johnson johnson jnj free report report better expect third quarter result raise outlook swiss giant novartis ag nvs free report too beat earning sale back new drug cosentyx entresto eli lilly company lly free report also report better expect result third quarter here have major biotech giant be set report third quarter result oct let see thing be shape gilead science inc gild free report be expect beat expectation report market close zack model stock need have positive earning esp zack rank strong buy buy hold beat zack consensus estimate gilead track record be pretty mixed company beating estimate last miss last quarter company beat expectation overall company record average positive earning surprise gilead currently carry zack rank earning esp combination zack rank positive esp make confident earning beat uncover best stock buy sell re report earning esp filter strong hiv performance other antiviral product sale be be drive continue uptake tenofovir alafenamide taf base product genvoya descovy odefsey expect trend continue third quarter well genvoya have already become most prescribe regimen treatment naïve switch patient launch drive hcv product sale taf base regimen now represent total gilead hiv prescription volume follow launch genvoya odefsey descovy specifically genvoya be now company bestselling hiv product treatment naïve patient share zack consensus estimate genvoya stand strong uptake truvada use pre exposure prophylaxis set be also expect boost sale read more be gilead poise beat earning season gilead science inc price ep surprise gilead science inc price ep surprise gilead science inc quotebristol myer squibb company bmy free report be likely beat expectation report result market open bristol myer track record have be positive so far company deliver positive earning surprise last quarters miss expectation company average positive earning surprise last quarters be company currently carry zack rank earning esp see complete list today zack rank stock here bristol myer high profile immuno oncology drug opdivo be expect be primary sale driver third quarter meanwhile rheumatoid arthritis drug orencia receive approval treat psoriatic arthritis unite state well europe july moreover june bristol myer announce availability subcutaneous administration option orencia patient moderately severely active polyarticular juvenile idiopathic arthritis label expansion new administration option be expect fuel growth drug read more be beat store bristol myer earning bristol myer squibb company price ep surprise bristol myer squibb company price ep surprise bristol myer squibb company quotecelgene corporation celg free report be schedule report result open bell celgene have excellent track record company beating earning estimate last quarters last quarter company beat expectation overall company have deliver average positive surprise celgene currently carry zack rank esp combination zack rank positive esp make confident earning beat expect company beat estimate once again back strong performance key drug revlimid drug perform well first half combat challenge uneven buy pattern coverage gap continue momentum core indication label expansion global launch help product keep contribute top line zack consensus estimate drug currently stand read more be celgene poise beat earning season celgene corporation price ep surprise celgene corporation price ep surprise celgene corporation quotealexion pharmaceutical inc alxn free report be schedule report result open bell last quarter company earning surpass zack consensus estimate also alexion track record be excellent have consistently beaten expectation last quarters average positive earning surprise company currently carry zack rank esp make surprise prediction difficult alexion blockbuster drug soliris continue perform well alexion continue identify treat consistently high number new patient paroxysmal nocturnal hemoglobinurium pnh atypical hemolytic uremic syndrome ahus soliris country operate platform alexion be also work expand soliris label additional indication label expansion additional indication give soliris access higher patient population increase commercial potential drug significantly alexion pharmaceutical inc price ep surprise alexion pharmaceutical inc price ep surprise alexion pharmaceutical inc quotezack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
1162,LLY,ve already get busy day earning report sift market participant take heart large most major company report open bell have outperformed expectation case wide margin today market close expect wave report company such free report chipotle cmg free report let dig breakfast portion earning result zack rank buy rate caterpillar cat free report be pre market trading follow blowout result earning revenue bottom line share amount positive earning surprise zack consensus mile ahead cent share cat fiscal sale reach far surpass expect year construction growth china shore oil gas business north america drive quarterly growth most notably remarkably cat earning surprise be roughly line heavy machinery manufacturer trail quarters earning beat bolster surprise more caterpillar have also up full year guidance share be previous zack consensus estimate cat also carry zack style score general motor gm free report also outperformed expectation morning share easily outperformed expect result be still more year year quarterly sale well have be look gm look bring electric car market next year half also have post positive earning surprise least past straight quarters trail quarter average share gm be point today pre market defense aerospace major unite technology utx free report top expectation earning revenue guidance be third straight earning beat parent company pratt whitney otis elevator many other company share beat zack consensus cent top line actual outperformed have be look full year guidance be also raise share industrial supply giant mmm free report also beat top bottom line estimate prior tuesday open earning share revenue surprising share expect full year guidance be also ratchete notably previous zack consensus estimate share report share be thus far today pre market mcdonald mcd free report post mixed earning report morning beating earning estimate penny share be bit shy expect zack esp call cent beat exactly even negative impact hurricane harvey irma hit same store sale texas florida fact comp be quarter international be share be currently early trading other company morning have surpass expectation also raise full year guidance be stanley black decker swk free report eli lilly lly free report polaris pii free report please check company quote page click ticker link find depth report latest earning news
1163,LLY,tuesday october ve already get busy day earning report sift market participant take heart large most major company report open bell have outperformed expectation case wide margin today market close expect wave report company such free report chipotle cmg free report let dig breakfast portion earning result zack rank buy rate caterpillar cat free report be pre market trading follow blowout result earning revenue bottom line share amount positive earning surprise zack consensus mile ahead cent share cat fiscal sale reach far surpass expect year construction growth china shore oil gas business north america drive quarterly growth most notably remarkably cat earning surprise be roughly line heavy machinery manufacturer trail quarters earning beat bolster surprise more caterpillar have also up full year guidance share be previous zack consensus estimate cat also carry zack style score general motor gm free report also outperformed expectation morning share easily outperformed expect result be still more year year quarterly sale well have be look gm look bring electric car market next year half also have post positive earning surprise least past straight quarters trail quarter average share gm be point today pre market defense aerospace major unite technology utx free report top expectation earning revenue guidance be third straight earning beat parent company pratt whitney otis elevator many other company share beat zack consensus cent top line actual outperformed have be look full year guidance be also raise share industrial supply giant mmm free report also beat top bottom line estimate prior tuesday open earning share revenue surprising share expect full year guidance be also ratchete notably previous zack consensus estimate share report share be thus far today pre market mcdonald mcd free report post mixed earning report morning beating earning estimate penny share be bit shy expect zack esp call cent beat exactly even negative impact hurricane harvey irma hit same store sale texas florida fact comp be quarter international be share be currently early trading other company morning have surpass expectation also raise full year guidance be stanley black decker swk free report eli lilly lly free report polaris pii free report please check company quote page click ticker link find depth report latest earning news mark vickerysenior editorquestion comment article author click here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1164,LLY,anthera pharmaceutical inc anth free report announce positive top line datum extension phase ii bright sc study evaluate key pipeline candidate blisibimod treatment patient iga nephropathy igan notably bright sc study be randomize double blind placebo controlled initiate june evaluate efficacy safety tolerability immunogenicity blisibimod patient igan anthera share price movement show stock have significantly underperform industry so far year stock have plunge versus industry increase period extension phase ii bright sc study demonstrated tendency lower proteinurium blisibimod compare placebo treat patient study also show trend preservation renal function egfr patient treat blisibimod candidate be well tolerate study compare placebo trial be conduct total patient patient enrolled study be treat year have opportunity complete least week treatment anthera be plan share result fda proceed phase iii trial patient same indication remind investor company have mid stage development candidate sollpura acquire eli lilly company lly free report july candidate be be develop treat patient low digestive enzyme level exocrine pancreatic insufficiency epi due cystic fibrosis other potential disease company initiate phase iii solution study sollpura third quarter december company announce study have narrowly miss primary endpoint change coefficient fat absorption cfa inferiority margin however sollpura achieve statistical criterion nitrogen absorption later anthera too report positive datum extension phase solution study earlier march company currently have approve product hence successful development candidate be crucial portfolio boost anthera pharmaceutical inc priceanthera pharmaceutical inc price anthera pharmaceutical inc quotezack rank stock carry zack rank hold better rank stock pharma sector be aduro biotech inc adro free report acadium pharmaceutical inc acad free report carry zack rank buy see complete list today zack rank strong buy stock here aduro biotech loss share estimate reduce last day company deliver positive surprise trail quarters average beat acadium loss share estimate narrow last day company come positive earning surprise last quarters average beat zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
1165,LLY,indianapoli base eli lilly company lly free report be global healthcare company core product number primary care pharmaceutical market lilly generate revenue pharmaceutical product animal health segment company portfolio include zyprexa schizophrenia bipolar disorder gemzar pancreatic cancer evista osteoporosis cymbalta depression ciali erectile dysfunction strattera attention deficit hyperactivity disorder adhd erbitux cancer alimta chemotherapy lilly also have strong presence diabetes market however many key product cymbalta alimta be face generic competition company also have new product trulicity cyramza jardiance taltz portfolio have start contribute revenue lilly earning performance have be mixed earning miss expectation last quarters beating other bring average negative surprise currently lilly have zack rank buy definitely change follow company earning report be just release have highlighted key stat just reveal announcement earning beat lilly beat second quarter earning company report ep consensus call ep revenue beat revenue also beat expectation lilly post revenue compare consensus estimate up outlook lilly raise previously issue adjust earning sale outlook adjust earning share be now expect range versus previously revenue be expect range higher expect previously zack consensus estimate earning revenue be share respectively stock price impact share decline pre market trading concurrent earning release lilly announce new drug application nda resubmission rheumatoid arthritis drug baricitinib not occur year be delay minimum month remind investor lilly partner incyte receive complete response letter crl fda april regard nda baricitinib pipeline setback propel share price decline earning sale beat quartereli lilly company price consensus eli lilly company price consensus eli lilly company quotecheck back later full lilly earning report later more stock news tech opportunity worth driverless car artifical intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential
1166,LLY,be not much activity cancer space last week notable be immuno oncology partnership deal sign amgen cytomx develop cell base therapy cancer acquisition late stage prostate cancer candidate endocyte also fda grant breakthrough therapy designation seattle genetic adcetric moreover patent trademark office rule favor eli lilly patent litigation alimta let see news detail key newsamgen inc amgn free report cytomx therapeutic inc ctmx free report enter strategic immuno oncology collaboration jointly develop cell engage bispecific probody amgen pay cytomx upfront be invest latter stock deal initial work be do cytomx amgen be responsible late stage study apart upfront payment equity investment cytomx also be eligible receive milestone well opt right profit royalty outside sale product be commercialize addition technology platform expand amgen immuno oncology capability cytomx have strong partner amgen also regular flow fund read more amgen enter immuno oncology partnership cytomx amgen inc price consensus amgen inc price consensus amgen inc quoteendocyte inc ecyt free report acquire late stage prostate cancer candidate abx gmbh lu psma upfront payment pursuant acquisition endocyte now have exclusive worldwide license develop candidate commercialize successful approval candidate be most advanced target radioligand therapeutic development prostate cancer be believe have market opportunity fact lu psma target prostate specific membrane antigen psma present patient metastatic castration resistant prostate cancer mcrpc candidate have also show high response rate late stage prostate cancer patient study present recent european society medical oncology investor be encourage announcement news evident stock price appreciation oct read more endocyte inks deal prostate cancer candidate endocyte inc price consensus endocyte inc price consensus endocyte inc quoteseattle genetic inc sgen free report lymphoma drug adcetris be grant breakthrough therapy designation status frontline treatment advanced classical hodgkin lymphoma recently complete phase iii study evaluate drug indication grant status be expect speed development review process application label expansion drug be expect be file year read more seattle genetic adcetris get breakthrough therapy status seattle genetic inc price consensus seattle genetic inc price consensus seattle genetic inc quoteother newscelsion corporation clsn free report small biotech company announce datum early stage study immunotherapy candidate gen show evident biological activity newly diagnosed stage iii iv ovarian cancer study evaluate drug combination neoadjuvant chemotherapy follow interval debulk surgery candidate have achieve disease control rate patient population meanwhile patent trademark office rule favor eli lilly company lly free report dispute related vitamin regimen patent key cancer drug alimta parte review be initiate neptune generic sandoz drug have generate more company revenue first half approval generic version patent expiration june have strong negative impact lilly top line separate news aveo oncology announce result pre plan futility analysis phase iii study kidney cancer candidate fotivda review result independent statistician suggest continuation study modification look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1167,LLY,nordisk nvo free report share gain friday announce fda have approve label expansion victoza drug be now approve treatment reduce risk major adverse cardiovascular cv event include heart attack stroke cv death adult type ii diabetes establish cv disease victoza be once daily human glucagon peptide glp analogue approve treatment type ii diabetes adult drug be main revenue contributor company sale first half nordisk share have outperformed industry year date stock rally compare industry gain same time frame note fda approval be base datum pivotal leader study cv outcome evaluate drug more person type ii diabetes high risk major cv event study evaluate drug combination standard care period year datum study demonstrated victoza significantly reduce risk cv death drug lower risk fatal heart attack fatal stroke compare placebo show absolute risk reduction study cv disease be lead cause death diabetic patient addition new indication label victoza be expect bring more revenue now be prescribe diabetes medication also reduce patient cv risk however last year fda approve eli lilly company lly free report label expansion diabetes drug jardiance include cv risk reduction datum drug update label have already be launch january increase competition victoza moreover other company merck co inc mrk free report astrazeneca plc azn free report be also develop drug same indication notably merck be deny approval fda april include cv outcome datum tecos study label januvia also astrazeneca bydureon fail reduce cv risk phase iiib iv cv outcome study exscel nordisk price consensus nordisk price consensus nordisk quotenovo nordisk currently have zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1168,LLY,second quarter report cycle seem have get good start abundance positive surprise particularly revenue front meanwhile earning revenue growth also better expectation jul member accounting index total market capitalization report result accord earning preview total earning index member be year quarter improvement revenue beat ratio be earning revenue earning momentum be expect continue season report total earning company second quarter be expect grow year year higher revenue follow earning growth first quarter increase revenue highest almost year pharma bigwig only johnson johnson jnj free report swiss company novartis ag nvs free report have report so far report mixed second quarter result beating earning miss sale be third consecutive sale miss due slowdown pharmaceutical product sale however be optimistic sale growth accelerate second half other hand novartis second quarter result be encourage company beat earning sale estimate however sandoz performance be disappointing due pricing pressure here have pharma giant be set report second quarter result jul let see thing be shape quarter eli lilly company lly free report lilly be schedule release earning market open have deliver positive earning surprise last quarter lilly earning performance have be mixed earning miss expectation last quarters beating other result average negative surprise eli lilly company price ep surprise eli lilly company price ep surprise eli lilly company quarter lilly have earning esp zack rank buy zack consensus estimate be peg share uncover best stock buy sell re report earning esp filter new product trulicity cyramza taltz jardiance have support top line past few quarters expect trend continue second quarter well however decline sale alimta cymbalta zyprexa be expect continue due loss exclusivity read more be beat card eli lilly earning previous article show lilly be likely beat earning quarter however estimate change thereafter be not certain beat earning season biogen inc biib free report biogen well know name multiple sclerosis ms market be also schedule announce result open bell biogen earning performance have be pretty impressive so far have deliver back back positive surprise average earning beat last quarters be last quarter company deliver positive earning surprise biogen inc price ep surprise biogen inc price ep surprise biogen inc company have earning esp zack rank hold see complete list today zack rank strong buy stock here biogen expect relatively stable demand key ms drug tecfidera tysabri patient growth ex market offset modest decline due rise competition drug roche ocrevus read more biogen keep earning streak alive amgen inc amgn free report biotech giant be expect report market hour amgen deliver positive earning surprise last quarter amgen performance have be pretty impressive company report positive surprise consistently average earning beat last quarters be amgen inc price ep surprise amgen inc price ep surprise amgen inc company have earning esp zack rank amgen growth drug prolium xgeva continue do well biosimilar competition slowdown sale mature product put pressure sale growth read more amgen report earning card more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1169,LLY,key news week include priority review roche rhhby free report experimental hemophilia drug eu approval novartis nvs free report advanced breast cancer drug meanwhile deal involve company astrazeneca plc azn free report eli lilly company lly free report be also announce week recap week most important storiespriority review roche hemophilia drug roche investigational hemophilia treatment emicizumab get priority review fda agency expect give decision feb roche be look get emicizumab prophylaxis preventative approve once weekly subcutaneous treatment adult adolescent child hemophilia factor viii inhibitor accord information provide company person hemophilia develop inhibitor standard factor viii replacement therapy result treatment option be limit be increase risk life threaten well repeat bleed also read roche hemophilia drug grant priority review lilly inks multus year deal topas lilly have enter multus year research option agreement focuse immune tolerance germany base biotechnology company topas therapeutic initial focus be external antigen thought induce inflammation autoimmune disease pre clinical proof principle study be conduct topas receive funding lilly lilly have option license develop candidate produce collaboration deal signify lilly focus immunology immune tolerance have be attract interest quite few large player celgene signing exclusive global research collaboration anokion privately hold company develop novel tolerance induce therapeutic autoimmune disease earlier year astrazeneca mrna focuse deal ethris astrazeneca enter strategic deal germany base ethris development mrna therapy respiratory disease year strategic research deal be focuse use ethris proprietary snim rna technology new stabilize immunogenic mrna therapy respiratory disease astrazeneca make upfront payment upfront provide research funding well other payment include research development milestone payment sale related royalty astrazeneca have option take exclusive worldwide license target collaboration be not first time astrazeneca have sign mrna focuse deal company be collaborate moderna therapeutic mrna therapeutic candidate treatment range cancer cardiovascular metabolic renal disease well meanwhile astrazeneca also announce result new sub analysis datum phase iii pegasus timi study show risk reduction cardiovascular cv death treatment brilinta compare placebo patient take low dose aspirin still high risk event major cause acute coronary syndrome cv death astrazeneca be zack rank hold stock see complete list today zack rank strong buy stock here cardiome brinavess regulatory update cardiome pharma share be news fda have inform company datum package resubmission regulatory application antiarrhythmic drug brinavess not be sufficient company be look resubmit new drug application nda brinavess base original file year accumulate safety datum brinavess sale country well interim result more patient enrolled spectrum study prospective post authorization eu safety study pre clinical datum subsequent study complete company fda request eu nod novartis advanced breast cancer drug novartis cdk inhibitor kisqali gain approval eu use combination inhibitor first line treatment postmenopausal woman hr locally advanced metastatic breast cancer approval be largely expect consider positive committee medicinal product human use chmp opinion earlier year june accord information provide company woman be diagnosed advanced breast cancer year world third patient early stage breast cancer eventually develop advanced disease kisqali be approve mar novartis be work launch full commercial campaign gain formulary coverage share novartis have gain year date outperform industry cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index gain last trading session major stock bristol myer squibb bmy free report be lose last month be merck co mrk free report decline see last pharma stock roundup here multiple sclerosis drug price focus mixed datum bmy opdivo next pharma world watch usual pipeline regulatory update surprising tech stock keep eye ontech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
1170,LLY,week company allergan agn free report teva teva free report mylan myl free report be limelight mylan teva be news related fda approval mylan generic version teva top selling brand drug copaxone allergan be fire agreement saint regis mohawk tribe restasis recap week most important storiesallergan restasis deal fire allergan deal saint regis mohawk tribe announce early september have come fire lawmaker question unconventional move adopt company protect blockbuster eye drug restasis generic competition term deal allergan transfer patent related restasis tribe be grant exclusive license patent return allergan pay execution agreement well annual royalty restasis be allergan second best selling drug bring sale almost original patent drug active ingredient be set expire allergan file additional patent extend protection lawmaker point sovereign status native american tribe make patent challenge lengthy complex tribe be immune legal claim make generic drug maker challenge patent fact tribe be filing dismiss ongoing parte review ipr restasis patent base sovereign immunity ipr challenge deal have basically raise concern curb generic competition pharmaceutical industry discourage generic drugmaker make cheaper copy cat version expensive drug allergan have be ask committee oversight government reform provide certain document information deal oct mylan gain teva loss major development mylan gain fda approval generic version teva top selling brand drug copaxone multiple sclerosis mylan gain approval mg thrice weekly dosage well once daily mg formulation mylan be first applicant challenge mg patent company therefore enjoy day exclusivity formal communication fda regard same be yet come mylan have launch product accord quintilesim brand sale mg mg dose be approximately respectively month end jul mylan also gain approval mg dose eu fda approval generic copaxone be big boost mylan be major blow teva be currently face whole lot challenge teva issue statement say launch mg formulation final resolution pending patent infringement lawsuit mylan be treat risk launch mean mylan have pay significant damage court uphold patent protect drug entry mg formulation entry second generic version mg formulation sandoz momenta have be market quite glatopa generic version mg dose be expect cut teva earning least cent share additional detail be company announce third quarter result november entry generic copaxone just add exist list problem be face teva read more teva share plummet mylan copaxone generic get fda approval nordisk get fda approval fiasp nordisk nvo free report have strong presence diabetes market provide regulatory update diabetes franchise company gain fda approval fiasp fast act mealtime insulin treatment adult diabetes approval process be not exactly company receive complete response letter last year agency have ask additional information related assay immunogenicity clinical pharmacology datum read more nordisk fiasp get fda nod diabetes adult meanwhile european medicine agency ema committee medicinal product human use chmp endorse company plan update eu label tresiba include result devote study show significant reduction risk severe hypoglycemia nordisk be zack rank buy stock see complete list today zack rank strong buy stock here sanofi regeneron score pcsk inhibitor litigation sanofi sny free report partner regeneron get major boost court appeal federal circuit order new trial related amgen claim regard patent pcsk inhibitor court also vacated permanent injunction lawsuit mean sanofi regeneron continue selling pcsk inhibitor praluent unite state favorable court ruling lilly company get positive ruling patent front be eli lilly company lly free report company say patent trial appeal board patent trademark office pto rule favor regard vitamin regimen patent cancer therapy alimta pemetrexed injection patent be upheld alimta be safe generic competition decision have remove overhang share alimta bring sale more dollar first half week lilly also gain fda approval new cancer treatment verzenio use woman hr advanced breast cancer lilly have gain year date compare rally industry belong cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index gain so far week major stock lilly be last month bristol myer be glaxo gsk free report decline see last pharma stock roundup here drug get crl label expansion merck bmy drug next pharma world watch usual pipeline regulatory update stock watch massive equifax stock spiked recent news datum breach affect american stock be best buy candidate right now do future hold cybersecurity industry equifax be just most recent victim computer hacking identity theft be more common ever zack have just release cybersecurity investor guide inform zack com reader year space more importantly highlight cybersecurity pick strong profit potential get new investing guide now
1171,LLY,eli lilly company lly free report announce have receive favorable ruling patent trademark office pto dispute related vitamin regimen patent key cancer drug alimta pemetrexed disodium parte review ipr ruling pto validate alimta vitamin regimen patent thereby remove major overhang lilly markedly ipr be initiate neptune generic sandoz generic arm novartis ag nvs free report remind investor january year court appeal rule favor lilly lawsuit generic drugmaker teva pharmaceutical teva free report regard validity infringement same patent confirm earlier decision district court pto ipr ruling be consistent previous alimta decision so far year lilly share price have rise compare favorably industry growth compound patent cover alimta unite state expire january year vitamin regimen patent remain valid june pediatric exclusivity expire alimta patent be ultimately upheld remain challenge compound patent have already expire major european country japan dec more generic manufacturer include teva sandoz be seek approval unite state market generic form alimta prior expiration vitamin regimen patent notably alimta be top revenue grosser lilly longer commercial life alimta provide top line support several product lilly portfolio be already face patent expiration entry generic competition alimta follow loss effective patent protection cause rapid decline revenue product first half alimta sale decline year year outside unite state sale cancer drug be be hurt due loss exclusivity several country however sale be be affected increase competition owing entry immuno oncology agent market favourable ipr narrow chance generic competition alimta have hurt sale more lilly carry zack rank hold see complete list today zack rank strong buy stock here better rank large cap drug company same space be pfizer inc pfe hold zack rank buy share company have rally trade profit big league trump policy stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
1172,LLY,eli lilly company lly free report report third quarter adjust earning share beat zack consensus estimate share earning rise year quarter backed volume drive pharma sale growth higher operate profit revenue beatquarterly revenue also beat zack consensus estimate sale grow year year backed strong performance new drug well lilly diabetes product lilly diabetes product record revenue growth worldwide volume rise strong performance new product trulicity taltz basaglar jardiance lartruvo offset decline sale establish product zyprexa alimta ciali strattera effient higher realize price several drug also contribute sale growth quarter revenue revenue rise quarter backed volume growth new product revenue grow ex revenue rise establish product record growth quarter include forteo humalog sale other establish product decline quarter alimta sale decline reflect lower demand unite state due competitive pressure mainly immuno oncology agent outside unite state sale alimta be hurt loss exclusivity several country increase competition lower realize price zyprexa sale decline due loss exclusivity humulin sale decrease quarter due lower realize price unfavorable buy pattern china ciali sale decline hurt lower demand unite state well increase competition generic sale decline quarter strattera sale decline cymbalta sale decline effient sale decline quarter new product trulicity generate revenue year year revenue benefit growth glp market market share gain cyramza revenue be year year backed continue strong outside revenue improve revenue cyramza ex revenue benefit strong volume japan revenue increase drive increase volume jardiance sale be drive increase market share grow sglt class basaglar record revenue compare previous quarter backed strong launch uptake basaglar lilly partner boehringer ingelheim follow insulin sanofi sny free report blockbuster drug lantus be launch unite state mid december generate revenue quarter taltz bring sale compare previous quarter reflect strong launch uptake lartruvo olaratumab generate revenue third quarter compare previous quarter lartruvo be launch unite state eu soft tissue sarcoma fourth quarter lilly partner incyte corporation incy free report rheumatoid arthritis ra drug olumiant baricitinib have be launch select european country japan drug generate sale third quarter compare previous quarter backed strong launch uptake germany however unite state lilly receive complete response letter crl fda baricitinib april want additional datum august lilly incyte announce re submit nda baricitinib much faster previously expect nda be expect be re submit end january next year lilly elanco animal health segment sale rise due inclusion revenue acquisition boehringer ingelheim vetmedica feline canine rabies acquire january however worldwide competitive pressure continue hurt sale segment concurrent earning release lilly say be explore strategic alternative elanco animal health business include sale merger create separate company initial public offer decision regard same be expect be make later middle next year lilly ultimately opt retain business gross margin operate income risesadjust gross margin quarter decrease basis point manufacturing efficiency be offset negative product mix effect foreign exchange rate international inventory sell operate income increase total operate expense percent revenue decline basis point quarter outlook uppedlilly raise previously issue adjust earning sale outlook second time year adjust earning share be now expect range compare expect previously revenue be expect range expect previously gross margin be expect be approximately same previously expect adjust tax rate be still expect be approximately previously approximately marketing selling administrative expense be still expect range research development expense be project be compare expect previously takelilly third quarter result be strong company beating estimate count pharma giant also raise sale earning outlook year increase revenue guidance be support strong uptake trend new product also extent due positive impact euro share be pre market trading so far year lilly share price have rise compare increase industry go forward new product trulicity taltz basaglar cyramza jardiance lartruvo be expect see higher revenue lilly also expect establish product trajenta forteo humalog continue do well lilly be also progress well pipeline earlier month lilly gain fda approval verzenio abemaciclib cdk inhibitor metastatic breast cancer lilly have launch medicine include verzenio plan launch more however alimta continue be impact competition other headwind include competition immuno oncology agent well loss exclusivity many drug emerge market lilly carry zack rank hold see complete list today zack rank strong buy stock here biogen inc biib free report also report third quarter result today beat estimate earning sale however share be more pre market trading sale multiple sclerosis drug tecfidera decline sequentially quarter eli lilly company price consensus ep surprise eli lilly company price consensus ep surprise eli lilly company quotetoday stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1173,LLY,pharmaceutical sector have be grab investor attention late nyse arca pharmaceutical index gain large cap pharmaceutical industry year date outpace gain new drug approval tax reform be expect provide further impetus stock however factor drug pricing competition biosimilar continue act major deterrent other hand company eli lilly company lly free report be resort workforce reduction leaner cost structure front apart johnson johnson jnj free report acquisition actelion ltd june nothing much have happened space merck co mrk free report recently announce acquire germany base rigontec privately hold immuno oncology focuse biotech boost immune oncology pipeline nevertheless propose tax reform be expect boost cash balance company turn be used merger acquisition here have picked largest drug company look well poise growth be prudent choice add portfolio base switzerland novartis ag nvs free report be leader health care solution wide array drug service novartis have presence field oncology neuroscience ophthalmology generic novartis have strong oncology portfolio drug afinitor exjade jakavi zykadia tasigna jadenu improve formulation exjade recent fda approval kisqali advanced metastatic breast cancer breakthrough gene transfer treatment kymriah suspension acute lymphoblastic leukemia have further boost portfolio approval be major boost novartis give potential car therapy space growth driver cosentyx entresto more offset impact generic erosion mainly due glivec cosentyx achieve blockbuster status believe approval new drug label expansion exist one boost top line go forward novartis currently carry zack rank buy see complete list today zack rank strong buy stock here novartis stock have gain year date strength oncology drug approval first car therapy continue boost performance pfizer inc pfe free report lead pharmaceutical company unite state focus development wide range product include human animal biologic well small molecule medicine vaccine consumer health care product pfizer be look drive growth licensing deal collaborative agreement company be look expand label approve drug ibrance xeljanz xalkori eliquis pfizer also boast strong pipeline moreover pfizer be evaluate various biosimilar molecule several stage development give potential market share company have moved last month compare favorably industry gain pfizer presently carry zack rank earning estimate company have be static past day bagsværd denmark base nordisk nvo free report be global leader diabetes market company be also key player hemophilia care growth hormone therapy hormone replacement therapy obesity company portfolio include drug levemir novorapid victoza novomix novomix novomix novoseven norditropin additionally obesity drug saxenda liraglutide mg be launch unite state uptake have be encourage victoza be currently market leader glp segment expect victoza continue be significant contributor company top line august fda approve new indication victoza reduce risk major adverse cardiovascular cv event adult type ii diabetes establish cv disease believe label expansion drug further boost top line company currently carry zack rank company share have rally year date company earning estimate have moved last day headquarter leverkusen germany bayer ag bayry free report be life science company core competency area health care agriculture bayer have be consistently make effort transform pure life science company drug launch last few quarters be expect continue drive top line bayer be look label expansion oncology drug stivarga be approve treatment metastatic colorectal cancer metastatic stromal tumor company have inked several strategic deal undertake meaningful acquisition recent past bayer be look acquire cash transaction combine business be expect boost bayer crop science business provide accretion bottom line bayer currently carry zack rank buy company share have gain year date earning estimate company have moved north last day bottom line challenge form pricing pressure competition remain healthcare sector nevertheless pick outperformer space backed solid zack rank positive price movement lead investor gain earning season stock watch massive equifax stock spiked recent news datum breach affect american stock be best buy candidate right now do future hold cybersecurity industry equifax be just most recent victim computer hacking identity theft be more common ever zack have just release cybersecurity investor guide inform zack com reader year space more importantly highlight cybersecurity pick strong profit potential get new investing guide now
1174,LLY,johnson johnson jnj free report announce have submit supplemental new drug application snda fda label expansion diabetes drug invokana include cardiovascular indication base datum large canvas outcome program application include indication risk reduction cardiovascular event type ii diabetes patient also apply invokana fix dose combination invokamet invokamet xr filing be base datum canvas program evaluate invokana sglt inhibitor compare placebo cv event type ii diabetes patient have establish cardiovascular cv disease be risk cv disease primary endpoint study be defined major adverse cardiovascular event mace include cv death nonfatal myocardial infarction nonfatal stroke study show invokana be successful reduce risk heart attack stroke canvas program comprise nearly identical large outcome study call canvas canvas however study also show drug increase risk amputation so far year johnson johnson share price have increase compare unfavorably gain record industry belong many pharma company be work hard get label diabetes medicine update include cardiovascular benefit death cardiovascular disease be significantly higher adult diabetes compare diabetes addition positive cv outcome label diabetes drug give sale shot arm eli lilly company lly free report receive fda approval last year include cv risk reduction datum empa reg outcome study label jardiance update label include cardiovascular indication be launch jan american diabetes association ada have also update diabetes treatment guideline european commission also approve jardiance label update cardiovascular indication august nordisk nvo free report victoza liraglutide be approve fda new indication reduce risk major adverse cardiovascular cv event adult type ii diabetes establish cv disease fda decision be base result landmark leader trial demonstrated victoza statistically significantly reduce risk cardiovascular death fatal heart attack fatal stroke versus placebo add standard care absolute risk reduction however merck co inc mrk free report be deny approval fda include cardiovascular outcome datum tecos study label dpp iv inhibitor januvia sitagliptin other medicine contain januvia astrazeneca bydureon also fail reduce cardiovascular risk phase iiib iv cardiovascular outcome study exscel johnson johnson price johnson johnson price johnson johnson quotejohnson johnson carry zack rank sell see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1175,LLY,eli lilly company lly free report announce number leadership change order focus bring newer drug market regard company promote josh smiley post chief financial officer cfo effective jan june company announce current cfo derica rice retire year end company also promote dan skovronsky senior vice president science technology president lilly research lab change be effective june also myle neill have be promote senior vice president president manufacturing operation aarti shah be senior vice president chief information officer have be offer post executive officer become part lilly executive committee addition appointment company also announce retirement marium crowe president manufacturing operation retire december year service jan lundberg vice president science technology president lilly research lab retire end year lilly so far year lilly share price have increase compare industry gain note company have make change order focus new medicine diabetes cancer immunology pain last month company also announce restructure initiative order streamline operation so focus develop new medicine improve cost structure announce plan reduce global workforce approximately position initiative be expect amass annualize saving approximately begin furthermore be also close several site plant iowa office new jersey center china save cost however company face share challenge several key drug portfolio zyprexa cymbalta be face generic competition due loss exclusivity meanwhile blockbuster drug alimta sale be also be affected entry immuno oncology agent market outside unite state sale be already be hurt due loss exclusivity several country other headwind include competition immuno oncology agent well recent high profile pipeline setback also lilly animal health segment do not do too well first half due worldwide competitive pressure eli lilly company price eli lilly company price eli lilly company quotezack rank stock considerlilly carry zack rank hold better rank stock health care sector include regeneron pharmaceutical inc regn free report biogen inc biib free report aduro biotech inc adro free report regeneron sport zack rank strong buy biogen aduro carry zack rank buy see complete list today zack rank stock here regeneron earning share estimate have increase last day company pull positive earning surprise trail quarters average beat share price company have increase year date biogen earning share estimate have moved last day company deliver positive earning surprise trail quarters average beat share price company have increase year date aduro loss estimate share have narrow last day company come positive earning surprise trail quarters average beat today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1176,LLY,issue update report zoetis inc zts free report aug zoetis boast robust diversify product portfolio company business be divide category infective vaccine parasiticide medicated feed additive other pharmaceutical zoetis market offering primarily core species cattle swine poultry sheep fish collectively livestock dog cat horse collectively companion animal zoetis derive majority revenue diversify product portfolio medicine vaccine be used treat protect livestock companion animal company continue strengthen diverse portfolio product lifecycle innovation strong customer relationship access new market technology apoquel other product launch continue drive growth companion animal portfolio company expect witness stronger growth companion animal portfolio drive dermatology portfolio apoquel cytopoint further penetration simparica ongoing uptake new vaccine latest datum show dog dermatology problem be treat apoquel cytopoint first quarter addition new approval further boost portfolio zoetis receive approval clavamox chewable cytopoint european union april canada march zoetis stock have moved year so far compare industry loss however disease outbreak animal be concern zoetis livestock product such outbreak hurt regional global sale particular animal derive food product result reduce export same due heighten export restriction import prohibition turn dampening demand livestock product moreover zoetis face stiff competition other animal health medicine vaccine company merck animal health animal health division merck co mrk free report elanco animal health division eli lilly co lly free report bayer animal health animal health division bayer ag bayry free report boehringer ingelheim animal health animal health division boehringer ingelheim zack rank zoetis currently carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1177,LLY,nordisk nvo free report announce result sustain study show person type ii diabetes be treat once weekly semaglutide experience superior reduction hba body weight compare treatment eli lilly co lly free report trulicity dulaglutide add metformin fact semaglutide be glucagon peptide glp analogue be evaluate treatment adult type ii diabetes currently be review regulatory agency include fda european medicine agency japanese pharmaceutical medical device agency share company have rally compare zack classify industry gain year date basis notably week study evaluate efficacy safety dosage semaglutide addition initial standard care therapy metformin dulaglutide metformin mg semaglutide be compare dulaglutide mg semaglutide be compare mg dulaglutide add metformin study present dose semaglutide be statistically significant result superior reduction hba addition show person treat dose semaglutide experience statistically significant superior weight loss dose meanwhile superior glucose control weight loss achieve semaglutide compare dulaglutide be consistent entire sustain program fact result reveal potential semaglutide set new standard treatment type ii diabetes nordisk have strong pipeline primarily focuse therapeutic protein insulin glp blood clot factor human growth hormone company be make effort develop new treatment diabetes be core area expertise key pipeline candidate include semaglutide nonacog beta pegol potential approval candidate boost company top line nordisk price nordisk price nordisk quotezack rank stock considernovo nordisk currently hold zack rank hold better rank stock health care sector include alexion pharmaceutical inc alxn free report regeneron pharmaceutical inc regn free report alexion regeneron sport zack rank strong buy see complete list today zack rank stock here alexion pharmaceutical earning share estimate have moved last day company deliver positive earning surprise trail quarters average beat share price company have increase year date regeneron earning share estimate have increase last day company pull positive earning surprise trail quarters average beat share price company have increase year date simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
1178,LLY,merck mrk free report announce fda have grant tentative approval lusduna nexvue company biosimilar version sanofi sny free report lantus insulin glargine treatment person type type ii diabetes lusduna nexvue deliver insulin pre filled dose device note candidate be formerly know mk fda have grant provisional approval trade name lusduna nexvue be used once product be make available merck share have underperform industry so far year stock have gain compare broader industry increase lusduna meet regulatory safety efficacy standard approval be tentative due ongoing litigation sanofi final approval lusduna be subject resolution sanofi litigation september last year sanofi sue merck patent infringement lantus litigation automatically invoked stay final fda approval lusduna month event court rule favor merck be sooner notably lantus have be major contributor sanofi top line have account total sale however company consider conditional approval significant milestone be advance candidate step closer market remind investor merck be develop lusduna collaboration samsung bioepis agreement term merck be responsible clinical development manufacturing bioepis be partially funding development currently application regulatory approval lusduna treatment patient type type ii diabetes be review eu remind investor eli lilly company lly free report be already marketing follow insulin glargine product basalgar dec separate press release merck announce collaboration pfizer pfe free report modernization pharmaceutical packaging introduction corning valor glass enhance storage delivery drug formulation merck company inc pricemerck company inc price merck company inc quotezack rankmerck currently carry zack rank buy see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1179,LLY,second quarter earning season pharma sector kick week industry bellwether johnson johnson jnj free report swiss pharma giant novartis nvs free report report result meanwhile merck mrk free report gain tentative approval fda follow biologic basal insulin company launch immediately due ongoing patent infringement case recap week most important storiesa look novartis result industry bellwether swiss pharma giant novartis report second quarter result earlier week surpass earning expectation revenue fall short company raise outlook year operational sale growth expect accelerate second half factor help include earlier launch tremfya more moderate erosion remicade business compare previous expectation well continue strong performance key drug contribution new product medical device segment be also expect pick back half year strong growth vision care segment expect continue consumer segment however continue be impact weaker macroeconomic dynamic read more beat earning lag sale up view novartis second quarter result be better expect company beating earning revenue entresto cosentyx continue perform well sandoz sale decline reflect pricing pressure meanwhile alcon performance improve encourage company raise alcon sale outlook low single digit growth read more novartis top earning sandoz face pricing pressure novartis stock have gain year date outperform rally industry belong tentative approval merck follow basal insulin merck get tentative approval fda biosimilar version sanofi sny free report blockbuster diabetes drug lantus lusduna nexvue insulin glargine injection technically follow biologic basal insulin have be develop merck funding samsung bioepis however merck have launch product due automatic month stay result patent infringement lawsuit initiate sanofi sep merck launch product expiry stay period favorable court ruling occur first note biosimilar version lantus be already market form lilly lly free report boehringer ingelheim basaglar enter market mid dec lantus sale decline first quarter include decline reflect lower average net price patient switch toujeo impact formulary exclusion pricing pressure increase once merck product enter market sanofi merck be zack rank buy stock see complete list today zack rank strong buy stock here sanofi nanobody deal ablynx sanofi have enter research collaboration global exclusive licensing agreement belgian company ablynx focuse development nanobody base therapeutic treatment various immune mediate inflammatory disease deal sanofi gain access certain nanobody ablynx exist portfolio well ablynx scientist proprietary nanobody platform sanofi make upfront payment other financial detail include milestone payment well tiered royalty collaboration sanofi be look expand drug discovery pipeline immunology eu nod astrazeneca kyntheum astrazeneca azn free report psoriasis treatment kyntheum gain approval eu iceland liechtenstein norway company say partner leo pharma gain approval use biologic medicine treatment moderate severe plaque psoriasis adult be candidate systemic therapy kyntheum be approve trade name siliq feb black box warning regard risk patient suicidal thought behavior cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index gain last trading session major stock astrazeneca be gain last month astrazeneca be gain see last pharma stock roundup here fda panel vote novartis car drug sny buy vaccine co next pharma world watch second quarter earning result company lilly bristol myer bmy free report astrazeneca other make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1180,LLY,biogen inc biib free report well know name multiple sclerosis ms market report second quarter result jul market open last quarter company deliver positive earning surprise biogen share have decline year so far zack classify biom genetic industry record increase biogen earning performance have be pretty impressive so far have deliver back back positive surprise average earning beat last quarters be let see thing be shape announcement factor considerat first quarter call company have say expect relatively stable demand tecfidera tysabri multiple sclerosis drug patient growth ex market offset modest decline due rise competition drug roche ocrevus remain be see second quarter performance reflect trend meanwhile combine number patient used avonex plegridy be decline patient transition other oral multiple sclerosis therapy other high efficacy product zinbryta launch collaboration abbvie inc abbv free report aug be expect continue contribute revenue eu drug benefit increase use high efficacy product spinraza approve spinal muscular atrophy dec be promising start backed robust underlie demand notably spinraza add top line first quarter contribute further sale conference call company have say be work expand access spinraza patient however call company have warn possible logistic coverage restriction drug well other market expect management provide update issue second quarter conference call biogen biosimilar product flixabi biosimilar reference remicade benepali biosimilar reference enbrel be also generate higher revenue trend continue quarter well headcount reduction restructure initiative be expect continue lower operate expense meanwhile expense be expect increase due increase business development payment second quarter call investor focus remain tecfidera scrip trend sale ramp spinraza pipeline progress acquisition plan earning whispersour proven model do not conclusively show biogen be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp be most accurate estimate stand zack consensus estimate be peg higher uncover best stock buy sell re report earning esp filter zack rank biogen zack rank increase predictive power esp however need have positive esp be confident earning beat caution sell rate stock zack rank go earning announcement especially company be see negative estimate revision biogen inc price ep surprise biogen inc price ep surprise biogen inc quotestock considerstock pharmaceutical sector have positive esp favorable zack rank includeeli lilly company lly free report schedule release result jul earning esp zack rank see complete list today zack rank stock here pfizer inc pfe free report earning esp zack rank company be schedule release result aug look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1181,LLY,radius health inc rdus free report announce first patient have be enroled phase study pipeline candidate rad rad be nonsteroidal selective androgen receptor modulator sarm be be evaluate treatment hormone receptor positive breast cancer phase trial be safety dose range study approximately patient suffering progressive metastatic locally advanced metastatic breast cancer postmenopausal woman metastatic hormone receptor positive breast cancer receive escalate dose rad oral administration period day part study primary safety outcome include rate dose limit toxicity adverse event related treatment tolerability measure dose interruption adjustment addition pharmacokinetic pharmacodynamic tumor response also be evaluate sarm mechanism action be differentiate selective estrogen receptor modulator serm selective estrogen receptor degrader serd consequently rad have significant potential complement future application elacestrant rad target distinct mechanism endocrine resistance note investigational new drug application submit fda rad have be accept radius share price have increase year date compare industry gain april fda approve tymlos abaloparatide sc treatment postmenopausal woman high risk osteoporosis fracture defined history osteoporotic fracture multiple risk factor fracture patient have fail be intolerant other osteoporosis therapy osteoporosis market unite state hold great promise approximately postmenopausal woman suffer osteoporotic fracture year tymlos be expect face significant competition eli lilly co lly free report forteo amgen inc amgn free report prolium moreover approve label carry box warning osteosarcoma malignant bone tumor company however suffer setback chmp issue second day list outstanding issue meanwhile radius clinical pipeline include investigational abaloparatide transdermal patch potential use osteoporosis investigational drug elacestrant rad potential use hormone drive hormone resistant breast cancer vasomotor symptom postmenopausal woman zack rank key pickradius health currently carry zack rank hold better rank stock healthcare sector be aduro biotech adro free report carry zack rank buy see complete list today zack rank strong buy stock here aduro biotech loss share estimate narrow last day company deliver positive surprise trail quarters average beat today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1182,LLY,sep issue update report nektar therapeutic nktr free report company focuse develop treatment utilize pegylation advanced polymer conjugate technology platform company portfolio comprise drug movantik opioid induced constipation oic adynovate treat hemophilia drug be show impressive performance nektar share global license agreement astrazeneca azn free report latter be grant worldwide exclusive right develop market sell movantik well fix dose combination product company also have licensing collaboration manufacturing contract shire plc shpg free report adynovate receive royalty sale milestone related drug licensing agreement be expect provide regular fund company also nektar have make significant progress lead candidate onzeald formerly know nktr currently accelerate assessment eu treat adult advanced breast cancer well brain metastase response be anticipate soon nektar have also initiate randomize phase iii confirmatory study attain onzeald compare single agent chemotherapy physician choice trial be be conduct patient advanced breast cancer shortly complain brain metastase positive result evaluation support regulatory filing unite state company be further develop several other candidate important therapeutic area include oncology pain infective immunology interesting one include nktr phase iii chronic pain nktr phase ii solid tumor nktr phase autoimmune disease remind investor july nektar announce positive top line result oral human abuse potential hap study nktr order assess abuse potential compare oxycodone notably fda grant fast track designation nktr development program successful development candidate turn drive company top line consider lucrative market target importantly nektar enter co development deal eli lilly company lly free report nktr earlier july pursuant agreement nektar be responsible complete ongoing phase study candidate however go forward phase ii study same lilly be capture total cost lower nektar development expense nktr however nektar proprietary market product well underdeveloped candidate be subject stiff competition various other pharmaceutical biotechnology company company be expect face intense rivalry pain market several manufacturer develop pain therapy competitor include collegium pharmaceutical xtampza teva pharmaceutical naproxen name few also player pegylation polymer conjugate chemistry technology space be biogen biib savient pharmaceutical dr reddy nordisk other nektar heavy reliance partner revenue still remain huge concern partnership related setback seriously weigh company stock watch massive equifax hack cybersecurity stock spiked recent news datum breach affect american stock be best buy candidate right now do future hold cybersecurity industry equifax be just most recent victim computer hacking identity theft be more common ever zack have just release cybersecurity investor guide inform zack com reader year space more importantly highlight cybersecurity pick strong profit potential get new investing guide now
1183,LLY,expect eli lilly company lly free report beat expectation report second quarter result jul market open last quarter company deliver positive earning surprise so far year lilly share price have rise compare increase zack classify large cap pharma industry lilly earning performance have be mixed earning miss expectation last quarters beating other bring average negative surprise let see thing be shape quarter factor playcontinu trend past few quarters new product trulicity cyramza taltz jardiance be likely support top line second quarter trulicity sale be be drive growth glp market market share gain jardiance sale continue be drive increase market share grow sglt class dec fda approve jardiance cv indication launch jan american diabetes association ada update diabetes treatment guideline first quarter call management have say launch cv indication ada addition jardiance treatment guideline jardiance new therapy volume have increase be expect translate higher sale however sale alimta cymbalta zyprexa be expect continue decline due loss exclusivity cymbalta have lose exclusivity europe canada zyprexa japan alimta several country outside also lower demand due competitive pressure mainly immuno oncology agent be hurt alimta sale nevertheless older product humalog trajenta forteo continue do well newly launch drug basaglar lartruvo add top line basaglar lilly partner boehringer ingelheim follow insulin sanofi sny free report blockbuster drug lantus be launch mid dec lartruvo olaratumab be launch eu soft tissue sarcoma fourth quarter new drug be expect generate decent revenue be report quarter new drug olumiant have be launch select european country add top line second quarter drug be review apr lilly receive complete response letter crl fda baricitinib fda require additional clinical datum delay approval drug update same be expect conference call animal health segment sale suffer last quarter due global competitive pressure remain be see trend improve quarter model proven model show lilly be likely beat earning have right combination key ingredient stock need have positive earning zack rank strong buy buy hold happen zack esp earning esp represent difference most accurate estimate share zack consensus estimate share be be meaningful indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank lilly have zack rank combination lilly favorable zack rank positive esp make confident earning beat upcoming release sell rate stock zack rank other hand never be consider go earning announcement especially company be see negative estimate revision eli lilly company price ep surprise eli lilly company price ep surprise eli lilly company quoteother stock considera couple stock large cap pharmaceutical sector also have positive earning esp favorable zack rank be nordisk nvo free report schedule release result aug have earning esp zack rank see complete list today zack rank stock here pfizer inc pfe free report have earning esp zack rank company be schedule release result aug look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1184,LLY,share radius health rdus free report drop more early morning trading hour monday company announce jesper høiland former top ranking executive nordisk nvo free report have be appoint new president chief executive officer høiland join radius integral moment company recently receive approval once daily injectable osteoporosis treatment tymlos be pleased welcome jesper radius health important time believe be uniquely qualify lead radius successful launch tymlos advancement exciting clinical stage asset include elacestrant say radius chairman kurt grave høiland replace bob serve radius ceo help lead company ipo not long market debut share radius reach peak more summer stock have struggle maintain momentum then be delighted be join radius exciting early stage tymlos say jesper høiland look forward guide continue development strong pipeline new appointment come wake radius health rival amgen amgn free report announcement own osteoporosis drug do not receive fda approval now list approve treatment build bone strength fight degenerative condition remain just eli lilly lly free report forteo remain market leader radius investor today appointment likely lead short term volatility fresh face top company management be much need ignition source zack rank sell stock today stock zack hottest strategy hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1185,LLY,be busy week fda oncologic drug advisory committee odac review several experimental treatment week include novartis nvs free report car cell drug meanwhile french pharma giant sanofi sny free report announce be acquire vaccine company recap week most important storiesfda panel support novartis car drug novartis get huge boost fda advisory panel voting unanimously favor company experimental car cell therapy ctl novartis be look get treatment approve pediatric young adult relapse refractory cell acute lymphoblastic leukemia positive vote be major milestone company become first launch car cell therapy fda follow advisory panel advice ctl be currently priority review advisory panel issue positive recommendation believe chance gain approval be high read more novartis car therapy drug recommend fda panel so far novartis have outperformed zack categorize large cap pharmaceutical industry share gain industry be fda nod psoriasis treatment jnj free report tremfya gain fda approval treatment moderate severe plaque psoriasis make drug first only biologic approve selectively block only il cytokine play key role plaque psoriasis psoriasis market be pretty crowd tremfya demonstrated superior result skin clearance compare humira head head analysis week tremfya be currently late stage study treatment active psoriatic arthritis phase iii program evaluate efficacy compare cosentyx treatment moderate severe plaque psoriasis mar pdufa date pfizer xeljanz label expansion pfizer pfe free report snda xeljanz have be accept review fda response expect mar timely approval make xeljanz first oral janus kinase jak inhibitor be available person live moderately severely active ulcerative colitis uc pfizer also get favorable vote fda advisory panel acute myeloid leukemia aml drug mylotarg newly diagnosed patient final decision fda be sep mylotarg be initially approve be subsequently withdraw market late stage study fail show clinical benefit moreover higher rate fatality result treatment related toxicity be observed mylotarg arm priority review lilly advanced breast cancer drug lilly lly free report get priority review fda cdk inhibitor abemaciclib company be look get abemaciclib approve monotherapy combination therapy fulvestrant patient advanced breast cancer give priority review status lilly get response fda first quarter currently approve cdk inhibitor include pfizer ibrance novartis kisqali read more lilly breast cancer drug get priority review status fda lilly also enter settlement agreement generic player settle patent infringement lawsuit related ciali tadalafil unit dose patent settlement agreement patent be previously set expire apr now end sep ciali be approve treatment erectile dysfunction ed frustrate urinary symptom benign prostatic hyperplasia bph ciali sale be lilly say adcirca tadalafil patent remain protected nov pediatric exclusivity be grant adcirca be approve pulmonary arterial hypertension read more lilly settle patent litigation ciali generic firm sanofi buy vaccine company sanofi fail effort acquire medivation actelion announce be acquire protein science base privately hold vaccine biotech company include upfront payment achievement certain milestone acquisition sanofi be look expand flu portfolio addition egg base vaccine protein science flublok quadrivalent influenza vaccine qiv be approve fda oct be only recombinant protein base flu vaccine approve agency acquisition be schedule close third quarter sanofi be zack rank buy stock see complete list today zack rank strong buy stock here mylan herceptin biosimilar get favorable panel vote mylan myl free report get boost biosimilar version herceptin trastuzumab get favorable recommendation fda advisory panel panel vote support eligible indication reference product include breast cancer metastatic adjuvant setting biosimilar version have be develop collaboration biocon cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index gain last trading session major stock astrazeneca azn free report be lilly gain almost last month astrazeneca be bristol myer be see last pharma stock roundup here mrk keytruda mm combo study clinical hold bayer revise outlook next pharma world watch second quarter earning result company be report jul more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1186,LLY,tuesday share company axovant science ltd axon free report have crash stock be currently share late morning trading say experimental alzheimer drug fail key late stage trial drug call intepirdine be be test patient suffer mild moderate alzheimer do not respond initial treatment late stage trial be highly anticipate intepirdine fail improve cognitive ability daily activity be also compare placebo be deeply disappoint trial result also be saddened million patient family impact alzheimer disease axovant ceo david hung say however believe fight alzheimer other important area unmet need neurology be too important be derail setback alzheimer be type dementia cause problem memory think behavior symptom develop slowly worsen time become severe enough interfere daily life alzheimer affect more american be sixth lead cause death be current cure alzheimer be treatment available symptom only drug have be approve treat symptom most recent drug approval axovant setback follow other company eli lilly lly free report merck mrk free report denmark lundbeck suffer fail alzheimer drug trial similar lundbeck drug idalopirdine intepirdine be so call ht antagonist work block ht receptor release acetylcholine be need normal cognition axovant isn give completely company be now testing intepirdine patient suffer condition know lewy body dementia disease symptom similar alzheimer parkinson trial result be expect end year company also test drug patient dementia be affect balance gait share axovant be year date stock experience nice rally back april dr hung come chief executive company have other drug development currently sit hold zack rank hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
1187,LLY,aug issue update report nektar therapeutic nktr free report company focuse development treatment utilize pegylation advanced polymer conjugate technology platform nektar share have significantly outperformed industry so far year have surge industry register decrease company portfolio comprise drug movantik opioid induced constipation oic adynovate treat hemophilia nektar have global license agreement astrazeneca azn free report latter be grant worldwide exclusive license develop market sell right movantik well fix dose combination product company also have licensing collaboration manufacturing contract shire plc shpg free report adynovate receive royalty sale milestone related drug also nektar have make significant progress lead candidate onzeald formerly know nktr currently accelerate assessment eu treat adult advanced breast cancer well brain metastase response be anticipate soon nektar have also initiate randomize phase iii confirmatory study attain onzeald compare single agent chemotherapy physician choice trial be be conduct patient advanced breast cancer shortly complain brain metastase positive result study support regulatory filing company be further develop several other candidate important therapeutic area include oncology pain infective immunology interesting one include nktr phase iii chronic pain nktr phase ii solid tumor nktr phase autoimmune disease remind investor july nektar announce positive top line result oral human abuse potential hap study nktr order assess abuse potential compare oxycodone notably fda grant fast track designation nktr development program successful development candidate turn boost company top line consider lucrative market be target importantly nektar enter co development deal eli lilly company lly free report nktr month pursuant agreement nektar be responsible complete ongoing phase study candidate however go forward phase ii study same lilly be capture total cost possibly lower company development expense nktr however nektar proprietary market product well candidate development be subject stiff competition various pharmaceutical biotechnology company company be expect face intense rivalry pain market several manufacturer develop pain therapy competitor include collegium pharmaceutical xtampza teva pharmaceutical naproxen name few also player pegylation polymer conjugate chemistry technology space be biogen biib savient pharmaceutical dr reddy nordisk other nektar heavy reliance partner revenue remain concern partnership related setback seriously weigh company nektar therapeutic price consensusnektar therapeutic price consensus nektar therapeutic quotezack ranknektar currently carry zack rank hold see complete list today zack rank strong buy stock here trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
1188,LLY,nektar therapeutic nktr free report share have decline almost aug company report second quarter result biotech report wider expect loss sale miss estimate nektar second quarter loss cent share be wider zack consensus estimate loss cent report loss be also wider year loss cent share nektar share have significantly outperformed industry so far year company share have surge industry have register decrease quarterly revenue rise year quarter increase revenue mainly be attribute rise product sale royalty revenue however top line miss zack consensus estimate quarter top line comprise product sale royalty revenue cash royalty revenue license collaboration other revenue second quarter product sale increase year however cash royalty revenue decrease company report royalty revenue register huge improvement second quarter compare year quarter be mainly thank royalty revenue movantik sale license collaboration other revenue come compare year fall revenue mainly be attribute recognition receive daiichi sankyo sublicense onzeald formerly know nktr europe second quarter research development expense climb primarily due investment pipeline include key candidate nktr nktr general administrative expense be massive jump mainly be attribute payment settlement litigation regard cross license agreement enzon inc florida base pharma company pipeline most advanced candidate company portfolio be onzeald currently accelerate assessment eu treatment adult advanced breast cancer have brain metastase however company be inform last month committee medicinal product human use chmp have adopt negative opinion conditional marketing application candidate eu subsequently same month company file request examine opinion adopt chmp apart onzeald candidate company immuno oncology portfolio be nktr phase ii study evaluate nktr potential combination treatment regimen bristol myer squibb bmy free report opdivo be underway second quarter nektar announce have start dose patient trial plan enroll patient target cancer indication company expect report initial datum dose escalation part study soon notably nektar announce research collaboration agreement japanese pharma company takeda pharmaceutical explore combination nktr oncology compound takeda cancer portfolio last month nektar announce have enter strategic collaboration contract eli lilly company lly free report co develop nktr phase study ongoing treatment number autoimmune other chronic inflammatory condition outlook updatednektar raise revenue outlook account upfront payment expect receive lilly company now estimate revenue range compare project previously drive same reason nektar also raise expect cash position year end approximately compare estimate previously nektar therapeutic price consensus ep surprisenektar therapeutic price consensus ep surprise nektar therapeutic quotezack rank key picksnektar currently carry zack rank hold better rank stock health care sector be enzo inc carry zack rank buy see complete list today zack rank strong buy stock here enzo loss share estimate narrow cent cent cent cent last day company come positive earning surprise trail quarters average beat stock surge so far year make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1189,LLY,celldex therapeutic inc cldx free report incur second quarter loss cent share be narrower zack consensus estimate loss cent well year loss cent share lower cost higher revenue lead narrower loss quarter total revenue quarter rise year year beating zack consensus estimate manufacturing service agreement international aids vaccine initiative lead higher revenue quarter share biotech company rise hour trading tuesday however stock have not do too well year so far have decline year date increase register industry research development expense decline year period general administrative spend decline jun celldex have cash cash equivalent marketable security compare mar celldex expect cash anticipate proceed future sale common stock agreement cantor be enough fund work capital requirement plan operation however guidance assume celldex pay future kolltan contingent milestone stock not cash pipeline updatecelldex most advanced pipeline candidate be glembatumumab vedotin currently be evaluate treatment triple negative breast cancer phase iib metric study metastatic melanoma phase ii enrolment metric study be expect be complete september year top line datum expect second quarter datum phase ii metastatic melanoma study glemba single agent be present june annual meeting american society clinical oncology asco glemba perform well single agent set response rate disease control rate median duration response month patient have fail prior line therapy study also include new cohort glembatumumab varlilumab arm datum expect year end glembatumumab checkpoint inhibitor arm include bristol myer squibb company bmy free report opdivo merck co inc mrk free report keytruda apart glembatumumab vedotin celldex have several promising candidate pipeline include varlilumab cdx phase advanced renal cell carcinoma other varlilumab be be evaluate combination bristol myer opdivo phase ii study include cohort indication colorectal cancer ovarian cancer head neck squamous cell carcinoma renal cell carcinoma glioblastoma celldex plan complete enrolment cohort phase ii portion study first quarter meanwhile company present datum phase potion varlilumab opdivo combination study asco june datum show combination be well tolerate test dose level increase autoimmunity inappropriate immune activation kolltan acquisition nov celldex gain right kolltan cancer pipeline candidate cdx cdx cdx be be evaluate phase study refractory stromal tumor gist other kit positive tumor datum expect year end phase ii study cdx patient recurrent metastatic head neck squamous cell cancer be refractory eli lilly company lly free report bristol myer erbitux be expect be initiate fourth quartercelldex therapeutic inc price consensus ep surprise celldex therapeutic inc price consensus ep surprise celldex therapeutic inc quotecelldex carry zack rank sell see complete list today zack rank strong buy stock here more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
1190,LLY,world heart day be observed year september raise awareness world cardiovascular cv disease cv disease more commonly know heart disease stroke be basically disease heart blood vessel accord world heart federation cv disease be biggest killer world accounting death year number expect cross factor contribute number include uncontrolled hypertension high cholesterol level obesity smoking diabetes sedentary lifestyle theme world heart day be share power focus inspiring person world be heart healthy focus be create heart healthy environment help reduce cardiovascular risk be work home simple change lifestyle include healthy eating exercise lower alcohol consumption give smoking be way cut even prevent risk cv disease accord fda person die cardiovascular disease day unite state add american year give statistic be not surprising several healthcare company devote significant amount dollar develop treatment device cardiovascular other disease increase risk heart issue accord gbi research report more product be active development cv disease focus be main indication hypertension heart failure dyslipidemia thrombosis importantly be not just healthcare company be involved fitness segment many cv disease be preventable address behavioral risk factor food consumption smoking lack exercise person be become more conscious health have lead tech company come fitness tracker help keep track heart rate calory burn sleep pattern help management lifestyle disease diabetes obesity world heart day come let take look well position stock segment market biotelemetry inc beat free report malvern pa base biotelemetry be wireless medical technology company provide health information aim improve quality life reduce cost care company provide cardiac monitoring service original equipment manufacturing primary focus cardiac monitoring device centralize core laboratory service zack rank buy stock have strong earning track record have surpass expectation last quarters recent acquisition lifewatch have position company largest provider remote healthcare service world biotelemetry look well position rapidly evolve connect health market expect serve more patient share biotelemetry have gain year date significantly outperform industry rally edward lifescience corp ew free report edward lifescience hold lead position patient focuse innovation structural heart disease critical care monitoring company portfolio include product annuloplasty ring catheter heart valf enable treatment patient cardiovascular disease edward lifescience be focuse develop structural heart therapy estimate global transcatheter aortic valve replacement tavr opportunity cross drive increase awareness expand indication improve technology share zack rank strong buy stock hold strong position approximately global surgical heart valve segment be year date compare industry rally company have consistently surpass earning expectation last quarters novartis ag nvs free report swiss drugmaker novartis have be news lately gain approval first car cell treatment unite state company be also key player heart failure segment zack rank stock have approve drug form entresto treatment heart failure reduce ejection fraction heart failure debilitating life threaten condition be estimate affect more person world heart failure patient suffer reduce ejection fraction novartis be work generate more datum entresto heart failure more active plan study novartis also have good earning track record earning surpass expectation last quarters share zack rank stock be year date compare industry rally addition stock be several other company involved therapeutic area include company merck mrk free report nordisk nvo free report eli lilly lly free report other company be key player diabetes market accord information provide american heart association adult diabetes be time more likely die heart disease adult diabetes merck lilly be zack rank hold stock nordisk be zack rank stock see complete list today zack rank stock here hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
1191,LLY,johnson johnson jnj free report announce fda have deny approval investigational rheumatoid arthritis ra treatment sirukumab il inhibitor want additional safety datum fda issue complete response letter crl biologic license application bla sirukumab be file september last year company be look get sirukumab approve treatment adult patient moderately severely active ra have have inadequate response be intolerant more disease modify rheumatic drug dmard regulatory application be review eu japan well propose trade name sirukumab be plivensia so far year share price have increase compare unfavorably gain record industry belong crl be somewhat expect last month fda arthritis advisory committee have not recommend approval sirukumab raise safety concern panel be concern increase mortality rate evaluate dose mg mg sirukumab fda crl have ask additional clinical datum further evaluate safety candidate plan meet fda follow discussion crl be expect delay drug approval be previously expect happen year july year partner sirukumab base drug giant glaxosmithkline plc gsk free report inform termination collaboration remind investor eli lilly company lly free report partner incyte corporation incy free report have also receive crl experimental jak inhibitor baricitinib treat ra fda demand additional datum however august company inform re submit nda baricitinib much faster previously expect not be require conduct additional study nda be expect be re submit january next year ra be common chronic life long autoimmune disease affect person unite state carry zack rank hold see complete list today zack rank strong buy stock here hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
1192,LLY,key highlight pharma sector include complete response letter crl fda johnson johnson jnj free report investigational rheumatoid arthritis ra treatment fda approval merck mrk free report bristol myer squibb bmy free report cancer drug recap week most important storiescrl ra drug janssen biotech get crl fda sirukumab treatment moderately severely active ra agency have ask additional datum safety sirukumab do not come surprise consider investigational treatment fail get support fda advisory panel last month give safety concern raise panel request additional datum be more less expect intend meet agency determine requirement gain approval il inhibitor meanwhile company have submit new drug application nda first darunavir base single tablet regimen treatment hiv approval make combination only complete regimen potential deliver advantage single table regimen high genetic barrier resistance darunavir demonstrated safety profile taf fda nod merck keytruda merck pd therapy keytruda have gain fda approval yet indication cancer therapy be already available wide range indication now be used previously treat patient recurrent locally advanced metastatic gastric junction gej adenocarcinoma tumor express pd mark tenth new indication keytruda year period keytruda be key product merck portfolio drug bring sale first half company be work expand label drug be currently more study cover wide range cancer treatment setting read more merck keytruda get fda nod advanced gastric cancer merck be zack rank hold stock see complete list today zack rank strong buy stock here allergan announce share buy back cfo departure allergan agn free report continue work return capital shareholder company announce intention buy back share worth come shortly company complete share buyback program allergan also reaffirm commitment increase cash dividend year reiterate commitment maintain investment grade credit rating pay debt company also announce departure tessa hilado executive vice president chief financial officer cfo be retire company once successor be appoint bristol myer opdivo get approval bristol myer also gain approval indication immune oncology therapy opdivo latest approval opdivo now be used treatment hepatocellular carcinoma patient previously treat nexavar sorafenib make opdivo first only immuno oncology agent be approve patient population read more bristol myer opdivo get approval liver cancer company also gain approval japan use opdivo treatment unresectable advanced recurrent gastric cancer have progressed chemotherapy gastric cancer be highly prevalent asian country be second most commonly diagnosed cancer japan bristol myer also enter clinical trial collaboration abbvie combination opdivo abbvie investigational antibody drug conjugate abbv be evaluate meet overexpressing small cell lung cancer nsclc bristol myer stock have gain year date compare rally industry belong priority review aradigm drug aradigm get priority review linhaliq treatment cystic fibrosis bronchiectasis ncfbe patient chronic infection pseudomona aeruginosa aeruginosa response agency regard approval status drug be jan ncfbe severe chronic rare disease affect more person unite state person europe drug currently approve treatment condition be significant unmet need aradigm share be news cap pharmaceutical industry yr returnlarge cap pharmaceutical industry yr nyse arca pharmaceutical index be so far week major stock lilly lly free report be pfizer pfe free report be last month bristol myer be glaxo gsk free report decline see last pharma stock roundup here pfizer file suit supernus hit study update next pharma world watch usual pipeline regulatory update hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
1193,LLY,jul issue update report immunogen inc imgn free report immunogen be development stage biotechnology company focuse develop target cancer therapeutic used proprietary antibody drug conjugate adc technology company share have significantly outperformed zack categorised medical drug industry so far year have soar industry have register increase immunogen have make significant progress regard lead pipeline candidate mirvetuximab soravtansine be currently phase iii study forward single agent therapy have be put trial treat patient platinum resistant ovarian cancer tumor express high medium level fr alpha have receive prior treatment regimen combination regimen mirvetuximab soravtansine ovarian cancer be phase ib ii forward ii study aim expand eligible patient population follow successful completion dose escalation phase ii expansion cohort combination roche avastin be also ongoing immunogen expect report initial datum forward ii study soon notably mirvetuximab soravtansine enjoy orphan drug status eu treatment ovarian cancer platinum resistant ovarian cancer market provide immense commercial potential immunogen be set face intense competition approval nonetheless mirvetuximab soravtansine look promising juncture sanction be huge boost company apart mirvetuximab soravtansine immunogen be work develop couple other candidate include imgn imgn imgn be be evaluate phase study treat acute myeloid leukemia datum expect later year company plan file investigational new drug application inda imgn treat hematological malignancy third quarter immunogen have agreement several big healthcare company include amgen inc amgn free report bayer eli lilly company lly free report novartis nvs free report roche sanofi takeda agreement turn allow other company use immunogen adc technology provide fund form license milestone fee royalty clinical material revenue support fee immunogen inc price inc price consensus immunogen inc quotezack carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1194,LLY,merck co inc mrk free report announce fda have approve pd therapy keytruda monotherapy third line treatment advanced gastric junction adenocarcinoma keytruda be already approve many type cancer treatment setting include lung cancer melanoma head neck cancer classical hodgkin lymphoma bladder cancer drug label have now be expand include treatment heavily pre treat patient recurrent locally advanced metastatic gastric junction cancer tumor express pd determine fda approve test however approval tenth new indication keytruda come accelerate basis continue approval dependent further benefit demonstrated clinical study fda approval be base datum keynote study keytruda be key top line driver merck bring sale second quarter sequentially year year sale continue be drive launch new indication globally keytruda sale gain particularly strong momentum new indication first line lung cancer outside keytruda sale be primarily drive melanoma indication meanwhile keytruda development program also significantly advanced year regulatory approval new indication additional indication europe important approval include advanced bladder cancer unite state eu advanced microsatellite instability high cancer first approval combination therapy eli lilly company lly free report cancer drug alimta pemetrexed carboplatin pem carbo commonly used chemo regimen lung cancer further keytruda datum readout be pending year keytruda be continuously grow expand new indication market globally keytruda be be study more type cancer more study include more combination study merck be collaborate several company include amgen inc amgn free report incyte glaxo pfizer inc pfe free report separately evaluation keytruda combination other regimen merck carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1195,LLY,eli lilly company lly free report partner incyte corporation incy free report announce pipeline candidate baricitinib meet primary endpoint phase ii study patient moderate severe atopic dermatitis ad type eczema so far year lilly share have underperform industry stock have be industry gain notably result show week treatment patient treat baricitinib mg topical corticosteroid tcs achieve greater improvement sign symptom ad versus patient treat tcs alone thereby suggest baricitinib have potential become oral treatment option patient suffering atopic dermatitis be unable achieve adequate control topical steroid however patient treat mg dose group baricitinib combination tcs primary endpoint be not statistically different compare treatment tcs alone week treatment patient treat baricitinib mg tcs combination patient treat baricitinib mg tcs combination witness improvement sign symptom ad compare patient tcs alone therefore base phase ii result lilly incyte plan initiate phase iii study atopic dermatitis later year baricitinib once daily oral medication be already market eu trade name olumiant treatment rheumatoid arthritis ra remind investor unite state fda have issue complete response letter crl baricitinib new drug application nda rheumatoid arthritis april fact fda have ask additional clinical datum determine most appropriate dose well further characterize safety concern treatment arm july lilly have declare nda resubmission baricitinib not occur be delay minimum month august lilly incyte announce re submit nda baricitinib much faster previously expect end nda be expect be re submit january consequently company expect revise submission include new safety efficacy datum be classify fda class ii resubmission decision fda be therefore expect month importantly new clinical study not be require markedly regeneron pharmaceutical inc regn free report partner sanofi sny free report dupixent injection be recently launch unite state treatment adult moderate severe ad march currently drug be review eu same indication eli lilly company price eli lilly company price eli lilly company quotezack ranklilly carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1196,LLY,several important development be report week key highlight include termination hepatitis virus deal approval first cancer biosimilar unite state presentation datum company pfizer pfe free report bristol myer squibb bmy free report other recap week most important hcv deal termination achillion pharmaceutical achn free report share fall termination company partnership agreement johnson johnson janssen pharmaceutical hepatitis virus hcv janssen say not continue development jnj combination direct act antiviral al odalasvir simeprevir decision discontinue development do not come big surprise give intense competition pricing dynamic hcv market achillion intend focus development advanced multiple small molecule factor inhibitor complement alternative pathway read more achillion hcv partnership terminate stock fall first cancer biosimilar get fda nod fda approve allergan agn free report amgen mvasi biosimilar version roche blockbuster cancer drug avastin bevacizumab mvasi be used eligible indication reference product approval be line expectation consider favorable vote biosimilar get fda advisory panel recently approval be quite boost company well effort lower drug price so far biosimilar be yet make significant dent reference product sale unite state mvasi be review eu pfizer xtandi prosper late stage study pfizer partner astella pharma well be path boost sale prostate cancer drug xtandi company announce positive top line datum late stage study prosper patient metastatic castration resistant prostate cancer crpc company plan discuss datum regulatory authority expansion drug label xtandi sale have be pressure receive boost approval patient population bristol myer sign deal present cancer datum bristol myer squibb present datum european society medical oncology esmo congress show treatment opdivo lead superior recurrence free survival compare yervoy patient resect high risk melanoma read more bristol myer report positive result melanoma study meanwhile company have sign deal halozyme latter enhanze technology global collaboration license agreement be focuse use halozyme technology subcutaneous administration bristol myer immuno oncology drug thereby provide patient more flexible convenient treatment delivery option bristol myer shell upfront make future milestone royalty payment dilutive transaction be expect hit bristol myer earning penny earning cent lilly baricitinib fare well mid stage eczema study eli lilly company lly free report incyte present new safety efficacy datum mid stage study baricitinib eczema annual meeting european academy dermatology venereology eadv baricitinib combine mid potency topical corticosteroid tcs significantly improve sign symptom eczema compare tcs alone company intend commence phase iii program eczema indication later year baricitinib be currently approve eu trade name olumiant moderate severe active rheumatoid arthritis however approval be yet come unite state regulatory filing be resubmit jan lilly stock have gain year date compare rally industry belong teva appoint new ceo teva teva free report have finally end search chief executive officer ceo company announce appointment kare schultz company president ceo seasoned veteran healthcare industry schulz bring almost year experience segment schulz be recently serve president ceo lundbeck be responsible implement significant restructure initiative launch robust turnaround strategy schulz have daunting task ahead consider challenge be face teva include generic pricing erosion company need work pay debt divest core business increase focus core area generate cash deliver pipeline get generic business back track read more teva hire kare schultz ceo be recovery card positive fda panel vote glaxo shingle vaccine glaxosmithkline gsk free report get positive vote fda vaccine related biological product advisory committee vrbpac shingrix prevention herpes zoster shingle adult age give positive vote chance gain approval look pretty high note merck zostavax live attenuate virus vaccine be currently available prevention shingle same patient population read more glaxo shingle candidate get positive fda committee vote glaxo be zack rank hold stock see complete list today zack rank strong buy stock here cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index be last trading session almost major stock record gain pfizer gain bristol myer slip last month bristol myer be glaxo decline see last pharma stock roundup here lilly cut job streamline operation nvs ceo step next pharma world watch usual pipeline regulatory update fda advisory panel be meeting sep discuss supplemental new drug application snda submit pfizer cancer drug sutent adjuvant treatment adult patient high risk recurrent renal cell carcinoma rcc follow nephrectomy surgical removal cancer contain kidney moreover fda decision regard label expansion merck pd therapy keytruda use treatment recurrent advanced gastric junction adenocarcinoma be sep look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1197,LLY,medical sector biotech stock have perform well first half year challenge rise competition pipeline setback slowdown growth mature product generic competition certain key drug sector re-cover pricing controversy defy uncertainty surround president trump propose healthcare policy factor be responsible biotech sector perform well current year so far be increase fda approval new product sale ramp success innovation strong clinical study result continue strong performance legacy product few other event also contribute rally sector past month include pharmaceutical giant gilead science gild free report decision acquire immunotherapy focuse company kite pharma fda approval novartis ag nvs gene transfer treatment kymriah suspension treatment patient year age cell precursor acute lymphoblastic leukemia be refractory second later relapse be good news sector kymriah formerly ctl be first chimeric antigen receptor cell car therapy be approve further company alexion pharmaceutical inc alxn free report eli lilly company lly free report announce restructure initiative include job cut recently former reduce global workforce lilly do same company plan invest cost saving new drug line extension turn bode well growth sector well industry rank broader drug market be year date outpace gain zack industry medical biom genetic versus large cap pharma versus have outperformed index zack industry rank medical biom genetic be top zack industry medical drug rank be top large cap pharma be top back testing show top zack rank industry outperform bottom factor more stock pick cash favorable trend drug biotech space be right time add few stock have growth potential have take help zack stock screener select right stock shortlist stock vast universe pharmaceutical company have picked stock carry zack rank strong buy buy see complete list today zack rank stock here further narrow list have select have growth score research show stock growth score combine zack rank offer best upside potential here be stock fulfilled criterium therapeutic inc cort free report carry zack rank stock have growth score share company have gain year date outperform medical drug industry gain also be expect record earning growth sale be expect grow heska corp hska free report carry zack rank stock have growth score share company have gain year date outperform medical biom genetic industry gain also be expect record earning growth sale be expect grow sangamo therapeutic inc sgmo free report carry zack rank stock have growth score share company have gain year date outperform medical biom genetic industry gain also be expect record earning growth sale be expect grow lundbeck hluyy free report carry zack rank stock have growth score share company have gain year date outperform large cap pharma industry gain also be expect record earning growth sale be expect grow trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
1198,LLY,total earning total healthcare market capitalization be revenue growth earning growth be weak compare many other sector earning revenue beat ratio respectively be particularly encourage fact healthcare be fourth sector surprised investor most earning trail aerospace technology material most notable player johnson johnson jnj free report be first major drug company report earning july follow eli lilly company lly free report bristol myer squibb company bmy free report july july respectively other major drug company merck mrk free report pfizer pfe free report report july august respectively industry prime post solid result earning beat few lag revenue front johnson johnson earning world biggest maker healthcare product continue long streak earning beat narrowly miss top line estimate earning share come cent ahead zack consensus estimate higher year quarter revenue grow year year fall shy zack consensus estimate johnson johnson raise full year earning share guidance revenue guidance zack consensus estimate be peg earning share revenue time earning release jnj have gain date earning announcement read brighten outlook healthcare etfs focus pfizer earning drug giant beat earning miss revenue earning share cent come couple cent zack consensus estimate revenue fall shy estimate annual basis earning share rise revenue decline pfizer expect revenue range raise lower end earning share guidance zack consensus estimate be correctly peg revenue earning share share pfe be earning announcement merck earning focusearning share come surpass zack consensus estimate cent improve year quarter revenue inched year year be zack consensus estimate merck raise revenue guidance reiterate earning share projection year zack consensus estimate be currently peg revenue earning share stock have lose follow earning announcement bristol myer earning focusbristol myer report earning share cent penny ahead estimate increase year quarter revenue grow edge past zack consensus estimate company raise low end earning share guidance year zack consensus estimate time earning announcement be peg share bmy be date earning announcement see healthcare etfs here eli lilly earning focusearning eli lilly outpaced zack consensus estimate cent come higher year quarter revenue grow beat estimate other drug maker eli lilly also raise revenue earning guidance now expect revenue range compare previous expectation earning share range versus expect previously zack consensus estimate time earning release be peg revenue earning share share lly have lose earning release etf string earning beat fail boost pharma etfs see rough trading past day have highlighted detail powershare dynamic pharmaceutical fund pjp be far most popular choice pharma space follow dynamic pharmaceutical intellidex index product have aum see moderate volume share day fund charge bps fee expense hold stock fund invest share focus firm etf have lose past day have zack etf rank hold rating high risk outlook read lie ahead pharma etfs second half ishare pharmaceutical etf ihe free report etf provide exposure pharma stock tracking dow jone select pharmaceutical index focus firm be top hold basket accounting combine total asset suggest heavy concentration product have aum charge bps fee expense volume be light exchange share day fund have shed past day have zack etf rank buy rating high risk outlook spdr pharmaceutical etf xph free report fund provide exposure pharma company tracking pharmaceutical select industry index aum trade good volume share day charge bps fee year total product hold security focus firm take share product be same period have zack etf rank high risk outlook vaneck vector pharmaceutical etf etf follow mvis list pharmaceutical index hold stock basket johnson johnson take top spot basket asset pfizer bristol myer merck eli lilly collectively account asset product have amassed asset base trade moderate volume share day expense ratio come fund have lose past day have zack etf rank medium risk outlook read etfs buy avoid healthcare bill failure want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
1199,LLY,radius health inc rdus free report post loss share second quarter wider loss share year quarter wider zack consensus estimate loss year year increase net loss be attributable increase general administrative expense radius share price increase year date industry gain company report sale tymlos abaloparatide first week launch miss zack consensus estimate quarter detailresearch development expense report quarter be year year due decrease regulatory professional fee associate abaloparatide sc regulatory application decrase elacestrant rad project cost decrease development cost associate abaloparatide td general administrative expense report quarter jump increase be attribute growth professional support cost include cost associate increase headcount tymlos higher compensation expense include stock base compensation due increase headcount be also responsible increase cost radius health inc price ep surprise radius health inc price ep surprise radius health inc quotepipeline updateson apr fda approve radius health lead candidate tymlos injection treatment postmenopausal woman high risk osteoporosis fracture defined history osteoporotic fracture multiple risk factor fracture patient have fail be intolerant other available osteoporosis therapy company be develop formulation abaloparatide abaloparatide sc abaloparatide transdermal meanwhile radius health marketing authorisation application maa eladyno abaloparatide sc treatment postmenopausal woman osteoporosis europe be review committee medicinal product human use chmp european medicine agency company however suffer setback chmp issue second day list outstanding issue consequently radius be work chmp address issue company expect response prior end radius health announce positive top line result complete month activextend clinical trial tymlos meet primary secondary endpoint company expect submit snda fda connection activextend result year end company report positive datum ongoing phase dose escalation expansion study elacestrant advanced metastatic breast cancer company discuss datum ongoing phase study fda determine next step elacestrant breast cancer program include design phase ii trial follow discussion fda agree single arm monotherapy phase ii study patient be appropriate agency also provide additional feedback propose clinical protocol include confirmation primary endpoint be objective response rate durability response fda also state study result demonstrate superiority then available therapy single arm phase ii trial be consider pivotal study accelerate approval long company have also commence confirmatory study time new drug application nda submission addition elacestrant be also be evaluate low dose estrogen receptor ligand potential relief frequency severity moderate severe hot flash postmenopausal woman vasomotor symptom company expect report result phase iib clinical study elacestrant potential treatment postmenopausal vasomotor symptom second half company wider expect loss second quarter be disappointing expense continue increase launch tymlos company be move ahead plan contract manage care organization access cover life commercial medicare part plan osteoporosis market have great potential approximately postmenopausal woman experience osteoporotic fracture year tymlos be expect face significant competition eli lilly co lly free report forteo amgen inc amgn free report prolium moreover approve label carry box warning osteosarcoma malignant bone tumor company however suffer setback chmp issue second day list outstanding issue zack rank key pickradius health currently have zack rank sell better rank stock healthcare sector be gilead science inc gild free report currently carry zack rank buy see complete list today zack rank strong buy stock here gilead earning share estimate increase last day follow strong result second quarter company deliver positive earning surprise trail quarters average beat today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1200,LLY,week company pfizer pfe free report allergan agn free report teva teva free report report second quarter result pfizer report mixed quarter allergan top expectation teva however have tough quarter meanwhile bristol myer bmy free report announce immune oncology io focuse deal include acquisition recap week most important storiesa look earning result big company pfizer allergan teva report second quarter result week pfizer surpass earning estimate miss revenue raise concern company top line growth prospect prevnar enbrel sale decline quarter pfizer be face key loss exclusivity loe viagra later year lyrica end read more pfizer surpass earning estimate miss sale meanwhile allergan top earning sale estimate raise outlook well read more allergan earning sale top restasis sale teva share fall dismal quarter company miss earning sale reflect performance generic business continue deterioration venezuela generic business be hit accelerate price erosion lower volume mainly due customer consolidation higher competition delay new product launch teva lower outlook year slash dividend well company also expect exit market globe year end be cut headcount close actavis generic business deal teva have lose value year date versus decline industry abbvie drug get fda nod cgvhd johnson johnson jnj free report abbvie btk inhibitor imbruvica gain fda approval first cancer indication chronic graft versus host disease cgvhd adult failure more systemic line therapy make imbruvica first only approve treatment patient population mark sixth indication imbruvica stock have gain year date outperform rally industry belong bristol myer acquisition deal worth bristol myer announce be acquire ifm therapeutic venture backed biotech company work treatment modulate novel target innate immune system treat cancer autoimmunity inflammatory disorder acquisition bristol myer gain full right ifm preclinical sting stimulator interferon gene nlrp agonist program be focuse cancer sting agonist program include lead asset nlrp agonist program include potential first class pipeline candidate acquisition schedule close third quarter strengthen bristol myer immune oncology io pipeline deal see bristol myer shell upfront additional payment be make first product program achievement certain milestone additional milestone payment be make further product result program bristol myer sign io focuse deal week company sign clinical collaboration agreement clovis oncology immunotherapy opdivo be evaluate combination clovis parp inhibitor rubraca mid late stage study different type tumor meanwhile opdivo label be expand week treatment adult pediatric year older patient microsatellite instability high msi mismatch repair deficient dmmr metastatic colorectal cancer mcrc have progressed follow treatment oxaliplatin irinotecan accelerate approval be grant basis overall response rate orr duration response however note merck keytruda gain approval earlier year patient msi dmmr wider patient population merck label include patient solid tumor have progressed follow prior treatment have satisfactory alternative treatment option well colorectal cancer patient disease have progressed follow treatment certain chemotherapy drug ra drug fail get fda advisory panel support investigational rheumatoid arthritis ra treatment plivensia sirukumab il inhibitor fail get support fda arthritis advisory committee safety concern company be look get plivensia approve treatment adult patient moderately severely active ra have have inadequate response be intolerant more disease modify rheumatic drug dmard ra be common chronic life long autoimmune disease affect person fda be not require do so usually follow advice advisory panel consider safety concern raise panel agency well ask additional information grant approval pfizer drug get advisory panel support pfizer supplemental new drug application snda jak inhibitor xeljanz mg twice daily xeljanz xr mg once daily treatment adult patient active psoriatic arthritis psa get support fda arthritis advisory committee advisory panel vote favor approve propose dose xeljanz psa indication decision fda be dec xeljanz currently approve ra bring sale first half priority review astrazeneca btk inhibitor astrazeneca azn free report investigational btk inhibitor acalabrutinib be grant priority review fda company be look get drug approve use patient relapse refractory mantle cell lymphoma mcl have receive least prior therapy response agency be expect first quarter acalabrutinib be also give breakthrough therapy designation btd indication astrazeneca imfinzi also get btd week treatment patient locally advanced unresectable small cell lung cancer nsclc disease have not progressed follow platinum base chemoradiation therapy positive datum lilly migraine drug lilly lly free report present late stage datum investigational migraine drug lasmiditan say meet primary endpoint well key secondary endpoint result be consistent result present earlier late stage study lilly expect file fda approval second half lilly be zack rank buy stock see complete list today zack rank strong buy stock here cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index decline last trading session major stock pfizer be lilly lose last month be astrazeneca gain see last pharma stock roundup here nvs earning merck drug get tentative fda nod next pharma world watch usual pipeline regulatory update today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1201,LLY,have already crossed halfway mark second quarter report cycle earn season have show broad base growth record earning quarter jul member accounting index total market capitalization report result accord earning preview company beat count compare first quarter total earning index member be year quarter improvement revenue beat ratio be earning revenue medical segment have also perform well so far earning increase revenue report total earning company second quarter be expect grow year year higher revenue plenty result still come actual earning growth quarter exceed mark follow earning growth first quarter increase revenue highest almost year johnson johnson jnj free report begin earning season pharma sector mixed second quarter result performance novartis nvs free report lilly lly free report biogen inc biib free report be encourage company beat earning revenue estimate lilly biogen also raise earning revenue estimate other pharma bigwig report last week abbvie inc abbv free report report better expect result earning sale surpass expectation lymphoma drug imbruvica record record growth merck co inc mrk free report also beat estimate earning sale second quarter mainly backed strong sale pd inhibitor keytruda let take look pharma biotech company be set report second quarter result aug let see thing be shape quarter pfizer inc pfe free report pfizer be schedule release earning open bell deliver positive earning surprise last quarter pfizer earning performance have be mixed earning miss expectation last quarters beating same twice result average negative surprise quarter pfizer have earning esp zack rank hold indicate likely beat zack consensus estimate be peg cent share uncover best stock buy sell re report earning esp filter pfizer inc price ep surprise pfizer inc price ep surprise pfizer inc quotenew product xeljanz rheumatoid arthritis ibrance breast cancer well older product lyrica neuropathic pain eliquis blood thinner be likely contribute top line meaningfully read more be beat card pfizer earning aerie pharmaceutical inc aeri free report aerie pharma be schedule announce result close bell aerie pharma have miss estimate past quarters have average negative earning surprise company have earning esp zack rank buy see complete list today zack rank strong buy stock here aerie pharmaceutical inc price ep surprise aerie pharmaceutical inc price ep surprise aerie pharmaceutical inc approve product portfolio aerie depend heavily late stage candidate rhopressa roclatan aerie have submit regulatory application rhopressa expect submit same eu second half hence expect investor focus remain pipeline update read more card aerie earning season incyte corporation incy free report company be expect report market open incyte deliver earning surprise last quarter incyte performance have be pretty impressive company report positive surprise consistently average earning beat last quarters be company have earning esp zack rank zack consensus estimate be peg loss cent share incyte corporation price ep surprise incyte corporation price ep surprise incyte corporation quotemore stock news company verge apple rundid miss apple stock explosion launch iphone now look be pivotal year get emerge technology expect rock market demand soar almost nothing report suggest save life decade turn save healthcare cost bonus zack special report name breakthrough best stock exploit apple company be already strong coil potential mega gain click see right now
1202,LLY,array biopharma arry free report announce fda have accept review new drug application ndas seek approval combination binimetinib mg twice daily encorafenib mg once daily combo treat patient braf mutant advanced unresectable metastatic melanoma fda have set action date june application nda submission be support encourage datum phase iii columbus study conduct part array share have underperform industry year date stock have be compare industry gain same time frame september array have announce positive top line datum part phase iii study result evaluation show combination combo mg twice daily encorafenib mg once daily have significantly improve progression free survival pfs comparison roche hold ag rhhby free report zelboraf vemurafenib thus meeting primary endpoint additionally combo therapy be generally well tolerate adverse event be consistent previous trial company have further reveal positive datum part columbus study be specifically design evaluate give combination combo reduce encorafenib dose mg compare lower dosage fact median pfs patient treat combo be month compare month patient treat single agent encorafenib fusion be also endure well study currently array be evaluate encorafenib collaboration eli lilly company lly free report erbitux cetuximab binimetinib phase iii beacon crc study patient braf mutant colorectal cancer experimental trial be be perform special protocol assessment spa fda patient enrollment same be expect be complete remind investor array have regain development right binimetinib novartis pharma ag nvs free report march array biopharma inc price array biopharma inc price array biopharma inc quotezack rankarray currently carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1203,LLY,abbvie abbv free report share increase almost company announce oral jak selective inhibitor upadacitinib meet primary endpoint phase iii study treatment patient rheumatoid arthritis ra fact abbvie share have rally outperform industry rise so far year phase iii select study be multus center randomize double blind placebo controlled parallel group study be design evaluate efficacy safety dose mg mg upadacitinib compare placebo week patient moderate severe ra be stable dose conventional synthetic dmard have have show inadequate response dosage study meet primary endpoint highly statistically significant clinically meaningful result dose compare placebo trial primary endpoint be acr response low disease activity lda result show patient receive mg patient administer mg dose once daily upadacitinib achieve acr response week treatment comparison patient receive placebo lda be achieve patient mg mg dose arm respectively compare patient receive placebo additionally study meet secondary endpoint too notably select be second ongoing phase iii study select ra clinical trial program conduct upadacitinib other research be also underway upadacitinib treat crohn disease ulcerative colitis atopic dermatitis remind investor last week company announce upadacitinib have meet primary endpoint phase iib study atopic dermatitis company plan advance candidate phase iii study next year give indication note abbvie already have strong presence ra market blockbuster drug humira however several company be work develop biosimilar version humira induce competition market company also ra market be extremely crowd include drug johnson johnson simponi ucb cimzia other significantly eli lilly lly free report jak inhibitor olumiant be recently approve eu pfizer pfe free report xeljanz be market unite state treat ra strong competition upadacitinib approval also amgen amgn free report have already receive approval market humira biosimilar drug have not be launch yet due ongoing litigation upadacitinib be approve reduce potential negative impact humira generic abbvie top line abbvie inc priceabbvie inc price abbvie inc quotezack rankabbvie currently carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1204,LLY,eli lilly company lly free report announce plan thursday reduce global workforce approximately position initiative be expect amass annualize saving approximately begin drug giant plan invest saving new drug overall growth company lilly be look forward launch new medicine end next year probably galcanezumab migraine prevention galcanezumab abemaciclib breast cancer share lilly be thursday so far year lilly share price have rise compare increase industry lilly expect most layoff come voluntary early retirement program be offer employee plan be expect be complete december be also close several site plant iowa office new jersey center china save cost job cut be not expect affect lilly adjust earning forecast lilly expect achieve total operate expense efficiency less revenue end earlier company have expect operate expense efficiency less lilly face share challenge several key drug portfolio zyprexa cymbalta be face generic competition due loss exclusivity meanwhile blockbuster drug alimta sale be also be affected entry immuno oncology agent market outside sale be already be hurt due loss exclusivity several country other headwind include competition immuno oncology agent well recent high profile pipeline setback latest be delay approval rheumatoid arthritis candidate baricitinib unite state also lilly animal health segment do not do too well first half due worldwide competitive pressure cost saving likely help lilly offset impact challenge extent lilly carry zack rank hold stock considerbetter rank biotech stock include alexion pharmaceutical inc alxn free report ligand pharmaceutical incorporate lgnd free report regeneron pharmaceutical inc regn free report zack rank strong buy see complete list today zack rank stock here share alexion be year date estimate have rise respectively past day share ligand have rise so far year estimate have rise respectively past day regeneron share year so far estimate have rise have go past day more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1205,LLY,last week several pharma major report second quarter result meanwhile important study datum be release merck mrk free report astrazeneca azn free report recap week most important storiesa look earning result big pharma company merck lilly lly free report glaxo roche bristol myer bmy free report astrazeneca report second quarter result last week bristol myer lilly merck beat expectation merck maintain outlook year read more merck beat earning sale keep view bristol myer update same read more bristol myer beat earning tweak view lilly be hit baricitinib update report beat raise quarter read more key takeaway lilly call baricitinib cancer pipeline meanwhile astrazeneca result be shadow disappointing mystic datum imfinzi treatment naïve small cell lung cancer nsclc patient company share fall read more astrazeneca beat earning fall fail study british drugmaker glaxo set new priority company company decide allocate capital priority asset current respiratory hiv infectious disease potential oncology immuno inflammation therapy area glaxo also say more pre clinical clinical program be stop read more glaxosmithkline beat earning lower guidance lilly merck be zack rank buy stock see complete list today zack rank strong buy stock here merck keytruda miss endpoint hnscc study be lot update merck last week addition earning result company be hit disappointing result late stage study evaluate pd therapy keytruda monotherapy patient previously treat recurrent metastatic head neck squamous cell carcinoma hnscc study fail meet pre specify primary endpoint overall survival os be latest keytruda related setback merck earlier month company have announce fda have place clinical hold combination study keynote keynote keynote be conduct keytruda multiple myeloma mm meanwhile look merck second quarter result show keytruda remain strong lung cancer set keytruda be currently more study include more combination study merck astrazeneca sign oncology collaboration merck astrazeneca be collaborate global development merck keytruda astrazeneca parp inhibitor lynparza different type cancer lynparza currently approve brca mutate ovarian cancer multiple line treatment be different study range tumor type include breast prostate pancreatic cancer deal cover evaluation parp mek inhibitor pd pd inhibitor astrazeneca stand receive include upfront payment certain license option additional achievement regulatory sale milestone merck stock have gain year date ytd lag rally industry belong astrazeneca have gain ytd janssen inks deal bavarian nordic johnson johnson janssen pharmaceutical company denmark base biotech company bavarian nordic enter additional worldwide exclusive license collaboration agreement janssen get exclusive right bavarian nordic mva bn technology additional program target vaccine hepatitis virus hbv hiv make upfront payment equity investment worth bavarian nordic also be eligible receive milestone payment worth tiered royalty future sale deal company be now collaborate program combine bavarian nordic mva bn technology janssen advac technology platform pfizer astella xtandi breast cancer program drop astella report result last week provide update pipeline show company partner pfizer pfe free report have decide drop development xtandi breast cancer development program include phase iii study triple negative breast cancer phase ii study pr positive positive breast cancer astella say decision be base discussion pfizer change competitive landscape need further diagnostic development new phase ii datum ongoing program xtandi include metastatic castration resistant prostate cancer phase iii prostate cancer patient metastatic biochemical recurrence phase iii metastatic hormone sensitive prostate cancer phase iii hepatocellular cancer phase ii cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index decline last trading session major stock merck be astrazeneca lose last month be bristol myer gain see last pharma stock roundup here nvs earning merck drug get tentative fda nod next pharma world watch second quarter earning result company pfizer shire shpg free report allergan agn free report other moreover fda arthritis advisory committee be meeting aug discuss regulatory application investigational rheumatoid arthritis treatment plivensia sirukumab more stock news company verge apple rundid miss apple stock explosion launch iphone now look be pivotal year get emerge technology expect rock market demand soar almost nothing report suggest save life decade turn save healthcare cost bonus zack special report name breakthrough best stock exploit apple company be already strong coil potential mega gain click see right now
1206,LLY,abbvie inc abbv free report report better expect result second quarter company surpass earning sale expectation year so far abbvie share have rally thus favorably compare industry increase company report second quarter earning share marginally beat zack consensus estimate share earning grow year year company post revenue report quarter again narrowly surpass zack consensus estimate revenue also increase year year operational basis revenue increase quarter detailkey drug humira record sale growth operational basis revenue come sale increase humira sale ex market be operational basis report basis growth major market category drive upside increase competition new class drug well indirect biosimilar competition international market second quarter net revenue imbruvica stand year year sale imbruvica be compare year figure abbvie record international profit sharing johnson johnson jnj free report other product deliver impressive performance include duodopa show revenue operational report basis product call creon report revenue operational report basis hcv product viekira record sale sequentially sale be also operational report basis respectively due intense pricing competitive pressure hcv market adjust sg expense dip expense escalate quarter adjust operate margin be sale report quarter outlookabbvie reiterate previously issue outlook company maintain adjust ep range thus reflect year year growth mid point abbvie inc price consensus ep surpriseabbvie inc price consensus ep surprise abbvie inc quotezack rank key picksabbvie currently carry zack rank hold better rank stock health care sector be eli lilly company lly free report sanofi sny free report carry zack rank buy see complete list today zack rank stock here eli lilly earning share estimate inched last day company share have shot so far year sanofi earning share estimate increase last day company deliver positive earning surprise trail quarters average beat share company have rise so far year hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1207,LLY,be quite few important development week eli lilly company lly free report announce be streamline operation cut workforce focus develop new medicine improve cost structure meanwhile novartis nvs free report announce ceo be step recap week most important storieslilly streamline operation cut job lilly announce restructure plan see company streamline operation so focus develop new medicine improve cost structure company be cut job most reduction expect voluntary early retirement program lilly also be close certain site move production larchwood ia animal health manufacturing facility exist plant fort dodge ia research development office bridgewater nj lilly china research development center shanghai china also shut lilly expect generate annualize saving be used improve cost structure new product launch label expansion study streamline program result company incur pre tax charge post tax charge cent share be recognize third fourth quarters cut report earning guidance adjust earning outlook remain unchanged lilly also say streamline effort now expect achieve opex revenue ratio less indicate improvement previous forecast merck buy rigontec immuno oncology focuse deal immune oncology space continue attract interest big pharma player merck mrk free report announce intention acquire rigontec deal worth include upfront payment rigontec expertise lie access retinoic acid inducible gene rig pathway be part innate immune system goal induce immediate long term tumor immunity acquisition add rigontec lead candidate rgt merck pipeline rgt be currently early stage development patient various tumor also read merck opt buy german immuno oncology biotech merck also announce european commission have expand label pd therapy keytruda treatment certain patient locally advanced metastatic urothelial carcinoma type bladder cancer also read merck keytruda get eu approval bladder cancer bmy opdivo impress rcc study bristol myer squibb company bmy free report have mixed news pd immune checkpoint inhibitor opdivo company say late stage study checkmate evaluate opdivo yervoy be stop early show overall survival os benefit patient previously untreated advanced metastatic renal cell carcinoma rcc follow plan interim analysis independent datum monitoring committee dmc recommend study be stop early combination provide rcc patient new first line treatment option approval indication boost sale significantly be significant unmet need area rcc be most common type kidney cancer adult year survival rate advanced metastatic stage be second set opdivo related news be not so encourage company say partial clinical hold have be place fda opdivo base combination study multiple myeloma fda decide place study partial hold follow identification risk identify combination study evaluate merck keytruda multiple myeloma mylan face month delay herceptin biosimilar decision mylan nv myl free report partner biocon have bit longer get response fda biosimilar version roche blockbuster drug herceptin trastuzumab fda inform mylan be extend target action date month so review clarificatory information submit part application review process result regulatory body now issue response regard approval status biosimilar dec biosimilar version have receive favorable vote july fda oncologic drug advisory committee odac herceptin be approve wide range indication include breast cancer metastatic adjuvant setting novartis ceo retire replacement announce novartis ceo joseph jimenez be step position board director have appoint vasant vas global head drug development chief medical officer successor effective feb also read replace jimenez novartis ceo novartis stock have gain year date outperform rally industry belong novartis be zack rank hold stock see complete list today zack rank strong buy stock here fda issue warning letter pfizer pfizer get warning letter fda regard manufacturing facility meridian medical technology inc brentwood mo letter mention significant violation current good manufacturing practice cgmp requirement combination product company have be accuse fail thoroughly investigate several serious component product failure epipen product manufacture behalf mylan include failure associate patient death severe illness earlier year march meridian medical technology have announce voluntary recall epipen product follow receipt previously disclose report outside unite state failure activate device due potential defect supplier component cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index be last trading session most major stock record gain astrazeneca azn free report rise bristol myer be last month bristol myer be merck decline see last pharma stock roundup here novartis car drug get fda nod lilly give baricitinib update next pharma world watch usual pipeline regulatory update safety effectiveness glaxosmithkline plc gsk free report shingle vaccine shingrix be review fda vaccine related biological product committee vrbpac sep more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1208,LLY,cancer be second most common cause death precede only heart disease traditional cancer treatment include surgery radiation chemotherapy however immunotherapy gene therapy other new novel therapy be be develop improve supplement replace traditional cancer treatment target reduce remove cancerous growth accord report american cancer society almost new cancer case be expect be diagnosed create significant need effective cancer medication go say big pharma company be gear develop bring innovative cancer treatment market well expand label market oncology drug pharma biotech giant have significant financial resource disposal have even collaborate pool resource technology here discuss pharma giant possess industry strongest oncology pipeline portfolio astrazeneca azn free report astrazeneca be work strengthen oncology product portfolio have several candidate pipeline company target be launch least new oncology medicine include lynparza tagrisso imfinzi be already approve market interesting candidate company immuno oncology pipeline be imfinzi durvalumab be evaluate multiple cancer alone combination other regimen include phase iii trial combination tremelimumab first line urothelial cancer nsclc small cell lung cancer head neck squamous cell carcinoma hnscc other imfinzi be launch first indication second line advanced bladder cancer other phase iii oncology candidate astrazeneca pipeline include acalabrutinib blood cancer moxetumomab pasudotox leukaemia selumetinib thyroid cancer savolitinib kidney cancer lynparza presently market advanced ovarian cancer be also different study range tumor type include breast prostate pancreatic cancer well earlier line setting ovarian cancer tagrisso be also be evaluate earlier line setting lung cancer astrazeneca carry zack rank hold see complete list today zack rank strong buy stock here so far year astrazeneca share have moved compare unfavorably increase large cap pharma industry pfizer pfe free report pfizer newly approve immunotherapy bavencio be be consider significant top line driver new york base pharma giant bavencio avelumab receive fda approval metastatic merkel cell carcinoma mcc march advanced bladder cancer bavencio be review eu mcc decision expect third quarter pfizer be focuse continuously grow expand bavencio new indication market globally pfizer have also initiate avelumab double triple combination study chemotherapy target therapy have avelumab combination therapy immuno oncology agent development pfizer other oncology candidate have also be approve fda recently besponsa relapse refractory acute lymphoblastic leukemia august mylotarg new relapse cd positive acute myeloid leukemia september other cancer candidate pfizer pipeline include talazoparib advanced breast cancer dacomitinib advanced nsclc egfr activate mutation pfizer be also aggressively work expand label approve cancer drug ibrance xalkori pfizer also carry zack rank hold so far year pfizer share have moved abbvie abbv free report abbvie be work expand accelerate presence oncology build grow position hematological oncologyabbvie imbruvica currently approve several cancer indication have multus dollar potential abbvie be explore potential expand imbruvica label solid tumor autoimmune disease abbvie be position imbruvica pipeline molecule treatment be several company sponsored study acquisition cancer drugmaker stemcentrx abbvie gain late stage candidate rovalpituzumab tesirine rova additional early stage compound solid tumor indication significant portfolio pre clinical asset rova be currently registrational study small cell lung cancer sclc phase arm basket study rova neuroendocrine tumor be also ongoing accord abbvie candidate have blockbuster potential be launch abbvie intend study candidate additional indication estimate peak sale close abbvie be also study market cancer drug venclyxto venclexta expand label address broader relapse refractory cll patient population expand earlier line therapy broaden other hematologic malignancy abbvie also carry zack rank so far year abbvie share have moved bristol myer bmy free report bristol myer pd inhibitor opdivo have be perform impressively bristol myer be work expand label opdivo further alone combination therapy yervoy other cancer agent further bristol myer cancer portfolio include multiple myeloma drug empliciti leukemia drug sprycel contribute top line addition bristol myer be evaluate other immune system pathway treatment cancer pathway help company bring market potentially immunotherapy combination monotherapy help fight different type cancer bristol myer also carry zack rank so far year bristol myer share have moved other not far behindmerck mrk free report be also conduct numerous study evaluate highly successful pd therapy keytruda more type cancer more study include more combination study roche rhhby free report dominate breast cancer space strong demand franchise drug herceptin perjeta kadcyla apart strong breast cancer franchise roche oncology portfolio also boast lung cancer drug avastin tarceva immuno oncology drug tecentriq newly approve multiple sclerosis drug ocrevus label expansion effort be ongoing cancer drug swiss drugmaker novartis nvs free report also boast many experimental cancer drug pipeline include couple biosimilar version popular cancer drug novartis cancer pipeline be bolster deal buy most glaxo gsk free report oncology portfolio lilly lly free report also layer oncology strategy call hold july involve build key treatment cyramza lartruvo abemaciclib foundational agent focuse develop new standard care change therapy combination regimen include immuno therapy cancer market be fierce not pipeline candidate be successful however pharma biggy have enough late stage cancer program portfolio be chance quite few rollout come year surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
1209,LLY,novartis ag nvs free report announce chief executive officer ceo joseph jimenez step position vasant global head drug development chief medical officer replace effective feb be member executive committee joined novartis lead consumer health division be division head novartis pharmaceutical novartis be currently go transitional stage march novartis acquire certain oncology product pipeline compound glaxosmithkline plc gsk free report exchange sell influenza vaccine business glaxo january novartis divest animal health division eli lilly lly free report approximately company blockbuster drug diovan be face stiff generic competition unite state eu japan gleevec lose exclusivity unite state february company also lose patent protection drug eu december lead generic competition loss patent protection top selling drug continue hurt sale late performance alcon business have be quite disappointing due lower surgical equipment sale result competition face intraocular lens slowdown demand equipment purchase restructure initiative company segment performance remain dismal particular surgical business be take longer turnaround hence novartis be mull strategic option alcon include retain business separation capital transaction such spin initial public offer company throw light plan alcon later last week company get boost fda have approve breakthrough gene transfer treatment kymriah suspension treatment patient year age cell precursor acute lymphoblastic leukemia approval open new frontier treatment cancer advance immunocellular therapy child young adult cell comprise approximately cancer diagnosis child year be most common cause childhood cancer unite state novartis stock have rally year so far compare industry gain zack rank key picknovartis currently carry zack rank hold better rank stock healthcare sector be aduro biotech inc adro free report carry zack rank buy see complete list today zack rank strong buy stock here aduro biotech loss share estimate narrow last day company deliver positive surprise trail quarters average beat zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
